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Abstract	  
The	   neuronal	   ceroid	   lipofuscinosis	   (NCLs,	   Batten	   Disease)	   are	   inherited,	   fatal	  
neurodegenerative	   disorders	   of	   childhood.	   In	   all	   forms	   of	   NCL,	   astrocyte	  
activation	  occurs	   early	   in	   the	  disease	   and	  precedes	   neuronal	   loss.	  However,	   in	  
the	  most	   common	   juvenile	   form	   (JNCL),	   which	   is	   caused	   by	   a	  mutation	   in	   the	  
Cln3	  gene,	  this	  astrocyte	  response	  appears	  to	  be	  compromised.	  Since	  astrocytes	  
are	   crucial	   for	   the	   functioning	  and	   survival	   of	  neurons,	   and	  emerging	  evidence	  
highlights	  the	  pivotal	  role	  that	  reactive	  astrocytosis	  plays	  in	  the	  pathogenesis	  of	  
CNS	  diseases,	  any	  deficits	  in	  the	  biology	  of	  these	  cells	  could	  significantly	  impact	  
neuronal	  health.	  In	  order	  to	  study	  the	  functioning	  of	  JNCL	  astrocytes,	  these	  cells	  
were	   isolated	   from	   a	   well-­‐characterised	   mouse	   model	   of	   the	   disease,	   Cln3	  
deficient	  mice	  (Cln3-­‐/-­‐	  mice),	  and	  their	  basic	  biology	  characterised.	  These	  studies	  
revealed	  that	  Cln3-­‐/-­‐	  astrocytes	  have	  a	  disrupted	  actin	  and	  intermediate	  filament	  
cytoskeleton.	  Possibly	  due	  to	  these	  defects,	  Cln3-­‐/-­‐	  astrocytes	  have	  an	  attenuated	  
ability	   to	   response	   to	   an	   activation	   stimulus,	   just	   as	   observed	   in	   vivo,	   and	   to	  
divide	  and	  migrate.	  They	  also	  display	  pronounced	  defects	  in	  their	  ability	  to	  take-­‐
up	   glutamate	   and	   to	   secrete	   a	   range	   of	   proteins,	   including	   cytokines,	  
neuroprotective	   factors	   and	   the	   anti-­‐oxidant	   glutathione,	   that	   become	   even	  
more	   evident	   upon	   stimulation.	   Additionally,	   their	   impaired	   calcium	   signalling	  
suggests	  that	  communication	  might	  be	  altered	  in	  these	  cells.	  Most	   importantly,	  
using	  a	  co-­‐culture	  system,	  these	  Cln3-­‐/-­‐	  glia	  were	  shown	  to	  negatively	  impact	  the	  
health	  of	  both	  Cln3-­‐/-­‐	  and	  wild-­‐type	  neurons,	  with	  the	  mutant	  neurons	  being	  the	  
most	   severely	   affected,	   probably	   because	   of	   their	   own	   compromised	   biology.	  
This	   includes	   a	   reduction	   in	   neurite	   complexity	   and	   displacement	   of	   the	   axon	  
initial	  segment	  (AIS),	  which	  modulates	  neuronal	  excitability	  and	  the	  initiation	  of	  
axon	  potentials.	  Thus,	   these	  data	   show,	   for	   the	   first	   time,	   that	   JNCL	  astrocytes	  
are	   functionally	   compromised	   and	   might	   play	   an	   active	   role	   in	   the	  
neurodegeneration	   observed	   in	   JNCL.	   Further,	   this	   information	   raises	   the	  
possibility	   that,	   in	   future,	   astrocytes	   should	   be	   considered	   as	   targets	   for	  
therapeutic	  interventions.	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The	  neuronal	   ceroid	   lipofuscinoses	   (NCLs)	   are	  a	   subgroup	  of	   lysosomal	   storage	  
disorders	   that	   form	   the	   most	   common	   group	   of	   childhood	   neurorogenerative	  
diseases.	  They	  are	  inherited,	  with	  only	  one	  exception,	  in	  an	  autosomal	  recessive	  
manner	  and	  are	  all	   fatal	   (Goebel,	  1995;	  Haltia,	  2006;	  Haltia	  and	  Goebel,	  2012).	  
Most	   of	   the	   NCLs	   share	   clinical	   characteristics,	   including	   epileptic	   seizures,	  
mental	  and	  motor	  deterioration,	  that	  ultimately	  lead	  to	  the	  premature	  death	  of	  
the	   affected	   individuals	   (Cooper,	   2003;	   Jalanko	  and	  Braulke,	   2009;	  Mole	  et	   al.,	  
2011;	  Haltia	  and	  Goebel,	  2012).	  The	  different	  forms	  of	  NCLs	  also	  share	  common	  
pathological	   features	   including	   the	   accumulation	   of	   autofluorescent	   storage	  
material	   and	   progressive,	   yet,	   selective	   neuronal	   loss	   that	   is	   preceded	   by	   glial	  
activation	  (Bible	  et	  al.,	  2004;	  Pontikis	  et	  al.,	  2004;	  Tyynelä	  et	  al.,	  2004;	  Pontikis	  et	  
al.,	   2005;	   Jalanko	   and	   Braulke,	   2009;	   Weimer	   et	   al.,	   2009;	   Mole	   et	   al.,	   2011;	  
Kuronen	   et	   al.,	   2012;	   Schmiedt	   et	   al.,	   2012).	   Despite	  much	   research	   the	   exact	  
neuropathological	   mechanisms	   underlying	   these	   devastating	   brain	   disorders	  
remains	  elusive.	  	  	  
The	   research	   described	   in	   this	   thesis,	   uses	   a	   tissue	   culture	   approach,	   to	  
investigate	  the	  hypothesis	  that	  astrocytes	  play	  a	  key	  role	  in	  the	  pathology	  of	  the	  
most	  common	  form	  of	  NCL,	   the	   juvenile	   form	  (JNCL).	  This	  hypothesis	  stemmed	  
from	  observations	  that,	   in	  JNCL,	  as	   in	  all	   forms	  of	  NCL,	  glial	  activation	  precedes	  
neuronal	  loss,	  but	  in	  mouse	  models	  of	  JNCL,	  and	  in	  the	  human	  disease,	  this	  glial	  
activation	  appears	   to	  be	  attenuated	   (Pontikis	  et	  al.,	  2004;	  Tyynelä	  et	  al.,	  2004;	  
Pontikis	  et	  al.,	  2005).	  	  	  
In	   this	   introduction	   I	   will	   discuss	   what	   is	   known	   about	   lysosomal	   storage	  
disorders	  including	  the	  NCLs,	  and	  JNCL	  in	  particular.	  I	  will	  give	  an	  overview	  of	  the	  
cellular	   dysfunctions	   associated	   with	   these	   diseases	   and	   include	   evidence	  
detailing	  why	  astrocytes	  could	  be	  important	  players	  in	  this	  field.	  	  	  	  
1.1	  Lysosomal	  storage	  disorders	  
The	   discovery	   of	   the	   lysosome	   by	   Christian	   de	  Duve	  manifested	   the	   birth	   of	   a	  
new	   era	   in	   the	   field	   of	   cell	   biology	   (Duve,	   1975).	   Ten	   years	   later,	   the	   first	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lysosomal	  disorder,	   Pompe	  disease,	  was	   identified	   (HERS,	   1963).	   Subsequently,	  
many	  similar	  conditions	  caused	  by	   inborn	  errors	   in	  metabolism	  and	  resulting	   in	  
the	  build	  up	  of	   lipids	  within	   cells	   have	  been	   identified.	   These	  were	   collectively	  
referred	  to	  as	  ‘inborn	  lysosomal	  diseases’	  (HERS,	  1965;	  Vellodi,	  2005).	  Currently	  
lysosomal	  storage	  disorders	   (LSDs)	   forms	  a	  group	  of	  at	   least	  70	  distinct	  genetic	  
diseases	  (Futerman	  and	  van	  Meer,	  2004;	  Cox	  and	  Cachón-­‐González,	  2012).	  Each	  
of	   these	   diseases	   result	   either	   from	   a	   defect	   in	   the	   activity	   of	   a	   particular	  
lysosomal	  protein,	  or	   from	  non-­‐lysosomal	  proteins	  whose	   functions	  are	   related	  
to	   lysosomal	   biogenesis	   (Futerman	   and	   van	   Meer,	   2004;	   Ballabio	   and	  
Gieselmann,	   2009;	   Walkley,	   2009;	   Bellettato	   and	   Scarpa,	   2010;	   Vitner	   et	   al.,	  
2010;	  Schultz	  et	  al.,	  2011).	  These	  defects	   cause	   the	  accumulation	  of	  unwanted	  
substrates	  that	  should	  have	  been	  metabolized	  by	  the	  cell.	  Individually,	  LSDs	  are	  
rare,	  but	  collectively	  they	  show	  a	  prevalence	  of	  about	  1	  in	  5000-­‐7500	  live	  births	  
(Meikle	   et	   al.,	   1999;	   Futerman	   and	   van	   Meer,	   2004).	   A	   variety	   of	   pathogenic	  
cascades	  have	  been	  implicated	  in	  different	  forms	  of	  LSDs,	  some	  are	  common	  to	  
many	  LSDs,	  whereas	  others	  are	  impaired	  only	  in	  a	  subset	  of	  LSDs	  (Kiselyov	  et	  al.,	  
2007;	  Vitner	  et	  al.,	  2010;	  Schultz	  et	  al.,	  2011)	  but,	  as	  stated	  above,	  all	  involve	  the	  
lysosome.	  	  
The	  lysosome	  	  
Lysosomes	   are	   cellular	   organelles	   that	   degrade	   other	   worn-­‐out	   cellular	  
organelles,	  proteins,	  lipids,	  carbohydrates,	  and	  possibly	  also	  viruses	  and	  bacteria	  
(Duve,	  1975;	  Kornfeld	  and	  Mellman,	  1989;	  Dell'Angelica	  et	  al.,	  2000;	  Eskelinen	  et	  
al.,	  2003;	  Bonifacino,	  2004;	  Luzio	  et	  al.,	  2007).	  By	  controlling	  the	  degradation	  of	  
components	   they	   receive	   via	   endocytosis,	   autophagy	   or	   the	   biosynthetic	  
pathway,	   lysosomes	  are	  one	  of	  the	  most	  important	  organelles	   in	  the	  regulation	  
of	   cellular	   homeostasis	   (Sachse	   et	   al.,	   2002;	   Eskelinen	   et	   al.,	   2003;	   Eskelinen,	  
2005;	   Luzio	   et	   al.,	   2007).	   Lysosomes	   are	  membrane-­‐bound,	   thus,	   allowing	   the	  
acid-­‐dependent	  digestive	  enzymes	  within	  them	  to	  work	  at	  the	  required	  optimum	  
pH,	   4.5-­‐5.0,	   which	   is	   maintained	   by	   the	   vacuolar	   H+-­‐adenosine	   triphosphate	  
(ATP)ase	   (Mullins	   and	   Bonifacino,	   2001;	   Nishi	   and	   Forgac,	   2002).	   Ultimately,	  
degraded	   products	   are	   re-­‐used	   by	   the	   cell	   after	   being	   transported	   across	   the	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lysosomal	  membrane	  and	  released	  into	  the	  cytosol.	  Lysosomal	  enzymes	  may	  also	  
be	  released	  into	  the	  cytosol,	  where	  they	  may	  be	  involved	  in	  apoptotic	  pathways,	  
or	   into	   the	  extracellular	   space	   to	  digest	   extracellular	  material	   (Eskelinen	  et	   al.,	  
2003;	   Luzio	   et	   al.,	   2007;	   Schröder	   et	   al.,	   2007;	   Braulke	   and	   Bonifacino,	   2009;	  
Lübke	  et	  al.,	  2009;	  Schröder	  et	  al.,	  2010).	  	  
	  
The	   metabolic	   activities	   of	   lysosomes	   are	   complemented	   by	   lysosome-­‐related	  
organelles	   (LROs),	   such	   as	   major	   histocompatibility	   complex	   (MHC)	   class	   II	  
compartments,	   lytic	   granules,	   melanosomes	   and	   platelet-­‐dense	   granules	  
(Dell'Angelica	   et	   al.,	   2000).	   LROs	   share	   many	   functional	   properties	   with	  
lysosomes,	   but	   they	   differ	   from	   them	  by	   containing	   cell-­‐type	   specific	   proteins,	  
such	  as	  tyrosinase-­‐related	  protein	  1	  (TRP-­‐1)	  in	  melanosomes,	  that	  is	  involved	  in	  
synthesis	  of	  melanin;	  and	  P-­‐selectin	  in	  platelet-­‐dense	  granules,	  that	  is	  thought	  to	  
function	   as	   a	   receptor	   for	   adhesive	   proteins	   and	  mediate	   platelet	   aggregation	  
(Jackson,	  1988;	  Israels	  et	  al.,	  1992;	  McNicol	  and	  Israels,	  1999;	  Dell'Angelica	  et	  al.,	  
2000;	   Dell'Angelica,	   2004).	   LROs	   also	   require	   additional	   cellular	   machinery	   for	  
their	   biosynthesis	   (Dell'Angelica	   et	   al.,	   2000;	   Bonifacino,	   2004;	   Dell'Angelica,	  
2004).	  For	  instance,	  the	  multi-­‐subunit	  protein	  complex,	  biogenesis	  of	  lysosome-­‐
related	   organelles	   complex-­‐1	   (BLOC-­‐1),	   is	   pivotal	   for	   the	   biogenesis	   of	  
melanosomes	  and	  platelet	  dense	  granules	  (Dell'Angelica,	  2004;	  Lee	  et	  al.,	  2012).	  	  
	  
Lysosomes,	  however,	  are	  not	  just	  the	  cells	  ‘waste	  disposal	  and	  recycling	  unit’	  but	  
together	  with	   LROs	   are	   involved	   in	  multiple	   cellular	   processes	   (see	   Figure	   1.1)	  
including	  plasma	  membrane	  repair,	  pathogen	  defense	  via	  phagocytosis	  and	  MHC	  
class	  II	  antigen	  presenting	  and	  phagocytosis,	  apoptotic	  cell	  death,	  cell	  signaling,	  
cholestetol	   and	   cytosolic	   Ca2+	   homeostasis	   and	   autophagy	   (Luzio	   et	   al.,	   2007;	  
Saftig	   and	   Klumperman,	   2009;	   Schröder	   et	   al.,	   2010;	   Lloyd-­‐Evans	   and	   Platt,	  
2011).	   Thus,	   any	   defect	   in	   lysosome	   function	   can	   be	   devastating	   due	   to	   their	  
impact	  on	  multiple,	  crucial	  cellular	  functions	  (Futerman	  and	  van	  Meer,	  2004;	  Cox	  
and	  Cachón-­‐González,	  2012).	  This	   is	  manifested	  by	  the	  rapidly	  growing	  number	  
of	  human	  disorders	   that	  exhibit	  primary	  or	   secondary	  defects	   in	   the	   lysosomal	  
system	  (Vellodi,	  2005;	  Parkinson-­‐Lawrence	  et	  al.,	  2010).	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Figure	  1.1	  Lysosomal	  functions.	  Lysosomes	  are	  acidic	  organelles,	  whose	  pH	  is	  maintained	  
by	  the	  proton	  transportation	  activity	  of	  H+-­‐ATPase,	  and	  are	  involved	  in	  a	  range	  of	  crucial	  cellular	  
functions.	  The	  main	  role	  of	  lysosome	  is	  to	  degrade	  cellular	  waste	  internalized	  by	  endocytosis,	  and	  
intracellular	   components	   via	   autophagy,	   subsequently	   they	  participate	   in	   recycling	  proteins	   for	  
re-­‐use	   by	   the	   cell.	   Both	   the	   process	   of	   macroautophagy,	   which	   depends	   on	   the	   fusion	   of	  
lysosomes	   with	   autophagosomes	   to	   create	   autolysosomes	   controlling	   turnover	   of	   cytoplasmic	  
components,	   and	   chaperon-­‐mediated	   autophagy	   (direct	   lysosomal	   transport	   of	   cytosolic	  
proteins)	  are	  regulated	  by	  lysosome-­‐associated	  membrane	  proteins	  (LAMPs).	  Another	  lysosomal	  
membrane	   protein	   called	   Niemann-­‐Pick	   C1	   protein	   (NPC1)	   controls	   the	   lysosomal	   cholesterol	  
efflux,	   important	   in	   regulation	   of	   cellular	   cholesterol	   homeostasis.	   Lysosomes	   play	   a	   role	   in	  
apoptotic	  cell	  death	  via	  release	  of	  cathepsins.	  Lysosomes	  are	  also	  pivotal	  for	  cellular	  pathogenic	  
defense	  by	  regulating	  the	  maturation	  of	  phagosomes	  to	  phagolysosomes	  in	  phagocytosis,	  and	  by	  
being	   involved	   in	   major	   histocompatibility	   complex	   (MHC)	   class	   II-­‐dependent	   antigen	  
presentation.	   Finally,	   lysosome	   exocytosis	   and	   plasma	   membrane	   repair	   activities	   may	   link	  
lysosomes	   with	   autoimmunity,	   pathogen	   entry	   and	   neurite	   growth.	   Lysosomes	   are	   also	  
important	  in	  intracellular	  Ca2+-­‐homeostasis	  by	  functioning	  as	  intracellular	  Ca2+	  stores.	  
	  
Lysosomal	  proteins	  
Proteins	  essential	  for	  the	  function	  of	  lysosomes	  can	  be	  classified	  as	  either	  soluble	  
lysosomal	   hydrolases,	   also	   known	   as	   acid	   hydrolases,	   and	   integral	   lysosomal	  
membrane	   proteins.	   Each	   of	   the	   50	   known	   acid	   hydrolases,	   including	  
proteinases,	  peptidases,	  lipases,	  nucleases,	  glycosidases	  and	  sulphatases,	  act	  on	  
specific	  substrates	  and	  collectively	  define	  the	  catabolic	  activity	  of	   the	   lysosome	  
(Schröder	  et	   al.,	   2010).	   Some	  of	   these	  proteases	  are	  expressed	  only	   in	   specific	  
tissues,	  but	  most	  of	   them	  are	  expressed	  ubiquitously	   (Brix	   and	   Jordans,	   2005).	  
Soluble	   lysosomal	   proteins	   are	   synthesized	   as	   inactive	   precursors,	   and	   their	  
transportation	   to,	   and	   subsequent	   activation	   within,	   lysosomes	   is	   highly	  
regulated	   (Braulke	   and	   Bonifacino,	   2009).	   Lysosomal	   proteins	   are	   heavily	  
glycosylated	   and	   oligosaccharide	   modifications	   are	   used	   for	   their	   correct	  
targeting	   to	   lysosomes.	   Indeed,	   the	   best	   understood	   pathway	   for	   transport	   of	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lysosomal	   enzymes	   is	   mediated	   by	   mannose	   6-­‐phoshate	   moieties	   that	   are	  
attached	  to	  lysosomal	  proteins	  in	  the	  Golgi	  (Braulke	  and	  Bonifacino,	  2009;	  Saftig	  
and	  Klumperman,	  2009).	  This	  modification	  is	  recognized	  by	  different	  mannose	  6-­‐
phosphate	   receptors	   (MPRs)	   in	   the	  Trans-­‐Golgi-­‐network	   (TGN),	  and	   this	   ligand-­‐
receptor	   complex	   then	  binds	   clathrin-­‐associated	   adaptor	   proteins	   (APs)	   and/or	  
Golgi-­‐localized,	  γ-­‐ear	  containing,	  ADP	  ribosylation	  factor-­‐finding	  proteins	  (GGAs)	  
(Kornfeld	   and	   Mellman,	   1989;	   Bonifacino	   and	   Traub,	   2003;	   Braulke	   and	  
Bonifacino,	   2009)	   for	   transport	   in	   clathrin-­‐coated	   vesicles	   to	   the	   early	  
endosomes	   (EEs).	   Due	   to	   the	   acidic	   pH	   of	   endosomes	   the	   lysosomal	   enzymes	  
become	  dissociated	  from	  MPRs	  and	  these	  released	  enzymes	  remain	  in	  the	  lumen	  
during	  EEs	  maturation	   to	   late	  endosomes	   (LEs).	  When	  LEs	   fuse	  with	   lysosomes	  
activation	  of	  the	  enzymes	  is	  initiated,	  while	  MPRs	  are	  returned	  back	  to	  the	  TGN	  
by	  recycling	  endosomes	  to	  carry	  out	  further	  rounds	  of	  hydrolase	  sorting	  (Braulke	  
and	   Bonifacino,	   2009;	   Saftig	   and	   Klumperman,	   2009).	   Alternative	   lysosomal	  
targeting	   systems,	   including	   sortilin	   based	   lysosomal	   targeting	   of	   cathepsin	   D,	  
cathepsin	  H	  and	  acid	  sphingomyelinase,	  also	  exist	  (Lefrancois	  et	  al.,	  2003;	  Canuel	  
et	   al.,	   2008).	   Cathepsins	   constitute	   the	  main	   class	   of	   lysosomal	   proteases,	   and	  
they	  can	  be	  divided	  into	  three	  subgroups,	  cysteine,	  aspartyl	  or	  serine	  cathepsins,	  
according	  to	  the	  amino	  acid	  at	  their	  active	  site	  (Conus	  and	  Simon,	  2008).	  Overall,	  
having	   specific	   delivery	   systems	   for	   lysosomal	   proteins	   protects	   the	   cells	   from	  
the	  potentially	  harmful	  effects	  of	  prematurely	  activated	  lysosomal	  enzymes.	  	  
	  
The	  mammalian	   lysosome	   contains	  multiple	   lysosomal	  membrane	   proteins,	   of	  
which	   at	   least	   120	  have	  been	   identified	   (Schröder	   et	   al.,	   2007;	   Callahan	   et	   al.,	  
2009;	   Lübke	   et	   al.,	   2009;	   Schröder	   et	   al.,	   2010).	   Two	   of	   the	  main	   functions	   of	  
lysosomal	  membrane	   proteins	   are	   to	   assure	   the	   acidification	   of	   the	   lysosomal	  
lumen	  by	  a	  proton	  pump	  action,	  and	   to	  prevent	   the	   release	  of	  hydrolases	   into	  
the	   cytoplasm	   in	   order	   to	   protect	   the	   cell	   from	   unwanted	   degradation	   of	  
cytosolic	   proteins/organelles	   (Eskelinen	   et	   al.,	   2003).	   Other	   functions	   include	  
facilitation	   of	   protein	   import	   from	   the	   cytosol	   into	   the	   lumen	   of	   lysosomes,	  
membrane	  fusion	  between	  lysosomal	  vacuoles	  and/or	  fusion	  of	   lysosomes	  with	  
other	  membrane	   organelles,	   such	   as	   endosomes,	   phagosomes	   and	   the	   plasma	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membrane,	   and	   transport	   of	   degradation	   products	   to	   the	   cytoplasm	   (Fukuda,	  
1991;	   Eskelinen	   et	   al.,	   2003;	   Eskelinen,	   2006).	   The	  main	   lysosomal	  membrane	  
proteins	   are,	   lysosome-­‐associated	   membrane	   proteins	   (LAMPs),	   lysosomal	  
membrane	   glycoproteins	   (LGPs)	   and	   lysosomal	   integral	   membrane	   proteins	  
(LIMPs),	  some	  of	  which	  can	  be	  expressed	  in	  a	  cell-­‐type	  specific	  or	  tissue-­‐specific	  
manner	  (Eskelinen	  et	  al.,	  2003;	  Schröder	  et	  al.,	  2007;	  2010).	  These	  proteins	  also	  
form	  a	  protective	  polysaccharide-­‐based	  glycocalyx	  coat	  on	  the	  inner	  side	  of	  the	  
lysosomal	   membrane	   that	   protects	   it	   from	   digestion	   by	   lysosomal	   enzymes	  
(Eskelinen	  et	  al.,	  2003).	  It	  has	  been	  estimated	  that	  LAMPs	  and	  LIMPs	  are	  closely	  
packed	   and	   comprise	   more	   than	   50%	   of	   the	   total	   membrane	   protein	   of	   late	  
endosomes	   and	   lysosomes	   (Marsh	   et	   al.,	   1987).	   Type	   1	   lysosomal	   membrane	  
proteins,	  which	  include	  lysosomal	  associated	  membrane	  protein	  1-­‐	  and	  2	  (LAMP-­‐
1	  and	  LAMP-­‐2),	  are	  the	  major	  protein	  components	  of	  the	  lysosomal	  membrane.	  
Thus,	   LAMP	   proteins	   are	   routinely	   used	   as	   lysosomal	   markers	   (Kornfeld	   and	  
Mellman,	   1989).	   Mutations	   in	   the	   LAMP-­‐2	   gene	   cause	   a	   lysosomal	   glycogen	  
storage	  disease,	  called	  Danon	  disease,	  in	  humans,	  and	  disruption	  of	  both	  LAMPs	  
is	   associated	   with	   an	   increased	   accumulation	   of	   autophagic	   vacuoles	   and	  
unesterified	   cholesterol	   (Eskelinen,	   2006).	   Very	   little	   is	   known	   about	   the	  
mechanisms	   for	   the	   transport	   of	   lysosomal	   membrane	   proteins	   to	   lysosomes,	  
but	   this	   is	   thought	   to	   be	   regulated	   by	   phosphorylation	   and	   lipid	   modification	  
based	   signal	   recognition	   (Braulke	  and	  Bonifacino,	   2009).	   For	  example,	  many	  of	  
the	   lysosomal	   membrane	   proteins	   have	   been	   shown	   to	   use	   clathrin/AP/GGA-­‐
dependent	   mechanisms	   for	   transportation	   towards	   endo/lysosomes	   when	  
exiting	   from	   the	   TGN	   either	   directly,	   or	   indirectly	   via	   the	   cell	   surface,	   if	   a	  
constitutive	   secretory	   pathway	   is	   followed	   (Eskelinen	   et	   al.,	   2003;	   Braulke	   and	  
Bonifacino,	   2009;	   Saftig	   and	   Klumperman,	   2009).	   The	   targeting	   of	   some	  
lysosomal	   membrane	   proteins	   occurs	   independently	   of	   the	   clathrin/AP/GGA-­‐
system,	   and	   some	   of	   them	   contain	   a	   number	   of	   distinct	   sorting	   motifs.	   Thus,	  
under	  different	  cellular	  conditions	  the	  targeting	  of	  lysosomal	  membrane	  proteins	  
may	  vary	  depending	  on	  which	  distinct	  trafficking	  pathways	  are	  being	  used	  (Saftig	  
and	  Klumperman,	  2009).	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Common	  features	  of	  LSDs	  	  
Intact	   lysosomal	   activity	   is	   pivotal	   for	   cellular	   survival	   and	   functioning,	   as	  
described	  above.	  Thus,	  when	  lysosomal	  function	  is	  altered,	  neuronal	  dysfunction	  
and	  neurodegeneration	  can	  follow	  (Kopra	  et	  al.,	  2004;	  Walkley,	  2007;	  Wasser	  et	  
al.,	  2007;	  Sann	  et	  al.,	  2009;	  Walkley,	  2009;	  Walkley	  et	  al.,	  2010).	  Since	  the	  mid-­‐
1960s,	  starting	  from	  Gaucher	  disease,	  the	  genetic	  and	  biochemical	  abnormalities	  
present	   in	   many	   LSDs	   have	   been	   elucidated	   (Futerman	   and	   van	   Meer,	   2004;	  
Walkley,	  2009;	  Bellettato	  and	  Scarpa,	  2010;	  Schultz	  et	  al.,	  2011;	  Cox	  and	  Cachón-­‐
González,	  2012).	  Nearly	  all	  LSDs	  are	  autosomal	  recessively	   inherited	  monogenic	  
disorders,	   except	   for	   two	   that	   are	   x-­‐linked,	   Fabry	   disease	   and	  
mucopolysaccharidosis	   (MPS)	   type	   II	   (Hunter	   syndrome)	   (Desnick	   et	   al.,	   1989)	  
(Hopwood	   et	   al.,	   1993),	   and	   an	   adult	   form	   of	   autosomal	   dominant	  NCL	   (Parry	  
disease)	   (Nijssen	  et	  al.,	  2003),	  caused	  by	  mutations	   in	  DNAJC5/CLN4	  (Anderson	  
et	  al.,	  2012).	  
	  
The	   storage	  material	   that	   accumulates	   in	  different	   LSDs	   is	   heterogeneous	  with	  
several	  types	  of	  accumulating	  macromolecules	  having	  been	  identified,	  including	  
lipids,	   amino	   acids,	   glycoproteins,	   mucopolysaccharides,	   sphingolipids,	  
oligosaccharides	   and	   sulfatides	   (Futerman	   and	   van	   Meer,	   2004;	   Ballabio	   and	  
Gieselmann,	   2009;	   Schultz	   et	   al.,	   2011;	   Cox	   and	   Cachón-­‐González,	   2012).	   Such	  
accumulating	   intracellular	   material	   has	   been	   used	   as	   a	   general	   basis	   for	  
classifying	   the	   LSDs.	   Since	   there	   are	   obvious	   limitations	   with	   this	   type	   of	  
classification	   system,	   LSDs	   have	   also	   been	   grouped	   according	   to	   the	  
characteristics	   of	   the	   defective	   protein	   in	   question	   (Futerman	   and	   van	   Meer,	  
2004;	   Bellettato	   and	   Scarpa,	   2010;	   Schultz	   et	   al.,	   2011;	   Cox	   and	   Cachón-­‐
González,	   2012).	   The	   vast	   majority	   of	   LSDs	   are	   caused	   by	   mutations	   in	   genes	  
encoding	  soluble	  lysosomal	  enzymes,	  resulting	  in	  loss	  of	  the	  protein	  product,	  an	  
attenuation	   in	   catalytic	   activity,	   or	   a	   disruption	   of	   correct	   folding	   and	  
glycosylation	   in	   the	   Golgi/endoplasmic	   reticulum	   (ER)	   complex.	   Alternatively,	  
LSDs	  can	  be	  caused	  by	  mutations	   in	  non-­‐enzymatic	   lysosomal	  proteins	  that	  are	  
either	  soluble	  or	  integral	  membrane	  proteins	  (Ruivo	  et	  al.,	  2009;	  Walkley,	  2009;	  
Filocamo	  and	  Morrone,	  2011).	  Broadly,	  these	  mutated,	  non-­‐enzymatic	  lysosomal	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proteins	   are	   involved	   in	   other	   crucial	   steps	   in	   lysosome	   biology,	   such	   as	  
trafficking,	   activation/stabilization	   or	   post-­‐translational	   modifications	   of	  
lysosomal	  enzymes,	  or	   in	  the	  transportation	  of	  a	  range	  of	  molecules	  across	  the	  
lysosomal	  membrane	   (Futerman	  and	  van	  Meer,	  2004;	  Ruivo	  et	  al.,	  2009;	  Saftig	  
and	   Klumperman,	   2009;	   Filocamo	   and	   Morrone,	   2011).	   Even	   if	   the	   genetic	  
defects	  underlying	  most	  of	  the	  LSDs	  have	  been	  identified,	  the	  primary	  cause	  of	  
many	  of	  these	  diseases	  is	  still	  not	  fully	  understood.	  It	  is	  possible	  that	  a	  range	  of	  
pathological	   mechanisms,	   such	   as	   altered	   lipid	   metabolism	   and	  
autophagosytosis,	   abnormalities	   in	   Ca2+	   homeostasis	   and	   mitochondrial	  
functions	  arise	  as	  result	  of	  genetic	  defects	   in	  LSDs,	  and	  these	  mechanisms	  may	  
be	  similar	  across	  these	  diseases	  (Ballabio	  and	  Gieselmann,	  2009;	  Walkley,	  2009;	  
Bellettato	   and	   Scarpa,	   2010;	   Lloyd-­‐Evans	   and	   Platt,	   2011;	   Cox	   and	   Cachón-­‐
González,	  2012).	  Thus,	  clear-­‐cut	  genotype-­‐phenotype	  correlations	  have	  not	  been	  
established	   in	  many	  of	   these	  diseases	   (Walkley,	  2009).	  The	  progression	  of	  LSDs	  
may	   also	   be	   influenced	   by	   environmental	   factors	   and	   other	   modifying	   genes	  
(Futerman	   and	   van	   Meer,	   2004;	   Walkley,	   2009).	   This	   raises	   the	   important	  
question	   of	   how	   mutations	   in	   a	   single	   gene,	   required	   primarily	   for	   lysosomal	  
activities,	   might	   lead	   to	   such	   a	   diverse	   array	   of	   secondary	   cellular	   pathogenic	  
events	  and	  clinical	  manifestations?	  
	  
Many	  LSDs	  are	  clinically	  non-­‐symptomatic	  at	  birth,	  moreover,	  children	  with	  LSDs	  
typically	  meet	   early	   developmental	  milestones.	   This	   is	   followed	   by	   a	   phase	   of	  
developmental	  delay,	   indicating	  that	   lysosomal	  dysfunction	   itself	  does	  not	  alter	  
the	   complex	  events	   that	   take	  place	  during	  early	  brain	  development	   (Schultz	  et	  
al.,	   2011).	   With	   more	   than	   half	   of	   LSDs	   affecting	   the	   brain,	   as	   the	   disease	  
progresses,	   these	   children	   suffer	   from	   a	   wide	   range	   of	   clinical	   manifestations	  
including	   mental	   retardation,	   dementia,	   blindness	   and/or	   deafness,	   motor	  
system	   dysfunction,	   seizures,	   sleep	   and	   cognitive	   disturbances	   (Wraith,	   2004;	  
Walkley,	   2009;	  Mole	   et	   al.,	   2011;	   Cox	   and	  Cachón-­‐González,	   2012).	   Very	   often	  
LSDs	   result	   in	   the	   devastating	   disability	   and	   premature	   death	   of	   the	   affected	  
individual.	   Typically,	   it	   is	   believed	   that	   the	   complex	   pathogenic	   processes	  
observed	   are	   initiated	   by	   lysosomal	   dysfunction	   resulting	   in	   accumulation	   of	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storage	   material	   leading	   to	   deficits	   in	   other	   cellular	   compartments,	   and	  
eventually	  dysfunction	  of	  the	  whole	  cell	  ending	  in	  cell	  death.	  Other	  players	  such	  
as	   glial	   activation	   have	   also	   been	   suggested	   to	   contribute	   to	   these	   events	   in	  
many	  LSDs	  (Walkley,	  2009;	  Bellettato	  and	  Scarpa,	  2010;	  Cooper,	  2010).	   Indeed,	  
one	   common	   neuropathic	   feature	   of	   LSDs	   is	   a	   neuroinflammatory	   response	  
mediated	   by	   the	   brain’s	   immune	   defense	   system,	   mainly	   microglia	   and	  
astrocytes	   (Cooper,	   2003;	   2010;	   Pressey	  et	   al.,	   2010;	  Macauley	  et	   al.,	   2011;	  Di	  
Malta	  et	  al.,	  2012a).	  Suppressing	  the	  glial	   response	   in	  some	  of	   these	  disorders,	  
such	  as	   in	  Sandhoff	  disease	  and	  Niemann-­‐Pick	  Type	  C	  disease,	  have	  resulted	   in	  
improved	  motor	  performance,	  attenuated	  disease	  progression	  or	  increased	  life-­‐
span,	   demonstrating	   the	   importance	   of	   glial	   cells	   in	   these	   diseases	   (Wu	   and	  
Proia,	   2004;	   Zhang	   et	   al.,	   2008;	   Smith	   et	   al.,	   2009).	   Many	   of	   the	   common	  
pathological	  manifestations	  of	  LSDs,	  including	  the	  NCLs,	  have	  also	  been	  shown	  to	  
occur	   in	   other	   neurodegenerative	   disorders	   such	   as	   Parkinson	   disease	   and	  
Alzheimer	  disease	   (Zhang	  et	  al.,	  2009a;	  Bellettato	  and	  Scarpa,	  2010;	  Wong	  and	  
Cuervo,	  2010).	  Thus,	  it	  has	  been	  proposed	  that	  despite	  differences	  in	  the	  primary	  
cause	   of	   such	   neurodegenerative	   disorders,	   many	   of	   them	   share	   common	  
pathological	  processes.	  Hence,	  gaining	  a	  better	  understanding	  of	  these	  common	  
mechanisms	   in	   one	   disease	   may	   be	   applicable	   to	   a	   broad	   range	   of	   other	  
neurological	   disorders,	   and	   may	   increase	   the	   applicability	   of	   any	   therapeutic	  
intervention	  based	  on	  inhibiting	  such	  mechanisms.	  	  
	  
1.2	  Neuronal	  ceroid	  lipofuscinosis	  	  
The	   term	   neuronal	   ceroid	   lipofuscinosis	   (NCLs)	   was	   first	   used	   by	   Zeman	   and	  
Dyken	  in	  1969	  to	  describe	  a	  group	  of	  inherited	  lysosomal	  storage	  disorders	  that	  
were	   clinically	   characterized	  by	  progressive	  decay	  of	   visual,	  motor,	   and	  mental	  
functions	   (Zeman	   and	   Dyken,	   1969).	   Prior	   to	   this	   the	   NCLs	   were	   classified	   for	  
many	   decades	   among	   the	   so	   called	   ‘amaurotic	   family	   idiocies’	   due	   to	   their	  
clinical	  resemblance	  to	  Tay-­‐Sachs	  disease	  (Haltia,	  2006;	  Haltia	  and	  Goebel,	  2012).	  
The	   dramatic	   differences	   observed	   between	   the	   appearances	   of	   infantile	   (Tay-­‐
Sachs),	   late	   infantile	   (Jansky-­‐Bielschowsky)	   and	   juvenile	   (Spielmeyer-­‐Sjögren)	  
	   29	  
forms	   of	   NCL,	  made	   it	   clear	   that	   the	   NCLs	   are	   a	   biochemically	   heterogeneous	  
group	   of	   diseases	   (Zeman	   and	   Dyken,	   1969;	   Haltia,	   2003).	   Based	   on	   recent	  
advances,	   especially	   in	   molecular	   genetic	   studies,	   at	   least	   13	   different	   NCL	  
disease-­‐causing	   genes	   have	   been	   cloned	   and	   are	   listed	   in	   Table	   1.1	   (Goebel,	  
1995;	  Mole	  et	  al.,	  2011).	  Most	  NCLs	   (also	  called	  Batten	  disease)	  are	  autosomal	  
recessive	   disorders	   and	   collectively	   form	   the	   most	   common	   fatal	   autosomal-­‐
recessive	   neurodegenerative	   disease	   of	   children,	   with	   incidences	   ranging	   from	  
0.6	   in	   100,000	   to	   13.6	   in	   100,000	   live	   births	   (Santavuori,	   1988;	   Goebel,	   1995;	  
Augestad	  and	  Flanders,	  2006;	  Moore	  et	  al.,	  2008;	  Mole	  et	  al.,	  2011).	  Like	  other	  
storage	   disorders	   the	   NCLs	   have	   been	   named	   after	   the	   predominant	   storage	  
material	  that	  accumulates	  within	  cells,	  which	   is	  similar	  to	  ceroid	  and	  lipofuscin,	  
(Goebel,	  1995;	  Haltia,	  2003;	  Seehafer	  and	  Pearce,	  2006;	  Mole	  et	  al.,	  2011).	  They	  
are	  also	  grouped	  by	  their	  age	  of	  onset	  (infantile,	  late	  infantile,	  juvenile)	  and	  gene	  
defect	   (Mole	   et	   al.,	   2011)	   (see	   Table	   1.1).	   Perhaps,	   more	   simplistically,	   these	  
different	  forms	  can	  be	  grouped	  into	  those	  that	  have	  defects	  in	  genes	  encoding	  a	  
soluble	   lysosomal	  proteins:	   CLN1	   (PPT1)	   in	   infantile	   (INCL),	   CLN2	   (TPP1)	   in	   late	  
infantile	   (LINCL),	  CLN5	   in	  Finnish	  variant	  LINCL,	  cathepsin	  D	  or	  CTSD	   (CLN10)	   in	  
congenital-­‐NCL	   and	   cathepsin	   F	   (CLN4/	  DNAJC5)	   in	   adult	   onset	  NCL,	   and	   those	  
that	   have	   defects	   in	   genes	   that	   encode	   transmembrane	   proteins:	   CLN3	   in	  
juvenile	   (JNCL),	   CLN6	   in	   variant	   LINCL,	  CLN7	   in	   variant	   LINCL	  or	   Turkish	   variant	  
LINCL,	  CLN8	  in	  epilepsy	  with	  mental	  retardation	  (EPMR)	  or	  LINCL	  variant	  3	  (Mole	  
et	   al.,	   2011;	   Kousi	   et	   al.,	   2012),	   an	   updated	   database:	  
http://www.ucl.ac.uk/ncl/mutation.shtml).	  The	  main	  cellular	  location	  of	  many	  of	  
these	  transmembrane	  NCL-­‐proteins,	  whose	  primary	  functions	  are	  still	  unknown,	  
is	  either	  endosomal	  or	  lysosomal	  (Kyttälä	  et	  al.,	  2004;	  Siintola	  et	  al.,	  2006;	  Getty	  
and	   Pearce,	   2011).	   Additionally,	   a	   common	   feature	   of	   some	   NCLs	   caused	   by	  
mutations	   in	   either	   soluble	   or	   transmembrane	   forms,	   such	   as	   PPT1,	   CLN8	   and	  
CLN3,	   is	   their	   additional	   vesicular	   localization	   in	   the	   cell	   periphery,	   thus,	   these	  
proteins	  have	  been	  proposed	  to	  play	  particular	  roles	  in	  excitatory	  cells,	  especially	  
at	  neuronal	  synapses	  (Isosomppi	  et	  al.,	  1999;	  Heinonen	  et	  al.,	  2000;	  Lehtovirta	  et	  
al.,	   2001;	   Ahtiainen	   et	   al.,	   2003;	   Lonka	   et	   al.,	   2004;	   Getty	   and	   Pearce,	   2011).	  
However,	  despite	  the	  vast	  depth	  of	  knowledge	  about	  the	  genetic	  basis	  of	  NCLs,	  it	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is	   currently	   still	   unknown	   how	  mutations	   in	   these	   genes	   that	   encode	   proteins	  
that	   function	   primarily	   in	   the	   endosomal/lysosomal	   system,	   lead	   to	   such	  
























Table	   1.1	  NCL	   classification.	   This	  table	  contains	   information	  about	  all	  13	  known	  forms	  of	  
NCL	  showing	   the	  age	  of	  onset,	  gene	  defects,	  affected	  proteins	   (red)	  and	   their	  known	   functions	  
(blue),	  existing	  mouse	  models,	  and	  other	  animal	  models	  (Mole	  et	  al.,	  2011).	  
	  
Although,	   as	   mentioned	   above,	   the	   predominant	   storage	   material	   in	   NCL	   is	  
ceroid	   and	   lipofuscin,	   its	   composition	   is	   heterogeneous	   and	   differs	   between	  
different	   forms	   of	   NCLs	   (Seehafer	   and	   Pearce,	   2006).	   Generally,	   it	   is	   a	  
combination	  of	  oxidized	  proteins,	  proteolipids,	  and	  very	  small	  amounts	  of	  metal	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ions	   (Brunk	   and	   Terman,	   2002;	   Terman	   and	   Brunk,	   2004).	   Post-­‐mitotic	   cells	  
accumulate	   lipofuscin	   over	   time,	   and	   this	   is	   often	   considered	   as	   a	   hallmark	   of	  
aging	   where	   the	   accumulation	   rate	   of	   lipofuscin	   inversely	   correlates	   with	  
longevity	  (Terman	  and	  Brunk,	  2004).	  The	  main	  protein	  component	  of	  the	  storage	  
material	  that	  accumulates	  in	  JNCL	  and	  in	  all	  the	  different	  late-­‐infantile	  variants	  is	  
the	  subunit	  C	  of	  the	  mitochondrial	  ATP-­‐synthase	  (SCMAS),	  while	  in	  the	  infantile,	  
and	  congenital	   form	  it	   is	  the	  sphingolipid	  activating	  proteins,	  saposins	  A	  and	  D,	  
that	  accumulate	  (Palmer	  et	  al.,	  1992;	  Tyynelä	  et	  al.,	  1993;	  Haltia,	  2003;	  Seehafer	  
and	  Pearce,	  2006;	  Siintola	  et	  al.,	  2006).	  	  
	  
Regardless	   of	   their	   genetic	   heterogeneity,	   the	   different	   forms	   of	   NCLs	   share	  
several	  common	  pathological	  features	  (Cooper	  et	  al.,	  2006;	  Haltia,	  2006;	  Cooper,	  
2010;	  Haltia	   and	  Goebel,	   2012).	   These	   include	   an	   early	   glial	   response	   (Cooper,	  
2003;	  Bible	  et	  al.,	  2004;	  Mitchison	  et	  al.,	  2004;	  Pontikis	  et	  al.,	  2004;	  Oswald	  et	  al.,	  
2005;	   Pontikis	   et	   al.,	   2005;	   Haber	   et	   al.,	   2006;	   Haltia,	   2006;	   Kay	   et	   al.,	   2006;	  
Kuronen	  et	  al.,	  2012;	  Schmiedt	  et	  al.,	  2012),	  synaptic	  abnormalities	   (Virmani	  et	  
al.,	  2005;	  Kim	  et	  al.,	  2008;	  Partanen	  et	  al.,	  2008;	  Kielar	  et	  al.,	  2009),	  and	  selective	  
loss	  of	  particular	   types	  of	  neurons	   (Mitchison	  et	  al.,	  2004;	  Oswald	  et	  al.,	  2005;	  
Cooper	   et	   al.,	   2006;	  Haltia,	   2006;	  Mole	   et	   al.,	   2011;	  Haltia	   and	  Goebel,	   2012).	  
Indeed,	   one	   unifying	   feature	   of	   NCL	   pathogenesis	   is	   glial	   activation	   (both	  
astrocytosis	  and	  microgliosis),	  which	  differs	  between	  forms	  of	  NCLs	  in	  its	  timing	  
and	  level	  of	  activation.	  For	  instance,	  in	  CLN6	  sheep	  (a	  naturally	  occurring	  model	  
of	   variant	   LINCL)	   the	   activation	   of	   astrocytes,	   microglia	   and	   perivascular	  
macrophages	   is	   already	   apparent	   prenatally,	   hence,	   glial	   activation	   precedes	  
neuronal	  loss	  by	  several	  months	  (Oswald	  et	  al.,	  2005;	  Kay	  et	  al.,	  2006).	  In	  Ppt1-­‐/-­‐	  
mice	   (model	   of	   INCL),	   an	   early	   activation	   of	   astrocytes	   takes	   place	   before	  
neuronal	  loss,	  then	  subsequently	  activation	  of	  microglia	  is	  observed	  (Kielar	  et	  al.,	  
2007).	  Early	  glia	  activation,	  which	  occurs	  long	  before	  neuronal	  loss,	  has	  also	  been	  
reported	   in	   different	   mouse	   models	   of	   JNCL	   (Pontikis	   et	   al.,	   2004;	   2005).	  
However,	   unlike	   in	   other	   forms	   of	   NCL,	   glia	   activation	   in	   JNCL	   appears	   to	   be	  
attenuated,	  since	  astrocytes	  fail	  to	  become	  fully	  hypertrophied	  and	  up-­‐regulate	  
GFAP	  and	  microglia	  fail	  to	  transform	  fully	   into	  macrophages	  (described	  in	  more	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detail	   below)	   (Pontikis	   et	   al.,	   2004;	   Tyynelä	   et	   al.,	   2004;	   Pontikis	   et	   al.,	   2005).	  
Indeed,	  Cln3	  deficient	  microglia,	  have	  been	  shown	   to	  display	   specific	  biological	  
deficits	   in	   vitro	   further	   suggesting	   that	  microglial	   biology	   is	   altered	   in	   JNCL	   (S.	  
Dihanich,	  unpublished	  data).	  Thus,	  the	  main	  aim	  of	  this	  thesis	  was	  to	  investigate	  
the	   potential	   implications	   of	   Cln3	   deficiency	   on	   the	   biology	   of	   astrocytes,	   and	  
how	  glia	  may	  impact	  neuronal	  survival	  and	  function	  in	  this	  disease.	  
	  
JNCL	  
Worldwide,	  JNCL	  is	  the	  most	  common	  form	  of	  NCL,	  and	  it	  is	  caused	  by	  mutations	  
in	   the	  CLN3	   gene	   (International	  Batten	  Disease	  Consortium,	  1995).	   To	  date,	  57	  
disease	   causing	   mutations	   have	   been	   reported	   in	   CLN3	   (NCL	   gene	   mutation	  
database:	  http://www.ucl.ac.uk/ncl),	  with	   the	  most	   common	  mutation	   being	   a	  
1.02-­‐kb	   deletion	   (c.462-­‐677del,	   g.6060-­‐7025del)	   of	   exons	   7	   and	   8	   that	   can	   be	  
found	   in	   85-­‐90%	   of	   all	   JNCL	   alleles	   in	   homozygous	   form	   (International	   Batten	  
Disease	  Consortium,	  1995,	  Munroe	  et	  al.,	  1997,	  Kousi	  et	  al.,	  2012).	  This	  deletion	  
mutation	   results	   in	   a	   frameshift	   and	   a	   truncated	   protein.	   The	   remaining	   JNCL	  
patients	   are	   compound	   heterozygous	   for	   the	   1.02-­‐kb	   deletion	   with	   another	  
mutation	  such	  as	  a	  small	   insertion,	  deletion,	  missense,	  nonsense,	  splice	  site,	  or	  
intron	   changes	   (Mole	   et	   al.,	   2011).	   The	   incidence	   of	   JNCL	   differs	   in	   different	  
countries,	  with	  the	  highest	  incidence	  of	  7	  per	  100,000	  live	  births	  being	  observed	  
in	  Scandinavia	  (Santavuori,	  1988;	  Uvebrant	  and	  Hagberg,	  1997).	  
	  
JNCL	  pathogenesis	  
In	   JNCL	   the	   first	   symptom,	   which	   is	   typically	   the	   onset	   of	   progressive	   visual	  
failure,	  is	  observed	  between	  4	  to	  7	  years	  of	  age	  and	  leads	  eventually	  to	  blindness	  
within	   2	   to	   10	   years	   (Boustany	   et	   al.,	   1988;	   Järvelä	   et	   al.,	   1997;	   Haltia,	   2003;	  
Goebel	   and	  Wisniewski,	   2004;	  Krohne	  et	   al.,	   2010;	  Mole	  et	   al.,	   2011).	  By	  8	   -­‐	   9	  
years	   of	   age,	   progressive	   deterioration	   of	   short-­‐term	   memory	   and	   other	  
cognitive	   functions	   begins.	   Spontaneous	   epileptic	   seizures	   commonly	   appear	  
between	  7	  and	  18	  years	  of	  age,	  and	  worsen	  as	  the	  disease	  progresses	  (Järvelä	  et	  
al.,	   1997;	   Lamminranta	   et	   al.,	   2001).	   By	   their	   mid-­‐teens	   motor	   skill	   deficits	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develop	  in	  affected	  individuals,	  and	  progress	  to	  complete	  immobility.	  Generally,	  
neuroimaging	  based	  studies	  have	  revealed	  progressive	  brain	  atrophy,	  mainly	   in	  
the	   cerebral	   hemispheres,	   after	   the	   age	   of	   10-­‐12	   years	   (Raininko	   et	   al.,	   1990;	  
Autti	   et	   al.,	   1996),	   and	   the	   extent	   of	   cerebellar	   atrophy	   has	   been	   shown	   to	  
correlate	   positively	  with	   impairments	   in	  motor	   function	   (Raininko	   et	   al.,	   1990;	  
Nardocci	  et	  al.,	  1995;	  Autti	  et	  al.,	  1996).	  Additionally,	  JNCL	  patients	  experience	  a	  
range	   of	   behavioral	   and	   psychiatric	   problems	   including	   aggressiveness,	  
hallucinations,	  sleep	  problems	  and	  depression	  (Santavuori	  et	  al.,	  1993;	  Järvelä	  et	  
al.,	   1997;	   Bäckman	   et	   al.,	   2005;	   Adams	   et	   al.,	   2006).	   JNCL	   eventually	   leads	   to	  
premature	  death	  by	  the	  age	  of	  thirty	  or	  forty,	  with	  the	  mean	  age	  being	  24	  years	  
(Järvelä	  et	  al.,	  1997;	  Wisniewski	  et	  al.,	  1998).	  	  
	  
Post	   mortem	   examination	   of	   brain	   tissue	   samples	   derived	   from	   JNCL	   patients	  
have	  revealed	  that	  a	  mild	  to	  moderate	   loss	  of	  neurons	   is	  evident	   in	  all	  parts	  of	  
the	   JNCL	   brain,	   resulting	   in	   cerebral	   and	   cerebellar	   atrophy	   (Autti	   et	   al.,	   1997;	  
Haltia	  et	  al.,	  2001;	  Tyynelä	  et	  al.,	  2004).	  Selective	  neuronal	  depletion	  occurs	   in	  
cerebral	  cortical	   layers	  II	  and	  V,	  as	  well	  as	   in	  the	  corpus	  striatum	  and	  amygdala	  
with	  severe	  loss	  of	  granule	  cells	  (Braak	  and	  Goebel,	  1978;	  1979;	  Braak	  and	  Braak,	  
1993).	   Neurodegeneration	   also	   takes	   place	   in	   different	   hippocampal	   areas	  
(Tyynelä	   et	   al.,	   2004).	   Indeed,	   selective	   loss	   of	   hippocampal	   and	   cortical	   γ-­‐
aminobutyric	   acid	   (GABA)ergic	   interneurons	   is	   the	   most	   prominent	   feature	   of	  
JNCL	   pathogenesis	   (Braak	   and	   Goebel,	   1978;	   1979;	   Tyynelä	   et	   al.,	   2004).	  
Generally,	   neuronal	   loss	   seems	   to	   take	   place	   in	   brain	   regions	   where	   reactive	  
astrocytosis	   and	   microglia	   activation	   are	   also	   apparent	   (Haltia	   et	   al.,	   2001;	  
Tyynelä	   et	   al.,	   2004;	   Mole	   et	   al.,	   2011).	   The	   whole	   retina	   is	   often	   almost	  
completely	  destroyed	  and	  replaced	  by	  scar	  tissue,	  which	  is	  composed	  of	  Müeller	  
glia	  cells	  as	  well	  as	  other	  astrocytes	  (Bozorg	  et	  al.,	  2009;	  Mole	  et	  al.,	  2011).	  The	  
accumulation	  of	   storage	  material	   can	  be	   found	  within	  various	  neural	   cell	   types	  
(Palmer	  et	  al.,	  1992;	  Haltia,	  2003;	  Mole	  et	  al.,	  2011),	  but	  is	  not	  believed	  to	  be	  the	  
cause	   of	   neuronal	   loss,	   suggesting	   that	   additional	   mechanisms	   facilitate	  
neurodegeneration	   in	  JNCL	  (Autti	  et	  al.,	  1997;	  Tyynelä	  et	  al.,	  2004;	   Jalanko	  and	  
Braulke,	   2009;	  Mole	   et	   al.,	   2011).	   Another	   specific	   feature	   of	   JNCL	   patients	   is	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their	   autoimmune	   response	   demonstrated	   by	   the	   occurrence	   of	   circulating	  
autoantibodies	   against	   glutamic	   acid	   decarboxylase	   (GAD65)	   and	   other	  
unidentified	  antigens	   in	  the	  brain	  (Chattopadhyay	  et	  al.,	  2004;	  Lim	  et	  al.,	  2006;	  
Castaneda	  et	  al.,	  2008).	  	  	  
Lessons	  learned	  from	  different	  mouse	  models	  of	  JNCL	  
To	  date	  different	  gene	   targeting	   strategies	  have	  been	  applied	   to	  generate	   four	  
different	  mouse	  models	   for	   JNCL,	  Cln3Δex1-­‐6	   (Cln3-­‐/-­‐)	  knock-­‐out	  mice,	   the	  model	  
used	  for	  studies	  described	  in	  this	  thesis	  (Mitchison	  et	  al.,	  1999),	  Cln3Δex7-­‐8	  knock-­‐
out	  mouse	  (Katz	  et	  al.,	  1999),	  the	  Cln3Δex7/8	  knock-­‐in	  mouse	  (Cotman	  et	  al.,	  2002)	  
and	  Cln3lacZ	  β-­‐galactosidase	  reporter	  mice	  (Eliason	  et	  al.,	  2007).	  The	  Cln3-­‐/-­‐	  model	  
represents	  a	  null-­‐allele	  model	  (Mitchison	  et	  al.,	  1999),	  and	  the	  two	  other	  models	  
represent	   replications	   of	   the	   most	   common	   disease-­‐causing	   1.02kb	   CLN3	  
deletion	  (Katz	  et	  al.,	  1999;	  Cotman	  et	  al.,	  2002).	  
	  
All	   of	   these	   mouse	   models	   exist	   on	   the	   same	   strain	   background	   and	   have	  
phenotypes	   that	   resemble	   those	   in	   human	   JNCL	   patients,	   making	   them	   all	  
acceptable	   models	   of	   this	   disease.	   For	   instance,	   accumulation	   of	   storage	  
material,	   glial	   response	   accompanied	   by	   neurodegeneration	   and	   variable	  
neurological	   defects	   associated	  with	   onset	   and	   disease	   progression	   have	   been	  
reported	   in	   these	   different	   models	   (Katz	   et	   al.,	   1999;	   Mitchison	   et	   al.,	   1999;	  
Chattopadhyay	  et	  al.,	  2002;	  Cotman	  et	  al.,	  2002;	  Kovács	  et	  al.,	  2006;	  Eliason	  et	  
al.,	  2007;	  Katz	  et	  al.,	  2008;	  Osório	  et	  al.,	  2009;	  Weimer	  et	  al.,	  2009).	  For	  example,	  
severe	  loss	  of	  Purkinje	  cells	  accompanied	  by	  activated	  cerebellar	  Bergmann	  glia	  
(type	  of	  astrocyte)	  in	  the	  cerebellum	  of	  Cln3-­‐/-­‐	  mice	  has	  been	  shown	  to	  precede	  
deficits	   in	   motor	   coordination	   and	   balance,	   providing	   a	   link	   between	   glial	  
mediated	  neuronal	   loss	  and	  decline	   in	  motor	  skills	   in	   JNCL	  (Kovács	  et	  al.,	  2006;	  
Weimer	  et	  al.,	  2009).	  Variable	  visual	  defects	  have	  been	  reported	  in	  these	  models	  
(Seigel	  et	  al.,	  2002;	  Sappington	  et	  al.,	  2003;	  Weimer	  et	  al.,	  2006;	  Katz	  et	  al.,	  2008;	  
Osório	   et	   al.,	   2009).	   Decreased	   optic	   nerve	   axon	   density	   and	   myelination,	  
together	  with	   impaired	   fast	  axonal	   transport	  of	  amino	  acids	  and	  altered	  action	  
potentials	  have	  been	  reported	  in	  Cln3-­‐/-­‐	  mice,	  and	  propose	  that	  visual	  defects	  in	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JNCL	  are	  caused	  by	  pathological	  events	  taking	  place	  outside	  the	  retina,	  perhaps	  
in	  the	  thalamic	  nuclei	  that	  receive	  retinal	  input	  (Sappington	  et	  al.,	  2003;	  Weimer	  
et	  al.,	  2006).	  However,	  impaired	  retinal	  function	  has	  been	  shown	  in	  the	  Cln3Δex7/8	  
knock-­‐in	   mouse	   model	   (Cotman	   et	   al.,	   2002).	   Autoantibodies	   and	   loss	   of	  
GABAergic	   interneurons,	   two	   typical	   pathological	   features	   observed	   in	   JNCL	  
patients,	   have	   also	   been	   reported	   in	   Cln3-­‐/-­‐	   mice	   (Mitchison	   et	   al.,	   1999;	  
Chattopadhyay	  et	  al.,	  2002;	  Pontikis	  et	  al.,	  2004;	  Castaneda	  et	  al.,	  2008).	  	  
	  
An	   important	   observation	   in	   two	   of	   the	   most-­‐studied	   models	   (Cln3-­‐/-­‐	   and	  
Cln3Δex7/8	   knock-­‐in	   mouse)	   was	   that	   glial	   activation	   occurs	   early	   in	   disease	  
progression	  and	   takes	  place	   in	   specific	  brain	   regions	  prior	   to	  any	  neuronal	   loss	  
(Pontikis	  et	  al.,	  2004;	  2005;	  Weimer	  et	  al.,	  2009).	  Detailed	  studies	  in	  Cln3-­‐/-­‐	  mice	  
revealed	   up-­‐regulation	   of	   markers	   of	   astrocytosis	   and	   microglia	   activation	   in	  
presymptomatic	   Cln3-­‐/-­‐	   mice	   (5	   months	   of	   age),	   prior	   to	   loss	   of	   GABAergic	  
interneurons	   in	   the	  hippocampus	  and	  neocortex	   (evident	  at	  14	  months	  of	  age)	  
(Pontikis	  et	  al.,	  2004).	  Furthermore,	   in	  the	  cerebellum	  of	  Cln3-­‐/-­‐	  mice,	  activated	  
Bergmann	  glial	  cells	  could	  be	  found	  bordering	  regions	  where	  Purkinje	  cells	  were	  
nearly	   completely	   lost	   (Weimer	   et	   al.,	   2009).	   Additionally,	   neuritogenesis	   was	  
found	   to	  be	  defective	   in	   the	   surviving	  Purkinje	   cells,	  with	   these	  cells	  exhibiting	  
dendritic	   mis-­‐orientation	   and	   altered	   dendritic	   spine	   density	   (Weimer	   et	   al.,	  
2009).	   This	   activation	   of	   glia	   and	   loss	   of	   Purkinje	   cells,	   in	   addition	   to	   altered	  
Purkinje	   cell	   dendritic	   spine	   morphology	   occurs	   before	   deficits	   in	   motor	  
coordination	   and	   balance	   become	   apparent	   (Kovács	   et	   al.,	   2006).	   Thus,	   it	  
appears	   that	   early	   glial	   activation	   precedes	   selective	   neuronal	   loss	   leading	  
eventually	  to	  the	  typical	  clinical	  manifestations	  observed	  in	  JNCL.	  	  
	  
The	  topology	  and	  intracellular	  localization	  of	  CLN3	  
CLN3	  encodes	  a	  438-­‐amino	  acid	  protein	  with	  a	  predicted	  molecular	  weight	  of	  43	  
kilodaltons	  (kDa),	  expressed	  throughout	  the	  whole	  body	  including	  muscle,	  brain	  
and	  lungs	  (Margraf	  et	  al.,	  1999;	  Stein	  et	  al.,	  2010;	  Ding	  et	  al.,	  2011).	  Overall,	  the	  
mRNA	  levels	  for	  CLN3	  in	  the	  central	  nervous	  system	  (CNS)	  are	  relatively	  low,	  with	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the	   highest	   expression	   being	   observed	   in	   the	   gastrointestinal	   tract	   and	   in	  
secretory/glandular	   tissue	   around	   birth	   (The	   International	   Batten	   Disease	  
Consortium	  1995;	  Pane	  et	  al.,	  1999;	  Chattopadhyay	  and	  Pearce,	  2000).	  CLN3	  has	  
no	   identified	  homologous	  proteins,	  or	  functional	  domains,	  however,	  CLN3	  does	  
display	   some	   similarity	   with	   fatty	   acid	   desaturases	   and	   with	   the	   equilibrative	  
nucleoside	  transporter	  family	  SLC29	  (Baldwin	  et	  al.,	  2004;	  Narayan	  et	  al.,	  2006b).	  
Despite	   the	   lack	   of	   homology	   with	   other	   proteins,	   CLN3	   is	   highly	   conserved	  
across	   species,	   highlighting	   the	   fundamental	   role	   this	   protein	   must	   play	  
(Taschner	  et	  al.,	  1997;	  Muzaffar	  and	  Pearce,	  2008).	  The	  membrane	  topology	  of	  
the	  human	  CLN3	  has	  been	  extensively	  studied	  (Mitchison	  et	  al.,	  1997;	  Ezaki	  et	  al.,	  
2003;	  Mao	  et	  al.,	  2003;	  Kyttälä	  et	  al.,	  2004;	  Nugent	  et	  al.,	  2008),	  and	  according	  to	  
current	   consensus,	   CLN3	   contains	   multiple	   membrane	   spanning	   domains	  
(predicted	  4-­‐10)	  with	   its	   carboxy	   terminus	   facing	   the	  cytoplasmic	   side	   (Ezaki	  et	  
al.,	   2003;	   Kyttälä	   et	   al.,	   2004;	   Nugent	   et	   al.,	   2008).	   The	   positioning	   of	   the	   N-­‐
terminus	  is	  still	  under	  debate,	  but	  based	  on	  in	  vivo	  data	  this	  is	  also	  thought	  to	  be	  
cytoplasmic	  making	  CLN3,	  most	  likely,	  a	  type	  III	  transmembrane	  protein	  (Ezaki	  et	  
al.,	  2003;	  Kyttälä	  et	  al.,	  2004;	  2005).	  However,	  uncertainty	  will	  remain	  until	  the	  
crystal	   structure	   of	   CLN3	   is	   available.	   Additionally,	   several	   predicted	  
posttranslational	   modifications,	   such	   as	   glycosylation,	   prenylation,	  
myristoylation	   and	   phosphorylation	   may	   alter	   the	   topological	   organization	   of	  
CLN3	   (Pullarkat	   and	   Morris,	   1997;	   Järvelä	   et	   al.,	   1998;	   Golabek	   et	   al.,	   1999;	  
Kaczmarski	  et	  al.,	  1999;	  Ezaki	  et	  al.,	  2003;	  Mao	  et	  al.,	  2003;	  Storch	  et	  al.,	  2007;	  
Nugent	  et	  al.,	  2008).	  For	  example,	  CLN3	  has	  been	  shown	  to	  undergo	  prenylation,	  
which	   refers	   to	   the	  addition	  of	  hydrophobic	  molecules	   to	  a	  protein,	   leading	   to	  
facilitation	   of	   CLN3’s	   membrane	   interactions	   and	   trafficking	   along	   the	  
endo/lysosomal	   compartments	   (Pullarkat	   and	   Morris,	   1997;	   Kaczmarski	   et	   al.,	  
1999;	  Storch	  et	  al.,	  2007).	  Overall,	  such	  posttranslational	  modifications	  appear	  to	  
be	  tissue	  -­‐	  and	  cell	  type-­‐specific,	  since	  mass	  spectrometric	  analysis	  has	  indicated	  
that	   the	   glycosylation	   of	   CLN3	   varies	   in	   different	   tissues	   (Ezaki	   et	   al.,	   2003),	  
perhaps	  suggesting	  differential	  roles	  for	  CLN3	  in	  different	  cell-­‐types	  and	  tissues.	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Due	   to	   its	   low	   expression	   levels	   and	   the	   highly	   hydrophobic	   nature	   of	   CLN3	  
producing	   antibodies	   against	   this	   protein	   has	   been	   highly	   challenging.	   Hence,	  
determining	   the	   precise	   localization	   of	   this	   protein	   in	   different	   cell	   types	   has	  
been	   problematic,	   and	   this	   has	   hindered	   progress	   towards	   discovering	   the	  
precise	   function	   of	   CLN3	   (Phillips	   et	   al.,	   2005;	   Getty	   and	   Pearce,	   2011).	  
Localization	  studies	  have	  been	  conducted	  using	  a	  wide	  range	  of	  techniques	  and	  
by	  using	  different	  CLN3	  antibodies,	   epitope	   tags	   and	  expression	   constructs.	   To	  
date,	   many	   studies	   propose	   that	   the	   primary	   location	   of	   CLN3	   in	   mammalian	  
cells	   is	   LEs/lysosomes	   (Fossale	   et	   al.,	   2004;	   Storch	   et	   al.,	   2004;	   Phillips	   et	   al.,	  
2005;	   Storch	   et	   al.,	   2007;	   Tuxworth	   et	   al.,	   2009;	   Getty	   and	   Pearce,	   2011;	  
Tuxworth	   et	   al.,	   2011)	   and	   that	   transport	   to	   these	   compartments	   may	   be	  
facilitated	  by	  interactions	  between	  CLN3	  and	  the	  adaptor	  proteins	  AP-­‐1	  and	  AP-­‐3	  
(Kyttälä	   et	   al.,	   2005).	   In	   addition,	   CLN3	   has	   been	   proposed	   to	   localize	   to	  
numerous	   other	   intracellular	   compartments	   including	   the	   ER,	   EEs,	   recycling	  
endosomes,	   Golgi,	   nucleus,	   lipid	   rafts,	   cytoplasm,	   mitochondria,	   neuronal	  
processes,	   synaptosomes	   and	   the	   plasma	   membrane	   (proposed	   cellular	  
localization,	   functions,	   and	   interaction	   partners	   of	   CLN3	   are	   summarized	   in	  
Figure	   1.2)	   (Katz	   et	   al.,	   1997;	   Järvelä	   et	   al.,	   1999;	   Kremmidiotis	   et	   al.,	   1999;	  
Margraf	   et	   al.,	   1999;	   Luiro	   et	   al.,	   2001;	   Phillips	   et	   al.,	   2005;	  Getty	   and	   Pearce,	  
2011).	  Whether	  CLN3	  is	  expressed	  or	  is	  actively	  functioning	  in	  any	  other	  cellular	  
compartments,	   except	   in	   LEs/lysosomes,	   is	   still	   unknown.	   Interestingly,	   in	  
neurons,	   in	   addition	   to	   being	   located	   in	   LEs/lysosomes	   CLN3	   has	   also	   been	  
localized	   to	   neuronal	   processes	   and	   synaptosomes;	   particularly	   in	   EEs,	  
presynaptic	   vesicles,	   and	   in	  vesicles	   that	   remain	   to	  be	   identified	   (Järvelä	  et	  al.,	  
1999;	  Haskell	  et	  al.,	  2000;	  Luiro	  et	  al.,	  2001;	  Fossale	  et	  al.,	  2004;	  Kyttälä	  et	  al.,	  
2004;	  Storch	  et	  al.,	  2004).	  This	  distribution	  would	  suggest	  a	  neuron-­‐specific	  role	  
for	   CLN3	   relating	   to	   synaptic	   functioning/transmission.	  However,	   it	   is	   plausible	  
that	  some	  of	  the	  proposed	  localizations	  of	  CLN3	  may	  be	  false	  positives	  caused	  by	  
lack	   of	   good	   CLN3	   antibodies,	   mislocalization	   in	   over-­‐expression	   studies	   and	  
interference	  with	  the	  normal	  targeting	  of	  CLN3	  in	  studies	  were	  terminal	  epitope	  
tags	  are	  applied	  (Phillips	  et	  al.,	  2005).	  Currently,	  there	  is	  no	  information	  available	  
on	  the	  specific	  localization	  of	  CLN3	  in	  glial	  cells.	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The	  proposed	  functions	  of	  CLN3	  
A	   crucial	   step	   in	   understanding	   the	   molecular	   basis	   of	   JNCL	   is	   to	   identify	   the	  
precise	  function	  of	  CLN3.	  To	  data,	  the	  exact	  function	  of	  the	  highly	  hydrophobic	  
CLN3	  protein	  remains	  unresolved	  despite	  a	  decade	  of	  intensive	  research	  into	  the	  
primary	  cause	  of	  JNCL.	  This	  is	  because,	  as	  stated	  above,	  the	  hydrophobic	  nature	  
of	  this	  protein	  has	  hindered	  the	  development	  of	  sufficiently	  specific	  monoclonal	  
or	   polyclonal	   antibodies	   against	   native	   CLN3,	  making	   the	   validation	   of	   cellular	  
topology,	   localization	   and	   identification	   of	   interaction	   partners	   by	   co-­‐
immunoprecipitation	   and	   colocalization	   challenging	   in	   mammalian	   cells.	  
However,	   using	   a	   range	   of	   animal/yeast	   models	   various	   functions	   have	   been	  
attributed	   to	   CLN3,	   including	   autophagy,	   intracellular	   trafficking,	   regulation	   of	  
lysosomal	   pH	   and	   size,	   processing	   of	   lysosomal	   proteins,	   arginine	  metabolism,	  
mitochondrial	   function,	   apoptotic	   pathway	   regulation,	   lipid	   metabolism	   and	  
oxidative	  homeostasis	  (summarized	  in	  Figure	  1.2)	  (Getty	  and	  Pearce,	  2011;	  Mole	  
et	  al.,	  2011).	  Indeed,	  the	  primary	  function	  of	  CLN3	  may	  have	  a	  knock	  on	  effect	  on	  
several	  pathways,	  or	  CLN3	  may	  have	  several	  primary	  functions	  each	  affecting	  a	  
different	   pathway	   and	   some	   of	   these	   may	   be	   cell-­‐type	   specific.	   The	   potential	  
functions	   of	   CLN3	   and	   their	   roles	   in	   JNCL	   pathogenesis	   are	   described	   below.	  
Additionally,	   these	   functions	   may	   be	   linked	   with	   pathways	   mediated	   by	  
numerous	  interaction	  partners	  of	  CLN3	  (described	  below).	  	  	  
Autophagy.	   The	   intralysosomal	   accumulation	   of	   mitochondrial	   ATP	   synthase	  
subunit	  C	  upon	  CLN3	  deficiency	  potentially	  links	  the	  functional	  role	  of	  CLN3	  with	  
autophagy,	  since	  autophagy	  is	  essential	  for	  mitochondrial	  turnover	  (Rubinsztein	  
et	   al.,	   2005).	   Indeed,	   CLN3	  has	   been	   linked	  with	   autophagosomal	  membranes,	  
and	  the	  buildup	  of	  subunit	  c	  protein	  has	  been	  found	  in	  autophagic	  vacuoles	  and	  
lysosomes	  by	  means	  of	   immunoblotting	   (Fossale	  et	  al.,	  2004;	  Cao	  et	  al.,	  2006).	  
Moreover,	   in	   Cln3Δex7/8	   mice,	   CLN3	   deficiency	   has	   been	   shown	   to	   impair	   the	  
maturation	   of	   autophagosomes	   based	   on	   their	   ultrastructural	   morphology,	  
leading	   to	   activation	   of	   autophagy	   based	   on	   an	   increased	   LC3-­‐II/LC3-­‐I	   ratio	  
(autophagy	  marker,	  microtubule-­‐associated	  protein	  I	   light	  chain	  3;	  LC3).	  Studies	  
on	  cerebellar	  neuronal	  cell	  cultures	  derived	  from	  Cln3Δex7/8	  mice	  suggest	  that	  this	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protein	   may	   also	   be	   involved	   in	   the	   trafficking	   of	   autophagic	   vacuoles	   to	   the	  
perinuclear	  region	  where	  the	  fusion	  with	  LEs/lysosomes	  takes	  place	  (Cao	  et	  al.,	  
2006).	   The	   suggested	   link	   between	   CLN3	   and	   autophagy	   is	   supported	   by	  
experiments	   where	   restoring	   autophagy	   in	   cerebellar	   Cln3Δex7/8	   cells	   using	  
lithium,	   or	   an	   inositol	   monophosphatase	   (IMPase)	   inhibitor	   called	   L690,330	  
(Sarkar	  et	  al.,	  2005),	  resulted	  in	  protection	  of	  these	  cells	  from	  cell	  death	  induced	  
by	   amino	   acid	   deprivation	   (Chang	   et	   al.,	   2011).	   Thus,	   defects	   in	   autophagy	  
particularly	   in	  CLN3	  neurons	  may	   increase	   their	   susceptibility	   to	   cell	  death	  and	  
be	  a	  key	  element	  in	  neuronal	  pathogenesis	  in	  JNCL.	  	  
Intracellular	  trafficking.	  In	  addition	  to	  disrupted	  autophagy,	  CLN3	  deficiency	  has	  
been	   linked	  with	   a	   number	   of	   disrupted	   intracellular	   trafficking	   processes.	   For	  
instance,	   Cln3-­‐silenced	   HeLa	   cells	   displayed	   an	   impaired	   exit	   of	   mannose	   6-­‐
phosphate	   receptor	   from	   the	   TGN	   (Metcalf	   et	   al.,	   2008).	   Further,	   an	   altered	  
localization	   of	   LEs/lysosomes	   together	   with	   impaired	   endocytosis	   has	   been	  
reported	   in	   cerebellar	   neuronal	   Cln3Δex7/8	   precursor	   cells	   (Fossale	   et	   al.,	   2004;	  
Cao	  et	  al.,	  2011).	  Finally,	  fast	  axonal	  transport	  of	  amino	  acids	  in	  the	  optic	  nerves	  
of	  Cln3-­‐/-­‐	  mice	   is	   attenuated	   (Weimer	   et	   al.,	   2006).	   This	  may	   lead	   to	   impaired	  
communication	   between	   the	   retina	   and	   projection	   nuclei	  within	   the	   thalamus,	  
resulting	   in	   a	   reduced	   number	   of	   neurons	   within	   the	   dorsal	   lateral	   geniculate	  
nucleus	   (LGNd)	   in	   Cln3-­‐/-­‐	   mice	   (Weimer	   et	   al.,	   2006).	   Hence,	   a	   lack	   of	   axonal	  
transport	  may	  provide	  a	  mechanistic	  explanation	  for	   the	  visual	  deficits	   in	   JNCL.	  
Overall,	  it	  appears	  that	  CLN3	  may	  be	  required	  for	  intracellular	  trafficking	  of	  both	  
cellular	  organelles	  and	  small	  molecules.	  	  	  
Lysosome	  related	  functions.	  In	  the	  budding	  yeast,	  S.	  cerevisiae,	  deletion	  of	  BTN1	  
(homologue	   of	   Cln3)	   results	   in	   a	   reduced	   vacuolar	   pH	   (Croopnick	   et	   al.,	   1998;	  
Pearce	   and	   Sherman,	   1998;	   Pearce	   et	   al.,	   1999a),	   while	   in	   the	   fission	   yeast	   S.	  
pombe	   an	   increased	   lysosomal	   pH	   is	   observed	   (Gachet	   et	   al.,	   2005).	   Despite	  
these	   contrasting	   results,	   these	   experiments	   suggest	   that	   the	   btn1	   protein	   is	  
involved	  in	  vacuolar	  pH	  maintenance	  (Pearce	  and	  Sherman,	  1998;	  Pearce	  et	  al.,	  
1999a;	   1999b;	   Gachet	   et	   al.,	   2005).	   Furthermore,	   elevated	   lysosomal	   pH	   is	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evident	   in	   fibroblasts	  derived	  from	  JNCL	  patients	   (Holopainen	  et	  al.,	  2001).	  The	  
size	   of	   lysosomes	   has	   also	   been	   shown	   to	   be	   affected	   by	   alterations	   in	   CLN3	  
expression	  (Golabek	  et	  al.,	  2000;	  Holopainen	  et	  al.,	  2001;	  Kitzmüller	  et	  al.,	  2008)	  
and	  a	  number	  of	  reports,	  using	  mouse	  models,	  human	  cell	  lines	  and	  post	  mortem	  
tissue,	   have	   revealed	   changes	   in	   both	   the	   activity	   and	   processing	   of	   lysosomal	  
proteins,	  such	  as	  cathepsins	   (mutated	   in	  congenital	  NCL)	  and	  TPP1	  (mutated	   in	  
late	  infantile	  NCL)	  with	  CLN3	  deficiency	  (Prasad	  and	  Pullarkat,	  1996;	  Sleat	  et	  al.,	  
1998;	   Junaid	   and	   Pullarkat,	   1999;	  Mitchison	   et	   al.,	   1999;	   Golabek	   et	   al.,	   2000;	  
Fossale	  et	  al.,	  2004;	  Eliason	  et	  al.,	  2007;	  Metcalf	  et	  al.,	  2008).	  Lysosomal	  import	  
of	   arginine	   was	   demonstrated	   to	   be	   attenuated	   in	   JNCL	   patient	   lymphoblasts	  
(Ramirez-­‐Montealegre	  and	  Pearce,	  2005),	  moreover,	  alterations	  in	  mitochondrial	  
arginine	  metabolism,	  as	  well	  as	   in	  plasma	  membrane	  arginine	  uptake,	   in	  Cln3-­‐/-­‐	  
mice	   link	   CLN3	   functioning	  with	   the	   regulation	   of	   cellular	   arginine	  metabolism	  
(Chan	  et	  al.,	  2009).	  For	  instance,	  altered	  arginine	  levels	  may	  cause	  the	  observed	  
changes	  in	  the	  activities	  of	  the	  urea	  cycle	  enzymes	  associated	  with	  the	  citrulline-­‐
nitric	  oxide	   (NO)	   recycling	  pathway	  and	  alterations	   in	   regulation	  of	  nitric	  oxide	  
synthase	  (NOS)	  in	  Cln3-­‐/-­‐	  mice	  (Chan	  et	  al.,	  2009).	  Overall,	  these	  studies	  highlight	  
the	  range	  of	   lysosomal	   functions	  attributed	  to	  CLN3,	  which	  may	  act	  to	  catalyze	  
the	  neuropathological	  events	  observed	   in	   JNCL.	   For	  example,	  alterations	   in	  NO	  
signaling	  have	   the	  potential	   to	  alter	   a	   range	  of	  physiological	  processes	   such	  as	  
apoptosis,	   synaptic	   function	   and	   immune	   response	   (Garthwaite	   and	   Boulton,	  
1995;	   Szabó,	   1996;	   Prast	   and	   Philippu,	   2001;	   Holán	   et	   al.,	   2002;	   Bronte	   and	  
Zanovello,	  2005;	  Guix	  et	  al.,	  2005).	  	  	  
Proteolipid	  modifications.	   It	   has	   been	   speculated,	   based	  on	   sequence	   analysis	  
and	  gas	  chromatography/mass	  spectrometry	  desaturase	  assays,	   that	  CLN3	  may	  
be	   a	   novel	   palmitoyl-­‐protein	   Δ9-­‐desaturase,	   which	   converts	   membrane-­‐
associated	   palmitoylated	   proteins	   to	   their	   respective	   palmitoleated	   products,	  
(Narayan	   et	   al.,	   2006b;	   2008).	   Thus,	   CLN3	   may	   potentially	   be	   involved	   in	  
proteolipid	  modifications.	  Furthermore,	  metabolic	  labeling	  of	  fibroblasts	  derived	  
from	   JNCL-­‐patients	   revealed	   that	   CLN3	   may	   be	   involved	   in	   phospholipid	  
bis(monoacetylglyceryl)phosphate	   (BMP)	   synthesis	   (Hobert	   and	   Dawson,	   2007)	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contributing	   to	   the	   determination	   of	   membrane	   properties	   of	   intracellular	  
organelles.	   For	   instance,	   negatively	   charged	   BMP	   may	   participate	   in	   the	  
degradation	  of	  lipids	  and	  membranes	  at	  the	  interface	  of	  the	  inner	  membranes	  of	  
lysosomes	   by	   facilitating	   the	   adhesion	   of	   the	   positively	   charged	   soluble	  
lysosomal	   proteins	   (Gallala	   and	   Sandhoff,	   2011).	   Thus,	   mutated	   human	   CLN3	  
could	   participate	   in	   lysosomal	   pathogenesis	   via	   altering	   membrane	   lipid	  
metabolism.	  	  
Oxidative	   homeostasis.	   Increased	   protein	   oxidation,	   possibly	   arising	   from	  
significant	   alterations	   in	   the	   levels	   of	   pro-­‐and	   antioxidant	   molecules,	   such	   as	  
decreased	   levels	   of	   glutathione	   (major	   antioxidant	   in	   the	   brain),	   have	   been	  
observed	   in	   the	   CNS	   of	   both	  Cln3-­‐/-­‐	   and	  Cln3Δex7/8	   mice	   (Benedict	   et	   al.,	   2007;	  
Weimer	   et	   al.,	   2007;	   Herrmann	   et	   al.,	   2008).	   Additionally,	   oxidative	   stress	  
induced	  cell	  death	  was	  observed	  to	  be	  accelerated	   in	  cerebellar	  precursor	  cells	  
derived	   from	   Cln3Δex7/8	   mice	   (Fossale	   et	   al.,	   2004),	   and	   Drosophila	   lacking	  
functional	   CLN3	   were	   shown	   to	   be	   hypersensitive	   to	   oxidative	   stress,	   while	  
responding	   normally	   to	   other	   kinds	   of	   physiological	   stresses	   (Tuxworth	   et	   al.,	  
2011).	   Taken	   together,	   CLN3	   appears	   to	   be	   required	   for	  managing	   the	   cellular	  
response	   to	   oxidative	   stress,	   possibly	   via	   affecting	   antioxidant	   production	   and	  
this	  may	  contribute	  to	  neuronal	  degeneration	  in	  JNCL.	  
Neuronal	   activity	   altering	   functions.	   Increasing	   evidence	   links	   CLN3	   with	  
neuronal	   cell	   communication.	   Autoantibodies	   detected	   against	   GAD65,	   an	  
enzyme	   that	   converts	   the	   excitatory	   neurotransmitter	   glutamate	   to	   the	  
inhibitory	  neurotransmitter	  GABA,	   could	   result	   in	   the	  decreased	  activity	  of	   this	  
enzyme	   in	   the	   Cln3-­‐/-­‐	   mouse	   brain	   (Chattopadhyay	   et	   al.,	   2002;	   Pears	   et	   al.,	  
2005).	   This	   may	   be	   one	   the	   reasons	   behind	   diminished	   GABA	   production	   and	  
elevated	  presynaptic	   levels	  of	   glutamate	   in	   these	  brains,	  which	   in	   turn	  may	  be	  
linked	   to	   the	   preferential	   loss	   of	   GABAergic	   neurons	   observed	   in	   both	   JNCL	  
patients	  and	  Cln3-­‐/-­‐	  mice	  (Braak	  and	  Goebel,	  1978;	  1979;	  Mitchison	  et	  al.,	  1999;	  
Chattopadhyay	   et	   al.,	   2002;	   Pontikis	   et	   al.,	   2004;	   Tyynelä	   et	   al.,	   2004).	   In	  
addition,	  cerebellar	  granule	  cells	  derived	  from	  Cln3-­‐/-­‐	  and	  Cln3Δex7/8	  mice	  exhibit	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particular	   vulnerability	   to	   2-­‐amino-­‐3-­‐(5-­‐methyl-­‐3-­‐oxo-­‐1,2-­‐oxazol-­‐4-­‐yl)	   propanoic	  
acid	  (AMPA)	  and/or	  N-­‐Methyl-­‐D-­‐aspartic	  acid	  (NMDA)-­‐type	  glutamate	  receptor-­‐
mediated	  excitotoxic	  insults	  (Kovács	  et	  al.,	  2006;	  Kovács	  and	  Pearce,	  2008;	  Finn	  
et	  al.,	  2011).	   Indeed,	  selective	   inhibition	  of	  AMPA	  receptors	   in	  Cln3-­‐/-­‐	  mice	  was	  
shown	  to	  lead	  to	  improvements	  in	  the	  motor	  function	  (Kovács	  and	  Pearce,	  2008;	  
Kovács	  et	  al.,	  2011).	  Furthermore,	   the	   receptor	  binding	  sites	  of	  cholinergic	  and	  
glutamergic	  receptors	  were	  shown	  to	  be	  reduced	  in	  Cln3Δex7/8	  mice	  (Herrmann	  et	  
al.,	  2008),	  and	  the	  reduced	  expression	  of	  dopamine	  transporters	  and	  receptors	  
in	   JNCL	   patients	   in	   various	   brain	   regions	   provides	   additional	   evidence	   for	  
disrupted	   neuronal	   communication	   (Ruottinen	   et	   al.,	   1997;	   Aberg	   et	   al.,	   2000;	  
Rinne	  et	  al.,	  2002).	  Finally,	  early	  abnormalities	   in	  dopamine	  catabolism,	  causing	  
neuronal	  loss	  in	  the	  substantia	  nigra,	  has	  also	  been	  demonstrated	  to	  precede	  the	  
development	  of	  motor	  deficits	   in	  Cln3-­‐/-­‐	  mice	   (Weimer	  et	  al.,	  2007).	  Therefore,	  
several	   lines	  of	  evidence	  propose	  that	  CLN3	   is	  an	  essential	  part	  of	   the	  complex	  
regulatory	   processes	   involved	   in	   neuronal	   activity	   and	   information	   processing.	  
However,	   the	  mechanisms	  behind	  this,	  and	  how	  they	  may	  relate	   to	   the	  clinical	  
manifestations	  of	  JNCL	  remain	  elusive.	  
In	  conclusion,	  CLN3	  has	  been	  proposed	  to	  have	  multiple	   functions,	  which	  most	  
likely	   display	   cellular	   specificity.	   However,	   the	   primary	   function	   of	   this	   protein	  
remains	  unknown,	  given	  that	  the	  lack	  of	  specific	  antibodies	  has	  made	  conducting	  
experiments	   to	   determining	   the	   localization,	   trafficking	   and	   overall	   function	   of	  
CLN3	  difficult.	  Broadly,	  it	  appears	  that	  CLN3	  may	  play	  a	  role	  in	  the	  trafficking	  of	  
subcellular	   organelles	   and	   maintenance	   of	   cellular	   homeostasis.	   Research	   has	  
also	  provided	  some	  evidence	  that	  CLN3	  may	  have	  multiple	  interaction	  partners,	  
which	  may	  mediate	   the	  observed	  participation	  of	   this	  protein	   in	   the	  numerous	  
biological	  processes	  described.	  	  
Protein	  interaction	  partners	  of	  CLN3	  
By	   applying	   different	   techniques,	   such	   as	   a	   yeast-­‐2-­‐hybrid	   (Y2H)	   screen,	  
mammalian	   two-­‐hybrid	   and	   GST-­‐pull	   down	   assays,	   many	   protein	   interaction	  
partners	   of	   CLN3	   have	   been	   proposed,	   which	   in	   turn	   have	   highlighted	   the	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potential	   involvement	  of	  this	  protein	   in	  a	  range	  of	  cellular	   functions	  (Phillips	  et	  
al.,	  2005;	  Getty	  and	  Pearce,	  2011;	  Mole	  et	  al.,	  2011;	  Uusi-­‐Rauva	  et	  al.,	  2012).	  For	  
instance,	   CLN3	   appears	   to	   interact	  with	   the	   cytoskeletal	   protein	  β-­‐fodrin	   (β-­‐II-­‐
spectrin	  chain)	  and	  the	  associated	  multifunctional	  Na+-­‐K+-­‐ATPase	  complex	  (Uusi-­‐
Rauva	  et	  al.,	  2008).	  Via	  β-­‐fodrin,	  CLN3	  might	  also	  be	  indirectly	  connected	  to	  actin	  
and	   centractin	   (ARP1),	   creating	   not	   only	   a	   link	   between	   CLN3	   and	   the	  
cytoskeleton,	   but	   also	   with	   dynein,	   myosin	   and	   maybe	   other	   motor	   proteins	  
involved	   in	   intracellular	   transport	   (Beck	   and	   Nelson,	   1996;	   De	   Matteis	   and	  
Morrow,	   2000;	   Bennett	   and	   Baines,	   2001).	   It	   has	   been	   demonstrated	   that	   β-­‐
fodrin	  architecture	  was	  altered	  in	  both	  JNCL	  patient	  fibroblasts	  and	  Cln3-­‐/-­‐	  mouse	  
brain	   sections	   (Uusi-­‐Rauva	   et	   al.,	   2008).	   However,	   abnormal	   β-­‐fodrin	  
cytoarchitecture	  did	  not	  lead	  to	  an	  altered	  ion	  pumping	  activity	  of	  the	  associated	  
Na+-­‐K+-­‐ATPase	   complex	   in	   Cln3-­‐/-­‐	   primary	   embryonic	   (E16.5)	   cortical	   neuronal	  
cultures.	   Instead,	   endocytosis,	   and	   thus	   the	   plasma	   membrane-­‐associated	  
expression	   of	   this	   ATPase,	   explored	   by	   means	   of	   TIRF-­‐microcopy,	   was	  
significantly	   altered.	   Thus,	   CLN3	   could	   be	   involved	   in	   the	   formation	   of	   a	  
multiprotein	  complex	  with	  β-­‐fodrin	  and	  Na+-­‐K+-­‐ATPase	  at	  the	  plasma	  membrane	  
(Nelson	  and	  Hammerton,	  1989;	  Uusi-­‐Rauva	  et	  al.,	  2008;	  Kizhatil	  et	  al.,	  2009).	  The	  
activity	   of	   this	   Na+-­‐K+-­‐ATPase	   is	   responsible	   for	  maintaining	   the	   relatively	   high	  
concentrations	  of	  intracellular	  potassium,	  but	  low	  concentrations	  of	  sodium	  ions,	  
found	   in	   resting	  neurons	   (resting	  potential),	   and	   for	   returning	  neurons	  back	   to	  
baseline	  after	  depolarization	  (Rakowski	  et	  al.,	  1989;	  Wright,	  2004).	  Additionally,	  
the	  different	  functional	  subunits	  (α,	  β	  and	  the	  auxiliary	  FXYD	  protein	  subunits)	  of	  
this	  Na+-­‐K+-­‐ATPase	  also	  carry	  out	  a	  range	  of	  activities	  (Geering,	  2005;	  2008).	  For	  
example,	  the	  chaperone	  function	  of	  the	  β-­‐subunit	  is	  involved	  in	  the	  formation	  of	  
tight	   junctions,	   cell	   polarity,	   cell-­‐cell	   adhesion	   and	   in	   inhibition	  of	   cell	  motility,	  
potentially	   linking	  CLN3	  with	  a	  number	  of	  secondary	   functions	   (Geering,	  2008).	  
Furthermore,	   abnormal	   formation	   of	   β-­‐fodrin	   containing	   complexes	   may	   have	  
neuron	   specific	   implications,	   since	   at	   the	   synapse	   β-­‐fodrin	   interacts	   with	  
synapsin-­‐1,	   a	   protein	   involved	   in	   synaptic	   transmission/neurotransmission	  
regulation	  (Zimmer	  et	  al.,	  2000).	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CLN3	   has	   also	   been	   proposed	   to	   interact	   with	  Hook1,	   which	   is	   a	   microtubule	  
binding	   proteins	   associated	   with	   the	   regulation	   of	   endocytosis	   (Krämer	   and	  
Phistry,	   1996;	   1999;	   Luiro	   et	   al.,	   2004).	   Indeed,	   by	   analysing	   the	   trafficking	   of	  
fluorescent	  low-­‐density	  lipoprotein	  (BODIPY	  FL-­‐LDL)	  and	  biotinylated	  transferrin,	  
receptor-­‐mediated	  endocytosis	  and	  recycling	  were	  demonstrated	  to	  be	  defective	  
in	   JNCL	   patient	   fibroblasts,	   possibly	   due	   to	   the	   lack	   of	   correct	   CLN3-­‐Hook1	  
interactions.	   Furthermore,	   via	   HooK1,	   CLN3	   may	   have	   an	   indirect	   connection	  
with	   the	   endocytic	   guanosine	   triphosphate	   (GTP)ases	   Rab7,	   Rab9	   and	   Rab11	  
reinforcing	  its	  role	  in	  endocytic	  membrane	  trafficking	  (Tuvim	  et	  al.,	  2001;	  Luiro	  et	  
al.,	   2004;	  Heasman	  and	  Ridley,	   2008).	   Indeed,	   recently,	   CLN3	  was	  proposed	   to	  
interact	   directly	   with	   active	   GTP-­‐bound	   Rab7	   and	   with	   Rab7-­‐interacting	  
lysosomal	  protein	  (RILP),	  which	   is	  a	  dynein	  motor	  protein	  (Jordens	  et	  al.,	  2001;	  
Uusi-­‐Rauva	   et	   al.,	   2012).	   Abnormalities	   in	   these	   connections	   were	   shown	   to	  
affect	   the	   movement	   and	   intracellular	   localization	   of	   late	   endosomes	   and	  
lysosomes,	   proposing	   a	   regulatory	   role	   for	   CLN3	   in	   these	   cellular	   transport	  
mechanisms.	   Hook1	   is	   also	   known	   to	   interact	   with	   Ankyrin	   G,	   which	   is	   a	  
scaffolding	  protein	  associated	  with	  the	  spectrin-­‐actin	  cytoskeleton	  and	  targeting	  
of	  proteins,	  such	  as	  voltage-­‐gated	  sodium	  channels	  and	  cell	  adhesion	  proteins,	  to	  
the	   peripheral	   membrane	   (Zhou	   et	   al.,	   1998;	   De	   Matteis	   and	   Morrow,	   2000;	  
Jenkins	  and	  Bennett,	  2001;	  Garrido	  et	  al.,	  2003;	  Weimer	  et	  al.,	  2005;	  Pan	  et	  al.,	  
2006;	   Kizhatil	   et	   al.,	   2009).	   However,	   no	   defects	   were	   discovered	   in	   the	  
interactions	  between	  Hook1	  and	  Ankyrin	  G,	  or	  their	  localization	  in	  tissue	  derived	  
from	  Cln3-­‐/-­‐	  mice	  (Weimer	  et	  al.,	  2005).	  It	  was	  speculated,	  however,	  that	  nearly	  a	  
threefold	   increase	   in	   the	   expression	   of	   Hook1,	   caused	   by	   a	   lack	   of	   CLN3,	  may	  
lead	   to	   alterations	   in	   the	   functioning	   and	   positioning	   of	  membrane	   associated	  
proteins	  via	  altered	  Hook1-­‐Ankyrin	  G	  interactions.	  	  
The	   C-­‐terminus	   of	   CLN3	   has	   been	   shown	   to	   form	   a	   connection	  with	   the	   Ca2+-­‐
binding	  protein	  calsenilin	  (Chang	  et	  al.,	  2007),	  which	  exerts	  its	  functions	  both	  in	  
the	   cytosol	   and	   in	   the	   nucleus	   (Buxbaum	   et	   al.,	   1998;	   Carrión	   et	   al.,	   1999;	  
Burgoyne	  et	  al.,	  2004).	  For	  instance,	  calsenilin	  has	  been	  shown	  to	  enhance	  Ca2+	  
induced	  apoptosis,	   regulate	  A-­‐type	  currents	   influencing	  neuronal	  excitability	  via	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binding	  to	  voltage-­‐gated	  potassium	  channels,	  be	   involved	   in	   trafficking	  of	  Golgi	  
glycosyltransferases	   and	   it	   may	   even	   function	   as	   a	   transcription	   repressor	   by	  
interacting	  with	  downstream	  regulatory	  element	   (DRE)	  sites	   in	  DNA	  (Carrión	  et	  
al.,	  1999;	  An	  et	  al.,	  2000;	  Jo	  et	  al.,	  2001;	  Lilliehook	  et	  al.,	  2002;	  Quintero	  et	  al.,	  
2008).	   In	   vitro	   binding	   and	   immunoprecipitation	   assays	   revealed	   that	   when	  
intracellular	   Ca2+	   concentrations	   are	   high,	   the	   CLN3-­‐calsenilin	   connection	   is	  
disrupted	  leading	  to	  a	  reduction	  in	  cell	  death	  induced	  by	  high	  Ca2+	  (Chang	  et	  al.,	  
2007).	   Hence,	   CLN3	   deficiency	   may	   expose	   cells	   to	   Ca2+-­‐	   induced	   cell	   death	  
suggesting	  that	  CLN3	  may	  have	  anti-­‐apoptotic	  abilities	  via	  regulation	  of	  calsenilin	  
mediated	  cell	  death	  pathways.	  	  
Recently,	   it	  was	   proposed	   from	   a	   yeast-­‐2-­‐hybrid	   screen,	   and	   confirmed	   by	   co-­‐
immunoprecipitation	  studies,	  that	  the	  C-­‐terminal	  segment	  of	  CLN3	  connects	  with	  
cytoskeleton	  associated	  non-­‐muscle	  myosin	  heavy	  chain	  IIB	  (myosin-­‐IIB),	  (Getty	  
et	  al.,	  2011).	  Myosin-­‐IIB	  is	  an	  actin-­‐binding	  protein,	  predominantly	  expressed	  in	  
the	   brain,	   that	   is	   involved	   in	   actin-­‐cross	   linking	   and	   has	   actin	   contractile	  
properties	   making	   it	   central	   for	   determining	   cell	   polarity,	   adhesion,	   division,	  
growth	  and	  motility	  (Simons	  et	  al.,	  1991;	  Rochlin	  et	  al.,	  1995;	  Tullio	  et	  al.,	  2001;	  
Lo	  et	  al.,	  2004;	  Ryu	  et	  al.,	  2006;	  Vicente-­‐Manzanares	  et	  al.,	  2007;	  2009).	  Indeed,	  
primary	   mouse	   embryonic	   fibroblasts	   derived	   from	   Cln3-­‐/-­‐	   mice	   exhibited	  
significant	  migration	  defects	  in	  a	  scratch	  assay	  (Getty	  et	  al.,	  2011).	  The	  migration	  
of	   these	   Cln3-­‐/-­‐	   cells	   was	   not	   impaired	   by	   blebbistatin,	   which	   is	   an	   inhibitor	   of	  
myosin	   II	  ATPase,	  as	   it	  was	   in	  WT	  cells,	  proposing	  that	  migration	  of	  Cln3-­‐/-­‐	  cells	  
was	  already	  compromised	  due	  to	  dysregulated	  myosin-­‐IIB	  function	  (Getty	  et	  al.,	  
2011).	  Additionally,	   the	  morphology	  of	  Cln3-­‐/-­‐	   fibroblasts	  was	  altered,	   they	  had	  
elongated,	   narrow	   cell	   bodies	   and	   a	   disrupted	   myosin-­‐IIB	   intracellular	  
distribution	  (Getty	  et	  al.,	  2011).	  In	  neuronal	  cells	  myosin-­‐IIB	  is	  pivotal	  for	  axonal	  
outgrowth	   and	   dendritic	   tree	   formation	   by	   controlling	   growth	   cone	   motility	  
(Bridgman	  et	  al.,	  2001;	  Tullio	  et	  al.,	  2001;	  Ryu	  et	  al.,	  2006).	  Additionally,	  myosin-­‐
IIB	   participates	   in	   synaptic	   transmission	   by	   altering	   vesicle	   trafficking	   in	  
presynaptic	  nerve	  terminals	  (Takagishi	  et	  al.,	  2005).	  Thus,	  CLN3	  via	  its	  interaction	  
with	   myosin-­‐IIB	   may	   be	   linked	   to	   various	   neuronal	   cell	   specific	   activities,	   and	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more	  generally	  to	  determination	  of	  cellular	  morphology.	  	  
CLN3	  has	  been	  shown	  to	  bind	  to	  Shwachman-­‐Bodian-­‐Diamon	  syndrome	  protein	  
(SBDS)	  in	  S.	  cerevisiae	  	  (yeast	  homologues:	  Btn1	  and	  Sdo1,	  respectively),	  and	  this	  
interaction	   was	   also	   confirmed	   by	   co-­‐immunoprecipitation	   of	   CLN3	   and	   SBDS	  
from	  NIH-­‐3T3	  cells	  (Vitiello	  et	  al.,	  2010).	  SBDS	  protein	  is	  mutated	  in	  Shwachman-­‐
Bodian-­‐Diamon	  syndrome,	  which	   is	  an	  autosomal	   recessive	  disorder	  associated	  
with	   defects	   in	   immunity,	   skeletal	   and	   hematological	   malfunctions,	   exocrine	  
pancreatic	  deficiency	  and	  cardiac	  disorders	   (Boocock	  et	  al.,	  2003;	  Burroughs	  et	  
al.,	   2009).	   SBDS	   is	   a	   highly	   conserved	   protein	   whose	   proposed	   functions	   are	  
many	   fold,	   including	   regulation	   of	   apoptosis,	   mitosis,	   inhibition	   of	   genomic	  
instability,	   ribosomal	   functions	   via	   connection	   with	   60S	   and	   other	   ribosomal	  
proteins,	   regulation	   of	   DNA	   and	   ER	   stress	   responses	   (Ganapathi	   et	   al.,	   2007;	  
Hesling	   et	   al.,	   2007;	  Menne	   et	   al.,	   2007;	   Austin	   et	   al.,	   2008;	   Ball	   et	   al.,	   2009;	  
Watanabe	   et	   al.,	   2009).	   Deletion	   of	   the	   Btn1	   protein	   in	   yeast	   developed	  
modifications	   in	   vacuolar	   pH	   and	   vATPase-­‐dependent	   transportation	   of	  H+	   and	  
ATP	   hydrolysis,	   while	   deletion	   of	   Sdo1	   lead	   to	   a	   decrease	   in	   both	   of	   these	  
properties	  (Vitiello	  et	  al.,	  2010).	  Hence,	  both	  of	  these	  proteins	  appear	  to	  function	  
within	  the	  same	  pathway.	  It	  was	  proposed	  that	  Sdo1	  (SBDS)	  acts	  as	  a	  regulatory	  
element	   of	   Btn1	   (CLN3),	   and	   thus	   provides	   a	   mechanism	   underlying	   the	  
abnormal	   vacuole/lysosome	  biology	   in	   JNCL.	  However,	   this	   hypothesis	   remains	  
untested	  in	  mammalian	  cells.	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Figure	   1.2.	   The	   properties	   of	   CLN3.	   This	   image	   summarizes	   the	   proposed	   cellular	  
localizations	  of	  the	  transmembrane	  protein	  CLN3.	  The	  primary	  location	  of	  CLN3	  is	  thought	  to	  be	  
endo/lysosomal,	  but	  many	  other	   locations	  have	  also	  been	  suggested.	  CLN3	  has	  many	  proposed	  
interaction	  partners,	   and	  most	   likely	  CLN3	   interacts	  with	   these	  proteins	   in	   a	   dynamic	   and	   cell-­‐
type	  dependent	  fashion.	  	  
	  
The	   research	  described	  above	  highlights	   that	  CLN3	   is	  a	  multifunctional	  protein,	  
required	   for	   many	   aspects	   of	   a	   cell’s	   biology,	   including	   protein	   trafficking,	  
lysosomal	   functioning,	   transmission	   of	   signals	   required	   for	   cell-­‐cell	  
communication,	  organization	  of	  the	  cell’s	  structural	  framework	  and	  regulation	  of	  
apoptotic	  pathways	  (summarized	  in	  Figure	  1.2).	  Possibly	  many	  of	  these	  functions	  
can	   be	   related	   to	   activities	   of	   the	   numerous	   potential	   interaction	   partners	   of	  
CLN3,	  as	  described	  above.	  Whether	  CLN3	  interacts	  with	  same	  proteins	  in	  all	  cell	  
types,	  and	  whether	  it	  has	  cell	  type	  specific	  functions	  remain	  elusive.	  Particularly	  
interesting	   from	   the	   JNCL	   point	   of	   view	   are	   the	   proposed	   neuron-­‐specific	  
functions	   of	   CLN3,	   whose	   alterations	   may	   directly	   lead	   to	   the	   clinical	   and	  
pathological	  manifestations	   typical	   of	   JNCL	   (Järvelä	   et	   al.,	   1999;	   Haskell	   et	   al.,	  
2000;	  Luiro	  et	  al.,	  2001;	  Chattopadhyay	  et	  al.,	  2002;	  Kyttälä	  et	  al.,	  2004;	  Pears	  et	  
al.,	  2005;	  Kovács	  et	  al.,	  2006;	  Storch	  et	  al.,	  2007;	  Finn	  et	  al.,	  2011;	  Kovács	  et	  al.,	  
2011).	  However,	  as	  stated,	  glial	  activation	  has	  been	  shown	  to	  precede	  neuronal	  
loss,	  and	  the	  appearance	  of	  the	  first	  clinical	  symptoms	   in	  different	  JNCL	  mouse	  
models	  (Mitchison	  et	  al.,	  1999;	  Cotman	  et	  al.,	  2002;	  Pontikis	  et	  al.,	  2004;	  2005;	  
Kovács	   and	   Pearce,	   2008;	  Weimer	   et	   al.,	   2009).	   Given	   the	   importance	   of	   glial	  
cells	  for	  the	  proper	  functioning	  of	  neurons	  in	  both	  the	  healthy	  and	  diseased	  CNS	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(Verkhratsky	  and	  Butt,	  2007;	  Barres,	  2008;	  Allen	  and	  Barres,	  2009;	  Sofroniew	  and	  
Vinters,	   2010;	   Verkhratsky	   and	   Parpura,	   2010),	   any	   abnormalities	   in	   glial	  
functioning	   may	   significantly	   disrupt	   this	   relationship.	   In	   JNCL,	   as	   previously	  
stated,	  the	  glia	  response	  appears	  attenuated	  (Pontikis	  et	  al.,	  2004;	  Tyynelä	  et	  al.,	  
2004;	  Pontikis	  et	  al.,	  2005)	  and	  our	   recent	   in	  vitro	   studies	  have	  confirmed	  that	  
Cln3-­‐/-­‐	  microglia	   have	   an	   impaired	   ability	   to	   respond	   to	   an	   activation	   stimulus,	  
both	  in	  terms	  of	  changing	  their	  morphology	  and	  in	  secreting	  a	  specific	  sub-­‐set	  of	  
proteins	   (S.	   Dihanich,	   unpublished	   data).	   This	   has	   provided	   the	   first	   direct	  
evidence	  for	  a	  functional	  role	  of	  CLN3	  in	  glia	  cells.	  The	  research	  described	  in	  this	  
thesis	   extends	   these	   studies	   to	   astrocytes,	   to	   determine	   how	   CLN3	   deficiency	  
impacts	   their	   function	   (Chapters	   3	   and	   4),	   and	   the	   impact	   that	   these	   cells	  
together	  with	  Cln3-­‐/-­‐	  microglia	  may	  have	  on	  neuronal	  health	  (Chapter	  6).	  	  
In	   the	   next	   sections,	   the	   importance	   of	   glial-­‐neuronal	   interactions	   is	   discussed	  
together	   with	   the	   problems	   that	   can	   arise	   when	   this	   communication	   breaks	  
down.	  
1.3	  Cells	  of	  the	  central	  nervous	  system	  
The	  adult	  CNS	  is	  composed	  of	  neurons	  and	  glia	  (astrocytes,	  oligodendrocytes	  and	  
microglia	   (Kandel	   et	   al.,	   2012)	   and	   although	   the	   CNS	   contains	   many	   different	  
type	   of	   neurons,	   these	   are	   far	   outnumbered	   by	   the	   glia	   (HAWKINS	   and	  
OLSZEWSKI,	   1957;	   Pfrieger	   and	   Barres,	   1995;	   Barres,	   2008;	   Purves,	   2011).	   The	  
cellular	   interactions	   between	   neurons	   and	   glia	   are	   extremely	   complex	   and	  
essential	   for	   the	   proper	   functioning	   of	   the	   CNS.	   Among	   the	   most	   important	  
functions	   of	   glial	   cells	   are	   to	   provide	   structural	   and	   homeostatic	   support	   for	  
neurons,	   insulate	  neurons	  electrically,	   guide	  neuronal	  differentiation,	  and	  clear	  
cell	  debris	   (Verkhratsky	  and	  Butt,	  2007;	  Allen	  and	  Barres,	  2009;	  Kettenmann	  et	  
al.,	  2011).	   In	  addition	  to	  being	  pivotal	   in	  the	  healthy	  CNS,	  glia	  also	  help	  defend	  
the	  brain	  against	  infection	  and	  disease	  (Pekny	  and	  Nilsson,	  2005;	  Sofroniew	  and	  
Vinters,	  2010;	  Zhang	  et	  al.,	  2010;	  Liu	  et	  al.,	  2011;	  Singh	  et	  al.,	  2011).	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Neurons	  
Neurons	  are	  highly	  specialized	  cells	  that	  send	  and	  receive	  information,	  allowing	  
communication	  within	   the	  brain,	  and	  between	  the	  brain	  and	   the	  body	   (Purves,	  
2011;	   Kandel	   et	   al.,	   2012).	   They	   communicate	   with	   one	   another	   by	  means	   of	  
action	   potentials	   (rapid	   reversals	   of	   voltage	   across	   the	   plasma	   membrane	   of	  
axons)	  (Barnett	  and	  Larkman,	  2007;	  Debanne	  et	  al.,	  2011;	  Purves,	  2011;	  Sasaki	  et	  
al.,	  2011;	  Kandel	  et	  al.,	  2012).	  The	  action	  potential	  travels	  along	  the	  axon	  to	  the	  
synapse,	   where	   the	   electrical	   signal	   is	   converted	   into	   a	   chemical	   signal	  
(neurotransmitters)	   that	   is	   propagated	   to	   the	   dendritic	   spines	   of	   the	  
postsynaptic	   neuron	   (Llinás	   et	   al.,	   1985;	   Llinás,	   1988;	   Wang	   et	   al.,	   2009a).	  
Neurons	   frequently	   have	   multiple	   dendrites	   that	   form	   complex	   branched	  
networks	   that	  are	   specialized	   to	   receive	  presynaptic	   inputs	   (Jan	  and	   Jan,	  2001;	  
Häusser,	  2007;	  Conde	  and	  Cáceres,	  2009).	  	  
	  
The	  initiation	  of	  the	  action	  potential	  takes	  place	  in	  a	  specialized	  region	  located	  at	  
the	  start	  of	  an	  axon,	  called	  the	  axonal	  initial	  segment	  (AIS),	  that	  is	  composed	  of	  
multiple	   proteins,	   including	   a	   high	   number	   of	   Na+	   channels	   required	   for	  
membrane	   depolarization	   (Ogawa	   and	   Rasband,	   2008;	   Grubb	   and	   Burrone,	  
2010a;	   Buffington	   and	   Rasband,	   2011;	   Grubb	   et	   al.,	   2011).	   The	   arrival	   of	   an	  
action	  potential	   at	   the	   synapse	   results	   in	   the	   influx	  of	  Ca2+	   and	   the	   fusion	  and	  
release	   of	   synaptic	   vesicles	   containing	   neurotrasmitters	   with	   the	   plasma	  
membrane	   (Sudhof,	   2004;	   Lodish	   et	   al.,	   2007;	   Purves,	   2011).	   The	   released	  
neurotransmitters	   then	   interact	   with	   receptors	   expressed	   by	   post-­‐synaptic	  
neurons	  (Sudhof,	  2004).	  The	  membrane	  fusion	  of	  synaptic	  vesicles	  requires	  the	  
interaction	  of	   specific	   proteins	   called	   soluble	  N-­‐ethylmaleimide-­‐sensitive	   factor	  
(NSF)	   attachment	   protein	   receptor	   (SNARE)-­‐complex	   proteins	   (Söllner	   et	   al.,	  
1993a;	   1993b;	   Kavalali,	   2002;	   Ungar	   and	   Hughson,	   2003;	   Ramakrishnan	   et	   al.,	  
2012).	  These	  include,	  vesicle-­‐associated	  membrane	  protein	  1	  (VAMP1)	  and/or	  2,	  
also	   called	   synaptobrevins,	   on	   synaptic	   vesicles	   that	   interact	  with	   syntaxin	   and	  
synaptosomal-­‐associated	   protein	   25	   (SNAP25)	   on	   the	   presynaptic	   plasma	  
membrane	   enabling	   SNARE-­‐mediated	   vesicle	   fusion	   and	   exocytosis	   of	  
neuroactive	   factors	   (Rizo	  et	   al.,	   2006;	  Ramakrishnan	  et	   al.,	   2012).	   The	   synaptic	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vesicle	   proteins	   synaptophysin	   1	   and	   2	   are	   also	   involved	   in	   the	   regulation	   of	  
SNARE-­‐complex	  formation	  via	  interaction	  with	  VAMPs	  (Washbourne	  et	  al.,	  1995;	  
Becher	  et	  al.,	  1999).	  Furthermore,	   the	  post-­‐synaptic	  neuronal	  membranes,	  and	  
thus	   synaptic	   transmission,	  may	  be	  altered	  by	  other	  molecules	  and	  metal	   ions,	  
such	  as	  zinc,	  which	  may	  be	  present	  in	  the	  synaptic	  cleft	  (Huang,	  1997).	  Neuronal	  
cells	  are	  also	  capable	  of	  altering	  the	  expression	  of	  neurotransmitter	  receptors	  at	  
synaptic	   membranes,	   which	   modifies	   their	   response	   to	   pre-­‐synaptic	   stimuli	  
(Beattie	   et	   al.,	   2000;	   Man	   et	   al.,	   2000;	   Carroll	   et	   al.,	   2001;	   Shi	   et	   al.,	   2001).	  
Additionally,	   increasing	  evidence	  demonstrates	  that	  glia,	  particularly	  astrocytes,	  
are	   pivotal	   regulators	   of	   neuronal	   activity	   via	   active	   participation	   in	   the	  
regulation	  of	  synaptic	  transmission	  and	  plasticity,	  suggesting	  that	  brain	  function	  
results	  from	  the	  coordinated	  activity	  of	  neuron-­‐glia	  networks,	  and	  not	  exclusively	  
from	  neuronal	  networks	  (Volterra	  and	  Meldolesi,	  2005;	  Allen	  and	  Barres,	  2009;	  
Perea	   et	   al.,	   2009;	   Araque	   and	   Navarrete,	   2010;	   Perea	   and	   Araque,	   2010;	  
Santello	  et	  al.,	  2012;	  Verkhratsky	  et	  al.,	  2012a).	  
Astrocytes	  	  
Active	   research	   on	   astrocytes	   over	   the	   last	   three	   decades	   has	   significantly	  
increased	  our	  knowledge	  of	   their	   function.	  Originally	  described	  as	  a	  connective	  
tissue	  that	  binds	  nervous	  elements	   together	   (Rudolf	  Virchow,	  1858),	  astrocytes	  
are	  now	  recognized	  as	  not	  only	  being	  pivotal	  for	  providing	  metabolic	  and	  trophic	  
support	   for	   neural	   networks,	   but	   also	   as	   active	   participants	   in	   synaptic	  
transmission,	   CNS	   synaptogenesis,	   brain	   energy	   metabolism	   and	   blood-­‐brain	  
barrier	   (BBB)	   maintenance	   (Ridet	   et	   al.,	   1997;	   Volterra	   and	   Meldolesi,	   2005;	  
Abbott	   et	   al.,	   2006;	   Verkhratsky	   and	   Butt,	   2007;	   Allen	   and	   Barres,	   2009;	  
Kimelberg,	   2010;	   Parpura	   and	   Zorec,	   2010;	   Sofroniew	   and	   Vinters,	   2010;	  
Verkhratsky	   and	   Parpura,	   2010).	   These	   cells	   also	   use	   Ca2+-­‐based	   signaling	   as	   a	  
form	  of	  communication	  (basic	  astrocyte	  functions	  are	  summarized	  in	  Figure	  1.3)	  
(Allen	  and	  Barres,	  2009;	  Verkhratsky	  and	  Parpura,	  2010;	  Nag,	  2011).	  Astrocytes	  
have	  been	  shown	  to	  be	  critical	  participants	  in	  numerous	  disorders	  that	  affect	  the	  
CNS,	  including	  all	  forms	  of	  NCLs	  (Bible	  et	  al.,	  2004;	  Pontikis	  et	  al.,	  2004;	  Tyynelä	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et	  al.,	  2004;	  Pekny	  and	  Nilsson,	  2005;	  Sofroniew	  and	  Vinters,	  2010;	  Macauley	  et	  
al.,	  2011;	  Kuronen	  et	  al.,	  2012;	  Schmiedt	  et	  al.,	  2012).	  
	  
Astrocytes	  are	  divided	  into	  two	  main	  subtypes,	  protoplasmic	  and	  fibrous,	  based	  
on	   their	   morphological	   appearance.	   Protoplasmic	   astrocytes	   are	   located	  
throughout	  the	  gray	  matter	  and	  have	  several	  stem	  branches,	  which	  give	  rise	  to	  
numerous,	   very	   complex,	   finely	   branching	   processes	   (Verkhratsky	   and	   Butt,	  
2007;	   Theodosis	   et	   al.,	   2008;	   Matyash	   and	   Kettenmann,	   2010).	   Fibrous	  
astrocytes	   are	   located	   throughout	   the	  white	  matter	   and	   extend	   long	   fiber-­‐like	  
processes	  (Peters	  et	  al.,	  1991;	  Verkhratsky	  and	  Butt,	  2007).	  However,	  as	  well	  as	  
these	   two	   main	   astrocyte	   classes,	   that	   are	   both	   composed	   of	   heterogeneous	  
groups	   of	   astrocytes,	   there	   are	   also	   Bergmann	   glial	   cells	   in	   the	   cerebellum;	  
interlaminar	  and	  polarized	  astrocytes	  of	   the	  deep	  cortical	   layers	   in	   the	  primate	  
brain;	   Müller	   glial	   cells	   of	   the	   retina;	   perivascular	   and	   marginal	   astrocytes;	  
tanycytes	   located	  at	   the	  ventricular	  walls	  of	   the	  hypothalamus	  and	  spinal	  cord;	  
velate	  astrocytes	  of	  the	  cerebellum	  where	  each	  one	  forms	  a	  sheath	  surrounding	  
a	  granule	  neuron;	  and	  pituicytes	  in	  the	  neurohypophysis	  (Oberheim	  et	  al.,	  2006;	  
Verkhratsky	  and	  Butt,	  2007;	  Oberheim	  et	  al.,	  2009;	  Kimelberg,	  2010;	  Kimelberg	  
and	  Nedergaard,	  2010;	  Matyash	  and	  Kettenmann,	  2010;	  Zhang	  and	  Barres,	  2010;	  
Oberheim	   et	   al.,	   2012).	   Thus,	   overall,	   astrocytes	   comprise	   a	   heterogeneous	  
population	   of	   cells,	   and	   it	   is	   believed	   that	   their	   different	  morphologies	   reflect	  
their	   functional	   diversity	   (Zhang	   and	   Barres,	   2010;	  Molofsky	   et	   al.,	   2012).	   It	   is	  
also	   important	   to	   note	   that	   human	   astrocytes	   are	   considerably	  more	   complex	  
morphologically	  than	  their	  rodent	  counterparts	  (Oberheim	  et	  al.,	  2009).	  
	  
Both	   protoplasmic	   and	   fibrous	   astrocytes	   connect	   with	   blood	   vessels	   via	   their	  
endfeet	  processes,	   and	  connect	  with	  one	  another	  via	  gap	   junctions	   comprising	  
connexins	   43	   (Cx43)	   and	   30	   (Cx30)	   protein	   subunits,	  which	   enable	   diffusion	   of	  
small	   molecules	   between	   connected	   astrocytes	   (Freeman,	   2010;	   Matyash	   and	  
Kettenmann,	  2010;	   Sofroniew	  and	  Vinters,	  2010;	  Zhang	  and	  Barres,	  2010).	   The	  
close	   connection	   with	   blood	   vessels	   enables	   astrocytes	   to	   control	   CNS	   blood	  
flow,	  as	  a	  response	  to	  neuronal	  activity,	   in	  a	  coordinated	  manner	  via	  release	  of	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vasoactive	  molecules	  including	  prostaglandins	  (PGE),	  nitric	  oxide	  and	  arachidonic	  
acid	   (AA)	   (Gordon	   et	   al.,	   2007;	   Iadecola	   and	   Nedergaard,	   2007).	   Protoplasmic	  
astrocytes	   also	   form	   close	   connections	   with	   synapses	   where	   they	   control	  
transmitter	  and	   ion	  homeostasis,	  and	   therefore	   regulate	   synaptic	   transmission.	  
The	  processes	  of	  fibrous	  astrocytes	  connect	  with	  axons	  at	  nodes	  of	  Ranvier,	  the	  
unmyelinated	   sites	   of	   action	   potential	   propagation,	   providing	   a	   location	   for	  
direct	  signaling	  between	  axons	  and	  astrocytes	  (Butt	  et	  al.,	  1994;	  1999;	  Freeman	  
et	   al.,	   2010;	   Matyash	   et	   al.,	   2010;	   Sofroniew	   and	   Vinters,	   2010;	   Zhang	   et	   al.,	  
2010).	   Under	   physiological	   conditions	   protoplasmic	   astrocytes	   have	   non-­‐
overlapping	   domains,	   which	  may	   become	   disrupted	   under	   severe	   pathological	  
conditions	   leading	   to	   long-­‐term	   reorganization	   of	   tissue	   architecture	   with	  
consequences	   that	   remain	  poorly	  understood	   (Bushong	  et	  al.,	  2002;	  Ogata	  and	  
Kosaka,	   2002;	  Wilhelmsson	   et	   al.,	   2006;	   Halassa	   et	   al.,	   2007;	   Verkhratsky	   and	  
Butt,	  2007;	  Sofroniew	  and	  Vinters,	  2010;	  Sun	  and	  Jakobs,	  2011).	  
	  
	  
Figure	  1.3.	  Functions	  of	  astrocytes	  in	  the	  healthy	  CNS.	  Schematic	  representation	  that	  
summarizes	   the	   functions	   of	   astrocytes	   in	   the	   healthy	   CNS.	   Astrocytes	   are	   in	   close	   connection	  
with	  blood	  vessels	  via	  endfeet,	  and	  with	  synapses	  via	  their	  highly	  complex	  processes.	  Astrocytes	  
are	  connected	  to	  one	  another	  via	  gap	  junctions	  that	  allow	  diffusion	  of	  soluble	  factors	  (examples	  
given	   in	   brackets).	   Arachidonic	   acid	   (AA)	   released	   by	   astrocytes	   causes	   contraction	   of	   blood	  
vessels,	  while	   prostaglandin	   (PGE)	   induce	  nitric	   oxide	   (NO)	  mediated	  dilation	  of	   the	   vessels.	   In	  
contrast,	   astrocytes	   can	   take	   up	   glucose	   and	   H2O	   from	   the	   blood.	   Astrocytes	   can	   regulate	  
synaptic	   activity	   via	   release	   and	   uptake	   of	   numerous	   neuro-­‐	   and	   glial-­‐active	   factors	   (examples	  
given	  in	  brackets).	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During	   development	   astrocytes	   are	   generated	   after	   neurons	   (Verkhratsky	   and	  
Butt,	   2007),	   despite	   this,	   astrocytes	   are	   important	   for	   the	   maturation	   and	  
survival	   of	   neurons	   within	   both	   the	   grey	   and	   white	   matter.	   During	   the	  
development	   of	   the	   white	   matter,	   impaired	   gap	   junction-­‐mediated	   astrocyte	  
communication	  has	  been	   shown	   to	   result	   in	  dysmyelination	   (Lutz	   et	   al.,	   2009).	  
Additionally,	   in	   the	  gray	  matter,	   for	  example,	  astrocytes	  guide	  the	  migration	  of	  
neuroblasts	  and	  developing	  axons	  by	  establishing	  molecular	  boundaries	  via	   the	  
expression	  of	  astrocyte-­‐derived	  extracellular	  matrix	  molecules,	  such	  as	  tenascin-­‐
C,	  and	  different	  proteoglycans,	  such	  as	  chondroitin	  sulfate	  proteoglycans	  (CSPG)	  
and	  keratin	  sulfate	  proteoglycans	  (KSPG)	  (Powell	  et	  al.,	  1997a;	  1997b;	  Powell	  and	  
Geller,	   1999).	   Furthermore,	   astrocyte-­‐derived	  molecules	   like	   thrombospondins	  
have	  been	  shown	  to	  be	  pivotal	  for	  the	  development	  and	  functioning	  of	  synapses	  
(Ullian	  et	  al.,	  2001;	  2004a;	  Christopherson	  et	  al.,	  2005;	  Barres,	  2008).	  In	  addition	  
to	   enhancing	   synaptic	   formation,	   astrocytes	   play	   an	   equally	   important	   role	   in	  
developmental	   synaptic	   pruning	   by	   producing	   complement	   C1q	   expression	  
inducing	   factors	   at	   synapses,	   which	   triggers	   microglia	   based	   removal	   of	   that	  
synapse	  (Stevens	  et	  al.,	  2007;	  Barres,	  2008;	  Stephan	  et	  al.,	  2012).	  	  
	  	  	  
Ca2+	  signaling	  in	  astrocytes	  	  
As	  stated	  above,	  astrocytes	  play	  an	  active	  role	  in	  brain	  function	  and	  information	  
processing,	  both	  during	  development	  and	  in	  the	  postnatal	  brain.	  A	  large	  number	  
of	   these	   functions	   are	   regulated	   by	   the	   astrocyte’s	   intracellular	   Ca2+	   signaling	  
system.	   It	   was	   first	   reported	   about	   20	   years	   ago	   that	   individually	   cultured	  
astrocytes	  display	   intracellular	  Ca2+	  elevations	   in	  response	  to	  neurotransmitters	  
(Cornell-­‐Bell	   et	   al.,	   1990a).	   Indeed,	   astrocytes	   express	   receptors	   for	   a	   whole	  
range	   of	   neurotransmitters,	   and	   their	   strategic	   location	   in	   close	   proximity	   to	  
synapses	  provides	  a	  perfect	  opportunity	   for	  astrocytes	  to	  monitor	  and	  regulate	  
neuronal	   activity	   (Haydon,	   2001;	   Fellin	   et	   al.,	   2006b;	   Theodosis	   et	   al.,	   2008;	  
Halassa	   and	   Haydon,	   2010).	   Astrocytes	   also	   display	   transient,	   spontaneous	  
increases	   in	   intracellular	   Ca2+,	   independent	   of	   any	   external	   stimulus,	   that	   can	  
spread	   into	   adjacent	   astrocytes	   as	   a	   synchronous	   intercellular	   Ca2+	   wave	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(Cornell-­‐Bell	   et	   al.,	   1990a;	   Hirase	   et	   al.,	   2004;	   Fiacco	   and	   McCarthy,	   2006;	  
Scemes	  and	  Giaume,	  2006;	  Kuga	  et	  al.,	  2011).	  Additionally,	  neurons	  and	  glia	  can	  
communicate	  via	  Ca2+	  since	  neuronal	  activity	  can	  directly	  induce	  glial	  Ca2+	  waves	  
(Dani	  et	  al.,	  1992),	  and	  glial	  Ca2+	  waves	  can	  directly	  cause	  calcium	  transients	  and	  
activation	  of	  neurons	   (Nedergaard,	  1994;	  Parpura	  et	  al.,	  1994;	  Hassinger	  et	  al.,	  
1995;	  Newman	  and	  Zahs,	  1998).	  	  
	  
Many	   studies	   on	   astrocytes	   in	   vitro,	   in	   situ	   and	   in	   vivo	   have	   identified	   the	  
expression	   of	   numerous	   metabotropic	   and	   ionotropic	   receptors	   that,	   upon	  
activation	  via	  binding	  of	  neurotransmitters,	   such	  as	  ATP	  and	  glutamate,	   trigger	  
Ca2+	   release	   from	   the	   ER	   (basic	   Ca2+-­‐signaling	   mechanisms	   are	   presented	   in	  
Figure	  1.4)	  (Finkbeiner,	  1993;	  Porter	  and	  McCarthy,	  1995;	  Kirischuk	  et	  al.,	  1996;	  
Porter	  and	  McCarthy,	  1996;	  Hamilton	  et	  al.,	  2008;	  Verkhratsky	  et	  al.,	  2009).	  This	  
occurs	   through	   activation	   of	   the	   phospholipase	   C	   (PLC)/inositol	   1,4,5-­‐
triphosphate	   (IP3)	   pathway	   (Franke	   et	   al.,	   2012;	   Illes	   et	   al.,	   2012).	   Upon	  
activation	  of	  metabotropic	  G-­‐protein	  coupled	   receptors	   (GPCR),	  PLC	  hydrolyzes	  
the	   membrane	   lipid	   phosphatidylinositol	   4,5-­‐bisphosphate	   (PIP2)	   to	   generate	  
diacylglycerol	  (DAG)	  and	  IP3,	  resulting	  in	  IP3-­‐receptor	  (IP3-­‐R)	  activation	  and	  Ca2+	  
release	   from	   the	   ER	   (Scemes,	   2000;	   Parri	   and	   Crunelli,	   2003;	   Fiacco	   and	  
McCarthy,	   2006;	   Scemes	   and	   Giaume,	   2006).	   Cells	   have	  many	  mechanisms	   to	  
clear	  cytosolic	  Ca2+,	  either	  by	  pumping	  it	  out	  from	  the	  cell	  via	  plasma	  membrane	  
Ca2+	  ATPases	  (PMCA),	  or	  sodium-­‐calcium	  exchangers	  (NCX),	  which	  can	  operate	  in	  
both	   directions,	   or	   by	   storing	   it	   in	   intracellular	   Ca2+-­‐stores	   such	   as	   the	   ER,	   as	  
illustrated	  in	  Figure	  1.4	  (Koch	  et	  al.,	  1986;	  Jaiswal,	  2001;	  Carafoli,	  2002;	  Guerini	  
et	  al.,	  2005;	  Petersen	  et	  al.,	  2005;	  Case	  et	  al.,	  2007;	  Verkhratsky	  et	  al.,	  2012a).	  
Efficient	   Ca2+-­‐clearance	  mechanisms	   are	   essential	   since	   excess	   Ca2+	  may	   cause	  
aggregation	  of	  proteins,	  nuclei	  acids	  and	  lipids,	  which	  may	  be	  detrimental	  for	  the	  
cell	  (Carafoli,	  2002;	  Petersen	  et	  al.,	  2005).	  As	  mentioned	  above,	  one	  of	  the	  major	  
roles	  of	  the	  ER	  is	  to	  function	  as	  a	  dynamic	  Ca2+	  store	  making	  the	  ER	  an	  integral	  
part	   of	   the	   astrocyte’s	   Ca2+	   homeostatic	   machinery.	   Ca2+	   pumps,	   such	   as	   the	  
sarco	  (endo)	  plasmic	  reticulum	  calcium	  ATPase	  (SERCA),	  play	  an	   important	  part	  
in	   ER	   based	   Ca2+	   clearance	   activities,	   by	   transporting	   Ca2+	   into	   the	   ER	   lumen	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against	   it’s	   concentration	   gradient	   (Gunteski-­‐Hamblin	   et	   al.,	   1988;	  Vangheluwe	  
et	   al.,	   2005).	   Additionally,	   mitochondria	   and	   lysosomes	   can	   also	   participate	   in	  
intracellular	  Ca2+	  clearance	  and	  storage	  (Duchen,	  2000;	  Michelangeli	  et	  al.,	  2005;	  
Lloyd-­‐Evans	  and	  Platt,	   2011).	   Finally,	   influx	  of	  Ca2+	  from	   the	  extracellular	   space	  
can	  also	  occur	  via	  store-­‐operated	  channels	  (SOC),	  which	  respond	  to	  fluctuations	  
in	   intracellular	   levels	   of	   Ca2+	   and	   depletion	   of	   intracellular	   Ca2+	   stores	  
(Verkhratsky	  et	  al.,	  1998;	  Lo	  et	  al.,	  2002;	  Parpura	  et	  al.,	  2011;	  Verkhratsky	  et	  al.,	  
2012a).	   Recently,	   the	   Ca2+	   sensor	   stromal	   interacting	   molecule	   1	   (STIM1)	   and	  
Calcium	   release-­‐activated	   calcium	   channel	   protein	   1	   have	   been	   shown	   to	  
mediate	  the	  store-­‐operated	  Ca2+	  entry	  (SOCE)	  pathways	  in	  astrocytes	  (Moreno	  et	  
al.,	  2012).	  	  	  
	   	  




Figure	  1.4.	  Basic	  calcium	  signaling	  mechanisms	   in	  astrocytes.	  Several	  mechanisms	  
are	  involved	  in	  intracellular	  Ca2+	  accumulation.	  This	  could	  be	  caused	  by	  the	  entry	  of	  Ca2+	  from	  the	  
extracellular	   space	   through	   ionotropic	   or	   metabotropic	   receptors	   (GPCR),	   store-­‐operated	  
channels	   (SOC)	   or	   via	   plasma	   membrane	   Na+/Ca2+	   exchangers	   (NCX).	   Intracellular	   Ca2+-­‐stores	  
(endoplasmic	   reticulum	   (ER),	   mitochondria	   or	   lysosomes),	   may	   also	   function	   as	   an	   additional	  
source	  for	  cytosolic	  Ca2+,	  which	  can	  be	  released	  from	  the	  ER	  via	  IP3-­‐receptors	  (IP3-­‐R)	  activated	  by	  
GPCR	   and	   phospholipase	   C	   (PLC)	   based	   production	   of	   IP3.	   The	   sarco	   (endo)	   plasmic	   reticulum	  
calcium	   ATPase	   (SERCA)	   functions	   to	   refill	   the	   ER	   Ca2+-­‐stores.	  Mitochondrial	   Ca2+	  uptake	   takes	  
place	   via	   voltage-­‐dependent	   anion	   channels	   (VDAC),	   or	   mitochondrial	   NCX,	   whereas	  
mitochondrial	   Ca2+	   release	   occurs	   via	   transient	   opening	   of	   the	   mitochondrial	   permeability	  
transition	   pore	   (MPTP).	   Lysosomes	   are	   also	   involved	   in	   the	   regulation	   of	   intracellular	   Ca2+-­‐
homeostasis.	  Cytosolic	  Ca2+	  can	  be	  cleared	  to	  the	  extracellular	  space	  by	  plasma	  membrane	  Ca2+	  
ATPases	   (PMCA).	   Cytosolic	   Ca2+	   influx	   or	   efflux	   may	   also	   occur	   via	   plasma	   membrane	   NCX,	  
depending	  on	  the	  intracellular	  Na+	  concentration.	  	  	  
	  
	  
The	  mechanisms	  behind	  spontaneous	  Ca2+	  oscillations	   in	  astrocytes,	  particularly	  
those	   that	   occur	   in	   absence	   of	   any	   stimulus,	   are	   not	   fully	   understood.	   The	  
observed	   increase	   in	  Ca2+	  concentrations	  during	   these	  oscillations	   is	   thought	   to	  
be	   generated	   by	   release	   from	   the	   ER	   Ca2+	  store	   via	   IP3-­‐R	   activation	   and	   influx	  
from	   an	   extracellular	   source	   possibly	   through	   voltage-­‐gated	   calcium	   channels	  
(VGCCs)	  (Duffy	  and	  MacVicar,	  1994;	  Jalonen	  et	  al.,	  1997;	  Parri	  et	  al.,	  2001;	  Nett	  
et	   al.,	   2002;	   Parri	   and	   Crunelli,	   2003;	  Wang	   et	   al.,	   2006;	   Parpura	   et	   al.,	   2011;	  
Verkhratsky	  et	  al.,	  2012a).	  Importantly,	  these	  spontaneous	  Ca2+	  oscillations	  have	  
been	  shown	  to	  induce	  NMDA	  receptor	  mediated	  neuronal	  excitability	  in	  situ	  via	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glutamate	   release	   from	  astrocytes	   (Parri	   et	   al.,	   2001;	  Parri	   and	  Crunelli,	   2003).	  
NMDA	   receptors	   are	   essential	   for	   a	   range	   of	   neuronal	   functions	   including	  
neuronal	   differentiation,	   synaptogenesis	   and	   migration	   (Komuro	   and	   Rakic,	  
1993;	  1998).	  Thus,	   spontaneous	  astrocytic	  Ca2+	  oscillations	  may	  be	   related	   to	  a	  
wide	  range	  of	  neuronal	  activities.	  	  	  	  
	  
The	  propagation	  of	  Ca2+	  waves	  within	  astrocyte	  networks	   involves	   two	  possible	  
mechanisms:	  1)	  gap	   junction-­‐mediated	  diffusion	  of	  molecules,	   such	  as	   IP3,	   that	  
induce	  Ca2+	  release	  from	  intracellular	  Ca2+	  stores	  in	  neighboring	  cells	  (Boitano	  et	  
al.,	   1992;	  Giaume	  and	  Venance,	   1998;	   Scemes	   and	  Giaume,	   2006),	   2)	   released	  
chemical	   transmitters,	   such	   as	   ATP,	   that	   bind	   to	   receptors	   on	   neighboring	  
astrocytes	  to	  induce	  intracellular	  signaling	  cascades	  leading	  to	  Ca2+	  release	  from	  
intracellular	  stores	  (Guthrie	  et	  al.,	  1999;	  Cotrina	  et	  al.,	  2000;	  Kozlov	  et	  al.,	  2006).	  
This	   propagation	   of	   Ca2+	   signals	   may	   facilitate	   efficient	   communication	   within	  
astrocyte	  networks,	  referred	  to	  as	  the	  astrocyte	  ‘syncytium’,	  that	  forms	  intimate	  
associations	   across	  many	   synapses,	   potentially	   enabling	   the	   synchronization	   of	  
neuronal	   activity	   via	   secretion	   of	   neuroactive	   factors	   (gliotransmission),	   and	  
creating	   a	   powerful	   buffering	   capacity	   within	   these	   networks	   (Aguado	   et	   al.,	  
2002;	  Kuga	  et	  al.,	  2011;	  Parpura	  et	  al.,	  2012).	  	  
	  
Astrocytic	  Ca2+	  elevations	  may	  also	  result	   in	  the	  release	  of	  gliotransmitters	  such	  
as	  ATP	  (Coco	  et	  al.,	  2003;	  Pascual	  et	  al.,	  2005),	  glutamate	  (Parpura	  et	  al.,	  1994;	  
Fellin	  et	  al.,	  2004;	  Parpura	  et	  al.,	  2011)	  and	  D-­‐serine	  (Schell	  et	  al.,	  1995;	  Mothet	  
et	   al.,	   2005;	   Henneberger	   et	   al.,	   2010).	   These	   gliotransmitters	   form	   the	  
molecular	   basis	   for	   glial-­‐glial	   and	   glial-­‐neuronal	   communication	   (Cornell-­‐Bell	   et	  
al.,	  1990a;	  Araque	  et	  al.,	  1999;	  2001;	  Fellin	  et	  al.,	  2006b;	  Zorec	  et	  al.,	  2012).	  For	  
instance,	   release	   of	   D-­‐serine	   from	   astrocytes	   can	   control	   NMDA-­‐receptor	  
dependent	  plasticity	  in	  a	  whole	  network	  of	  excitatory	  synapses	  located	  within	  an	  
astrocyte	   syncytium,	   and	   thus	   facilitate	   long-­‐term	   potentiation	   (LTP)	   and	  
memory	  formation	  (Henneberger	  et	  al.,	  2010).	  Additionally,	  glutamate	  released	  
by	  astrocytes	  may	  regulate	  synaptic	  transmission	  and	  neuronal	  excitability	  (Bezzi	  
et	   al.,	   1998;	   Pasti	   et	   al.,	   2001),	   and	   ATP,	   which	   becomes	   metabolized	   to	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adenosine,	   may	   cause	   activity-­‐dependent	   heterosynaptic	   depression	   at	  
excitatory	  synapses	  (Grover	  and	  Teyler,	  1993;	  Pascual	  et	  al.,	  2005;	  Serrano	  et	  al.,	  
2006).	   This	   release	   of	   gliotransmitters	   from	   astrocytes	   may	   occur	   via	   release	  
through	   unpaired	   connexons	   (hemichannels),	   ionotropic	   purinergic	   receptors,	  
transporters	   such	   as	   exchange	   via	   the	   cystine-­‐glutamate	   antiporter	   or	   organic	  
anion	   transporters,	   or	   via	   Ca2+	   dependent	   exocytosis	   (Szatkowski	   et	   al.,	   1990;	  
Parpura	  et	  al.,	  1994;	  Cotrina	  et	  al.,	  1998;	  Warr	  et	  al.,	  1999;	  Iglesias	  et	  al.,	  2009;	  
Verkhratsky	  and	  Parpura,	  2010;	  Parpura	  et	  al.,	  2011;	  Verkhratsky	  et	  al.,	  2012a).	  	  	  
	  
Astrocytes	  as	  regulators	  of	  CNS	  homeostasis	  
One	   of	   the	   most	   fundamental	   functions	   of	   astrocytes	   is	   to	   regulate	   CNS	  
homeostasis	   (see	   Figure	   1.5)	   (Verkhratsky	   and	   Butt,	   2007;	   Allen	   and	   Barres,	  
2009;	  Sofroniew	  and	  Vinters,	  2010).	  This	  encompasses	  many	  different	  activities,	  
including	   cellular	   homeostasis	   by	   controlling	   neurogenesis;	   defensive	  
homeostasis	  by	  functioning	  as	  part	  of	  the	  adaptive/defensive	  immune	  response	  
in	   the	   CNS;	  morphological	   homeostasis	   by	   controlling	  migratory	   pathways	   for	  
neural	   cells	   during	   development	   and	   synaptogenesis/pruning;	   molecular	  
homeostasis	   by	   controlling	   levels	   of	   neurotransmitters	   and	   hormones	   in	   the	  
extracellular	  space;	  metabolic	  homeostasis	  by	  controlling	  and	  storing	  (glycogen)	  
and	  providing	  energy	  substrates	  (lactate)	  for	  neurons;	  and	  organ	  homeostasis	  by	  
regulating	   the	   BBB	   (Verkhratsky	   and	   Butt,	   2007;	   Sofroniew	   and	   Vinters,	   2010;	  
Verkhratsky	   et	   al.,	   2012a).	   Moreover,	   astrocytes	   are	   also	   important	   for	   the	  
maintenance	   of	   fluid,	   ion	   and	   pH	   homeostasis.	   For	   instance,	   astrocytes	   can	  
maintain	   the	  extracellular	  pH	  and	   ion	   levels	  within	  physiological	   limits	  because	  
they	   express	   bicarbonate	   transporters,	   proton	   ATPases,	   Na+/H+	   exchangers,	  
monocarboxylic	   transporters	   and	   transporters	   of	   K+	   (Simard	   and	   Nedergaard,	  
2004;	  Obara	  et	  al.,	  2008).	  Their	  expression	  of	  transporters	  for	  neurotransmitters,	  
such	  as	  glutamate,	  glycine	  and	  GABA,	  enable	  astrocytes	  to	  control	  the	   levels	  of	  
these	   neurotransmitters	   at	   synaptic	   sites,	   and	   thus	   dictate	   synaptic	   activity	  
(Adams	  et	  al.,	  1995;	  Conti	  et	  al.,	  2004;	  Sattler	  and	  Rothstein,	  2006;	  Seifert	  et	  al.,	  
2006;	   Goubard	   et	   al.,	   2011).	   Upon	   being	   taken	   into	   astrocytes,	   these	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neurotransmitters	   are	   converted	   by	   specific	   enzymes	   into	   their	   precursors,	   for	  
example,	   glutamine	   synthetase	  will	   convert	   glutamate	   to	  glutamine,	  which	   can	  
the	  be	  returned	  to	  the	  synapse,	  taken	  up	  by	  neurons	  and	  converted	  back	  into	  an	  
active	  neurotransmitter	  (Westergaard	  et	  al.,	  1995).	  Lastly,	  astrocytes	  connected	  
via	   gap	   junctions	   within	   functional	   networks	   may	   synchronize	   their	   ability	   to	  
scavenge	   potentially	   detrimental	   molecules	   such	   as	   glutamate	   and	   potassium,	  
thus,	   protecting	   neurons	   from	   their	   harmful	   effects	   (Seifert	   et	   al.,	   2006;	   de	  
Lanerolle	  et	  al.,	  2010).	  	  	  
	  
Astrocytes	   are	   positioned	   perfectly	   to	   take	   up	   glucose	   from	   blood	   vessels	   by	  
employing	   their	   endfeet	   (Morgello	   et	   al.,	   1995;	   Simard	   et	   al.,	   2003;	  McKenna,	  
2012).	   Under	   physiological	   conditions	   the	  main	   energy	   substrate	   in	   the	   CNS	   is	  
glucose,	   which	   is	   taken	   up	   by	   astrocytes	   or	   neuronal	   cells	   via	   glucose	  
transporters	  (GLUT1	  in	  astrocytes,	  GLUT3	  in	  neuronal	  cells).	  Glucose	  can	  then	  be	  
utilized	  by	  the	  tricarboxylic	  acid	   (TCA)	  cycle	   in	  mitochondria	  to	  satisfy	  neuronal	  
energy	   demands,	   while	   some	   glucose	   in	   converted	   to	   lactate	   or	   glycogen	  
(Pellerin	  et	  al.,	  2007).	  It	  has	  been	  discovered	  that	  astrocytes	  store	  energy	  in	  form	  
of	   glycogen,	   which	   they	   can	   convert	   into	   lactate	   to	   help	   neurons	   to	   sustain	  
glutamatergic	   neurotransmission	   during	   times	   when	   synaptic	   activity	   is	   high	  
(called	   ANLS:	   astrocyte-­‐neuron	   lactate	   shuttle	   hypothesis,	   presented	   in	   Figure	  
1.5)	   (Pellerin,	  2003;	  Occhipinti	  et	  al.,	  2009;	  Pellerin	  and	  Magistretti,	  2012).	   It	   is	  
believed	  that	  glutamate	  released	  into	  the	  synaptic	  space	  upon	  neuronal	  activity	  
is	  co-­‐transported	  with	  Na+	  into	  astrocytes	  by	  glutamate	  transporters	  (GLAST	  and	  
GLT-­‐1	   in	   rodent	   astrocytes).	   This	   activates	   the	   astrocytic	   Na+/K+	  ATPase,	  which	  
functions	   to	   clear	   the	   accumulating	   intra-­‐astrocytic	   Na+	   and	   allow	   entry	   of	  
extracellular	   K+	   in	   an	   ATP	   dependent	   manner.	   Additionally,	   glutamine	  
synthetase,	   the	  enzyme	  that	  converts	  glutamate	   to	  glutamine	  so	   that	   it	   can	  be	  
returned	   to	   neurons	   for	   conversion	   back	   to	   glutamate,	   requires	   ATP.	   Thus,	   to	  
meet	  the	  energy	  demands	  arising	  from	  Na+/K+	  ATPase	  and	  glutamine	  synthetase	  
activity,	   astrocytic	   glycolysis,	   which	   primarily	   utilizes	   blood-­‐derived	   glucose,	   is	  
activated	  to	  produce	  pyruvate	  (ATP	  production)	  and	  lactate.	  This	  lactate	  is	  then	  
transported	   to	   neurons	   by	   monocarboxylate	   transporters	   (MCT1,	   or	   4	   in	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astrocytes	  and	  MCT2	  in	  neurons)	  and	  used	  to	  fuel	  the	  neuronal	  energy	  demands.	  
Thus,	   shuttling	   lactate	   is	   an	   essential	   element	   in	   energy	   coupling	   between	  
astrocytes	   and	   neurons.	   Indeed,	   it	   has	   been	   shown	   that	   correct	   functioning	   of	  
MCTs	   is	   required	   for	   long-­‐term	  memory	   formation	  and	   for	   the	  maintenance	  of	  
LTP	  (Pellerin	  et	  al.,	  2005;	  Pierre	  and	  Pellerin,	  2005;	  Isaac	  et	  al.,	  2007;	  Maekawa	  et	  
al.,	  2009;	  Pierre	  et	  al.,	  2009).	  Consequently,	  disrupting	  the	  expression	  of	  MCTs	  in	  
astrocytes	  causes	  amnesia,	  which	  can	  be	  rescued	  by	  L-­‐lactate	  supplementation,	  
re-­‐enforcing	   the	   importance	   of	   correct	   astrocyte-­‐neuron	   lactate	   transport	   for	  














Figure	  1.5.	  Lactate	  shuttling	  mediates	  metabolic	  coupling	  between	  neurons	  and	  
astrocytes.	  Glutamate	  released	  in	  the	  synaptic	  cleft	  during	  glutamatergic	  neurotransmission	  is	  
co-­‐transported	  with	  Na+	   to	   astrocytes	   via	   glutamate	   transporters	   (GLAST,	  GLT-­‐1).	   The	   resulting	  
increase	   in	   intra-­‐astrocytic	   Na+	   concentration	   activates	   the	   glia-­‐specific	   Na+/K+	   ATPase	   that	  
functions	   to	   clear	   Na+	   and	   to	   allow	   the	   influx	   of	   K+	   in	   an	   ATP	   dependent	   fashion.	   Glutamine	  
synthetase	  produces	   glutamine	   (Gln)	   from	  glutamate	   (Glu),	   also	   in	   an	  ATP	  dependent	  manner.	  
Glutamine	  diffuses	  from	  astrocytes	  into	  the	  extracellular	  space	  and	  into	  neurons	  where	  it	  is	  used	  
to	  resynthesize	  glutamate.	  Both	  the	  ATPase	  pump	  activation	  and	  the	  glutamine	  synthesis	  activate	  
astroglial	   glycolysis,	   which	   utilizes	   blood-­‐derived	   glucose	   to	   produce	   the	   required	   energy	  
substrate	  pyruvate	  (Pyr)	  and	  subsequently	  lactate.	  Lactate	  is	  released	  into	  the	  extracellular	  space	  
via	   the	   astrocytic	  monocarboxylate	   transporter	   (MCT1),	  where	   it	   gets	   taken	  up	  by	  neurons	   via	  
MCT2	  and	  preferentially	  converted	  to	  pyruvate	  and	  used	  as	  the	  major	  fuel	  for	  neuronal	  activity.	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Astrocytes	  also	  play	  a	  critical	  role	  in	  protecting	  neurons	  from	  oxidative	  stress	  via	  
the	  synthesis	  and	  secretion	  of	  the	  antioxidant,	  glutathione	  (GSH;	  reduced	  form)	  
composed	   of	   cysteine	   (Cys),	   glycine	   (Gly)	   and	   glutamate	   (Glu)	   (Heales	   et	   al.,	  
1996;	  Dringen,	  2000;	  Chen	  et	  al.,	  2001;	  Dringen	  et	  al.,	  2001;	  Gegg	  et	  al.,	  2005;	  
Frade	   et	   al.,	   2008).	   System	   Xc-­‐	  mediates	   the	   uptake	   of	   cystine	   into	   astrocytes	  
(particularly	   under	   high	   intra-­‐astrocytic	   concentrations	   of	   Glu),	   where	   it	   gets	  
rapidly	   reduced	   to	   cysteine,	  which	   is	   a	   rate-­‐limiting	   precursor	   in	   the	   synthesis	  
GSH	   (Bridges	   et	   al.,	   2012).	   GSH	   production	   is	   especially	   important	   in	   the	   CNS,	  
where	  metabolic	  activity	  resulting	  in	  the	  production	  of	  free	  radicals	  is	  high,	  and	  
endogenous	   levels	   of	   other	   antioxidants	   are	   fairly	   low	   (Dringen,	   2000).	   Both	  
immunofluorescence	   and	   histochemical	   studies	   on	   brain	   material	   have	   shown	  
that	  neurons	  contain	   low	   levels	  of	  GSH,	  while	  glial	  cells	  display	  a	  much	  greater	  
GSH	  content	   (Slivka	  et	  al.,	   1987;	  Philbert	  et	  al.,	   1991;	  Pearce	  et	  al.,	   1997).	   The	  
release	   of	   GSH	   by	   astrocytes	   via	   multidrug	   resistance-­‐associated	   protein	   1	  
(Mrp1)	  is	  well	  established	  	  (presented	  in	  Figure	  1.6)	  (Yudkoff	  et	  al.,	  1990;	  Juurlink	  
et	   al.,	   1996;	   Sagara	   et	   al.,	   1996;	   Dringen	   et	   al.,	   1999b;	   Hirrlinger	   et	   al.,	   2002;	  
Minich	   et	   al.,	   2006)	   (Hirrlinger	   et	   al.,	   2002;	   Minich	   et	   al.,	   2006).	   Once	   in	   the	  
extracellular	   space	   GSH	   is	   cleaved	   by	   the	   astrocyte-­‐associated	   ectoenzyme	   γ-­‐
glutamyl	   transpeptidase	   (γGT)	   to	   produce	   cysteinylglycine	   (CysGly)	   (Dringen	   et	  
al.,	   1997).	   The	  astrocyte-­‐derived	  CysGly	   is	   then	   further	   cleaved	  by	   the	  neuron-­‐
associated	  ectoenzyme	  aminopeptidase	  N	  (ApN)	  to	  produce	  L-­‐cysteine,	  which	  is	  
taken	  up	  by	  neurons	  via	  excitatory	  amino	  acid	  carried	  1	  (EAAC1)	  (Aoyama	  et	  al.,	  
2008).	  This	  mechanism	  provides	  neurons	  with	  sufficient	  L-­‐cysteine,	  which	  is	  the	  
liming	   substrate	   for	  neuronal	  GSH	  production	   (Aoyama	  et	   al.,	   2006).	   Indeed,	   it	  
has	  been	  shown	  that	  intracellular	  GSH	  levels	  in	  neurons	  are	  higher	  in	  neurons	  co-­‐
cultured	  with	  astrocytes	   than	   in	  pure	  neuronal	   cultures	   (Dringen	  et	   al.,	   1999b;	  
Gegg	  et	  al.,	  2005).	   Importantly,	  oxidative	  stress	  resulting	  possibly	  from	  the	   lack	  
of	   antioxidant	   production	   has	   been	   suggested	   to	   contribute	   towards	   neuronal	  
loss	   in	   JNCL	   (Fossale	  et	  al.,	   2004;	  Benedict	  et	  al.,	   2007;	  Tuxworth	  et	  al.,	   2011).	  
Indeed,	   reduced	   glutathione	   levels	   observed	   in	   the	   Cln3-­‐/-­‐	   mouse	   brain	   would	  
suggest	  that	  astrocytic	  glutathione	  production	  or	  secretion	  may	  be	  disrupted	  in	  
this	  disease	  (Benedict	  et	  al.,	  2007).	  	  













Figure	   1.6.	   Astrocytes	   provide	   the	   substrates	   for	   neuronal	   glutathione	  
production.	   In	  astrocytes,	  cystine	  (C-­‐C)	  transported	  by	  system	  xc-­‐	  (X)-­‐transporter	  into	  the	  cells	  
is	   reduced	   into	   cysteine	   (Cys),	   which	   together	   with	   glutamate	   (Glu)	   is	   used	   for	   astrocytic	  
glutathione	  (reduced	  form	  GSH)	  synthesis.	  GSH	  is	  released	  by	  astrocytes	  via	  multidrug	  resistance	  
protein	   1	   (Mrp1).	   GSH	   is	   then	   cleaved	   by	   the	   astrocyte-­‐associated	   enzyme	   γ-­‐glutamyl	  
transpeptidase	   (γGT)	   and	   the	   neuron-­‐associated	   enzyme	   aminopeptidase	   (ApN)	   to	   produce	  
cysteine,	  which	  gets	  taken	  up	  by	  neurons	  via	  excitatory	  amino	  acid	  carrier	  1	   (EAAC1).	  Cysteine,	  
which	  is	  the	  rate	  limiting	  substrate	  for	  neuronal	  GSH	  production,	  is	  then	  used	  for	  neuronal	  GSH	  
synthesis.	   Alternatively,	   Cys	   can	   become	   oxidixed,	   thus,	   supplying	   C-­‐C	   to	   support	   system	   xc
-­‐	  
activity.	  	  	  	  
	  
Basic	  cytoskeletal	  organization	  in	  astrocytes	  
The	   cytoskeleton	   of	   any	   cell,	   not	   only	   astrocytes,	   is	   the	  most	   integral	   cellular	  
component	   for	   its	   existence	   and	   proper	   functioning.	   The	   cytoskeleton	   of	   an	  
astrocyte	   is	   composed	   of	   three	   main	   types	   of	   polymers,	   actin	   filaments,	  
microtubules,	   and	   a	   group	   of	   polymers	   collectively	   termed	   intermediate	  
filaments,	   that	   are	   crucial	   for	   controlling	   cell-­‐shape	   and	   many	   cellular	  
mechanisms	   such	   as	   proliferation,	   migration,	   uptake	   and	   release	   of	   soluble	  
factors	  (Etienne-­‐Manneville,	  2004;	  Pekny	  and	  Pekna,	  2004;	  Potokar	  et	  al.,	  2007;	  
Wade,	  2007;	  Dominguez	  and	  Holmes,	  2011;	  Middeldorp	  and	  Hol,	   2011).	   These	  
different	   components	   of	   the	   cytoskeleton	   are	   all	   organized	   into	   functional	  
networks	   that	   together	   arrange	   and	   support	   the	   structure	   of	   intracellular	  
compartments	   and	   keep	   the	   shape	   of	   the	   cell	   intact,	   but	   that	   can	   also	  
dynamically	   restructure	   their	   network	   in	   response	   to	   external	   and	   internal	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stimuli.	   The	   key	   differences	   between	   the	  main	   cytoskeletal	   polymers	   are	   their	  
mechanical	  rigidity,	  their	  polarity,	  the	  dynamics	  of	  their	  reorganization,	  and	  the	  
type	   of	   molecular	   motors	   they	   form	   functional	   partners	   with	   (reviewed	   in	  
Fletcher	  and	  Mullins,	  2010).	  
	  
Microtubules	   are	   composed	   of	   α-­‐	   and	   β-­‐tubulin	   heterodimers,	   have	   complex	  
dynamics	  of	  assembly	  and	  disassembly,	  and	  out	  of	  three	  main	  polymers	  they	  are	  
the	  stiffest	  (Desai	  and	  Mitchison,	  1997;	  Amos	  and	  Schlieper,	  2005).	  These	  α-­‐	  and	  
β-­‐tubulin	   dimers	   polymerize	   end	   to	   end	   into	   protofilaments,	   which	   ultimately	  
form	  the	  building	  blocks	   for	   the	  hollow	  microtubule	  structure	   (Mandelkow	  and	  
Mandelkow,	   1994).	   Altogether	   thirteen	   (this	   number	  may	   vary)	   protofilaments	  
bind	  together	  laterally	  to	  form	  a	  single	  microtubule	  and	  this	  basic	  structure	  can	  
subsequently	  be	  extended	  further	  by	  the	  addition	  of	  more	  protofilaments	  (Amos	  
and	  Schlieper,	  2005).	  Microtubules	  have	  a	  distinct	  polarity,	  which	  defines	  some	  
of	   their	   biological	   activities.	   Tubulin	   polymerizes	   in	   a	   specific	   manner,	   an	   α-­‐
subunit	  from	  one	  tubulin	  dimer	  contacts	  a	  β-­‐subunit	  of	  the	  next	  tubulin	  dimer	  to	  
form	   a	   protofilament	   with	   one	   end	   exposing	   only	   α-­‐subunits	   (-­‐	   end),	   and	   the	  
other	  end	  only	  β-­‐subunits	  (+	  end).	  Since	  the	  protofilaments	  bundle	  parallel	  with	  
each	  other,	  in	  a	  fully	  formed	  microtubule	  there	  is	  one	  (–)	  end	  with	  only	  exposed	  
α-­‐subunits,	  and	  one	  (+)	  end	  with	  only	  exposed	  β-­‐subunits	  (Desai	  and	  Mitchison,	  
1997).	  	  
	  
Microtubules	   are	   extremely	   dynamic	   structures,	   since	   they	   are	   constantly	  
assembled	   and	   disassembled	   at	   the	   (+)	   end	   in	   a	   GTP-­‐GDP	   dependent	  manner	  
(Weisenberg	  and	  Deery,	  1976;	  Weisenberg	  et	  al.,	  1976;	  Mitchison	  and	  Kirschner,	  
1984;	  van	  der	  Vaart	  et	  al.,	  2009).	  Microtubules	  can	  form	  nearly	  linear	  tracks	  that	  
span	   the	   length	  of	   the	  whole	   cell,	  making	   them	  essential	   for	   the	  development	  
and	  maintenance	  of	  cell	  shape	  (Brangwynne	  et	  al.,	  2006;	  Efremov	  et	  al.,	  2011).	  
Furthermore,	  microtubules	  are	  involved	  in	  the	  intracellular	  transport	  of	  vesicles,	  
mitochondria	   and	   other	   cellular	   components,	   cell	   signaling,	   cell	   division	   and	  
mitosis	   (Potokar	   et	   al.,	   2007;	   2008;	   Garnham	   and	   Roll-­‐Mecak,	   2012).	   Many	  
factors	   facilitate	   such	   functional	   diversity:	   the	   binding	   of	   various	   regulatory	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proteins,	   including	   microtubular	   associated	   proteins	   (MAPs)	   (Couchie	   et	   al.,	  
1985;	   Itoh	  and	  Hotani,	   2004);	   the	  expression	  of	  different	   tubulin	   isotypes	  with	  
different	  functions	  (Sullivan,	  1988;	  Nielsen	  et	  al.,	  2001;	  Miller	  et	  al.,	  2010);	  and	  
post-­‐translational	   modification	   of	   tubulin	   (Garnham	   and	   Roll-­‐Mecak,	   2012).	   In	  
addition	   to	   the	   movement	   of	   microtubules	   generated	   by	   their	   own	   dynamic	  
instability,	   motor	   proteins	   can	   move	   along	   α-­‐	   and	   β-­‐fibers	   (Mallik	   and	   Gross,	  
2004).	  The	  most	  common	  microtubule	  motor	  proteins	  are	  dynein,	  which	  moves	  
towards	   the	   (-­‐)	   end,	   and	   kinesin,	  which	  moves	   towards	   the	   (+)	   end.	   The	  main	  
function	   of	   these	   motors	   is	   to	   allow	   transport	   of	   cargo	   between	   different	  
intracellular	  compartments	  and	  locations	  (Goldstein	  and	  Yang,	  2000;	  Karcher	  et	  
al.,	   2002;	   Mallik	   et	   al.,	   2004;	   Gennerich	   and	   Vale,	   2009;	   Akhmanova	   and	  
Hammer,	  2010;	  Hirokawa,	  2011).	  	  	  
	  
Actin	   forms	   the	   thinnest	   filaments	   of	   the	   cytoskeleton	   (6nm	   in	   diameter)	   and	  
exists	   in	   two	   states	  within	   the	   cell,	   as	  monomers	   (G-­‐actin)	   or	   as	   two-­‐stranded	  
helical	   filaments	   (F-­‐actin)	   that	   are	   formed	   from	   the	   assembly	   of	   the	   G-­‐actin	  
monomers	  (Guasch	  et	  al.,	  2003;	  Pollard	  and	  Cooper,	  2009;	  Efremov	  et	  al.,	  2011).	  
In	  a	  similar	  fashion	  to	  microtubules,	  actin	  filaments	  are	  polarized	  (Cramer,	  1999).	  
These	   filaments	   grow	   faster	   at	   one	   end	   and	   assembly	   and	   disassembly	   is	  
regulated	  by	  binding	  and	  dissociation	  of	  ADP/ATP,	  which	   is	  controlled	  by	  many	  
actin-­‐binding	  proteins	  (cross-­‐linking	  proteins,	  motor	  proteins,	  branching	  proteins	  
and	  polymerization	  proteins)	   (Remedios	  et	  al.,	  2003).	  For	   instance,	   interactions	  
between	   actin	   filaments	   and	   myosin	   motor	   proteins	   are	   important	   in	   cellular	  
mobility	   and	   protein	   trafficking	   (Stachelek	   et	   al.,	   2001;	   Vicente-­‐Manzanares	   et	  
al.,	   2007;	   2009).	   The	   actin	   cytoskeleton	   also	   plays	   a	   fundamental	   role	   in	  
phagocytosis,	   adhesion,	   and	   the	   uptake	   and	   released	   of	   soluble	   factors	  
(Zigmond,	   1996;	   Potokar	   et	   al.,	   2007).	   For	   instance,	   disrupting	   the	   actin	  
cytoskeleton	  by	  using	  agents	  such	  as	  cytochalasin	  D	  alters	  various	  fundamental	  
functions	   of	   astrocytes	   including	   glutamate	   clearance,	   hormone	  modulation	   of	  
cell	   growth,	  many	   aspects	   of	   calcium	   signaling	   and	  Cl-­‐	   conductance	   (Cotrina	   et	  
al.,	  1998;	  Lascola	  et	  al.,	  1998;	  Duan	  et	  al.,	  1999;	  Sergeeva	  et	  al.,	  2000).	  Generally	  
the	   dynamic	   organization	   of	   the	   actin	   cytoskeleton	   is	   regulated	   by	   small	   Rho	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GTPases	  (Hall,	  1998;	  Bishop	  and	  Hall,	  2000).	  
Intermediate	   filaments	   (IF)	   are	  generally	  considered	   to	  be	   the	   least	   rigid	  of	  all	  
the	  cytoskeletal	  polymers,	  and	  they	  have	  the	  ability	  to	  crosslink	  with	  each	  other,	  
as	  well	  with	  actin	  filaments	  and	  microtubules	  (Stewart,	  1993;	  Fuchs	  and	  Weber,	  
1994;	  Wiche,	  1998;	  Wiche	  and	  Winter,	  2011).	  IFs	  are	  not	  polarized,	  and	  as	  such	  
the	  directional	  movement	  of	  molecular	  motors	  is	  not	  supported	  by	  IFs	  (Zackroff	  
and	   Goldman,	   1979;	   Ananthakrishnan	   and	   Ehrlicher,	   2007).	   IFs	   are	   dynamic	  
components	  of	  the	  cytoskeleton	  that	  are	  encoded	  by	  approximately	  70	  genes	  in	  
eukaryotic	   cells	   (Hesse	   et	   al.,	   2001;	   Zimek	   et	   al.,	   2003).	   Structurally,	   all	   IFs	  
proteins	  are	  predicted	  to	  have	  the	  same	  secondary	  structure;	  a	  non-­‐alpha-­‐helical	  
N-­‐terminal	   head,	   a	   C-­‐terminal	   tail	   domain,	   and	   a	   central	   alpha-­‐helical	   domain,	  
termed	   the	   rod	   (Fuchs	   and	   Weber,	   1994).	   IFs	   can	   also	   form	   homo-­‐	   or	  
heteropolymers	   with	   each	   other	   resulting	   in	   the	   formation	   of	   a	   variety	   of	  
possible	  IF	  protein	  networks	  (Steinert	  et	  al.,	  1999).	  The	  IF	  network	  forms	  a	  crucial	  
part	  of	  the	  astrocyte	  cytoskeleton,	  and	  is	  composed	  from	  GFAP,	  vimentin,	  nestin	  
and	  synemin	  (Pekny	  and	  Pekna,	  2004).	  GFAP	  is	  the	  main	  IF	  in	  mature	  astrocytes	  
and	  it	  is	  also	  required	  during	  astrocyte	  development	  (Middeldorp	  and	  Hol,	  2011),	  
while	   both	   vimentin	   and	   nestin	   are	   expressed	   abundantly	   by	   immature	  
astrocytes	   (Pekny	   and	   Pekna,	   2004).	   However,	   nestin	   requires	   vimentin	   as	   a	  
polymerization	  partner	  because	  nestin	  cannot	  form	  IFs	  on	  its	  own	  or	  with	  GFAP	  
(Eliasson	  et	  al.,	  1999).	  The	  functional	  importance	  of	  each	  astrocyte-­‐expressed	  IFs	  
under	  physiological	   conditions	   is	  not	  well	  understood	   (Pekny	  and	  Pekna,	  2004;	  
Sofroniew	   and	   Vinters,	   2010).	   When	   faced	   with	   pathological	   situations,	  
astrocytes	  up-­‐regulate	  the	  expression	  of	  GFAP,	  vimentin	  and	  nestin	  and	  change	  
their	  morphology	   (Mucke	   and	   Eddleston,	   1993;	   Pekny	   et	   al.,	   1999;	   Pekny	   and	  
Pekna,	   2004).	   In	   order	   to	   study	   the	   individual	   roles	   of	   each	   IF	   in	   astrocytes,	  
studies	  in	  mice	  deficient	  in	  either	  GFAP	  (GFAP-­‐/-­‐)	  (Gomi	  et	  al.,	  1995;	  Liedtke	  et	  al.,	  
1996;	  McCall	   et	   al.,	   1996;	   Pekny	  and	  Nilsson,	   2005),	  Vimentin	   (Vim-­‐/-­‐)	   (Colucci-­‐
Guyon	  et	  al.,	  1994),	  or	  both	  IFs	  (GFAP-­‐/-­‐Vim-­‐/-­‐)	  (Eliasson	  et	  al.,	  1999;	  Macauley	  et	  
al.,	   2011)	   have	   been	   generated.	   These	   studies	   demonstrated	   that	   IF	   up-­‐
regulation	  is	  responsible	  for	  both	  positive	  and	  negative	  outcomes	  in	  the	  diseased	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CNS.	  For	  instance,	  GFAP-­‐/-­‐Vim-­‐/-­‐Ppt1-­‐/-­‐	  mice	  were	  used	  to	  study	  the	  role	  of	  IFs	  in	  
reactive	  astrocytosis	  in	  INCL	  (Macauley	  et	  al.,	  2011).	  Upon	  attenuated	  astrocyte	  
activation,	   due	   to	   the	   lack	   of	   intermediate	   filament	   expression	   in	   the	  	  	  	  	  	  	  	  	  	  	  	  	  
GFAP-­‐/-­‐Vim-­‐/-­‐Ppt1-­‐/-­‐	   mice,	   the	   disease	   appeared	   earlier	   and	   progressed	   more	  
rapidly	   than	   in	  Ppt1-­‐/-­‐	  mice.	   Thus,	   in	   INCL,	   astrocyte	   activation	   appears	   to	   help	  
protect	   against	   neurodegeneration	   (Macauley	   et	   al.,	   2011).	   The	   process	   of	  
astrocyte	  activation	  is	  reviewed	  in	  more	  detailed	  below.	  
	  	  	  
Recently	   it	   has	   been	   proposed	   that	   IFs,	   together	   with	   actin	   filaments	   and	  
microtubules,	   are	   involved	   in	   vesicle	   delivery	   and	   transport	   in	   astrocytes	  
(Potokar	  et	  al.,	  2007;	  2008;	  Kreft	  et	  al.,	  2009;	  Potokar	  et	  al.,	  2010).	  Investigating	  
the	   mobility	   of	   fluorescently	   labeled	   vesicles	   in	   cultured	   astrocytes	   with	  
depolymerized	  IFs,	  or	  in	  astrocytes	  derived	  from	  GFAP-­‐/-­‐Vim-­‐/-­‐	  mice,	  revealed	  that	  
IFs	   are	   crucial	   for	   determining	   the	   directional	   mobility	   of	   exocytotic	   vesicles	  
(Potokar	  et	  al.,	  2007).	  In	  addition,	  astrocyte	  IFs	  have	  also	  been	  shown	  to	  reduce	  
stimulation-­‐dependent	   mobility	   of	   whole	   subcellular	   compartments	   such	   as	  
endosomes	  and	  lysosomes,	  and	  also	  to	  regulate	  the	  mobility	  of	  recycling	  vesicles	  
(vesicles	   that	   fuse	   to	   and	   are	   then	   retrieved	   from	   the	   plasma	   membrane)	   in	  
cultured	   astrocytes	   (Potokar	   et	   al.,	   2010).	   Furthermore,	   interferon	   γ	   (IFNγ)	  
induced	   activation	   has	   been	   shown	   to	   increase	   membrane	   MHC	   class	   II	  
expression	  in	  astrocytes	  (Hirsch	  et	  al.,	  1983;	  Shrikant	  and	  Benveniste,	  1996).	  For	  
this	   to	  occur,	   the	  MHC	   II	   complex	  needs	   to	  be	  delivered	   to	   the	   cell	   surface	  by	  
being	   transported	   in	   membrane-­‐bound	   vesicles.	   Live	   cell	   imaging	   of	   cultured	  
astrocytes	   revealed	   faster	   movement	   of	   such	   vesicles	   in	   IFNγ	   treated	   WT	  
astrocytes	   compared	   to	   the	   IF-­‐deficient	   astrocytes	   derived	   from	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
GFAP-­‐/-­‐Vim-­‐/-­‐	  mice	  (Vardjan	  et	  al.,	  2012).	  Thus,	  IFs	  appear	  to	  facilitate	  the	  delivery	  
of	   membrane-­‐associated	   protein	   complexes	   in	   activated	   astrocytes.	   Generally,	  
the	  upregulation	  of	   IFs	  under	  pathological	   conditions	  may	  alter	   the	   function	  of	  
astrocytes	   by	   influencing	   vesicle	   trafficking,	   which	   may	   subsequently	   impact	  
exocytosis	  and	  endocytosis	  and	  alter	  cell-­‐cell	  communication,	  based	  on	  diffusion	  
of	  soluble	  factors	  between	  astrocytes	  and	  other	  neural	  cells.	  Any	  abnormalities	  
in	  the	  dynamic	  organization	  of	  IF	  networks	  may	  significantly	  alter	  such	  functions.	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1.4	  Astrocytes	  in	  disease	  
Reactive	  astrocytosis,	  the	  process	  of	  astrocyte	  activation,	  takes	  place	  in	  response	  
to	  virtually	  all	  forms	  of	  acute	  and	  chronic	  CNS	  injury	  or	  disease	  and	  can	  be	  both	  
harmful	  and	  beneficial	  (summarized	  in	  Figure	  1.7)	  (Ridet	  et	  al.,	  1997;	  Sofroniew,	  
2009;	  Sofroniew	  and	  Vinters,	  2010;	  Colangelo	  et	  al.,	  2012;	  Parpura	  et	  al.,	  2012).	  
For	   instance,	   scar-­‐forming	   reactive	   astrocytes	   that	   inhibit	   axonal	   regeneration	  
are	   often	   seen	   as	   detrimental	   to	   clinical	   outcome	   (Fawcett	   and	   Asher,	   1999;	  
Sofroniew,	   2009),	   yet,	   reactive	   astrocytes	   can	   be	   beneficial	   in	   several	   ways	  
including:	  1)	  uptake	  of	  excess	  and	  potentially	  excitotoxic	  glutamate	  (Swanson	  et	  
al.,	   2004;	   Kim	   et	   al.,	   2011;	   Coulter	   and	   Eid,	   2012);	   2)	   stabilization	   of	   the	  
extracellular	   fluid	  and	   ion	  balance	   (Simard	  and	  Nedergaard,	  2004;	  Obara	  et	  al.,	  
2008;	  Zador	  et	  al.,	  2009);	  and	  3)	  protection	  from	  oxidative	  stress	  via	  glutathione	  
production	  (Heales	  et	  al.,	  1996;	  Dringen,	  2000;	  Chen	  et	  al.,	  2001;	  Dringen	  et	  al.,	  
2001;	   Gegg	   et	   al.,	   2005;	   Frade	   et	   al.,	   2008;	   Vargas	   et	   al.,	   2008).	   Indeed,	   via	  
enhanced	   soluble	   factor	   secretion,	  activated	  astrocytes	  not	  only	  alter	  neuronal	  
biology,	  but	  also	   impact	   the	   interplay	  between	   themselves	  and	  other	  glial	   cells	  
(Liberto	   et	   al.,	   2004;	   Lucas	   et	   al.,	   2006;	   Bélanger	   and	   Magistretti,	   2009;	  
Sofroniew,	  2009;	  Lehnardt,	  2010;	  Liu	  et	  al.,	  2011;	  Singh	  et	  al.,	  2011).	  Finally,	  the	  
gap	   junction	   mediated	   coupling	   within	   the	   astrocyte	   syncytium	   may	   also	   be	  
altered	  upon	  reactive	  astrocytosis	  (Kielian,	  2008).	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Figure	  1.7.	  Reactive	  astrocytosis.	  A	  number	  of	  cellular	  and	  molecular	  triggers	  may	  lead	  to	  
activation	  of	  astrocytes	  (reactive	  astrocytosis).	  Upon	  activation	  several	  molecular	  and	  functional	  
changes	  occur.	  Such	  changes	  may	  have	  a	  neuroprotective	  or	  neurotoxic	  impact	  that	  may	  result	  in	  
disrupted	  connection	  between	  astrocytes	  and	  neuronal	  synapses.	  Astrocyte	  connectivity	  via	  gap	  
junctions	   and	   the	   interplay	   between	   astrocytes	   and	   other	   glial	   cells	  may	   also	   be	   altered	   upon	  
astrocyte	  activation.	  
	  
The	  changes	  that	  astrocytes	  undergo	  upon	  activation	  differ	  greatly	  depending	  on	  
the	   nature	   and	   severity	   of	   the	   insult,	   but	   include	   alterations	   in	   molecular	  
expression,	  progressive	   cellular	  hypertrophy	  and,	   in	   severe	  cases,	  proliferation,	  
disruption	   of	   individual	   astrocytic	   domains	   and	   scar	   formation	   (Pekny	   and	  
Nilsson,	   2005;	   Sofroniew,	   2009;	   Sofroniew	   and	   Vinters,	   2010).	   According	   to	  
current	   understanding,	   astrocytes	   (mainly	   post-­‐mitotic	   in	   the	   healthy,	   mature	  
CNS),	  may	  become	  proliferative	  only	  under	  very	  severe	  circumstances,	  such	  as	  in	  
severe	   focal	   lesions,	   infections	   or	   areas	   suffering	   from	   chronic	  
neurodegeneration	  (Lindholm	  et	  al.,	  1992;	  Norton	  et	  al.,	  1992;	  Satoh	  et	  al.,	  1996;	  
Bush	   et	   al.,	   1999;	   Horner	   et	   al.,	   2000;	   Colodner	   et	   al.,	   2005;	   Sofroniew	   and	  
Vinters,	  2010).	  One	  hypothesis	  behind	  the	  proliferation	  of	  activated	  astrocytes	  is	  
that	  such	  cells	  revert	  to	  a	  immature	  state,	  making	  them	  capable	  of	  proliferating	  
in	   similar	   fashion	   to	   immature,	   stem-­‐cell	   like	   astrocytes	   (Cahoy	   et	   al.,	   2008;	  
Zamanian	  et	  al.,	  2012).	  	  
	  
Generally,	   upregulation	   of	   GFAP,	   is	   the	   best-­‐known	   hallmark	   of	   reactive	  
astrocytosis	  (Pekny	  and	  Pekna,	  2004;	  Pekny	  and	  Nilsson,	  2005),	  but	  up-­‐regulation	  
of	   vimentin	   and	   re-­‐expression	   of	   nestin	   are	   also	   established	   hallmarks	   of	   this	  
process	  (Pekny	  and	  Pekna,	  2004;	  Pekny	  and	  Nilsson,	  2005).	  Thus,	  it	  appears	  that	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IF	   proteins	   may	   play	   a	   particular	   role	   in	   astrocytes	   activation.	   This	   has	   been	  
confirmed	   in	   a	   number	   of	   mouse	   models	   with	   different	   types	   of	   genetic	  
depletion	  of	  astrocyte	   IF	  proteins	   (Pekny,	  2001;	  Pekny	  and	  Pekna,	  2004;	  Pekny	  
and	   Nilsson,	   2005).	  GFAP-­‐/-­‐	   mice	   developed	   normally,	   but	   displayed	   enhanced	  
neuronal	   LTP	   compared	   to	   control	  mice,	   suggesting	   that	  GFAP	   is	   an	   important	  
factor	   in	   astrocyte-­‐neuronal	   interactions	   (McCall	   et	   al.,	   1996).	   Upon	   ischemia,	  
however,	  the	  LTP	  and	  also	  paired	  pulse	  facilitation	  (PPF)	  seen	  in	  GFAP-­‐/-­‐	  mice	  was	  
significantly	  depressed,	  which	  was	  accompanied	  by	  a	  marked	  increase	  in	  the	  loss	  
of	   CA1	   and	   CA3	   hippocampal	   pyramidal	   neurons	   compared	   to	   control	   mice	  
(Tanaka	   et	   al.,	   2002).	   Similarly,	   ablating	   scar-­‐forming,	   reactive	   astrocytes	   in	  
models	   of	   traumatic	   brain	   injury	   (Myer	   et	   al.,	   2006),	   autoimmune	  
encephalomyelitis	  (Voskuhl	  et	  al.,	  2009),	  spinal	  cord	  injury	  (Faulkner	  et	  al.,	  2004),	  
ischemia	   (Li	   et	   al.,	   2008)	   and	   in	   INCL	   (Macauley	   et	   al.,	   2011)	   resulted	   in	  more	  
dramatic	   tissue	   damage,	   increased	   neurodegeneration	   and	   accelerated	  
neuroinflammation.	   Thus,	   in	   some	   cases	   the	   IF	   protein	  mediated	   activation	   of	  
astrocytes	   appears	   to	   play	   a	   protective	   role	   against	   pathogenic	   disease	  
progression.	   However,	   in	   some	   cases	   the	   lack	   of	   IFs	   makes	   astrocytes	   act	   as	  
protective	   and	   beneficial	   players	   to	   halt	   the	   progression	   of	   the	   pathogenic	  
events.	   For	   instance,	   the	  GFAP-­‐/-­‐Vim-­‐/-­‐	  astrocytes	   in	   an	   entorhinal	   cortex	   lesion	  
mouse	  model	  (CNS	  trauma	  model)	  showed	  a	  profoundly	  reduced	  hypertrophy	  of	  
astrocyte	  processes,	  when	  compared	  to	  reactive	  astrocytes	  in	  WT	  mice,	  and	  this	  
was	   accompanied	   by	   significant	   synaptic	   regeneration	   in	   the	   hippocampus,	  
suggesting	  that	  reactive	  astrocytes	  act	  as	  inhibitors	  of	  neuroregeneration	  in	  this	  
type	  of	  CNS	  insult	  (Wilhelmsson	  et	  al.,	  2004).	  Indeed,	  other	  studies	  suggest	  that	  
several	   aspects	   of	   CNS	   regeneration	   are	   improved	   in	   absence	   of	   astrocytic	   IFs	  
(Larsson	   et	   al.,	   2004;	   Cho	   et	   al.,	   2005;	  Widestrand	   et	   al.,	   2007).	   For	   example,	  
adult	   hippocampal	   neurogenesis	   has	   been	   demonstrated	   to	   be	   increased	   in	  
GFAP-­‐/-­‐Vim-­‐/-­‐	  mice	  compared	   to	  WT	  mice,	   thus,	  modulating	  astrocyte	   IF	   related	  
reactivity	  may	  regulate	  adult	  neurogenesis	  (Larsson	  et	  al.,	  2004).	  Attenuation	  of	  
post-­‐traumatic	   reactive	   astrocytosis	   in	   an	   optic	   nerve	   injury	   model	   has	   been	  
shown	   to	   aid	   axon	   regeneration,	   again	   suggesting	   that	   long	   lasting	   reactive	  
astrocytosis	  has	  a	  negative	   impact	  on	  neuronal	   regeneration	  (Cho	  et	  al.,	  2005).	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Overall,	   the	   specific	   role	   of	   reactive	   astrocytosis	   in	   progression	   of	   pathological	  
events	  seems	  to	  be	  disease	  type	  specific.	   In	  an	  effort	  to	  explore	  the	  underlying	  
mechanisms	   of	   reactive	   astrocytosis	   in	   CNS	   disorders,	   the	   presence	   of	   factors	  
mediating	   inflammatory	   responses,	   such	   as	   presence	   of	   inflammatory	   cells	  
(CD45+	   leukocytes,	   CD68+	   macrophages,	   CD3+	   T-­‐cells)	   and	   expression	   levels	   of	  
soluble	  inflammatory	  factors	  (pro-­‐	  and	  anti-­‐inflammatory	  cytokines,	  chemokines	  
e.g),	  have	  been	  investigated	  (Christopherson	  et	  al.,	  2005;	  Garwood	  et	  al.,	  2011;	  
Macauley	  et	  al.,	  2011;	  Parpura	  et	  al.,	  2012;	  Vardjan	  et	  al.,	  2012;	  Zamanian	  et	  al.,	  
2012).	  	  
	  
An	  immune	  response	  can	  occur	  in	  the	  brain	  as	  a	  result	  of	  virtually	  any	  CNS	  insult	  
or	  disease	  such	  as	  different	  forms	  of	  NCLs	  (Allan	  and	  Rothwell,	  2003;	  Saha	  et	  al.,	  
2008;	  Frank-­‐Cannon	  et	  al.,	  2009;	  Macauley	  et	  al.,	  2011;	  Mole	  et	  al.,	  2011).	  The	  
process	   of	   neuroinflammation,	   like	   astrocytosis,	   may	   have	   a	   beneficial	   or	  
detrimental	   impact	  on	  disease	  progression	   (Allan	   and	  Rothwell,	   2003;	   Lucas	   et	  
al.,	   2006;	   Frank-­‐Cannon	  et	   al.,	   2009).	  Microglial	   cells	   are	  generally	   accepted	  as	  
the	  main	   immune	  cells	  of	   the	  brain	   (Lehnardt,	  2010;	  Kettenmann	  et	  al.,	  2011),	  
however,	   astrocytes	   function	   as	   essential	   regulators	   of	   this	   inflammatory	  
response.	  Numerous	  studies	  have	  revealed	  that	  activated	  astrocytes	  can	  release	  
a	   wide	   selection	   of	   potent	   mediators	   of	   neuroinflammation,	   including	  
chemokines,	  cytokines	  and	  growth	  factors,	  that	  may	  exert	  either	  neuroprotective	  
or	  harmful	  effects	  on	  neuronal	  survival	  and	  function	  in	  the	  injured	  brain	  (Ridet	  et	  
al.,	  1997;	  John	  et	  al.,	  2003;	  Farina	  et	  al.,	  2007;	  Ricci	  et	  al.,	  2009;	  Ransohoff	  and	  
Brown,	  2012).	  	  
	  
Understanding	   the	   precise	   role	   of	   astrocytes	   in	   neuroinflammation	   has	   been	  
challenging	  due	  the	  fact	  that	  astrocyte	  are	  able	  to	  secrete	  an	  extensive	  range	  of	  
soluble	   factors	   in	   response	   to	   many	   different	   stimuli,	   including	   Interferon-­‐γ	  
(IFNγ),	   interleukin-­‐6	   (IL-­‐6),	   interleukin-­‐10	   (IL-­‐10)	   and	   tumor	   necrosis	   factor-­‐α	  
(TNF-­‐α)	   (Ridet	   et	   al.,	   1997;	   Farina	   et	   al.,	   2007;	   Ransohoff	   and	   Brown,	   2012).	  
Moreover,	   various	   cytokine	   receptors	   are	   expressed	   upon	   astrocytes,	   and	   as	  
such	   cytokine	   signaling	   can	   occur	   both	   in	   an	   autocrine	   and	   paracrine	   fashion	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(John	  et	  al.,	  2003).	  Another	   issue	   that	  has	  made	  establishing	   the	  exact	   roles	  of	  
individual	  secreted	  proteins	  challenging	  is	  that	  many	  of	  them	  interact	  with	  each	  
other	  either	  antagonistically	  or	  synergistically	   (John	  et	  al.,	  2003;	  Trendelenburg	  
and	   Dirnagl,	   2005).	   Thus,	   it	   is	   likely	   that	   many	   cytokines,	   for	   example,	   may	  
simultaneously	  mediate	  both	  neuroprotective	  and	  harmful	  effects.	  For	  instance,	  
some	   research	   has	   shown	   that	   IL-­‐1β	   can	   exacerbate	   the	   outcome	   of	   neuronal	  
injury	  both	  in	  vivo	  and	  in	  vitro	  (Relton	  and	  Rothwell,	  1992;	  Hailer	  et	  al.,	  2005).	  In	  
contrast,	  other	  studies	  have	  shown	  IL-­‐1β	  can	  exhibit	  neuroprotective	  properties,	  
such	   as	   aiding	   remyelination,	   blood-­‐brain	   barrier	   repair,	   neurotrophic	   factor	  
production	  and	  protection	  against	  ischemia	  induced	  neurodegeneration,	  possibly	  
via	  enhancing	  production	  of	  various	  growth	  factors	  such	  as	  ciliary	  neurotrophic	  
factor	   (CNTF),	   nerve	   growth	   factor	   (NGF)	   and	   platelet-­‐derived	   growth	   factor	  
(PDGF)	   (Gadient	  et	  al.,	  1990;	  Strijbos	  and	  Rothwell,	  1995;	  DeKosky	  et	  al.,	  1996;	  
Ohtsuki	   et	   al.,	   1996;	   Silberstein	   et	   al.,	   1996;	  Herx	   et	   al.,	   2000;	  Herx	   and	   Yong,	  
2001;	   Juric	   and	   Carman-­‐Krzan,	   2001).	   In	   addition	   to	   secreting	   IL-­‐1β,	   astrocytes	  
express	  the	  IL-­‐1-­‐receptor	  and	  can	  thus	  respond	  to	  IL-­‐1β	  themselves	  by	  secreting	  
neuroprotective	  factors	  such	  as	  NGF,	  CNTF	  and	  fibroblast	  growth	  factor-­‐2	  (FGF-­‐
2)	  (Juric	  and	  Carman-­‐Krzan,	  2001;	  John	  et	  al.,	  2003;	  Liberto	  et	  al.,	  2004).	  Thus,	  via	  
protein	   secretion	   astrocytes	   are	   able	   to	   regulate	   their	   own	   biology	   and	  
importantly	  alter	  the	  survival	  and	  functioning	  of	  neuronal	  cells,	  as	  well	  as	  other	  
glial	  cells.	  	  
	  
Communication	  between	  astrocytes	  and	  microglia	  
Reactive	   gliosis	   is	   a	   very	   complex	   phenomenon	   involving	   interactions	   between	  
different	  glial	  cells	  and	  neurons,	  leading	  eventually	  to	  neuronal	  survival	  or	  death,	  
axonal	   regeneration	  or	  withdrawal	   (Fok-­‐Seang	  et	  al.,	  1998;	  Allan	  and	  Rothwell,	  
2001;	  Liberto	  et	  al.,	  2004;	  Ricci	  et	  al.,	  2009;	  Sofroniew	  and	  Vinters,	  2010;	  Liu	  et	  
al.,	  2011).	  Generally	  activation	  of	  microglia	  and	  astrocytes	  correlates	  closely	  with	  
disease	   progression	   and	   severity	   (Pontikis	   et	   al.,	   2004;	   Teismann	   and	   Schulz,	  
2004;	  Pontikis	  et	  al.,	  2005;	  Block	  et	  al.,	  2007;	  Weimer	  et	  al.,	  2009;	  Garwood	  et	  
al.,	  2011;	  Liu	  et	  al.,	  2011).	  In	  many	  cases,	  microglial	  activation	  precedes	  astrocyte	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activation,	   and	   the	   former	   may	   accelerate	   the	   latter	   (Saura,	   2007;	   Liu	   et	   al.,	  
2011;	  Pascual	  et	  al.,	  2012).	  Indeed,	  microglial	  cells	  are	  considered	  to	  be	  the	  first	  
line	   of	   defense,	   and	  under	   physiological	   conditions,	  microglia	   are	   ramified	   and	  
apply	  their	  motile	  processes	  to	  control	  and	  police	  the	  pathogenic	  modifications	  
occurring	   in	   their	   local	   microenvironment	   within	   the	   CNS	   (Nimmerjahn	   et	   al.,	  
2005;	   Kettenmann	   et	   al.,	   2011;	   Pascual	   et	   al.,	   2012;	   Kettenmann	   et	   al.,	   2013).	  
Once	   the	   microenvironment	   changes	   microglia	   become	   activated	   very	   rapidly	  
and	   undergo	   a	   pronounced	   morphological	   transformation,	   proliferate	   and	  
increase	   secretion	   of	   various	   soluble	   factors	   (Aloisi,	   2001;	   Raivich	   et	   al.,	   2002;	  
Davalos	  et	  al.,	  2005;	  Kingwell,	  2012).	  This	  may	  lead	  to	  astrocyte	  activation,	  which	  
may	  also	  be	  a	  microglia-­‐independent	  phenomenon	  (Liu	  et	  al.,	  2011;	  Tian	  et	  al.,	  
2012).	  Activated	  astrocytes,	  on	  the	  other	  hand,	  not	  only	  facilitate	  the	  activation	  
and	  recruitment	  of	  more	  distant	  microglia,	  but	  may	  also	  inhibit	  some	  actions	  of	  
these	  activated	  microglia	  (Hailer	  et	  al.,	  2001;	  Liu:2011gy	  Min	  et	  al.,	  2006;	  Tian	  et	  
al.,	   2012).	   For	   instance,	   the	   propagation	   of	   astrocyte	   calcium	  waves	   has	   been	  
proposed	   to	   be	   involved	   in	   astrocyte-­‐mediated	   facilitation	   of	   microglial	  
activation.	  This	  suggestion	  is	  based	  on	  the	  demonstration	  that	  ATP	  released	  from	  
astrocytes	  upon	  calcium	  wave	  propagation	  can	  activate	  surrounding	  microglia	  by	  
inducing	   their	   rapid	   proliferation,	   promoting	   secretion	   of	   cytokines	   and	  
microglial	  migration	  towards	  injury	  site	  (Hide	  et	  al.,	  2000;	  Verderio	  and	  Matteoli,	  
2001;	  Schipke	  et	  al.,	  2002;	  Bianco	  et	  al.,	  2005;	  Davalos	  et	  al.,	  2005;	  Haynes	  et	  al.,	  
2006).	  The	  inhibitory	  influences	  of	  activated	  astrocytes	  upon	  microglia	  activation	  
are	  manifold	  (Liu	  et	  al.,	  2011).	  These	   include	  the	  ability	  of	  transforming	  growth	  
factor-­‐β	  (TGF-­‐β),	  which	   is	  mainly	  produced	  by	  astrocytes	  (Ramírez	  et	  al.,	  2005),	  
to	   deactivate	   microglia	   by	   downregulating	   the	   expression	   of	   molecules	  
associated	   with	   antigen	   presentation	   and	   production	   of	   pro-­‐inflammatory	  
cytokines,	  NO	  and	  oxygen	  free	  radicals	  (Herrera-­‐Molina	  and	  Bernhardi,	  2005).	  	  	  	  	  	  	  	  
	  
Astrocytes	   and	   microglial	   cells	   communicate	   with	   each	   other	   via	   the	   proteins	  
they	  secrete	  (Krieglstein	  et	  al.,	  1995;	  Vincent	  et	  al.,	  1997).	  For	   instance,	  TGF-­‐1β	  
secreted	   by	   activated	   astrocytes	   has	   been	   reported	   to	   have	   neuroprotective	  
properties,	  which	  may	  be	  due	  to	  its	  inhibitory	  effect	  on	  microglia,	  making	  them	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revert	  to	  an	  anti-­‐inflammatory	  phenotype	  (Prehn	  et	  al.,	  1993;	  Henrich-­‐Noack	  et	  
al.,	   1996;	   Ruocco	   et	   al.,	   1999;	   Schilling	   et	   al.,	   2001;	   Paglinawan	   et	   al.,	   2003).	  
Additionally,	  activation	  of	  the	  chemokine	  receptor	  (CXCT4)	  in	  activated	  microglia	  
may	  result	  in	  TNF-­‐α	  release	  that	  in	  turn	  can	  cause	  the	  Ca2+-­‐	  dependent	  release	  of	  
glutamate	   from	   astrocytes	   (Bezzi	   et	   al.,	   2001).	   This	   microglial-­‐	   and	   TNF-­‐α-­‐
dependent	  potentiation	  of	  astrocyte	  glutamate	  release	  may	  lead	  to	  excitotoxity	  
and	   the	   subsequent	   apoptotic	   death	   of	   surrounding	   neurons.	   In	   summary,	   the	  
proteins	   released	   by	   astrocytes	   have	   significant	   consequences	   on	   neuronal	  
function	   and	   survival,	   and	   upon	   microglial	   activation.	   These	   consequences	  
depend	   on	   various	   factors,	   such	   as	   type,	   duration	   and	   severity	   of	   the	   insult	  
(Lucas	  et	  al.,	  2006).	  In	  vitro	  systems	  where	  astrocytes	  and	  microglial	  cells	  are	  co-­‐
cultured	  together	  with	  neurons	  provide	  a	  useful	  tool	  to	  explore	  such	  connectivity	  
between	  these	  different	  glial	  cell	  types	  and	  to	  determine	  how	  this	  may	  influence	  
neurons.	   This	   approach	  will	   be	   used	   in	   this	   thesis	   to	   determine	   the	   impact	   of	  
Cln3	  deficient	  glial	  cells	  on	  neuronal	  health	  (Chapter	  6).	  	  
	  
A	  previous	   in	  vitro	  study	  revealed	  that	  CLN3	  deficiency	  causes	  a	  whole	  range	  of	  
biological	   alterations	   in	   microglia	   (S.	   Dihanich,	   unpublished	   data).	   Cln3-­‐/-­‐	  
microglia	   displayed	   a	   compromised	   morphology	   under	   both	   unstimulated	  
(increased	  number	  of	  morphologically	  activated	  Cln3-­‐/-­‐	  microglia)	  and	  stimulated	  
conditions	   (impaired	  morphological	   transformation	   in	   Cln3-­‐/-­‐	   microglia),	   as	   has	  
also	  been	  observed	   in	  vivo	   (Pontikis	  et	  al.,	  2004;	  2005).	  Furthermore,	  activated	  
Cln3-­‐/-­‐	   microglia	   displayed	   specific	   protein	   secretion	   deficits,	   releasing	  
significantly	  less	  of	  the	  chemokines:	  macrophage	  inflammatory	  protein-­‐1γ	  (MIP-­‐
1γ),	   MIP-­‐1,	   regulated	   and	   normal	   T	   cell	   expressed	   and	   secreted	   (RANTES),	   a	  
matrix	   metalloproteinase:	   matrix	   metalloproteinase-­‐1	   (MMP-­‐1)	   and	   a	  
glycoprotein:	   Von	   Willebrand	   factor	   (vWF).	   This	   deficiency	   in	   chemokine	  
secretion	  by	  activated	  Cln3-­‐/-­‐	  microglia	   is	  particularly	   interesting	   in	   terms	  of	   the	  
interplay	   between	   microglia	   and	   astrocytes	   in	   JNCL	   disease.	   Chemokines	   are	  
involved	  in	  immune	  cell	  recruitment	  and	  phagocytosis	  (Ransohoff,	  2009;	  Rostène	  
et	   al.,	   2011).	   As	   such,	  Cln3-­‐/-­‐	  microglia	  may	   have	   a	   reduced	   capacity	   to	   attract	  
immune	  cells,	  such	  as	  astrocytes,	  potentially	  explaining	  the	  attenuated	  astrocyte	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response	   evident	   in	   Cln3-­‐/-­‐	   mice.	   For	   instance,	   stimulation	   of	   astrocytes	   with	  
RANTES	   has	   been	   shown	   to	   induce	   chemokine	   synthesis	   (monocyte	  
chemoattractant	   protein-­‐1	   (MCP-­‐1),	   MIP-­‐2,	   RANTES	   etc.),	   and	   up-­‐regulate	  
intercellular	   adhesion	   molecule-­‐1	   (ICAM-­‐1)	   (Luo	   et	   al.,	   2002).	   Astrocytic	  
expression	  of	  ICAM-­‐1	  has	  potential	  implications	  in	  the	  regulation	  of	  the	  immune	  
system,	  since	  ICAM-­‐1	  has	  been	  shown	  to	  be	  required	  for	  optimal	  stimulation	  of	  
naïve	  T-­‐cells	   (Siu	  et	  al.,	  1989;	  Van	  Seventer	  et	  al.,	  1990;	  Kuhlman	  et	  al.,	  1991).	  
Thus,	  diminished	  secretion	  of	  RANTES	  by	  Cln3-­‐/-­‐	  microglia	  may	  plausibly	   lead	  to	  
down-­‐regulation	  of	   ICAM-­‐1	   in	  astrocytes,	  which	  would	   result	   in	   impaired	  T-­‐cell	  
adhesion	  and/or	  activation	  causing	  impaired	  immune-­‐response	  in	  Cln3-­‐/-­‐	  mice.	  	  
	  
In	  summary,	  astrocytes	  contribute	  to	  both	  physiological	  and	  pathophysiological	  
mechanisms	   within	   the	   brain.	   The	   intimate	   structural-­‐functional	   relationship	  
between	   astrocytes	   and	   neurons	   is	   required	   for	   correct	   synaptic	   transmission	  
and,	  thus,	  for	  many	  higher	  brain	  functions	  (Fellin	  et	  al.,	  2006b;	  Perea	  et	  al.,	  2009;	  
Araque	   and	   Navarrete,	   2010;	   Perea	   and	   Araque,	   2010;	   Santello	   et	   al.,	   2012).	  
Neuron-­‐mediated,	   or	   otherwise	   evoked,	   and/or	   spontaneous	   fluctuations	   in	  
astrocyte	   intracellular	  Na+	   or	   Ca2+	   concentrations	   can	   lead	   to	   increased	   lactate	  
production	   and	   the	   secretion	   of	   various	   gliotransmitters	   via	   Ca2+-­‐dependent	  
exocytosis	   (Pellerin	   and	  Magistretti,	   1994;	   Pellerin,	   2003;	   Pellerin	   et	   al.,	   2007;	  
Parpura	  and	  Zorec,	  2010;	  Santello	  et	  al.,	  2012;	  Zorec	  et	  al.,	  2012;	  Verkhratsky	  et	  
al.,	  2012a).	  Such	  release	  and	  uptake	  of	  a	  complex	  range	  of	  soluble	  factors	  forms	  
the	   basis	   for	   communication	   within	   the	   astrocyte	   syncytium,	   and	   also	   for	  
bidirectional	   neuron-­‐glial	   communication.	   Furthermore,	   reactive	   astrocytosis	  
manifests	  itself	  in	  virtually	  all	  CNS	  pathologies	  (Ridet	  et	  al.,	  1997;	  Sofroniew	  and	  
Vinters,	   2010;	   Singh	   et	   al.,	   2011).	   The	   complex	   changes	   that	   take	   place	  within	  
reactive	   astrocytes	   may	   have	   both	   beneficial	   and	   detrimental	   consequences	  
depending	   on	   the	   disease	   context	   (Sofroniew,	   2009;	   Sofroniew	   and	   Vinters,	  
2010).	   Dysfunction	   of	   either	   astrocytes	   themselves,	   or	   the	   process	   of	   reactive	  
astrocytosis,	   as	   has	   been	  observed	   in	   vivo	   in	  Cln3-­‐/-­‐	  mice	   (Pontikis	   et	   al.,	   2004;	  
2005),	  may	  significantly	  alter	  the	  course	  of	  disease	  progression	  making	  them	  as	  
integral	  component	  of	  pathogenesis	  (Pekny	  and	  Pekna,	  2004;	  Pekny	  and	  Nilsson,	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2005;	  Zhang	  et	  al.,	  2008;	  Macauley	  et	  al.,	  2011;	  Di	  Malta	  et	  al.,	  2012a).	  As	  such,	  
investigating	   how	   Cln3	   deficiency	   impairs	   astrocyte	   biology	   may	   provide	  
important	  clues	  on	  their	  contribution	  to	  the	  pathogenesis	  of	  JNCL.	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1.5	  Aims	  of	  this	  thesis	  
An	  early	  glial	   response	  precedes	  neuronal	   loss	   in	  all	   forms	  of	  NCL.	  However,	   in	  
the	   Juvenile	   form	   this	   glial	   response	   is	   apparently	   attenuated,	   with	   astrocytes	  
failing	   to	   become	   hypertrophied	   and	   exhibiting	   a	   reduced	   upregulation	   of	   the	  
intermediate	  filament	  protein,	  GFAP,	  and	  microglia	  failing	  to	  fully	  transform	  into	  
brain	  macrophages.	   This	  may	  have	  a	   significant	   impact	  on	   the	  pathogenesis	   of	  
JNCL,	   since	   proper	   glial	   function	   is	   crucial	   for	   the	  maintenance	   of	   correct	   CNS	  
homeostasis	   that	   is	   essential	   for	   normal	   neuronal	   function	   and	   survival.	   Initial	  
studies	  on	  the	  biology	  of	  Cln3-­‐/-­‐	  microglia,	  using	  a	  tissue	  culture	  approach	  have	  
revealed	  that	  not	  only	  do	  these	  cells	  fail	  to	  fully	  transform	  upon	  stimulation,	  but	  
that	   their	  protein	   secretion	  profile	   is	   altered	   in	   a	  way	   that	  may	   influence	   their	  
interactions	  with	  astrocytes.	  	  
	  
The	  main	   aim	   of	   this	   PhD	   thesis	  was	   to	   extend	   these	   studies	   to	   astrocytes,	   to	  
investigate	  how	  the	  loss	  of	  CLN3	  function	  impacts	  the	  biology	  of	  these	  cells,	  and	  
whether	  the	  compromised	  biology	  of	  glial	  cells	  contributes	  to	  the	  pathogenesis	  
of	  JNCL.	  Additionally,	  in	  order	  to	  be	  able	  to	  assess	  neuron	  glial	  interaction	  more	  
effectively,	   the	   impact	  of	  CLN3	  deficiency	  on	  some	  aspects	  of	  the	  neuronal	  cell	  
biology	  was	  also	  characterized.	  	  
This	  study	  has	  four	  specific	  aims:	  
	  
1) To	  compare	  the	  response	  of	  Cln3-­‐/-­‐	  and	  wild	  type	  (WT)	  astrocytes	  to	  
activation	  stimuli	  
2) To	  investigate	  whether	  Cln3-­‐/-­‐	  astrocytes	  differ	  functionally	  from	  WT	  
astrocytes.	  
3) To	  explore	  how	  CLN3	  deficiency	  affects	  neuronal	  cell	  biology	  
4) To	  investigate	  whether	  Cln3-­‐/-­‐	  glia	  influence	  neuronal	  health	  	  
	  
These	  studies	  revealed	  that	  the	  function	  of	  astrocytes	  is	  dramatically	  altered	  by	  
loss	  of	  CLN3	  and,	  most	   importantly,	   that	  Cln3-­‐/-­‐	  glia	  have	  a	  negative	   impact	  on	  
the	  health	  of	  both	  JNCL	  and	  WT	  neurons.	  In	  contrast	  healthy	  glia	  were	  found	  to	  
ameliorate	  the	  defects	  observed	  in	  Cln3-­‐/-­‐	  neurons.	  These	  findings	  provide	  novel	  
information	  about	  the	  role	  that	  glial	  cells	  may	  play	   in	  the	  pathogenesis	  of	  JNCL	  
and	  point	  to	  astrocytes	  as	  novel	  targets	  for	  future	  therapeutic	  approaches.	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Chapter	  2	  
Materials	  and	  Methods	  
	   	  
	   78	  
2.1	  Animals	  
Homozygous	  Cln3ex1-­‐6	  mice	  (Cln3-­‐/-­‐	  mice)	  on	  a	  C57BL/6J	  background	  were	  used	  as	  
a	  model	  of	  JNCL	  (Mitchison	  et	  al.,	  1999)	  and	  homozygous	  Tpp1	  deficient	  mice	  on	  
a	  C57BL/6J	  background	  backcrossed	  with	  NODSCID	  mice	  were	  used	  as	  a	  model	  of	  
LINCL	   (Sleat	   et	   al.,	   2004).	  Wild	   type	   (WT)	  mice	  on	   the	   same	   strain	  background	  
were	  used	  as	  controls.	  All	  animal	  housekeeping	  and	  procedures	  were	  carried	  out	  
according	   to	   the	   UK	   Scientific	   Procedures	   (Animals)	   Act	   (1986),	   under	   the	  
authority	  of	  Project	  License	  70/6567.	  	  
	  
2.2	  Histology	  	  
Mouse	  tissue	  for	  histological	  analysis	  
Sections	  from	  Cln3-­‐/-­‐	  and	  Tpp1-­‐/-­‐	  mouse	  brains	  were	  used	  to	  study	  glial	  activation.	  
Control	   tissue	  was	   generated	   from	  WT	  mice.	  Mice	  were	   deeply	   anaesthetised	  
with	   sodium	   pentobarbitone	   (1g/kg),	   then	   injected	   into	   the	   left	   ventricle	   with	  
100μl	   heparin	   (5,000	   units/ml)	   before	   being	   transcardially	   perfused	   with	  
phosphate	   buffered	   saline	   (PBS)	   followed	   by	   a	   freshly	   prepared	   and	   filtered	  
solution	  of	   4%	  paraformaldehyde	   (PFA)	   in	   PBS.	   The	  brains	  were	   then	   removed	  
carefully	  and	  post-­‐fixed	  overnight	  at	  4°C	  in	  4%	  PFA,	  before	  being	  cryoprotected	  
in	   30%	   sucrose	   in	   Tris	   buffered	   saline	   plus	   0.05%	   sodium	  azide	   (TBS-­‐A)	   at	   4°C.	  
Brains	   were	   bisected	   along	   the	  midline,	   the	   cerebella	   were	   removed	   and	   one	  
hemisphere	  of	  each	  brain	  was	  cut	  into	  sequential	  40μm	  coronal	  sections	  using	  a	  
Microm	   freezing	   microtome.	   The	   sections	   were	   collected	   and	   stored	   in	  
cryoprotectant	   solution	   (TBS-­‐A	   +	   30%	  ethylene	   glycol	   +	   15%	   sucrose).	   To	   carry	  
out	  subsequent	  quantitative	  analyses,	  a	  1	  in	  6	  series	  of	  sections	  were	  selected	  as	  




To	  investigate	  glial	  activation	  in	  the	  human	  NCL	  brain,	  paraffin-­‐embedded	  tissue	  
blocks	  prepared	  from	  the	  primary	  visual	  cortical	  region	  of	  human	  LINCL	  and	  JNCL	  
post	  mortem	  tissue	  (n=2	  in	  both	  cases)	  were	  obtained	  from	  the	  Human	  Brain	  and	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Spinal	   Fluid	   Resource	   Centre,	   Los	   Angeles	   and	   the	   MRC	   London	  
Neurodegenerative	   Diseases	   Brain	   Bank,	   Institute	   of	   Psychiatry,	   King’s	   College	  
London.	  These	  specimens	  were	  obtained	  from	  routine	  autopsies	  of	  NCL	  patients	  
with	  informed	  written	  consent	  from	  their	  families.	  Following	  autopsy,	  tissue	  was	  
fixed	   immediately	   by	   using	   4%	   neutral	   buffered	   formaldehyde,	   processed	   and	  
embedded	  in	  paraffin	  wax	  blocks.	  Study	  protocols	  for	  the	  use	  of	  human	  material	  
were	  approved	  by	  the	  Ethical	  Research	  Committees	  of	  the	  Institute	  of	  Psychiatry	  
(approval	  numbers	  223/00,	  181/02).	  	  
	  
7µm	   thick	   sections	  were	   cut	   from	  paraffin	  wax	   using	   a	   Leitz	   1400	   base	   sledge	  
microtome.	  The	  cut	  sections	  were	  transferred	  to	  20%	  IMS	  (Industrial	  Methylated	  
Spirit,	   Sigma)	   to	   aid	   flattening,	   and	   then	   floated	   into	   a	   water	   bath	   containing	  
deionised	  water	  at	  45°C.	  Flattened	  sections	  were	  mounted	  on	  clean	  Superfrost	  
Plus	  slides	   (VWR)	  and	  placed	  overnight	  on	  a	  hotplate	  at	  45°C	  to	  allow	  them	  to	  
adhere	   properly	   to	   the	   glass.	   To	   aid	   the	   adhering,	   these	   sections	  were	   placed	  
overnight	  in	  an	  oven	  at	  37°C	  before	  staining.	  	  
	  
2.3	  Primary	  cell	  cultures	  
	  
Mixed	  glial	  cultures	  
These	   cultures	   were	   generated	   from	   post-­‐natal	   day	   1-­‐4	   (P1-­‐P4)	   Cln3-­‐/-­‐	   or	   WT	  
mouse	   cerebral	   cortices.	   Tissue	  was	  dissected	  out	   in	   cold	  Hanks’	  Balanced	  Salt	  
Solution	   (HBSS,	   GIBCO	   Life	   Technologies)	   then	   incubated	   in	   trypsin-­‐
ethylenediaminetetraacetic	  acid	  (EDTA)	  (0.5mg/ml,	  Sigma;	  1ml	  per	  4	  cortices)	  for	  
10	   minutes	   at	   37°C	   followed	   by	   the	   addition	   of	   an	   equal	   volume	   of	   trypsin	  
inhibitor	  (0.5mg/ml,	  Sigma).	  The	  trypsinised	  tissue	  was	  dissociated	  by	  passing	  10-­‐
15	  times	  through	  a	  5ml	  pipette	  followed	  by	  three	  times	  through	  a	  21G,	  and	  then	  
23G,	   syringe	   using	   a	   1ml	   hypodermic	   needle.	   After	  washing	   twice	   in	   HBSS	   (by	  
centrifugation	   at	   900rpm	   for	   5	  minutes)	   cells	  were	   re-­‐suspended	   in	   Dilbecco’s	  
Modified	  Eagles	  Medium	  (DMEM,	  Gibco),	  supplemented	  with	  10%	  foetal	  bovine	  
serum	  (FBS,	  Biosera)	  and	  penicillin/streptomycin	  (50	  U/ml	  /	  50μg/ml,	  P/S,	  Sigma)	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and	  plated	  onto	  dried	  poly-­‐D-­‐lysine	   (PDL,	  25µg/ml,	  Sigma)	  coated	  T75	   (Corning	  
Costar)	   flasks	   at	   a	   density	   of	   2-­‐3	   cortices	  per	   flask	   in	   10ml	  of	   culture	  medium.	  
Cultures	  were	   then	   incubated	   at	   37°C	   in	   a	   humidified	   incubator	   (5%	  CO2).	   The	  
next	   day	   half	   of	   the	   culture	   medium	   was	   replaced	   with	   fresh	   medium,	   and	  
thereafter	   half	   of	   the	   medium	   in	   each	   flask	   was	   replaced	   with	   fresh	   medium	  
every	   2-­‐3	   days.	   Once	   these	   cultures	   researched	   confluence	   (12-­‐14	   days)	   they	  
were	  composed	  of	  a	  base	  layer	  of	  non-­‐dividing	  astrocytes	  and	  an	  upper	  layer	  of	  
dividing	  microglia	  and	  a	  few	  oligodendrocytes.	  At	  this	  point	  cultures	  were	  either	  
maintained	   as	   mixed	   glial	   cultures	   for	   minimum	   of	   three	   weeks,	   to	   allow	   the	  
maturation	   and	   growth	   of	   all	   glial	   cells,	   and	   used	   in	   co-­‐culture	   experiments	  
described	  below	  (cultures	  derived	  from	  P2-­‐P4	  WT	  and	  Cln3-­‐/-­‐	  mice)	  or	  they	  were	  
used	   to	  generate	  pure	  astrocyte	   cultures	   (cultures	  derived	   from	  P1-­‐P2	  WT	  and	  
Cln3-­‐/-­‐	  mice).	  	  
	  
Cortical	  astrocyte	  cell	  cultures	  
These	  cultures	  were	  generated	  from	  mixed	  glial	  cultures	  using	  a	  modification	  of	  
the	  shaking	  method	  reported	  by	  McCarthy	  and	  de	  Vellis,	  as	  previously	  described	  
(McCarthy	  and	  de	  Vellis,	  1980;	  Williams	  et	  al.,	  1995).	  Flasks	  containing	  the	  mixed	  
glial	  cultures	  were	  shaken	  at	  180rpm	  on	  a	  Stuart®	  Shaker	  (Barloworld	  Scientific)	  
for	  10-­‐12	  hours	  at	  37°C	   in	  a	  humidified	   incubator	   (5%	  CO2)	  to	  detach	  microglia	  
cells	   and	   oligodendrocytes.	   These	   floating	   cells	   were	   then	   removed	   with	   the	  
medium	   leaving	   behind	   a	   monolayer	   consisting	   mainly	   of	   astrocytes.	   This	  
monolayer	  was	   then	   cultured	   in	   growth	  medium	   (same	  as	  used	   for	  mixed	  glial	  
cultures),	  supplemented	  with	  Ara-­‐C	  (Arabinofuranosyl	  Cytidine,	  2x10-­‐5	  mol/l)	  for	  
7	  days	  in	  vitro	  (DIV)	  to	  remove	  any	  remaining	  dividing	  cells.	  Using	  this	  procedure	  
we	  were	  able	  to	  generate	  astrocyte	  cultures	  that	  were	  >99%	  pure	  (see	  below).	  	  
Once	   the	   mixed	   glia	   or	   astrocytes	   cultures	   were	   ready	   to	   be	   used	   for	  
experiments,	   they	   were	   treated	   with	   trypsin-­‐EDTA	   (0.5mg/ml,	   5ml/T75	   cell	  
culture	   flask)	   for	   5-­‐10	   minutes	   at	   37°C,	   followed	   by	   the	   addition	   of	   an	   equal	  
volume	   of	   trypsin	   inhibitor	   (0.5mg/ml).	   Detached	   cells	   were	   then	   collected	   by	  
centrifugation	   at	   900rpm	   for	   5	   minutes,	   resuspended	   in	   HBSS	   and	   then	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centrifuged	   once	   more,	   before	   being	   diluted	   in	   growth	   medium	   for	   plating.	  
When	   these	   cells	   were	   used	   for	   immunofluorescence	   staining	   or	   for	   protein	  
secretion	  analysis	   they	  were	  plated	  on	  PDL	  coated	  coverslips	   (13mm	  diameter,	  
VWR)	   at	   a	   density	   of	   20,000-­‐30,000	   cells/coverslip	   placed	   in	   wells	   of	   24-­‐well	  
plates	   (Corning	   Costar).	   For	   intracellular	   Ca2+-­‐measurements	   astrocytes	   were	  
plated	   on	   PDL-­‐coated	   coverslips	   (25mm	   diameter,	   VWR)	   at	   density	   of	   50,000	  
(low	  density),	  75,000	  (normal	  density)	  or	  100,000	  (high	  density)	  cells/coverslips.	  
For	   Western	   blot	   analysis,	   glutamate	   clearance	   and	   all	   glutathione	  
measurements,	  astrocytes	  were	  plated	  at	  a	  density	  of	  100,000	  cells/6-­‐well	  plate	  
(Corning	   Costar,	   PDL-­‐coated).	   When	   lactate	   secretion	   and	   cell	   migration	   were	  
examined	   astrocytes	   were	   plated	   at	   a	   density	   of	   50,000	   cells/24-­‐well	   plate	  




WT	  or	  Cln3-­‐/-­‐	  mouse	  cerebral	   cortices	   from	  P0	  mice	  were	  dissected	  out	   in	   cold	  
dissociation	  medium	   (DM:	  Ca2+/Mg2+	   free	  HBSS	   from	  Gibco	  supplemented	  with	  
33.4mM	  glucose,	  10mM	  Kynurenic	  acid,	  100mM	  MgCl2	  and	  1M	  Hepes	  (pH	  7.4),	  
all	   chemicals	   used	   were	   obtained	   from	   Sigma).	   This	   tissue	   was	   dissociated	   by	  
incubation	  in	  5ml	  of	  papain	  solution	  (50	  U/ml	  made	  in	  90	  μg/μl	  cysteine-­‐HCL,	  pH	  
7.4)	  at	  37	  °C	  for	  10	  minutes	  (repeated	  twice),	  then	  washed	  three	  times	  with	  DM	  
before	  addition	  of	  3ml	  of	  trypsin	  inhibitor	  (100mg	  trypsin	  inhibitor	  plus	  100mg	  of	  
bovine	  serum	  album	  (BSA)	  in	  10ml	  of	  DM,	  pH	  7.4)	  for	  3	  minutes	  at	  37	  °C,	  to	  stop	  
protease	   activity.	   The	   trypsin	   inhibitor	   treatment	   was	   repeated	   twice	   more.	  
Subsequently,	   cells	  were	  washed	   three	   times	  with	  DM	   and	   then	   suspended	   in	  
3ml	   of	   growth	  medium	   (Neurobasal	  medium	   (Gibco)	   supplemented	  with	   10ml	  
B27	   (x50,	  Gibco),	  50	  U/ml/50μg/ml	  P/S,	  2mM	   l-­‐glutamine).	  The	  cell	   suspension	  
was	   then	  pipetted	  10-­‐15	   times	  using	  a	  200ul	  pipette	  until	   fully	  dissociated	  and	  
the	  cells	  pelleted	  (900rpm	  for	  5	  minutes)	  and	  re-­‐suspended	  in	  growth	  medium.	  
Cells	  were	  then	  plated	  at	  a	  concentration	  of	  250,000-­‐300,000	  cells/coverslip	  on	  
PDL	   (50μg/ml)	   coated	   13mm	   glass	   coverslips	   (VWR)	   placed	   in	   24-­‐	   well	   plates	  
(Corning	  Costar)	  and	   incubated	  at	  37°C	   in	  a	  humidified	   incubator	  (5%	  CO2).	  For	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Western	   blot	   analysis,	   neuronal	   cells	   were	   plated	   at	   a	   density	   of	   1,000,000	  
cells/6-­‐well	   plate	   (Corning	   Costar,	   PDL-­‐coated).	   Every	   two	   days,	   half	   of	   the	  
growth	  medium	  was	   replaced	  with	   fresh	   growth	  medium	   and	   to	   prevent	   glial	  
growth	  cultures	  were	  grown	  in	  Ara-­‐C	  (2.5μM,	  added	  at	  2	  DIV)	  containing	  growth	  
medium.	   The	   composition	   of	   these	   cultures	   was	   assessed	   by	  
immunofluorescence	  staining	  after	  7	  DIV.	  The	  vast	  majority	  of	  the	  cells	  in	  these	  
cultures	  were	  neurons,	  with	  small	  numbers	  of	  astrocytes,	  microglia	  and	  very	  few	  
oligodendrocytes.	   Using	   this	   procedure	   we	   were	   able	   to	   generate	   neuronal	  
cultures	  that	  were	  >94%	  pure	  (see	  below).	  	  
Neuron-­‐glia	  co-­‐cultures	  	  
Co-­‐cultures	  were	  composed	  of	  neurons	  that	  had	  been	  cultured	  for	  7	  DIV	  prior	  to	  
being	   combined	  with	   3-­‐4	  week	   old	  mixed	   glial	   cultures.	   To	   generate	   these	   co-­‐
cultures,	  approximately	  50,000	  mixed	  WT	  or	  Cln3-­‐/-­‐	  glial	  cells	  were	  plated	  on	  top	  
of	  WT	  or	  Cln3-­‐/-­‐	   neuronal	   cultures.	  The	   following	  day,	   the	  neuronal	   cell	   culture	  
medium	  was	  replaced	  with	  fresh	  medium	  to	  remove	  any	  floating,	  unbound	  glial	  
cells	  from	  the	  wells.	  After	  2	  or	  7	  DIV,	  supernatants	  were	  collected	  for	  cytotoxicity	  
assays	   and	   cultures	   were	   fixed	   for	   immunofluorescence	   staining,	   as	   described	  
below.	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2.4	  Analysis	  of	  cell	  division	  in	  vitro	  
Once	   activated,	   astrocytes	   may	   re-­‐enter	   the	   cell-­‐cycle	   (Ridet	   et	   al.,	   1997;	  
Sofroniew	   and	   Vinters,	   2010).	   To	   investigate	   whether	   Cln3-­‐/-­‐	   astrocytes	   differ	  
from	   their	   WT	   counterparts	   in	   their	   ability	   to	   proliferate	   in	   response	   to	  
activation,	   the	   incorporation	   of	   5'-­‐bromo-­‐2'-­‐deoxyuridine	   (BrdU)	   was	   used,	   to	  
detect	  cells	  in	  S-­‐phase	  of	  the	  cell	  cycle,	  in	  combination	  with	  immunostaining	  for	  
Ki67	  to	  detect	  all	  cells	  capable	  of	  proliferating.	  BrdU	  (10µM,	  Sigma)	  was	  added	  
directly	  to	  medium	  bathing	  lipopolysaccharide	  (LPS)/IFNγ	  activated	  or	  untreated	  
astrocytes.	   6	   hour	   after	   addition	   of	   BrdU,	   cells	   were	   fixed	   in	   4%	  
paraformaldehyde	   in	  PBS	   for	  15	  minutes	  and	   then	  stored	   in	  PBS	  until	  analysed	  
for	  BrdU	  and	  Ki67	  expression.	  	  
	  	  
2.5	  Immunostaining	  protocols	  
Immunofluorescence	  staining	  in	  vitro	  
For	   immunofluorescence	  analysis	   cultures	   grown	  on	   coverslips	  were	   fixed	  with	  
4%	   PFA	   for	   10-­‐20	  minutes	   at	   room	   temperature,	   and	   then	   permeabilised	  with	  
0.1%	   Triton	   X-­‐100	   (Sigma)	   for	   5-­‐15	   minutes	   (except	   when	   otherwise	   stated).	  
Following	  three	  washes	  in	  phosphate	  buffered	  saline	  (PBS)	  cells	  were	  incubated	  
with	  the	  appropriate	  primary	  antibody	  (Table	  2.1)	  diluted	   in	  either	  10%	  normal	  
goat	  serum	  (NGS)	  or	  normal	  donkey	  serum	  (NDS)	  in	  PBS,	  or	  3%	  BSA	  (depending	  
on	   the	   host	   species	   that	   the	   secondary	   antibody	   was	   raised	   in)	   for	   1	   hour	   at	  
room	  temperature	  or	  overnight	  at	  4oC.	  Where	  antibody	  classes	  permitted,	  cells	  
were	  incubated	  with	  various	  primary	  antibodies	  simultaneously.	  Coverslips	  were	  
then	  washed	  three	  times	  in	  PBS	  and	  incubated	  for	  30	  minutes	  to	  1	  hour	  at	  room	  
temperature	   with	   the	   appropriate	   secondary	   antibodies	   (Table	   2.2)	   in	   the	  
presence	   of	   10%	   NGS	   or	   NDS,	   or	   3%	   BSA.	   Where	   appropriate,	   nuclei	   were	  
counterstained	   with	   DAPI	   (4'-­‐6-­‐Diamidino-­‐2-­‐phenylindole,	   0.5-­‐1μg/ml,	   1:2000,	  
Sigma).	   Coverslips	   were	   mounted	   using	   either	   Fluoromout	   G	   or	   Prolong	   gold	  
(both	  Southern	  Biotech).	  In	  all	  experiments,	  to	  ensure	  that	  the	  observed	  staining	  
was	   specific,	   controls	  were	   included	   in	  which	  primary	  antibodies	  were	  omitted	  
and/or	  incorrect	  secondary	  antibodies	  were	  used.	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Immunofluorescence	  staining	  for	  BrdU	  	  
Fixed	   cells	   were	   treated	   with	   95%	   methanol	   for	   30	   minutes	   at	   room	  
temperature.	  After	  rinsing	  with	  PBS,	  cells	  were	  permeabilized	  with	  1M	  HCl	  for	  10	  
minutes	   on	   ice,	   followed	   by	   2M	   HCl	   for	   10	  minutes	   at	   room	   temperature.	   To	  
neutralize	   the	   acid,	   0.1M	   sodium	  borate	   (Sigma)	  was	   added	   for	   12	  minutes	   at	  
room	  temperature.	  After	  a	  1	  hour	  block	  in	  15%	  NGS,	  astrocytes	  were	  incubated	  
with	  the	  anti-­‐BrdU	  and	  Ki67	  antibodies	  overnight	  at	  4°C.	  The	  following	  day,	  the	  
standard	  protocol	  for	  immunofluorescence	  staining	  (see	  above)	  was	  followed.	  To	  
calculate	   the	   percentage	   of	   Ki67,	   BrdU	   and	   BrdU/Ki67	   expressing	   cells	   per	  
coverslip,	   an	   average	   of	   the	   values	   from	   the	   5	   fields	   from	   a	   total	   of	   three	  
coverslips	  per	  experiment	  was	  used.	  	  
	  
Immunohistochemistry	  for	  mouse	  tissue	  
Sections	   for	   immunohistochemistry	   were	   prepared	   as	   described	   above.	  
Endogenous	  peroxidase	  activity	  was	  reduced	  in	  1%	  H202	  in	  TBS	  for	  40	  minutes	  at	  
room	  temperature.	  Next,	  sections	  were	  rinsed	  in	  TBS	  before	  unspecific	  antibody	  
binding	  was	  blocked	  in	  15%	  normal	  serum	  in	  TBS-­‐T	  (TBS	  +	  0.3%	  Triton-­‐X)	  for	  30	  
minutes	   at	   room	   temperature.	   Sections	   were	   then	   incubated	   with	   the	  
appropriate	  primary	  antibody	  (see	  Table	  2.1	  for	  details)	  diluted	  in	  10%	  NS	  in	  TBS-­‐
T	  at	  4°C	  overnight.	  Sections	  were	  then	  rinsed	  with	  TBS	  prior	  to	   incubation	  with	  
the	  appropriate	  biotinylated	  secondary	  antibody	  diluted	  in	  10%	  NS	  in	  TBS-­‐T	  for	  2	  
hours	   (see	   Table	   2.2	   for	   details).	   Sections	   were	   then	   rinsed	   further	   with	   TBS	  
before	  addition	  of	  the	  avidin-­‐biotinperoxidase	  complex	  (Vectastain	  Elite	  ABC	  kit,	  
Vector	  Laboratories)	  diluted	  at	  1:1.000	  in	  TBS,	  for	  2	  hours.	  The	  visualization	  was	  
carried	   out	   by	   a	   standard	   DAB	   reaction	   (0.05%	   3,3’-­‐diaminobenzidine	  
tetrahydrochloride	   HCl;	   Sigma)	   for	   5-­‐15	   minutes	   depending	   on	   the	   primary	  
antibody	  used.	  This	  reaction	  was	  stopped	  by	  rinsing	  the	  sections	  with	  cold	  TBS.	  
The	   sections	   were	   then	   mounted	   onto	   chrome-­‐gelatine	   coated	   slides,	   dried	  
overnight	   at	   room	   temperature,	   cleared	   and	   dehydrated	   in	   100%	   industrial	  
methylated	   spirit	   (IMS)	   and	   100%	   xylene	   before	   the	   sections	  were	   covered	   by	  
placing	  a	  coverslip	  onto	  them	  with	  DPX	  (VWR).	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Immunohistochemical	  staining	  of	  paraffin	  sections	  	  
A	   series	   of	   adjacent	   7µm	   paraffin	   sections	   from	   JNCL	   and	   LINCL	   cases	   were	  
immunohistochemically	  stained	  for	  the	  astrocyte	  marker	  GFAP	  and	  the	  microglial	  
marker	  CD68	  to	  study	  the	  extent	  of	  glial	  activation	  in	  human	  tissue.	  To	  reveal	  the	  
relationship	   between	   neuronal	  morphology	   and	   glial	   activation,	   these	   sections	  
were	   also	   counterstained	   with	   hematoxylin.	   Firstly,	   sections	   were	   dewaxed	   in	  
xylene	   and	   endogenous	   peroxidase	   activity	  was	   quenched	   by	   treating	   sections	  
with	  1%	  H2O2	   in	  methanol	   for	  30	  minutes.	  Sections	  were	   then	  washed	  under	  a	  
running	  tap	  and	  antigen	  retrieval	  performed	  by	  boiling	  sections	  in	  0.01M	  Citrate	  
buffer	   at	  pH	  6.0	   for	   20	  minutes,	   before	   rinsing	   in	  deionised	  water	   followed	  by	  
TBS.	   The	   sections	   were	   then	   outlined	   with	   a	   grease	   pen	   (PAP-­‐pen,	   Dako)	   and	  
blocked	   in	   15%	   normal	   Swine	   serum	   (Dako)	   in	   TBS-­‐T	   for	   30	  minutes.	   Sections	  
were	   then	   incubated	  with	   the	  anti-­‐GFAP	  and	  anti-­‐CD68	  antibodies	  diluted	  with	  
10%	  normal	   swine	   serum	   in	   TBS-­‐T	   overnight.	   The	   following	   day,	   sections	  were	  
rinsed	  in	  TBS	  and	  then	  incubated	  for	  30	  minutes	  in	  the	  appropriate	  biotinylated	  
secondary	   antibodies	   diluted	   1:200	   in	   TBS-­‐T	   plus	   10%	   normal	   swine	   serum.	  
Subsequently,	   sections	   were	   rinsed	   three	   times	   in	   TBS	   for	   5	   minutes	   and	  
incubated	  in	  avidin-­‐biotin	  peroxidase	  complex	  diluted	  1:1000	  in	  TBS	  (Vectastain	  
Elite	   ABC	   kit;	   Vector	   Laboratories)	   for	   30	  minutes	   at	   room	   temperature.	   After	  
rinsing	   in	   TBS	   the	   sections	   were	   incubated	   in	   0.05%	   3,3’-­‐diaminobenzidine	  
tetrahydrochloride	  HCl	  (DAB,	  Sigma)	  and	  0.001%	  H202	  in	  TBS	  for	  5	  to	  10	  minutes	  
to	  visualize	  immunoreactivity.	  This	  reaction	  was	  stopped	  by	  adding	  ice-­‐cold	  TBS	  
to	  the	  sections.	  Sections	  were	  then	  counterstained	  in	  0.7%	  Harris’s	  haematoxylin	  
(Sigma)	  for	  10-­‐30	  seconds	  followed	  by	  differentiation	  in	  0.5%	  HCl	  containing	  70%	  
IMS	  for	  5-­‐10	  seconds.	  The	  stain	  was	  then	  allowed	  to	  develop	  by	  leaving	  sections	  
in	   running	   tap	   water,	   before	   dehydration	   in	   graded	   concentrations	   of	   IMS,	  
clearing	   in	   xylene,	   and	   then	   coverslipped	   with	   DPX	   [p-­‐xylene-­‐bis(pyridinium	  
bromine)]	  (VWR).	  
	   	  







































Table	   2.1.	   Details	   of	   primary	   antibodies	   used.	   Abbreviations:	   glial	   fibrillary	   acidic	  
protein	  (GFAP),	  cluster	  of	  differentiation	  68	  (CD68),	  oligodendrocyte	  marker	  4	  (O4),	  5'-­‐bromo-­‐2'-­‐
deoxyuridine	  (BrdU),	  microtubular	  associated	  proteins	   (MAP2),	  ankyrin	  G	  (AnkG),	  voltage-­‐gated	  
sodium	   channel	   (PanNav),	   neuronal	   specific	   nuclear	   protein	   (NeuN),	   synaptosome-­‐associated	  
protein	   25	   (SNAP25),	   vesicle-­‐associated	   membrane	   protein	   2	   (VAMP2),	   lysosome-­‐associated	  
membrane	  proteins	  1	  (LAMP1),	  cathepsin	  D	  (Cath	  D),	  early	  endosome	  antigen	  1	  (EEA1),	  connexin	  
43	   (Cx43),	   tumor	   necrosis	   factor-­‐α	   (TNF-­‐α),	   macrophage	   inflammatory	   protein-­‐1γ	   (MIP-­‐1γ),	  
immunohistochemistry	  (IHC),	  immunocytochemistry	  (ICC),	  Western	  blotting	  (WB).	  	  
	  









Table	  2.2.	  Details	  of	  secondary	  antibodies	  used.	  
	  
2.6	  In	  vitro	  studies	  on	  astrocyte,	  neuronal	  and	  co-­‐cultures	  based	  on	  
immunostaining	  
	  
Analysis	  of	  culture	  composition	  
The	  purity	  of	  the	  astrocyte	  or	  neuronal	  cultures,	  and	  the	  composition	  of	  mixed	  
glial	   cultures	   were	   assessed	   using	   an	   array	   of	   cell-­‐type	   specific	   markers.	   Glial	  
GFAP	  was	  used	  to	  identify	  astrocytes,	  oligodendrocyte	  marker	  4	  (O4)	  to	  identify	  
oligodendrocytes,	  cluster	  of	  differentiation	  (CD68)	  to	  identify	  microglial	  cells	  and	  
MAP2	  and/or	  neuronal	  specific	  nuclear	  protein	  (NeuN)	  to	  identify	  neurons.	  	  
	  
Cytoskeletal	  staining	  	  
To	   compare	   the	   cytoskeletal	   organization	   of	   WT	   and	   Cln3-­‐/-­‐	   astrocytes,	   the	  
expression	  of	   actin,	  microtubules	   and	   intermediate	   filaments	  was	   investigated.	  
24	   hour	   after	   plating	   cells	   were	   fixed	   differently	   according	   to	   the	   cytoskeletal	  
polymer	   under	   investigation.	  GFAP	   immunoreactivity	  was	   used	   to	   visualize	   the	  
intermediate	  filament	  organization	  of	  astrocytes;	  Phalloidin	  was	  used	  to	  visualize	  
F-­‐actin	   filaments;	   and	   primary	   antibodies	   against	   β-­‐	   and	   α-­‐microtubules	   were	  
used	   to	   visualize	   microtubular	   organization.	   In	   order	   to	   visualize	   the	   F-­‐actin	  
filaments	  with	  phalloidin,	   cells	  were	  washed	  once	  with	  a	  1:1	  mixture	  of	  buffer	  
(20mM	   Pipes	   (pH	   6.1),	   276	   mM	   KCl,	   6mM	   MgCl2,	   4mM	   EDTA	   and	   640mM	  
sucrose)	   and	   MilliQ	   H2O,	   then	   fixed	   for	   10	   minutes	   at	   room	   temperature	   in	  
phalloidin	   (1:300,	   Invitrogen,	   AlexaFluor	   546)	   diluted	   in	   an	   EM-­‐Grade	   PFA	  
(Polysciences	   Inc.)	   solution	   (50%	   buffer	   described	   above,	   25%	   EM-­‐Grade	   PFA,	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and	  25%	  MilliQ	  H2O).	  After	  this	  step,	  cells	  were	  washed	  once	  with	  buffer	  solution	  
and	  twice	  with	  PBS.	  DAPI	  (1:2000	  diluted	  in	  PBS)	  was	  added	  for	  5	  minutes	  prior	  
to	  mounting	   in	  Prolong	  gold	  mounting	  solution	  (Invitrogen).	  For	  visualization	  of	  
microtubular	   structures	   cultures	   were	  washed	   twice	  with	   cold	   TBS,	   then	   fixed	  
and	  permeabilized	  with	  ice-­‐cold	  methanol	  for	  5	  minutes,	  followed	  by	  incubation	  
in	   ice-­‐cold	  methanol/acetone	   for	   5	  minutes.	   Cultures	  were	   then	  washed	   three	  
times	   in	   TBS	   before	   a	   blocking	   step	   was	   carried	   out	   (2%	   BSA	   in	   TBS-­‐T	   for	   10	  
minutes	   in	   room	   temperature)	   followed	   by	   incubation	   with	   anti-­‐β-­‐	   and	   α-­‐
microtubules	   antibodies	   diluted	   in	   2%	   BSA	   /TBS-­‐T	   for	   30	   minutes	   at	   room	  
temperature.	   After	   washing	   the	   cultures	   three	   times	   in	   TBS-­‐T,	   the	   cells	   were	  
incubated	  with	  the	  relevant	  secondary	  antibodies	  diluted	  in	  2%	  BSA	  in	  TBS-­‐T	  for	  
1	  hour	  at	  room	  temperature.	  	  
	  
Localization	  of	  the	  AIS	  
The	  axon	  initial	  segment	  (AIS)	  and	  its	  localization	  along	  the	  axon	  is	  considered	  to	  
be	  a	   reflection	  of	  neurons	   information-­‐processing	   capabilities,	   since	   these	   cells	  
have	   been	   shown	   to	   dynamically	   re-­‐locate	   their	   AIS	   in	   a	   activity-­‐dependent	  
manner	   enabling	   them	   to	   fine-­‐tune	   their	   own	  excitability	   (Grubb	   and	  Burrone,	  
2010b).	  To	  obtain	   information	  about	  the	  position	  of	  the	  AIS	  along	  the	  axons	  of	  
WT	   and	   Cln3-­‐/-­‐	   neurons,	   5	   or	   7	   day	   old	   neuronal	   cultures	   were	   exposed	   to	  
depolarization	  by	  increasing	  the	  KCl	  content	  of	  the	  culture	  medium	  from	  5mM	  to	  
15mM	  for	  48	  hour.	  The	  NaCl	  content	  of	  the	  medium	  bathing	  control	  cultures	  was	  
also	   increased	   to	   15mM	   to	   provide	   isotonic	   control	   conditions	   for	   this	  
experiment.	  It	  is	  known	  that	  AIS	  re-­‐localization	  is	  dependent	  on	  the	  activity	  of	  L-­‐
type	   calcium	   channels	   (Grubb	   and	   Burrone,	   2010b).	   Thus,	   to	   investigate	   the	  
mechanism	   behind	   re-­‐localization	   of	   the	   AIS	   in	   WT	   and	   Cln3-­‐/-­‐	   neurons,	   1μM	  
nifedipine	   (Sigma)	   was	   added	   to	   the	   medium	   in	   certain	   experiments.	   The	  
location	   for	   the	   AIS	   was	   determined	   using	   an	   anti-­‐ankyrin	   G	   (AnkG)	   antibody,	  
anti-­‐PanNav	   (voltage	   gated	   sodium	   channel	   marker)	   was	   used	   to	   identify	   the	  
localization	  of	  all	  different	  isoforms	  of	  potassium	  channels	  crucial	  for	  initiation	  of	  
action	   potentials,	   and	   MAP2	   was	   used	   to	   visualize	   neuronal	   cell	   bodies	   and	  
processes.	  Additionally,	  a	  cocktail	  of	  anti-­‐calbindin,	  -­‐calretinin,	  and	  -­‐parvalbumin	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antibodies	  was	  used	  to	  identify	  inhibitory	  neurons	  present	  in	  these	  cultures.	  	  
	  
Immunofluorescence	  staining	  was	  carried	  out	  as	  described	  above	  except	  for	  the	  
fixation	   step.	   For	   AnkG	   labeling,	   cultures	   were	   fixed	   with	   4%	   PFA	   (TAAB	  
Laboratories,	   in	   3%	   sucrose,	   60mM	   PIPES,	   25mM	   HEPES,	   5mM	   EGTA,	   1mM	  
MgCl2,	  pH	  7.4),	   for	  20	  minutes	  at	   room	  temperature,	  and	   then	   incubated	  with	  
the	   antibody	   for	   1	   hour	   at	   room	   temperature.	   For	   staining	   with	   the	   PanNav	  
antibody,	   a	   1%	   PFA	   fixation	   was	   used	   for	   20	   minutes	   at	   room	   temperature	  
followed	  by	  a	  3	  hour	  incubation	  with	  the	  antibody.	  	  
	  
All	   image	   acquisition	   and	   analysis	   was	   done	   blind	   to	   experimental	   group,	   as	  
previously	   described	   (Grubb	   and	   Burrone,	   2010b).	   Neurons	   with	   a	   detectable	  
AIS,	   that	   clearly	   originated	   from	   the	   soma	   of	   one	   particular	   cell,	   were	   imaged	  
using	  a	  x40	  oil	  immersion	  objective	  on	  a	  Zeiss	  laser	  scanning	  confocal	  microscope	  
coupled	   to	   Zeiss	   imaging	   software,	   using	   488nm	  and	  543nm	   lasers,	   along	  with	  
the	   appropriate	   excitation	   and	   emission	   filters.	   Acquired	   image	   stacks	   were	  
converted	  into	  single	  maximum	  intensity	  z-­‐axis	  projections,	  which	  were	  saved	  as	  
16bit	   TIFF	   files	   and	   analyzed	   with	   custom-­‐written	   functions	   in	   Matlab	  
(Mathworks).	   To	  measure	   the	  position	  of	   the	  AIS	  along	   the	  axon,	  a	   line	  profile	  
was	  drawn	   starting	   at	   the	   soma	  and	  moving	   along	   the	   axon	  past	   the	  detected	  
AnkG	   staining.	   Averaged	   profiles	   were	   then	   smoothed	   using	   a	   40-­‐point	  
(approximately	   5μm)	   sliding	   mean,	   and	   normalized	   between	   1	   (maximum	  
smoothed	   fluorescence,	   location	   of	   the	   AIS	   max	   position)	   and	   0	   (minimum	  
smoothed	   fluorescence).	   The	   AIS	   start	   (most	   proximal)	   and	   end	   (most	   distal)	  
positions	  were	  acquired	  where	  the	  normalized	  and	  smoothed	  profile	  dropped	  to	  
0.33.	   The	   position	   with	   the	   peak	   fluorescence	   value	   was	   considered	   as	   the	  
position	  of	  maximum	  value	  of	  each	  profile,	  representing	  the	  area	  within	  the	  AIS	  
with	  the	  highest	  amount	  of	  AnkG	  expression.	  In	  each	  experiment	  a	  minimum	  of	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Neurite	  complexity	  measurements	  
Axonal	   and	   dendritic	   processes	   are	   one	   of	   the	   defining	   characteristics	   of	  
neurons,	   and	   are	   a	   critical	   determinant	   of	   neuronal	   connectivity	   (Pfenninger,	  
2009;	  Meldolesi,	  2011;	  Purves,	  2011).	  To	  compare	  the	  ability	  of	  WT	  and	  Cln3-­‐/-­‐	  P0	  
cortical	   neurons	   to	   extend	   these	   processes,	   neurite	   complexity	   was	   analyzed,	  
with	   ‘neurite’	  being	  used	  as	  a	   collective	   term	   for	  dendrites	  and	  axons	   that	   are	  
formed	  by	  neurons	  in	  culture.	  To	  do	  this,	  the	  number	  of	  primary,	  secondary,	  and	  
tertiary	   neurites	   was	   counted,	   the	   total	   length	   of	   all	   primary	   neurites	   was	  
measured,	   as	   well	   as	   the	   length	   of	   the	   longest	   primary	   neurite	   (which	  
presumably	  represents	  the	  axon).	  Additionally,	  the	  soma	  sizes	  of	  these	  neurons	  
were	  determined.	  To	  visualize	  neuronal	  morphology	  cultures	  were	  stained	  with	  
MAP2,	  as	  described	  above,	  and	  images	  taken,	  using	  the	  x40	  objective	  on	  a	  Zeiss	  
AxioImager	  Z1	  fluorescence	  microscope,	  of	  40	  cells	  per	  genotype	  per	  experiment	  
in	  a	  way	  that	  the	  whole	  neuron	  was	  imaged.	  All	  these	  quantitative	  measures	  of	  
neurite	   complexity	   and	   soma	   size	  were	   carried	  out	  manually	   from	  40	   cells	   per	  
genotype	   in	  each	  experiment	   (repeated	  three	  times)	  using	  the	   ImageJ	  program	  
with	   set	  μm/pixel	   calibration.	   Similar	  measurements	  of	   neurite	   complexity	   and	  
soma	  size	  were	  also	  obtained	  from	  neurons	  co-­‐cultured	  with	  glial	  cells.	  	  
	  
Distribution	  of	  SNARE-­‐complex	  proteins	  
The	   interactions	   among	   the	   synaptic	   vesicle	   proteins	   VAMP2,	   SNAP25	   and	  
syntaxin1	  (so	  called	  SNARE	  proteins)	  are	  crucial	  for	  the	  fusion	  of	  synaptic	  vesicles	  
with	   presynaptic	   terminals	   allowing	   the	   release	   of	   neurotansmitters	   (review	   in	  
Kavalali,	  2002).	  Through	  interactions	  with	  VAMP2,	  synaptophysin	  has	  also	  been	  
proposed	  to	  be	  involved	  in	  this	  fundamental	  process	  (Washbourne	  et	  al.,	  1995;	  
Schubert	  et	  al.,	  2011).	  In	  addition,	  endosomes	  may	  play	  an	  important	  role	  in	  the	  
transport	   of	   these	   proteins	   to	   the	   synapse.	   Since	   synaptic	   pathology	   has	   been	  
reported	  in	  the	  NCLs	  (Kim	  et	  al.,	  2008;	  Partanen	  et	  al.,	  2008;	  Kielar	  et	  al.,	  2009),	  
the	  expression	  patterns	  of	  these	  SNARE	  complex	  proteins,	  and	  the	  distribution	  of	  
endosomes,	  was	  compared	  in	  Cln3-­‐/-­‐	  and	  WT	  cortical	  neuron	  cultures.	  MAP2	  was	  
used	   to	   identify	   neurons	   in	   combination	   with	   antibodies	   against	   SNAP25,	  
VAMP2,	   synaptophysin	   and	   early	   endosome	   antigen	   1	   (EEA1).	   In	   all	   cultures	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nuclei	  were	  visualized	  using	  DAPI.	  	  
	  
The	   number	   of	   SNAP25,	   VAMP2,	   synaptophysin	   expressing	   puncta	   and	   EEA1	  
expressing	  early	  endosomes	  were	  quantified	  along	  the	  neurites	  of	  WT	  and	  Cln3-­‐/-­‐	  
cortical	   neurons	   in	   order	   to	   study	   their	   transport	   along	   neuronal	   processes.	  
These	   measurements	   were	   carried	   out	   in	   two	   regions	   along	   each	   neurite:	   0-­‐
25μm	  and	  25μm-­‐50μm	  from	  the	  start	  of	  the	  neurite.	  Identical	  image	  acquisition	  
parameters	  were	  applied	  within	  each	  experiment,	  and	  subsequent	  quantification	  
was	   carried	   out	   using	   ImageJ.	   Specific	   threshold	   values	   were	   determined	   and	  
applied	  within	  each	  experimental	  set	  of	   images	  to	  distinguish	  SNAP25,	  VAMP2,	  
synaptophysin	   and	  EEA1	   immunopositive	  puncta	   from	  background.	  An	  average	  
of	  the	  values	  from	  the	  10-­‐20	  cells	  counted	  per	  experiment	  was	  used	  to	  provide	  
the	  percentage	  area	  of	  puncta	  immunoreactive	  for	  each	  protein	  in	  the	  regions	  of	  
the	   neurite	   under	   investigation.	   In	   co-­‐culture	   experiments	   the	   distribution	   of	  
SNAP25	  and	  synaptophysin	  (neuron	  specific	  SNARE-­‐proteins)	  were	  explored	  only	  
qualitatively.	   In	   addition,	   Western	   blotting	   was	   used	   to	   measure	   the	   total	  
intracellular	  expression	  of	  each	  of	  these	  proteins	   in	  both	  neuronal	  cultures	  and	  
in	  co-­‐cultures,	  as	  described	  below.	  	  
	  
Analysis	  of	  cell	  death	  in	  co-­‐cultures	  
Live/dead	  analyses	  
To	   reveal	   the	   identity	   of	   the	   cells	   undergoing	   cell	   death	   in	   co-­‐cultures,	   a	  
live/dead	   fixable	  cellular	  marker	  conjugated	   to	  a	   red	   fluorochrome	   (Invitrogen)	  
was	  used	  in	  combination	  with	  cell-­‐type	  specific	  markers	  (GFAP,	  CD68	  and	  MAP2	  
to	   identify	   astrocytes,	   microglia	   and	   neurons,	   respectively).	   On	   the	   day	   of	  
analyses	  (after	  9	  or	  14	  days	  in	  culture),	  the	  Live/Dead	  dye	  (1μl/well)	  was	  added	  
to	   the	   culture	   medium	   and	   incubated	   for	   30	   minutes	   at	   37°C	   to	   allow	  
damaged/dying	   cells	   to	   take	   up	   this	   amine-­‐reactive	   fluorescent	   dye.	   Cultures	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Cytotoxicity	  
Overall	   cytotoxicity	   in	   co-­‐cultures	   was	   evaluated	   by	   measuring	   lactate	  
dehydrogenase	  (LDH)	  release	  using	  a	  Cytotox	  96	  assay	  kit	  (Promega)	  according	  to	  
manufacturer’s	  instructions.	  This	  assay	  is	  based	  on	  the	  enzymatic	  conversion	  of	  a	  
tetrazolium	   salt	   (INT)	   into	   a	   red	   formazan	   product,	   at	   a	   level	   that	   is	   directly	  
proportional	  to	  amount	  of	  LDH	  present	  in	  the	  sample.	  This	  product	  is	  measured	  
at	   492nm	   by	   using	   a	   plate	   reader	   (Wallac	   1420	   Victor3	   plate	   reader,	   Perkin-­‐
Elmer,	  Waltham).	   After	   collection	   of	   half	   of	   the	  medium	   from	   each	   culture	   to	  
measure	  the	  %LDH	  released	  into	  the	  medium,	  the	  remaining	  cells	  were	  lysed	  in	  
0.1%	  Triton	  X-­‐100	  for	  30	  minutes.	  The	  LDH	  content	  of	  these	  latter	  samples	  was	  
used	  as	  a	  measure	  of	  total	  LDH	  content	  (100%	  LDH).	  LDH	  release	  from	  cells	  was	  
calculated	  as	  a	  percentage	  of	  total	  LDH	  (%LDH)	  in	  each	  sample,	  and	  presented	  as	  
average	  of	  %LDH±SEM.	  
	  
Pharmacological	  activation	  of	  astrocytes	  
To	   compare	   the	   ability	   of	   WT	   or	   Cln3-­‐/-­‐	   astrocytes	   to	   respond	   to	   activation,	  
primary	   astrocytes	   cultures	   were	   exposed	   to	   LPS	   (Sigma)	   plus	   IFNγ	   (Thermo	  
Scientific)	   (Bolaños	   et	   al.,	   1994).	   These	   compounds	  were	   added	  directly	   to	   the	  
culture	  medium	  to	  give	  a	  final	  concentration	  of	  1µg/ml	  LPS	  and	  100	  U/ml	  of	  IFNγ.	  
WT	  and	  Cln3-­‐/-­‐	  astrocytes	  were	  exposed	  to	  this	  activating	  stimulus	  for	  a	  range	  of	  
times,	   as	   indicated	   in	   the	   specific	   experiments	   described	   below.	   In	   all	   cases,	  
untreated	   cultures	   that	   did	   not	   receive	   any	   stimulation	  were	   used	   as	   controls.	  
Following	  stimulation	  cell	  responses	  were	  compared	  by	  (1)	  immunofluorescence	  
staining	   to	  study	  cell	  morphology	  and	  protein	   localization;	   (2)	  Western	  blotting	  
to	  quantify	  protein	  expression;	   (3)	  HPLC	  to	  analysis	   the	  synthesis	  and	  secretion	  
of	  glutathione;	  (4)	  assessing	  migration	  using	  a	  scratch	  assay;	  and	  (5)	  collection	  of	  
cell	  medium	  from	  cultures	  for	  analysis	  of	  secreted	  soluble	  factors.	  	  
	  
Activation	  of	  specific	  signaling	  cascades	  by	  LPS	  and	  IFNγ	  
To	   assess	   the	   ability	   of	   LPS	   and	   IFNγ	   to	   transduce	   a	   signal	   in	   astrocytes	   the	  
nuclear	   translocation	   of	   appropriate	   downstream	   signaling	   components	   were	  
investigated.	  Upon	  binding	  to	  its	  receptor,	  toll-­‐like	  receptor	  4	  (TLR4),	  LPS	  initiates	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a	   downstream	   signaling	   cascade	   that	   ultimately	   leads	   to	   the	   nuclear	   trans-­‐
localization	   of	   the	   phosphorylated	   forms	   of	   the	   nuclear	   factor-­‐κβ	   (NF-­‐κB)	  
subunits	   P65	   and	   P50,	   resulting	   in	   the	   expression	   of	   NF-­‐κB	   regulated	   genes	  
(Wang	  and	  Baldwin,	  1998;	  Chow	  et	  al.,	  1999).	  Upon	  binding	  to	  its	  receptor,	  IFNγ-­‐
R,	  IFNγ	  on	  the	  other	  hand,	  activates	  the	  Janus	  kinase	  (JAK)-­‐signal	  transducer	  and	  
activator	  of	  transcription	  (STAT)	  signaling	  pathway	  leading	  to	  the	  nuclear	  trans-­‐
localization	  of	  phosphorylated	  form	  of	  STAT1	  and	  the	  inhibition	  or	  activation	  of	  
the	   transcription	   of	   genes	   regulated	   by	   this	   factor	   (Horvath,	   2004).	   Therefore,	  
the	   ability	   of	   LPS	   to	   activate	   P-­‐P65	   and	   IFNγ	   to	   activate	   P-­‐STAT1	   in	   stimulated	  
and	  non-­‐stimulated	  WT	  and	  Cln3	  deficient	  astrocyte	  cultures	  was	  analyzed.	  GFAP	  
was	   used	   to	   identify	   astrocytes	   and	   phospo-­‐specific	   primary	   antibodies	   were	  
used	   to	   identify	   the	   NF-­‐κB	   subunit	   P65	   (P-­‐P65)	   and	   STAT1	   (P-­‐STAT1).	   The	  
standard	   immunofluorescence	   staining	   protocol	   described	   above	  was	   followed	  
except	   when	   labeling	   with	   anti-­‐P-­‐STAT1	   where,	   a	   10	   minutes	   incubation	   in	  
methanol	  at	  room	  temperature	  was	  used	  to	  permeabilise	  cells,	  and	  blocking	  was	  
carried	  out	  with	  15%	  NGS	  for	  1	  hour.	  The	  percentage	  of	  cells	  expressing	  either	  P-­‐
P65	  or	  P-­‐STAT1	  in	  their	  nuclei	  was	  quantified,	  as	  described	  below.	  	  
	  
Assessment	  of	  morphological	  changes	  following	  activation	  
To	  visualize	  the	  morphological	  changes	  that	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  underwent	  
upon	   activation	   with	   LPS/IFNγ,	   cultures	   were	   stained	   with	   GFAP	   and	   the	  
observed	  changes	  in	  cell	  soma	  size	  measured	  using	  ImageJ.	  Images	  of	  5	  random	  
fields	   of	   cells,	   whose	   processes	   were	   not	   overlapping,	   were	   taken	   from	   two	  
different	  coverslips	  per	  genotype,	  per	  experiment.	  The	  soma	  size	  of	   these	  cells	  
was	   then	   measured	   by	   manually	   drawing	   around	   the	   body	   of	   each	   cell	   and	  
allowing	  ImageJ	  to	  calculate	  the	  enclosed	  area	  by	  using	  the	  μm/pixel-­‐information	  
provided.	  The	  average	  cell	  body	  size	  of	  Cln3-­‐/-­‐	  astrocytes	  was	  normalized	  to	  the	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Cell	  counts	  
Where	   data	   analysis	   included	   cell	   counts	   from	   immunostained	   cultures,	   five	  
random	   fields	   were	   counted	   per	   culture,	   and	   averaged	   to	   determine	   the	  
percentage	   of	   cells	   expressing	   each	   marker	   within	   the	   total	   population.	   All	  
counts	   were	   averaged	   from	   at	   least	   three	   coverslips	   per	   condition,	   and	   were	  
obtained	   from	   at	   least	   three	   different	   experiments	   (unless	   otherwise	   stated),	  
and	  the	  standard	  error	  of	  the	  mean	  calculated	  (SEM).	  
	  
2.7	  Western	  blotting	  
This	  technique	  was	  use	  to	  assess	  changes	  in	  levels	  of	  proteins	  in	  WT	  and	  Cln3-­‐/-­‐	  
astrocytes	  known	   to	  accompany	  astrocyte	  activation,	   such	  as	  GFAP,	  nestin	  and	  
vimentin.	  In	  all	  experiments	  activation	  with	  LPS/IFNγ	  was	  carried	  out	  for	  24	  or	  48	  
hour	  and	  untreated	  samples	  were	  used	  as	  controls.	  	  
	  
Preparation	  of	  cell-­‐lysates	  
After	  activation,	  cultures	  were	  washed	  twice	  with	  ice-­‐cold	  PBS	  then	  150µl	  of	  ice-­‐
cold	  lysis	  buffer	  (50mM	  Tris-­‐HCL,	  pH	  7.5,	  150nM	  NaCl,	  1mM	  EDTA,	  1%	  Triton	  X-­‐
100,	  protease	  inhibitor	  cocktail	  set	  III	  (1:1000)	  and	  phosphatase	  inhibitor	  cocktail	  
set	  II	  (1:100)	  (Calbiochem))	  was	  added	  and	  the	  cells	  scraped	  into	  the	  buffer.	  This	  
lysate	  was	   then	   incubated	   on	   ice	   for	   10	  minutes	   and	   spun	   at	   14000rpm	   for	   5	  
minutes.	  Before	  storage	  at	  -­‐80°C,	  40µl	  of	  4×sample	  buffer	  (150mM	  Tris-­‐HCL,	  pH	  
6.8,	   12%	   SDS,	   30%	   glycerol,	   a	   few	   grains	   of	   bromophenol	   blue	   and	   5%	   β-­‐
mercaptoethanol)	  was	  added.	  On	  the	  day	  the	  gel	  was	  run,	  samples	  were	  thawed	  
and	  boiled	  for	  5	  minutes	  at	  95	  °C,	  then	  spun	  briefly	  at	  14000rpm.	  To	  allow	  equal	  
loading	  of	  the	  samples,	  a	  BCA	  protein	  assay	  kit	   (Thermo	  Scientific)	  was	  used	  to	  
quantify	  the	  total	  amount	  of	  protein	  in	  each	  sample	  according	  to	  manufacturer’s	  
instructions.	  
	  
Electrophoresis,	  transfer	  of	  proteins	  and	  sample	  quantification	  
Samples	   (20μg/sample)	  were	   run	   on	   a	   12%	  NuPAGE®	   Bis-­‐Tris,	   sodium	   dodecyl	  
sulfate	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	   gel	   for	   approximately	   2	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hours	  at	  120V.	  The	  gels	  were	  then	  incubated	  for	  5-­‐10	  minutes	  in	  transfer	  buffer	  
(25mM	   Tris-­‐HCL,	   192mM	   Glycine,	   0.01%	   SDS	   and	   20%	   methanol),	   before	  
proteins	   were	   transferred	   to	   Immuno-­‐Blot	   polyvinylidene	   difluoride	   (PVDF)	  
membranes	   (Bio-­‐Rad	   laboratories,	   Hercules,	   CA)	   that	   had	   been	   incubated	   in	  
methanol	   for	   10	  minutes,	   followed	   by	   5-­‐10	  minutes	   in	   transfer	   buffer	   (25mM	  
Tris-­‐HCL,	   192mM	   Glycine,	   0.01%	   SDS	   and	   20%	   methanol).	   The	   Transfer	   was	  
carried	  out	  at	  30V	  for	  1.5	  hour.	  Membranes	  were	  then	  blocked	  for	  1h	  in	  5%	  non-­‐
fat	  dry	  milk	  in	  TBS	  containing	  0.1%	  Tween-­‐20	  (TBS-­‐T)	  to	  prevent	  the	  non-­‐specific	  
binding	  of	  antibodies,	  and	  incubated	  with	  primary	  antibodies,	  diluted	  in	  3%	  BSA	  
containing	   0.1%	   Tween-­‐20,	   overnight	   at	   4°C.	   Membranes	   were	   then	   washed	  
three	   times	   in	   TBS-­‐T	   and	   incubated	   with	   the	   relevant	   fluorescently	   labeled	  
secondary	  antibodies,	  diluted	  in	  5%	  non-­‐fat	  dry	  milk	  in	  TBS-­‐T	  for	  1	  hour,	  at	  room	  
temperature	   before	   being	   washed	   three	   times	   in	   TBS-­‐T.	   After	   washing,	  
immunoreactive	   bands	   were	   visualized	   using	   an	   Odyssey	   Infrared	   Imaging	  
System	   (Li-­‐COR	   Biosciences).	   Quantification	   of	   protein	   levels	   was	   performed	  
from	   three	   biological	   replicates	   using	   a	   gel	   quantification	   program	  provided	   in	  
ImageJ.	   The	   arbitrary	   fluorescent	   values	   that	   represent	   the	   relative	   amount	   of	  
protein	  obtained	  from	  Cln3-­‐/-­‐	  cell	  samples	  were	  normalized	  to	  corresponding	  WT	  
cell	  samples.	  
	  
Western	   blotting	   analysis	   was	   also	   used	   to	   quantify	   the	   expression	   levels	   of	  
SNARE-­‐complex	  and	  EEA1-­‐proteins	  expressed	  by	  neurons	   that	  had	  been	  grown	  
alone	  or	   in	   co-­‐cultures	  with	   glial	   cells.	   In	   these	  experiments,	   neuronal	   cultures	  
were	   lysed	   after	   7	  DIV,	   and	   co-­‐cultures	  were	   lysed	   after	   14	  DIV,	   following	   the	  
same	  protocol	  as	  described	  above,	  except	  here,	  the	  arbitrary	  fluorescent	  values	  
for	   each	   protein	   in	   each	   sample	   were	   normalized	   to	   β-­‐actin	   values.	   Three	  
biological	  replicates	  were	  quantified	  in	  each	  case.	  	  	  
	  
2.8	  Protein	  secretion	  profiling	  assay	  
Protein	  secretion	  is	  one	  of	  the	  fundamental	  properties	  of	  astrocytes,	  which	  they	  
use	   to	   communicate	   with	   and	   control	   the	   biology	   of	   other	   cells	   in	   the	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surrounding	  tissue	  (Majumder	  et	  al.,	  1996;	  Ridet	  et	  al.,	  1997;	  Liberto	  et	  al.,	  2004;	  
Bélanger	   and	  Magistretti,	   2009;	  McKimmie	   and	   Graham,	   2010;	   Allaman	   et	   al.,	  
2011).	  The	  quantitative	  analysis	  of	  the	  levels	  of	  proteins	  secreted	  by	  Cln3-­‐/-­‐	  and	  
WT	  astrocytes	  grown	  under	  basal	  conditions,	  and	  at	  various	  time	  points	  (6	  hour,	  
24	  hour	  and	  72	  hour)	  after	  activation	  with	  LPS/IFNγ,	  was	  carried	  out	  by	  Myriad	  
RBM	  (Austin,	  TX,	  USA)	  (RodentMAP	  version	  2.0	  cytokine	  analysis).	  	  	  
	  
All	   supernatant	   samples	   were	   collected	   and	   stored	   at	   -­‐80°C	   until	   sent	   for	  
analysis.	  Before	  shipping,	  samples	  were	  allowed	  to	   thaw	  at	   room	  temperature,	  
mixed	  well	  by	  vortexing	  then	  centrifuged	  at	  13000	  x	  g	  (5	  minutes)	  to	  remove	  any	  
cell	   debris.	   Simultaneous	   analysis	   of	   59	   different	   proteins	   from	   each	   of	   the	  
samples,	  was	  carried	  out	  by	  Myriad	  RBM	  (quantified	  proteins	  listed	  in	  Chapter	  4,	  
Table	   4.1)	   using	   an	   automated	   quantification	   system	   described	   briefly	   below.	  
Sample	  were	  added	  into	  the	  capture	  microsphere	  multiplexes	  of	  the	  RodentMAP	  
(multi-­‐analyte	   profiling)	   version	   2.0	   using	   robotics,	   thoroughly	   mixed	   and	  
incubated	  for	  1	  hour	  at	  room	  temperature.	  Multiplexed	  cocktails	  of	  biotinylated	  
reporter	   antibodies	   for	   each	  multiplex	  were	   then	   added,	  mixed	   and	   incubated	  
for	  a	  further	  hour	  at	  room	  temperature.	  The	  reaction	  was	  then	  developed	  using	  
a	   Streptavidin-­‐phycoerythrin	   solution	   by	   incubation	   for	   1	   hour	   at	   room	  
temperature.	   Results	  were	  processed	  using	   a	   Luminex	   100	   instrument	   and	   the	  
data	  analyzed	  using	  patented	  data	  analysis	  software	  developed	  by	  Myriad	  RBM.	  
Appropriate	   control	   samples	  were	   run	  with	   each	  multiplex	   to	   ensure	   accurate	  
assay	   performance.	   The	   expression	   levels	   of	   59	   different	   proteins	   were	  
quantified	   from	   three	   different	   biological	   samples	   for	   each	   treatment	   per	  
genotype.	   These	  values	  were	  normalized	   to	   the	   relative	  number	  of	   cells	   in	   the	  
culture	  from	  which	  the	  medium	  was	  collected,	  as	  determined	  by	  counting	  DAPI	  
stained	  nuclei	   in	   five	   random	   fields	   from	  each	   fixed	   culture	   subsequent	   to	   cell	  
supernatant	   collection.	   The	   difference	   in	   secreted	   protein	   levels	   between	  WT	  
and	  Cln3-­‐/-­‐	  astrocytes	  are	  presented	  as	  %	  Change	  in	  tables	  4.1	  and	  4.2	  of	  Chapter	  
4.	  Some	  selected	  secreted	  proteins	  levels	  are	  also	  presented	  as	  a	  time	  course	  of	  
altered	  secretion	  levels	  over	  time.	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2.9	  Glutathione	  measurements	  	  
Determination	  of	  intracellular	  reduced	  glutathione	  levels	  using	  reverse-­‐phase	  
HPLC	  	  
	  
The	   principle	   underlying	   this	  method	   is	   the	   separation	   of	   reduced	   glutathione	  
(GSH)	   from	  other	   components	  within	   the	   samples	   by	   using	   reverse-­‐phase	   high	  
performance	  liquid	  chromatography	  (HPLC).	  In	  this	  particular	  method	  the	  mobile	  
phase:	  15mM	  orthophosphoric	   acid	   (OPA)	   is	   forced	   through	  a	   chromatography	  
column	  contains	  C18	  chains	  under	  high	  pressure.	  Hydrophobic	   interactions	  with	  
the	  C18	  chains	  delay	  the	  progress	  of	  molecules	  as	  they	  are	  forced	  to	  pass	  through	  
the	  column.	  Retention	  time,	  which	  is	  the	  time	  taken	  for	  a	  particular	  molecule	  to	  
be	   eluted	   from	   the	   column,	   depends	  upon	   the	  molecule’s	   hydrophobicity,	   and	  
remains	  identical	  under	  the	  same	  conditions.	  	  
	  
To	  quantify	  GSH	   levels	   in	  our	  samples,	  an	  electrochemical	  method	  of	  detection	  
was	   used	   (Riederer	   et	   al.,	   1989).	   Eluent	   from	   the	   column	   was	   passed	   into	   an	  
electrical	  cell	  (model	  5010)	  that	  forms	  part	  of	  the	  Coulochem	  II	  electrochemical	  
detector	  (ESA,	  Analytical	  Aylesbury,	  UK),	  which	  includes	  two	  electrodes	  in	  series	  
set	  to	  constant	  voltage	  optimized	  for	  the	  proteins	  being	  measured.	  The	  voltage	  
at	  the	  upstream	  electrode	  (E1)	  is	  set	  below	  that	  which	  the	  protein	  of	  interest	  will	  
oxidize	  in	  order	  to	  remove	  the	  more	  readily	  oxidized	  proteins	  within	  the	  sample.	  
The	  downstream	  electrode	  (E2)	  is	  set	  to	  a	  voltage,	  which	  is	  the	  optimal	  oxidizing	  
voltage	   for	   the	  molecule	  of	   interest.	   The	   retention	   time	   is	  used	   to	   identify	   the	  
molecules,	   and	   the	   peak	   height	   at	   this	   time	   corresponds	   to	   the	   current	   they	  
induce	  at	  E2.	  Thus,	  peak	  height	   is	  directly	  proportional	   to	   the	  concentration	  of	  
the	  molecule	  of	   interest.	   Figure	  2.1	   illustrates	   typical	   chromatograms	  obtained	  















Figure	   2.1.	   A	   typical	   GSH-­‐chromatogram	   from	   reverse-­‐phase	   HPLC.	   This	   figure	  
illustrates	   a	   typical	   chromatogram	   from	   a	   reverse-­‐phase	   HPLC	   run	   designed	   to	   quantify	   the	  
amount	   of	   reduced	   form	   of	   glutathione	   (GSH).	   The	   peak	   height	   is	   directly	   proportional	   to	   the	  
concentration	  of	  GSH.	  	  	  	  
	  
The	  correct	  voltage	  at	  E2	  for	  the	  molecule	  of	  interest	  was	  initially	  determined	  by	  
using	   a	   voltammogram,	   where	   a	   standard	   concentration	   of	   the	   protein	   of	  
interest	  is	  run	  through	  the	  column	  at	  a	  range	  of	  different	  voltages,	  and	  the	  peak	  
height	   is	  plotted	  against	  voltage.	  The	  optimal	  voltage	  is	  chosen	  based	  on	  which	  
of	   the	   voltages	   provides	   the	   maximal,	   or	   near	   maximal,	   peak	   height	   while	  
maintaining	  the	  background	  current	  low	  and	  producing	  a	  clean,	  narrow	  peak	  on	  
the	  chromatograph.	  
	  
Preparation	  of	  astrocyte	  samples	  for	  GSH	  measurement	  
To	   perform	   intracellular	   glutathione	   (GSH)	  measurements,	   some	   cultures	  were	  
stimulated	  with	  LPS	  (1µg/ml)	  plus	   IFNγ	   (100U/ml)	   for	  24	  hour	  or	  48	  hour	  while	  
others	   received	   no	   stimulation	   and	  were	   used	   as	   controls.	   Cells	   were	   washed	  
twice	   in	   1ml	   HBSS	   (minus	   phenol	   red),	   removed	   from	   wells	   with	   1ml	   trypsin-­‐
EDTA	  (0.5	  mg/ml,	  minus	  phenol	  red),	  then	  centrifuged	  at	  500	  x	  g	  for	  5	  minutes	  at	  
4°C.	   Cell	   pellets	   were	   resuspended	   in	   300µl	   of	   isolation	   medium	   (320mM	  
sucrose,	   10mM	   Tris,	   1mM	   EDTA,	   pH	   7.4)	   and	   frozen	   in	   liquid	   nitrogen	   before	  
being	   stored	   at	   -­‐80°C.	   The	   GSH	   levels	   obtained	   were	   normalized	   to	   the	   total	  
amount	  of	  protein	  in	  each	  sample,	  which	  was	  determined	  using	  a	  Lowry	  protein	  
assay	  (Thermo	  Scientific)	  according	  to	  the	  manufacturer’s	  instructions.	  	  
	  
Measurement	  of	  intracellular	  levels	  of	  glutathione	  
Intracellular	   GSH	   levels	   were	   determined	   electrochemically,	   and	   separation	   by	  
reverse-­‐phase	  HPLC,	  as	  described	  above	  (Riederer	  et	  al.,	  1989;	  Gegg	  et	  al.,	  2005).	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To	  do	  this,	   samples	  were	  thawed	  and	  GSH	  was	  extracted	  by	  the	  addition	  of	  an	  
equal	   volume	   of	   15mM	   OPA,	   followed	   by	   thorough	   vortexing.	   Unwanted	  
proteins	  in	  the	  sample	  were	  pelleted	  by	  centrifugation	  at	  10,000	  g	  for	  5	  minutes	  
(Eppendorf	   5415R).	   The	   supernatant	   was	   then	   injected	   into	   the	   HPLC	   using	   a	  
Jasco	   autosampler	   (model	   AS-­‐2055	   Plus;	   Jasco,	   Essex,	   UK)	   with	   an	   injection	  
volume	  of	  50μl.	  Subsequently,	   the	  sample	  was	  passed	  through	  a	  3mm	  x	  10mm	  
guard	  column,	  and	   into	  a	  4.6mm	  x	  250mm	  analytical	  column	  packed	  with	  5μM	  
octadecasilyl-­‐silica	   (HPLC	   Technology	   Co	   Ltd,	   purchased	   from	   Chromacol	   Ltd,	  
Hertfordshire,	   UK).	   	   Both	   of	   these	   columns	  were	   kept	   in	   a	   block	   heater	   set	   at	  
30°C	   (model	   7970;	   Jones	   Chromatography,	   Mid	   Glamorgan,	   UK).	   The	   mobile	  
phase	  was	  pumped	  through	  the	  HPLC-­‐system	  at	  0.5ml.min-­‐1	  by	  using	  a	  Jasco	  PU-­‐
1580	  pump	  (Jasco,	  Essex,	  UK).	  Normally	  in	  this	  type	  of	  setup	  the	  pressure	  of	  the	  
column	  was	  in	  the	  range	  of	  50	  –	  70	  kg.cm-­‐2,	  and	  the	  retention	  time	  for	  the	  GSH	  
was	  around	  9.5-­‐14	  minutes.	  The	  electrode	  potentials	  were	  set	  at	  E1=100	  mV	  and	  
E2=450	   mV,	   and	   the	   total	   run	   time/sample	   was	   20	   minutes.	   A	   Chromjet	  
integrator	   (model	   SP4400;	   ThermoFinnigan,	   Thermo	   Fisher	   Scientific,	   Hemel	  
Hempstead,	  UK),	  which	  is	  connected	  to	  the	  E2	  electrode,	  recorded	  the	  generated	  
current	  generating	  chromatograms	  in	  real-­‐time.	  Standards	  of	  5μM	  GSH	  in	  15mM	  
OPA	  were	  run	  at	  the	  beginning	  and	  end	  of	  each	  the	  experiment.	  Peak	  heights	  of	  
these	   standards	   were	   used	   to	   calculate	   the	   appropriate	   GSH	   concentration	   in	  
each	   sample,	   which	   were	   corrected	   for	   sample	   dilution,	   normalized	   for	  
intracellular	   protein	   content,	   and	   shown	   as	   nmol/mg	   protein.	   Three	   replicates	  
were	   used	   in	   each	   experiment,	   and	   these	   experiments	   were	   repeated	   four	  
separate	  times.	  
	  
Measurement	  of	  intracellular	  levels	  of	  oxidized	  and	  total	  glutathione	  
In	  addition	  to	  the	  GSH,	  the	  oxidized	  form	  (GSSG)	  may	  also	  exist	  in	  cells.	  In	  order	  
to	  calculate	  the	  total	  levels	  of	  glutathione	  in	  the	  samples,	  from	  which	  GSSG	  levels	  
can	  be	   calculated,	   cells	  were	  prepared	   for	  HPLC	   as	  described	   above.	  However,	  
subsequent	   to	   cell	   suspension	   in	   isolation	  medium,	   samples	  were	   split	   in	   half.	  
One	  half	  of	  each	   sample	  was	  used	   for	  GSH	  measurements	  as	  described	  above,	  
and	   the	   remaining	   half	   was	   treated	   with	   glutathione	   reductase	   (GR)	   in	   the	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presence	  of	  reduced	  nicotinamide	  adenosine	  dinucleotide	  phosphatase	  (NADPH)	  
to	   convert	   the	   GSSG	   to	   GSH	   (Stewart	   et	   al.,	   2002).	   To	   do	   this,	   samples	   were	  
incubated	   at	   37°C	   for	   10	   minutes	   with	   an	   equal	   volume	   of	   isolation	   medium	  
(320mM	  sucrose,	  10mM	  Tris,	  1mM	  EDTA,	  pH	  7.4)	  containing	  500uM	  NADPH	  and	  
2	   units	   of	   GR,	   snap-­‐frozen	   in	   liquid	   nitrogen	   and	   stored	   at	   -­‐80°C	   until	   used	   to	  
determine	  GSH	  levels	  by	  HPLC,	  as	  described	  above.	  The	  difference	  between	  total	  
glutathione	   concentration	   and	   GSH	   concentration	   was	   used	   to	   calculate	   the	  
concentration	   of	   GSSG.	   These	   measurements	   were	   carried	   out	   from	   three	  
different	  samples,	  and	  repeated	  once.	  
	  
Determination	  of	  glutathione	  levels	  in	  the	  culture	  medium	  
Glutathione	   levels	   in	   the	   culture	   medium	   were	   measured	   using	   the	   GSH-­‐Glo	  
glutathione	   assay	   kit	   (Promega)	   that	   consists	   of	   a	   two-­‐step	   reaction	   system	  
allowing	  the	  quantification	  of	  reduced	  glutathione	  levels	  based	  on	  a	  luminescent	  
signal	   (Figure	   2.2).	   In	   the	   first	   step,	   glutathione	   S-­‐transferase	   (GST)	   produces	  
luciferin	   from	   luciferin-­‐NT,	  which	   is	  a	   luciferin	  byproduct	   that	   is	  only	   formed	   in	  
the	   presence	   of	   reduced	   glutathione	   (GSH).	   In	   the	   second	   reaction,	   stabilized	  
luciferase	  from	  Photinus	  pyralis	  induces	  the	  release	  of	  light	  by	  luciferin.	  The	  light	  






Figure	  2.2.	  Schematic	   illustration	  of	  the	  GSH-­‐Glo	  glutathione	  assay.	  The	  GSH-­‐Glo	  
glutathione	  assay	  is	  performed	  in	  two	  steps.	  In	  the	  first	  step,	  samples	  are	  treated	  with	  a	  luciferin-­‐
NT	   substrate	   and	   glutathione	   S-­‐transferase.	   Glutathione	   present	   in	   the	   sample	   drives	   the	  
formation	  of	  luciferin.	  In	  the	  second	  step,	  Luciferin	  Detection	  Reagent	  is	  added	  to	  produce	  light.	  
The	  amount	  of	  light	  detected	  is	  directly	  proportional	  to	  the	  amount	  of	  GSH	  in	  the	  reaction.	  Image	  
was	   obtained	   from	   Promega	   webpage	   (http://www.promega.com/products/pm/gsh-­‐glo-­‐
glutathione-­‐assay/).	  	  
	  
This	   experiment	   was	   carried	   out	   according	   to	   the	  manufacturer’s	   instructions.	  
Briefly,	  prior	  to	  the	  start	  of	  the	  experiment,	  the	  medium	  was	  changed	  to	  serum-­‐
free,	   phenol	   red-­‐free	   medium	   (otherwise	   identical	   to	   the	   routinely	   used	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astrocyte	  cell	  culture	  medium).	  At	  the	  end	  of	  an	  incubation	  period	  of	  8	  hour,	  half	  
of	  the	  medium	  was	  removed	  to	  be	  used	  for	  GSH	  measurements,	  and	  centrifuged	  
at	   5031	   g	   for	   2	   minutes	   to	   pellet	   any	   cell	   debris.	   To	   make	   sure	   the	   obtained	  
results	  were	  not	  due	  to	  unspecific	  release	  of	  GSH,	  the	  other	  half	  of	  the	  medium	  
was	  used	  to	  measure	  the	  amount	  of	  LDH	  released	  into	  in	  the	  medium,	  which	  was	  
compared	  to	  total	  amount	  of	  LDH	  per	  sample	  (100%	  LDH)	  obtained	  by	  lysing	  the	  
cells	   in	   the	   culture	   with	   Triton	   X-­‐100	   (final	   concentration	   0.1%).	   The	   LDH	  
measurements	  were	  carried	  out	  as	  described	  above	  (cytotoxicity	  assay).	  	  
	  
In	   some	   experiments,	   the	   importance	   of	   the	   actin	   cytoskeleton	   to	   glutathione	  
secretion	   was	   examined	   by	   using	   an	   inhibitor	   of	   actin	   polymerization	   called	  
Cytochalasin	  D	  (1μM).	  This	  inhibitor	  was	  added	  to	  the	  WT	  astrocytes	  30	  minutes	  
prior	  to	  the	  start	  of	  the	  8	  hour	  measurement	  period,	  otherwise	  the	  extracellular	  
GSH	  measurements	  were	  carried	  out	  as	  described	  below.	  	  
	  	  
In	  order	  to	  measure	  the	  total	  amount	  of	  glutathione,	  50μl	  of	  each	  of	  the	  sample	  
was	   treated	   with	   tris-­‐2-­‐carboxyethyl	   phosphine	   (TCEP),	   which	   is	   a	   strong	  
reducing	  agent	   that	   converts	   the	  oxidized	   form	  of	  glutathione	   into	  measurable	  
GSH,	  for	  10	  minutes	  at	  room	  temperature.	  For	  the	  GSH	  measurements,	  50μl	  of	  
sample	  was	  combined	  with	  50μl	  of	  GSH-­‐Glo	  reagent,	  which	  contained	  luciferin-­‐
NT	  and	  glutathione	  S-­‐transferase	  in	  50mM	  tricine	  buffer	  (pH	  7.9),	   in	  a	  well	  of	  a	  
96-­‐well	  plate	   (Corning).	  The	   samples	  were	   then	  mixed	  briefly	  and	   incubated	  at	  
room	   temperature	   for	   30	   minutes.	   100μl	   of	   the	   luciferin	   detection	   reagent,	  
which	   was	   reconstituted	   with	   luciferin	   detection	   buffer	   according	   to	   the	  
manufacturer’s	   instructions,	  was	   then	   added	   to	   each	   of	   the	   sample-­‐containing	  
wells	  and	  their	  luminesence	  recorded	  using	  a	  plate	  reader	  (Wallac	  1420	  Victor3	  
plate	  reader,	  Perkin-­‐Elmer,	  Waltham).	  GSH	  concentrations	  in	  each	  sample	  were	  
then	  calculated	  using	  a	  standard	  curve,	  which	  was	  run	  alongside	  the	  samples	  in	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2.10	  Cell	  mobility	  assay	  
In	  order	  to	  investigate	  whether	  the	  ability	  of	  the	  Cln3-­‐/-­‐	  astrocytes	  to	  migrate	  was	  
compromised,	  a	   scratch	  wound	  assay	  was	  performed.	  Once	  astrocytes	  cultures	  
were	  confluent	  (24	  –	  72	  hours	  after	  plating)	  a	  scratch	  was	  made	  using	  the	  Essen	  
Wound-­‐maker,	   generating	   a	   cell-­‐free	   region	   that	   was	   approximately	   800μm	   –	  
900μm	  wide.	  Cultures	  were	   then	  washed	   three	   times	  with	  PBS,	   to	   remove	  any	  
cell	   debris	   from	   the	   scratched	   area,	   before	   the	   addition	   of	   growth	   medium	  
containing	  Ara-­‐C	  (to	  inhibit	  cell	  proliferation),	  to	  which	  LPS/IFNγ	  was	  or	  was	  not	  
added.	  Cultures	  were	  then	  placed	  in	  the	  IncuCyte	  live	  cell	  imaging	  system	  (Essen)	  
and	  the	  wound	  width	  measured	  every	  1	  hour	  for	  24	  hour.	  The	  rate	  of	  migration	  
was	   obtained	   by	  measuring	   the	  width	   of	   the	   existing	  wound	   over	   time.	   Three	  
samples	   per	   condition	  were	   analyzed	   in	   each	   experiment	   and	   this	   experiment	  
was	  repeated	  four	  times.	  
	  
2.11	  Intracellular	  calcium	  measurements	  
Fluctuations	   in	   the	   levels	   of	   intracellular	   Ca2+	   ([Ca2+]i)	   were	   investigated	   to	  
determine	  the	  ability	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  to	  generate	  spontaneous	  Ca2+-­‐
oscillations	  and	  calcium	  waves,	  to	  response	  to	  ATP-­‐treatment	  and	  to	  study	  Ca2+-­‐
release	  from	  the	  ER	  following	  thapsigargin	  (SERCA-­‐pump	  inhibitor)-­‐treatment.	  	  
	  
To	   measure	   intracellular	   Ca2+-­‐levels,	   cells	   were	   loaded	   with	   5μM	   fura-­‐2	   AM	  
(Invitrogen),	   together	   with	   0.005%	   Pluronic	   acid	   (Sigma)	   diluted	   in	   astrocyte	  
growth	  medium,	   for	  30	  minutes	  at	   room	  temperature.	  Cells	  were	  then	  washed	  
three	  times	  with	  HBSS	  (-­‐phenol	  red,	  +Ca2+/Mg2+),	  and	  recording	  medium	  added.	  
The	   composition	   of	   this	   medium	   varied	   in	   each	   experiment	   (see	   below	   for	  
details).	  Measurements	   were	   obtained	   using	   a	   Nikon	   epifluorescence	   inverted	  
microscope	   equipped	   with	   a	   20	   X	   fluorite	   objective	   (Tokyo,	   Japan).	   In	   this	  
system,	  a	  Xenon	  arc	  lamp	  creates	  excitation	  light,	  which	  is	  selected	  using	  10nm	  
bandpass	   filters,	   centered	   at	   340nm	  and	   380nm,	   that	   are	   kept	   in	   a	   computer-­‐
controlled	   filter	   wheel,	   both	   with	   emission	   at	   >515nm	   (Cairn	   Research,	  
Faversham,	  UK).	  A	  CCD	  camera	  (Orca	  ER;	  Hamamatsu,	  Welwyn	  Garden	  City,	  UK)	  
was	  used	  to	  collect	  the	  emitted	  light,	  which	  passes	  through	  a	  long-­‐pass	  filter.	  All	  
	   103	  
imaging	   data	   was	   collected	   at	   5	   seconds	   intervals,	   digitized	   and	   subsequently	  
analyzed	   using	   Kinetic	   Imaging	   software	   (Wirral,	   UK).	   The	   traces	   obtained	   are	  
presented	  as	  ratios	  of	  excitation	  at	  340nm	  and	  380nm	  and	  were	  acquired	  from	  
at	  least	  two	  coverslips	  (approximately	  50	  cells/field),	  and	  from	  two	  separate	  cell	  
preparations.	  The	  concentration	  of	   free	   intracellular	  Ca2+	   is	  proportional	   to	   the	  
ratio	   of	   fluorescence	   at	   340/380.	   This	   relationship	   is	   described	   by	   the	  
Grynkiewicz	  equation	  (Grynkiewicz	  et	  al.,	  1985):	  	  
	  
[Ca2+]I	  (nM)=Kd	  X	  [(R-­‐Rmin)/Rmax-­‐R)]	  X	  Sfb,	  
	  
where	  Kd	   (for	  Ca2+	  binding	   to	   fura-­‐2	  at	  37°C)	  =	  225nM,	  R=340/380	   ration,	  Rmax	  
=340/380	   ration	   under	   Ca2+-­‐saturating	   conditions,	   Rmin	   =340/380	   ratio	   under	  
Ca2+-­‐free	  conditions,	  and	  Sfb=ratio	  of	  baseline	  fluorescence	  (380nm)	  under	  Ca2+-­‐
free	  and	  Ca2+-­‐bound	  conditions.	  HBSS	  buffer	  (-­‐phenol	  red,	  +Ca2+/Mg2+)	  was	  used	  
as	   the	   recording	  medium	   in	   all	   spontaneous	   Ca2+	  oscillation	   studies.	  When	   the	  
response	   of	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   to	   ATP	   (100μM)	   treatment	   was	   under	  
investigation,	   [Ca2+]i	   measurements	   were	   carried	   out	   in	   a	   special	   recording	  
buffer:	   a	   HEPES-­‐buffered	   salt	   solution	   (156mM	   NaCl,	   3mM	   KCl,	   2mM	  MgSO4,	  
1.25mM	  KH2PO4,	  2mM	  CaCl2,	  10mM	  glucose,	  and	  10mM	  HEPES,	  pH	  7.35).	  When	  
the	  effect	  of	  thapsigargin	  (1μM)	  on	  ER-­‐Ca2+	  release	  was	  explored,	  the	  recording	  
medium	   used	   was	   HBSS	   buffer	   (-­‐phenol	   red,	   -­‐Ca2+/Mg2+)	   to	   avoid	   any	  
extracellular	   Ca2+.	   Subsequently,	   in	   order	   to	   allow	   the	   store	   operating	   calcium	  
entry	   (SOCE)	   to	   take	  place	  after	  ER-­‐Ca2+	  depletion	  was	  complete,	  Ca2+	   (100μM)	  
made	  in	  HBSS	  buffer	  (-­‐phenol	  red,	  -­‐Ca2+/Mg2+)	  was	  added	  to	  cells.	  	  
	  
2.12	  Lactate	  secretion	  assay	  
In	  the	  CNS	  energy	  is	  transferred	  from	  astrocytes	  to	  neurons	  in	  the	  form	  of	  lactate	  
(Pellerin	  et	  al.,	  1998).	  To	  compare	  the	  ability	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  cultures	  
to	  secrete	  lactate,	  culture	  medium	  was	  replaced,	  24	  hour	  after	  cells	  were	  plated,	  
with	  500μl	  of	  serum-­‐free,	  phenol-­‐red-­‐free	  DMEM	  containing	  glucose	  (4.5g/l),	  P/S	  
(50U/ml	   /	   50μg/ml),	   and	   l-­‐glutamine	   (2mM).	  After	   a	   4	  hour	   incubation,	  half	   of	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the	  culture	  medium	  was	  collected	  and	  centrifuged	  at	  400	  g	  for	  4	  minutes,	  at	  4°C,	  
then	   stored	   in	   -­‐80°C	   until	   lactate	   measurements	   were	   carried	   out,	   while	   the	  
other	  half	  was	  used	  to	  quantify	  the	  total	  amount	  of	  protein	  in	  each	  sample	  using	  
a	   BCA	   protein	   assay	   kit.	   Lactate	   was	   measured	   using	   a	   fluorometric	   L-­‐Lactate	  
Assay	   Kit	   (Abcam),	   according	   to	   the	  manufacturer’s	   instructions.	   In	   this	   assay,	  
lactate	  present	  in	  the	  sample	  reacts	  with	  the	  provided	  enzyme	  mix	  to	  generate	  a	  
product,	   which	   interacts	   with	   a	   lactate	   probe	   to	   produce	   color	   (570nm).	  
Absorbance	  was	  measured	  using	  a	  microplate	  reader	  (Wallac	  1420	  Victor3	  plate	  
reader,	  Perkin-­‐Elmer,	  Waltham).	  In	  each	  assay,	  a	  standard	  curve	  was	  generated	  
using	  cell-­‐free	  culture	  media	  containing	  known	  concentrations	  of	  L-­‐lactate,	  and	  
the	  concentration	  of	  L-­‐lactate	  in	  each	  sample	  was	  calculated	  from	  this	  standard	  
curve.	   The	   obtained	   lactate	   levels	   were	   normalized	   to	   the	   total	   amount	   of	  
protein	  in	  each	  sample,	  and	  presented	  as	  mean	  percentage	  of	  lactate	  (from	  total	  
amount	   of	   protein	   present	   in	   sample)±SEM.	   Three	   technical	   repeats	   were	  
measured	  in	  each	  experiment,	  and	  the	  experiment	  was	  repeated	  four	  times.	  	  
	  
2.13	  Glutamate	  clearance	  assay	  	  
To	   evaluate	   the	   glutamate	   clearance	   capacity	   of	   WT	   and	   Cln3-­‐/-­‐	   astrocytes,	  
culture	  medium	  was	  replaced	  with	  1.5ml	  of	  serum	  free,	  phenol	  red	  free	  DMEM	  
supplemented	  with	  2mM	  glutamate.	  After	  incubation	  for	  2	  hour	  at	  37°C	  to	  allow	  
astrocytes	   to	   take	   up	   some	   of	   the	   added	   glutamate,	   750μl	   of	   medium	   was	  
removed,	  and	  the	  glutamate	  concentration	  determined	  using	  a	  Glutamate	  Assay	  
kit	  (Abcam),	  according	  to	  manufacturer’s	  instructions.	  In	  this	  assay	  the	  provided	  
glutamate	  enzyme	  mix	  recognizes	  glutamate	  present	  in	  the	  sample	  leading	  to	  a	  
colour	  reaction	  that	  can	  be	  detected	  at	  450nm	  and	  measured	  using	  a	  microplate	  
reader	   (Wallac	   1420	   Victor3	   plate	   reader,	   Perkin-­‐Elmer,	  Waltham).	   In	   order	   to	  
calculate	   the	  concentration	  of	  glutamate	   remaining	   in	  each	  sample,	  a	   standard	  
curve	  was	  created	  using	  cell-­‐free	  culture	  media	  containing	  known	  concentrations	  
of	   glutamate.	   The	   amount	   of	   glutamate	   that	   was	   taken	   up	   by	  WT	   and	   Cln3-­‐/-­‐	  
astrocytes	  was	  obtained	  by	  comparing	  these	  values	  to	  control	  samples	  in	  which	  
serum-­‐free,	  phenol-­‐free	  medium	  +2mM	  glutamate	  was	  added	  to	  wells	   that	  did	  
not	   contain	   any	   astrocytes.	   These	  numbers	  were	  normalized	   to	   the	   amount	  of	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total	   cell	   protein	   in	   each	   sample,	   which	   was	   determined	   using	   a	   BCA	   protein	  
assay	   kit.	   Data	   is	   presented	   as	   the	   mean	   percentage	   ±	   SEM.	   Three	   technical	  
repeats	  were	  measured	  per	  experiment	  and	  this	  experiment	  was	  repeated	  four	  
times.	  	  
	  
2.14	  Fluorescence	  microscopy	  
Immunofluorescently	  stained	  cells	  were	  visualized	  (except	  in	  the	  AIS-­‐localization	  
studies,	   see	   above)	   using	   a	   Zeiss	   AxioImager	   Z1	   fluorescence	  microscope	   (Carl	  
Zeiss,	   Ltd)	   with	   a	   monochrome	   AxioCamMR3	   camera	   using	   AxioVision	   4.8.	  
Imaging	  software	  (Carl	  Zeiss,	  Welwyn	  Garden	  City).	  	  	  
	  
2.15	  Statistics	  
All	   quantitative	   data	   was	   collected	   using	   Microsoft	   Excel	   spreadsheets,	   and	  
analyzed	   using	   Graphpad	   PRISM.	   Most	   frequently,	   to	   allow	   comparisons	   of	  
groups,	   one-­‐way	   ANOVA	   with	   Bonferoni	   correction	   was	   used	   to	   test	   for	  
statistical	   significance.	   However,	   when	   two	   groups	   were	   compared	   with	   each	  
other	  a	  Student’s	  T-­‐test	  was	  used.	   In	  the	  AIS	  analysis	  where	  the	   impact	  of	  high	  
potassium	   induced	   depolarization	   on	   AIS	   localization	   was	   examined,	   non-­‐
parametric	  group	  comparisons	  were	  carried	  out	  using	  the	  Mann-­‐Whitney	  U-­‐test	  
for	   two	   independent	   samples.	   A	   non-­‐parametric,	   two-­‐way	   ANOVA	   on	   ranked	  
data	   was	   used	   to	   test	   the	   impact	   of	   Nifedipine	   on	   AIS-­‐localization	   in	   non-­‐
depolarized	   and	   depolarized	   neurons	   (effect	   of	   drug	   x	   treatment	   interaction).	  
The	   Kolomogrov-­‐Smirnov	   test	   was	   used	   to	   test	   the	   difference	   in	   frequency	  
distributions	   between	   two	   samples.	   In	   general,	   three	   technical	   replicates	  were	  
used,	   and	   experiments	   were	   repeated	   at	   least	   three	   times	   (unless	   otherwise	  
stated).	   Data	   was	   presented	   as	   mean	   ±	   SEM	   (unless	   otherwise	   stated)	   and	  
changes	   were	   considered	   significant	   with	   a	   p-­‐value	   of	   ≤	   0.05.	   P-­‐values	   ≤	   0.05	  
marked	  with	   *,	   P-­‐values	   ≤	   0.01	  marked	  with	   **,	   P-­‐value	   ≤	   0.001	  marked	  with	  
***.	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Chapter	  3	  	  
The	  basic	  biology	  of	  Cln3-­‐/-­‐
astrocytes	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3.1	  Introduction	  
During	   development	   astrocytes	   are	   crucial	   players	   in	   the	   regulation	   of	  
neurogenesis	   (Song	   et	   al.,	   2002)	   and	   in	   the	   formation	   of	   brain	   circuits	   (Müller	  
and	  Best,	  1989).	  In	  the	  adult	  brain	  astrocytes	  not	  only	  actively	  participate	  in,	  and	  
dictate,	   many	   of	   the	   brain’s	   important	   functions,	   but	   also	   provide	   a	   defense	  
against	   potential	   pathological	   insults	   (see	   Chapter	   1,	   Sections	   1.3	   and	   1.4).	  
Moreover,	   astrocytes	   form	   intimate	   connections	   with	   neurons,	   especially	   at	  
synapses,	   where	   astrocytes	   perform	   many	   essential	   ‘housekeeping’	   roles,	  
including	  providing	  metabolic	   support	   to	  neurons,	   controlling	  neurotransmitter	  
and	   ion	   homeostasis	   and	   monitoring	   and	   responding	   to	   synaptic	   activity	  
(reviewed	  in	  Verkhratsky	  and	  Parpura,	  2010;	  Parpura	  et	  al.,	  2012).	  	  
	  
Considerable	  evidence	  has	  now	  accumulated	  that	  astrocytes	  become	  activated	  in	  
response	  to	  all	  forms	  of	  CNS	  disease	  or	  injury,	  a	  phenomenon	  generally	  referred	  
to	  as	   reactive	  astrocytosis	   (Pekny	  and	  Nilsson,	  2005).	   This	   reactive	  astrocytosis	  
has	  been	  shown	  to	  influence	  the	  progression	  and	  outcome	  of	  disease,	  and	  may	  
be	   either	   harmful	   or	   beneficial	   (Ridet	   et	   al.,	   1997;	   Pekny	   and	   Nilsson,	   2005;	  
Sofroniew	  and	  Vinters,	  2010)	  (see	  also	  Chapter	  1,	  section	  1.4).	  The	  changes	  that	  
astrocytes	  undergo	  upon	  activation	  appear	  to	  differ	  with	  the	  nature	  and	  severity	  
of	   the	   insult	   (Sofroniew,	   2009;	   Sofroniew	   and	   Vinters,	   2010),	   but	   include	  
increased	  secretion	  of	  various	  cytokines,	  progressive	  cellular	  hypertrophy	  and,	  in	  
severe	   cases,	   proliferation	   and	   eventually	   glial	   scar	   formation.	   Generally,	   the	  
upregulation	   of	   intermediate	   filament	   proteins,	   in	   particular	   GFAP,	   by	   reactive	  
astrocytes	   is	  considered	   to	  be	  one	  of	   the	  best-­‐known	  hallmarks	  of	   this	  process	  
(Pekny	   and	   Pekna,	   2004),	   together	   with	   upregulation	   of	   vimentin	   and	   re-­‐
expression	  of	  the	  stem/progenitor	  cell	  marker	  nestin	  (Pekny	  and	  Nilsson,	  2005;	  
Sofroniew	  and	  Vinters,	  2010).	  	  
	  
As	  mentioned	  above	  (see	  Chapter	  1,	  Section	  1.4),	  intimate	  interactions	  between	  
neurons	   and	   astrocytes	   exists	   in	   both	  healthy	   and	  diseased	  brains,	   yet	   despite	  
much	   research	   the	   actual	   role	   that	   astrocytes	   play	   in	   the	   diseased	   CNS	   is	   still	  
poorly	   understood	   (Sofroniew	   and	   Vinters,	   2010;	   Zamanian	   et	   al.,	   2012).	   Such	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information	  could	  be	  beneficial	  in	  understanding	  disease	  progression	  and	  in	  the	  
development	  of	  novel	  therapeutic	  interventions	  to	  combat	  CNS	  diseases.	  Indeed,	  
this	  may	  be	  particularly	  relevant	  when	  considering	  JNCL,	  the	  disease	  I	  focus	  upon	  
in	  this	  thesis.	  
	  
In	   JNCL,	   as	   in	   all	   the	   other	   forms	   of	   NCL,	   activation	   of	   both	   astrocytes	   and	  
microglial	  cells	  has	  been	  shown	  to	  precede	  neuronal	  loss	  (Mitchison	  et	  al.,	  2004;	  
Pontikis	  et	  al.,	  2004;	  2005;	  Cooper	  et	  al.,	  2006).	  However,	  in	  JNCL	  this	  early	  glial	  
response	  appears	  to	  be	  impaired,	  since	  astrocytes	  fail	  to	  become	  hypertrophied	  
and	  microglia	  fail	  to	  transform	  into	  phagocytotic	  brain	  macrophages	  (Pontikis	  et	  
al.,	  2004;	  2005).	  This	  impaired	  activation	  of	  glia	  in	  JNCL	  is	  markedly	  different	  to	  
the	  pronounced	  glial	  responses	  seen	  in	  mouse	  models	  of	  all	  other	  forms	  of	  NCL	  
(Bible	  et	  al.,	  2004;	  Kielar	  et	  al.,	  2007;	  Partanen	  et	  al.,	  2008;	  Kuronen	  et	  al.,	  2012;	  
Schmiedt	  et	   al.,	   2012).	  Recently,	  we	  have	   shown	   that	   cultured	  Cln3-­‐/-­‐	  microglia	  
have	   a	   similarly	   incomplete	   morphological	   response	   to	   artificial	   stimulation,	  
paralleling	  our	  in	  vivo	  observations.	  In	  addition,	  these	  microglia	  displayed	  specific	  
differences	   in	  their	  cytokine	  expression	  profile	  compared	  to	  wild	  type	  microglia	  
(S.	   Dihanich,	   unpublished	   data),	   in	   particular,	   chemokines	   involved	   in	   directed	  
chemotaxis	  (MIP-­‐1γ,	  MIP-­‐2	  and	  Rantes)	  were	  significantly	  downregulated.	  	  
	  
In	   this	   chapter,	   I	   describe	   in	   vitro	   experiments	   designed	   to	   systematically	  
characterize	  the	  biology	  of	  Cln3-­‐/-­‐	  astrocytes	  using	  astrocyte	  cultures	  established	  
from	   the	   cortices	   of	   P1-­‐P2	   WT	   and	   Cln3-­‐/-­‐	   mice.	   Specifically,	   I	   compare	   the	  
cytoskeletal	  structure	  and	  endo/lysosomal	  system	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes,	  in	  
order	   to	  build	  a	  picture	  of	  how	  mutations	   in	   the	  Cln3	   gene	   influence	   the	  basic	  
properties	   and	   structural	   organization	  of	   this	   cell	   type.	   I	  will	   then	  ask	  whether	  
cultured	   Cln3-­‐/-­‐	   astrocytes	   show	   an	   impaired	   morphological	   response	   to	  
stimulation	  as	  seen	  in	  vivo.	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3.2	  Results	  
Attenuated	  glial	  response	  in	  Cln3-­‐/-­‐	  mice	  and	  in	  human	  JNCL	  
Unlike	   in	   other	   forms	   of	   NCLs	   in	   which	   a	   robust	   glia	   activation	   is	   observed	  
(Oswald	  et	  al.,	  2005;	  Kielar	  et	  al.,	  2007;	  Partanen	  et	  al.,	  2008;	  Macauley	  et	  al.,	  
2009),	   the	  morphological	   response	  of	  astrocytes	  and	  microglia	   is	  attenuated	   in	  
Cln3-­‐/-­‐	   mice	   (Pontikis	   et	   al.,	   2004;	   2005).	   Using	   an	   increase	   in	   GFAP	   and	   CD68	  
expression	   as	   a	   hallmark	   of	   astrocyte	   and	   microglia	   activation	   respectively	  
(Pekny	   2004),	   we	   investigated	   whether	   this	   attenuated	   glial	   response	   is	   also	  
evident	  in	  post	  mortem	  tissue	  from	  JNCL	  patients.	  	  
	  
We	   first	   compared	   the	   extent	   of	   astrocyte	   and	  microglia	   activation	   in	   cortical	  
sections	   from	   Cln3-­‐/-­‐	   and	   Tpp1-­‐/-­‐	   mice,	   a	   mouse	   model	   for	   Late	   Infantile	   NCL	  
(LINCL),	   one	   of	   the	   earliest	   onset	   and	   fastest	   progressing	   forms	   of	  NCL.	   In	   the	  
cortex	   of	   Tpp1-­‐/-­‐	   mice,	   astrocytes	   appeared	   to	   be	   fully	   activated,	   displaying	  
intense	  GFAP	  immunoreactivity,	  with	  many	  thickened	  processes	  and	  pronounced	  
hypertrophy	  compared	   to	   the	  GFAP	  expressing	  astrocytes	   in	   the	  cortex	  of	  age-­‐
matched	  WT	  mice	  (Figure	  3.1	  A	  a,	  figure	  provided	  by	  Andrew	  Wong).	  In	  contrast,	  
as	   described	   previously	   in	   the	   Cln3-­‐/-­‐	   cortex,	   (Pontikis	   et	   al.,	   2004;	   2005),	  
astrocyte	  activation	  appears	  compromised	  early	   in	   the	  disease	  progression	   (6.5	  
months,	   and	   12	   months),	   with	   GFAP	   expressing	   astrocytes	   in	   Cln3-­‐/-­‐	   mice	  
exhibited	   only	   thin	   cellular	   processes	   (Figure	   3.1	   A	   a,	   compare	   higher	  
magnification	  images).	  However,	  by	  the	  end	  stages	  of	  the	  disease	  (21	  months	  of	  
age)	   GFAP	   expressing	   astrocytes	   in	   Cln3-­‐/-­‐	   mice	   appear	   to	   become	   fully	  
hypertrophied,	  as	  observed	  in	  the	  Tpp1-­‐/-­‐	  mice.	  Additionally,	  a	  gradual	  increase	  in	  
the	  number	  of	   CD68	  expressing	   activated	  microglia	  was	  detected	   in	   the	  Cln3-­‐/-­‐	  
mouse	  cortex	  over	  the	  course	  of	  the	  disease,	  which	  again	   is	   in	  agreement	  with	  
previous	   findings	   suggesting	   that	   the	   early	   activation	   of	   Cln3-­‐/-­‐	   microglia	   is	  
attenuated	  both	   in	  vivo	  and	   in	  vitro	  (Figure	  3.1	  A	  b)	  (Pontikis	  et	  al.,	  2004;	  2005;	  
Kielar	  et	  al.,	  2007,	  Dihanich,	  unpublished	  data).	  At	  the	  end	  stage	  of	  the	  disease,	  it	  
appears	  that	  the	  activation	  of	  both	  Cln3-­‐/-­‐	  astrocytes	  and	  microglia	  is	  attenuated	  
early	  in	  the	  disease	  process,	  with	  these	  glial	  cells	  failing	  to	  completely	  transform.	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To	   examine	   whether	   a	   similar	   attenuated	   glial	   response	   was	   also	   evident	   in	  
human	  JNCL,	  the	  extent	  and	  nature	  of	  astrocytosis	  and	  microglia	  activation	  were	  
compared	   in	   JNCL	   and	   LINCL	   post	   mortem	   cortical	   tissue	   (Figure	   3.1	   B,	   figure	  
provided	   by	   Andrew	  Wong).	   Sections	   from	   the	   cortex	   of	   both	   JNCL	   and	   LINCL	  
cases	   were	   immunostained	   for	   either	   GFAP	   or	   CD68	   and	   counterstained	   with	  
haematoxylin.	  Numerous	   intensely	  stained	  hypertrophied	  astrocytes	  with	  many	  
thickened	  processes	  were	  observed	  in	  the	  cortex	  of	  LINCL	  cases	  (Figure	  3.1	  B).	  In	  
comparison,	   markedly	   fewer	   and	   less	   intensely	   stained	   GFAP	   expressing	  
astrocytes	   were	   observed	   in	   the	   cortex	   of	   JNCL	   cases,	   and	   these	   astrocytes	  
appeared	  smaller	  with	  fewer	  and	  thinner	  processes.	  Similarly,	  dramatically	  fewer	  
and	   less	  morphologically	   transformed	   CD68	   positive	  microglia	   were	   evident	   in	  
JNCL,	   compared	   to	   a	   high	   number	   of	   CD68	   positive	   morphologically	   activated	  
microglia	  and	  macrophages	  in	  LINCL	  cortical	  tissue.	  This	  impaired	  morphological	  
response	   in	   human	   JNCL	   glia	   correlates	   with	   the	   in	   vivo	   findings	   in	   mice	   as	  
presented	  here	   (Figure	  3.1	  A)	  and	  as	  previously	   reported	   (Pontikis	  et	  al.,	  2004;	  
2005).	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Figure	  3.1.	  Attenuated	  glia	  response	  in	  Cln3-­‐/-­‐	  mice	  tissue	  and	  in	  human	  JNCL.	  
Cortical	   sections	   from	  WT,	  Tpp1-­‐/-­‐	   and	  Cln3-­‐/-­‐	  mice	  or	   from	   control,	   LINCL	   and	   JNCL	   cases	  were	  
stained	  with	  GFAP	  or	  CD68	  to	  investigate	  the	  level	  of	  reactive	  astrocytosis	  or	  microglia	  activation,	  
respectively.	  (A)	  A	  profound	  reactive	  astrocytosis	  (a)	  and	  microglia	  (b)	  activation	  was	  apparent	  in	  
Tpp1-­‐/-­‐	  mouse	  sections,	  as	  determined	  by	  the	  presence	  of	  hypertrophied	  astrocytes	  with	  intense	  
GFAP	   expression	   and	   morphologically	   transformed	   microglia;	   brain	   macrophages	   with	   round,	  
non-­‐process	  bearing	  cell	  bodies,	  with	  intense	  CD68	  expression	  compared	  to	  WT	  mice	  tissue.	  This	  
reactive	  astrocytosis	  and	  microglia	  activation	  was	  much	   less	  profound	   in	  Cln3-­‐/-­‐	  mice	  section	  at	  
the	  early	  stages	  of	  the	  dsease	  (6.5,	  and	  12	  months).	  However,	  at	  the	  end	  stage	  of	  the	  disease	  (12	  
months),	  a	  complete	  activation	  of	  both	  astrocytes	  and	  microglia	  can	  be	  observed	  in	  Cln3-­‐/-­‐	  mice.	  
(B)	  Reactive	  astrocytosis	  was	  observed	  in	  both	  human	  INCL	  and	  JNCL,	  but	  to	  different	  extents.	  In	  
LINCL	   cases	   astrocytes	   were	   intensely	   stained,	   with	   hypertrophied	   cell	   bodies	   and	   numerous	  
thickened	   processes.	   In	   JNCL	   cases	   GFAP	   staining	   was	   paler	   and	   fewer	   less	   hypertrophied	  
astrocytes	  with	   thinner	   processes	  were	   evident.	  Also	  microglia	   activation	  was	   less	   profound	   in	  
JNCL	  cases	  with	  only	   few	  CD68	  positive	  microglia	  being	  evident.	  Scale	  bar	   in	   (A	  a,	  b)	   is	  100μm,	  
and	  (A	  a,	  b	  higher	  magnification),	  and	  (B)	  is	  10μm.	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Generation	  of	  pure	  astrocyte	  cell	  cultures	  
In	   order	   to	   compare	   the	   biology	   of	   Cln3-­‐/-­‐	   and	   wild	   type	   astrocytes,	   pure	  
astrocyte	  cultures	  were	  generated	  from	  P1-­‐P2	  wild	  type	  or	  Cln3-­‐/-­‐	  cortices	  using	  a	  
modification	  of	  the	  shaking	  method	  described	  by	  Mccarthy	  and	  de	  Vellis	  (1980)	  
(McCarthy	  and	  de	  Vellis,	  1980)	  (see	  Chapter	  2,	  Section	  2.3).	  	  
	  
Initially,	  these	  cultures	  were	  composed	  of	  microglia,	  astrocytes	  and,	  occasionally,	  
a	   few	   oligiodendrocytes.	   To	   isolate	   the	   astrocytes	   these	   mixed	   cultures	   were	  
shaken	   (180rpm,	   10-­‐12	   hours)	   as	   soon	   as	   they	   became	   confluent	   (after	  
approximately	  12-­‐14	  days).	  At	  this	  stage	  the	  astrocytes	  have	  formed	  a	  monolayer	  
on	   the	   base	   of	   the	   culture	   dish,	   and	   have	   stopped	   dividing	   due	   to	   contact	  
inhibition.	   The	  microglia	   and	  oligodendrocytes	   sit	   on	   top	  of	   the	  astrocytes	  and	  
are	   easily	   detached	   by	   the	   shaking.	   After	   replacement	   of	   the	   medium	   the	  
remaining	   cells,	   mainly	   astrocytes,	   were	   treated	   for	   one	   week	   with	   Ara-­‐C	   (an	  
anti-­‐mitotic	   agent)	   to	   remove	   any	   remaining	   dividing	   microglia	   and	  
oligodendrocytes.	   The	   purity	   of	   these	   cultures	   was	   then	   assessed	   by	  
immunocytochemistry	   using	   CD68	   to	   identify	   microglia,	   O4	   to	   identify	  
oligodendrocytes,	  GFAP	  to	  identify	  astrocytes	  and	  MAP2	  together	  with	  NeuN	  to	  
identify	  neurons	  (Figure	  3.2	  A,	  3.2	  B,	  3.2	  C).	  DAPI	  was	  used	  to	  identify	  all	  nuclei,	  
as	   an	   aid	   to	   cell	   counting.	   Cells	  were	   identified	   as	   astrocytes	   if	   they	  expressed	  
GFAP	  and/or	   if	   they	  did	  not	  express	  either	  CD68,	  04,	  or	  any	  neuronal	  markers,	  
because	   it	   is	  well	   established	   that	   not	   every	   astrocyte	   in	   vitro	   expresses	  GFAP	  
(Cahoy	  et	  al.,	  2008).	  	  
	  
Neither	   WT	   nor	   Cln3-­‐/-­‐	   astrocyte	   cultures	   contained	   MAP2/NeuN	   expressing	  
neuronal	   cells	   (Figure	   3.2	   B).	   Indeed,	   the	   primary	   astrocyte	   cell	   cultures	  
generated	  using	  this	  procedure	  were	  >	  98%	  pure	  with	  1%	  -­‐	  2%	  of	  the	  population	  
being	  CD68+	  microglia,	  and	  O4+	  oligodendrocytes	  being	  rare	  (0.1%)	  (Figure	  3.2	  A-­‐
D).	   All	   the	   astrocyte	   cultures	   used	   in	   this	   study	   from	  here	   onwards	   have	   been	  
generated	  and	  their	  purity	  checked	  as	  described	  here.	  	  
	  
	   	  




































Figure	   3.2.	   Generation	   of	   astrocyte	   cultures.	   Primary	   cortical	   astrocyte	   cultures	  
generated	   from	   P1-­‐P2	  Cln3-­‐/-­‐	   or	  WT	  mice	  were	   stained	  with	   CD68	   to	   identify	  microglia,	   O4	   to	  
identify	   oligodendrocytes,	  MAP2	   together	  with	  NeuN	   to	   identify	   neurons	   and	  GFAP	   to	   identify	  
astrocytes.	  DAPI	  was	  used	  to	  visualize	  all	  nuclei.	  WT	  and	  Cln3-­‐/-­‐	  astrocyte	  cultures	  contained	  few	  
microglia	   or	   oligodendrocytes	   (A)	   and	   no	   neurons	   (B).	   The	   vast	   majority	   of	   cells	   were	   GFAP-­‐
expressing	   astrocytes	   (C).	   The	   percentage	   of	   each	   cell	   type	   was	   determined	   by	   counting	   5	  
random	  fields	  per	  coverslip	  and	  a	  minimum	  of	  three	  coverslips	  per	  experiment.	  The	  means	  ±	  SEM	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Cln3-­‐/-­‐	  and	  WT	  primary	  astrocytes	  respond	  similarly	  to	  activation	   in	  vitro	  with	  
LPS	  and	  IFNγ	  
As	  described	  above,	  glial	  activation	  seems	  to	  be	  attenuated	   in	  JNCL	  (see	  Figure	  
3.1	  (Pontikis	  et	  al.,	  2004;	  2005).	  In	  order	  to	  investigate	  this	  response	  further	  and	  
in	   a	   controlled	   manner,	   where	   Cln3-­‐/-­‐	   and	   WT	   astrocytes	   could	   be	   directly	  
compared,	   we	   used	   a	   combination	   of	   the	   bacterial	   endotoxin	   LPS	   and	   the	  
cytokine	   IFNγ	   to	   activate	   primary	   astrocytes	   in	   vitro.	   This	   is	   a	   commonly	   used	  
activation	  method	  for	  astrocytes,	  and	  it	  has	  been	  previously	  demonstrated	  that	  
LPS	  synergizes	  with	  IFNγ	  to	  produce	  a	  maximal	  transcriptional	  response	  in	  these	  
cells	  (Chung	  and	  Benveniste,	  1990;	  Bolaños	  et	  al.,	  1994;	  Schindler	  and	  Brutsaert,	  
1999;	  Gegg	  et	  al.,	  2005;	  Sheng	  et	  al.,	  2011;	  Cortés-­‐Vieyra	  et	  al.,	  2012).	  However,	  
before	   being	   able	   to	   study	   the	   response	   of	  Cln3-­‐/-­‐	  astrocytes	   to	   activation,	   we	  
first	  needed	  to	  determine	  whether	  these	  cells	  retained	  the	  ability	  to	  response	  to	  
this	  stimulus.	  
	  	  
Toll-­‐like	   receptor	   4	   (TLR4),	   which	   is	   required	   for	   LPS	   mediated	   activation	   of	  
downstream	   signaling	   pathways,	   belongs	   to	   the	   IL-­‐1R/TLR	   superfamily	   and	   in	  
general	   is	   involved	   in	   the	  host	  defense	  against	  Gram-­‐negative	  bacteria	   (O'Neill,	  
2000).	  TLR4	  has	  also	  been	  shown	  to	  be	  expressed	  in	  primary	  astrocytes	  in	  culture	  
(Bowman	  et	  al.,	  2003).	  Upon	  binding	  of	  LPS	  to	  TLR4,	  the	  receptor	  dimerizes	  and	  
undergoes	   a	   conformational	   change	   allowing	   the	   recruitment	   of	   downstream	  
signaling	   molecules	   and	   activation	   of	   downstream	   kinases,	   including	   the	  
transcriptional	   factor	  NF-­‐κB	   (Akira	  and	  Takeda,	  2004).	  More	  precisely,	  NF-­‐κB	   is	  
activated	  after	  nuclear	  translocation	  and	  phosphorylation	  of	  the	  NF-­‐κB	  subunits	  
p65	   and	   p50	   (Gorina	   et	   al.,	   2011)	   (Figure	   3.3	   A).	   Subsequently,	   the	   NF-­‐κB	  
activation	   induces	   expression	   of	   its	   target	   genes,	   such	   as	   TNF-­‐α,	   IL-­‐27,	   IL-­‐15,	  
MMP-­‐9	  and	  VCAM-­‐1	  (Gorina	  et	  al.,	  2011).	  	  
	  
IFNγ	   is	   a	   multifunctional	   cytokine	   that	   organizes	   a	   diverse	   array	   of	   biological	  
responses	   (Boehm	  et	   al.,	   1997;	  Billiau	   et	   al.,	   1998).	   Indeed,	   it	   has	  been	   shown	  
that	   astrocytes	   express	   the	   receptor	   for	   INFγ	   and	   can	   thus	   have	   a	   biological	  
respond	  to	  this	  ligand	  (Rubio	  and	  de	  Felipe,	  1991;	  Wang	  and	  Zhou,	  2005).	  Upon	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binding,	  INFΥ	  causes	  a	  conformational	  change	  in	  its	  receptor,	  IFNγ-­‐R,	  which	  leads	  
to	   phosphorylation	   and	   activation	   of	   Jak2	   and	   Jak1	   and	   recruitment	   of	   STAT1.	  
Phosphorylation	   of	   Stat1	   (P-­‐STAT1)	   induces	   its	   dissociation	   from	   the	   receptor,	  
which	   allows	  P-­‐STAT1	   to	   translocate	   to	   the	  nucleus	  where	   it	   binds	   to	   an	   IFNγ-­‐
activated	   site	   (GAS)	  element	   to	  either	  activate	  or	   suppress	   the	   transcription	  of	  
IFNγ-­‐regulated	  genes,	  such	  as	  ICAM-­‐1,	  interferon	  regulatory	  transcription	  factor-­‐
2	  (IRF-­‐2),	  TNF-­‐α	  and	  IFNβ	  (Schroder	  et	  al.,	  2004)	  (Figure	  3.4	  A).	  
	  
To	   ensure	   that	   exposure	   to	   LPS	   plus	   IFNγ	   resulted	   in	   the	   transduction	   of	   an	  
activation	  signal	  in	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocytes,	  the	  nuclear	  localization	  of	  the	  
phosphorylated	   form	   of	   NF-­‐κB	   subunit	   P65	   (P-­‐P65)	   and	   STAT-­‐1	   (P-­‐STAT1)	   was	  
compared	  (see	  Chapter	  2,	  Section	  2.6).	  LPS/IFNγ	  stimulation	  is	  known	  to	  induce	  a	  
rapid	   nuclear	   localization	   of	   the	   downstream	   activators	   P-­‐P65	   and	   P-­‐STAT1	  
(Baeuerle	   and	  Henkel,	   1994;	  Haspel	   et	   al.,	   1996;	  Wang	   and	  Baldwin,	   1998),	   so	  
the	   nuclear	   localization	   of	   these	   proteins	   was	   quantified	   after	   growth	   under	  
basal	   conditions	   or	   after	   stimulation	  with	   LPS/IFNγ	   (1μg/ml	   /	   100U/ml)	   for	   15	  
minutes,	   30	  minutes,	   2	   hours,	   6	   hours	   and	   12	   hours	   (Figure	   3.3	   B	   and	   C,	   and	  
Figure	   3.4	   B	   and	   C).	   The	   selected	   time	   points	   allowed	   the	   evaluation	   of	   both	  
rapid	   and	   long-­‐term	   nuclear	   expression	   of	   these	   downstream	   activators.	   The	  
concentrations	   of	   LPS	   and	   IFNγ	   used	   in	   this	   study	   were	   selected	   based	   on	  
previous	   studies	   (Bolaños	   et	   al.,	   1994;	   Gegg	   et	   al.,	   2005).	   At	   the	   end	   of	   the	  
experiment	  cells	  were	  fixed	  with	  4%	  PFA,	  and	  immunostaining	  carried	  out	  for	  P-­‐
P65	  and	  P-­‐STAT1	  following	  the	  described	  protocols	  (see	  Chapter	  2,	  Section	  2.6).	  	  
 
Under	   basal	   conditions	   only	   a	   few	   cells	   had	   a	   nuclear	   P-­‐P65	   signal	   in	   WT	  
(0.9±0.5%)	   and	   Cln3-­‐/-­‐(0.9±0.7%)	   astrocyte	   cultures,	   indicating	   that	   there	   was	  
hardly	   any	   activation	   of	   the	   NF-­‐κB	   signaling	   cascade	   under	   these	   conditions.	  
Upon	   treating	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   with	   LPS/IFNγ,	   a	   proportion	   of	   cells	  
exhibit	   nuclear	   P-­‐P65	   signal	   (Figure	   3.3	   B	   and	   C).	   This	   proportion	   ranged	   from	  
18.9±7.1%	   (15	  minutes)	   to	   51.8±6.1%	   (2	   hours)	   in	  WT	   astrocyte	   cultures,	   and	  
from	   29.6±8.1%	   (15	   minutes)	   to	   56.4±10.4%	   (2	   hours)	   in	   Cln3-­‐/-­‐	   astrocyte	  
cultures.	  However,	  there	  was	  no	  significant	  difference	  in	  the	  percentage	  of	  cells	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expressing	  nuclear	  P-­‐P65	  between	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  at	  any	  of	   the	  time	  
points	  tested	  (Figure	  3.3	  C).	  Thus,	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  can	  respond	  to	  
LPS	   treatment	   and	   the	   NF-­‐κB	   signaling	   mechanism	   appears	   not	   to	   be	   grossly	  
altered	  in	  Cln3-­‐/-­‐	  astrocytes.	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Figure	  3.3.	  LPS	  induced	  signaling	  is	  not	  altered	  in	  Cln3-­‐/-­‐	  astrocytes.	  WT	  and	  Cln3-­‐/-­‐	  
astrocytes	  were	  stained	  with	  GFAP	  and	  phospho	  specific	  P65	  to	  identify	  cells	  where	  activation	  of	  
NF-­‐κB	   had	   occurred.	   DAPI	   was	   used	   to	   visualize	   all	   nuclei.	   (A)	   Schematic	   illustration	   of	   the	  
signaling	  pathway	   induced	  by	  LPS	   in	  astrocytes.	   LPS	  activates	  TLR4	   leading	   to	  NF-­‐κB	  activation.	  
The	   NF-­‐κB	   transcription	   factor	   is	   activated	   after	   nuclear	   translocation	   of	   the	   phosphorylated	  
forms	  of	  the	  Nf-­‐κB	  subunits	  P65	  and	  P50,	   followed	  by	   induction	  of	  NF-­‐κB	  target	  genes,	  such	  as	  
TNF-­‐a,	   IL-­‐15,	  MMP-­‐9,	  and	  VCAM-­‐1.	   (B)	  Few	  WT	  or	  Cln3-­‐/-­‐	  astrocytes	  with	  nuclear-­‐located	  P-­‐P65	  
were	   observed	   under	   basal	   conditions,	   while	   many	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   had	   P-­‐P65	  
expressed	   in	  the	  nucleus	  upon	  exposure	  to	  LPS.	   (C)	  The	  percentage	  of	  cells	  expressing	  P-­‐P65	   in	  
the	  nucleus	  was	  determined	  by	  counting	  5	  random	  fields	  per	  coverslip	  and	  a	  minimum	  of	  three	  
coverslips	  per	  experiment.	  The	  means	  ±SEM	  shown	  in	  (C)	  are	  from	  three	  separate	  experiments.	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The	  activation	  of	   the	   JAK-­‐STAT1	  pathway	   in	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  was	  
studied	   by	   staining	   untreated	   or	   LPS/INFγ	   treated	   cultures	   with	   an	   antibody	  
against	  P-­‐STAT1	  (Figure	  3.4	  B),	  and	  the	  percentage	  of	  cells	  expressing	  nuclear	  P-­‐
STAT1	  quantified	  (Figure	  3.4	  C).	  There	  were	  no	  cells	  with	  a	  nuclear	  P-­‐STAT1	  signal	  
in	  untreated	  WT	  and	  Cln3-­‐/-­‐	  cultures	  (Figure	  3.4	  C).	  However,	  upon	  treating	  WT	  
and	  Cln3-­‐/-­‐	  astrocytes	  with	  LPS/IFNγ,	  a	  large	  proportion	  of	  cells	  exhibit	  a	  nuclear	  
P-­‐STAT1	  signal	  (Figure	  3.4	  B	  and	  C).	  This	  proportion	  ranged	  from	  86.7±17.4%	  (15	  
minutes)	  to	  92.0±16.7%	  (2	  hours)	  in	  WT	  astrocyte	  cultures,	  and	  from	  89.1±23.0%	  
(15	  minutes)	   to	   88.3±17.0%	   (2	   hours)	   in	  Cln3-­‐/-­‐	   astrocyte	   cultures.	   Again	   there	  
was	   no	   significant	   difference	   in	   the	   proportion	   of	   cells	   expressing	   P-­‐STAT1	  
between	   WT	   and	   Cln3-­‐/-­‐	   astrocyte	   cultures.	   Thus,	   this	   JAK-­‐STAT1	   signaling	  
cascade	   is	  activated	  upon	  LPS/INFγ	  exposure	   in	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocytes.	  
Based	  on	  these	  studies	  we	  consider	  that	  LPS/INFγ	  can	  be	  used	  to	  study	  whether	  
there	  are	  any	  biological	  differences	  in	  the	  response	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  
to	  activation.	  	  
	   	  




































Figure	   3.4.	   INFγ	   induced	   signaling	   is	   not	   altered	   in	   Cln3-­‐/-­‐	   astrocytes.	   WT	   and	  	  	  
Cln3-­‐/-­‐	  astrocytes	  were	  stained	  with	  GFAP	  and	  phospho	  specific	  STAT1	  to	  identify	  cells	  where	  the	  
JAK-­‐STAT1	   pathway	   had	   been	   activated.	   DAPI	   was	   used	   to	   visualize	   all	   nuclei.	   (A)	   Schematic	  
illustration	  of	  the	  signaling	  pathway	  induced	  by	  INFγ	  in	  astrocytes.	  INFγ	  activates	  INF-­‐R	  causing	  a	  
conformational	  change	  in	  the	  IFNγ-­‐R,	  and	  activation	  of	  the	  JAK-­‐STAT1	  pathway:	  phosphorylation	  
of	   STAT1	   (P-­‐STAT1)	  and	  dissociation	  of	   STAT1	   from	   the	   IFNγ-­‐R	  allowing	   it	   to	   translocate	   to	   the	  
nucleus	  where	  it	  binds	  to	  the	  promoter	  of	  IFNγ-­‐regulated	  activation	  sites	  (GAS)	  to	  either	  activate	  
or	  suppress	  transcription	  of	  IFNγ-­‐regulated	  genes,	  such	  as	  ICAM-­‐1,	  IRF-­‐2,	  TNF-­‐α	  and	  IFNβ.	  (B)	  No	  
WT	  and	  Cln3-­‐/-­‐	  astrocytes	  with	  nuclear	  P-­‐STAT1	  were	  observed	  under	  basal	  conditions,	  however	  
the	  vast	  majority	  of	  these	  astrocytes	  had	  a	  nuclear	  P-­‐STAT1	  signal	  upon	  exposure	  to	  INFγ.	  (C)	  The	  
percentage	   of	   cells	   expressing	   P-­‐STAT1	   in	   the	   nucleus	   was	   determined	   by	   counting	   5	   random	  
fields	  per	  coverslip	  and	  a	  minimum	  of	  three	  coverslips	  per	  experiment.	  There	  was	  no	  difference	  
between	  WT	  and	  Cln3-­‐/-­‐	  in	  their	  response	  to	  INFγ.	  The	  means	  ±SEM	  shown	  in	  (C)	  are	  from	  three	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Expression	  of	  intermediate	  filaments	  is	  altered	  in	  Cln3-­‐/-­‐	  astrocytes	  cultured	  
under	  basal	  conditions	  and	  after	  activation	  with	  LPS/INFγ	  	  
Under	   pathological	   conditions,	   astrocytes	   undergo	   various	   changes,	   including	  
upregulation	   of	   genes	   encoding	   the	   IF	   proteins,	   GFAP,	   Vimentin	   and	   Nestin	  
(Mucke	   and	   Eddleston,	   1993).	   Intriguingly,	   these	   changes,	   particularly	   in	   GFAP	  
expression,	   appear	   attenuated	   in	   both	  Cln3-­‐/-­‐	  mice	   and	   in	   human	   JNCL	   patient	  
tissue,	  as	  described	  previously	  (Figures	  3.1	  A	  and	  B).	  To	  further	  explore	  changes	  
in	   intermediate	   filament	   proteins	   following	   stimulation	   in	   WT	   and	   Cln3-­‐/-­‐	  
astrocytes,	   the	   expression	   levels	   of	   GFAP,	   nestin	   and	   vimentin	   was	   quantified	  
from	  cell	  lysates	  derived	  from	  untreated	  and	  LPS/IFNγ	  treated	  (24	  hours	  and	  48	  
hours)	  astrocyte	  cultures	  using	  Western	  blotting	  (see	  Chapter	  2,	  Section	  2.7).	  	  
	  
Astrocyte	  cultures	  were	  generated	  as	  described	  before,	  and	  then	  passaged	  onto	  
6-­‐well	   plates.	   Approximately	   24	   hours	   after	   plating	   the	  medium	  was	   replaced	  
with	   fresh	   medium,	   to	   which	   LPS/IFNγ	   was	   added	   to	   activate	   the	   astrocytes.	  
Control	  cultures	  received	  no	  LPS/IFNγ.	  After	  24	  hours	  or	  48	  hours	  the	  cells	  were	  
lysed	   and	   the	   BCA	   (bicinchoninic	   acid)	   protein	   quantification	   kit	   (Thermo	  
Scientific)	  used	  to	  quantify	   the	  total	  amount	  of	  protein	   in	  each	  sample	  prior	   to	  
loading	  equal	  amounts	  of	  protein	  (20μg)	  per	  sample	  onto	  a	  12%	  SDS-­‐PAGE	  gel.	  
The	  expression	   levels	  of	  each	   intermediate	   filament	  protein	   in	   samples	   treated	  
with	  LPS/IFNγ	  were	  normalized	  to	  expression	  levels	  in	  untreated	  samples.	  	  
	  
No	  significant	  differences	  were	  detected	  in	  the	  expression	  levels	  of	  GFAP	  after	  24	  
hours	   LPS/IFNγ	   treatment	   compared	   to	   untreated	   samples	   in	   neither	   WT	  
(15±20.3%	  increase)	  nor	  in	  Cln3-­‐/-­‐	  astrocytes	  (9.2±28.4%	  decrease)	  (Figure	  3.5	  A).	  
GFAP	  expression	  was	  however	  significantly	  upregulated	  (23.8±3.6%	  increase)	   in	  
WT	  astrocytes	  after	  48	  hours	  of	  LPS/IFNγ	  treatment	  compared	  to	  controls	  (Figure	  
3.5	   A).	   In	   Cln3-­‐/-­‐	   astrocytes	   such	   an	   upregulation	   of	   GFAP	   did	   not	   occur	  
(5.0±17.4%	  increase	  in	  LPS/IFNγ	  treated	  versus	  untreated	  samples,	  Figure	  3.5	  A).	  
Unlike	  GFAP,	  Nestin	   (Figure	  3.5	  B)	  and	  vimentin	   (Figure	  3.5	  C)	  expression	  were	  
not	   significantly	   altered	   in	   LPS/IFNγ	   treated	   WT	   or	   Cln3-­‐/-­‐	   astrocytes	   after	   24	  
hours	  or	  48	  hours	  when	  compared	  to	  untreated	  samples.	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These	  results	  indicate	  that	  WT	  astrocytes	  respond	  to	  activation	  with	  LPS/IFNγ	  by	  
upregulating	  expression	  of	  GFAP,	   just	   like	  astrocytes	  do	   in	  vivo,	  whereas	  Cln3-­‐/-­‐	  
astrocytes	   appeared	   to	   be	   less	   capable	   of	   such	   an	   upregulation.	   Neither	  
genotype	  responded	  to	  LPS/IFNγ	  treatment	  by	  upregulating	  vimentin	  or	  nestin.	  
Based	  on	  these	  results,	  the	  activation	  process	  is	  attenuated	  in	  Cln3-­‐/-­‐	  astrocytes	  
in	   vitro,	   which	   is	   in	   agreement	   with	   the	   in	   vivo	   and	   post-­‐mortem	   findings	  
described	   above	   (Figure	   3.1).	   However,	   since	   quantification	   of	   housekeeping	  
proteins	  was	   not	   conducted	   in	   this	   study,	   additional	  work	   is	   required	   to	   verify	  
these	  results.	  	  	  	  
	   	  





























Figure	  3.5.	  Lack	  of	  GFAP	  upregulation	  in	  Cln3-­‐/-­‐	  astrocytes.	  WT	  and	  Cln3-­‐/-­‐	  astrocyte	  
were	   plated	   onto	   6-­‐well	   plates,	   some	   cultures	   were	   activated	   for	   24	   hours	   or	   48	   hours	   with	  
LPS/IFNγ,	   others	   received	   no	   treatment.	   Cultures	   were	   lysed	   and	   equal	   amounts	   of	   protein	  
(20ug)	  per	  sample	  were	  loaded	  onto	  a	  12%	  SDS-­‐PAGE	  gel.	  After	  Western	  blotting	  the	  expression	  
levels	   of	   intermediate	   filament	   proteins	   were	   quantified	   and	   the	   levels	   from	   samples	   treated	  
with	   LPS/IFNγ	   were	   compared	   to	   those	   from	   untreated	   samples.	   (A)	   GFAP	   expression	   was	  
upregulated	   in	   WT	   but	   not	   in	   Cln3-­‐/-­‐	   LPS/IFNγ	   treated	   cultures.	   (B)	   Nestin	   and	   (c)	   vimentin	  
expression	  did	  not	   significantly	   change	   in	  WT	  or	  Cln3-­‐/-­‐	   astrocytes	  under	  any	  conditions	   tested.	  
Results	  are	  from	  n=3	  experiments.	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The	   levels	   of	   intermediate	   filament	   expression	   in	   WT	   and	   Cln3-­‐/-­‐	   astrocytes,	  
under	   the	  same	  experimental	   conditions	  as	  above,	  were	  compared	   to	  examine	  
whether	   there	   was	   any	   difference	   between	   their	   expression	   levels	   between	  
these	  two	  genotypes.	  Untreated	  Cln3-­‐/-­‐	  astrocytes	  expressed	  more	  GFAP	  protein	  
compared	   to	   WT	   astrocytes	   after	   24	   hours	   (50.0±21.4%	   increase)	   and	   this	  
difference	  reached	  significance	  after	  48	  hours	  (121.5±54.8%	  increase)	  (Figure	  3.6	  
A).	   Under	   LPS/IFNγ	   exposure,	   GFAP	   expression	   levels	   were	   higher	   in	   Cln3-­‐/-­‐	  
astrocytes	   compared	   to	   WT	   counterparts	   after	   24	   hours	   of	   treatment	  
(47.1±15.6%)	   and	   after	   48	   hours	   of	   treatment	   (18.7±35.3%),	   but	   these	  
differences	  were	  not	  statistically	  significant	  (Figure	  3.6	  A).	  Interestingly,	  the	  level	  
of	  nestin	  was	  significantly	  lower	  in	  untreated	  Cln3-­‐/-­‐	  astrocytes	  compared	  to	  WT	  
after	  24	  hours	  (25.3±1.5%	  reduction)	  and	  after	  48	  hours	  (42.6±15.6%	  reduction).	  
However,	  there	  was	  no	  clear	  difference	  in	  nestin	  expression	  between	  Cln3-­‐/-­‐	  and	  
WT	  astrocytes	   in	   LPS/IFNγ	   treated	   samples	   (Figure	   3.6	  B).	   Vimentin	   expression	  
was	   slightly	   higher	   in	   untreated	   Cln3-­‐/-­‐	   astrocytes	   after	   24	   hours	   (36.6±22.5%	  
increase)	  when	   compared	   to	  WT	   samples,	   and	   slightly	   reduced	   after	   48	   hours	  
(15.0±32.4%	   decrease),	   but	   these	   differences	   were	   not	   statistically	   significant.	  
Again,	  after	  LPS/IFNγ	  treatment,	  vimentin	  expression	  levels	  were	  very	  similar	  in	  
both	  genotypes	  (Figure	  3.6	  C).	  Thus,	  the	  Cln3-­‐/-­‐	  astrocytes	  have	  significantly	  more	  
intracellular	  GFAP,	  and	  significantly	   less	  nestin	  under	  untreated	  conditions	  than	  
do	  WT	  astrocytes.	  This	  may	  suggest	  that	  Cln3-­‐/-­‐	  astrocytes	  have	  a	  more	  activated	  
(higher	   GFAP	   expression),	   but	   less	   immature	   (lower	   nestin	   expression)	  
phenotype	  than	  WT	  astrocytes	  under	  resting	  conditions.	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Figure	   3.6.	   Cln3-­‐/-­‐	  astrocytes	   express	   more	   GFAP	   and	   less	   nestin	   under	   basal	  
conditions.	   The	  expression	  levels	  of	   intermediate	  filaments	  were	  quantified	  in	  untreated	  and	  
LPS/IFNγ	  treated	  samples	  after	  24	  hours	  and	  48	  hours	  and	  the	  levels	  expressed	  by	  WT	  and	  Cln3-­‐/-­‐	  
astrocyte	  compared.	  (A)	  GFAP	  expression	  was	  upregulated	  in	  untreated	  Cln3-­‐/-­‐	  samples	  compared	  
to	  WT.	  (B)	  Nestin	  expression	  was	  downregulated	   in	  untreated	  Cln3-­‐/-­‐	  samples	  compared	  to	  WT.	  
(C)	  Vimentin	  expression	  did	  not	  significantly	  differ	  between	  untreated	  or	  treated	  WT	  and	  Cln3-­‐/-­‐	  
astrocytes.	  Results	  are	  from	  n=3	  experiments.	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Cln3-­‐/-­‐	  astrocytes	  have	  disrupted	  intermediate	  filament	  and	  actin	  cytoskeleton	  
organization,	  but	  show	  normal	  α-­‐	  and	  β-­‐	  microtubular	  organization	  	  
Cytoskeletal	   elements,	   actin	   microfilaments,	   microtubules	   and	   intermediate	  
filaments,	   form	   a	   dynamic	   network	   within	   astrocytes,	   that	   is	   vital	   for	   their	  
function	   under	   both	   physiological	   and	   pathological	   conditions	   (Cotrina	   et	   al.,	  
1998;	  Pekny	  and	  Pekna,	  2004;	  Potokar	  et	  al.,	  2007;	  Sofroniew	  and	  Vinters,	  2010)	  
(see	  Chapter	  1,	  Sections	  1.3	  and	  1.4).	  Various	  studies	  have	  suggested	  that	  CLN3	  
is	  either	  directly	  or	  indirectly	  connected	  with	  a	  number	  of	  cytoskeletal	  elements	  
and	  that	  CLN3	  deficiency	  may	  result	  in	  cytoskeleton	  related	  dysfunction	  in	  these	  
cells.	   For	   example,	   via	   myosin-­‐IIB	   interaction,	   CLN3	   may	   be	   involved	   in	   cell	  
migration	  via	  actin-­‐based	  cytoskeleton	  re-­‐organization	  (Getty	  and	  Pearce,	  2011;	  
Getty	  et	  al.,	  2011;	  reviewed	  in	  Mole	  et	  al.,	  2011).	  	  
	  
In	  order	  to	  explore	  whether	  the	  cytoskeleton	  within	  Cln3-­‐/-­‐	  astrocytes	  had	  been	  
altered,	   WT	   and	   Cln3-­‐/-­‐	   astrocyte	   cultures	   were	   labeled	   using	   antibodies	   that	  
recognize	  GFAP	   to	   identify	   the	  major	   intermediate	   filament	   in	   these	   cells,	   and	  
antibodies	   against	   α-­‐	   and	   β-­‐tubulin	   to	   identify	   microtubules	   (see	   Chapter	   2,	  
Section	  2.6).	  Phalloidin	  was	  used	  to	  visualize	  F-­‐actin	  filaments	  (Figure	  3.7).	  	  	  
	  
The	  intermediate	  filament	  organization	  of	  GFAP	  expressing	  Cln3-­‐/-­‐	  astrocytes	  was	  
highly	   disrupted,	   appearing	   disorganized	   and	   lacking	   a	   fine	   fibrous	   appearance	  
(Figure	   3.7,	   see	   arrow	   heads	   in	   b).	   In	   contrast,	   the	   intermediate	   filament	  
organization	  looked	  highly	  structured	  in	  WT	  astrocytes	  (Figure	  3.7,	  see	  arrows	  in	  
a).	  In	  addition,	  GFAP	  expressing	  Cln3-­‐/-­‐	  astrocytes	  appeared	  to	  have	  a	  larger	  cell	  
body	   than	   GFAP	   expressing	   WT	   astrocytes	   (this	   difference	   in	   soma	   size	   was	  
evident	  with	  all	  cytoskeletal	  components	  –	  compare	  a	  to	  b,	  c	  to	  d,	  e	  to	  f,	  and	  g	  to	  
h).	   Quantitative	   measurements	   of	   soma	   size	   confirmed	   this	   observation	   (see	  
Figure	   3.8).	   Furthermore,	   most	  WT	   astrocytes	   displayed	   a	   highly	   ordered	   and	  
well-­‐defined	   F-­‐actin	   filament	   organization	   (examples	   marker	   with	   arrows),	  
whereas	   the	   F-­‐actin	   filaments,	   as	   seen	   with	   GFAP	   expressing	   intermediate	  
filaments,	   appeared	   less	   defined	   and	   were	   highly	   disorganized	   in	   Cln3-­‐/-­‐	  
astrocytes	   (Figure	  3.7,	   –	   compare	   c	   to	  d,	  examples	  marked	  with	   arrow	  heads).	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Indeed,	   most	   Cln3-­‐/-­‐	   astrocytes	   lacked	   the	   presence	   of	   F-­‐actin	   filaments	   that	  
spanned	   the	   cell	   body,	   a	   feature	   common	   for	   WT	   astrocytes	   cultured	   under	  
these	  untreated,	  basal	  conditions	  (Figure	  3.7	  –	  compare	  c	  to	  d).	  However,	  the	  α-­‐	  
and	   β-­‐microtubular	   organization	   of	  WT	   and	   Cln3-­‐/-­‐	   astrocytes	   appeared	   similar	  
(Figure	   3.7	   –	   compare	   e	   to	   f	   and	   g	   to	   h,	   examples	   marker	   with	   arrows).	   In	  
conclusion,	   enlarged	  Cln3-­‐/-­‐	   astrocytes	   have	   an	   abnormally	   organized	   actin	   and	  
intermediate	  filament	  cytoskeleton,	  but	  have	  an	  apparently	  normal	  organization	  
of	  microtubules.	  	  
	   	  









































Figure	   3.7.	   Cln3-­‐/-­‐	   astrocytes	   have	   a	   disrupted	   cytoskeleton.	   To	   investigate	   their	  
cytoskeletal	  organization	  and	  morphology,	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  were	  stained	  with	  GFAP	  to	  
visualize	   intermediate	   filaments,	   phalloidin	   to	   visualize	   F-­‐actin,	   and	  α-­‐	   or	   β-­‐tubulin	   to	   visualize	  
microtubules.	   DAPI	   was	   used	   to	   visualize	   all	   nuclei.	   WT	   astrocytes	   had	   a	   well	   organized	  
intermediate	  filament,	  F-­‐actin	  and	  microtubule	  cytoskeleton	  (arrows),	  while	  Cln3-­‐/-­‐	  astrocytes	  had	  
a	   highly	   disrupted	   intermediate	   filament	   and	   F-­‐actin	   cytoskeleton	   (arrow	   heads)	   but	   their	  
microtubule	  structure	  appeared	  normal	  (arrow).	  The	  cell	  body	  size	  of	  Cln3-­‐/-­‐	  astrocytes	  appeared	  
larger	  that	  of	  WT	  astrocytes.	  Scale	  bar	  is	  25μm.	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Morphological	  response	  to	  LPS/IFNγ	  is	  attenuated	  in	  Cln3-­‐/-­‐	  astrocytes	  
As	  well	   as	   up-­‐regulating	   cytoskeletal	   proteins,	   astrocytes	   respond	   to	   activation	  
by	   changing	   morphologically.	   Upon	   activation,	   cultured	  WT	   astrocytes	   change	  
from	   flat,	   polygonal	   cells	   to	   smaller,	   contracted	   and	   highly	   branched	   cells	  
(Levison	   et	   al.,	   1998).	   As	   described	   above,	   this	   process	   appears	   attenuated	   in	  
vivo	   in	  Cln3-­‐/-­‐	  mice	  and	   in	  JNCL	  patients	  (see	  Figure	  3.1).	  To	  determine	  whether	  
this	   is	  also	   the	  case	   in	  vitro,	   the	  morphology	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  were	  
compared	   under	   basal	   and	   stimulation	   conditions	   (LPS/INFγ	   treatment	   for	   24	  
hours	  or	  48	  hours,	  see	  Chapter	  2,	  Section	  2.6).	  Staining	  with	  GFAP	  was	  used	  to	  
reveal	   the	  morphology	  of	   these	  cells.	  As	  described	  above,	   the	  untreated	  Cln3-­‐/-­‐	  
astrocytes	   had	   a	   strikingly	   different	   morphology	   when	   compared	   with	   WT	  
astrocytes;	   they	   appeared	   to	   be	   bigger	   and	   flatter	   with	   a	   disorganized	  
cytoskeleton	   (Figure	  3.8	  A	  –	  compare	  a	   to	  b).	  Upon	  stimulation,	  WT	  astrocytes	  
had	   already	   begun	   to	   transform	   morphologically	   after	   24	   hours	   exposure	   to	  
LPS/INFγ;	   changing	   from	   broad,	   non-­‐process-­‐bearing	   flat	   cells,	   to	   have	   a	  
shrunken	  soma	  and	  multiple	  processes	  (see	  arrow	  heads	   in	  Figure	  3.8	  A,	   image	  
c).	   These	   characteristic	   morphological	   changes	   became	   more	   apparent	   with	  
prolonged	   LPS/LPSγ	   exposure	   (Figure	   3.8,	   image	   e).	   In	   contrast,	   no	   significant	  
morphological	   transformation	   of	   Cln3-­‐/-­‐	   astrocytes	   could	   be	   detected	   until	   48	  
hours	  of	  exposure	  to	  LPS/INFγ,	  when	  their	  soma	  size	  decreased	  and	  some	  cells	  
extended	  more	  processes	  (Figure	  3.8	  A,	  images	  d	  and	  f).	  In	  order	  to	  quantify	  this	  
morphological	  transformation	  we	  decided	  to	  compare	  the	  soma	  size	  of	  WT	  and	  
Cln3-­‐/-­‐	  astrocytes	  under	  basal	  conditions	  and	  after	  stimulation.	  This	  was	  carried	  
out	  using	  ImageJ	  by	  drawing	  a	  line	  around	  the	  borders	  of	  a	  GFAP	  expressing	  cell	  
soma	   and	   allowing	   the	   program	   to	  measure	   the	   enclosed	   area	   (Figure	   3.8	   B).	  
After	   LPS/IFNγ	   activation	   for	   24	   hours	   or	   48	   hours,	   the	   cell	   soma	   of	   WT	  
astrocytes	   reduced	   in	   size.	   This	   reduction	   was	   statistically	   significant	   after	   24	  
hours	   (30.5±3.3%	   decrease),	   but	   did	   not	   reach	   statistical	   significance	   after	   48	  
hours,	  most	   likely	   due	   to	   smaller	   body	   size	   of	   untreated	  WT	   astrocytes	   at	   this	  
timepoint,	  due	  to	  the	  prolonged	  period	  that	  these	  cells	  had	  been	  kept	  in	  culture	  
(21.1±5.1%	   decrease).	   As	   noted	   in	   Figures	   3.2	   and	   3.7	   above,	   and	   confirmed	  
here,	  Cln3-­‐/-­‐	   astrocytes	   have	   significantly	   bigger	   cell	   bodies	   that	  WT	   astrocytes	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under	  basal	  conditions	  (84.3±15.8%	  increase)	  (Figure	  3.8	  C	  and	  A	  –	  compare	  a	  to	  
b).	   After	   24	   hours	   of	   LPS/IFNγ	   treatment	   the	   soma	   size	   of	   Cln3-­‐/-­‐	   astrocytes	  
remains	  unchanged	  (Figure	  3.8	  C,	  and	  A	  –	  compare	  b	  to	  d).	  However,	  after	  a	  48	  
hours	   exposure	   to	   LPS/INFγ,	   Cln3-­‐/-­‐	   astrocytes	   also	   start	   to	   change	   their	   soma	  
size,	   and	   there	   was	   no	   significant	   difference	   in	   size	   when	   compared	   to	   WT	  
astrocyte	  soma	  at	  this	  time	  point	  (Figure	  3.8	  C,	  and	  A	  –	  compare	  e	  to	  f).	  	  
	  
These	   results	   suggested	   that	   cultured	   Cln3-­‐/-­‐	   astrocytes	   have	   an	   attenuated	  
ability	   to	   change	   their	   morphology	   upon	   activation,	   only	   undergoing	   a	  
morphological	  transformation	  after	  a	  prolonged	  exposure	  to	  stimuli.	  Moreover,	  
Cln3-­‐/-­‐	   astrocytes	   also	   have	   enlarged	   cell	   bodies	   under	   basal	   conditions.	   The	  
abnormal	   actin	   and	   intermediate	   cytoskeletal	   organization	   in	  Cln3-­‐/-­‐	   astrocytes	  
(see	  Figure	  3.7)	   could	  partly	  cause	   their	  altered	  morphological	  appearance	  and	  
slower	  morphological	  transformation.	  	  
	  	   	  



























Figure	   3.8.	  Attenuated	  morphological	   transformation	  of	  Cln3-­‐/-­‐	   astrocytes.	  WT	  
and	  Cln3-­‐/-­‐	  astrocyte	  were	  treated	  with	  LPS/IFNγ 	  for	  24	  hours	  or	  48	  hours.	  Untreated	  cells	  were	  
grown	   under	   basal	   conditions.	   Following	   activation,	   cells	   were	   stained	  with	   GFAP,	   to	   visualize	  
morphological	  changes	  and	  DAPI	  was	  used	  to	  visualize	  all	  nuclei.	  (A)	  WT	  astrocytes	  changed	  their	  
morphology	  dramatically	  after	  a	  24	  hours	  exposure	  to	  LPS/INFγ	  and	  these	  changes	  become	  more	  
enhanced	   over	   time.	   In	   general	   Cln3-­‐/-­‐	   astrocytes	   remain	   morphologically	   unchanged	   after	   24	  
hours	   of	   stimulation,	   but	   showed	   changes	   after	   48	   hours	   activation.	   (B)	   ImageJ	   was	   used	   to	  
quantify	   the	   cell	   some	   size	   across	   all	   these	   experimental	   conditions.	   (C)	   Cell	   soma	   sizes	   were	  
determined	  by	  quantifying	  10	  random	  fields	  per	  coverslip	  and	  a	  minimum	  of	  two	  coverslips	  per	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WT	  astrocytes	  proliferate	  more	  actively	  than	  Cln3-­‐/-­‐	  astrocytes	  	  
The	   issue	   of	   astrocyte	   proliferation	   in	   the	   diseased	   brain	   is	   still	   highly	  
controversial.	  In	  healthy	  CNS	  tissue,	  astrocytes	  do	  not	  actively	  proliferate,	  indeed	  
the	  majority	  of	  them	  appear	  to	  be	  post-­‐mitotic	  (Bush	  et	  al.,	  1999;	  Colodner	  et	  al.,	  
2005;	   Horner	   et	   al.,	   2000;	   Norton	   et	   al.,	   1992).	   According	   to	   our	   current	  
understanding,	   there	   is	   no	   astrocyte	   proliferation	   under	   conditions	   where	  
reactive	   astrocytosis	   is	   moderate,	   or	   mild	   (Sofroniew,	   2009;	   Sofroniew	   and	  
Vinters,	   2010).	   However,	   astrocytes	   may	   become	   proliferative	   in	   more	   severe	  
conditions,	   such	   as	   in	   severe	   focal	   lesions,	   infections	   or	   areas	   suffering	   from	  
chronic	  neurodegeneration	  (Lindholm	  et	  al.,	  1992;	  Norton	  et	  al.,	  1992;	  Satoh	  et	  
al.,	  1996;	  Bush	  et	  al.,	  1999;	  Horner	  et	  al.,	  2000;	  Colodner	  et	  al.,	  2005;	  Gadea	  et	  
al.,	   2008;	   Carlén	   et	   al.,	   2009).	   Therefore,	   the	   ability	   of	   Cln3-­‐/-­‐	   astrocytes	   to	  
proliferate	  in	  vitro	  was	  tested	  under	  both	  basal	  and	  activated	  conditions.	  	  
	  
To	   investigate	   the	   proliferation	   of	  WT	   and	   Cln3-­‐/-­‐	   astrocytes,	   these	   cells	   were	  
exposed	  to	  LPS/INFγ	  for	  24	  hours	  or	  48	  hours,	  and	  were	  given	  a	  6	  hours	  pulse	  of	  
BrdU,	  that	  will	  be	  incorporated	  into	  cells	  that	  go	  though	  S-­‐phase	  during	  this	  time	  
period	  (see	  Chapter	  2,	  Section	  2.4).	  Subsequently	  cells	  were	  fixed	  and	  analyzed	  
for	  BrdU	  incorporation	  and	  the	  expression	  of	  Ki67,	  which	  labels	  cells	  in	  any	  active	  
phase	  of	  the	  cell	  cycle	  (G1,	  S	  phase	  and	  G2,	  but	  not	  in	  G0)	  (Figure	  3.9	  A	  and	  B).	  	  
	  
Under	   basal	   conditions	   the	   percentages	   of	   dividing	   astrocytes	   (%Ki67)	   in	   WT	  
cultures	  were	  8.3±5.6%	  (24	  hours)	  and	  18.0±2.3%	  (48	  hours)	  (Figure	  3.9	  C).	  Upon	  
stimulation	  this	  percentage	  increased	  to	  24.7±6.0%	  (24	  hours)	  and	  23.8±6.7%	  (48	  
hours).	  As	   such,	  activation	   for	  24	  or	  48	  hours	  did	  not	   significantly	   increase	   the	  
number	  of	  dividing	  cells	  within	  WT	  cultures	  (Figure	  3.9	  Compare	  A	  to	  B	  and	  C).	  
Neither	  did	  the	  percentage	  of	  WT	  astrocytes	  that	  went	  through	  S	  phase	  (labeled	  
with	  BrdU)	  during	  the	  last	  6	  hours	  of	  culture	  increase	  significantly	  upon	  LPS/IFNγ	  
treatment	  (Figure	  3.9	  Compare	  A	  to	  B	  and	  C).	  Similarly,	  the	  percentage	  of	  Ki67+	  
or	  BrdU+	  cells	  observed	  in	  Cln3-­‐/-­‐	  astrocyte	  cultures	  did	  not	  change	  significantly	  in	  
response	  to	  LPS/IFNγ	  treatment	  (Figure	  3.9	  Compare	  A	  to	  B	  and	  C).	  However,	  the	  
percentage	   of	   Ki67+	   astrocytes	   in	   Cln3-­‐/-­‐	   cultures	   was	   always	   less,	   under	   basal	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conditions	   and	   upon	   LPS/IFNγ	   treatment,	   than	   that	   seen	   in	   WT	   astrocyte	  
cultures,	  although	  this	  difference	  was	  not	  statistically	  significant.	  In	  contrast,	  the	  
percentage	  of	  astrocytes	  that	  went	  through	  S	  phase	  (BrdU+)	  in	  a	  6	  hours	  period	  
in	  Cln3-­‐/-­‐	  cultures	  was	  significantly	  lower	  under	  untreated	  conditions	  at	  24	  hours	  
and	   48	   hours	   (%BrdU	   labeled	   astrocytes	   was	   67.8±7.9%	   (24h	   untreated)	   and	  
68.5±10.9%	   (48h	   untreated)	   lower	   in	   Cln3-­‐/-­‐	   cultures	   compared	   with	   WT	  
astrocytes).	  The	  percentage	  of	  BrdU	  labeled	  cells	  in	  Cln3-­‐/-­‐	  astrocyte	  cultures	  was	  
also	   lower	   compared	   to	  WT	   after	   stimulation,	   but	   these	   differences	   were	   not	  
statistically	  different.	  Calculating	  the	  labeling	  index	  (%BrdU/Ki67,	  Figure	  3.9	  C)	  to	  
determine	  whether	  their	  overall	  pattern	  of	  proliferation	  is	  perturbed	  revealed	  no	  
significant	   difference	   between	   WT	   and	   Cln3-­‐/-­‐	   astrocyte	   cultures	   under	   any	  
condition	  analyzed	  (Figure	  3.9	  C).	  
	  
Taken	  together,	   these	  data	  suggest	  that	  under	  resting	  conditions	  only	  very	   few	  
astrocytes	   are	   dividing,	   and	   LPS/IFNγ	   based	   stimulation	   does	   not	   change	   this	  
significantly	   in	   cultures	   from	  either	   genotype.	  However,	   the	   rate	   of	   division	   of	  
Cln3-­‐/-­‐	  astrocytes	  appeared	  to	  be	  slower,	  as	   indicated	  by	  a	   lower	  percentage	  of	  
BrdU	  expressing	  cells,	  particularly	  under	  resting	  conditions.	  	  
	   	  






































Figure	  3.9.	  Proliferation	  of	  Cln3-­‐/-­‐	  astrocytes	  is	  attenuated.	  WT	  and	  Cln3-­‐/-­‐	  astrocyte	  
cultures	  were	  activated	  with	  LPS/IFNγ 	  for	  24	  hours	  or	  48	  hours.	  Untreated	  cells	  were	  kept	  under	  
basal	   conditions.	   Cultures	   were	   treated	   with	   BrdU	   for	   6h,	   then	   fixed	   and	   analyzed	   for	   the	  
expression	  of	  BrdU	  and	  Ki67.	  DAPI	  was	  used	  to	  visualize	  nuclei.	  (A)	  Shows	  a	  representative	  field	  
of	  BrdU	  and	  Ki67	  positive	  cells	  from	  treated	  and	  untreated	  WT	  or	  Cln3-­‐/-­‐	  astrocyte	  cultures	  after	  
24	   hours,	   and	   48	   hours	   (B).	   (C)	   Percentage	   of	   Ki67,	   BrdU	   and	   BrdU/Ki67	   expressing	   cells	   in	  
treated	   and	   untreated	   WT	   and	   Cln3-­‐/-­‐	   astrocyte	   cultures.	   Results	   expressed	   as	   mean	  
percentages±SEM	  were	  generated	  by	  counting	  5	  random	  fields	  per	  coverslip	  and	  three	  coverslips	  
per	  experiment.	  Experiment	  was	  repeated	  four	  times.	  Scale	  bar	  is	  50	  μm.	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No	  accumulation	  of	  autofluorescent	  storage	  material	  occurs	  within	  cultured	  
WT	  or	  Cln3-­‐/-­‐	  astrocytes	  	  
One	  of	  the	  main	  pathological	  features	  of	  lysosomal	  storage	  disorders	  is	  a	  striking	  
accumulation	  of	  autofluorescent	  storage	  material	  mainly	  within	  cells	  in	  the	  CNS	  
and	   less	   so	   throughout	   the	   rest	   of	   body	   of	   the	   affected	   individual.	   In	   JNCL	  
autofluorescent	   ceroid	   lipofuscin	   deposits	   enriched	   in	   subunit	   c	   of	   the	  
mitochondrial	  ATP	  synthase	  complex	  accumulate	  within	  autolysosomes	  (Palmer	  
et	  al.,	  1992).	  According	  to	  recent	  evidence	  there	  is	  no	  direct	  connection	  between	  
accumulation	  of	  storage	  material	  and	  neuron	   loss	   in	  NCLs	   (Cooper	  et	  al.,	  2006;	  
Griffey	   et	   al.,	   2006).	   Nevertheless,	   since	   such	   deposits	   are	   a	   hallmark	   of	   this	  
disease,	   we	   investigated	   whether	   such	   autofluorescent	   storage	   material	   was	  
visible	  within	  the	  cortex	  of	  Cln3-­‐/-­‐	  mice	  as	  well	  as	  cultured	  Cln3-­‐/-­‐	  astrocytes.	  
	  
Cortical	   tissue	   derived	   from	   WT	   and	   Cln3-­‐/-­‐	   mice	   was	   used	   to	   examine	  
accumulation	   of	   autofluorescent	   storage	   material	   (Figure	   3.10	   A,	   pictures	  
provided	  by	  Andrew	  Wong).	  Compared	  to	  WT	  cortical	   tissue	  a	  clear	   increase	   in	  
autofluorescent	  storage	  material	  could	  be	  seen	   in	  Cln3-­‐/-­‐	  mouse	  tissue	  exposed	  
to	   a	   488nm	   wavelength.	   Three	   different	   wavelengths,	   488nm,	   546nm	   and	  
633nm,	  were	  used	  to	  visualize	  the	  accumulation	  of	  any	  autofluoresecent	  storage	  
material	  within	  cultured	  astrocytes.	  Neither	  WT	  nor	  Cln3-­‐/-­‐	  astrocytes	  displayed	  
autofluorescence	  (Figure	  3.10	  B).	  This	  could	  be	  due	  to	  the	  relatively	  short	  period	  
of	   time	   these	   Cln3-­‐/-­‐	   astrocytes	   had	   been	   grown	   in	   culture.	   However,	   Cln3-­‐/-­‐	  
astrocytes	   have	   a	   highly	   compromised	   biology	   as	   presented	   above,	   and	   in	  
Chapter	  4,	  supporting	  the	  observations	   that	   the	  build-­‐up	  of	   this	  material	   is	  not	  





























Figure	  3.10.	  No	  accumulation	  of	  autofluorescent	  storage	  material	  within	  Cln3-­‐/-­‐	  
astrocytes.	   (A)	  Cortical	   tissue	  derived	  from	  WT	  and	  Cln3-­‐/-­‐	  mice	  were	  used	  to	   investigate	  the	  
accumulation	   of	   autofluorescent	   storage	   material	   in	   vivo	   when	   exposed	   to	   one	   wavelength,	  
488nm.	  More	  autofluorescent	  material	  was	  evident	   in	  Cln3-­‐/-­‐	   than	   in	  WT	  cortical	  tissue.	   (B)	  The	  
accumulation	  of	  autofluorescent	  storage	  material	  was	  analysed	  in	  primary	  cortical	  WT	  and	  Cln3-­‐/-­‐	  
astrocyte	   cultures.	   Cells	   were	   exposed	   to	   three	   particular	   wavelengths,	   488nm,	   546nm	   and	  
633nm,	  to	  visualize	  any	  autofluorescent	  material	  within	  cells	  and	  DAPI	  was	  used	  to	  visualize	  all	  
nuclei.	   Neither	  WT	   nor	  Cln3-­‐/-­‐	   astrocytes	   showed	   accumulation	   of	   any	   autofluorescent	   storage	  
material	  within	  their	  cell	  bodies.	  Scale	  bar	  in	  (A)	  is	  50μm	  and	  in	  (B)	  scale	  bar	  in	  20μm.	  	  
	  
	  
CLN3	  is	  expressed	  within	  the	  endo/lysosomal	  compartment	  (Fossale	  et	  al.,	  2004;	  
Kyttälä	  et	  al.,	  2005;	  Phillips	  et	  al.,	  2005;	  Uusi-­‐Rauva	  et	  al.,	  2008;	  2012),	  but	  the	  
functioning	  of	  CLN3	  within	  this	  compartment	  is	  not	  well	  understood	  (see	  Chapter	  
1,	  Section	  1.2).	  Thus,	  our	  next	  step	  using	  these	  astrocyte	  cultures	  was	  to	  look	  at	  
the	  organization	  of	  the	  endo/lysosomal	  system.	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Cln3-­‐/-­‐	  astrocytes	  have	  an	  altered	  late	  endo-­‐lysosomal	  associated	  protein	  
expression	  pattern	  	  
Lysosomes	   are	   very	   dynamic	   organelles	   and	   their	   intracellular	   localization	  may	  
vary.	  For	  example	  an	  acidic	  intracellular	  pH	  causes	  a	  redistribution	  of	  lysosomes	  
from	   their	   predominantly	   perinuclear	   location	   into	   the	   cytosol,	   also	   nutrients	  
have	   been	   shown	   to	   alter	   lysosomal	   positioning	   in	   the	   cell	   (Korolchuk	   and	  
Rubinsztein,	   2011;	   Korolchuk	   et	   al.,	   2011).	   Under	   normal	   physiological	  
conditions,	   lysosomes	  are	  maintained	  in	  the	  perinuclear	  region	  by	  mictotubule-­‐
associated	  motors	  (Jordens	  et	  al.,	  2001).	  We	  therefore	  decided	  to	  study	  whether	  
loss	  of	  CLN3	  altered	  late	  endosomal/lysosomal	  distribution	  within	  astrocytes	  by	  
studying	   the	   expression	   of	   cathepsin	   D	   and	   LAMP1.	   Cathepsin	   D,	   which	   is	   a	  
lysosomal	   aspartyl	   protease,	   was	   detected	   using	   an	   antibody	   that	   recognizes	  
both	   the	   processed	   cathepsin	   D	   isoform	   present	   in	   lysosomes,	   and	   the	  
unprocessed	   precursor	   forms	   present	   in	   the	   Trans-­‐Golgi	   network,	   and	   endo-­‐
lysosomal	  pathway.	  The	  LAMP1	  antibody	  used	   is	   typically	   considered	   to	  detect	  
protein	   expressed	   on	   the	   lysosomal	   membrane,	   or	   in	   late	   endosomes	   or	   pre-­‐
lysosomes	   (Reggio	   et	   al.,	   1984;	   Chen	   et	   al.,	   1985;	   Lippincott-­‐Schwartz	   and	  
Fambrough,	   1986;	   Eskelinen	   et	   al.,	   2003).	   It	   has	   been	   shown	   that	   lysosomal	  
membrane	  proteins	   (such	  as	  LAMP1)	  can	  be	  packaged	   into	  vesicles	  at	   the	  TGN	  
that	   are	   different	   from	   vesicles	   that	   transport	   lysosomal	   hydrolases	   (such	   as	  
cathepsin	  D),	  and	  co-­‐localization	  of	  these	  two	  proteins	  can	  be	  consider	  to	  mark	  
mature	  lysosomes	  (Karlsson	  and	  Carlsson,	  1998).	  	  	  
 
Immunostaining	   of	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   with	   cathepsin	   D	   or	   LAMP1	  
antibodies	   revealed	  a	  punctate,	  vesicular	   staining	  pattern	  clustered	  around	   the	  
nucleus	   and	   dispersed	   within	   the	   cytosol	   (Figure	   3.11).	   However,	   in	   Cln3-­‐/-­‐	  
astrocytes,	   less	  cathepsin	  D	  and	  LAMP1	  appeared	  within	  the	  perinuclear	  region	  
when	   compared	   with	   WT	   astrocytes	   (Figure	   3.11),	   suggesting	   that	   the	  
distribution	   or	   amount	   of	   endo/lysosomes	   is	   altered	   in	   Cln3-­‐/-­‐	   astrocytes.	  
Moreover,	  there	  appeared	  to	  be	  more	  cathepsin	  D	  and	  LAMP1	  positive	  vesicles	  
in	   WT	   astrocytes	   compared	   to	   Cln3-­‐/-­‐	   astrocytes,	   and	   both	   cathepsin	   D	   and	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LAMP1	   positive	   vesicles	   appeared	   to	   be	   fractionally	   smaller	   in	   the	   Cln3-­‐/-­‐	  
astrocytes.	  Finally,	  co-­‐localization	  of	  cathepsin	  D	  and	  LAMP1	  can	  be	  considered	  
to	   identify	   mature	   lysosomes,	   and	   it	   appears	   that	   in	   WT	   astrocytes	   more	   co-­‐
localization	   is	   observed	   than	   in	  Cln3-­‐/-­‐	   astrocytes	   (Figure	   3.11,	   compare	   higher	  
power	   images	   between	   WT	   and	   Cln3-­‐/-­‐	   astrocytes).	   This	   suggests	   that	  
endo/lysosomal	  trafficking	  and	  maturation	   is	  altered,	  even	   if	   these	  changes	  are	  




Figure	   3.11.	   CLN3	   affects	   compartmentalization	   of	   cathepsin	   D	   and	   LAMP1	  
endo-­‐lysosomal	   markers.	   WT	   and	  Cln3-­‐/-­‐	   astrocytes	  were	   stained	  with	   antibodies	   against	  
GFAP	  to	  visualize	  astrocytes,	  cathepsin	  D	  (CathD)	  to	  visualized	  both	  unprocessed	  and	  processed	  
forms	  of	  this	  lysosomal	  hydrolase	  and	  LAMP1	  to	  visualize	  the	  late	  endosomes,	  pre-­‐lysosomes	  and	  
mature	  lysosomes.	  DAPI	  was	  used	  to	  visualize	  all	  nuclei.	  Both	  CathD	  and	  LAMP1	  were	  localized	  in	  
dispersed	  vesicles	  within	  the	  cytosol,	  as	  well	  in	  the	  perinuclear	  area	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes.	  
CathD	  and	  LAMP1	  positive	  vesicles	  dispersed	  equally	  in	  the	  cytosols	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes.	  
However,	   they	   were	   more	   numerous	   in	   WT	   than	   Cln3-­‐/-­‐	   astrocytes,	   with	   these	   vesicles	   being	  
localized	   closer	   to	   the	   nucleus	   in	  WT	   astrocytes.	   Higher	  magnifications	   show	   co-­‐localization	   of	  
CathD	  and	  LAMP1	  as	  an	   indication	  of	  mature	   lysosomes,	  with	  more	  co-­‐localization	  apparent	   in	  
WT	  astrocytes.	  Scale	  bar	  is	  20μm	  in	  x40	  magnification,	  and	  10μm	  in	  higher	  power	  images.	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The	  expression	  and	  distribution	  of	  early	  endosomes	  is	  not	  influenced	  by	  lack	  of	  
CLN3	  protein	  in	  astrocytes	  	  
CLN3	  has	   frequently	  been	   reported	   to	  be	  associated	  with	   the	  early	   endosomal	  
marker	   EEA1	   especially	   along	   neuronal	   processes,	   but	   less	   so	   in	   non-­‐neuronal	  
cells,	  such	  as	  HELA-­‐cells	  (Kyttälä	  et	  al.,	  2004).	  Thus,	  to	  obtain	  information	  about	  
the	  association	  of	  CLN3	  with	  the	  endosomal	  system	  in	  astrocytes,	  the	  effect	  of	  its	  
absence	  on	  the	  localization	  of	  EEA1-­‐positive	  early	  endosomes	  (EEs)	  was	  assessed	  
by	  immunofluorescence	  microscopy.	  	  	  
No	  significant	  difference	  was	  observed	  in	  the	  distribution	  of	  EEA1	  positive	  early	  
endosomes	  between	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  (Figure	  3.12).	  In	  both	  of	  these	  cell	  
types	   EEs	   are	   relatively	   evenly	   distributed	   around	   the	   cytosol,	   with	   a	   slight	  
preference	   to	   be	   located	   around	   the	   nucleus.	   There	   was	   also	   no	   apparent	  
difference	   in	   the	   intensity	   and	   size	   of	   the	   EEs	   between	   these	   two	   genotypes.	  
However,	   possibly	   due	   to	   the	   larger	   cell	   body	   size	   of	   Cln3-­‐/-­‐	   astrocytes	   (see	  





Figure	   3.12	   Expression	   and	   distribution	   of	   EEA1	   is	   not	   altered	   in	   Cln3-­‐/-­‐	  
astrocytes.	  WT	   and	  Cln3-­‐/-­‐	   astrocyte	   cultures	  were	   stained	  with	  GFAP	   to	   visualize	   astrocytes	  
and	  EEA1	  to	  visualize	  early	  endosomes.	  In	  both	  genotypes	  the	  EEA1	  expressing	  EEs	  had	  a	  similar	  
intensity,	  size	  and	  distribution.	  Scale	  bar	  is	  20μm.	  	  	  
The	  expression	  and	  distribution	  of	  Rab7	  is	  influenced	  by	  the	  lack	  of	  CLN3	  
protein	  in	  astrocytes	  
The	  endocytosis	  pathway	  regulates	  many	  physiological	  events	  in	  the	  cell.	  Rab7	  is	  
a	   late-­‐endosome/lysosome	  associated	   small	  GTPase	   that	  plays	  a	  pivotal	   role	   in	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endocytosis.	   Together	   with	   its	   interaction	   partners	   such	   as	   RILP,	   Rab7	  
contributes	  to	  processes	  such	  as	  endosomal	  sorting,	  biogenesis	  of	  lysosomes	  and	  
phagocytosis	   (see	   Chapter	   1,	   Section	   1.2)	   (Jordens	   et	   al.,	   2001;	   Zhang	   et	   al.,	  
2009b).	   As	   early	   endosomes	   mature	   into	   late	   endosomes	   they	   underdo	   a	   so-­‐
called	  Rab-­‐conversion	  where	  Rab5	   is	  displaced	  by	  Rab7	   (Rink	  et	  al.,	  2005).	  This	  
conversion	   takes	  place	   simultaneously	  with	   the	  dynein-­‐mediated	  movement	  of	  
endosomes	   down	   microtubules	   from	   the	   periphery	   of	   the	   cell	   towards	   the	  
microtubule-­‐organizing	   center	   located	   in	   the	   perinuclear	   region	   (Driskell	   et	   al.,	  
2007;	   Johansson	   et	   al.,	   2007).	   Recently,	   it	   has	   been	   demonstrated	   that	   CLN3	  
interacts	  with	  Rab7	   in	  various	  cellular	  models	   (Luiro	  et	  al.,	  2004;	  Uusi-­‐Rauva	  et	  
al.,	   2012).	   Considering	   the	   importance	   of	   the	   correct	   functioning	   of	   the	   small	  
GTPase	   Rab7	   to	   the	   overall	   endo-­‐lysosomal	   homeostasis	   in	   the	   cell,	   the	  
expression	  pattern	  of	  Rab7	  was	  investigated	  in	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocytes.	  	  
	  
In	  both	  genotypes	  Rab7	  expressing	  late	  endosomes	  were	  localized	  mainly	  in	  the	  
cytosol.	  Overall	   there	  appeared	  to	  be	  more	  Rab7	  expressing	   late	  endosomes	   in	  
WT	  than	  in	  Cln3-­‐/-­‐	  astrocytes.	  Additionally,	  these	  Rab7	  expressing	  LEs	  tended	  to	  
be	   clustered	   in	   a	   band	   adjacent	   to	   the	  nucleus	   in	  WT	  astrocytes	   (marked	  with	  
dashed	  line,	  Figure	  3.13),	  but	  were	  more	  randomly	  expressed	  within	  the	  cytosol	  
of	   Cln3-­‐/-­‐	   astrocytes.	   Thus,	   CLN3	   may	   be	   involved	   in	   the	   expression	   and	  
localization	  of	  Rab7,	  highlighting	  the	  potential	  importance	  of	  CLN3	  in	  functioning	  






















Figure	  3.13	  Rab7	  labeled	  late	  endosomes	  show	  an	  altered	  localization	  in	  Cln3-­‐/-­‐	  
astrocytes.	  WT	  and	  Cln3-­‐/-­‐	   astrocytes	  were	   labeled	  with	  GFAP	   to	   visualize	   astrocytes	   and	   an	  
antibody	   that	   recognizes	   the	   small	  GTPase	  Rab7,	  which	   labels	   late	   endosomes	   (LEs).	   DAPI	  was	  
used	   to	   label	   all	   nuclei.	   Rab7	   was	   distributed	   around	   the	   cytosol	   of	   both	   WT	   and	   Cln3-­‐/-­‐	  
astrocytes.	   In	  WT	  astrocytes	  Rab7	   labeled	  LEs	  were	  more	  numerous	  and	   localized	   in	  a	  band	  of	  
vesicles	   around	   the	   nucleus	   (marked	  with	   dashed	   line),	  whereas	   Rab7	   positive	   LEs	  were	  more	  
randomly	   distributed	   in	   Cln3-­‐/-­‐	  astrocytes	   and	   were	   fewer	   in	   number.	   The	   density	   and	   size	   of	  




There	   is	   an	   increasing	   evidence	   that	   points	   towards	   the	   involvement	   of	   both	  
microglia	  and	  astrocytes	  in	  the	  early	  stages	  of	  disease	  progression	  in	  all	  forms	  of	  
NCLs.	   Unusually,	   mouse	   models	   of	   JNCL	   display	   an	   attenuated	   microglia	   and	  
astrocyte	  response	  (Pontikis	  et	  al.,	  2004;	  2005)	   (Figure	  3.1),	  which	   is	   in	  marked	  
contrast	  to	  the	  pronounced	  glial	  response	  observed	  in	  models	  of	  other	  forms	  of	  
NCL	  (Bible	  et	  al.,	  2004;	  Oswald	  et	  al.,	  2005;	  Cooper,	  2010;	  Kuronen	  et	  al.,	  2012;	  
Schmiedt	  et	  al.,	  2012).	  In	  this	  chapter	  we	  used	  an	  in	  vitro	  approach	  to	  investigate	  
the	  basic	   structure	  of	   JNCL	  astrocytes	  and	   their	   response	   to	  stimulation.	  Cln3-­‐/-­‐	  
astrocytes	   were	   found	   to	   have	   abnormal	   cytoskeletal	   organization,	   with	  
disrupted	  actin	  and	   intermediate	   filaments,	  accompanied	  by	  altered	  expression	  
levels	   of	   intermediate	   filament	   proteins.	   Their	   cell	   bodies	   were	   significantly	  
larger	   than	   wild-­‐type	   astrocytes	   and	   they	   showed	   a	   diminished	   ability	   to	  
transform	  morphologically	  upon	  activation,	  possibly	  due	  to	  severe	  abnormalities	  
in	  their	  cytoskeleton.	  As	  might	  be	  expected	  from	  cells	  lacking	  a	  highly	  conserved	  
lysosomal	  protein,	  the	  number	  and	  localization	  of	  late	  endosomes	  and	  lysosomes	  
was	   altered	   in	   Cln3-­‐/-­‐	   astrocytes,	   with	   these	   cells	   displaying	   a	   more	   dispersed	  
cytosolic	   localization	  of	  both	  of	  these	  compartments,	  and	  a	  reduced	  number	  of	  
mature	  lysosomes.	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Implications	  of	  a	  disrupted	  cytoskeleton	  on	  the	  biology	  of	  Cln3-­‐/-­‐	  astrocytes	  	  
Emerging	  evidence	  indicates	  that	  a	  large	  number	  of	  neurodegenerative	  diseases	  
are	   associated	  with	   dysfunctional	   cytoskeletal	   components,	   resulting	   in	   effects	  
upon	   vesicle	   or	   cellular	   organelle	   trafficking,	   vesicular	   biogenesis,	   and	   synaptic	  
signaling	   in	  neurons	  (McMurray,	  2000).	   In	  this	  chapter	   I	  show	  for	  the	  first	   time	  
that	  Cln3-­‐/-­‐	  astrocytes	  have	  cytoskeletal	  abnormalities	  (Chapter	  3,	  Figure	  3.7).	  	  	  
	  
Some	  of	  the	  proposed	  interaction	  partners	  for	  CLN3	  connect	  this	  protein	  directly	  
with	  the	  cytoskeleton	  (Luiro	  et	  al.,	  2004;	  Weimer	  et	  al.,	  2005;	  Uusi-­‐Rauva	  et	  al.,	  
2008;	   Getty	   et	   al.,	   2011).	   For	   instance,	   CLN3	   has	   been	   reported	   to	   form	   a	  
transient	   interaction	  with	  the	  Hook1	  protein,	  which	   is	  a	  microtubule-­‐associated	  
protein	   (Luiro	   et	   al.,	   2004).	   However,	   microtubular	   organization	   in	   Cln3-­‐/-­‐	  
astrocytes	  was	  not	  altered,	  suggesting	  that	  in	  astrocytes	  the	  link	  between	  CLN3-­‐
Hook1	   is	   not	   crucial	   for	   the	   correct	   organization	   of	   the	   microtubular	  
cytoskeleton.	  However,	  Hook1	  also	  indirectly	  links	  CLN3	  with	  Ankyrin	  G,	  which	  is	  
an	  adaptor	  protein	  binding	  to	  the	  spectrin-­‐actin	  cytoskeleton	  that	  functions	  as	  a	  
scaffold	  protein	  between	  many	  cytosolic	  proteins	  and	  the	  peripheral	  membrane	  
(Luiro	   et	   al.,	   2004).	   The	   severely	   disorganized	   actin	   cytoskeleton	   observed	   in	  
Cln3-­‐/-­‐	  astrocytes	  could	  potentially	  arise	  because	  the	  ankyrin	  G/Hook1	  interaction	  
with	   the	   spectrin/actin	   cytoskeleton	   is	   compromised	   in	   these	   cells	   leading	   into	  
incorrect	   polymerization	   of	   actin	   microfilaments,	   although	   this	   awaits	  
experimental	   verification.	   Furthermore,	   the	   C-­‐terminal	   fragment	   of	   CLN3	   has	  
been	   shown	   to	   interact	   with	   nonmuscle	   myosin-­‐IIB,	   which	   is	   an	   actin-­‐binding	  
motor	  protein	  (Getty	  et	  al.,	  2011),	  and	  could	  further	  explain	  the	   lack	  of	  correct	  
polymerization	  of	  actin	   in	  Cln3-­‐/-­‐	  astrocytes.	  CLN3-­‐myosin	   interactions	  have	  also	  
been	  associated	  with	  neuronal	  processes	  and	  synapse	  development	  and	  will	  be	  
discussed	  in	  this	  connect	   in	  Chapter	  5.	  Additionally,	  among	  other	  defects,	  upon	  
myosin-­‐IIB	   deficiency	   cell	   migration	   is	   markedly	   impaired	   (Lo	   et	   al.,	   2004).	  
Indeed,	  Cln3-­‐/-­‐	  mouse	  embryonic	   fibroblasts	   show	  a	   reduced	  ability	   to	  migrate,	  
which	  could	  be	  due	  to	  the	  loss	  of	  correct	  CLN3-­‐myosin-­‐IIB	  functional	  interaction	  
in	   these	   cells	   (Getty	   et	   al.,	   2011).	   Based	   on	   evidence	   discussed	   above	   and	  
detected	   defects	   in	   actin	   cytoskeleton	   organization	   in	   Cln3-­‐/-­‐	   astrocytes,	   their	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ability	   to	  migrate	  was	   subsequently	   investigated	  by	  performing	  a	   scratch	  assay	  
(see	  Chapter	  4,	  Figure	  4.12).	  	  
	  	  
The	  intermediate	  filament	  (IF)	  network,	  composed	  of	  GFAP,	  nestin	  and	  vimentin	  
forms	  an	  important	  component	  of	  the	  cytoskeleton	  of	  astrocytes	  (Eliasson	  et	  al.,	  
1999).	   In	  this	  study,	   IF	  organization	  was	  also	  found	  to	  be	  highly	  disorganized	   in	  
Cln3-­‐/-­‐	   astrocytes.	   Many	   emerging	   roles	   for	   IFs	   in	   astrocytes	   have	   been	  
discovered,	  yet	  the	  principal	  function	  of	  individual	  IFs	  remains	  unresolved	  (Pekny	  
and	   Pekna,	   2004;	   Middeldorp	   and	   Hol,	   2011).	   Numerous	   mouse	   models	   have	  
been	   created	   that	   either	   overexpress	   or	   lack	   GFAP	   and/or	   Vimentin,	   whose	  
knock-­‐down	  together	  with	  GFAP	  is	  required	  for	  total	  ablation	  of	  IFs	  in	  astrocytes	  
(Pekny	  and	  Pekna,	  2004;	  Middeldorp	  and	  Hol,	  2011).	  These	  studies	  indicate	  that	  
IFs	   are	   required	   for	  migration,	   neuronal-­‐glial	   interactions,	   gliotransmission	   and	  
formation	  of	  the	  BBB	  (Pekny	  and	  Pekna,	  2004;	  Pekny	  and	  Nilsson,	  2005).	  As	  such,	  
any	  of	  these	   important	  functions	  may	  be	  compromised	   in	  Cln3-­‐/-­‐	  astrocytes	  due	  
to	  a	  disrupted	   IF	  cytoskeleton	  and	  astrocyte	  migration	   in	  addition	   to	  neuronal-­‐
glial	  interactions	  will	  be	  investigated	  further	  in	  Chapters	  4.	  and	  6	  respectively.	  	  
	  
IFs	  are	  not	  normally	  considered	  to	  be	  required	  elements	  for	  cell	  motility,	  unlike	  
actin	   filaments	   and	  microtubules.	   However,	   the	  motility	   of	   primary	   astrocytes	  
derived	   from	  GFAP-­‐/-­‐,	   Vim-­‐/-­‐,	   and	  GFAP-­‐/-­‐Vim-­‐/-­‐	   mice	   was	   found	   to	   be	   severely	  
compromised,	   as	   was	   their	   morphology	   (Lepekhin	   et	   al.,	   2001).	   Moreover,	  
changes	   in	  GFAP	   expression	   has	   also	   been	   observed	   to	   ability	   of	   astrocytes	   to	  
proliferate	  (Rutka	  and	  Smith,	  1993;	  Toda	  et	  al.,	  1994;	  Elobeid	  et	  al.,	  2000).	  This	  
could	  explain	  our	  findings	  that	  GFAP	  is	  overexpressed	  by	  Cln3-­‐/-­‐	  astrocytes	  under	  
unstimulated	  conditions	  (Results	  Chapter	  3,	  Figure	  3.6),	  and	  these	  cells	  show	  an	  
attenuated	   ability	   to	   proliferate	   (Chapter	   3,	   Figure	   3.9).	   Moreover,	   GFAP	   has	  
been	  demonstrated	  to	  be	  involved	  in	  mitosis	  and	  cytokinesis,	  further	  reinforcing	  
the	   potential	   link	   between	   GFAP	   expression	   abnormalities	   and	   the	   attenuated	  
proliferation	   observed	   in	   Cln3-­‐/-­‐	   astrocytes	   (Inagaki	   et	   al.,	   1994;	   Pekny	   et	   al.,	  
1998;	  Yasui	  et	  al.,	  1998;	  Kawajiri	  et	  al.,	  2003).	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One	  of	  the	  most	  pivotal	  functions	  of	  astrocytes	  is	  associated	  with	  their	  ability	  to	  
secrete	   and	   respond	   to	   different	   gliotransmitters,	   such	   as	   ATP,	   glutamate,	   D-­‐
serine,	   chemokines	   and	   cytokines	   (Volterra	   and	   Meldolesi,	   2005;	   Verkhratsky	  
and	   Butt,	   2007;	   Halassa	   and	  Haydon,	   2010;	   Parpura	   and	   Zorec,	   2010).	   Various	  
different	  mechanisms	  have	  been	  proposed	  to	  be	  involved	  in	  gliotranmission.	  The	  
main	  one	  being	  exocytosis,	   that	   is	   dependent	  on	  an	   intracellular	  Ca2+	   signaling	  
response	   (Parpura	  and	  Zorec,	  2010;	  Zorec	  et	  al.,	  2012).	  Overall,	   this	  process	  of	  
exocytosis	  of	  gliotransmitters	  requires	  packaging	  of	  vesicles	  with	  the	  releasable	  
cargo,	  transport	  of	  these	  cargo	  containing	  vesicles	  along	  the	  cytoskeleton	  to	  the	  
plasma	  membrane,	  where	   they	  dock	  and	   fuse	  with	   the	  membrane	  and	   release	  
their	   cargo	   into	   the	   extracellular	   space	   (Bezzi	   et	   al.,	   2004;	   Crippa	   et	   al.,	   2006;	  
Halassa	   and	   Haydon,	   2010).	   It	   has	   been	   demonstrated	   in	   vitro	   that	  
depolymerization	   of	   IFs	   influences	   the	   directional	   mobility	   of	   vesicles	   in	  
astrocytes	   (Potokar	  et	   al.,	   2007).	   Importantly,	  by	  disrupting	   the	   IF	  network	   the	  
track	   length	   of	   vesicles	   was	   reduced	   (Stenovec	   et	   al.,	   2007),	   and	   the	   overall	  
mobility	   of	   the	   vesicles	   was	   decreased	   (Potokar	   et	   al.,	   2008)	   Moreover,	   the	  
stimulus-­‐accelerated	   mobility	   of	   recycling	   glutamategic	   vesicles,	   stimulus-­‐
inhibited	   mobility	   of	   peptidergic	   vesicles	   and	   stimulus-­‐mediated-­‐inhibition	   of	  
endo/lysosomes	  mobility	  was	   absent	   in	  GFAP-­‐/-­‐Vim-­‐/-­‐	   astrocytes	   (Potokar	  et	   al.,	  
2010).	  Thus,	  changes	   in	   IF	  expression	   that	  accompany	  astrocyte	  activation	  may	  
result	   in	   altered	   vesicle	   trafficking	   and	   hence	   astrocyte	   functioning	   under	  
pathological	  conditions	  (Potokar	  et	  al.,	  2008;	  2010;	  2011).	  Thus,	  keeping	  in	  mind	  
that	   the	   IF	   and	   actin	   cytoskeleton	   are	   both	   disrupted	   in	   Cln3-­‐/-­‐	   astrocytes,	   we	  
considered	   that	   their	   ability	   to	   secrete	   various	  proteins	  may	  be	  disrupted,	   and	  
experiments	   to	   test	   this	   hypothesis	   are	   described	   in	   Chapter	   4	   (see	   Tables	   4.1	  
and	  4.2	  and	  Figure	  4.7).	  	  	  
	  
Gene	  expression	  microarray	  studies	  of	  the	  whole	  brain,	  cerebellum,	  retinae	  and	  
pure	   hippocampal	   neuronal	   cultures	   all	   derived	   from	   Cln3-­‐/-­‐	   mice	   revealed	   a	  
range	   of	   differentially	   expressed	   genes	   with	   particular	   emphasis	   on	   genes	  
involved	   in	   neurotransmitter	   metabolism,	   immunoresponse,	   metabolism	   and,	  
crucially,	   cytoskeletal	   organization	   (Brooks	   et	   al.,	   2003;	   Elshatory	   et	   al.,	   2003;	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Chattopadhyay	   et	   al.,	   2004;	   Luiro	   et	   al.,	   2006).	   However,	   none	   of	   these	  
experiments	   specifically	   focused	   on	   astrocytes	   or	   reported	   alterations	   in	   the	  
expression	  of	  any	  astrocyte	  specific	  markers.	  In	  future	  it	  would	  be	  informative	  to	  
carry	  out	  such	  gene	  expression	  studies	  on	  pure	  Cln3-­‐/-­‐	  astrocyte	  cultures.	  	  	  
	  
Observations	   presented	   here	   on	   the	   cytoskeletal	   abnormalities	   in	   Cln3-­‐/-­‐	  
astrocytes	   provide	   novel	   insights	   into	   the	   possible	   importance	   of	   CLN3	   in	   the	  
organization	   of	   the	   cytoskeleton	   in	   this	   cell	   type.	   Indeed,	   the	   disordered	  
intermediate	   filament	  and	  actin	  cytoskeleton,	  as	  discussed	  above,	  could	  be	  the	  
result	   of	   the	   CLN3	   protein	   being	   required	   for	   the	   correct	   assembly	   of	   these	  
polymers	  in	  astrocytes,	  either	  by	  interacting	  with	  them	  directly,	  or	  indirectly	  via	  
proposed	  interaction	  partners,	  such	  as	  myosin-­‐IIB	  and	  Hook1	  (Luiro	  et	  al.,	  2004;	  
Weimer	   et	   al.,	   2005;	   Getty	   et	   al.,	   2011).	   Systematic	   screening	   of	   interaction	  
partners	   for	   CLN3	   specifically	   in	   astrocytes	   would	   enable	   the	   confirmation	   of	  
proteins	  involved	  in	  this	  process.	  However,	  such	  studies	  are	  difficult	  to	  conduct	  
due	   to	   the	   lack	   of	   specific	   antibodies	   against	   CLN3	   (Phillips	   et	   al.,	   2005).	  
Nevertheless,	  methods	  such	  as	  glutathione	  S-­‐transferase	   (GST)	   interaction	  pull-­‐
down	  assays	   combined	  with	  matrix-­‐assisted	   laser	  desorption/ionization-­‐time	  of	  
flight	  (MALDI-­‐TOF)	  mass	  spectrometric	  analysis	  could	  be	  applied	  to	  address	  this	  
question	   (Luo	  et	  al.,	   1997;	  Berggård	  et	  al.,	   2007;	   Lalonde	  et	  al.,	   2008;	  Miernyk	  
and	   Thelen,	   2008).	   Regardless	   of	   not	   knowing	   the	   precise	  mechanisms	   behind	  
the	  disrupted	  actin	  and	  intermediate	  filament	  cytoskeleton	  in	  Cln3-­‐/-­‐	  astrocytes,	  
these	   abnormalities	   are	   bound	   to	   have	   severe	   functional	   implications	   for	   the	  
overall	  biology	  of	  these	  cells.	  For	  example,	  agents	  such	  as	  cytochalasin	  D,	  which	  
inhibits	  the	  actin	  microfilament	  polymerization,	  has	  significant	  effects	  on	  a	  range	  
of	   astrocyte	   functions,	   including	   Ca2+	   based	   signaling	   (Cotrina	   et	   al.,	   1998),	  
glutamate	   clearance	   (Duan	   et	   al.,	   1999),	   and	   astrocyte	   migration	   (Etienne-­‐
Manneville	   and	   Hall,	   2001).	   The	   ability	   of	   Cln3-­‐/-­‐	   to	   carry	   out	   these	   particular	  
functions	   were	   therefore	   investigated,	   see	   Chapter	   4.	   Taken	   together	   these	  
findings	  support	  the	  hypothesis	  that	  CLN3	  is	  involved	  in	  cytoskeletal	  organization	  
(Jalanko	  and	  Braulke,	  2009;	  Getty	  and	  Pearce,	  2011)	  linking	  CLN3	  to	  a	  wide	  range	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of	   cellular	   activities	   dependent	   on	   dynamic	   re-­‐arrangement	   of	   different	  
cytoskeletal	  components.	  	  
	  
Altered	  intermediate	  filament	  protein	  expression	  in	  Cln3-­‐/-­‐	  astrocytes	  
When	  astrocytes	  undergo	  major	   structural	   changes,	   as	   they	  do	  during	   reactive	  
astrocytosis,	   the	   demand	   for	   cytoarchitectural	   structural	   support	   provided	   by	  
intermediate	   filament	   networks	   becomes	   increasingly	   necessary	   (Pekny	   et	   al.,	  
1995;	   Pekny	   and	   Pekna,	   2004).	   Thus,	   the	   disrupted	   cytoskeletal	   structure	   of	  	  
Cln3-­‐/-­‐	   astrocytes,	   described	   above,	   together	   with	   the	   significant	   differences	  
detected	  in	  their	  expression	  levels	  of	  intermediate	  filament	  proteins,	  could	  have	  
a	   major	   impact	   on	   their	   ability	   to	   change	   morphologically.	   Indeed,	   our	   data	  
suggest	   that	   this	   is	   the	  case	   for	  Cln3	  deficient	  astrocytes	   in	  vitro,	  and	   in	  vivo	   in	  
both	  murine	  and	  human	  JNCL	  (see	  Chapter	  3,	  Figures	  3.1	  and	  3.5	  and	  3.6).	  	  
	  
Our	  data	   revealed	   that	   the	   level	  of	  GFAP	  expression	   in	  Cln3-­‐/-­‐	  astrocytes	  grown	  
under	  basal	  conditions	  was	  significantly	  higher	  than	  that	  of	  WT	  astrocytes.	  This	  
would	  suggest	  that	  the	  properties	  of	  Cln3-­‐/-­‐	  astrocytes	  are	  already	  different	  from	  
the	   moment	   of	   isolation,	   perhaps	   due	   to	   differences	   in	   the	   molecular	   cues	  
present	   in	   the	  Cln3-­‐/-­‐	  brains,	  even	  at	   this	  early	  developmental	   stage,	   leading	   to	  
the	  initiation	  of	  astrocytosis	  in	  these	  diseased	  mice.	  Embryos	  from	  different	  JNCL	  
mice	   models	   do	   not	   show	   any	   overt	   abnormalities	   in	   brain	   architecture	   and	  
onset	  of	  neurological	  deficits	  only	  become	  evident	  starting	   from	  1-­‐4	  months	  of	  
age,	   depending	  on	   the	  mouse	  model	   (Katz	   et	   al.,	   1999;	  Mitchison	  et	   al.,	   1999;	  
Cotman	  et	  al.,	  2002;	  Eliason	  et	  al.,	  2007).	  Accordingly,	  JNCL	  patients	  often	  have	  
apparently	  normal	  development	  and	  neurological	  functions,	  until	  they	  reach	  the	  
pre-­‐teen	  years	  (Mole	  et	  al.,	  2011).	  It	  is	  feasible	  that	  CLN3	  is	  important	  for	  some	  
aspects	  of	  CNS	  development,	  and	  it	  may	  be	  possible	  that	  accumulative	  negative	  
effects	   arising	   from	   CLN3	   deficiency	   start	   during	   developmental	   stages,	   for	  
instance,	   resulting	   in	   altered	   intermediate	   filament	   expression,	   as	   observed	   in	  
astrocytes	   isolated	   from	  P2	  cortex	   (see	  Results	  Chapter,	  Figure	  3.6).	   Such	  early	  
changes	  may	   represent	   a	   primary	  defect	   that	   eventually	   leads	   to	   the	  neuronal	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dysfunction	  and	  neurodegeneration	  associated	  with	  JNCL.	  Certainly,	  based	  on	  in	  
vivo	   data,	   a	   glial	   response	   precedes	   neuronal	   loss	   in	   an	   extremely	   specific	  
manner	   in	  the	  Cln3-­‐/-­‐	  mouse	  brain,	  suggesting	  that	  primary	  pathogenic	  changes	  
may	   also	   be	   glial-­‐based	   rather	   than	   being	   purely	   neuronal	   in	   this	   disease.	   A	  
mouse	  in	  which	  astrocytes	  constitutively	  overexpress	  GFAP	  has	  been	  engineered	  
(Messing	  et	  al.,	  1998;	  Duan	  et	  al.,	  1999),	  and,	   interestingly,	   in	  this	  model	  these	  
astrocytes	   contained	   highly	   complex	   intracellular	   aggregates	   of	   IFs	   and	   small	  
stress	  proteins.	  These	   small	   stress	  proteins	  were	   identified	  as	  Rosenthal	   fibers.	  
Intriguingly	   the	   accumulation	   of	   these	   fibers	   is	   also	   the	   hallmark	   of	   Alexander	  
disease,	  which	   is	  an	  autosomal	  dominant	  neurodegenerative	  disorder	   (Messing	  
et	   al.,	   1998;	  Quinlan	   et	   al.,	   2007).	   Thus,	   the	  over	   expression	  of	  GFAP	   in	  Cln3-­‐/-­‐	  
astrocytes	  may	  have	  a	  detrimental	  neurotoxic	  effect.	  	  
	  
Activated	   astrocytes	   upregulate	   GFAP,	   as	   well	   as	   vimentin	   and	   nestin,	   in	   the	  
diseased	   brain	   (Pekny	   and	   Pekna,	   2004;	   Pekny	   and	  Nilsson,	   2005).	   To	   activate	  
our	   cultured	   astrocytes	  we	   used	   LPS/IFNγ,	   which	   led	   to	   significantly	   increased	  
GFAP	  expression,	  but	  only	  in	  WT	  astrocytes	  (Chapter	  3,	  Figure	  3.5).	  This	  coincides	  
with	   our	   in	   vivo	   observations	   that	   astrocytes	   in	   the	   Cln3-­‐/-­‐	  mouse	   cortex,	   and	  
those	  in	  JNCL	  patients,	  fail	  to	  significantly	  upregulate	  GFAP	  to	  the	  same	  extent	  as	  
seen	   in	   other	   forms	   of	   NCL	   (Chapter	   3,	   Figure	   3.1).	   As	   such,	   Cln3-­‐/-­‐	   astrocytes	  
have	  an	  intrinsically	  reduced	  ability	  to	  upregulate	  GFAP	  upon	  activation,	  despite	  
expressing	   higher	   levels	   of	   this	   protein	   than	   WT	   astrocytes	   under	   resting	  
conditions.	   This	   could	   again	   have	   significant	   functional	   implications,	   since	  
impairment	   in	   the	   glial	   response	   to	   injury/disease	   has	   been	   shown	   to	   have	  
detrimental	  effect	  on	  disease	  progression	  in	  other	  forms	  of	  NCL	  (Macauley	  et	  al.,	  
2011).	  	  
	  
Based	  on	  gene	  expression	  prolifing	  the	  astrocyte	  cultures	  used	  in	  this	  study	  are	  
suggested	  to	  closely	  resemble	  immature	  instead	  of	  mature	  astrocytes	  (Cahoy	  et	  
al.,	  2008;	  Foo	  et	  al.,	  2011;	  Zamanian	  et	  al.,	  2012).	  As	  such,	  detectable	  expression	  
of	  GFAP	  together	  with	  nestin	  and	  vimentin	  was	  expected	  to	  be	  present	   in	  both	  
WT	   and	   Cln3-­‐/-­‐	   astrocyte	   cultures,	   even	   under	   basal	   conditions	   (Chapter	   3,	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Figures	  3.5	  and	  3.6).	  However,	  perhaps	  due	  to	  their	  immature	  nature,	  astrocytes	  
of	  neither	  genotype	  responded	  to	  LPS/IFNγ	  stimulation	  by	  upregulating	  vimentin	  
and	  nestin	   expression	   (Chapter,	   Figure	   3.5).	  However,	   the	   fact	   that	   nestin	  was	  
significantly	   downregulated	   in	   untreated	   	   	   Cln3-­‐/-­‐	   compared	   to	  WT	   astrocytes,	  
suggests	  that	  Cln3-­‐/-­‐	  astrocytes	  derived	  from	  postnatal	  mice	  are	  not	  fully	  capable	  
of	   returning	   to	   a	   stem	   cell	   like	   state,	   or	   they	   have	   taken	   on	   a	   more	   mature	  
phenotype.	   This	   could	   imply	   that	   reactivated	   astrocytes	   in	   Cln3-­‐/-­‐	   mice	   brain	  
display	   an	   attenuated	   plasticity	   hindering	   their	   ability	   to	   proliferate	   and	  
regenerate,	   which	   could	   have	   detrimental	   implications	   over	   the	   course	   of	  
disease	  progression	   in	   JNCL.	   In	  order	   to	  examine	   this	   issue	   further	   it	  would	  be	  
interesting	  to	  compare	  the	  self-­‐renewal	  and	  differentiation	  potential	  of	  reactive	  
astrocytes	  isolated	  from	  adult	  Cln3-­‐/-­‐	  mice	  with	  those	  from	  WT	  mice.	  This	  could	  
be	  done	  by	  growing	   these	  cells	   in	  vitro	  and	   testing	   their	  ability	   to	  differentiate	  
into	  different	  neural	  cell	   types,	  or	  by	  using	  transplanting	  studies	  to	  reveal	  their	  
developmental	  potential	  in	  vivo	  (Robel	  et	  al.,	  2011).	  
	  	  	  
Importance	  of	  accurate	  morphological	  dynamics	  in	  astrocytes	  
Protoplasmic	   astrocytes	   constitute	   the	  most	   common	   type	  of	   astrocytes	   in	   the	  
healthy	   gray	   matter.	   These	   astrocytes	   have	   extremely	   complex	   morphology,	  
having	   a	   relatively	   small	   cell	   body	   with	   many	   thin	   primary	   processes,	   which	  
extend	   into	   the	   neighboring	   neuronal	   networks	   forming	   a	   complex	   system	   of	  
very	   fine	   branches	   (Montagnese	   et	   al.,	   1988;	   Ogata	   and	   Kosaka,	   2002;	  
Oberheim:2006ea	   Nedergaard	   et	   al.,	   2003;	   Theodosis	   et	   al.,	   2008;	   Allen	   and	  
Barres,	   2009;	   Lushnikova	   et	   al.,	   2009).	   Astrocytes	   employ	   their	   processes	   to	  
ensheath	   structural	   elements	   of	   neurons,	   particularly	   synapses,	   as	   well	   as	   to	  
connect	   themselves	  with	   the	   vascular	   system.	   The	  properties	  of	   astrocytes	   are	  
incredibly	  diverse,	  as	  these	  cells	  not	  only	  function	  as	  a	  structural	  and	  nutritional	  
support	   system	   for	   neurons,	   but	   are	   active	   partners	   in	   information	   processing	  
and	  regulation	  of	   synaptic	   function,	  among	  other	   things	   (Verkhratsky	  and	  Butt,	  
2007;	  Sofroniew	  and	  Vinters,	  2010;	  Parpura	  et	  al.,	  2012;	  Zorec	  et	  al.,	  2012).	  One	  
property	  that	  enables	  astrocytes	  to	  carry	  out	  such	  a	  wide	  range	  of	  duties	  is	  their	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ability	  to	  transform	  their	  morphology	  dynamically	  in	  response	  to	  changes	  in	  their	  
environment	  (Theodosis	  et	  al.,	  2008;	  Allen	  and	  Barres,	  2009;	  Nag,	  2011;	  Sun	  and	  
Jakobs,	  2011).	  These	  types	  of	  structural	  alterations	  can	  be	  observed	  not	  only	  at	  
the	  level	  of	  their	  soma	  and	  primary	  processes,	  but	  also	  at	  the	  level	  of	  their	  fine,	  
distal	   processes	   that	   enwrap	   synapses.	   Indeed,	   one	   single	   astrocyte	   has	   been	  
estimated	   to	   enwrap	   around	   4-­‐8	   neuronal	   cell	   bodies	   and	   300-­‐600	   neuronal	  
processes	  (Halassa	  et	  al.,	  2007).	  This	  ability	  of	  astrocytes	  to	  interact	  with	  several	  
neurons	   facilitates	   their	   influence	  upon	  the	   local	  microenvironment	   (Halassa	  et	  
al.,	  2007).	  
	  
The	   attenuated	   morphological	   transformation	   in	   Cln3-­‐/-­‐	   astrocytes,	   which	   was	  
observed	  initially	  in	  vivo	  and	  is	  replicated	  here	  in	  vitro	  (Chapter	  3,	  Figures	  3.1	  and	  
3.8)	  may	   alter	   their	   functional	   repertoire.	   For	   instance,	   long-­‐term	   potentiation	  
has	   been	   shown	   to	   increase	   the	   surface	   area	   of	   the	   astrocyte	   process	  
enwrapping	   a	   synapse	   and	   the	   number	   of	   synapses	   enwrapped	   by	   a	   single	  
astrocyte	   (Lushnikova	   et	   al.,	   2009).	   Astrocytes	   also	   show	   a	   morphological	  
response	   to	   glutamate	   released	   from	   neurons	   by	   increasing	   their	   number	   of	  
filapodia	  (Cornell-­‐Bell	  et	  al.,	  1990b).	  Importantly,	  such	  morphological	  plasticity	  of	  
astrocytes	  may	  form	  the	  mechanistic	  basis	  for	  the	  correct	  release	  of	  neuroactive	  
molecules	   such	  as	   glutamate,	  ATP	  and	  D-­‐serine	   from	  astrocytes	   in	   response	   to	  
synaptic	   activity	   (Bezzi	   et	   al.,	   2004;	   Zhang	   et	   al.,	   2004;	   Mothet	   et	   al.,	   2005;	  
Pascual	  et	  al.,	  2005),	  as	  well	  as	  the	  correct	  positioning	  of	  glutamate	  transporters	  
that	  are	  essential	  for	  uptake	  of	  excess	  glutamate	  from	  the	  synaptic	  cleft	  (Huang	  
and	  Bergles,	  2004).	  Lastly,	  such	  re-­‐arrangement	  of	  astrocyte	  processes	  has	  been	  
suggested	   to	   be	   involved	   in	   stabilization	   of	   the	   structure	   of	   dendritic	   spines	  
(Murai	  et	  al.,	  2003;	  Carmona	  et	  al.,	  2009;	  Filosa	  et	  al.,	  2009).	  This	  is	  achieved	  by	  
localized	  expression	  of	  the	  glycosyl-­‐phosphatidylinositol	  (GPI)	  –	  anchored	  glyco-­‐
protein	  ephrin-­‐A3	  upon	  the	  astrocyte	  processes	  that	  envelop	  the	  synapse	  (Murai	  
et	   al.,	   2003).	   Ephrin-­‐A3	   subsequently	   activates	   the	   tyrosine	   kinase	   receptor	  
EphA4	   located	   on	   dendritic	   spines	   of	   adjacent	   neurons,	   and	   induces	   spine	  
retraction.	   In	   contrast,	   the	   inhibition	  of	   such	   interactions	  was	   shown	   to	  distort	  
spine	   shape	   and	   organization	   in	   hippocampal	   slices	   (Murai	   et	   al.,	   2003).	   This	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astrocyte-­‐neuron	   crosstalk	   is	   widely	   dependent	   on	   these	   dynamic	   changes	   in	  
astrocyte	   structure	   and	  may	   be	   compromised	   in	   Cln3-­‐/-­‐	   astrocytes,	   since	   even	  
under	   basal	   conditions	   these	   cells	   display	   morphological	   differences,	   having	  
larger	   and	   rounder	   cell	   bodies	   than	   WT	   astrocytes.	   This	   may	   result	   in	  
developmental	   differences	   between	   the	   brains	   of	   WT	   and	   Cln3-­‐/-­‐	   mouse	  
embryos,	  since	  during	  development	  and	  early	  postnatal	  stages,	  such	  problems	  in	  
morphological	   dynamics	   could	   directly	   lead	   into	   altered	   astrocyte-­‐neuron	  
crosstalk.	   Subsequently,	   this	   could	   gradually	   result	   in	   progressive	   changes	   in	  
neuronal	  function	  given	  the	  importance	  of	  astrocyte-­‐neuron	  crosstalk	  to	  synaptic	  
functioning	  and	  plasticity	   (Carmona	  et	  al.,	   2009;	   Filosa	  et	   al.,	   2009).	   The	  direct	  
impact	   of	   Cln3-­‐/-­‐	   glial	   cells	   on	   the	   morphological	   appearance	   (soma	   size	   and	  
neurite	   complexity)	   of	   both	  WT	   and	   Cln3-­‐/-­‐	   neurons	   was	   investigated	   in	   these	  
studies	   using	   co-­‐culture	   experiments	   and	   these	   results	   will	   be	   presented	   in	  
Chapter	  6.	  
	  
Reactive	   astrocytes	   undergo	   dramatic	   morphological	   changes	   in	   the	   diseased	  
brain,	  and	  they	  have	  been	  shown	  to	  develop	  highly	  hypertrophied,	  thick	  primary	  
processes,	  which	  can	  extend	  toward	  the	  core	  region	  of	  an	  injury	  (Wilhelmsson	  et	  
al.,	  2004).	  Given	  their	  close	  relationship	  with	  neurons	  and	  their	  ability	  to	  secrete	  
neuroactive	   substances,	   these	   hypertrophied	   astrocytes	   are	   considered,	   in	  
certain	   circumstances,	   to	   be	   vital	   for	   neuronal	   protection	   and	   regeneration	   as	  
well	  as	  for	  wound	  healing,	  whereas	   in	  other	  contexts	  they	  have	  been	  shown	  to	  
negatively	   impact	   neuronal	   regeneration	   and	   survival	   (Sofroniew,	   2009;	  
Sofroniew	  and	  Vinters,	  2010;	  Zamanian	  et	  al.,	  2012).	  Our	  data	  reveal	  that	  Cln3-­‐/-­‐	  
astrocytes	   display	   an	   attenuated	   ability	   to	   change	   their	   morphology	   upon	  
activation	  with	   LPS/IFNγ	   (see	   Chapter	   3,	   Figure	   3.8).	   Of	   direct	   relevance	  when	  
considering	  the	  cytoskeleton,	  astrocyte	  morphology	  and	  disease	  progression,	  is	  a	  
recent	   study	   revealing	   the	   contribution	   of	   astrocytes	   and	   their	   intermediate	  
filaments	  to	  the	  pathological	  progression	  of	  INCL	  (Macauley	  et	  al.,	  2011).	  It	  was	  
established	   that	   the	   additional	   absence	   of	   the	   intermediate	   filament	   proteins	  
GFAP	   and	   vimentin	   in	   Ppt1-­‐/-­‐	  mice	   (GFAP-­‐/-­‐Vimentin-­‐/-­‐Ppt1-­‐/-­‐),	   accelerated	   their	  
disease	   progression,	   suggesting	   that	   endogenous	   activation	   of	   astrocytes	   is	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protective	   against	   subsequent	   neuronal	   loss	   in	   INCL	   (Macauley	   et	   al.,	   2011).	  
Unlike	   in	   INCL,	  where	  a	  profound	  astrocytosis	   is	  observed,	   the	   failure	  of	  Cln3-­‐/-­‐	  
astrocytes	   to	   fully	   morphologically	   transform	   could	   result	   in	   a	   loss	   of	   this	  
protective	  influence	  of	  astrocytes.	  The	  generation	  of	  mice	  where	  only	  astrocytes	  
carry	   the	   Cln3	  mutations	  will	   help	   to	   identify	   the	   precise	   role	   of	   these	   cells	   in	  
JNCL	  pathogenesis.	  	  	  
	  
Microtubules,	  actin	  and	  a	  variety	  of	  actin-­‐binding	  proteins	  have	  been	  shown	  to	  
be	  involved	  in	  the	  morphological	  transformation	  of	  astrocytes	  (Ridet	  et	  al.,	  1997;	  
Small	  et	  al.,	  1999;	  Derouiche	  et	  al.,	  2002;	  Burgos	  et	  al.,	  2007).	  Myosin	  has	  also	  
been	   implicated	   in	   this	   process,	   since	   myosin	   enables	   cell	   contraction	   and	  
formation	   of	   extensions	   via	   its	   association	   with	   actin	   (Padmanabhan	   and	  
Shelanski,	   1998).	   As	   stated	   above,	   CLN3	   has	   been	   suggested	   to	   interact	   with	  
myosin	  (Getty	  et	  al.,	  2011).	  This	  interaction	  could	  provide	  a	  potential	  mechanistic	  
explanation	   for	   the	   lack	   of	   morphological	   transformation	   in	   Cln3-­‐/-­‐	   astrocytes	  
that	   we	   have	   observed.	   In	   addition,	   the	   Rho	   small	   GTPases	   are	   important	  
regulators	  of	  shape,	  adhesion	  and	  cell	  movements	  (Chen	  et	  al.,	  2006).	  As	  a	  step	  
towards	   identifying	  potential	  biomarkers	  and	  modifier	  genes,	  which	  may	  affect	  
the	   clinical	   progression	   of	   JNCL,	   genetic	   alterations	   in	   JNCL	   patients	   were	  
examined	  (Lebrun	  et	  al.,	  2011).	  Among	  such	  dysregulated	  genes	  was	  the	  guanine	  
nucleotide	   exchange	   factor	   1	   for	   small	   GTPases	   of	   the	   Ras	   family	   (RAPGEF1),	  
which	  activates	  downstream	  GTPases	  like	  Rho	  (Lebrun	  et	  al.,	  2011).	  Thus,	  altered	  
activation	  of	  Rho	  GTPases	  by	  RAPGEF1	  could	  lead	  to	  the	  observed	  compromised	  
morphological	   response	   in	  Cln3-­‐/-­‐	   astrocytes.	   Indeed,	  RAPGEF1	  plays	  a	   role	   in	  a	  
range	   of	   signal	   transduction	   pathways	   involved	   in	   regulation	   of	   growth,	  
differentiation,	  neuronal	  migration	  and	  radial	  glia	  attachment,	  especially	  during	  
brain	  development	  (Tanaka	  et	  al.,	  1994;	  Erickson	  and	  Cerione,	  2004;	  Richardson	  
et	  al.,	  2004;	  Rossman	  et	  al.,	  2005;	  Voss	  et	  al.,	  2008).	  One	  could	  directly	  test	  the	  
affect	   of	   alterations	   in	   activity	   of	   Rho	   GTPases	   on	   RAPGEF1	   in	   astrocytes	   by	  
either	   depleting	   or	   overexpressing	   this	   Rho	   activator,	   or	   by	   using	  
pharmacological	  agents	  to	  regulate	  Rho	  activity.	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Particularly	   interesting	   from	   a	   clinical	   perspective	   is	   the	   involvement	   of	  
astrocytes	   in	   epileptogenesis,	   which	   is	   one	   of	   the	   most	   prominent	   clinical	  
features	  of	  JNCL.	  Such	  mechanisms	  could	  include	  the	  Ca2+	  dependent	  release	  of	  
glutamate	   by	   astrocytes	   that	   directly	   excite	   neighboring	   neurons,	   or	   impaired	  
astrocytic	  glutamate	  and	  K+	  uptake	   (Tian	  et	  al.,	   2005;	  de	  Lanerolle	  et	  al.,	   2010;	  
Seifert	  and	  Steinhäuser,	  2011;	  Losi	  et	  al.,	  2012).	  Either	  of	  these	  events	  may	  result	  
in	   the	   formation	   of	   a	   hyperexcitable	   astrocyte-­‐neuron	   network,	   which	   could	  
cause	  a	  seizure.	  It	  may	  be	  that	  a	  disrupted	  cytoskeletal	  organization	  that	  results	  
in	  a	  dysfunctional	  morphological	  response,	  could	  also	  lead	  to	  alterations	  in	  both	  
glutamate	  and	  K+	  homeostasis	   in	  Cln3-­‐/-­‐	  astrocytes	  and	  thus	  contribute	  towards	  
increased	   seizure	   probability.	   Indeed,	   excess	   extracellular	   glutamate	   in	   Cln3-­‐/-­‐	  
mice	   (Chattopadhyay	   et	   al.,	   2002)	   and	   moderately	   altered	   expression	   of	   the	  
glutamate	  transporters	  EAAT1	  and	  EAAT2,	  that	  are	  expressed	  by	  astrocytes,	  have	  
been	  shown	   in	   JNCL	  patient	  samples	   (Hachiya	  et	  al.,	  2006).	  Additionally,	  we	  go	  
on	   to	   show	   that	   glutamate	   clearance	   is	   impaired	   in	   Cln3-­‐/-­‐	   astrocytes	   (Results	  
Chapter	   4,	   Figure	   4.11),	   and	   that	   Cln3-­‐/-­‐	   neurons	   have	   a	   distally	   located	   AIS	  
possibly	  due	  to	  hyperactivation	  (see	  Chapter	  5,	  Figures	  5.5-­‐5.10).	  	  	  	  
In	  this	  study	  immunolabeling	  with	  GFAP	  was	  used	  to	  visualize	  the	  morphology	  of	  
WT	   and	   Cln3-­‐/-­‐	   astrocytes,	   despite	   the	   fact	   that	   GFAP	   labeling	   does	   not	   fully	  
represent	   the	   complexity	   of	   astrocyte	   morphology	   (Bushong	   et	   al.,	   2002;	  
Verkhratsky	  and	  Butt,	  2007;	  Theodosis	  et	  al.,	   2008;	   Song	  et	  al.,	   2009;	  Matyash	  
and	  Kettenmann,	  2010;	  Sofroniew	  and	  Vinters,	  2010;	  Nag,	  2011;	  Sun	  and	  Jakobs,	  
2011).	   This	   is	   because	   distal	   astrocytic	   processes	   contain	   extremely	   small	  
amounts	  of	  intermediate	  filaments,	  including	  GFAP,	  and	  also	  not	  all	  astrocytes	  in	  
vitro	   express	   enough	   GFAP	   to	   enable	   immunocytochemical	   visualization.	  
Consequently,	   GFAP-­‐based	   labeling	   of	   astrocytes	   may	   significantly	  
underestimate	   the	   branching	   of	   their	   filamentous	   processes.	   Other	   labeling	  
methods	  such	  as	  Golgi	  staining,	  filling	  astrocytes	  with	  dyes,	  or	  the	  expression	  of	  
reporter	   proteins	   in	   astrocytes,	   have	   been	   demonstrated	   to	   provide	  markedly	  
more	  accurate	  illustrations	  of	  the	  structural	  complexity	  of	  astrocytes	  (Bushong	  et	  
al.,	   2002;	   Sun	   and	   Jakobs,	   2011).	   Nevertheless,	   labeling	   the	   WT	   and	   Cln3-­‐/-­‐	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astrocytes	  with	  GFAP	  provides	  a	  good	  comparison	  of	  the	  morphologies	  of	  these	  
two	  cell	  types	  under	  both	  basal	  and	  activated	  conditions.	  However,	   it	  would	  be	  
interesting	  to	  extend	  these	  studies	  on	  morphological	  differences	  between	  Cln3-­‐/-­‐	  
and	  WT	  astrocytes	  by	  using	  some	  of	  the	  other	  more	  complete	  labeling	  methods	  
available.	  	  
Cell	  proliferation	  defects	  in	  Cln3-­‐/-­‐	  astrocytes	  	  
Our	  data	   revealed	  evidence	   that	  Cln3-­‐/-­‐	   astrocytes	  proliferate	   less	  actively	   than	  
their	  wildtype	  counterparts	   (see	  Chapter	  3,	   Figure	  3.9).	  Generally,	  proliferation	  
of	  astrocytes	   in	   the	  adult	  brain	  has	  remained	  a	  controversial	   issue.	  Radial	  glial-­‐	  
based	   production	   of	   astrocytes	   stops	   shortly	   after	   birth,	   and	   in	   the	   post-­‐natal	  
brain	  astrocytes	  have	  previously	  been	  thought	  to	  derive	  either	  from	  progenitors	  
in	   the	   SVZ,	   or	   from	   local	   proliferative	   astrocytes	   (Cameron	   and	   Rakic,	   1991;	  
Levison	  and	  Goldman,	  1993;	  Marshall	  et	  al.,	  2003;	  Kriegstein	  and	  Alvarez-­‐Buylla,	  
2009).	  Recently	   it	  has	  been	  reported	  that	  existing	  mature	  astrocytes	  within	  the	  
post-­‐natal	   cortex	   act	   as	   a	   major	   source	   of	   new	   astrocytes	   (Ge	   et	   al.,	   2012).	  
However,	  generally	  in	  the	  healthy	  post-­‐natal	  brain,	  astrocyte	  turnover	  is	  very	  low	  
and	   the	   majority	   of	   mature	   astrocytes	   are	   post-­‐mitotic	   and	   long-­‐lasting	   cells	  
(Skoff	   and	   Knapp,	   1991;	   Norton	   et	   al.,	   1992;	   Bush	   et	   al.,	   1999;	   Horner	   et	   al.,	  
2000;	   Colodner	   et	   al.,	   2005).	   Astrocyte	   proliferation	   in	   different	   pathological	  
scenarios	  has	  also	  turned	  out	  to	  be	  a	  rather	  controversial	   issue	  (Sofroniew	  and	  
Vinters,	   2010),	   mostly	   due	   to	   lack	   of	   appropriate	   astrocyte-­‐specific	   markers	  
making	   it	   difficult	   to	   distinguish	   all	   astrocytes	   regardless	   of	   their	   maturation	  
state.	   In	   some	   pathological	   conditions	   where	   reactivation	   of	   astrocytes	   is	  
relatively	   mild,	   proliferation	   does	   not	   occur	   (Sofroniew,	   2009;	   Sofroniew	   and	  
Vinters,	   2010).	   However,	   in	   extremely	   severe	   situations,	   such	   as	   in	   cases	   of	  
infection	   and	   acute	   demyelinating	   lesions,	   where	   reactive	   astrocytosis	   is	   very	  
aggressive,	  actively	  dividing	  astrocytes	  have	  been	  reported	  in	  human	  specimens	  
(Colodner	   et	   al.,	   2005;	   Sofroniew	   and	   Vinters,	   2010),	   although	   the	   source	   of	  
these	  newly	  dividing	  astrocytes	   is	  not	  well	  understood	  (Bush	  et	  al.,	  1999;	  Buffo	  
et	   al.,	   2008;	   Gadea	   et	   al.,	   2008;	   Carlén	   et	   al.,	   2009;	   Sofroniew,	   2009).	  
Nevertheless,	   the	  ability	   to	  proliferate	  can	  be	  seen	  as	  an	   important	  part	  of	   the	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biology	  of,	   at	   least	   some,	   astrocytes	  under	  both	  physiological	   and	  pathological	  
conditions	  (Zamanian	  et	  al.,	  2012).	  Our	  data	  revealed	  that	  although	  the	  number	  
of	  Ki67	  proliferating	  astrocytes	  did	  not	  differ	  between	  WT	  and	  Cln3-­‐/-­‐	  astrocytes,	  
the	  Cln3-­‐/-­‐	   astrocytes	  divided	  more	  slowly,	  as	   indicated	  by	   the	  number	  of	  BrdU	  
expressing	   cells	  being	   significantly	   reduced	   in	   these	   cultures	   (Chapter	  3,	   Figure	  
3.9).	  The	  number	  of	  actively	  proliferating	  astrocytes	  (percentage	  of	  BrdU+	  cells)	  
was	   reduced	   in	   Cln3-­‐/-­‐	   astrocyte	   cultures	   under	   both	   basal	   and	   activated	  
conditions	   (Chapter	   3,	   Figure	   3.9).	   Lack	   of	   astrocyte	   proliferation	   during	   early	  
development	   (potentially	   associated	   with	   lack	   of	   CLN3	   function)	   could	   affect	  
neuronal	  guidance	  and	  process	  extension	  (Powell	  and	  Geller,	  1999;	  Emsley	  et	  al.,	  
2004).	  Indeed,	  it	  has	  been	  shown	  that	  in	  the	  cerebellum	  of	  Cln3-­‐/-­‐	  mice,	  activated	  
Bergmann	  glia	  were	  found	  within	  regions	  displaying	  dramatic	  Purkinje	  cells	   loss	  
was	   evident,	   and	   remaining	   Purkinje	   cells	   displayed	   defective	   migration,	  
neuritogenesis,	   and	   maturation	   (Weimer	   et	   al.,	   2009).	   This	   provides	   some	  
evidence	   that	   glial	   responses	   can	   negatively	   influence	   neuronal	   biology	   in	   the	  
Cln3-­‐/-­‐	  mouse	  brain.	  	  	  	  	  
	  
The	   proliferation	   of	   astrocytes	   in	   JNCL	   mice	   has	   been	   studied	   indirectly	   by	  
quantifying	   the	   number	   of	   S100β,	   a	   calcium	   binding	   protein	   expressed	  
predominantly	   in	   astrocytes	   regardless	   of	   their	   activation	   status	   (Boyes	   et	   al.,	  
1986),	   positive	   astrocytes	   in	   Cln3Δex7/8	   mice	   in	   brain	   regions	   where	   reactive	  
astrocytosis	  and	  subsequent	  neuronal	  loss	  were	  the	  most	  prominent	  (Pontikis	  et	  
al.,	   2005).	   In	   this	   study,	   no	   significant	   change	   in	   the	  number	  of	   S100β	  positive	  
astrocytes	   was	   found,	   either	   in	   the	   primary	   somatosensory	   barrel	   field	   cortex	  
(S1BF)	   or	   hippocampal	   CA1	   of	   Cln3Δex7/8	   mice,	   compared	   with	   wild-­‐type	  
littermate	  controls	  (Pontikis	  et	  al.,	  2005).	  Similar	  counts	  of	  the	  number	  of	  S100β	  
positive	   astrocytes	   were	   also	   made	   in	   Ppt1-­‐/-­‐	   mice,	   where	   significantly	   more	  
S100β	  positive	  astrocytes	  was	  observed	  in	  both	  the	  S1BF	  and	  CA1	  compared	  to	  
healthy	   controls	   (Parviainen,	  unpublished	  data).	  Based	  on	   these	  data	  astrocyte	  
numbers	  do	  appear	  to	  increase	  in	  at	  least	  some	  mice	  models	  of	  NCLs,	  whereas	  in	  
JNCL	  such	  an	  increase	  in	  astrocyte	  number	  does	  not	  occur.	  A	  thorough	  analysis	  
of	  glial	  proliferation	  in	  human	  JNCL	  brain	  sections	  is	  yet	  to	  be	  undertaken.	  In	  fact,	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such	  studies	  have	  never	  been	  conducted	  in	  any	  form	  of	  NCLs.	  This	  could	  plausibly	  
be	  achieved	  by	  identifying	  proliferating	  cells	  with	  the	  proliferation	  marker	  MIB-­‐1	  
in	   association	   with	   different	   glial	   cell	   specific	   markers,	   such	   as	   GFAP	   for	  
astrocytes	   and	   CD68	   for	   microglia.	   However,	   studies	   on	   lymphoblasts	   derived	  
from	   JNCL	   patients,	   and	   on	   immortalized	   JNCL	   lymphoblast	   cell	   lines,	   have	  
reported	   reduced	  growth	   rates	   in	   these	  mutant	  cell-­‐types	  compared	   to	  normal	  
cells	  (Persaud-­‐Sawin	  et	  al.,	  2002).	  This	  slower	  growth	  was	  not	  accompanied	  by	  a	  
reduced	  rate	  of	  thymidine	  incorporation	  into	  DNA,	  indicating	  that	  cell	  cycle	  entry	  
is	   not	   altered	   in	   these	   types	  of	   CLN3	  deficient	   cells.	   Alternatively,	   the	   reduced	  
BrdU	  incorporation	  observed	  in	  the	  present	  study	  suggests	  that	  Cln3-­‐/-­‐	  astrocytes	  
have	   a	   slower	   cell	   cycle	   time.	   Thus,	   perhaps,	   CLN3	   deficiency	   alters	   both	   the	  
entry	  and	  progression	  of	  cell	  cycle	  differently	  in	  different	  cell-­‐types.	  	  
	  
What	   could	   the	   slower	  division	  of	  Cln3-­‐/-­‐	   astrocytes	  mean?	   If	   indeed,	   astrocyte	  
division	   was	   also	   slower	   in	   Cln3-­‐/-­‐	   mice,	   this	   could	   lead	   to	   a	   smaller	   astrocyte	  
population	  and	  a	  net	  reduction	  in	  levels	  of	  secretion	  of	  molecules	  generated	  by	  
activated	  astrocytes.	  Subsequently,	  this	  could	  have	  either	  a	  negative	  or	  positive	  
impact	   on	   ongoing	   neurodegeneration	   in	   the	   Cln3-­‐/-­‐	   mice	   brain,	   since	   these	  
molecules	  could	  be	  involved	  in	  regulation	  of	  inflammation	  response,	  controlling	  
axonal	   regeneration,	   neuroprotection	   or	   reestablishments	   of	   proper	   neuronal	  
connectivity	  (Ridet	  et	  al.,	  1997;	  Dong	  and	  Benveniste,	  2001;	  Liberto	  et	  al.,	  2004;	  
Di	   Giovanni	   et	   al.,	   2005;	   Byrnes	   et	   al.,	   2007;	   Bélanger	   and	   Magistretti,	   2009;	  
Sofroniew	  and	  Vinters,	   2010;	   Zamanian	   et	   al.,	   2012).	   The	  purpose	  of	   activated	  
proliferating	  astrocytes	  remain	  elusive,	  yet	  the	  cell	  cycle	  plays	  a	  key	  role	   in	  this	  
process	   (Sherr,	   1996;	   Kato	   et	   al.,	   2003).	   Cell	   cycle	   progression	   is	   controlled	   by	  
two	   classes	   of	   proteins:	   the	   cyclins	   and	   cyclin-­‐dependent	   kinases	   (CDKs)	  
(Vermeulen	  et	  al.,	  2003).	  Moreover,	  by	  inhibiting	  the	  cell	  cycle	  via	  manipulating	  
the	  activity	  of	  these	  cell	  cycle	  regulators	  astrocyte	  activation	  can	  be	  reduced	  (Di	  
Giovanni	   et	   al.,	   2005;	  Wang	   et	   al.,	   2008).	   This	   reduction	  was	   accompanied	   by	  
decreased	   neuronal	   apoptosis,	   smaller	   lesion	   volume,	   and	   reduced	   glial	   scar	  
formation	  in	   in	  vivo	  models	  of	  MCAO,	  photothrombotic	   ischemia	  and	  traumatic	  
brain	   injury	   (Di	   Giovanni	   et	   al.,	   2005;	   Wang	   et	   al.,	   2008).	   Thus,	   in	   JNCL	   the	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disease-­‐associated	   reduced	   rate	   of	   astrocyte	   proliferation	   might	   also	   play	   a	  
positive	  role	  in	  the	  progression	  of	  this	  disease.	  	  
Alterations	  in	  endo/lysosomal	  distribution	  and	  maturation	  in	  Cln3-­‐/-­‐	  astrocytes	  	  
Lysosomes	  are	  dynamic	  cellular	  organelles,	  whose	  positioning	   in	  a	  cell	   is	  highly	  
regulated.	   Indeed,	  one	  of	   the	  key	  elements	  of	   the	  overall	  cell	  physiology	   is	   the	  
correct	   localization	   and	   expression	   of	   relevant	   endo-­‐lysosomal	   proteins	   to	  
ensure	  efficient	  degradation	  and	  recycling	  of	  cellular	  waste	  (Lippincott-­‐Schwartz	  
and	  Fambrough,	  1986;	  Theodosis	  et	  al.,	  2008;	  van	  Meel	  and	  Klumperman,	  2008).	  
Early	  endosome	  expression	  and	  localization	  was	  not	  altered	   in	  Cln3-­‐/-­‐	  astrocytes	  
(Chapter	  3,	  Figure	  3.12).	  However,	  Cln3-­‐/-­‐	  astrocytes	  showed	  specific	  alterations	  
in	   both	   the	   number	   of	   late	   endosomes	   and	   lysosomes,	   and	   the	   localization	   of	  
these	   compartments	   within	   the	   cell	   when	   compared	   to	  WT	   astrocytes.	   These	  
findings	   correlate	   well	   with	   the	   suggested	   cellular	   functions,	   and	   primary	  
localization	   of	   the	   CLN3	   protein,	   which	   both	   point	   towards	   endo/lysosomal	  
pathways	   (Fossale	   et	   al.,	   2004;	   Kyttälä	   et	   al.,	   2004;	   2005;	  Metcalf	   et	   al.,	   2008;	  
Getty	  and	  Pearce,	  2011;	  Uusi-­‐Rauva	  et	  al.,	  2012).	  The	  connection	  between	  CLN3	  
deficiency	   and	   compromised	   endo-­‐lysosomal	   organization	   has	   been	  
demonstrated	   in	  other	  models	   for	   JNCL	   (Fossale	  et	  al.,	  2004;	  Uusi-­‐Rauva	  et	  al.,	  
2012).	  For	  example,	  early	  and	   late	  endosomal	  compartments	  were	  found	  to	  be	  
more	   dispersed	   in	   Cln3Δex7/8	   cerebellar	   neurons	   compared	   to	   WT	   controls	  
(Fossale	   et	   al.,	   2004),	   as	  were	   late	   endosomes	   in	  Cln3-­‐/-­‐	   astrocytes	   (Chapter	   3,	  
Figures	   3.11	   and	   3.13).	   On	   the	   other	   hand,	   over-­‐expression	   of	   the	   protracted	  
disease	  causing	   late	  endosome/lysosome	   localized	  CLN3E295K	  mutation	   (Aberg	  
et	   al.,	   2009)	   in	   HeLa	   cells	   caused	   perinuclear	   clustering	   of	   late	  
endosomes/lysosomes	   (Uusi-­‐Rauva	   et	   al.,	   2012).	   Importantly,	   analyses	   of	  
fibroblasts	   isolated	   from	   JNCL	   patients	   (compound	   heterozygous	   mutation	  
(CLN3E295K/CLN3Δex7/8)	  or	  homozygous	  mutation	  (CLN3Δex7/8/CLN3Δex7/8))	  showed	  
perinuclear	   clustering	   of	   late	   endosomal	   compartments	   (Ogata	   and	   Kosaka,	  
2002;	  Huang	  and	  Bergles,	  2004;	  Luiro	  et	  al.,	  2004;	  Oberheim	  et	  al.,	  2006;	  Uusi-­‐
Rauva	   et	   al.,	   2012).	   Such	   findings	   supporting	   perinuclear	   accumulation	   of	  
endo/lysosomes	   upon	   CLN3	   mutation	   are	   in	   contrast	   with	   the	   findings	   in	   this	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study	   that	   show	   the	   opposite	   effect.	   This	  may	   be	   a	   reflection	   of	   the	   different	  
roles	  CLN3	  plays	  in	  different	  cell	  types,	  that	  may	  be	  dictated	  by	  cell	  type	  specific	  
localization	  of	  CLN3	  (Getty	  and	  Pearce,	  2011;	  Mole	  et	  al.,	  2011).	  Alternatively,	  it	  
has	  been	  suggested	  that	  mutations	  in	  Cln3	  rather	  than	  complete	  deletion	  of	  Cln3	  
may	   impact	   the	   cell	   differently	   due	   to	   a	   functionally	   active	   truncated	   CLN3	  
(Kitzmüller	   et	   al.,	   2008;	   Sarpong	   et	   al.,	   2009).	   This	   view,	   however,	   has	   been	  
challenged	   by	   evidence	   showing	   that	   truncated	   CLN3	   is	   not	   functionally	   active	  
(Phillips	  et	  al.,	  2005;	  Getty	  and	  Pearce,	  2011).	  	  
	  
The	  more	  dispersed	  cytosolic	   localization	  of	  Rab7	  expressing	   late	  endosomes	  in	  
Cln3-­‐/-­‐	  astrocytes	  correlates	  well	  with	  recent	  findings	  indicating	  that	  CLN3	  have	  a	  
direct	  connection	  with	  active	  GTP-­‐Rab7	  and	   its	  effector	  RILP	   (Uusi-­‐Rauva	  et	  al.,	  
2012).	   The	   Rab7	   protein	   is	   required	   for	   aggregation	   and	   fusion	   of	   late	  
endosomes	  with	  lysosomes	  and	  is	  important	  for	  maintenance	  of	  the	  perinuclear	  
localization	  of	   lysosomes	   (Bucci	  et	  al.,	   2000).	  Thus,	   it	   is	   feasible	   that	   the	  direct	  
connection	  between	  Rab7	  and	  CLN3	  is	   important	  for	  the	  correct	  transportation	  
and	  maturation	   of	   late	   endosomal	   and	   lysosomal	   compartments	   in	   astrocytes.	  
The	   reduced	   number	   of	   LAMP1/Cathepsin	   D	   expressing	   mature	   lysosomes	   at	  
perinuclear	   regions	   in	   Cln3-­‐/-­‐	   astrocytes	   (Results	   Chapter,	   Figure	   3.10),	   would	  
further	  suggest	  that	  transport	  from	  the	  TGN	  to	  late	  endo/lysosomes	  is	  impaired	  
in	  these	  cells.	  Furthermore,	  one	  of	  the	  potential	  interaction	  partners	  of	  CLN3	  is	  a	  
protein	  called	  Hook1	  (Luiro	  et	  al.,	  2004;	  Weimer	  et	  al.,	  2005),	  which	  may	  connect	  
CLN3	  to	  the	  microtubular	  cytoskeleton	  and	  members	  of	  the	  Rab	  GTPases	  family	  
involved	   in	   endocytosis	   and	   fusion	   of	   late	   endosomes	  with	   lysosomes	   (Krämer	  
and	  Phistry,	  1996;	  1999;	  Walenta	  et	  al.,	  2001;	  Richardson	  et	  al.,	  2004;	  Weimer	  et	  
al.,	  2005).	   Indeed,	  receptor-­‐mediated	  endocytosis	  was	  found	  defected	   in	  CLN3-­‐
deficient	   JNCL	   fibroblasts,	  which	  may	  potentially	  be	  explained	  by	  dysfunctional	  
CLN3-­‐Hook1	   interaction	   (Luiro	   et	   al.,	   2004).	   Additionally,	   co-­‐
immunoprecipitation	  studies	  suggested	  that	  Hook1	  may	  interact	  with	  endocytic	  
Rab7,	  9	  and	  11,	  possibly	   linking	  CLN3	  further	  with	  membrane	  trafficking	  events	  
(Luiro	  et	  al.,	  2004).	  Hence,	  disturbance	  in	  the	  interactions	  between	  Hook1-­‐Rab7-­‐
CLN3,	  or	  Rab7-­‐RILP-­‐CLN3	  protein	  complexes	  and	  the	  cytoskeleton	  may	  possibly	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provide	  a	  mechanistic	  explanation	  for	  the	  altered	  localization	  of	  endo/lysosonal	  
structures	   in	   Cln3-­‐/-­‐	   astrocytes.	   One	   could	   test	   the	   assembly	   of	   such	   protein	  
complexes	   in	  astrocytes	  by	   carrying	  out	  binding	   studies.	   Furthermore,	   it	  would	  
be	  interesting	  to	  explore	  the	  dynamic	  trafficking	  of	  endo/lysosomes	  in	  live	  Cln3-­‐/-­‐	  
astrocytes	   by	   using	   fluorescently	   labeled	   endo/lysosomal	   markers,	   such	   as	  
LysoTracker	   Red,	   LAMP-­‐1	   and	   LAMP-­‐2,	   under	   different	   pharmacological	  
manipulations.	   For	   example,	   induced	   alterations	   in	   the	   intracellular	   pH,	  where	  
acidification	   redistributes	   lysosomes	   from	   their	   predominantly	   perinuclear	  
location	   towards	   the	   cell	   periphery,	   could	  be	  used	   (Korolchuk	  and	  Rubinsztein,	  
2011).	   Prior	   to	   such	   studies,	   one	   would	   need	   to	   examine	   the	   pH	   in	   the	  
endo/lysosomal	   compartments	   in	   the	   Cln3-­‐/-­‐	   astrocytes,	   since	   CLN3	   (or	   btn1	  
protein	  in	  yeast)	  has	  been	  linked	  with	  regulation	  of	  lysosomal	  pH	  (Pearce	  et	  al.,	  
1999b;	  Golabek	  et	  al.,	  2000;	  Kim	  et	  al.,	  2003;	  Padilla-­‐Lopez	  and	  Pearce,	  2006).	  In	  
particular,	  CLN3	  deficiency	  has	  been	  shown	  to	  acidify	  lysosomal	  compartments	  in	  
human	   HEK-­‐293	   cells	   (Golabek	   et	   al.,	   2000),	   which	   itself	   could	   explain	   the	  
observed	   alterations	   in	   the	   distribution	   of	   lysosomes	   in	   Cln3-­‐/-­‐	   astrocytes.	  
Additionally,	  measuring	  endocytosis	  in	  these	  cells	  would	  give	  a	  direct	  answer	  to	  
the	  question	  of	  whether	  this	  process	  is	  affected	  in	  Cln3-­‐/-­‐	  astrocytes.	  	  
	  
The	   normally	   appearing	   expression	   and	   distribution	   of	   the	   early	   endosomes	   in	  
Cln3-­‐/-­‐	   astrocytes	   suggests	   that	   the	   CLN3	   protein	   is	   not	   involved	   in	   early	  
endosomal	   related	   processing	   in	   astrocytes.	   This	   finding	   agrees	   with	   previous	  
research	  showing	  that	  early	  endosomal	  expression	  patterns	  were	  not	  effected	  in	  
HELA	  cells	  over-­‐expressing	  the	  mutant	  CLN3E295K	  (Uusi-­‐Rauva	  et	  al.,	  2012).	  On	  
the	   other	   hand,	   early	   endosomal	   expression	   has	   been	   found	   to	   be	   altered	   in	  
Cln3Δex7/8	   cerebellar	   neurons	   (Fossale	   et	   al.,	   2004).	   It	   may	   well	   be	   that	   CLN3	  
protein	   dictates	   early	   endosome	   transportation	   and	   expression	   only	   in	   specific	  
cell	  types,	  such	  as	  in	  neuronal	  cells,	  via	  still	  unidentified	  mechanisms.	  	  
	  
Generally,	  endo/lysosomes	  are	  dynamic	  organelles	  and	   their	   localization	  within	  
cells	  is	  highly	  regulated	  and	  can	  be	  altered	  in	  response	  to	  various	  treatments.	  In	  
addition	   to	   alterations	   in	   intracellular	   pH,	   which	   is	   one	   of	   the	   best-­‐known	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effectors	  of	  intracellular	  lysosomal	  positioning,	  the	  positioning	  of	  lysosomes	  can	  
also	  be	  affected	  by	  nutrients,	  where	  addition	  of	  growth	  factors	  and	  amino	  acids	  
may	   induce	   movements	   of	   lysosomes	   toward	   the	   plasma	   membrane,	   while	  
starvation	   may	   lead	   to	   increased	   perinuclear	   localization	   (Korolchuk	   and	  
Rubinsztein,	  2011;	  Korolchuk	  et	  al.,	  2011).	  However,	  the	  physiological	  relevance	  
of	  such	  alterations	  in	  lysosomal	  positioning	  is	  not	  fully	  understood.	  One	  possible	  
explanation	  for	  the	  preferred	  perinuclear	  localization	  of	  lysosomes	  could	  be	  that	  
this	   positioning	   enables	   efficient	   fusion	   of	   autophagosomes,	   that	   are	   also	  
delivered	   to	   perinuclear	   regions	   via	   microtubule-­‐dependent	   transport,	   with	  
lysosomes	   (Korolchuk	   and	   Rubinsztein,	   2011).	   Autophagy	   is	   a	   nonselective	  
process	   involved	   in	   recycling	   of	   cytoplasmic	   components,	   and	   impaired	  
autophagy	  has	  been	  revealed	  to	  be	  a	  common	  feature	  of	  neurodegeneration	  in	  
Parkinson,	  Huntington,	  and	  Alzheimer	  diseases,	   and	   in	   LSDs	   (Rubinsztein	  et	  al.,	  
2005;	  Cao	  et	  al.,	  2006;	  Wong	  and	  Cuervo,	  2010;	  Korolchuk	  et	  al.,	  2011;	  Li	  et	  al.,	  
2011).	   Indeed,	   CLN3	   deficiency	   has	   also	   been	   linked	  with	   disrupted	   autophagy	  
(Cao	  et	   al.,	   2006;	  Chang	  et	   al.,	   2011).	   Interestingly,	   recently	   it	  was	   shown	   that	  
lysosomal	   storage	   in	   Sumf1-­‐/-­‐	   astrocytes	   (derived	   from	   a	   mouse	   model	   of	  
multiple	   sulfatase	   deficiency,	   MSD,	   which	   is	   a	   type	   of	   severe	   LSD)	   impairs	  
autophagosome	  maturation,	  which	   in	   turn,	   has	   an	   impact	  upon	   the	   survival	   of	  
co-­‐cultured	   cortical	   neurons	   (Di	   Malta	   et	   al.,	   2012b).	   As	   such,	   abnormal	  
autophagy	   caused	   by	   altered	   lysosomal	   positioning	   and	   maturation	   in	   Cln3-­‐/-­‐	  
astrocytes	  may	  also	  be	  an	  important	  component	  of	  neurodegeneration	  in	  JNCL.	  	  	  
	  
Taken	   together	   results	  described	   in	   this	   chapter,	   and	   in	   the	   literature,	   indicate	  
that	  changes	  in	  the	  endo/lysosomal	  compartments	  is	  a	  common	  feature	  in	  cells	  
carrying	   a	   Cln3	   mutation	   or	   deletion,	   although	   the	   exact	   changes	   observed	  
appear	  to	  be	  cell	  type	  specific.	  One	  potential	  common	  factor	  in	  all	  of	  these	  cell	  
types	  in	  which	  altered	  endo/lysosomal	  membrane	  trafficking	  has	  been	  observed	  
could	  be	  Rab7,	  since	  many	  abnormalities	  associated	  with	  CLN3	  deficiency	  can	  be	  
connected	   with	   functions	   related	   to	   Rab7.	   For	   example,	   CLN3	   deficiency	   has	  
been	   shown	   to	   affect	   lysosomal/vacuolar	   pH	   and	   size,	   processing	   of	   lysosomal	  
hydrolases,	  as	  well	  as	  autophagy	  (Pearce	  et	  al.,	  1999a;	  Holopainen	  et	  al.,	  2001;	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Fossale	  et	  al.,	  2004;	  Gachet	  et	  al.,	  2005;	  Cao	  et	  al.,	  2006),	  and	  all	  of	  these	  listed	  
abnormalities	  have	  previously	  been	  linked	  with	  dysfunctional	  Rab7	  (Press	  et	  al.,	  
1998;	  Bucci	  et	  al.,	  2000;	  Gutierrez	  et	  al.,	  2004;	  Jäger	  et	  al.,	  2004;	  Vanlandingham	  
and	  Ceresa,	  2009).	  One	  common	  link	  between	  CLN3	  and	  Rab7	  is	  their	  localization	  
in	   autophagosomal	   membranes,	   and	   they	   have	   both	   been	   proposed	   to	   be	  
involved	   in	  the	  maturation	  of	  autophagic	  vesicles	  (Jäger	  et	  al.,	  2004;	  Cao	  et	  al.,	  
2006).	   Indeed,	  careful	   investigation	  of	  autophagy	  pathways	   in	  Cln3-­‐/-­‐	  astrocytes	  
should	   be	   carried	   out	   to	   investigate	   this	   issue.	   For	   instance,	   live	   cell	   imaging	  
could	  be	  used	  to	  monitor	  trafficking	  of	  a	  fluorescently	  labeled	  LC3	  (widely	  used	  
autophagy	  marker)	  and	  labeled	  endo/lysosomal	  proteins	  in	  these	  cells	  (Bampton	  
et	  al.,	  2005).	  	  	  
	  
Are	  primary	  astrocyte	  cultures	  a	  good	  tool	  to	  study	  the	  biology	  of	  Cln3-­‐/-­‐	  
astrocytes?	  	  
Using	   an	   in	   vitro	   system	   in	   this	   study	   enabled	   us	   to	   address	   specific	   questions	  
regarding	  the	  function	  of	  Cln3-­‐/-­‐	  astrocytes	  in	  a	  controlled	  environment,	  without	  
the	   interference	   of	   factors	   present	   in	   an	   in	   vivo	   setting.	   Such	   in	   vitro	  
investigations	   of	   astrocyte	   biology	   has	   not	   previously	   been	   carried	   out	   in	   the	  
field	  of	  NCL	   research,	   yet	   this	  approach	  has	  been	   frequently	  used	   to	   study	   the	  
biological	   functions	   of	   astrocytes	   and	   the	   process	   of	   reactive	   astrocytosis	  
(Bolaños	  et	  al.,	  1996;	  Duan	  et	  al.,	  1999;	  Guthrie	  et	  al.,	  1999;	   John	  et	  al.,	  1999;	  
Lepekhin	   et	   al.,	   2001;	   Stewart	   et	   al.,	   2002;	  Morita	   et	   al.,	   2003;	   Paradisi	   et	   al.,	  
2004;	  Gegg	  et	  al.,	  2005;	  Frade	  et	  al.,	  2008;	  Lange	  et	  al.,	  2012).	  However,	  several	  
limitations	   regarding	   the	   use	   of	   this	   purification	   method	   have	   emerged.	   For	  
instance,	  it	  has	  been	  speculated	  that	  astrocytes	  isolated	  using	  this	  method	  may	  
be	  more	  similar	  to	  radial	  glia,	  astrocyte	  progenitor	  cells	  or	  perhaps	  even	  reactive	  
astrocytes,	  than	  the	  mature	  astrocytes	  of	  adult	  brain	  (Cahoy	  et	  al.,	  2008;	  Foo	  et	  
al.,	   2011;	   Lange	   et	   al.,	   2012).	   Additional	   causes	   for	   concern	   include	   the	  use	  of	  
serum	   in	   the	   growth	  medium,	   since	   prolonged	   culturing	   of	   cells	   in	   serum	  may	  
cause	   irreversible	   alterations	   in	   their	   properties	   (Jochems	   et	   al.,	   2002;	  
Gstraunthaler,	   2003;	   van	  der	  Valk	  et	   al.,	   2004).	   Indeed,	  using	   serum	   to	   culture	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any	  primary	  CNS	  derived	  cells,	  may	  be	  considered	  to	  be	  non-­‐physiological,	  since	  
most	   proteins	   present	   in	   serum	  would	   not	   be	   present	   in	   the	   CNS	  due	   to	   their	  
inability	   to	   cross	   the	   blood-­‐brain	   barrier	   (Banks,	   1999).	   Regardless	   of	   these	  
limitations,	   these	   astrocyte	   cultures	  provided	  an	  extremely	  useful	   tool	   offering	  
novel	  insights	  on	  how	  lack	  of	  CLN3	  could	  influence	  the	  biology	  of	  these	  cells,	  and	  
allowed	   direct	   comparison	   between	   them	   and	   ‘normal’	   wild-­‐type	   astrocytes.	  
Important	  finding	  made	  in	  such	  cultures	  can	  be	  further	  explored	  and	  confirmed,	  
for	  example,	  in	  organotypic	  slices	  or	  in	  vivo.	  	  
	  
Also,	  these	  astrocyte	  cultures	  were	  not	  100%	  pure,	  displaying	  a	  purity	  of	  >	  98%.	  
The	   very	   few	  other	   cells	   present	   in	   these	   cultures	  were	  mainly	  microglia	   cells,	  
and	   rarely	   oligodendrocytes.	   It	   is	   crucially	   important	   to	   ensure	   microglia	  
contamination	   is	   as	   minimal	   as	   possible	   in	   such	   cultures	   for	   several	   reasons:	  
microglia	  and	  astrocytes	  differ	  in	  their	  ontogenic	  origin	  (monocytic	  for	  microglia,	  
and	   neuroectodermal	   for	   astrocytes),	   astrocytes	   and	   microglia	   cells	   have	  
different	  physiological,	   and	   functional	   responses	  upon	  activation	   (Saura,	  2007).	  
For	  instance,	  microglia	  may	  carry	  out	  functions	  that	  were	  previously	  thought	  to	  
be	  astrocyte	  driven,	  such	  as	  LPS	  induced	  expression	  of	  nitric	  oxide	  synthetase-­‐2	  
(NOS2)	  and	  subsequent	  production	  of	  NO	  in	  culture	  conditions	  (Solà	  et	  al.,	  2002;	  
Saura,	  2007).	  Ideally	  one	  would	  wish	  to	  work	  with	  100%	  pure	  astrocyte	  cultures	  
to	   ensure	   that	   any	   results	   obtained	   can	   be	   directly	   attributed	   to	   these	   cells,	  
rather	   than	   any	   cell-­‐contaminants	   in	   the	   culture,	   or	   interactions	   of	   those	  
contaminating	   cells	   with	   the	   astrocytes.	   Given	   that	   the	   presence	   of	   the	   other	  
glial	   cells	   was	   minimal	   within	   these	   astrocyte	   cultures,	   the	   data	   we	   have	  
obtained	  most	  likely	  provide	  an	  accurate	  representation	  of	  differences	  between	  
WT	   and	   Cln3-­‐/-­‐	   astrocytes.	   Working	   with	   100%	   pure	   cultures	   might	   also	   be	  
problematic.	  Astrocytes	  do	  not	  exist	  in	  isolation	  in	  the	  CNS,	  instead	  existing	  and	  
functioning	   in	   close	   collaboration	   with	   other	   cell	   types,	   such	   as	   microglia	   and	  
neurons.	  As	  such,	  any	  results	  obtained	  from	  pure	  astrocyte	  cultures	  may	  not	  be	  a	  
true	  reflection	  of	  the	  complex	  range	  of	  astrocyte	  functions	   in	  vivo.	  Perhaps	  the	  
best	   answer	   is	   to	   initially	   examine	   the	   basic	   cellular	   biology	   in	   the	   simplest	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possible	  setting	  then	  move	  on	  to	  testing	  the	  gained	  information	  in	  more	  complex	  
settings;	  mixed	  cultures	  with	  different	  cell-­‐types.	  	  
	  
Moreover,	  one	  could	  argue	  whether	  the	  use	  of	  LPS/IFNγ	  to	  activate	  astrocytes	  is	  
valid.	   JNCL	   disease	   mechanisms	   include	   neuroinflammation	   (Seehafer	   et	   al.,	  
2011),	   and	   astrocyte	   and	  microglia	   activation	   has	   been	   implicated	   to	   underlie	  
these	   inflammatory	   responses	   in	   the	   CNS	   (Allan	   and	   Rothwell,	   2003;	   Schubert	  
and	   Ferroni,	   2003;	   Zhang	   et	   al.,	   2010;	   Garwood	   et	   al.,	   2011;	   Ransohoff	   and	  
Brown,	   2012).	   Several	   in	   vitro	   studies	   have	   demonstrated	   that	   astrocytes	  
respond	   to	   cytokines	   like	   IFNγ	   and	   to	  microbial	   products	   like	   LPS,	   and	   that	   in	  
astrocytes	   IFNγ	   synergizes	   with	   LPS	   to	   produce	   a	   maximal	   transcriptional	  
response	   (Chung	   and	   Benveniste,	   1990;	   Bolaños	   et	   al.,	   1994;	   Schindler	   and	  
Brutsaert,	  1999;	  Gegg	  et	  al.,	  2005;	  Sheng	  et	  al.,	  2011;	  Cortés-­‐Vieyra	  et	  al.,	  2012).	  
Thus,	  using	   these	  agents	   to	  mimic	  astrocyte	  activation	   should	  closely	   resemble	  
the	   reactive	   astrocytosis	   taking	   place	   in	   the	   Cln3-­‐/-­‐	   mouse	   brain.	   Indeed,	   this	  
activation	  method	  resulted	  in	  very	  similar	  changes	  in	  cultured	  WT	  astrocytes	  to	  
those	   observed	   to	   occur	   in	   vivo	   upon	   reactive	   astrocytosis;	   morphological	  
transformation,	  upregulation	  of	  intermediate	  filaments,	  and	  secretion	  of	  soluble	  
factors	  such	  as	  chemokines	  and	  cytokines	  (Chapter	  4,	  Tables	  4.1	  and	  4.2,	  Figure	  
4.7).	   Despite	   these	   limitations,	  we	   are	   confident	   that	   these	   cultures	   provide	   a	  
valid	  method	   for	   comparing	   the	   biological	   differences	   between	   Cln3-­‐/-­‐	  and	  WT	  
astrocytes.	   Ultimately,	   the	   significance	   of	   any	   fundamental	   findings	   from	   this	  
study	   will	   need	   to	   be	   confirmed	   in	   JNCL	   animal	   models,	   or	   perhaps	   in	  
differentiated	  iPS	  cells	  derived	  from	  JNCL	  patients.	  For	  example,	  mouse	  models	  
where	  only	  astrocytes,	  only	  microglia,	  or	  both	  microglia	  and	  astrocytes	  carry	  the	  
Cln3	   deletion,	   would	   enable	   the	   precise	   contribution	   of	   glial	   cells	   to	  
neurodegeneration	   in	   JNCL	   to	  be	  determined.	  Additionally,	   the	   role	  of	   reactive	  
astrocytosis	  in	  JNCL	  could	  be	  studied	  by	  depleting	  intermediate	  filaments	  (GFAP	  
and	   vimentin)	   required	   for	   astrocyte	   activation	   in	   a	   Cln3-­‐/-­‐	   mouse	   model	  	  	  	  	  	  	  
(GFAP-­‐/-­‐/Vim-­‐/-­‐/Cln3-­‐/-­‐),	   much	   as	   has	   already	   been	   done	   in	   Ppt1	   deficient	   mice	  
(Macauley	   et	   al.,	   2011).	   Together,	   these	   studies	   would	   establish	   whether	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astrocytes	   are	   indeed	   integral	   players	   in	   the	   neuropathology	   in	   JNCL,	   and	  
whether	  modulation	  of	  astrocyte	  activation	  will	  impact	  disease	  progression.	  	  
	  
Taken	  together,	  we	  have	  shown	  that	   isolated	  Cln3-­‐/-­‐	  astrocytes	  differ	  from	  their	  
healthy	   counterparts.	   They	   have	   an	   abnormal	   cytoskeletal	   organization	   and	  
enlarged	  cell	  body	  size,	  together	  with	  altered	  intermediate	  filament	  expression.	  
The	   expression	   of	   endosomal/lysosomal	   proteins	   and	   the	   distribution	   of	   these	  
compartments	  within	   the	   cytosol	  were	   also	   observed	   to	   be	   altered.	   Indeed,	   it	  
was	   demonstrated	   that	  Cln3-­‐/-­‐	  astrocytes	   showed	   an	   attenuated	  morphological	  
response	  to	  activation	  and	  an	  attenuated	  ability	  to	  proliferate,	  both	  of	  which	  are	  
dependent	  on	  functional	  cytoskeletal	  re-­‐organization.	  Furthermore,	  such	  deficits	  
are	  bound	  to	  affect	  other	  typical	  astrocyte	  functions	  that	  also	  depend	  upon	  the	  
cytoskeleton,	   such	  as	  protein	   secretion	  and	  uptake,	  as	  well	   as	  migration.	  Thus,	  
our	  next	  step	  was	  to	   investigate	  these	  possibilities	   (Chapter	  4).	  Having	  a	  better	  
picture	   of	   how	   Cln3-­‐/-­‐	   astrocytes	   differ	   from	   their	   healthy	   counterparts	   will	  
ultimately	   aid	   our	   understanding	   on	   the	   role	   of	   astrocytes	   as	   a	   potential	  
mediator	  of	  neuropathological	  events	  in	  JNCL.	  	  	  
	   	  
	   163	  
Chapter	  4	  
Functional	  differences	  between	  
WT	  and	  Cln3-­‐/-­‐	  astrocytes	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4.1	  Introduction	  	  
It	   has	   become	   increasingly	   apparent	   that	   astrocytes	   are	   not	   just	   passive	  
bystanders	  with	  supportive	  roles,	  but	  perform	  many	  vital	  functions	  in	  the	  healthy	  
CNS,	   including	  being	  active	  contributors	  to	  many	  higher	  brain	  functions	  such	  as	  
information	   processing	   and	   the	   formation	   of	   neuronal	   circuits	   (Sofroniew	   and	  
Vinters,	   2010).	   Furthermore,	   astrocytes	   are	   also	   active	   players	   in	   pathological	  
situations	   when	   they	   may	   contribute	   to,	   or	   play	   primary	   roles	   in,	   clinical	   and	  
pathological	  mechanisms	  (Liberto	  et	  al.,	  2004;	  Seifert	  et	  al.,	  2006;	  Barres,	  2008;	  
De	  Keyser	  et	  al.,	  2008;	  Sofroniew,	  2009;	  Takano	  et	  al.,	  2009).	  Thus,	  mutations	  in	  
astrocyte-­‐expressed	   genes	   that	   result	   in	   protein	   dysfunction	   may	   impact	   on	  
many	   brain	   functions	   and	   on	   disease	   progression.	  We	   have	   shown	   that	  Cln3-­‐/-­‐	  
astrocytes	  have	  a	  disrupted	  cytoskeleton,	  probably	  resulting	  in	  their	  attenuated	  
ability	   to	  morphologically	   transform	  and	  to	  proliferate,	  as	  well	  as	  alterations	   in	  
their	   endo/lysosomal	   system.	   These	   defects	   could	   impact	   on	   their	   ability	   to	  
perform	  a	  range	  of	  functions	  that	  are	  vital	  in	  a	  healthy	  brain	  (see	  Chapter	  3	  and	  
discussion	   therein).	   Indeed,	   various	   reports	   have	   suggested	   that	   defects	   in	  
several	   important	   cellular	   functions	   in	   which	   astrocytes	   are	   involved,	   may	  
contribute	  to	  the	  neuropathological	  events	  observed	  in	  JNCL.	  These	  include	  early	  
deficits	   in	   the	   regulation	  of	  oxidative	  stress	   (Benedict	  et	  al.,	  2007;	  Tuxworth	  et	  
al.,	   2011);	   the	   inability	   to	   effectively	   regulate	   extracellular	   glutamate	   levels,	  
together	   with	   an	   increased	   vulnerability	   of	   glutamate	   receptors	   towards	  
excitotoxicty	  (Chattopadhyay	  et	  al.,	  2002;	  Pears	  et	  al.,	  2005;	  Kovács	  and	  Pearce,	  
2008;	  Finn	  et	  al.,	  2011;	  Kovács	  et	  al.,	  2011);	  and	  an	  early	  inflammatory	  reaction	  
(Lim	  et	  al.,	  2006;	  2007;	  Seehafer	  et	  al.,	  2011).	  In	  this	  chapter	  we	  therefore	  tested	  
the	  ability	  of	  Cln3-­‐/-­‐	  astrocytes	  to	  carry	  out	  a	  range	  of	  basic	  functions.	  	  	  
	  
Calcium	   based	   signaling	   forms	   the	   basis	   for	   astrocyte-­‐astrocyte	   and	   astrocyte-­‐
neuron	  intercellular	  communication	  in	  the	  CNS	  (Cornell-­‐Bell	  et	  al.,	  1990a;	  Charles	  
et	   al.,	   1991;	  Haydon,	   2001;	   Zorec	  et	   al.,	   2012).	   For	   instance,	   ER	  mediated	  Ca2+	  
release	   via	   activation	  of	   the	  PLC	  pathway	   is	   required	   for	   gliotransmission	   -­‐	   the	  
secretion	  of	  molecules	   such	  as	  ATP,	   glutamate	  and	  D-­‐serine	  by	   astrocytes	   that	  
directly	  regulate	  the	  function	  of	  both	  neuronal	  and	  glial	  cells	  (Zorec	  et	  al.,	  2012)	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(see	  Chapter	  1,	  section	  1.3).	  Thus,	  basic	  Ca2+	  signaling	  mechanisms	  including	  the	  
increase	   in	   intracellular	   Ca2+	   upon	   ATP	   application;	   ER	   Ca2+	   release	   upon	  
inhibition	   of	   the	   SERCA-­‐calcium	   pump	   (to	   evaluate	   ER	   Ca2+	   content)	   and	  
subsequent	   clearance	   of	   the	   cytosolic	   Ca2+,	   and	   spontaneous	   Ca2+	   oscillations,	  
were	  compared	   in	  WT	  and	  Cln3-­‐/-­‐	  astrocytes.	  From	  these	  experiments	   it	  will	  be	  
possible	   to	   determine	   whether	   the	   response	   to	   external	   stimuli	  
(neurotransmitters),	   the	   intracellular	   pathways	   involved	   in	   Ca2+	   regulation,	   or	  
intercellular	  communication	  via	  a	  propagating	  Ca2+	  wave	  have	  remained	  intact	  in	  
Cln3-­‐/-­‐	  astrocytes.	  	  	  
	  
One	  the	  most	  fundamental	  ways	  in	  which	  astrocytes	  influence	  neuronal	  and	  glial	  
function	   in	   the	   CNS	   is	   via	   the	   secretion	   of	   soluble	   factors	   (Ridet	   et	   al.,	   1997;	  
Bélanger	   and	   Magistretti,	   2009;	   Sofroniew	   and	   Vinters,	   2010).	   To	   begin	  
examining	   whether	   protein	   secretion	   by	   astrocytes	   may	   play	   a	   role	   in	  
inflammation	  and	  progression	  of	  neurodegeneration	  in	  the	  Cln3-­‐/-­‐	  mouse	  brain,	  a	  
protein	  secretion	  assay	  to	  quantify	  a	  number	  of	  cytokines,	  chemokines,	  growth	  
factors	  and	  anti-­‐	  and	  pro-­‐inflammatory	  factors	  was	  performed.	  To	  gain	  a	  better	  
understanding	   on	   the	   contribution	   of	   astrocytes	   to	   the	   increased	   levels	   of	  
oxidative	  damage	  observed	   in	   JNCL,	   the	   ability	   of	  Cln3-­‐/-­‐	   astrocytes	   to	  produce	  
and	  secrete	  glutathione	  (the	  major	  antioxidant	  in	  the	  brain)	  was	  also	  examined.	  
Finally,	  to	  meet	  the	  high	  energy	  demands	  of	  neurons,	  astrocytes	  secrete	  lactate,	  
thus	  this	  ability	  was	  also	  tested.	  In	  addition	  to	  protein	  secretion,	  astrocytes	  also	  
contribute	   to	   neuron	   function	   and	   survival	   by	   keeping	   the	   levels	   of	   various	  
neurotransmitters	  under	  control	  with	  the	  synaptic	  cleft	  (Anderson	  and	  Swanson,	  
2000;	  Oliet	  et	  al.,	  2001;	  Sattler	  and	  Rothstein,	  2006;	  Seifert	  et	  al.,	  2006;	  Goubard	  
et	  al.,	  2011).	  Given	  that	  glutamate	  mediated	  excitotoxity	  has	  been	  suggested	  to	  
play	  a	  role	  in	  neurodegeneration	  in	  Cln3-­‐/-­‐	  mice	  (Kovács	  et	  al.,	  2006;	  Kovács	  and	  
Pearce,	   2008;	   Finn	   et	   al.,	   2011;	   Kovács	   et	   al.,	   2011),	   the	   ability	   of	   Cln3-­‐/-­‐	  
astrocytes	  to	  take	  up	  glutamate	  was	  also	  explored.	  	  
	  
It	   is	   well	   established	   that	   astrocytes	   are	   relatively	   mobile	   cells,	   and	   reactive	  
astrocytes	  have	  been	  shown	  to	  migrate	   to	   the	  site	  of	   injury	  and	   in	   some	  cases	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form	   an	   isolating	   glial	   scar	   (Silver	   and	   Miller,	   2004;	   Borán	   and	   García,	   2007).	  
Migration	   defects	   have	   been	   shown	   previously	   in	  Cln3-­‐/-­‐	   embryonic	   fibroblasts	  
(Getty	   et	   al.,	   2011),	   suggesting	   that	   the	   CLN3	   protein	   is	   involved	   in	   re-­‐
arrangement	   of	   the	   cytoskeleton	   enabling	   migration	   to	   take	   place.	   Hence,	  
potential	  migration	  defects	  were	  explored	  in	  Cln3-­‐/-­‐	  astrocytes	  by	  carrying	  out	  a	  
scratch	  assay.	  	  
	  
These	   functional	  assays	  will	  provide	  essential	   insights	   into	  the	  biology	  of	  Cln3-­‐/-­‐	  
astrocytes,	  and	  how	  their	  functional	  range	  is	  altered	  compared	  to	  healthy	  cells.	  
Also,	  these	  studies	  may	  reveal	  novel	  aspects	  of	  CLN3	  function	  in	  glial	  cells.	  Most	  
importantly,	  any	  alterations	  in	  the	  astrocyte-­‐related	  functions	  mentioned	  above	  
could	   have	   a	   significant	   impact	   on	   neuronal	   function	   and	   survival	   in	   JNCL.	  
Indeed,	   as	   discussed	   above,	  many	   of	   the	   problems	   reported	   in	   the	   JNCL	   brain	  
could	  arise	  by,	  or	  be	  exacerbated	  by,	  defects	  in	  astrocyte	  biology.	  Thus,	  a	  better	  
understanding	  of	  any	  defects	  in	  astrocyte	  functioning	  could	  provide	  novel	  targets	  
for	  therapies	  in	  JNCL.	  	  
	  
4.2	  Results	  
Calcium	  signaling	  in	  Cln3-­‐/-­‐	  astrocytes	  
Calcium	  is	  the	  most	  widespread	  signaling	  molecule	  used	  by	  all	  types	  of	  living	  cells	  
(Berridge	  et	   al.,	   2000;	  Carafoli,	   2002;	  Petersen	  et	   al.,	   2005).	  Numerous	   cellular	  
mechanisms	  exist	  to	  keep	  the	  intracellular	  calcium	  ([Ca2+]i)	  concentration	  tightly	  
controlled	   (concentration	   gradient	   between	   intracellular	   and	   extracellular	  
compartments	   is	   approximately	   20,000	   times)	   to	   ensure	   efficient	   Ca2+	   based	  
signaling	  and	  also	  to	  remove	  excess	  intracellular	  Ca2+	  due	  do	  its	  harmful	  effect	  on	  
biological	   pathways	   (Case	   et	   al.,	   2007).	   Astrocytes	   possess	   a	   chemical	   type	   of	  
excitability,	   which	   is	   based	   on	   movements	   of	   Ca2+	   between	   intracellular	  
compartments	   and	   cell	   membrane	   Ca2+	   fluxes	   (Verkhratsky	   and	   Kettenmann,	  
1996;	   Araque	   et	   al.,	   2001).	   This	   type	   of	   astrocyte	   Ca2+	   based	   excitability	   is	  
thought	   to	   form	   the	   basis	   for	   gliotransmission;	   a	   secretion	   of	   various	  
transmitters	   from	   astrocytes	   as	   a	   response	   to	   elevations	   in	   [Ca2+]i,	   which	   can	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signal	  to	  adjacent	  neurons	  or	  other	  glial	  cells	  (Zorec	  et	  al.,	  2012).	  Moreover,	  Ca2+	  
is	  exploited	  by	  astrocytes	  as	  an	  intercellular	  signal	  that	  enables	  the	  formation	  of	  
functionally	  connected	  astrocyte	  networks	  (Cornell-­‐Bell	  et	  al.,	  1990a;	  Dani	  et	  al.,	  
1992;	   Giaume	   and	   Venance,	   1998;	   Kuga	   et	   al.,	   2011).	   Astrocytes	   have	   been	  
shown	   to	   express	   numerous	   metabotropic	   receptors,	   that	   upon	   activation	  
ultimately	   trigger	   production	   of	   inositol	   1,4,5-­‐triphosphate	   (InsP3),	   leading	   to	  
InsP3-­‐induced	   calcium	   release	   from	   the	   ER	   (Kastritsis	   et	   al.,	   1992;	   Finkbeiner,	  
1993;	  Porter	  and	  McCarthy,	  1995;	  Kirischuk	  et	  al.,	  1996;	  Hamilton	  et	  al.,	  2008).	  
For	  example,	  ATP,	  which	  acts	  via	  P2Y-­‐receptors	  and	  the	  GTP-­‐binding	  protein	  Gq,	  
activates	  phospholipase	  C	  and	  subsequent	  formation	  of	  IP3.	  Upon	  binding	  to	  its	  
receptor	  (IP3-­‐receptor)	  located	  on	  the	  ER	  membrane,	  IP3	  initiates	  the	  opening	  of	  
this	   receptor	   leading	   to	   the	   release	  of	   stored	  Ca2+	  from	  the	  ER	   into	   the	  cytosol	  
resulting	  in	  the	  activation	  of	  a	  number	  of	  Ca2+	  dependent	  signaling	  mechanisms	  
(Fam	  et	  al.,	  2000;	  Hamilton	  et	  al.,	  2008).	  This	  type	  of	  IP3-­‐mediated	  release	  of	  Ca2+	  
from	   internal	   stores	   is	   a	   mechanism	   that	   is	   used	   by	   many	   classical	  
neurotransmitters	  including	  glutamate	  and	  acetylcholine	  (Ach)	  (Verkhratsky	  and	  
Kettenmann,	  1996;	  Verkhratsky	  et	  al.,	  1998).	  It	  has	  also	  been	  demonstrated	  that	  
intercellular	   diffusion	   of	   IP3	   via	   gap	   junctions	   and	   IP3-­‐induced	   Ca2+	   release,	  
together	   with	   ATP	   mediated	   signaling,	   represent	   the	   main	   mechanisms	  
governing	   the	   propagation	   of	   intercellular	   calcium	   waves	   that	   underlie	   long-­‐
range	   signaling	   in	   astrocyte	   networks	   (Guthrie	   et	   al.,	   1999;	   Kuga	   et	   al.,	   2011).	  
Numerous	  proteins	  are	  located	  in	  the	  ER	  that	  regulate	  the	  movements	  of	  [Ca2+]i	  
across	  its	  membrane,	  and	  help	  to	  maintain	  the	  high	  Ca2+	  gradient	  in	  the	  ER.	  For	  
example,	   an	   ATP-­‐dependent	   pump	   called	   smooth	   ER	   calcium	   ATPase	   (SERCA)	  
located	  in	  the	  ER	  membrane,	  is	  one	  of	  the	  main	  ways	  in	  which	  this	  high	  ER	  Ca2+	  
gradient	  is	  maintained	  in	  a	  cell	  (Mattson	  et	  al.,	  2000b).	  	  
	  
Many	  studies	  have	  illustrated	  that	  astrocytes	  have	  spontaneous	  Ca2+-­‐oscillations,	  
which	   occur	   independently	   without	   any	   externally	   applied	   stimulus,	   and	   that	  
such	   Ca2+	   signaling	  may	   be	   essential	   for	   communication	   between	   neurons	   and	  
astrocytes	  (Parri	  et	  al.,	  2001;	  Aguado	  et	  al.,	  2002;	  Nett	  et	  al.,	  2002).	  This	  increase	  
in	  intracellular	  Ca2+	  concentrations	  during	  spontaneous	  Ca2+	  oscillations	  is	  either	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initiated	   by	   the	   influx	   of	   extracellular	   Ca2+	   via	   voltage-­‐gated	   channels	   into	   the	  
cytosol	   (Parri	  et	  al.,	  2001;	  Aguado	  et	  al.,	  2002),	  or	  by	   release	   from	  the	  ER-­‐Ca2+	  
store	   (Parri	   and	   Crunelli,	   2003;	   Wang	   et	   al.,	   2006).	   These	   spontaneous	  
intracellular	  Ca2+	  signals	  have	  particular	  characteristics,	  such	  as	   large	  amplitude	  
and	   long	   duration.	   Furthermore,	   these	   oscillations	   may	   take	   place	  
asynchronously	   in	   the	   distal	   processes	   of	   astrocytes,	   or	   they	   may	   propagate	  
variable	  distances	  both	  intracellularly	  or	  intercellularly	  (Parri	  et	  al.,	  2001;	  Nett	  et	  
al.,	  2002;	  Hirase	  et	  al.,	  2004).	  	  
	  
No	  previous	  studies	  have	  been	  conducted	  to	  investigate	  the	  calcium	  signaling	  in	  
astrocytes	   in	   any	   of	   the	   different	   forms	   of	   NCLs.	   As	   such,	   this	   study	   provides	  
novel	  insights	  into	  the	  basic	  Ca2+-­‐based	  signaling	  properties	  of	  these	  cells.	  	  
Cln3-­‐/-­‐	  astrocytes	  have	  smaller	  and	  less	  frequent	  spontaneous	  calcium	  
oscillations,	  and	  do	  not	  form	  a	  synchronized	  calcium	  wave	  	  
To	   explore	   the	   spontaneous	   calcium	   oscillations	   in	   WT	   and	   Cln3-­‐/-­‐	   astrocytes,	  
cultures	  were	  prepared	  as	  described	   in	  Chapter	  2	  (Section	  2.3),	  then	  cells	  were	  
plated	   onto	   PDL	   coated	   25mm	   glass	   coverslips	   at	   a	   density	   of	   50,000	  
cells/coverslip	   to	   study	   spontaneous	   calcium	   oscillations	   in	   non-­‐sheet	   forming	  
(low	  density)	  astrocyte	  cultures;	  or	  at	  density	  of	  100,000	  cells/coverslip	  to	  study	  
spontaneous	   calcium	   oscillations	   in	   sheet-­‐forming	   (high	   density),	   astrocyte	  
cultures.	  	  
	  
Spontaneous	  calcium	  oscillations	  were	  analyzed	  within	  48	   -­‐72	  hours	  of	  plating.	  
[Ca2+]I,	  was	  measured	  using	  the	  ratiometric	  and	  sensitive	  calcium	  indicator,	  Fura-­‐
2.	   Cultures	   were	   incubated	   with	   Fura-­‐2	   AM,	   which	   is	   lipid	   soluble	   and	   thus	  
diffuses	  across	  the	  plasma	  membrane,	  in	  the	  presence	  of	  0.02%	  pluronic	  acid,	  to	  
aid	   loading,	   for	  a	  minimum	  of	  20	  minutes	  at	  37°C.	  Subsequently,	  cultures	  were	  
washed	   several	   times	   with	   recording	   medium	   (Chapter	   2,	   Section	   2.11).	   The	  
fluorescence	   measurements	   were	   obtained	   at	   room	   temperature	   using	   an	  
epifluorescence	  inverted	  microcope	  (Nikon,	  Japan)	  equipped	  with	  a	  20x	  fluorite	  
objective.	  In	  order	  to	  record	  the	  spontaneous	  Ca2+	  oscillations	  present	  in	  WT	  and	  
	   169	  
Cln3-­‐/-­‐	  astrocytes,	  cultures	  were	  left	  untouched	  for	  at	  least	  30	  -­‐	  45	  minutes	  (first	  
20	  minutes	  is	  illustrated	  in	  Figures	  4.1	  and	  4.2).	  
	  
When	  WT	  astrocytes	  were	  cultured	  as	  non-­‐sheet	  forming	  cells	  (low	  cell	  density)	  
they	  began	   to	   show	   spontaneous	   calcium	  oscillations	   approximately	   5	  minutes	  
after	  the	  start	  of	  the	  recordings,	  as	  can	  be	  seen	  from	  an	  increase	  in	  the	  ratio	  of	  
excitation	   at	   340nm	   and	   380nm	   (F	   340/380),	   which	   directly	   correlates	   with	  
increased	   [Ca2+]I	   (Figure	   4.1).	   Once	   initiated,	   these	   [Ca2+]I	   oscillations	   occurred	  
frequently	   and	   randomly	   in	  WT	   astrocytes	   (Figure	   4.1,	   grey	   bars	   illustrate	   the	  
frequency	   of	   the	   oscillations).	   The	   amplitude	   of	   these	   spontaneous	   calcium	  
oscillations	  was	  variable	  ranging	  from	  10%	  to	  120%	  above	  baseline	  (Figure	  4.1).	  
The	  spontaneous	  [Ca2+]I	  oscillations	  in	  non-­‐sheet	  forming	  Cln3-­‐/-­‐	  astrocytes	  were	  
much	   less	   frequent	   and	   had	   a	   smaller	   amplitude	   than	   those	   observed	   in	   WT	  
astrocytes	  (Figure	  4.1,	  compare	  the	  frequency	  and	  amplitude	  of	  the	  spontaneous	  
[Ca2+]I	  oscillations	  marked	  with	  grey	  between	  WT	  and	  Cln3-­‐/-­‐	  astrocyte	  cultures).	  
In	   addition,	   the	   initiation	   of	   the	   oscillations	   was	   more	   variable	   in	   Cln3-­‐/-­‐	  
astrocytes,	  ranging	  from	  a	  few	  minutes	  to	  around	  7	  -­‐	  8	  minutes	  after	  recordings	  
were	  started.	  As	  in	  WT	  cultures,	  the	  amplitudes	  of	  these	  oscillations	  in	  non-­‐sheet	  
forming	   Cln3-­‐/-­‐	   astrocytes	   were	   variable,	   generally	   ranging	   from	   10%	   to	   50%	  
above	  baseline,	  and	  rarely	  reaching	  more	  than	  100%	  above	  baseline	  (Figure	  4.1).	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Figure	   4.1.	   Cln3-­‐/-­‐	   astrocytes	   show	   specific	   alterations	   in	   spontaneous	   [Ca2+]I	  
oscillations.	   Recordings	  of	  Fura-­‐2	   fluorescence	   from	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  plated	  on	  PDL	  
coated	   25mm	   coverslip	   at	   a	   density	   of	   50,000	   cells/coverslip	   (non-­‐sheet	   forming,	   4.1)	   or	  
100,000/cells/coverslip	   (sheet	   forming,	   4.2).	   Spontaneous	   [Ca2+]I	   oscillations	   were	   measured	  
from	  undisrupted,	   non-­‐sheet	   forming	  WT	   and	  Cln3-­‐/-­‐	   astrocyte	   cultures	   under	   basal	   conditions	  
over	  a	  period	  of	  30-­‐45	  minutes,	  from	  which	  the	  first	  20	  minutes	   is	  shown.	  The	  figure	  illustrates	  
the	  spontaneously	  induced	  changes	  in	  [Ca2+]I	  in	  eight	  randomly	  selected	  WT	  and	  Cln3
-­‐/-­‐	  astrocytes	  
in	  one	  experiment.	  WT	  astrocytes	  had	  frequent,	  non-­‐synchronized	  and	  large	  spontaneous	  [Ca2+]I	  
oscillations	   marked	   with	   grey	   bars.	   The	   Cln3-­‐/-­‐	   astrocytes	   exhibited	   less	   frequent	   and	   smaller	  
spontaneous	   [Ca2+]I	   oscillations.	   Data	   is	   presented	   as	   340nm/380nm	   ratio,	   which	   directly	  
correlates	   with	   the	   change	   in	   intracellular	   free	   Ca2+	   levels.	   In	   total	   approximately	   30-­‐50	  
cells/experiment	  were	  recorded.	  This	  experiment	  was	  repeated	  twice.	  	  	  
	  
	  
In	   confluent,	   sheet-­‐forming	   astrocyte	   cultures	   waves	   of	   [Ca2+]I	  may	   propagate	  
from	  cell	  to	  cell	  (Cornell-­‐Bell	  et	  al.,	  1990a).	  This	  type	  of	  [Ca2+]I	  wave	  propagation	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between	  astrocytes	  may	  proceed	  with	  no	  obvious	  discontinuity,	  and	  with	  such	  a	  
high	   velocity	   that	   it	   appears	   that	   the	   closely	   connected	   cells	   exhibit	   a	  
simultaneous	   [Ca2+]I	   elevation,	   hence	   the	   name	   ‘calcium	   wave’.	   Also,	   these	  
intercellular	  calcium	  waves	  are	  distinguishable	   from	  spontaneous	  oscillations	   in	  
individual	  cells	  due	  to	  their	  larger	  amplitude	  and	  the	  prolonged	  plateau	  phase	  of	  
the	  [Ca2+]I	  elevation	  (Cornell-­‐Bell	  et	  al.,	  1990a).	  The	  mechanism	  enabling	  this	  type	  
of	  intercellular	  calcium	  signaling	  between	  astrocytes	  is	  not	  yet	  fully	  understood,	  
but	   is	   thought	  to	   involve	   intercellular	  diffusion	  of	   IP3	  via	  gap	   junctions	  and	  ATP	  
mediated	  signaling	  between	  adjacent	  astrocytes	  (Guthrie	  et	  al.,	  1999;	  Kuga	  et	  al.,	  
2011).	   Indeed,	   the	   formation	   of	   a	   propagating	   calcium	   wave,	   which	   initiated	  
approximately	   6min	   after	   the	   start	   of	   the	   recordings,	   was	   obvious	   in	   high-­‐
density,	   sheet-­‐forming	  WT	  astrocyte	   cultures	   (Figure	  4.2,	   synchronized	   calcium	  
wave	  marked	  with	  yellow	  bar).	  This	  synchronized,	  simultaneous	  [Ca2+]I	  elevation	  
among	  WT	  astrocytes	  had	  a	   typically	   large	  amplitude	   (from	  150%	  up	   to	  nearly	  
250%	   increase	  above	  baseline),	   and	  a	   clear	  plateau	  phase	  with	  prolonged	  high	  
intracellular	  calcium	  levels	  after	  the	  initiation	  of	  the	  wave	  (Figure	  4.2).	  In	  sheet-­‐
forming	   Cln3-­‐/-­‐	   astrocyte	   cultures,	   however,	   formation	   of	   a	   synchronized,	  
simultaneous	   [Ca2+]I	   elevation	   did	   not	   occur	   (Figure	   4.2).	   Instead,	   the	   Cln3-­‐/-­‐	  
astrocytes	  showed	  spontaneous	  calcium	  oscillations	  that	  did	  not	  propagate	  as	  a	  
wave.	   These	   spontaneous	   calcium	   oscillations	   occurred	   with	   a	   very	   low	  
frequency,	   similar	   to	   those	   observed	   in	   non-­‐sheet	   forming	   Cln3-­‐/-­‐	   astrocyte	  
cultures	   (compare	   frequency	   of	   spontaneous	   calcium	   oscillations	  marked	   with	  
grey	  in	  Cln3-­‐/-­‐	  astrocyte	  cultures	  in	  Figures	  4.1	  and	  4.2).	  However,	  most	  of	  these	  
[Ca2+]I	   oscillations	   in	   sheet-­‐forming	   Cln3-­‐/-­‐	   astrocyte	   cultures	   had	   a	   bigger	  
amplitude	   (ranging	   from	   10%	   to	   100%	   increase	   above	   baseline)	   than	   in	   non-­‐
sheet	  forming	  Cln3-­‐/-­‐	  astrocyte	  cultures	  (compare	  the	  amplitude	  of	  spontaneous	  
[Ca2+]I	   oscillations	   in	   Figures	   4.1	   and	   4.2).	   Overall,	   these	   results	   indicate	   that	  	  	  
Cln3-­‐/-­‐	  astrocytes	  have	  less	  frequent	  and	  smaller	  spontaneous	  [Ca2+]I	  oscillations	  
when	  compared	   to	  WT	  astrocytes.	  Moreover,	  Cln3-­‐/-­‐	  astrocytes	  do	  not	  create	  a	  
synchronized,	   propagating	   calcium	   wave	   suggesting	   that	   intercellular	   signaling	  
between	  Cln3-­‐/-­‐	  astrocytes	  is	  compromised.	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Figure	  4.2.	  Cln3-­‐/-­‐	   astrocytes	  do	  not	  generate	  a	   synchronized	  calcium	  wave.	   In	  
sheet-­‐forming	   WT	   astrocyte	   cultures	   a	   spontaneously	   occurring	   propagating	   [Ca2+]I	   wave	   was	  
generated,	  marked	  with	  yellow	  bar,	  whereas	  spontaneous	  Ca2+	  oscillations	  are	  marked	  with	  grey	  
bar.	  This	  synchronized	  [Ca2+]I	  wave	  had	  a	  large	  amplitude,	  and	  a	  prolonged	  plateau	  persisting	  for	  
several	   minutes	   after	   initiation.	   The	   sheet-­‐forming	   Cln3-­‐/-­‐	   astrocytes	   did	   not	   exhibit	   any	  
propagating	  calcium	  waves,	  instead,	  Cln3-­‐/-­‐	  astrocytes	  had	  non-­‐synchronized,	  spontaneous	  [Ca2+]I	  
elevations.	  In	  total	  40-­‐50	  cells/experiment	  were	  recorded.	  This	  experiment	  was	  repeated	  twice.	  	  
	  
One	  of	  the	  essential	  properties	  of	  astrocytes,	  which	  enables	  the	  intercytoplasmic	  
exchange	   of	   ions	   and	   small	   molecules,	   is	   that	   they	   are	   highly	   coupled	   by	   gap	  
junctions	  (Giaume	  and	  Venance,	  1998).	  Correct	  assembly	  of	  connexin	  proteins	  is	  
required	  for	  the	  formation	  of	  gap	  junctions	  and,	  in	  cultured	  astrocytes,	  the	  major	  
connexin	   is	   connexin	   43	   (Cx43)	   (Dermietzel	   et	   al.,	   1991;	   Giaume	   et	   al.,	   1991).	  
Indeed,	   synchronous	   [Ca2+]I	   waves	   that	   comprise	   hundreds	   of	   astrocytes	   have	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been	   proven	   to	   be	   sensitive	   to	   inhibition	   of	   gap	   junctions	   (Kuga	   et	   al.,	   2011).	  
Given	   that	   synchronous	   [Ca2+]I	   wave	   propagation	   did	   not	   occur	   in	   Cln3-­‐/-­‐	  
astrocyte	   cultures,	   Cx43	   expression	  was	   compared	   in	  WT	   and	  Cln3-­‐/-­‐	   astrocyte	  
cultures	   by	  means	   of	   fluorescence	   immunocytochemistry	   (Figure	   4.3).	   For	   this	  
experiment,	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  were	  plated	  onto	  PDL	  coated	  13mm	  glass	  
coverslips	  at	  a	  density	  of	  20,000	  cells/coverslip.	  Cultures	  were	  fixed	  with	  4%	  PFA	  
in	  PBS	  48h	  after	  plating	  and	  co-­‐labeled	  with	  antibodies	  against	  Cx43	  and	  GFAP.	  
Both	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  showed	  punctate	  Cx43	  staining	  localized	  relatively	  
evenly	  around	  the	  whole	  cell	  body,	  as	  visualized	  with	  GFAP	  (Figure	  4.3).	  Thus,	  no	  
dramatic	   difference	   in	   the	   localization	  of	   Cx43	  was	  observed	  between	  WT	  and	  
Cln3-­‐/-­‐	  astrocytes.	  However,	   there	  appeared	   to	  be	  more	  Cx43	  expression	   in	  WT	  
astrocytes	   particularly	   at	   cell-­‐to-­‐cell	   contact	   regions	   (marked	  with	   dashed	   line,	  
Figure	   4.3).	   To	   confirm	   this	   observation	   quantification	   of	   the	   levels	   of	   Cx43	  
expression	  in	  WT	  and	  Cln3-­‐/-­‐	  should	  be	  carried	  out.	  Additionally,	  the	  connectivity	  
between	   gap	   junctions	   (formed	   by	   connexin	   proteins)	   should	   be	   examined	   to	  
determine	   whether	   they	   are	   functionally	   intact	   in	   Cln3-­‐/-­‐	   astrocytes.	   However,	  
the	   observation	   that	   Cln3-­‐/-­‐	   astrocytes	   do	   express	   Cx43	   in	   a	   relatively	   similar	  
fashion	   to	   WT	   astrocytes	   suggests	   that	   gap	   junction	   formation	   is	   not	   overtly	  
disrupted	  in	  these	  cells.	  	  
	  
	  	  	  
Figure	  4.3.	  Connexin	  43	  is	  expressed	  by	  both	  Cln3-­‐/-­‐	  and	  WT	  astrocytes.	  WT	  and	  
Cln3-­‐/-­‐	  astrocyte	  cultures	  were	  stained	  with	  GFAP	  to	  visualize	  the	  astrocyte	  cell	  bodies	  and	  with	  
an	  antibody	  against	  connexin	  43	  (Cx43)	  and	  DAPI	  was	  used	  to	  visualize	  all	  nuclei.	  Both	  WT	  and	  
Cln3-­‐/-­‐	  astrocytes	  expressed	  Cx43,	  which	  was	  expressed	  throughout	  the	  cytosol	  of	  the	  cells	  with	  
no	  apparent	  difference	  in	  the	  localization.	  WT	  astrocytes	  express	  slightly	  more	  Cx43	  than	  Cln3-­‐/-­‐	  
astrocytes	  at	  cell-­‐to-­‐cell	  contact	  region	  marked	  with	  dashed	  line.	  Scale	  bar	  is	  20μm.	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Cln3-­‐/-­‐	  astrocytes	  have	  a	  normal	  response	  to	  ATP	  
It	   is	   well	   established	   that	   extracellular	   ATP	   can	   act	   as	   an	   activity-­‐dependent	  
signaling	  molecule,	  which	  is	  important	  for	  communication	  between	  neurons	  and	  
astrocytes	   (Fields	  and	  Stevens,	  2000;	  North	  and	  Verkhratsky,	  2006).	  ATP	  based	  
signaling	   is	   also	   important	   for	   propagation	   of	   the	   calcium	   wave,	   and	   thus	  
communication	  among	  astrocytes	  (Guthrie	  et	  al.,	  1999;	  Stout	  et	  al.,	  2002).	  Upon	  
binding	  to	  P2Y	  purinergic	  receptors,	  ATP	  induces	  PLC	  activation	  leading	  to	  IP3-­‐R	  
activation	  and	  release	  of	  Ca2+	  from	  the	  ER-­‐stores.	   In	  order	  to	  compare	  this	  ATP	  
induced	   Ca2+	   release	   from	   the	   ER	   in	   WT	   and	   Cln3-­‐/-­‐	   astrocytes,	   cultures	   were	  
established	   and	   the	   fluorescence	   based,	   ratiometric,	   calcium	   indicator,	   Fura-­‐2,	  
used	   to	   measure	   [Ca2+]I	   levels,	   as	   described	   above.	   Subsequent	   to	   Fura-­‐2AM	  
loading,	  cells	  were	  washed	  with	  recording	  medium	  and	  then	  the	  Ca2+	  recordings	  
were	  carried	  out	  in	  this	  same	  medium	  (see	  Chapter	  2,	  Section	  2.11).	  The	  addition	  
of	   ATP	   (100μM)	   took	   place	   approximately	   2	   minutes	   after	   the	   start	   of	   the	  
recordings.	  	  
	  
Examples	  of	  average	  Ca2+	  traces	  from	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  (50	  cells	  in	  each	  
case/experiment)	  upon	  ATP	  application	  are	  presented	   in	  Figure	  4.4	  A.	  This	  ATP	  
application	   induced	   a	   substantial,	   rapid	   increase	   in	   [Ca2+]I	   levels	   in	   both	   WT	  
(Δ(Max	   [Ca2+]I-­‐baseline)	   is	   2.44±0.42)	   and	   Cln3-­‐/-­‐	   (Δ(Max	   [Ca2+]I-­‐baseline)	   is	  
2.39±0.28)	   astrocytes,	   followed	   by	   a	   sustained	   (plateau)	   Ca2+	   elevation	   (Figure	  
4.4	   A	   and	   B).	   There	   was	   no	   significant	   difference	   in	   the	   elevation	   of	   [Ca2+]I	  
induced	  by	  ATP	  between	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  (Figure	  4.4	  B).	  To	  explore	  how	  
these	  cells	  return	  back	  to	  baseline	  following	  the	  ATP	  induced	  increase	   in	  [Ca2+]I	  
levels,	   the	   difference	   between	   the	   Maximum	   [Ca2+]I	   levels	   and	   [Ca2+]I	   levels	   2	  
minutes	  after	  ATP	  application	  were	  calculated	  (presented	  as	  Δ(Max	  [Ca2+]I-­‐[Ca2+]I	  
2	  min	  after	  ATP	  addition)	  (Figure	  4.4	  C).	  No	  significant	  difference	  in	  the	  ability	  of	  
WT	   and	   Cln3-­‐/-­‐	   astrocytes	   to	   return	   back	   to	   baseline	   was	   found	   (Figure	   4.4	   C,	  
Δ(Max	  [Ca2+]I-­‐[Ca2+]I	  2min	  after	  ATP	  addition)	  is	  1.68±0.31	  for	  WT	  astrocytes	  and	  
1.61±0.18	   for	   Cln3-­‐/-­‐	   astrocytes).	   These	   results	   suggest	   that	   WT	   and	   Cln3-­‐/-­‐	  
astrocytes	  have	  a	  very	  similar	  response	  to	  ATP,	  and	  that	  the	  cellular	  mechanisms	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involved	   in	   clearance	   of	   cytosolic	   Ca2+	   resulting	   from	   an	   ATP	   activated	   Ca2+	  
























Figure	  4.4.	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  show	  a	  similar	  response	  to	  ATP.	  Fura-­‐2	  was	  
used	  to	  measure	  changes	  in	  [Ca2+]I	  levels	  in	  both	  WT	  and	  Cln3
-­‐/-­‐	  astrocytes	  upon	  ATP	  application.	  
(A)	   Represents	   examples	   of	   typical	   calcium	   traces	   from	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   upon	   ATP	  
application	   (100μM),	   which	   have	   been	   marked	   with	   a	   horizontal	   line.	   These	   calcium	   traces	  
represent	   the	  average	   [Ca2+]I	  level	   (50	  cells	   in	  both	  cases/experiment)	  calculated	   from	  the	  ratio	  
Fura340/Fura380,	   normalized	   to	   the	   first	   readout.	   Both	   WT	   and	   Cln3
-­‐/-­‐	   astrocytes	   have	   a	   rapid,	  
transient	  increase	  in	  [Ca2+]I	   induced	  by	  ATP	  followed	  by	  a	  sustained	  (plateau)	  Ca
2+	  elevation.	  (B)	  
Shows	  no	  significant	  difference	  in	  the	  maximum	  increase	  in	  [Ca2+]I	  induced	  by	  ATP,	  presented	  as	  
Δ(Max	  [Ca2+]I	  –	  baseline)	   in	  WT	  and	  Cln3
-­‐/-­‐	  astrocytes.	   (C)	  Shows	  no	  significant	  difference	   in	  the	  
recovery	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  after	  ATP	  treatment	  presented	  as	  Δ(Max	  [Ca2+]I-­‐[Ca
2+]I	  2min	  
after	  ATP	  addition).	  In	  each	  experiment	  the	  intracellular	  calcium	  was	  measured	  from	  30-­‐55	  cells	  
and	  the	  experiment	  repeated	  six	  times.	  The	  mean	  percentages±SEM	  are	  shown	  in	  (B)	  and	  (C).	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Cln3-­‐/-­‐	  astrocytes	  release	  and	  clear	  ER-­‐stored	  calcium	  differently	  to	  WT	  
astrocytes	  	  
Many	   Ca2+	   signaling	  mechanisms	   are	   based	   on	   the	   highly	   regulated	   release	   of	  
Ca2+	  from	  intracellular	  stores,	  such	  as	  the	  ER.	  Indeed,	  the	  ER	  has	  its	  own	  inbuilt	  
Ca2+	  machinery	  to	  uptake	  and	  release	  Ca2+	  appropriately.	  This	  machinery	  includes	  
SERCA	   -­‐	   calcium	   pumps	   that	   transport	   Ca2+	   into	   the	   ER	   lumen	   against	   the	  
concentration	  gradient	  (Camello	  et	  al.,	  2002;	  Beck	  et	  al.,	  2004).	  Additionally,	  the	  
ER	  has	   Ca2+	  release	   channels:	   IP3-­‐receptors	   activated	  by	   the	   second	  messenger	  
IP3;	   and	   RYRs	   (ryanodine/caffeine	   receptors)	   (Bezprozvanny,	   2005;	   Hamilton,	  
2005).	  The	  Ca2+	  release	  from	  the	  ER	  is	  thought	  to	  be	  crucial	  for	  gliotransmission	  
and	  for	   intercellular	  signaling	  between	  astrocytes	  (Kuga	  et	  al.,	  2011;	  Parpura	  et	  
al.,	  2011;	  Verkhratsky	  et	  al.,	  2012a).	  Thus,	  as	  an	   intracellular	  Ca2+	  store,	   the	  ER	  
serves	  two	  opposing	  roles;	  as	  a	  Ca2+	  buffer	  by	  removing	  Ca2+	  from	  the	  cytosol	  via	  
activity	  of	  SERCA	  pumps,	  and	  as	  a	  releaser	  of	  Ca2+	  in	  response	  to	  cell	  activation,	  
causing	  an	  increase	  in	  the	  [Ca2+]i.	  Upon	  depletion	  of	  the	  intracellular	  Ca2+	  stores,	  
such	   as	   when	   thapsigargin	   is	   used	   to	   inhibit	   SERCA	   pump	   activity,	   the	   Ca2+	  
permeability	   of	   the	   plasma	   membrane	   increases.	   This	   type	   of	   Ca2+	   influx	  
pathway,	   associated	   with	   a	   reduced	   Ca2+	   content	   in	   internal	   stores,	   is	   called	  
either	  store-­‐operated	  or	  capacitative	  Ca2+	  entry	  (SOCE	  or	  CCE),	  and	  it	  takes	  place	  
via	   store-­‐operated	   Ca2+	   channels	   (SOC)	   (Putney,	   1990;	   Lo	   et	   al.,	   2002).	  
Physiologically,	  the	  SOCE	  is	  important	  for	  both	  refilling	  after	  depletion	  of	  the	  ER	  -­‐	  
Ca2+	  store	  and	  for	  producing	  the	  plateau	  phase	  of	  the	  transient	  [Ca2+]I	  elevations	  	  
-­‐	   providing	   enough	   intracellular	   Ca2+	  to	   outlast	   the	  period	  of	   cellular	   activation	  
(Putney,	  2007).	  	  
To	  compare	  the	  ER	  Ca2+	  content,	  Ca2+	  release	  from	  the	  ER	  and	  subsequent	  store-­‐
operated	   Ca2+	   entry	   form	   the	   extracellular	   space	   in	   WT	   and	   Cln3-­‐/-­‐	   astrocytes,	  
thapsigargin,	   a	   specific	   SERCA	   blocker,	   was	   used.	   WT	   and	   Cln3-­‐/-­‐	   astrocyte	  
cultures	   were	   loaded	  with	   Fura-­‐2AM,	   as	   described	   previously,	   then	   cells	   were	  
washed	   three	   times	   with	   HBSS	   (-­‐Ca2+/	   Mg2+)	   to	   make	   sure	   that	   no	   Ca2+	   was	  
present	  in	  the	  medium.	  The	  baseline	  recordings	  were	  made	  in	  HBSS	  (-­‐Ca2+/	  Mg2+)	  
and	   thapsigargin	   (1uM),	   prepared	   in	   HBSS	   (-­‐Ca2+/	   Mg2+),	   was	   added	   after	   1	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minute	  to	  specifically	  study	  the	  increase	  in	  [Ca2+]I	  due	  to	  ER	  Ca2+	  depletion.	  The	  
Ca2+	   release	   from	   the	   ER	  was	  monitored	  over	   the	  next	   3	  minutes,	   followed	  by	  
addition	  of	  Ca2+	   (100μM)	   to	   the	  medium	   to	   investigate	   the	  process	  of	   SOCE	   in	  
these	  cells.	  	  
	  
Thapsigargin	  administration	  induced	  highly	  variable	  responses	   in	  WT	  and	  Cln3-­‐/-­‐	  
astrocytes	   (compare	  examples	  of	  WT	  (10	  cells)	  and	  Cln3-­‐/-­‐	  (10	  cells)	  Ca2+	   traces,	  
Figure	  4.5	  A).	  The	  WT	  astrocytes	  release	  Ca2+	  from	  the	  ER	  relatively	  slowly,	  with	  
all	   astrocytes	   showing	   a	   similar	   increase	   in	   [Ca2+]i	   levels	   upon	   thapsigargin	  
treatment	  (Figure	  4.5	  A).	  In	  contrast,	  some	  of	  the	  Cln3-­‐/-­‐	  astrocytes	  show	  a	  large	  
and	   very	   rapid	   increase	   in	   [Ca2+]i	   levels	   upon	   thapsigargin	   treatment,	   whereas	  
some	  show	  a	  smaller	  and	  slower	  increase	  (Figure	  4.5	  A).	  The	  SOCE	  following	  Ca2+	  
depletion	  from	  the	  ER	  and	  subsequent	  application	  of	  Ca2+	  (at	  4	  minutes,	  marked	  
with	  blue	  horizontal	   line	   in	  Figure	  4.5	  A)	  was	  observed	  to	  be	  functional	   in	  both	  
WT	  and	  Cln3-­‐/-­‐	  astrocytes;	  seen	  as	  a	  similar	  transient	  increase	  in	  [Ca2+]i.	  	  
	  
In	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocyte	  cultures	  great	  variability	  in	  the	  changes	  in	  [Ca2+]i	  
levels	  was	  observed	  within	  one	  experiment	  in	  response	  to	  thapsigargin.	  Thus,	  in	  
order	   to	   further	   investigate	   the	   changes	   in	   [Ca2+]I	   transients	   in	   these	   cultures,	  
cells	  were	   grouped	   according	   to	   their	  maximum	  Ca2+	   response	   to	   thapsigargin	  
when	  compared	  to	  baseline.	  These	  groups	  were,	  0-­‐50%,	  50%-­‐100%,	  100%-­‐150%,	  
150%-­‐200%	  and	  >200%	   increase	   in	   [Ca2+]i.	   The	   average	  %	   increase	   for	  WT	  and	  
Cln3-­‐/-­‐	  astrocytes	  in	  each	  of	  these	  groups	  is	  presented	  in	  Figure	  4.5	  B,	  a.	  Most	  of	  
the	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   belonged	   to	   a	   group	   showing	   a	   100%-­‐150%	  
increase	   in	   [Ca2+]i	   upon	   thapsigargin	   treatment	   (47.4±1.8%	   of	   WT	   astrocyte	  
population,	   and	   25.9±12.9%	   of	   Cln3-­‐/-­‐	   astrocyte	   population).	   The	   second	  most	  
common	  group	   for	  WT	   astrocytes	  was	   the	   group	  with	   a	   50%-­‐100%	   increase	   in	  
[Ca2+]i	  upon	   thapsigargin	   treatment	   (33.7±8.2%	  of	  WT	  astrocyte	  population).	   In	  
contrast,	   the	   second	  most	   common	   group	   for	  Cln3-­‐/-­‐	   astrocytes	  was	   the	   group	  
with	  a	  >200%	  increase	  in	  [Ca2+]i	  upon	  thapsigargin	  treatment	  (21.4±5.7%	  of	  Cln3-­‐
/-­‐	  astrocyte	  population).	  No	  such	  grouping	  existed	  for	  WT	  astrocytes	   (Figure	  4.5	  
B,	   a).	   Similar	   differences	   in	   response	   to	   thapsigarding	   were	   confirmed	   using	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frequency	   distribution	   analysis	   (Figure	   4.5	   B,	   b).	   Cln3-­‐/-­‐	   astrocytes	   displayd	   a	  
larger	   variation	   in	   their	   response	   to	   thapsigargin	   compared	   to	   WT	   astrocytes	  
(Figure	   4.5	   B,	   b).	   This	   difference	   was	   statistically	   significant	   based	   on	   the	  
Kolmogorov-­‐Smirnov	  test	  (D=0.35	  and	  P=0.000).	  The	  maximum	  increase	  in	  [Ca2+]i	  
in	   response	   to	   thapsigargin	  within	   each	   group	  was	   also	   compared	   for	  WT	   and	  
Cln3-­‐/-­‐	  astrocytes	  (Figure	  4.5	  C).	  For	  WT	  astrocytes	  these	  were	  9.4±9.4%	  (0-­‐50%),	  
75.8±2.4%	  (50%-­‐100%),	  125.2±3.1%	  (100%-­‐150%)	  and	  169.8±1.8%	  (150%-­‐200%);	  
and	   for	   Cln3-­‐/-­‐	   astrocytes	   were	   18.1±10.9%	   (0-­‐50%),	   59.8±20.4%	   (50%-­‐100%),	  
103.7±31.6%	  (100%-­‐150%),	  171.0±1.2%	  (150%-­‐200%)	  and	  244.7±17.5%	  (>200%).	  
No	  significant	  differences	  were	  observed,	  except	  for	  the	  presence	  of	  the	  distinct	  
population	   of	  Cln3-­‐/-­‐	   astrocytes,	  which	   displayed	   a	   very	   high	   increase	   in	   [Ca2+]i	  
(244.7±17.5%)	   following	   thapsigargin	   treatment.	   Thus,	   both	   WT	   and	   Cln3-­‐/-­‐	  
astrocytes	   showed	   a	   heterogeneous	   response	   to	   thapsigargin,	   possibly	   due	   to	  
variability	  in	  their	  ER	  Ca2+	  content.	  Interestingly,	  a	  small	  subpopulation	  of	  Cln3-­‐/-­‐	  
astrocytes	   were	   identified	   that	   displayed	   a	   very	   high	   increase	   in	   [Ca2+]I	   upon	  
inhibition	  of	  SERCA-­‐pumps,	  suggesting	  that	  these	  astrocytes	  have	  a	  high	  amount	  
of	  stored	  intracellular	  Ca2+.	  	  


































Figure	   4.5.	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   display	   a	   variable	   response	   to	  
thapsigargin.	   Fura-­‐2	  was	  used	  to	  measure	  the	  changes	   in	  [Ca2+]I	  levels	   in	  both	  WT	  and	  Cln3-­‐/-­‐	  
astrocytes	   upon	   thapsigargin	   application,	   and	   subsequent	   Ca2+	  entry	   via	   SOCE	   upon	   externally	  
applied	   Ca2+	   (store	   operated	   calcium	   entry).	   (A)	   Examples	   of	   typical	   calcium	   traces	   in	  WT	   and	  
Cln3-­‐/-­‐	   astrocytes	   upon	   thapsigargin	   application	   (1μM)	   (marked	   with	   black	   horizontal	   line,	   10	  
randomly	   selected	   cells	   from	   one	   experiment	   in	   each	   case).	   Bath	   application	   of	   Ca2+	  (100μM),	  
which	   enabled	   SOCE,	   is	  marked	  with	  blue	  horizontal	   line.	   Thapsigargin	   induced	  heterogeneous	  
Ca2+	  transients	  in	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  and	  SOCE	  was	  not	  altered	  in	  either	  genotype.	  (B)	  
a	  Shows	  the	  average	  percentage	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  from	  total	  cells	  measured	  grouped	  
according	   to	   their	   maximum	   increase	   in	   [Ca2+]I	   upon	   thapsigargin	   treatment.	   Cln3
-­‐/-­‐	   astrocyte	  
cultures	  contain	  a	  subpopulation	  of	  cells	  that	  exhibit	  a	  high	  increase	  in	  [Ca2+]I	  upon	  thapsigargin	  
treatment.	   b	   The	   frequency	   distribution	   is	   greater	   in	   Cln3-­‐/-­‐	   astrocyte	   population.	   (C)	   Average	  
maximum	   increase	   in	   [Ca2+]I	   within	   grouped	  WT	   and	   Cln3
-­‐/-­‐	   astrocytes,	   showing	   no	   significant	  
differences	   between	  WT	   and	  Cln3-­‐/-­‐	   astrocyte	   cultures,	   except	   for	   the	   subpopulation	   of	  Cln3-­‐/-­‐	  
astrocytes	   with	   very	   high	   [Ca2+]I	   levels	   induced	   by	   thapsigargin.	   In	   each	   experiment	   the	  
intracellular	   calcium	   was	   measured	   from	   20-­‐50	   cells	   and	   was	   repeated	   four	   times.	   The	  mean	  
percentage±SEM	  are	  shown	  in	  (B)	  and	  (C).	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Following	  thapsigargin-­‐induced	  Ca2+	  release	  from	  the	  ER,	  Ca2+	  is	  cleared	  from	  the	  
cytosol	  by	  being	  taken	  up	  by	  other	  intracellular	  stores,	  such	  as	  mitochondria	  or	  
lysosomes,	   or	   by	   being	   transported	   into	   the	   extracellular	   space.	   In	   order	   to	  
compare	  these	  types	  of	  Ca2+	  clearance	  mechanisms	  in	  WT	  and	  Cln3-­‐/-­‐	  astrocytes,	  
the	  difference	  between	  the	  maximum	  increase	  in	  [Ca2+]I	  induced	  by	  thapsigargin	  
and	  remaining	  levels	  of	  [Ca2+]I	  after	  thapsigargin	  application	  (presented	  as	  Δ(Max	  
[Ca2+]I	   -­‐	   Min	   [Ca2+]I))	   	   were	   calculated	   (Figure	   4.6	   A,	   a	   and	   b).	   Due	   to	   the	  
heterogeneous	   response	   to	   thapsigargin	   in	   both	   WT	   and	   Cln3-­‐/-­‐	   astrocyte	  
cultures,	  as	  shown	  above,	  the	  recovery	  process	  was	  studied	  only	  between	  cells,	  
which	   had	   a	   similar	   response	   to	   thapsigargin	   treatment	   (increase	   in	   [Ca2+]I	  
induced	  by	  thapsigargin	  >50%	  and	  <200%	  compared	  to	  baseline).	  WT	  astrocytes	  
(Figure	  4.6	  A,	  a)	  showed	  a	  complete	  recovery	  after	  thapsigargin	  treatment,	  with	  
[Ca2+]I	   levels	   returning	   back	   to	   baseline.	   However,	   the	   recovery	   of	   Cln3-­‐/-­‐	  
astrocytes	   appeared	   attenuated	   (Figure	   4.6	   A,	   b),	   with	   prolonged	   high	   [Ca2+]I	  
levels	   being	   observed	   following	   treatment.	   Indeed,	   there	   was	   a	   significant	  
difference	   in	   Δ(Max	   [Ca2+]I	   -­‐	   Min	   [Ca2+]I)	   between	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	  
(26.0±5.6%	  decrease	  in	  Δ(Max	  [Ca2+]I	  -­‐	  Min	  [Ca2+]I)	  in	  Cln3-­‐/-­‐	  astrocytes	  compared	  
to	   WT)	   (Figure	   4.6	   B).	   Thus,	   this	   attenuated	   recovery	   in	   Cln3-­‐/-­‐	   astrocytes	  
following	   thapsigargin	   treatment	   may	   suggest	   that	   cytosolic	   Ca2+	   clearance	  
mechanisms	  are	  altered	  in	  Cln3-­‐/-­‐	  astrocytes.	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Figure	  4.6.	  Cytosolic	  Ca2+	   is	  not	  cleared	  properly	   in	  Cln3-­‐/-­‐	  astrocytes.	   (A)	  Typical	  
Ca2+	   traces	   (average	   of	   15-­‐30	   cells	   per	   genotype	   per	   experiment)	   in	   WT	   (a)	   and	   Cln3-­‐/-­‐	   (b)	  
astrocytes	   that	   have	   similar	   response	   to	   thapsigargin	   treatment	   (Max	   [Ca2+]I	   induced	   by	  
thapsigargin	   compared	   to	   baseline	   between	   50%	   and	   200%).	   The	   marked	   Δ(Max	   [Ca2+]I	   -­‐	   Min	  
[Ca2+]I	  illustrates	  the	  difference	  in	  cytosolic	  Ca
2+	  clearance	  between	  WT	  and	  Cln3-­‐/-­‐	  astrocytes.	  (B)	  
Shows	   mean	   average±SEM	   of	   Δ(Max	   [Ca2+]I	   -­‐	   Min	   [Ca
2+]I	   values	   normalized	   to	   WT	   astrocyte	  
values.	   The	   Cln3-­‐/-­‐	   astrocytes	   have	   a	   significantly	   smaller	   Δ(Max	   [Ca2+]I	   -­‐	   Min	   [Ca
2+]I	   value	  
compared	   to	   WT	   astrocytes.	   In	   each	   experiment	   10-­‐40	   cells	   were	   analyzed.	   Data	   is	   from	   4	  
separate	  experiments.	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Cln3-­‐/-­‐	  astrocytes	  show	  impaired	  protein	  secretion	  	  
Secretion	  of	  soluble	  factors	   is	  one	  of	  the	  key	  features	  of	  astrocytes	  under	  both	  
physiological	   and	   pathological	   conditions	   (Ridet	   et	   al.,	   1997;	   Dong	   and	  
Benveniste,	   2001;	   Lucas	   et	   al.,	   2006;	   Farina	   et	   al.,	   2007;	   Bélanger	   and	  
Magistretti,	   2009;	   Sofroniew	  and	  Vinters,	   2010).	  Astrocytes	   can	   secrete	  a	  wide	  
range	   of	   neurotrophic	   factors,	   such	   as	   NGF	   and	   BDNF,	   that	   can	   support	   the	  
survival	   of	   existing	   neurons,	   and	   potentially	   stimulate	   the	   growth	   and	  
differentiation	   of	   new	   neurons	   and	   synapses	   (Miklic	   et	   al.,	   2004).	   Under	  
pathological	   conditions,	   astrocytes	   may	   also	   enhance	   the	   secretion	   of	   a	   wide	  
range	  of	   cytokines,	   chemokines	   and	  mitogens	   that	   are	   all	   important	   players	   in	  
the	  inflammation	  process	  within	  the	  CNS	  (Ridet	  et	  al.,	  1997;	  Farina	  et	  al.,	  2007).	  
These	  secreted	  soluble	  factors	  may	  have	  positive	  or	  negative	  effects	  within	  the	  
brain	   (Ridet	  et	  al.,	  1997;	  Liberto	  et	  al.,	  2004;	  Cassina	  et	  al.,	  2005;	  Farina	  et	  al.,	  
2007;	   Bélanger	   and	   Magistretti,	   2009;	   Sofroniew	   and	   Vinters,	   2010),	   and	   this	  
response	   is	   compounded	   by	   the	   complex	   interactions	   that	   can	   occur	   between	  
astrocyte-­‐secreted	  proteins	  and	  those	  secreted	  by	  microglia,	  the	  other	  ‘immune’	  
cell	   in	   the	   brain	   (Minagar	   et	   al.,	   2002;	   Wyss-­‐Coray	   and	   Mucke,	   2002).	  
Neuroinflammation	   and	   the	   appearance	   of	   autoantibodies	   in	   the	   CNS	   of	   Cln3	  
deficient	  mice,	  as	  well	  as	  JNCL	  patient	  derived	  post	  mortem	  material,	  have	  been	  
shown	  to	  play	  a	  role	  in	  the	  pathogenesis	  of	  this	  disease	  (Mitchison	  et	  al.,	  1999;	  
Lim	   et	   al.,	   2007;	   Cooper,	   2010;	   Seehafer	   et	   al.,	   2011).	   To	   determine	   whether	  
difference	  in	  the	  protein	  secretion	  profile	  of	  Cln3-­‐/-­‐	  astrocytes	  could	  play	  a	  role	  in	  
JNCL,	  a	  quantitative	  immunoassay	  (conducted	  by	  Rules	  Based	  Medicine	  Inc.)	  was	  
used	  to	  compare	  the	  protein	  secretion	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  under	  basal	  
and	  LPS/IFNγ	  treated	  conditions.	  
	  
To	   compare	   the	   protein	   secretion	   profiles	   of	  WT	   and	   Cln3-­‐/-­‐	   astrocytes,	   tissue	  
culture	  supernatants	  were	  collected	  from	  untreated	  cultures	  and	  those	  that	  had	  
been	  treated	  with	  LPS/IFNγ	  for	  6	  hours,	  24	  hours	  or	  72	  hours.	  The	  quantitative	  
immunoassay	   employed	   (RodentMAP,	  Myriad	   RBM)	   enabled	   the	   simultaneous	  
analysis	  of	  59	  different	  proteins	  from	  each	  sample.	  Given	  that	  Cln3-­‐/-­‐	  astrocytes	  
proliferate	   slower	   than	  WT	   astrocytes	   (see	   Chapter	   3,	   Figure	   3.9),	   the	   protein	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expression	   levels	   obtained	   for	   each	   sample	   were	   normalized	   to	   the	   relative	  
number	   of	   cells	   present	   in	   the	   culture.	   Some	   of	   the	   proteins	   analyzed	   in	   this	  
assay	  were	  secreted	  below	  detectable	   levels,	  and	  thus	  were	  excluded	  from	  this	  
assay.	   The	   proteins	   analyzed	   were	   divided	   into	   subgroups	   according	   to	   their	  
function:	  chemokines,	  anti-­‐and	  pro-­‐	   inflammatory	  cytokines,	  mitogens,	  proteins	  
with	   vascular/haematological	   functions,	   and	   finally	   pleiotropic	   factors.	   All	   the	  
data	   from	   this	   analysis	   is	   presented	   in	   Tables	   4.1	   and	   4.2	   (abbreviations	  
explained	   in	   the	   list	   of	   abbreviations).	   Table	   4.1	   illustrates	   the	   differences	   in	  
secreted	  levels	  of	  each	  protein	  between	  Cln3-­‐/-­‐	  and	  WT	  astrocyte	  cultures	  under	  
basal	  conditions,	  while	  Table	  4.2	  illustrates	  differences	  between	  LPS/IFNγ	  treated	  
samples.	  The	  difference	   in	  secreted	  protein	   levels	   is	  presented	  as	   the	  %change	  
calculated	  by	  comparing	  protein	  expression	  values	  in	  Cln3-­‐/-­‐	  astrocyte	  samples	  to	  
those	  in	  the	  corresponding	  WT	  astrocyte	  samples.	  	  
	  
In	   general,	   this	   analysis	   revealed	   small,	   but	   specific,	   changes	   in	   the	   levels	   of	  
secreted	  proteins	  between	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  under	  untreated	  conditions	  
(Table	  4.1).	  However,	   the	   levels	  of	  secreted	  proteins	  were	  generally	  reduced	   in	  
Cln3-­‐/-­‐	   astrocyte	   cultures	   compared	   to	   their	   corresponding	   WT	   cultures	   upon	  
exposure	   to	   LPS/IFNγ	   (Table	   4.2).	   This	   reduction	   was	   more	   dramatic	   with	  
prolonged	  exposure	  to	  the	  activation	  stimulus	  (Table	  4.2).	  	  
	  
After	  24h	  of	  stimulation,	  proteins	  that	  were	  secreted	  at	  significantly	  lower	  levels	  
by	  Cln3-­‐/-­‐	  astrocytes	   could	   be	   observed	   in	   all	   categories	   studied.	  Out	   of	   the	   59	  
screened	   factors	   none	   (at	   6h),	   19	   (at	   24h)	   and	   42	   (at	   72h)	   were	   secreted	   at	  
significantly	   lower	   levels	   by	   Cln3-­‐/-­‐	   astrocytes	   upon	   activation	   with	   LPS/IFNγ.	  
These	   included	   the	   reduced	   secretion	   of	   several	   mitogens	   (M-­‐CFS,	   IL-­‐3,	   FGF2,	  
GM-­‐CSF,	   FGF-­‐9,	   TPO	   and	   IL-­‐5),	   chemokines	   (Eotaxin,	   MIP1a,	   MCP-­‐3,	   MCP-­‐1,	  
KC/GROa,	  MIP-­‐3b,	  MIP-­‐2,	  IP-­‐10,	  RANTES,	  MDC,	  MCP-­‐5,	  MIP-­‐1γ,	  GCP-­‐2	  and	  MIP-­‐
1b),	  anti-­‐	  and	  pro-­‐inflammatory	  cytokines	  (IL-­‐17a,	  IL-­‐6,	  IL-­‐12p70,	  IL-­‐1	  α,	  TNF	  α,	  IL-­‐
1b,	   IL-­‐10,	   IL-­‐2	  ).	   Importantly,	   these	   cells	   also	   showed	   an	   impaired	   ability	   to	  
secrete	   a	   range	   of	   neuroprotective	   proteins	   (IL-­‐6,	   IL-­‐3,	   GM-­‐CSF,	   IL-­‐10,	  MCP-­‐1,	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RANTES,	  and	  LIF).	  This	  data	   suggests	   that	   stimulated	  Cln3-­‐/-­‐	  astrocytes	  exhibit	   a	  
markedly	  altered	  protein	  secretion	  profile	  (see	  Figure	  4.7	  for	  specific	  examples).	  	  
	  
There	  were	  however,	  notable	  exceptions	  to	  these	  rules.	  Two	  of	  the	  chemokines:	  
macrophage	  inflammatory	  protein-­‐1γ	  (MIP-­‐1γ)	  and	  glutamate	  carboxypeptidase	  
2	   (GCP-­‐2)	  were	   both	   secreted	   at	   significantly	   lower	   levels	   by	  Cln3-­‐/-­‐	   astrocytes	  
compared	   to	  WT	   astrocytes	   under	   basal	   conditions	   (an	   observed	   reduction	   of	  
83.0±0.2%	   and	   95.5±16.7%	   respectively),	   as	   was	   one	   mitogen	   analyzed,	  
macrophage	  colony-­‐stimulating	  factor	  (M-­‐CSF,	  41.4±0.5%	  reduction	  compared	  to	  
WT	  at	  72h).	  
	  
Only	   one	   protein,	   tissue	   factor	   (TF),	   was	   secreted	   at	   higher	   levels	   by	   Cln3-­‐/-­‐	  
astrocytes	   that	  WT	   astrocytes	   under	   basal	   conditions	   (97.3±84.5%	   increase	   at	  
72h),	  which	  is	  the	  major	  initiator	  of	  the	  coagulation	  protease	  cascade.	  Indeed,	  it	  
has	  been	  suggested	  that	  astrocytes	   function	  as	   the	  primary	  source	  of	  TF	   in	   the	  
CNS,	   making	   astrocytes	   the	   main	   regulators	   of	   haemorrhage	   in	   the	   brain	  
(Eddleston	  et	  al.,	  1993).	  
	  
Three	  proteins	  were	  found	  to	  be	  secreted	  significantly	  more	  by	  Cln3-­‐/-­‐	  astrocytes	  
upon	  stimulation.	  These	  factors	  were	  the	  mitogen	  CRP	  (82.3±47.9%	   increase	  at	  
24h),	   fibrinogen	   (80.1±31.7%	   increase	  at	  24h)	  and	  the	  anti-­‐inflammatory	   factor	  
immunoglobulin	  A	  (IgG	  A)	  (130.2±70.5%	  increase	  at	  24h).	  Interestingly,	  CRP	  is	  an	  
acute-­‐phase	  protein,	  whose	  level	  increases	  during	  inflammation,	  and	  is	  involved	  
in	   the	  activation	  of	   the	  complement	  system	  via	  C1q	  complex	   (Thompson	  et	  al.,	  
1999;	  Wight	  et	  al.,	  2012).	  
	   	  



















Table	   4.1.	   Differences	   in	   protein	   secretion	   under	   basal	   unstimulated	  
conditions.	   This	   table	   presents	   differences	   between	   levels	   of	   secreted	   proteins,	   classified	  
according	  to	  their	  function,	  in	  supernatants	  collected	  after	  6h,	  24h	  and	  72h	  from	  Cln3-­‐/-­‐	  astrocyte	  
cultures	   and	  WT	   astrocyte	   cultures	   grown	  under	   basal	   conditions.	  Data	   presented	   as	  %change	  
(values	   from	   Cln3-­‐/-­‐	   astrocyte	   samples	   compared	   to	   corresponding	   WT	   astrocyte	   values)±SEM	  
from	  three	  biological	  replicates.	  Data	  not	  shown	  (-­‐)	  where	  protein	  levels	  were	  below	  quantifiable	  
detection	  levels.	  Abbreviations	  explained	  in	  the	  list	  of	  abbreviations	  page	  14.	  	  























Table	  4.2.	  Stimulated	  Cln3-­‐/-­‐	  astrocytes	  show	  attenuated	  protein	  secretion.	  This	  
table	   presents	   differences	   between	   levels	   of	   secreted	   proteins,	   classified	   according	   to	   their	  
function,	   in	   supernatants	   collected	   from	   Cln3-­‐/-­‐	   astrocytes	   and	   WT	   astrocytes	   after	   LPS/IFNγ	  
induced	   activation	   for	   6h,	   24h	   and	   72h.	   Data	   presented	   as	   %change	   (Cln3-­‐/-­‐	   astrocyte	   sample	  
values	   compared	   to	   corresponding	  WT	   astrocyte	   values)±SEM	   from	   three	   biological	   replicates.	  
Data	  not	  shown	  (-­‐)	  where	  protein	  levels	  were	  below	  quantifiable	  detection	  levels.	  Abbreviations	  
explained	  in	  the	  list	  of	  abbreviations	  page	  14.	  	  
	   187	  
To	  illustrate	  the	  change	  in	  the	  protein	  secretion	  between	  untreated	  and	  LPS/IFNγ	  
treated	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   over	   the	   studied	   time	   course,	   the	   protein	  
expression	   levels	   of	   some	   selected	   proteins	   are	   presented	   in	   Figure	   4.7	   A-­‐C.	  
Graphs	   showing	   the	   protein	   expression	   profile	   over	   6	   hours,	   24	   hours	   and	   72	  
hours	  of	  three	  chemokines,	  MIP-­‐2,	  MIP-­‐1β	  and	  MIP-­‐1α,	  are	  shown	  in	  Figure	  4.7	  
A,	   in	   which	   it	   is	   apparent	   that	   neither	   WT	   (blue	   line)	   nor	   Cln3-­‐/-­‐	   (red	   line)	  
astrocytes	  secrete	  high	  levels	  of	  any	  of	  these	  chemokines	  under	  basal	  conditions.	  
However,	  upon	  stimulation,	  secretion	  of	  these	  proteins	  is	  dramatically	  increased	  
from	  WT	   astrocytes	   (blue	   dotted	   line),	   whereas	   Cln3-­‐/-­‐	   astrocytes	   (red	   dotted	  
line)	  do	  not	  show	  any	  elevated	  secretion	  of	  these	  proteins	  (Figure	  4.7	  A).	  Similar	  
secretion	   profiles	   are	   illustrated	   for	   three	   proteins	   with	   neuroprotective	  
properties	   (IL-­‐6,	  TNF-­‐alpha	  and	  VEGF,	  Figure	  4.7	  B).	  Under	  basal	  conditions	  WT	  
and	  Cln3-­‐/-­‐	  astrocytes	  both	  secrete	  moderate	  amounts	  of	  these	  factors,	  whereas	  
LPS/IFNγ	   induced	  activation	  only	   results	   in	  enhanced	  secretion	  of	   these	   factors	  
by	   WT	   astrocytes.	   As	   mentioned	   above,	   not	   all	   the	   proteins	   screened	   were	  
secreted	  at	  lower	  levels	  by	  Cln3-­‐/-­‐	  astrocytes	  upon	  stimulation,	  for	  example,	  CRP	  
and	  IgG	  A	  were	  secreted	  at	  higher	  levels	  (Figure	  4.7	  C),	  thus	  it	  appears	  that	  Cln3-­‐/-­‐	  
astrocytes	  do	  have	  the	  capacity	  to	  secrete	  increased	  levels	  of	  some	  proteins	  into	  
their	  environment	  when	  they	  are	  stimulated.	  
	  
Overall,	   a	   significant	   decrease	   in	   the	   ability	   of	   Cln3-­‐/-­‐	   astrocytes	   to	   secrete	   a	  
range	   of	   proteins	   following	   stimulation	  was	   observed.	   One	   can	   speculate	   that	  
under	   chronic	   pathological	   situations,	   like	   in	   JNCL,	   this	   may	   have	   a	   significant	  
impact	  on	  disease	  progression.	  	  
	   	  





































Figure	   4.7.	   Cln3-­‐/-­‐	   astrocytes	   show	   alterations	   in	   their	   ability	   to	   secrete	  
proteins.	   Secreted	   protein	   levels	   were	   quantified	   from	   supernatant	   derived	   from	   untreated	  
and	   LPS/IFNγ	   treated	   WT	   and	   Cln3-­‐/-­‐	   astrocyte	   cultures.	   Examples	   of	   chemokines	   (A),	  
neuroprotective	   factors	   (B)	   and	   proteins	   secreted	   at	   elevated	   levels	   by	   Cln3-­‐/-­‐	   astrocytes	  
following	   activation	   (C),	   are	   provided.	   (A)	   Cln3-­‐/-­‐	   astrocytes	   secreted	   significantly	   less	   MIP-­‐1ß,	  
MIP-­‐1α	  and	  MCP-­‐1	  when	  treated	  with	  LPS/IFNγ	  that	  do	  WT	  astrocytes.	  There	  was	  no	  significant	  
difference	  between	  untreated	  WT	  and	  Cln3-­‐/-­‐	  samples.	  (B)	  Cln3-­‐/-­‐	  astrocytes	  secreted	  significantly	  
less	   IL-­‐6,	   TNF-­‐α	   and	   VEGF	   upon	   activation	   than	   did	  WT	   astrocytes.	   There	   was	   no	   significant	  
difference	  between	  untreated	  samples.	  (C)	  Cln3-­‐/-­‐	  astrocytes	  secreted	  significantly	  more	  CRP	  and	  
IgG	   A	   after	   24h	   exposure	   to	   LPS/IFNγ,	   no	   such	   change	   was	   observed	   in	   WT	   astrocytes.	   Data	  
presented	  as	  mean	  expression	  values±SEM.	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One	   possible	   explanation	   for	   the	   observed	   lack	   of	   protein	   secretion	   by	   Cln3-­‐/-­‐	  
astrocytes,	   may	   be	   an	   inability	   to	   produce	   these	   proteins	   by	   these	   cells.	   This	  
possibility	   was	   tested	   by	   quantifying	   the	   intracellular	   levels	   of	   two	   of	   these	  
proteins,	  TNF-­‐α	  and	  MIP-­‐1γ,	  for	  which	  good	  antibodies	  were	  available	  by	  means	  
of	  Western	  blotting.	  
	  
To	  carry	  out	   these	  measurements,	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  were	  plated	  on	  6-­‐
well	  plates	  (100,000	  cells/well)	  and	  grown	  for	  24h	  in	  the	  presence	  or	  absence	  of	  
LPS/IFNγ	  before	  lysates	  were	  prepared	  for	  Western	  blotting	  (Chapter	  2,	  Section	  
2.7).	  The	  intracellular	  expression	  levels	  of	  TNF-­‐α	  and	  MIP1-­‐γ	  were	  quantified	  and	  
the	   protein	   expression	   levels	   in	   Cln3-­‐/-­‐	   astrocyte	   samples	   were	   normalized	   to	  
matching	   WT	   samples.	   The	   intracellular	   TNF-­‐α	   levels	   were	   higher	   in	   both	  
untreated	  and	  LPS/IFNγ	  treated	  Cln3-­‐/-­‐	  astrocytes	  than	   in	  WT	  astrocytes	   (Figure	  
4.8	   A).	   This	   increase	   was	   statistically	   significant	   in	   LPS/IFNγ	   treated	   samples,	  
where	  Cln3-­‐/-­‐	  astrocytes	  contained	  36.4±8.4%	  more	   intracellular	  TNF-­‐α	  than	  WT	  
astrocytes.	  The	   intracellular	   levels	  of	  MIP1-­‐γ	  were	  very	  similar	   in	  untreated	  WT	  
and	   Cln3-­‐/-­‐	   astrocytes	   (Figure	   4.8	   B),	   but	   upon	   LPS/IFNγ	   stimulation	   the	  
intracellular	   level	   of	   MIP1-­‐γ	   was	   increased	   in	   Cln3-­‐/-­‐	   astrocytes	   (a	   26.2±40.1%	  
increase),	   but	   due	   to	   the	   high	   variability	   between	   measured	   samples	   this	  
increase	  was	  not	  statistically	  significant.	  Both	  of	  these	  proteins	  were	  observed	  to	  
be	   secreted	   less	   by	   Cln3-­‐/-­‐	   astrocytes	   upon	   LPS/IFNγ	   stimulation	   (Table	   4.2),	  
suggesting	   that	   intracellular	   accumulation	   of	   these	   proteins	   occurs	   in	   Cln3-­‐/-­‐	  
astrocytes.	  Thus,	  these	  observations	  support	  the	  view	  that	  Cln3-­‐/-­‐	  astrocytes	  are	  
able	  to	  produce	  proteins,	  they	  just	  fail	  to	  secrete	  them.	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Figure	  4.8.	  Protein	  synthesis	   is	  not	  reduced	   in	  Cln3-­‐/-­‐	  astrocytes.	  The	  intracellular	  
expression	   levels	   of	   TNF-­‐α	   and	  MIP1-­‐γ	  were	  quantified	   in	   untreated	   and	  24h	   LPS/IFNγ	   treated	  
samples.	   The	   expression	   levels	   of	   each	   protein	   from	  WT	   astrocyte	   samples	   was	   compared	   to	  
those	  from	  Cln3-­‐/-­‐	  astrocyte	  samples.	   (A)	  TNF-­‐α	  expression	  was	  upregulated	   in	  LPS/IFNγ	  treated	  
Cln3-­‐/-­‐	   samples	   compared	   to	  WT.	   No	   difference	   was	   observed	   in	   untreated	   conditions.	   (B)	   No	  
difference	   in	   MIP1-­‐α	   expression	   between	   untreated	   and	   LPS/IFNγ	   treated	   Cln3-­‐/-­‐	   and	   WT	  
samples.	  Data	  presented	  as	  mean	  percentages	  ±	  SEM	  from	  n=3	  experiments.	  	  	  
Cln3-­‐/-­‐	  astrocytes	  make,	  but	  fail	  to	  secrete,	  the	  antioxidant	  glutathione	  
Astrocytes	   protect	   neurons	   in	   many	   ways,	   including	   through	   metabolic	   and	  
antioxidant	  support.	  One	  of	  the	  most	  important	  neuroprotective	  molecules	  is	  the	  
antioxidant	   glutathione	   (GSH)	   (Schulz	   et	   al.,	   2000).	   Under	   oxidative	   stress	  
conditions,	  the	  trafficking	  of	  GSH	  between	  astrocytes	  and	  neurons	  is	  particularly	  
crucial	   (Dringen,	   2000).	   By	   secreting	   GSH	   into	   the	   extracellular	   environment	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astrocytes	   are	   able	   to	   increase	   neuronal	   GSH	   levels	   (Dringen	   et	   al.,	   1999).	  
Glutathione	   levels	  have	  been	   shown	   to	  be	   lower	   in	   the	   JNCL	  brain,	  which	  may	  
result	  in	  progressive	  oxidative	  damage	  in	  the	  CNS	  of	  Cln3-­‐/-­‐	  mice	  (Benedict	  et	  al.,	  
2007;	  Chan	  et	  al.,	  2009;	  Tuxworth	  et	  al.,	  2011).	  	  
	  
In	  order	  to	  study	  the	  role	  of	  astrocytes	   in	  defending	  the	  brain	  against	  oxidative	  
stress	  in	  JNCL,	  the	  ability	  of	  Cln3-­‐/-­‐	  astrocytes	  to	  produce	  and	  secrete	  glutathione	  
was	  examined.	  To	  do	  this,	  astrocytes	  were	  plated	  on	  6-­‐well	  plates	  at	  a	  density	  of	  
100,000	  cells	  per	  well	  and,	  on	  the	  following	  day,	  the	  medium	  was	  replaced	  with	  
fresh	  astrocyte	  medium	  containing	   LPS/IFNγ	  and	   incubated	   for	   either	   24	  or	   48	  
hours.	  Control	  cultures	  of	  both	  genotypes	  were	  maintained	  for	  the	  same	  length	  
of	  time,	  but	  without	  the	  addition	  of	  LPS/IFNγ.	  Subsequently,	  cells	  were	  washed,	  
lysed	  and	  samples	  for	  the	  GSH	  assay	  were	  prepared	  as	  described	  in	  material	  and	  
methods	  (Chapter	  2,	  Section	  2.9).	  A	  Lowry	  protein	  assay	  was	  used	  to	  determine	  
the	   amount	   of	   total	   protein	   in	   each	   sample	   and	   the	   intracellular	   levels	   of	   the	  
reduced	  form	  of	  GSH	  were	  measured	  by	  reverse-­‐phase	  HPLC.	  In	  basal,	  untreated	  
conditions,	  no	  significant	  differences	   in	  GSH	   levels	  were	  observed	  between	  WT	  
and	   Cln3-­‐/-­‐	   astrocytes	   (Figure	   4.9	   A).	   However,	   upon	   LPS/IFNγ	   treatment	   the	  
intracellular	  levels	  of	  the	  reduced	  form	  of	  GSH	  decreased	  significantly	  in	  the	  WT	  
astrocytes,	  with	   a	   56.3±12.0%	   reduction	   in	  GSH	   levels	   being	  observed	   after	   24	  
hours	   exposure,	   and	   a	   59.9±12.6%	   reduction	   after	   48	   hours	   (Figure	   4.9	   A).	   In	  
contrast,	   intracellular	   levels	  of	  the	  reduced	  form	  of	  GSH	  increased	  in	  the	  Cln3-­‐/-­‐	  
astrocytes	   after	   a	   24	   hours	   activation	   period,	   when	   compared	   to	   untreated	  
samples	   (63±33.6%	   increase),	   before	   returning	   nearly	   back	   to	   baseline	   at	   48	  
hours	   (28.1±19.3%	   increase)	   (Figure	  4.9	  A).	   These	  GSH	   levels	  were	   significantly	  
lower	   in	   WT	   astrocytes	   after	   LPS/IFNγ	   treatment	   than	   in	   Cln3-­‐/-­‐	   astrocytes	  
(59.6±12.2%	  decrease	  after	  24h	  and	  a	  51.9±14.3%	  decrease	  after	  48h).	  However,	  
since	   this	   experiment	   only	   measured	   the	   reduced	   form	   of	   glutathione,	   it	   is	  
feasible	   that	   the	  results	  obtained	  could	  be	  explained	  by	  an	  opposing	  change	   in	  
the	   level	   of	   oxidized	   glutathione	   (GSSG).	   This	   possibility	   was	   excluded	   by	  
indirectly	  measuring	   intracellular	   GSSG	   levels	   in	   these	   same	   samples.	   This	  was	  
carried	  out	  by	  incubating	  half	  of	  the	  sample	  volume	  with	  glutathione	  reductase	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(GR),	   thus	   converting	   any	   GSSG	   present	   to	   GSH.	   HPLC	   analysis,	   as	   described	  
above,	  was	  then	  used	  to	  measure	  the	  total	  glutathione	  and	  reduced	  GSH	  levels.	  
No	   measurable	   difference	   between	   intracellular	   levels	   of	   GSH	   and	   total	  
glutathione	   could	   be	   detected	   in	   any	   of	   these	   samples,	   suggesting	   that	   all	   the	  
intracellular	   glutathione	   in	   both	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   is	   present	   in	   its	  
reduced	   form	   (GSSG	   (total	   glutathione-­‐GSH)	   levels:	   0	   nmol/mg	   protein	   (WT	  
untreated),	  0.42±0.28	  nmol/mg	  protein	   (WT	  24h	  LPS/IFNγ),	  0	  nmol/mg	  protein	  
(WT	   48h	   LPS/IFNγ),	   1.31±0.51	   nmol/mg	   protein	   (Cln3-­‐/-­‐	  untreated),	   0	   nmol/mg	  
protein	   (Cln3-­‐/-­‐	  24h	  LPS/IFNγ),	  1.39±1.0	  nmol/mg	  protein	   (Cln3-­‐/-­‐	  48h	  LPS/IFNγ)).	  
These	   total	   glutathione	   measurements	   were	   carried	   out	   on	   only	   one	   set	   of	  
samples.	  	  	  
	  
As	  mentioned	   above,	   astrocytes	   are	   able	   to	   secrete	   glutathione.	   Therefore	   an	  
alternative	  explanation	  for	  the	  observed	  differences	  in	  the	  levels	  of	  intracellular	  
GSH	   between	   astrocytes	   of	   different	   genotypes	   could	   be	   the	   lack	   of	   GSH	  
secretion	   by	  Cln3-­‐/-­‐	  astrocytes,	   resulting	   in	   accumulation	   of	   intracellular	  GSH	   in	  
LPS/IFNγ	   treated	   samples.	   Because	  many	   components	   of	   the	   astrocyte	   culture	  
medium	   interfere	   with	   the	   electrochemical	   detection	   method	   used	   in	   HPLC	  
analysis,	  the	  secreted	  levels	  of	  glutathione	  in	  the	  culture	  medium	  were	  analyzed	  
by	  means	   of	   a	   luminescent	   GSH	   detection	   assay	   (Promega;	   Chapter	   2,	   Section	  
2.9).	  The	  glutathione	  that	  accumulated	  in	  the	  medium	  over	  a	  period	  of	  8	  hours	  
was	  quantified	  in	  samples	  collected	  from	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocyte	  cultures	  
that	   had	   either	   been	   treated	   with	   LPS/IFNγ,	   or	   maintained	   under	   basal	  
conditions.	  Since	  GSH	  secreted	  into	  the	  medium	  is	  readily	  oxidized,	  the	  GSSG	  was	  
converted	   to	   GSH	   using	   the	   strong	   reducing	   agent	   TCEP	   (12μM)	   prior	   to	  
measuring	  the	  total	  GSH.	  These	  values	  were	  normalized	  to	  the	  relative	  amount	  
of	  released	  LDH	  (%LDH	  from	  total	  LDH)	  in	  each	  sample	  to	  take	  into	  account	  any	  
possible	  unspecific	  release	  of	  intracellular	  content	  into	  the	  medium	  under	  these	  
experimental	   conditions.	   No	   significant	   difference	   in	   the	   total	   GSH	   levels	  
between	  untreated	  WT	   (2.5±1.1	  μM	  GSH/released	  %LDH)	   and	  Cln3-­‐/-­‐	   (0.28±0.1	  
μM	   GSH/released	   %LDH)	   samples	   was	   detected	   (Figure	   4.9	   B).	   This	   correlates	  
well	  with	  the	  observation	  that	   intracellular	   levels	  of	  GSH	  do	  not	  differ	  between	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untreated	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   (Figure	   4.9	   A).	   However,	   significantly	  
increased	  GSH	  levels	  were	  observed	  in	  medium	  collected	  from	  LPS/IFNγ	  treated	  
WT	   astrocyte	   cultures	   (4.3±1.1	   μM	   GSH/released	   %LDH),	   when	   compared	   to	  
medium	  collected	   from	  LPS/IFNγ	   treated	  Cln3-­‐/-­‐	   astrocyte	   cultures	   (0.4±0.2	  μM	  
GSH/released	  %LDH)	  (Figure	  4.9	  B).	  Based	  on	  these	  results	  it	  appears	  that	  Cln3-­‐/-­‐	  
astrocytes	   are	   fully	   capable	   of	   making	   GSH,	   but	   fail	   to	   secrete	   this	   important	  
antioxidant,	  particularly	  when	  activated	  with	  LPS/IFNγ.	  
	   	  


























Figure	   4.9.	   Cln3-­‐/-­‐	   astrocytes	   fail	   to	   secrete	   glutathione.	   Primary	   cortical	   WT	   and	  	  
Cln3-­‐/-­‐	   astrocytes	   cultured	   on	   6-­‐well	   plates	   were	   analyzed	   for	   their	   ability	   to	   synthesize	   GSH	  
(intracellular	  GSH,	   reduced	  form)	  and	   for	   their	  ability	   to	  secrete	  this	  protein	   (extracellular	   total	  
GSH,	  reduced	  form).	  (A)	  Reverse	  phase	  HPLC	  was	  used	  to	  measure	  the	  intracellular	  levels	  of	  the	  
reduced	   form	  of	  GSH	   in	  WT	  and	  Cln3-­‐/-­‐	   astrocytes	   treated	  with	  LPS/IFNγ	   for	  24	  or	  48	  hours,	  or	  
from	  untreated	  samples.	  The	  GSH	  levels	  in	  each	  sample	  were	  normalized	  to	  the	  total	  amount	  of	  
protein	   in	   that	   sample,	   thus	   results	   are	   presented	   in	   nmol/mg	   of	   protein.	   Additionally,	   these	  
results	   were	   normalized	   to	   untreated	   WT	   astrocyte	   GSH	   levels	   in	   each	   experiment.	   LPS/IFNγ	  
stimulation	  caused	  a	  significant	  decrease	   in	  the	   intracellular	   levels	  of	  GSH	   in	  WT	  astrocytes	  but	  
not	   in	   Cln3-­‐/-­‐	   astrocytes.	   (B)	   The	   GSH-­‐Glo	   kit	   was	   used	   to	   measure	   the	   total	   amount	   of	   GSH	  
secreted	  into	  the	  medium	  over	  an	  8	  hours	  period	  by	  cultures	  of	  untreated	  and	  LPS/IFNγ	  treated	  
WT	  and	  Cln3-­‐/-­‐	  astrocytes.	  TCEP	  (12uM)	  was	  used	  to	  convert	  of	  GSSH	  to	  GSH	  to	  measure	  the	  total	  
amount	  of	  GSH	  in	  each	  sample.	  These	  results	  were	  normalized	  to	  released	  %LDH	  from	  total	  LDH.	  
LPS/IFNγ	   treated	   Cln3-­‐/-­‐	   astrocytes	   secreted	   significantly	   reduced	   levels	   of	   GSH	   compared	   to	  
LPS/IFNγ	   treated	   WT	   astrocytes.	   The	   results	   are	   presented	   as	   average	   mean±SEM.	   Three	  
technical	  repeats	  were	  analyzed	  in	  each	  experiment,	  and	  the	  experiment	  was	  repeated	  four	  time	  
for	  the	  results	  in	  (A)	  and	  six	  times	  for	  the	  results	  in	  (B).	  	  
	  
	  
An	  intact	  actin	  cytoskeleton	  is	  required	  for	  glutathione	  secretion	  
The	  actin	  cytoskeleton,	  among	  other	  cytoskeletal	   components,	   is	   important	   for	  
exocytosis	   in	   astrocytes	   (Potokar	   et	   al.,	   2007),	   but	   our	   data	   revealed	   the	   actin	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cytoskeleton	  to	  be	  abnormally	  organized	   in	  Cln3-­‐/-­‐	  astrocytes	  (Chapter	  3,	  Figure	  
3.7).	  As	  such,	  the	  potential	  connection	  between	  the	  disrupted	  actin	  cytoskeleton	  
and	   lack	   of	   glutathione	   secretion	   was	   examined	   by	   treating	   WT	   astrocyte	  
cultures	  with	  cytochalasin	  D	  to	  inhibit	  the	  polymerization	  of	  actin.	  This	  resulted	  
in	   a	   dramatic	   alteration	   in	   the	   actin	   cytoskeletal	   organization	   in	   these	   cells	  
(Figure	   4.10	   A).	   Indeed,	   treatment	   with	   cytochalasin	   D	   (30	   minutes	   pre-­‐
incubation	  before	   the	   8	   hour	  measurement	  period,	   1μM)	   induced	   a	   significant	  
reduction	   (50.1±12.7%)	   in	   the	   levels	   of	   extracellular	   glutathione	   in	   LPS/IFNγ	  
treated	  WT	   astrocytes	   (Figure	   4.10	   B).	   Thus,	   an	   intact	   actin	   cytoskeletal	   is	   an	  

























Figure	  4.10.	  An	  intact	  actin	  cytoskeleton	  is	  essential	  for	  glutathione	  secretion.	  
To	  study	  the	  importance	  of	  the	  actin	  cytoskeleton	  for	  GSH	  secretion	  in	  astrocytes,	  cytochalasin	  D	  
was	  used.	  Cytochalasin	  D	  (1μM)	  was	  added	  to	  WT	  astrocytes	  for	  30	  minutes	  prior	  to	  the	  start	  of	  
the	  8	  hours	  period	  over	  which	  the	  accumulation	  of	  secreted	  GSH	  in	  the	  medium	  was	  measured.	  
Cells	   were	   then	   fixed	   and	   the	   actin	   cytoskeleton	   visualized	   with	   phalloidin.	   DAPI	   was	   used	   to	  
visualize	  all	   nuclei.	   (A)	  Cytochalasin	  D	   clearly	  disturbed	   the	  F-­‐actin	   filament	  organization	   in	  WT	  
astrocytes.	   (B)	  Disturbing	  actin	   cytoskeletal	  polymerization	   significantly	   inhibited	  GSH	  secretion	  
by	  WT	  astrocytes.	  Scale	  bar	  in	  (A)	  is	  10μm.	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Cln3-­‐/-­‐	  astrocytes	  secrete	  lactate	  normally,	  but	  show	  impaired	  glutamate	  
scavenging	  	  
Neuronal	   activity	   is	   tightly	   coupled	   with	   regionally	   regulated	   blood	   flow	   and	  
brain	  energy	  metabolism	  (Pellerin	  et	  al.,	  1998).	  It	  has	  become	  evident	  that	  highly	  
regulated	   metabolic	   interactions	   take	   place	   between	   astrocytes	   and	   neurons	  
(Tsacopoulos	  and	  Magistretti,	  1996).	  A	  central	  player	  in	  these	  interactions	  is	  the	  
glutamate	   released	   from	   neuronal	   cells	   during	   synaptic	   activity,	   and	   its	  
subsequent	  reuptake	  into	  astrocytes	  that	  enwrap	  synapses	  via	  specific	  glutamate	  
transporters	  such	  as	  GLT1	  and	  GLAST	  expressed	  by	  these	  cells	  (EAAT1	  and	  EAAT2	  
in	   humans)	   (Perego	   et	   al.,	   2000).	   This	   glutamate	   clearance	   by	   astrocytes	   has	  
been	   shown	   to	  be	  a	   sodium-­‐dependent	  process	   that	   triggers	   aerobic	   glycolysis	  
(glucose	  uptake	  and	  utilization	  for	  lactate	  production	  by	  astrocytes).	  During	  this	  
process,	  glutamate	  is	  co-­‐transported	  into	  the	  cells	  with	  Na+.	  This	  increased	  influx	  
of	  Na+	  leads	  to	  an	  activation	  of	  the	  astrocyte	  Na+/K+-­‐ATPase	  in	  an	  ATP-­‐dependent	  
manner	   resulting	   in	  enhanced	  glycolysis,	  which	  produces	   the	  energy	  substrates	  
pyruvate	   and	   lactate	   (see	   Figure	   1.5)	   (Parker	   and	   Hoffman,	   1967;	   Lipton	   and	  
Heimbach,	   1978;	   Paul	   et	   al.,	   1979;	   Lynch	   and	   Balaban,	   1987;	   Pellerin	   and	  
Magistretti,	   1994;	   Pellerin	   et	   al.,	   2007).	   Neurons	   can	   then	   take	   up	   the	   lactate	  
released	   by	   astrocytes	   and	   utilize	   it	   as	   their	   energy	   substrate.	   A	   particular	  
property	   of	   astrocytes	   that	  makes	   them	   an	   integral	   part	   of	   the	   energy	   supply	  
system	  for	  neuronal	  cells	  is	  the	  fact	  that	  their	  end-­‐feet,	  which	  are	  enriched	  in	  the	  
glucose	  transporter	  Glut1,	  cover	  virtually	  all	  intraparenchymal	  capillaries	  (Kacem	  
et	  al.,	  1998;	   Iadecola	  and	  Nedergaard,	  2007),	  enabling	  direct	  glucose	  uptake	  by	  
these	  cells	  from	  the	  blood	  supply.	  This	  forms	  the	  basis	  for	  the	  activity	  dependent	  
lactate	   shuttle	   between	   astrocytes	   and	   neurons	   and	   supplies	   the	   energy	   for	  
active	  synaptic	  transmission	  (Morgello	  et	  al.,	  1995;	  Pellerin	  et	  al.,	  1998;	  Pellerin	  
and	  Magistretti,	  2012).	  	  
	  
Previous	   NMR-­‐based	   studies	   on	   brain	   energy	   metabolism	   revealed	   a	   normal	  
metabolic	   profile	   in	   JNCL	   patients	   (Brockmann	   et	   al.,	   1996).	   Some	   defects	   in	  
energy	   metabolism,	   however,	   have	   been	   detected	   in	   different	   Cln3	   deficient	  
mouse	  models,	  where	  a	   shift	   towards	  gluconeogenesis	  and	  down-­‐regulation	  of	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genes	  involved	  with	  energy	  production	  in	  the	  mitochondria	  have	  been	  reported	  
(Brooks	   et	   al.,	   2003;	   Chattopadhyay	   et	   al.,	   2004).	   Despite	   this,	   no	   differences	  
have	  been	  observed	  in	  blood	  lactate	  levels	  between	  Cln3-­‐/-­‐	  mice	  and	  WT	  control	  
mice	   (Brooks	   et	   al.,	   2003;	   Chattopadhyay	   et	   al.,	   2004;	   Luiro	   et	   al.,	   2006).	  
However,	   normal	   systemic	   lactate	   levels	   do	   not	   necessarily	   mean	   that	   the	  
astrocyte-­‐neuron	   lactate	   shuttling	   in	   the	   brain,	   which	   is	   required	   to	   meet	  
neuronal	  energy	  demands,	  is	  also	  unaffected.	  Therefore,	  the	  lactate	  secretion	  of	  
Cln3-­‐/-­‐	  astrocytes	  was	  studied.	  	  
	  	  
Glutamate	  clearance	  by	  astrocytes	  has	  been	  shown	  to	  be	  essential	  in	  regulating	  
extracellular	  glutamate	  concentrations,	  thereby	  preventing	  excitotoxic	  neuronal	  
cell	   death	   and	   regulating	   synaptic	   transmission	   (Rothstein	   et	   al.,	   1996).	  
Excitotoxicity	  may	  also	  play	  a	  potential	   role	   in	  JNCL	  pathogenesis.	  This	   is	  based	  
on	   findings	   indicating	   that	   functional	   autoantibodies	   against	   GAD65,	   which	  
reduced	  the	  activity	  of	  GAD	  and	  thus	  increased	  levels	  of	  glutamate,	  are	  present	  
within	  the	  CNS	  of	  Cln3	  deficient	  mice,	  and	  in	  human	  JNCL	  (Chattopadhyay	  et	  al.,	  
2002;	  Lim	  et	  al.,	  2006).	  Additionally,	  metabolic	  profiling	  in	  Cln3-­‐/-­‐	  mice	  has	  shown	  
that	  altered	  glutamate/glutamine	  cycling,	   reduced	   levels	  of	  GABA	  and	  elevated	  
glutamate	  can	  be	  detected	  at	  an	  early	  stage	  of	  disease	  progression	  (Pears	  et	  al.,	  
2005).	  Thus,	  astrocyte	  dysfunction	   in	   JNCL	  could	  contribute	   towards	   the	  excess	  
accumulation	  of	  glutamate	  at	  the	  synapse	  and	  hence	  to	  neuronal	  death.	  	  	  	  	  	  	  	  
	  	  
To	  compare	  lactate	  secretion	  by	  WT	  and	  Cln3-­‐/-­‐	  astrocytes,	  cells	  were	  plated	  onto	  
PDL	  coated	  24-­‐well	  plates	  at	  a	  density	  of	  50,000	  cells/well.	  24	  –	  48	  hours	  after	  
plating,	   the	   medium	   was	   replaced	   with	   500μl	   medium	   used	   for	   lactate	  
measurements	  (Chapter	  2,	  Section	  2.12).	  After	  4	  hours	  incubation,	  this	  medium	  
was	  collected	  for	  lactate	  measurements	  using	  a	  Lactate	  Colorimetric	  Kit	  (Abcam).	  
Lactate	   levels	   in	   each	   sample	  were	   normalized	   to	   the	   total	   amount	   of	   protein	  
present,	  as	  measured	  using	  a	  BCA	  protein	  quantification	  kit	  (Thermo	  Scientific).	  
The	  secreted	  lactate	  values	  in	  Cln3-­‐/-­‐	  samples	  were	  additionally	  normalized	  to	  the	  
corresponding	  WT	  values	  in	  order	  to	  compare	  the	  results	  between	  experiments.	  
The	  medium	  collected	   from	  Cln3-­‐/-­‐	  astrocyte	  cultures	  exhibited	  a	  slight,	  but	  not	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significant,	   increase	   in	   lactate	   levels	   compared	   to	   that	   collected	   from	   WT	  
astrocytes	  (Figure	  4.11	  A).	  This	  result	  suggests	  that	  Cln3-­‐/-­‐	  astrocytes	  are	  able	  to	  
secrete	  the	  lactate	  that	  they	  produce	  as	  a	  result	  of	  normal	  glycolysis.	  	  
	  
To	   evaluate	  whether	   the	   uptake	   of	   glutamate	  was	   altered	   in	  Cln3-­‐/-­‐	  astrocytes,	  
astrocytes	  of	  both	  genotypes	  were	  plated	  on	  6-­‐well,	  and	  then	  24	  -­‐	  48	  hours	  later	  
the	   culture	  medium	   in	   each	  well	  was	   replaced	  with	   1.5ml	   of	   serum	   free	  HBSS	  
that	   also	   contained	   2mM	  glutamate.	   After	   incubation	   for	   2	   hours	   the	  medium	  
was	  removed	  and	  the	  remaining	  glutamate	  in	  the	  medium	  was	  determined	  using	  
a	   Glutamate	   Assay	   Kit	   (Abcam;	   Chapter	   2,	   Section	   2.13).	   Serum-­‐free	   medium	  
containing	  2mM	  glutamate	  placed	   in	  wells	   that	  did	  not	   contain	  astrocytes	  was	  
used	   as	   a	   control	   (100%	   remaining	   glutamate)	   for	   each	   experiment.	   The	  
‘remaining’	  glutamate	  values	  obtained	  were	  normalized	   to	   the	   total	  amount	  of	  
protein	   in	   each	   sample,	   and	   the	   values	   from	   Cln3-­‐/-­‐	   astrocyte	   cultures	   were	  
normalized	   to	   the	   corresponding	  WT	   astrocyte	   values	  within	   each	   experiment.	  
These	   measurements	   revealed	   that	   more	   glutamate	   remained	   in	   medium	  
collected	   from	   Cln3-­‐/-­‐	   astrocytes	   cultures	   that	   in	   medium	   collected	   from	   WT	  
astrocyte	   cultures.	   Indeed,	   the	   Cln3-­‐/-­‐	   astrocytes	   took	   up	   significantly	   less	  
(48.0±14.0%	  reduction	  in	  glutamate	  clearance)	  glutamate	  when	  compared	  to	  WT	  
astrocytes	   (Figure	   4.11	   B),	   suggesting	   that	   Cln3-­‐/-­‐	   astrocytes	   are	   not	   able	   to	  
scavenge	  excess	  glutamate	  as	  effectively	  as	  WT	  astrocytes.	  	  
	  
Based	   on	   these	   data,	   Cln3-­‐/-­‐	   astrocytes	   are	   able	   to	   produce	   and	   secrete	   the	  
energy	   metabolite	   lactate	   when	   sufficient	   levels	   of	   glucose	   are	   available.	  
However,	  Cln3-­‐/-­‐	  astrocytes	  did	  not	   take-­‐up	  glutamate	  as	  efficiently	  as	  did	   their	  
healthy	   counterparts,	   which	  may	   lead	   to	   excitotoxicity	   and	   thus	   contribute	   to	  
neuronal	  death	  in	  the	  JNCL	  brain.	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Figure	  4.11.	  Lactate	  secretion	  is	  not	  altered	  in	  Cln3-­‐/-­‐	  astrocytes,	  but	  glutamate	  
clearance	   is.	  WT	  and	  Cln3-­‐/-­‐	  astrocyte	  cultures	  plated	  on	  6-­‐well	  plates	  were	  used	  to	  measure	  
the	   ability	   of	   these	   cells	   to	   secrete	   lactate	   and	   take	   up	   glutamate.	   (A)	   The	   amount	   of	   lactate	  
secreted	  from	  WT	  and	  Cln3-­‐/-­‐	  astrocyte	  cultures	  over	  a	  4	  hours	  incubation	  period	  was	  measured	  
using	  a	   lactate	  assay	  kit.	   These	  values	  were	  normalized	   to	   total	   amount	  of	  protein,	   and	  values	  
from	   Cln3-­‐/-­‐	   astrocyte	   samples	   were	   normalized	   to	   WT	   astrocyte	   samples.	   There	   was	   no	  
significant	  difference	  in	  the	  ability	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  to	  secrete	  lactate.	  (B)	  The	  take-­‐up	  
of	  glutamate	  by	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  was	  assessed	  using	  a	  Glutamate	  Assay	  Kit.	  WT	  and	  Cln3-­‐
/-­‐	  astrocytes	  were	  incubated	  with	  2mM	  glutamate	  for	  2	  hours,	  and	  wells	  without	  astrocytes	  were	  
used	  as	  controls.	  The	  glutamate	  remaining	  in	  the	  medium	  was	  quantified	  and	  normalized	  to	  total	  
amount	  of	  protein,	   and	   the	  glutamate	  values	  of	  Cln3-­‐/-­‐	   astrocytes	  were	  normalized	   to	   those	  of	  
WT	   astrocyte	   samples.	   Cln3-­‐/-­‐	   astrocytes	   took	   up	   significantly	   less	   glutamate	   than	   did	   WT	  
astrocytes	   over	   the	   2	   hours	   period.	  Data	   is	   presented	   as	   average	  mean±SEM.	   This	   experiment	  
was	   repeated	   five	   times	   and	   three	   technical	   repeats	  were	   analyzed	   for	   each	   condition	   in	   each	  
experiment.	  	  
	  
Migration	  of	  Cln3-­‐/-­‐	  astrocytes	  is	  attenuated	  
Generally	  astrocyte	  motility	  has	  been	  associated	  with	  various	  processes	  including	  
embryonic	   development,	   wound	   healing	   and	   formation	   of	   a	   glial	   scar,	   local	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inflammation	  processes	  and	  angiogenesis	  (Cayre	  et	  al.,	  2009).	  Thus,	  migration	  is	  
an	   essential	   part	   of	   astrocyte	   biology	   and	   appropriate	   rearrangements	   of	   the	  
cytoskeleton	   are	  pivotal	   for	   this	   process.	  Our	   data	   reveal	   that	   the	   actin	   and	   IF	  
cytoskeleton	   is	  disorganized	   in	  Cln3-­‐/-­‐	   astrocytes,	   as	  was	   their	   ability	   to	   change	  
morphologically	   in	   response	   to	   stimulation	   (Chapter	   3,	   Figures	   3.7	   and	   3.8).	  
Moreover,	  recent	  reports	  suggest	  that	  CLN3	  deficiency	  leads	  to	  impaired	  cellular	  
motility	   in	   mouse	   embryonic	   fibroblasts	   via	   alterations	   in	   myosin-­‐IIB	   activity	  
(Getty	  et	  al.,	   2011).	   Thus,	   the	  possibility	   that	   the	  ability	  of	  Cln3-­‐/-­‐	   astrocytes	   to	  
migrate	   may	   also	   be	   perturbed	   was	   investigated	   using	   live	   cell	   imaging	   of	   a	  
‘scratch	  wound’	  assay.	  
	  
	  Astrocytes	  were	  plated	  on	  Essen	  Image	  Lock	  24-­‐well	  plates	  at	  50,000	  cells	  (WT	  
astrocytes)	   or	   100,000	   (Cln3-­‐/-­‐	   astrocytes)	   cells	   per	   well	   due	   to	   the	   observed	  
differences	   in	   the	   proliferation	   of	  WT	   and	  Cln3-­‐/-­‐	   astrocytes	   (Chapter	   3,	   Figure	  
3.9).	   After	   cells	   had	   formed	   a	   confluent	   monolayer	   and	   stopped	   dividing,	   an	  
Essen	  Wound-­‐maker	  was	  used	  to	  create	  a	  cell-­‐free	  wound.	  Subsequently,	   fresh	  
astrocyte	   culture	   medium	   with	   or	   without	   LPS/IFNγ,	   but	   containing	   Ara-­‐C	   (to	  
inhibit	  astrocyte	  proliferation	  during	  the	  experiment)	  was	  added	  to	  cultures	  and	  
the	  migration	  of	  WT	  and	  Cln3-­‐/-­‐	  astrocytes	  was	  analyzed.	   	   Images	  from	  the	  cells	  
were	   taken	   every	   1	   hour	   for	   24	   hours,	   and	   the	   width	   of	   the	   wound	   was	  
measured.	  The	  rate	  of	  migration	  was	  calculated	  from	  the	  change	  in	  wound	  width	  
over	  time,	  as	  previously	  described	  (Etienne-­‐Manneville	  and	  Hall,	  2001).	  	  
	  
Following	   mechanical	   disruption	   of	   the	   confluent	   monolayer,	   untreated	   and	  
LPS/IFNγ	   treated	   WT	   astrocytes	   migrated	   into	   the	   cell	   free	   area	   rapidly	   and	  
nearly	   closed	   the	   gap	   within	   24	   hours	   (Figure	   4.12	   A	   and	   B).	   The	   migration	  
distance	   of	   WT	   astrocytes	   did	   not	   significantly	   differ	   between	   treated	   and	  
untreated	   cultures	   (Figure	   4.12	   A	   and	   B).	   For	   example,	   the	   average	   distance	  
untreated	  WT	  astrocytes	  migrated	  during	  the	  first	  4h	  after	  the	  scratch	  had	  been	  
made	   was	   22.9±3.1μm,	   whereas	   LPS/IFNγ	   treated	   WT	   astrocytes	   migrated	  
24.1±4.9μm	   (Figure	   4.12	   B).	   The	   distance	   Cln3-­‐/-­‐	   astrocytes	  migrated	   over	   this	  
same	   time	   was	   significantly	   reduced	   in	   both	   untreated	   and	   LPS/IFNγ	   treated	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conditions	   (Figure	   4.12	   A	   and	   B).	   This	   can	   be	   seen	   from	   the	   distance	   Cln3-­‐/-­‐	  
astrocytes	  migrated	   during	   the	   first	   4	   hours	   of	   the	   experiment;	   12.8±2.8μm	   in	  
untreated	  conditions	  and	  7.6±3.2μm	  in	  LPS/IFNγ	  treated	  conditions	  (Figure	  4.12	  
B).	  Again	  activation	  with	  LPS/IFNγ	  did	  not	   significantly	  alter	   the	  distance	  Cln3-­‐/-­‐	  
astrocytes	  migrated	  over	   time	   (Figure	  4.12	  B).	  Moreover,	   the	   rate	  of	  migration	  
was	  significantly	  decreased	  in	  the	  absence	  of	  CLN3	  in	  both	  treated	  and	  untreated	  
conditions	   (Figure	   4.12	   C).	   The	   average	   migration	   rate	   for	   untreated	   WT	  
astrocytes	   was	   approximately	   5.3±0.6μm/h,	   and	   for	   LPS/IFNγ	   treated,	  
approximately	   5.3±0.4μm/h,	   while	   these	   numbers	   were	   2.3±0.6μm/h	   for	  
untreated	  and	  1.5±0.3μm/h	   for	   LPS/IFNγ	   treated	  Cln3-­‐/-­‐	   astrocytes	   (Figure	  4.12	  
C).	   Thus,	   the	   LPS/IFNγ	   treatment	   did	   not	   cause	   any	   significant	   changes	   in	   the	  
migration	   speed	   in	   either	   WT	   or	   Cln3-­‐/-­‐	   astrocyte,	   indicating	   that	   this	   type	   of	  
activation	   stimulus	   does	   not	   have	   any	   affect	   on	   the	   ability	   of	   astrocytes	   to	  
migrate	   in	   vitro.	   However,	   in	   all	   conditions	   tested	   WT	   astrocytes	   migrated	  
further	  and	  faster	  in	  the	  explored	  timescale	  than	  did	  Cln3-­‐/-­‐	  astrocytes.	  Thus,	  this	  
attenuated	   migration	   of	   Cln3-­‐/-­‐	   astrocytes	   could	   alter	   their	   functioning	   during	  
development	  and	  upon	  injury.	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Figure	   4.12.	   Scratch	   assay	   reveals	   a	  migration	  defect	   in	  Cln3−/−	  astrocytes.	  WT	  
and	  Cln3-­‐/-­‐	  astrocytes	  were	  plated	  on	  Essen	  Image	  Lock	  24-­‐well	  plates,	  grown	  to	  confluence	  then	  
scratched	   using	   an	   Essen	   wound	   maker.	   These	   cells	   were	   kept	   in	   astrocyte	   culture	   medium	  
containing	   Ara-­‐C,	   with	   or	   without	   LPS/IFNγ,	   as	   indicated.	   (A)	   Representative	   pictures	   of	   the	  
wound	  at	  three	  time-­‐points	  from	  untreated	  and	  LPS/IFNγ	  treated	  WT	  and	  Cln3-­‐/-­‐	  astrocytes.	   (B)	  
The	   distance	   each	   edge	   of	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   traversed	   every	   4	   hours	   was	   calculated	  
relative	  to	  the	  initial	  scratch	  distance.	  WT	  astrocytes	  migrated	  significantly	  further	  than	  did	  Cln3-­‐/-­‐	  
astrocytes.	  (C)	  The	  Rate	  of	  migration	  was	  measured	  by	  calculating	  the	  distance	  migrated	  by	  these	  
cells/h.	   Cln3-­‐/-­‐	   astrocytes	   migrated	   significantly	   slower	   than	  WT	   astrocytes.	   Data	   presented	   as	  
mean±SEM.	   In	  each	  experiment	   three	  wound	  widths	  were	  measured	  per	  well,	   and	   three	  wells	  
per	  experimental	  condition	  were	  quantified.	  This	  experiment	  was	  repeated	  four	  times.	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4.3	  Discussion	  	  
Any	  major	  alterations	  in	  the	  basic	  functions	  of	  astrocytes	  may	  have	  a	  significant	  
impact	  on	  neuronal	  function	  and	  survival	  (Volterra	  and	  Meldolesi,	  2005;	  Sidoryk-­‐
Wegrzynowicz	  et	   al.,	   2011).	   In	   this	   chapter	  we	  have	   shown	   that	  Ca2+	   signaling,	  
the	  basis	  for	  glial-­‐glial	  and	  glial-­‐neuronal	  cell	  communication	  in	  the	  brain	  (Fiacco	  
and	  McCarthy,	  2006;	  Zorec	  et	  al.,	  2012;	  Verkhratsky	  et	  al.,	  2012a),	  is	  abnormal	  in	  
Cln3-­‐/-­‐astrocytes,	  with	   smaller	  and	   less	   frequent	   spontaneous	  oscillations	  and	  a	  
lack	  of	  synchronized	  spontaneous	  calcium	  wave	  formation	  being	  observed,	  along	  
with	  altered	  ER-­‐calcium	  release	  and	  clearance.	  These	  cells	  were	  also	  shown	  to	  be	  
impaired	   in	   their	   ability	   to	   secrete	   (although	   not	   synthesize)	   a	   range	   of	  
chemokines,	   pro-­‐and	   anti-­‐inflammatory	   cytokines,	   neurotrophic	   factors	   and	  
mitogens	  upon	  stimulation.	  This	   finding	  was	  extended	  to	  the	  major	  antioxidant	  
of	   the	  brain,	  glutathione,	   that	  was	  synthesized	  but	  not	   secreted	  by	   these	  cells,	  
suggesting	  that	  loss	  of	  CLN3	  function	  in	  astrocytes	  could	  lead	  to	  oxidative	  stress-­‐
mediated	   neurodegeneration	   in	   JNCL	   (Dringen,	   2000;	   Schulz	   et	   al.,	   2000;	  
Benedict	  et	  al.,	  2007;	  Tuxworth	  et	  al.,	  2011).	  Furthermore,	  the	  observed	  failure	  
of	  Cln3-­‐/-­‐astrocytes	   to	   take-­‐up	   glutamate	   as	   effectively	   as	  WT	   astrocytes	   could	  
contribute	   towards	   excitotoxic	   neuronal	   loss	   in	   this	   disease	   (Sattler	   and	  
Rothstein,	   2006).	   Finally,	   we	   show	   that	   CLN3	   is	   important	   for	   the	   motility	   of	  
astrocytes	   since	   lack	   of	   this	   protein	   causes	   astrocytes	   to	   migrate	   significantly	  
slower	  than	  normal.	  Taken	  together	  these	  results	  indicate	  that	  many	  of	  the	  basic	  
functional	  properties	  of	  Cln3-­‐/-­‐	  astrocytes	  are	  abnormal	  and	  could	  directly	  impact	  
neuronal	  health,	  a	  hypothesis	  that	  will	  be	  tested	  in	  Chapter	  6	  of	  this	  thesis.	  	  	  
Specific	  alterations	  in	  Cln3-­‐/-­‐	  astrocytes	  calcium	  signaling	  	  
Ca2+	  based	  signaling	   forms	   the	  basis	   for	  many	   functions	  of	  astrocytes	   (Zorec	  et	  
al.,	  2012).	  An	  increase	  in	  [Ca2+]I	  levels	  in	  astrocytes	  may	  result	  in	  gliotransmission	  
(Halassa	  et	  al.,	  2007;	  Parpura	  and	  Zorec,	  2010;	  Verkhratsky	  et	  al.,	  2012a).	  Upon	  
being	  released	  into	  the	  extracellular	  space	  these	  gliotransmitters	  can	  exert	  their	  
actions	   on	   neighboring	   neuronal	   cells	   modulating	   synaptic	   transmission	   and	  
plasticity,	  or	  on	  other	  glial	  cells	  altering	  their	  neuroimmune	  responses	  (Agulhon	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et	   al.,	   2012).	   Thus,	   Ca2+	   based	   signaling	   is	   a	   crucial	   communication	   element	  
exploited	   by	   astrocytes	   to	   connect	   them	   to	   other	   cells	   in	   the	   CNS.	   Our	   data	  
revealed	   for	   the	   first	   time	   that	   the	   spontaneous	   [Ca2+]I	   transients	   in	   Cln3-­‐/-­‐	  
astrocytes	   were	   smaller	   and	   less	   frequent	   than	   in	   WT	   astrocytes	   (Chapter	   4,	  
Figure	   4.1).	   Additionally,	   Cln3-­‐/-­‐	   astrocytes	   did	   not	   create	   a	   synchronized,	  
propagating	   Ca2+	   wave	   when	   grown	   as	   closely	   connected	   astrocyte	   sheets	  
(Chapter	   4,	   Figure	  4.2).	   Both	  of	   these	  defects	  may	  be	   caused	  by	   abnormal	   ER-­‐
based	  Ca2+	  signaling,	  as	  discussed	  below.	  	  
	  
Many	  studies	  suggests	  that	  IP3-­‐dependent	  calcium-­‐induced	  calcium	  release	  from	  
the	  ER	  (CICR)	  is	  required	  for	  spontaneous	  Ca2+	  oscillations	  in	  astrocytes	  (Aguado	  
et	   al.,	   2002;	   Parri	   and	   Crunelli,	   2003;	   Tanaka	   et	   al.,	   2007).	   Initially	   a	   small	  
increase	   in	   [Ca2+]	   either	   via	   release	   from	   the	   ER	  or	   through	   voltage-­‐gated	  Ca2+	  
channels	  (VGCC)	  is	  required	  for	  initiation	  of	  the	  CICR,	  and	  this	  subsequently	  leads	  
to	   spontaneous	   Ca2+	  oscillations	   (Latour	   et	   al.,	   2003;	   2004;	  Wang	   et	   al.,	   2006).	  
These	  spontaneous	  Ca2+	  oscillations	  appeared	  to	  start	  moderately	  later	  in	  Cln3-­‐/-­‐	  
astrocytes	  than	  in	  WT	  counterparts.	  These	  data	  suggest	  that	  the	  CICR	  mechanism	  
is	   altered	   in	   these	   cells,	   or	   alternatively	   that	   the	   initial	   small	   increase	   in	   [Ca2+]	  
required	   for	   the	  activation	  of	  CICR	  does	  not	  occur	  with	   the	  same	  velocity	  as	   in	  
WT	  astrocytes.	  It	  may	  be	  that	  this	  small	  Ca2+	  increase,	  generated	  either	  through	  
voltage-­‐gated	  Ca2+	  channels	   (VGCC)	  expressed	  by	  cultured	  astrocytes	   (Latour	  et	  
al.,	  2003;	  2004),	  or	   from	  the	  ER	  via	  the	  activation	  of	   IP3-­‐receptors,	   is	  altered	   in	  
Cln3-­‐/-­‐	  astrocytes	  leading	  to	  a	  delayed	  initiation	  of	  spontaneous	  Ca2+	  oscillations.	  
Any	   alterations	   in	   either	   one	   of	   these	  mechanisms	  would	   also	   explain	   the	   low	  
frequency	   and	   smaller	   amplitude	   of	   the	   spontaneously	   induced	   increases	   in	  
[Ca2+]I	   in	   these	   Cln3	   deficient	   cells.	   Some	   evidence	   suggests	   that	   spontaneous	  
[Ca2+]I	  transients	  are	  a	  common	  feature	  of	  resting	  astrocytes	   in	  numerous	  brain	  
regions,	  but	  are	  absent	   in	   reactive	  astrocytes	   (Aguado	  et	  al.,	   2002).	  Given	   that	  
the	   Cln3-­‐/-­‐	   astrocytes	   showed	   increased	   GFAP	   expression	   under	   resting	  
conditions	   they	   may	   be	   more	   ‘activated’	   than	   WT	   astrocytes,	   and	   thus	   show	  
attenuated	   spontaneous	   [Ca2+]I	   transients	   (Chapter	   3,	   Figure	   3.6).	   It	   would	   be	  
interesting	   to	   study	   whether	   spontaneous	   [Ca2+]I	   transients	   in	   WT	   and	   Cln3-­‐/-­‐	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astrocytes	   are	   altered	   after	   these	   cells	   have	   been	   activated	   with	   LPS/IFNγ.	  
Spontaneous	  astrocytic	   [Ca2+]I	  oscillations	  have	  been	  shown	   to	   trigger	  neuronal	  
excitation	   in	   the	   thalamus	   (Parri	   et	   al.,	   2001).	   Thus,	   deregulated	   spontaneous	  
astrocytic	   [Ca2+]I	   oscillations	   could	   potentially	   lead	   to	   abnormal	   stimulation	   of	  
neuronal	   networks	   in	   the	  Cln3-­‐/-­‐	  mouse	   brain	   (Pasti	   et	   al.,	   1997;	   Araque	   et	   al.,	  
1998;	  Bezzi	  et	  al.,	  1998;	  Parri	  et	  al.,	  2001;	  Parpura	  et	  al.,	  2011).	  	  	  	  	  	   
 
Furthermore,	  spontaneously	  arising	   increases	   in	   [Ca2+]I,	  which	  are	  synchronized	  
among	  a	  group	  of	  astrocytes	  to	  create	  a	  propagating	  calcium	  wave	  (Cornell-­‐Bell	  
et	  al.,	  1990a;	  Cotrina	  et	  al.,	  2000;	  Arcuino	  et	  al.,	  2002;	  Bowser	  and	  Khakh,	  2007),	  
was	   not	   observed	   in	   Cln3-­‐/-­‐	   astrocytes.	   Two	   routes	   have	   been	   established	   to	  
enable	   calcium	   wave	   propagation	   between	   astrocytes:	   1)	   via	   intercellular	   gap	  
junctions,	  which	  allow	  diffusion	  of	  signaling	  molecules	  from	  one	  cell	  to	  another;	  
or	   2)	   via	   the	   extracellular	   space,	   which	   involves	   the	   release	   of	   signaling	  
molecules	  that	  may	  then	  activate	  receptors	  on	  the	  membranes	  of	  adjacent	  cells	  
(Scemes,	   2000;	   Scemes	  and	  Giaume,	  2006).	   The	  observed	   lack	  of	   synchronized	  
Ca2+	   wave	   propagation	   within	   cultured	   Cln3-­‐/-­‐	   astrocytes	   could	   be	   caused	   by	  
alterations	  in	  one	  or	  both	  of	  these	  mechanisms.	  The	  role	  of	  gap	  junctions	  in	  Ca2+	  
wave	   propagation	   in	   astrocytes	   has	   remained	   controversial,	   which	   may	   be	   a	  
reflection	  of	  the	  heterogeneous	  distribution	  of	  gap	  junctions	   in	  the	  CNS	  (Batter	  
et	  al.,	  1992;	  Blomstrand	  et	  al.,	  1999;	  Scemes	  et	  al.,	  2000).	  The	  expression	  pattern	  
of	   Cx43	   protein,	   which	   is	   the	   main	   gap	   junction-­‐forming	   connexin	   protein	   in	  
astrocytes	   (Giaume	   et	   al.,	   1991;	   Scemes	   et	   al.,	   1998),	   was	   not	   found	   to	   be	  
significantly	  altered	  in	  Cln3-­‐/-­‐	  astrocytes	  (Chapter	  4,	  Figure	  4.3).	  This	  observation	  
would	   indicate	   that	   Cln3-­‐/-­‐	   astrocytes	   at	   least	   express	   and	   localize	   proteins	  
involved	   in	   the	   formation	   of	   gap	   junctions	   correctly.	   However,	   based	   on	   this	  
simple,	   qualitative	   observation,	   one	   cannot	   exclude	   the	   possibility	   that	   gap	  
junction	   connectivity	   between	   Cln3-­‐/-­‐	   astrocytes	   is	   affected.	   As	   a	   next	   step	   it	  
would	  be	   important	   to	  measure	   the	  connectivity	  of	  gap	   junctions	  within	  Cln3-­‐/-­‐	  
astrocyte	   networks	   and	   compare	   this	   to	   their	  WT	   counterparts.	   This	   could	   be	  
achieved	   by	   using	   an	   intercellular	   dye	   coupling	   method;	   loading	   of	   a	   low	  
molecular	  weight	   fluorescent	  dye	   (such	  as	  Lucifer	  yellow	  CH)	   into	  astrocytes	   in	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culture	   and	  monitor	   its	   transfer	   between	   connected	   astrocytes	   (el-­‐Fouly	   et	   al.,	  
1987;	  Naus	  et	  al.,	   1997).	   This	  would	  help	   to	  provide	  a	  better	  understanding	  of	  
the	   trafficking	   of	   small	   molecules	   via	   gap	   junctions	   formed	   between	   Cln3-­‐/-­‐	  
astrocytes.	  	  
	  
ATP	  secretion	  by	  astrocytes	  and	  activation	  of	  P2Y1	  receptors	  on	  neighboring	  cells	  
has	  also	  been	  proposed	  to	  be	  important	  for	  astrocyte	  wave	  propagation	  (Scemes	  
et	  al.,	  2000;	  Bowser	  and	  Khakh,	  2007).	  Externally	  applied	  ATP	  produced	  normal	  
[Ca2+]i	  elevations	   in	  Cln3-­‐/-­‐	  astrocytes,	  and	  as	  such	  the	  ATP-­‐induced	  Ca2+	   release	  
from	   the	   ER	   via	   the	   activation	   of	   IP3-­‐receptor	   channels	   does	   not	   appear	   to	   be	  
affected	   in	  Cln3-­‐/-­‐	  astrocytes.	  However,	  perhaps	  the	  release	  of	  ATP	  required	  for	  
wave	  propagation	  is	  abnormal	  in	  Cln3-­‐/-­‐	  astrocytes,	  thus	  explaining	  at	  least	  partly	  
the	   poor	   propagation	   of	   their	   intercellular	   Ca2+	   wave,	   an	   explanation	   worth	  
considering	  since	  these	  cells	   fail	   to	  secretion	  a	  range	  of	   factors	   (Tables	  4.1	  and	  
4.2).	  One	  could	  test	  this	  possibility	  directly	  by	  measuring	  the	  release	  of	  ATP	  from	  
Cln3-­‐/-­‐	  astrocyte	  cultures.	  Furthermore,	  analyzing	  the	  expression	  pattern	  of	  P2Y1	  
receptors	   on	   Cln3-­‐/-­‐	   astrocytes	   would	   broaden	   the	   understanding	   of	   the	  
responsiveness	   of	   Cln3-­‐/-­‐	   astrocytes	   to	   purinergic	   based	   signaling,	   which	   is	  
important	   for	   astrocyte-­‐astrocyte	   and	   neuron-­‐astrocyte	   communication	   (Fields	  
and	   Burnstock,	   2006).	   Finally,	   to	   ensure	   these	   deficits	   observed	   in	   cultured	  
astrocytes	   truly	   reflect	   the	  situation	   in	   intact	   tissue,	   it	   is	  pivotal	   that	  Ca2+	  wave	  
propagation	  be	  studied	   in	  organotypic	  Cln3-­‐/-­‐	  cortical	  slices,	  and	  eventually	  also	  
in	  vivo	  by	  means	  of	  two-­‐photon	  microscopy,	  for	  example.	  	  
	  
It	   has	   been	   previously	   demonstrated	   that	   an	   intact	   actin	   cytoskeleton	   is	   a	   key	  
requirement	   for	   the	  generation	  of	  a	   long-­‐distance	  calcium	  wave	   (Cotrina	  et	  al.,	  
1998).	   Thus,	   the	   severely	   disrupted	   actin	   cytoskeleton	   observed	   in	   Cln3-­‐/-­‐	  
astrocytes	   may	   be	   the	   reason	   behind	   the	   lack	   of	   synchronized	   calcium	   wave	  
propagation	  by	  these	  cells,	  possibly	  due	  to	  its	  inability	  to	  serve	  as	  a	  scaffold	  for	  
signaling	  molecules	  required	  for	  this	  process,	  such	  as	  PIP2	  and	  IP3	  and	  IP3-­‐R,	  all	  of	  
which	  have	  been	  associated	  with	  actin	  in	  a	  number	  of	  systems	  (Feng	  and	  Kraus-­‐
Friedmann,	  1993;	  Sastry	  and	  Horwitz,	  1993;	  Miki	  et	  al.,	  1996;	  Cotrina	  et	  al.,	  1998;	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Tojkander	  et	  al.,	  2012).	  Additionally,	  CLN3	  has	  been	  suggested	  to	  be	  involved	  in	  
the	  control	  of	  Na+-­‐K+-­‐ATPase	  turnover	  at	  the	  plasma	  membrane	  via	  fodrin,	  which	  
is	  a	  cytoskeletal	  protein	  that	   is	  also	  associated	  with	  actin	  filaments	  (De	  Matteis	  
and	  Morrow,	   2000;	   Uusi-­‐Rauva	   et	   al.,	   2008).	   Na+-­‐K+-­‐ATPase	   is	   involved	   in	   the	  
regulation	   of	   ionic	   homeostasis	   and	   also	   participates	   in	   other	   intracellular	  
signaling	  events,	  including	  Ca2+	  signaling	  (Tian	  and	  Xie,	  2008).	  It	  has	  been	  shown	  
that	  ouabain,	  which	  is	  a	  ligand	  for	  Na+-­‐K+-­‐ATPase,	  can	  trigger	  calcium	  oscillations	  
in	  cultured	  primary	  astrocytes	  (Liu	  et	  al.,	  2007).	  Thus,	  a	   lack	  of	  turnover	  of	  this	  
protein	  at	  the	  plasma	  membrane,	  possibly	  due	  to	  a	  disrupted	  actin	  cytoskeleton,	  
could	  also	  influence	  calcium	  oscillations	  in	  Cln3-­‐/-­‐	  astrocytes.	  
	  
Cln3-­‐/-­‐	  astrocytes	  also	  displayed	  specific	  alterations	  in	  Ca2+	  released	  from	  the	  ER	  
in	  response	  to	  thapsigargin	  treatment	  (Chapter	  4,	  Figure	  4.5).	  A	  distinct	  subset	  of	  
Cln3-­‐/-­‐	  astrocytes	  had	  a	  very	  large	  and	  fast	  release	  of	  Ca2+	  from	  the	  ER,	  whereas	  
Ca2+	  release	  from	  the	  remaining	  Cln3-­‐/-­‐	  astrocytes	  was	  indistinguishable	  from	  that	  
of	  WT	   astrocytes.	   This	   finding	  may	   indicate	   the	   existence	   of	   distinct	   group	   of	  
Cln3-­‐/-­‐	   astrocytes	   with	   a	   very	   high	   [Ca2+]ER	   content,	   or	   that	   the	   mechanisms	  
behind	  the	  passive	  leakage	  of	  Ca2+	  from	  ER	  are	  impaired	  in	  these	  particular	  cells.	  
Moreover,	   the	  process	  of	  Ca2+	  clearance	   from	   the	   cytosol	   to	  other	   intracellular	  
stores	   or	   to	   the	   extracellular	   space	  was	   found	   to	   be	   attenuated	   in	   these	   cells,	  
which	  was	  demonstrated	  by	   the	  prolonged	  high	   levels	   of	   [Ca2+]I	  seen	   following	  
thapsigargin	   treatment.	   Numerically	   this	   could	   have	   been	   verified	   by	  
determining	   the	   TAU	   (decay)	   constant	   in	  WT	   and	   Cln3-­‐/-­‐	  astrocyte	   populations	  
following	   thapsigargin	   treatment.	   However,	   in	   order	   to	   determine	   the	   TAU	  
constant,	   Ca2+	   current	   readouts	   from	   a	   specific	   channel	   are	   required.	   In	   this	  
study,	  the	  Fura-­‐2-­‐	  Ca2+	   indicator,	  which	  provides	  ratiometric	  Ca2+	  readouts	  from	  
two	   channels	   was	   used,	   thus,	   the	   determination	   of	   the	   Tau	   constant	   was	   not	  
feasible	  and	  would	  require	  additional	  measurements.	  There	  are	  several	  possible	  
explanations	   for	   this	   result,	   including	   the	   enhanced	   release	   of	   Ca2+	  from	   other	  
intracellular	   Ca2+stores,	   or	   the	   impaired	   clearance	   of	   ER	   leaked	   Ca2+	  into	   these	  
stores;	   mainly	   mitochondria	   and	   lysosomes.	   Interestingly,	   dysregulated	  
lysosome-­‐based	  Ca2+	  signaling	  has	  been	  described	  previously	  in	  other	  lysosomal	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disorders	   (Lloyd-­‐Evans	   and	   Platt,	   2011).	   In	   fact,	   a	   number	   of	   acidic	   organelles,	  
such	  as	  lysosomes,	  endosomes,	  and	  the	  Golgi	  complex	  have	  been	  recognized	  to	  
function	  as	  intracellular	  Ca2+	  stores,	  in	  which	  Ca2+	  intake	  and	  release	  is	  mediated	  
by	  a	  number	  of	  calcium	  pumps,	  exchangers	  and	  receptors	  (Patel	  and	  Docampo,	  
2010).	   For	   instance,	   defective	   lysosomal	   Ca2+	   uptake	   and	   defective	   NAADP-­‐
mediated	   lysosomal	   Ca2+	   release	   has	   been	   shown	   to	   lead	   to	   a	   disruption	   of	  
endocytosis	  and	  lipid	  storage	  in	  Niemann-­‐Pick	  type	  C	  (NPC)	  disease	  (Lloyd-­‐Evans	  
et	  al.,	  2008).	  Furthermore,	  neutrophil	  cells	   in	  Chediak-­‐Higashi	  Syndrome	  exhibit	  
enhanced	   lysosomal	   Ca2+	   uptake	   (Styrt	   et	   al.,	   1988).	   Given	   that	   the	   primary	  
location	   of	   CLN3	   is	   thought	   to	   be	   in	   the	   lysosomal	   membrane,	   where	   the	  
important	   players	   of	   lysosomal	   Ca2+	   regulation	   are	   also	   located,	   altered	  
lysosomal	   Ca2+	   signaling	   may	   also	   play	   a	   role	   in	   the	   pathogenesis	   of	   JNCL.	  
Furthermore,	   lysosomal	   location	  and	  maturation	  was	   found	  abnormal	   in	  Cln3-­‐/-­‐	  
astrocytes	   (Chapter	   3,	   Figure	   3.11),	   which	   may	   alter	   lysosomal-­‐mediated	  
regulation	   of	   intracellular	   Ca2+	   homeostasis	   in	   these	   cells.	   Indeed,	   the	   lack	   of	  
cytosolic	  Ca2+	  clearance	  may	  suggest	   that	   lysosomal	  Ca2+	  regulation	   is	  disrupted	  
in	  JNCL,	  something	  that	  certainly	  warrants	  further	  investigation.	  
Mitochondria	  are	  also	  essential	  for	  the	  regulation	  of	  cytosolic	  Ca2+	  in	  astrocytes	  
(Duchen,	   2000;	   Reyes	   and	   Parpura,	   2008).	   Thus,	   mitochondrial-­‐mediated	   Ca2+	  
regulation	  may	  contribute	  towards	  the	  observed	  defects	  in	  Cln3-­‐/-­‐	  astrocyte	  Ca2+	  
signaling.	   Any	   impairments	   in	   mitochondrial	   Ca2+	   uptake	   may	   also	   deregulate	  
mitochondrial	  energy	  metabolism,	  since	  the	  mitochondrial	  Ca2+	  uptake	  pathway	  
provides	  a	  mechanism	  that	  couples	  energy	  demand	  to	  increased	  ATP	  production,	  
via	  calcium-­‐dependent	  up-­‐regulation	  of	  mitochondrial	  enzyme	  activity	  (Duchen,	  
1999).	   Previously,	   CLN3	   deficiency	   has	   been	   linked	   with	   abnormalities	   in	   the	  
mitochondrial	   function	   in	   a	   variety	   of	   cellular	   models	   (Brooks	   et	   al.,	   2003;	  
Chattopadhyay	  et	  al.,	   2004;	   Luiro	  et	  al.,	   2006).	  Thus,	   impaired	  Ca2+	  uptake	   into	  
mitochondria	   in	   Cln3-­‐/-­‐	   astrocytes	   may	   lead	   to	   a	   dysfunction	   in	   energy	  
metabolism.	   It	   would	   be	   interesting	   to	   study	   if	   mitochondrial	   Ca2+	   uptake,	   or	  
release	  in	  Cln3-­‐/-­‐	  astrocytes,	  is	  impaired	  by	  directly	  measuring	  the	  mitochondrial	  
Ca2+	  content	  using	  mitochondrially	  localized	  Ca2+	  indicators	  like	  rhod-­‐2	  (Boitier	  et	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al.,	   1999).	  Moreover,	   similar	   investigations	   could	  be	  extended	   to	   lysosomes	  by	  
using	   lysosome-­‐specific	   Ca2+	   indicators,	   such	   as	   genetically	   encoded	   Ca2+	  
indicator	   (GCaMP3)	   connected	   directly	   to	   TRPML1,	   which	   is	   one	   of	   the	   Ca2+	  
channels	   in	   the	   lysosomes	   (Shen	   et	   al.,	   2012).	   Alternatively,	   pharmacological	  
agents	   like	   glycyl-­‐L-­‐phenylalanine-­‐beta-­‐naphthylamide	   (GPN)	   could	   be	   used	   to	  
measure	   the	   lysosomal	   Ca2+	   content	   in	   Cln3-­‐/-­‐	   astrocytes	   following	   ER-­‐Ca2+	  
depletion	  with	  thapsigargin	  (Llyod-­‐Evans	  et	  al.,	  2008).	  	  
It	  has	  been	  well	  established	  that	  astrocytes	  express	  a	  whole	  range	  of	  receptors	  
that	  can	  be	  activated	  by	  many	  neurotransmitters,	  such	  as	  glutamate	  (Porter	  and	  
McCarthy,	  1996;	  Pasti	  et	  al.,	  1997),	  GABA	  (Kang	  et	  al.,	  1998)	  and	  ATP	  (Guthrie	  et	  
al.,	   1999).	   Ultimately	   the	   activation	   of	   these	   receptors	   evokes	   elevated	   Ca2+	  
levels	   in	   astrocytes	   inducing	   gliotransmission,	   resulting	   in	   the	   release	   of	   other	  
transmitters	  including	  glutamate,	  d-­‐serine	  and	  ATP.	  These	  gliotransmitters	  are	  all	  
neuroactive	   molecules	   that	   can	   modulate	   synaptic	   transmission,	   as	   well	   as	  
facilitate	   inter-­‐astrocytic	  Ca2+	  signaling	   (Guthrie	  et	  al.,	  1999;	  Fellin	  et	  al.,	  2004).	  
ATP	  evoked	  Ca2+	  elevations	  were	  normal	  in	  Cln3-­‐/-­‐	  astrocytes,	  indicating	  that	  Ca2+	  
based	  mechanisms	   involved	   in	   gliotransmission	  would	   also	   be	   unaffected.	  One	  
could	   measure	   the	   release	   of	   glutamate	   evoked	   by	   ATP	   stimulation	   in	   Cln3-­‐/-­‐	  
astrocytes	   to	   confirm	   this.	   In	   addition,	   intracellular	   calcium	   elevations	   in	  
astrocytes	  may	  be	  required	   for	   the	  secretion	  of	  other	  proteins,	   such	  as	  growth	  
factors	   and	   cytokine	   (Agulhon	   et	   al.,	   2012).	   However,	   the	   ability	   of	   Cln3-­‐/-­‐	  
astrocytes	  to	  secrete	  a	  range	  of	  proteins	  was	  studied	  and	  found	  to	  be	  severely	  
impaired	  (Chapter,	  Tables	  4.1	  and	  4.2),	  this	  may	  suggest	  that	  regardless	  of	  having	  
a	  normal	  ATP	  response	  the	  subsequent	  Ca2+	  triggered	  exocytosis	  may	  be	  affected	  
in	  these	  cells,	  perhaps	  explaining	  at	  least	  partially	  the	  lack	  of	  protein	  secretion.	  	   
	  	  
In	  cultured	  astrocytes,	  the	  addition	  of	  growth	  factors	  and	  cytokines	  were	  found	  
to	  induce	  significant	  changes	  in	  the	  nature	  and	  propagation	  of	  intracellular	  Ca2+	  
signals	   (Morita	   et	   al.,	   2003).	   For	   instance,	   growth	   factors	   like	   EGF	   and	   FGF	  
promoted	   Ca2+	   oscillations,	   but	   these	   were	   inhibited	   by	   pro-­‐inflammatory	  
cytokines	  like	  IL-­‐1β	  and	  TNF-­‐α	  (Morita	  et	  al.,	  2003).	  Interestingly,	  these	  enhanced	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calcium	   oscillations	   were	   found	   to	   be	   accompanied	   by	   an	   enlargement	   of	   the	  
calcium	   store,	   cell	   proliferation	   and	   the	   development	   of	   hypertrophy	   (Carafoli,	  
2002;	   Morita	   et	   al.,	   2003).	   Growth	   factor	   and	   cytokine	   secretion	   by	   Cln3-­‐/-­‐	  
astrocytes	   was	   revealed	   to	   be	   dramatically	   altered	   (Chapter	   4,	   Tables	   4.1	   and	  
4.2)	  and	  this	   in	  turn	  may	  be	  linked	  to	  attenuated	  morphological	  transformation	  
(Chapter	  3,	  Figure	  3.8)	  and	  proliferation	  (Chapter	  3,	  Figure	  3.9),	  which	  may	  both	  
also	  be	  linked	  with	  abnormal	  calcium	  oscillations	  observed	  in	  these	  cells	  (Chapter	  
4,	  Figures	  4.1	  and	  4.2)	  although	  this	  hypothesis	  awaits	  investigation.	  	  
	  
Alterations	   in	  astrocyte	  calcium	  signaling	  have	  been	   linked	  to	  a	  number	  of	  CNS	  
diseases.	   For	   example,	   in	   Alzheimer	   disease	   astrocytes	   display	   network-­‐wide	  
elevations	   in	   resting	   calcium	   levels,	   and	   enhanced	   network-­‐level	   functional	  
activity	   seen	   as	   more	   frequent	   propagation	   of	   intercellular	   calcium	   waves	  
(Kuchibhotla	  et	  al.,	  2009).	  Indeed,	  the	  propagation	  of	  intercellular	  calcium	  waves	  
has	  been	  postulated	   to	   function	  as	   a	  messenger	   to	   alert	   the	   rest	  of	   brain	   to	   a	  
pathological	   insult	   (Fiacco	   and	   McCarthy,	   2006;	   Scemes	   and	   Giaume,	   2006;	  
Agulhon	  et	  al.,	  2012).	  Cortical	  spreading	  depression	  (CSD)	  is	  a	  slowly	  propagating	  
wave	  of	  neuronal	  depolarization	  (Leão,	  1986;	  Gorji,	  2001;	  Gorji	  et	  al.,	  2001)	  that	  
has	   been	   shown	   clinically	   relevant	   in	   migraine,	   progression	   of	   cortical	   infarct	  
volume	  after	  stroke	  and	  trauma	  (Lauritzen,	  1994;	  Back	  et	  al.,	  1996;	  Hadjikhani	  et	  
al.,	   2001;	   Smith	   et	   al.,	   2006).	   Based	   on	   a	   number	   of	   studies,	   CSD	   may	   be	  
associated	   with	   calcium	   waves	   in	   astrocytes,	   with	   a	   currently	   unknown	  
physiological	   purpose	   (Basarsky	   et	   al.,	   1998;	   Kunkler	   and	   Kraig,	   1998;	  Martins-­‐
Ferreira	  et	  al.,	  2000;	  Strong	  et	  al.,	  2002;	  Peters	  et	  al.,	  2003;	  Fabricius	  et	  al.,	  2006;	  
Chuquet	   et	   al.,	   2007;	   Luo	   and	   Chen,	   2012).	   Nevertheless,	   these	   findings	   raise	  
questions	   about	   the	   impact	   of	   the	   alterations	   observed	   in	   calcium	   signaling	   in	  
Cln3-­‐/-­‐	   astrocytes,	   and	   whether	   these	   events	   are	   ultimately	   beneficial	   or	  
detrimental	  towards	  disease	  progression	  in	  JNCL?	  	  
	  
Epilepsy	   in	   one	   of	   the	   most	   prominent	   clinical	   features	   of	   JNCL	   (Mole	   et	   al.,	  
2011).	   Such	   seizures	   often	   consist	   of	   a	   synchronous	   neuronal	   discharge	   that	  
starts	   in	   a	   restricted	   brain	   area	   and	   then	   spreads	   to	   larger	   areas	   of	   the	   brain	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(Avoli	  et	  al.,	  2002;	  Pinto	  et	  al.,	  2005;	  Trevelyan	  et	  al.,	  2006).	  Thus,	  epilepsy	  can	  
be	   seen	   as	   a	   disorder	   of	   excess	   synchronization	   of	   neurons	   caused	   by	   an	  
imbalance	   between	   excitatory	   and	   inhibitory	   mechanisms	   that	   generate	  
neuronal	  hyperexcitability.	  In	  addition	  to	  the	  well-­‐known	  contribution	  of	  voltage-­‐
gated	  Na+,	  Ca2+	  and	  K+	  channels	  to	  epileptogenesis	  (Lerche	  et	  al.,	  2001;	  Graves,	  
2006),	   astrocytic	   Ca2+	   signaling	   has	   also	   been	   linked	   with	   this	   problem	   (de	  
Lanerolle	  et	  al.,	  2010;	  Seifert	  and	  Steinhäuser,	  2011).	  For	  instance,	  astrocytes	  can	  
directly	  stimulate	  groups	  of	  neighboring	  neurons	  via	  Ca2+	  dependent	  glutamate	  
release	   (Parpura	   et	   al.,	   1994),	   and	   synchronize	   the	   activation	   of	   extrasynaptic	  
NMDA-­‐receptors	   (Fellin	   et	   al.,	   2004).	   These	   basic	   findings	   suggest	   that	   Ca2+	  
dependent	  gliotransmission	  by	  astrocytes	  may	  be	  involved	  in	  seizure	  generation.	  
Moreover,	  it	  has	  been	  shown	  that	  the	  frequency	  of	  Ca2+	  oscillations	  in	  astrocytes	  
increases	   significantly	   during	   epileptic	   seizures	   (Tian	   et	   al.,	   2005;	   Fellin	   et	   al.,	  
2006a).	   The	   ATP-­‐mediated	   Ca2+	   waves	   that	   propagate	   through	   astrocyte	  
networks	  may	  also	  play	  a	  role	  in	  the	  control	  of	  the	  epileptic	  seizure	  propagation	  
(Fellin	   et	   al.,	   2006a;	   Losi	   et	   al.,	   2012;	   Torres	   et	   al.,	   2012).	   ATP	   released	   from	  
astrocytes	   through	  Cx43	  hemichannels	  may	  enhance	   inhibitory	   transmission	  by	  
acting	   upon	   the	   P2Y1	   receptors	   expressed	   in	   a	   specific	   group	   of	   hippocampal	  
interneurons	   (Torres	   et	   al.,	   2012).	   Thus,	   a	   lack	   of	   synchronized	   calcium	   wave	  
formation,	   as	   well	   as	   attenuated	   spontaneous	   calcium	   oscillations	   in	   Cln3-­‐/-­‐	  
astrocytes,	   may	   impact	   their	   ability	   to	   perform	   their	   inhibitory	   regulatory	  
activities,	  leading	  to	  neuronal	  hyperexcitability	  in	  the	  JNCL	  brain	  and	  initiation	  of	  
seizures.	  Moreover,	  autoantibodies	  against	  GAD65,	  which	  converts	  glutamic	  acid	  
to	  GABA,	  have	  been	  discovered	  in	  the	  serum	  of	  Cln3-­‐/-­‐	  mice	  and	  individuals	  with	  
JNCL	   (Chattopadhyay	   et	   al.,	   2002;	   Lim	   et	   al.,	   2006).	   The	   existence	   of	   these	  
autoantibodies	  has	  been	  proposed	   to	   lead	   to	  higher	   levels	  of	   glutamate	   in	   the	  
brain	   and	   may	   also	   contribute	   to	   the	   pronounced	   loss	   of	   GABAergic	   neurons	  
typical	   in	   JNCL	   (Chattopadhyay	   et	   al.,	   2002).	   Additionally,	  GAD65-­‐/-­‐	  mice	   have	  
been	  shown	  to	  develop	  spontaneous	  epileptic	  seizures,	  re-­‐enforcing	  the	  role	  of	  
the	   GABAergic	   inhibitory	   system	   in	   suppressing	   spontaneous	   epileptic	   seizures	  
(Kash	  et	  al.,	  1997).	  Together	  with	  attenuated,	  non-­‐synchronization	  of	  astrocytic	  
calcium	  oscillations,	   the	   lack	  of	  GABA	  production	  due	  to	  GAD65	  autoantibodies	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may	   severely	   affect	   the	   neuronal	   inhibition	   in	   Cln3-­‐/-­‐	   mice.	   Such	   events	   may	  
increase	  the	  susceptibility	  of	  these	  mice	  to	  epileptic	  seizures,	  and	  the	  same	  could	  
be	  true	  in	  JNCL	  patients.	  
	  
Given	  how	   important	  Ca2+	   signaling	   is	   for	   the	  overall	  biology	  of	  astrocytes,	  any	  
impairment	  of	   this	  process	   is	  bound	  to	  have	  significant	  consequences,	  not	  only	  
on	   astrocyte	   function,	   but	   also	   on	   the	   activities	   of	   other	   glial	   cells,	   and	  
importantly,	  neuronal	  cells.	  Thus,	  one	  may	  predict	  that	  the	  observed	  alterations	  
in	  astrocytic	  Ca2+	  signaling	  may	  be	  a	  key	  element	  in	  the	  pathological	  cascade	  that	  
occurs	  in	  the	  Cln3-­‐/-­‐	  mouse	  brain.	  	  
	  
Implications	  of	  impaired	  protein	  secretion	  in	  Cln3-­‐/-­‐	  astrocytes	  
Astrocytes	  secrete	  a	  wide	  array	  of	  soluble	  factors	  including	  chemokines,	  pro-­‐and	  
anti-­‐inflammatory	   cytokines,	   mitogens	   and	   growth	   factors,	   in	   addition,	  
astrocytes	  are	  highly	  responsive	  to	  virtually	  all	  of	  the	  factors	  they	  secrete	  (Ridet	  
et	  al.,	  1997;	  Dong	  and	  Benveniste,	  2001;	   John	  et	  al.,	  2003;	  Liberto	  et	  al.,	  2004;	  
Miklic	  et	  al.,	  2004).	  In	  contrast	  to	  the	  marked	  morphological	  difference	  between	  
Cln3-­‐/-­‐	  and	  WT	  astrocytes	  grown	  under	  basal	  conditions,	   their	  protein	  secretion	  
profile	   did	   not	   differ	   greatly	   (Chapter	   4,	   Table	   4.1).	   This	   is	   not	   surprising	   since	  
protein	   secretion	   by	   resting	   astrocytes	   is	   minimal,	   but	   is	   enhanced	   upon	  
astrocyte	   activation	   (Ridet	   et	   al.,	   1997;	   Sofroniew	   and	   Vinters,	   2010;	   Lee	   and	  
Haydon,	  2011).	  Nevertheless,	  Cln3-­‐/-­‐	  astrocytes	  did	  secrete	  significantly	  reduced	  
amounts	  of	  M-­‐CSF,	  MIP-­‐1γ,	  GCP-­‐2	  and	  TIMP1	  under	  resting	  conditions,	  whereas	  
secretion	  of	  TF	  was	  increased.	  TF,	  which	  is	  mainly	  produced	  by	  astrocytes	  in	  the	  
brain,	   is	   involved	   in	   the	  early	  stages	  of	  a	  cascade	   leading	   to	  blood	  coagulation,	  
and	   also	   mediates	   pro-­‐inflammatory	   responses	   (Eddleston	   et	   al.,	   1993;	   Chu,	  
2011).	   Indeed,	  several	   lines	  of	  evidence	  show	  that	  extracellular	  TF	  signaling	  via	  
protease-­‐activated	   receptors	   (PARs)	   is	   involved	   in	   angiogenesis,	   cell	  
adhesion/migration,	   innate	   immunity	   and	   has	   been	   shown	   to	   mediate	   many	  
pathophysiological	   mechanisms	   (Chu,	   2011).	   Hence,	   if	   upregulation	   of	   TF	  
expression	  by	  astrocytes	  also	  occurs	   in	  the	  Cln3-­‐/-­‐	  CNS,	  this	  could	  be	  one	  of	  key	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mechanisms	   in	   the	   initiation	  of	   the	  neuroimmune	   responses	  observed	   in	   these	  
mice.	  	  
	  
Upon	   LPS/IFNγ	  activation	   the	  differences	   in	  protein	   secretion	  profiles	  between	  
WT	  and	  Cln3-­‐/-­‐	  astrocytes	  become	  even	  more	  apparent,	  with	  the	  vast	  majority	  of	  
these	   screened	   proteins	   being	   secreted	   at	   a	   significantly	   lower	   level	   by	  Cln3-­‐/-­‐	  
astrocytes,	  although	  these	  cells	  appear	   to	  be	  still	   capable	  of	   synthesizing	   these	  
proteins	   (Chapter	   4,	   Figure	   4.8).	   Interestingly,	   under	   these	   experimental	  
conditions,	   a	   small	   subset	   of	   the	   screened	   proteins	  were	   secreted	   at	   a	   higher	  
level	  by	  Cln3-­‐/-­‐	  astrocytes,	  or	  at	  similar	  levels	  to	  WT	  astrocytes	  (Chapter	  4,	  Figure	  
4.7).	   This	  may	   suggest	   that	  astrocytes	  employ	  different	  mechanisms	   to	   secrete	  
specific	   types	  of	  proteins,	  and	  only	   some	  of	   these	  mechanisms	  are	  affected	  by	  
CLN3	  deficiency.	  Most	   likely,	   the	  observed	   cytoskeletal	   abnormalities,	   together	  
with	   atypical	   calcium	   signaling	   exhibited	   by	   Cln3-­‐/-­‐	   astrocytes	   may,	   at	   least	  
partially,	  explain	  these	  secretion	  results.	  
	  
One	  group	  of	  proteins	  secreted	  at	  significantly	   lower	   levels	  by	  Cln3-­‐/-­‐	  astrocytes	  
were	   the	   chemokines.	   These	   proteins	   are	   involved	   in	   nearly	   all	   pathological	  
conditions	  with	  an	  inflammatory	  component	  (Rostène	  et	  al.,	  2011).	  Indeed,	  over-­‐
expression	   of	   chemokines	   regulates	   recruitment	   of	   leukocytes	   to	   the	   site	   of	  
inflammation,	  which	  may	  cause	  exacerbated	  monocyte/macrophage	   infiltration	  
into	   the	  CNS	   (Ransohoff,	  2009;	  Saederup	  et	  al.,	  2010;	  Semple	  et	  al.,	  2010).	  For	  
instance,	   MCP-­‐1,	   has	   been	   shown	   to	   control	   the	   migration	   of	   microglia,	  
monocytes	  and	   lymphocytes	  to	  the	  site	  of	   inflammation	  within	  the	   injured	  CNS	  
(Simpson	   et	   al.,	   1998;	   Deng	   et	   al.,	   2009).	   Additionally,	   the	   expression	   of	  
chemokines	   by	   astrocytes	   has	   been	   shown	   to	   coincide	   with	   the	   presence	   of	  
ramified	  microglial	   cells,	  making	  astrocytes	  key	  players	   in	   influencing	  microglial	  
differentiation	   and	   activation	   (Rezaie	   et	   al.,	   2002).	   The	   dramatic	   reduction	   in	  
chemokine	  secretion	  observed,	  particularly	  by	  activated	  Cln3-­‐/-­‐	  astrocytes,	  could	  
therefore	  have	  a	  bearing	  on	  the	  attenuated	  microglial	  biology	  observed	  both	   in	  
vitro	   and	   in	   vivo	   (Pontikis	   et	   al.,	   2004;	   2005).	   Although,	   enhanced	   chemokine	  
secretion	   associated	   with	   chronic	   inflammation	  may	   become	   damaging	   to	   the	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brain,	   enhancing	   the	   destruction	   of	   axons,	   dendrites	   and	   synapses	   (Parpura	   et	  
al.,	   2012),	   chemokines,	   such	   as	   RANTES,	   MCP-­‐1	   have	   been	   shown	   to	   be	  
neuroprotective	  under	  certain	  in	  vitro	  conditions	  (Bruno	  et	  al.,	  2000;	  Eugenin	  et	  
al.,	   2003).	   Thus,	   in	   the	   Cln3-­‐/-­‐	   CNS	   any	   neuroprotection	   afforded	   by	   these	  
proteins	  would	  be	  severely	  reduced.	  	  
	  
Chemokine	   expression	   has	   previously	   been	   compared	   in	   Ppt1-­‐/-­‐	   vs.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
GFAP-­‐/-­‐Vim-­‐/-­‐Ppt1-­‐/-­‐	   mice	   brains,	   in	   which	   a	   dramatic	   increase	   in	   expression	   of	  
chemokines	   such	   as	   IP-­‐10,	   MIP1-­‐β,	   MIP-­‐2,	   MCP-­‐1,	   MCP3	   and	   MCP-­‐5	   were	  
reported	   in	   the	   latter	   (Macauley	  et	  al.,	  2011).	  This	   type	  of	  elevated	  chemokine	  
expression	   was	   associated	   with	   enhanced	   neuroinflammation	   and	   accelerated	  
disease	  progression	   in	  GFAP-­‐/-­‐Vim-­‐/-­‐Ppt1-­‐/-­‐	  mice.	  Based	  on	  these	  observations,	   it	  
may	  be	  that	  endogenously	  impaired	  chemokine	  secretion,	  as	  well	  as	  attenuated	  
astrocyte	   activation	  may	   actually	   play	   a	   beneficial	   role	   in	   the	   pathogenesis	   of	  
JNCL.	   It	   would	   be	   extremely	   informative	   to	   study	   the	   expression	   levels	   of	   the	  
proteins	  screened	  in	  this	  study	   in	  vivo	   to	  determine	  whether	  similar	  alterations	  
are	  also	  evident	  in	  the	  intact	  Cln3-­‐/-­‐	  mouse	  brain.	  	  	  	  	  	  	  
Along	   with	   chemokines,	   many	   mitogens,	   pro-­‐inflammatory,	   anti-­‐inflammatory	  
and	  haematological	  proteins	  were	  also	  secreted	  at	  a	  significantly	   lower	  level	  by	  
Cln3-­‐/-­‐	   astrocytes	   (Chapter	   4,	   Tables	   4.1	   and	   4.2).	   The	   biological	   significance	   of	  
these	  changes	  could	  be	  many	  fold	  due	  to	  these	  proteins	  having	  multiple	  effects	  
on	  different	  cell	  types	  under	  both	  physiological	  and	  pathological	  situations	  (Allan	  
and	  Rothwell,	  2003;	  Farina	  et	  al.,	  2007;	  Singh	  et	  al.,	  2011;	  Ransohoff	  and	  Brown,	  
2012).	   To	   further	   complicate	  matters,	  many	   of	   these	   proteins	   have	   synergistic	  
properties	   that	   can	   result	   in	  dramatic	   changes	   in	  both	  microglial	   and	  astrocyte	  
function.	   For	   instance,	   IL-­‐1β	   shows	   clear	  microglial	   immunoreactivity	   in	   Cln3-­‐/-­‐	  
mice	   and	   in	   human	   JNCL	   and	   is	   secreted	   normally	   by	   Cln3-­‐/-­‐	   microglia	   cells	  
(Dihanich,	  unpublished	  data,	   Lim	  and	  Cooper,	  unpublished	  data	  and	  Castaneda	  
et	  al.,	  2008).	  In	  contrast,	  Cln3-­‐/-­‐	  astrocytes	  failed	  to	  secrete	  IL-­‐1β.	  However,	  in	  the	  
intact	   Cln3-­‐/-­‐	   mouse	   brain	   IL-­‐1β	   secreted	   by	   microglia	   cells	   may	   induce	   IL-­‐6	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production	   in	   both	   glial	   cell-­‐types,	   stimulating	   inducible	   nitric	   oxide	   synthase	  
(iNOS)	  activity	  and	  thus	  leading	  to	  increased	  NO	  production	  by	  astrocytes	  (Rossi	  
and	   Bianchini,	   1996).	   Such	   increased	   production	   of	   NO	   due	   to	   the	   synergistic	  
interactions	  between	  these	  two	  glial	  cell	  types	  may	  be	  neurotoxic	  in	  JNCL	  (Brown	  
et	  al.,	  1995;	  Chao	  et	  al.,	  1995;	  Bolaños	  et	  al.,	  1997;	  Heales	  et	  al.,	  1997;	  Leist	  et	  
al.,	   1997;	   Murphy,	   2000;	   Wei	   et	   al.,	   2000).	   NO	   mediated	   signaling	   has	   been	  
previously	   investigated	   in	   different	  models	   of	   JNCL	   (Kim	   et	   al.,	   2003;	   Ramirez-­‐
Montealegre	   and	   Pearce,	   2005;	   Chan	   et	   al.,	   2009),	   and	   decreased	   arginine	  
(substrate	  for	  NO	  production)	  availability	  was	  speculated	  to	  cause	  abnormal	  NO	  
signaling	   in	   JNCL,	   which	   in	   addition	   to	   impacting	   neuronal	   viability	   could	   also	  
impact	   other	   processes	   such	   as	   cell	   energetics,	   apoptosis,	   vasodilation	   and	  
synaptic	   function	   (Garthwaite	   and	   Boulton,	   1995;	   Prast	   and	   Philippu,	   2001;	  
Bronte	  and	  Zanovello,	  2005).	  	  
	  
Another	   interesting	   player	   that	   could	   mediate	   the	   interactions	   between	  
astrocytes	  and	  microglia	  is	  TIMP-­‐1	  (Gardner	  and	  Ghorpade,	  2003;	  Welser-­‐Alves	  
et	   al.,	   2011).	   TIMP-­‐1	   is	   an	   endogenous	   MMP	   inhibitor	   important	   for	  
maintenance	  of	  proteolytic	  balance	   involved	   in	   cell	  migration,	  wound	  healing,	  
angiogenesis	   and	   neuronal	   survival	   (Gardner	   and	  Ghorpade,	   2003;	   Crocker	   et	  
al.,	  2004;	  Ogier	  et	  al.,	  2006;	  Stetler-­‐Stevenson,	  2008).	  Indeed,	  TIMP-­‐1	  knock-­‐out	  
mice	  displayed	  increased	  levels	  of	  MMP-­‐9	  activity,	  resulting	  in	  BBB	  breakdown	  
and	   increased	   lesion	   size	   in	   a	   focal	   cerebral	   ischemia	  model	   (Fujimoto	   et	   al.,	  
2008).	  Moreover,	  adenoviral-­‐mediated	  gene	  transfer	  of	  TIMP-­‐1	  and	  2	  resulted	  
in	   reduced	   levels	   of	   neuronal	   death	   in	   a	   model	   of	   global	   cerebral	   ischemia	  
(Magnoni	   et	   al.,	   2007).	   Importantly,	   TIMP	   proteins	   may	   also	   influence	   the	  
growth	  and	  morphology	  of	  neuronal	  cells	   in	  a	  MMP-­‐dependent	  manner	   (Qi	  et	  
al.,	   2003).	   Thus,	   severely	   decreased	   TIMP-­‐1	   secretion	   by	   Cln3-­‐/-­‐	   astrocytes	  
(observed	   in	   both	   untreated	   and	   LPS/IFNγ	   treated	   conditions,	   Tables	   4.1	   and	  
4.2)	   could	   have	   detrimental	   consequences	   that	   may	   result	   in	   a	   failure	   to	  
establish	  proper	  neuronal	  morphology	  and	  astrocyte	  motility,	  and	  in	  increased	  
neuronal	  cell	  death.	  Indeed,	  Cln3-­‐/-­‐	  astrocytes	  were	  found	  to	  negatively	  impact	  
the	   morphology	   and	   survival	   of	   cortical	   neurons	   derived	   from	   both	   WT	   and	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Cln3-­‐/-­‐	   deficient	   mice	   (Chapter	   6,	   Figures	   6.2-­‐6.5).	   Additionally,	   the	   observed	  
impaired	  migration	   of	   Cln3-­‐/-­‐	   astrocytes	   could	   plausibly	   be	   caused	   by	   reduced	  
TIMP-­‐1	   secretion,	   since	   TIMP-­‐1	   mediated	   regulation	   of	   MMP-­‐2	   has	   been	  
implicated	   in	  astrocyte	  motility	   (Ogier	  et	  al.,	  2006).	  Such	  hypotheses	  could	  be	  
investigated	  directly	   in	  astrocyte	  cultures	  or	  co-­‐culture	  systems	  by	  addition	  of	  
the	  recombinant	  form	  of	  the	  particular	  protein	  under	  study	  (for	  example	  TIMP-­‐
1),	  followed	  by	  monitoring	  any	  improvements	  in	  pathological	  phenotype.	  	  
	  
A	   wide	   range	   of	   proteins	   secreted	   by	   astrocytes	   have	   been	   shown	   to	   be	  
important	  in	  tissue	  regeneration	  and	  promotion	  of	  neuron	  survival	  (Ridet	  et	  al.,	  
1997;	   Meeuwsen	   et	   al.,	   2003;	   Farina	   et	   al.,	   2007).	   For	   instance,	   astrocytes	  
secrete	   an	   enormous	   array	   of	   neurotrophic	   and	   neuroprotective	   factors:	   NGF,	  
BDNF,	  CNTF,	  FGF-­‐2,	  VEGF,	  IL-­‐3,	  RANTES,	  LIF,	  IL-­‐10,	  MCP-­‐1	  and	  IL-­‐6	  in	  response	  to	  
CNS	   affecting	   injury	   or	   disease,	   and	   activation	   of	   the	   cytokine	   receptors	   they	  
express	  (Schwartz	  and	  Nishiyama,	  1994;	  Rudge	  et	  al.,	  1995;	  Uchida	  et	  al.,	  1998;	  
Dietrich	  et	  al.,	  1999;	  Dreyfus	  et	  al.,	  1999;	  Bruno	  et	  al.,	  2000;	  Messersmith	  et	  al.,	  
2000;	  Albrecht	  et	  al.,	  2002;	  Zambrano	  et	  al.,	  2007;	  Wang	  et	  al.,	  2009b;	  Moidunny	  
et	   al.,	   2010).	   Some	   of	   these	   factors	   were	   included	   in	   our	   protein	   secretion	  
analysis,	  and	  were	  found	  to	  be	  secreted	  at	  significantly	  lower	  levels	  by	  activated	  
Cln3-­‐/-­‐	  astrocytes.	  A	  few	  examples	  of	  these	  neuroprotective	  factors:	  IL-­‐6,	  TNF-­‐α,	  
VEGF,	  are	  discussed	  in	  more	  detail	  below.	  
	  
The	   expression	   of	   IL-­‐6	   in	   the	   brain	   has	   been	   shown	   to	   become	   increased	   in	   a	  
number	   of	   CNS	   disorders,	   including	   Alzheimer	   disease,	   Parkinson	   disease	   and	  
stroke	   (Gruol	   and	   Nelson,	   1997;	   Benveniste,	   1998).	   IL-­‐6	   has	   been	   shown	   to	  
function	  as	   a	  neurotrophic	   factor	   for	   forebrain	  neurons	   (Kushima	  et	   al.,	   1992),	  
and	   to	   protect	   PC12	   cells	   against	   hypoxia-­‐reoxygenation	   (Maeda	   et	   al.,	   1994).	  
Furthermore,	  glutamate-­‐induced	  neuron	  death	  in	  hippocampal	  cultures	  has	  been	  
shown	  to	  be	  reduced	  by	  IL-­‐6,	  and	  in	  vivo	  this	  protein	  has	  been	  shown	  to	  protect	  
against	  NMDA	  receptor	  mediated	  ischemic	   insult	  (Yamada	  and	  Hatanaka,	  1994;	  
Ali	  et	  al.,	  2000;	  Wang	  et	  al.,	  2009b).	  Hence,	  the	  lack	  of	  IL-­‐6	  secretion	  combined	  
with	  the	  attenuated	  glutamate	  clearance	  by	  Cln3-­‐/-­‐	  astrocytes	  (Chapter	  4,	  Figure	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4.11)	   may	   make	   an	   extremely	   detrimental	   combination,	   and	   may	   stimulate	  
neuron	  loss	  in	  JNCL.	  The	  mechanisms	  involved	  in	  IL-­‐6	  mediated	  neuroprotection,	  
including	  promotion	  of	  production	  and	   secretion	  of	  neurotrophic	   factors	   (NGF,	  
NT3	   and	  NT4/5),	  may	   be	   altered	   in	  Cln3-­‐/-­‐	   astrocytes	   that	   display	   reduced	   IL-­‐6	  
secretion.	   However,	   some	   authors	   have	   reported	   no	   beneficial	   effects	   of	   IL-­‐6	  
against	   excitotoxicity	   in	   cortical	   neurons	   (Toulmond	   et	   al.,	   1992),	   or	   rather	  
acceleration	   of	   NMDA	   induced	   neuronal	   death	   upon	   chronic	   exposure	   to	   IL-­‐6	  
(Qiu	   et	   al.,	   1998).	   Moreover,	   mice	   overexpressing	   IL-­‐6	   display	   significant	  
neurodegeneration,	  suggesting	  that	  chronic	   IL-­‐6	  over-­‐expression	  has	  neurotoxic	  
consequences	  (Campbell	  et	  al.,	  1993).	  Taken	  together,	  these	  data	  re-­‐enforce	  the	  
importance	  of	  appropriately	  regulating	  the	  concentration	  of	  IL-­‐6	  within	  the	  CNS.	  
Perhaps	   it	   is	   important	  that	  astrocytes	  are	  able	  to	  respond	  to	  acute	  changes	   in	  
the	   environment	   by	   increasing	   IL-­‐6	   secretion	   to	   guard	   against	   the	   initiation	   of	  
signaling	   cascades	   leading	   to	   neuronal	   cell	   death.	   Hence,	   the	   lack	   of	   IL-­‐6	  
secretion	   by	   activated	   Cln3-­‐/-­‐	   astrocytes	   over	   a	   relatively	   short	   period	   of	   time	  
would	  most	  likely	  accelerate	  the	  neurodegeneration	  observed	  in	  Cln3-­‐/-­‐	  mice.	  On	  
the	  other	  hand,	  reduced	  levels	  of	  IL-­‐6	  may	  equally	  have	  beneficial	  effects	  over	  a	  
longer	  period	  of	  time.	  	  	  	  
	  
Increasing	   evidence	   suggests	   that	   TNF-­‐α	   can	   be	   neuroprotective	   against	  
excitotoxicity	  in	  both	  in	  vitro	  and	  in	  vivo	  models	  (Bruce	  et	  al.,	  1996;	  Carlson	  et	  al.,	  
1998;	  Wilde	  et	  al.,	  2000;	  Orellana	  et	  al.,	  2007;	  Rojo	  et	  al.,	  2008).	  In	  addition,	  mice	  
deficient	   in	   TNF-­‐α	   receptors	   showed	   enhanced	   sensitivity	   to	   ischemic	   stroke	  
(Bruce	  et	  al.,	  1996).	  Under	  physiological	  conditions,	  TNF-­‐α	  produced	  by	  glia	  may	  
have	  the	  ability	  to	  enhance	  synaptic	  efficacy	  by	  increasing	  the	  surface	  expression	  
of	  AMPA	  receptors,	  making	  TNF-­‐α	  important	  for	  synaptic	  plasticity	  (Beattie	  et	  al.,	  
2002).	  Hence,	  the	  ability	  of	  TNF-­‐α	  to	  play	  its	  beneficial,	  neuroprotective	  role	  may	  
be	   impaired	   in	   the	   Cln3-­‐/-­‐	   mouse	   brain	   due	   to	   lack	   of	   TNF-­‐α	   secretion	   by	  
astrocytes.	  On	  the	  other	  hand,	  excessive	  TNF-­‐α	  secreted	  by	  activated	  astrocytes	  
may	   exacerbate	   tissue	   damage	   by	   inhibiting	   neurite	   outgrowth	   and	   inducing	  
oligodendrocyte	   cell	   death	   (D'Souza	   et	   al.,	   1996;	   Neumann	   et	   al.,	   2002).	  
Moreover,	   TNF-­‐α	   in	   combination	   with	   other	   cytokines,	   such	   as	   IL-­‐1,	   can	   have	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synergistic	   effects	   that	  may	   be	   neurotoxic	   (Chao	   et	   al.,	   1995;	  Hu	   et	   al.,	   1997).	  
Indeed,	   mice	   overexpressing	   TNF-­‐α	   only	   in	   astrocytes	   develop	   a	   neurological	  
disorder	  that	  is	  characterized	  by	  ataxia,	  seizures	  and	  paralysis	  (Akassoglou	  et	  al.,	  
1997).	   These	   conflicting	   data	   might	   reflect	   the	   complexity	   of	   actions	   of	   such	  
cytokines	   upon	   neuronal	   function	   and	   neurodegeneration,	   which	   may	   vary	  
greatly	   depending	   on	   the	   cell	   type,	   amount	   of	   cytokine	   secreted	   and	   type	   of	  
insult	   in	   question.	   Overall,	   reduced	   secretion	   of	   TNF-­‐α	   by	   reactive	   Cln3-­‐/-­‐	  
astrocytes	   may	   affect	   synaptic	   plasticity	   and	   the	   survival	   of	   different	   types	   of	  
neurons	  in	  JNCL.	  	  	  
 
VEGF	   is	   a	   trophic	   factor	   important	   for	   angiogenesis	   and	   endothelial	   cell	  
proliferation	  (Neufeld	  et	  al.,	  1999).	   Increasing	  evidence	  has	  also	  suggested	  that	  
VEGF,	   whose	   expression	   has	   been	   shown	   to	   increase	   upon	   CNS	   insults	  
(Chodobski	   et	   al.,	   2003;	   Sköld	   et	   al.,	   2005),	   also	   has	   neurotrophic,	   neurogenic	  
and	  neuroprotective	  functions	  (Pellerin	  and	  Magistretti,	  1994;	  Thau-­‐Zuchman	  et	  
al.,	  2010;	  Zheng	  et	  al.,	  2010;	  Ma	  et	  al.,	  2011).	  For	  instance,	  VEGF	  was	  shown	  to	  
be	  upregulated	  in	  both	  neurons	  and	  glial	  cells	  in	  various	  brain	  regions	  following	  
pilocarpine-­‐induced	   status	   epilepticus	   (Nicoletti	   et	   al.,	   2008).	   Furthermore,	  
administration	   of	   exogenous	   VEGF	   in	   this	   same	   model	   induced	   a	   significant	  
preservation	   of	   hippocampal	   neurons,	   suggesting	   a	   neuroprotective	   role	   for	  
VEGF.	   During	   development,	   VEGF	   may	   also	   stimulate	   axonal	   outgrowth	   and	  
promote	   the	   survival	   of	   dorsal	   root	   ganglion	   neurons	   and	   developing	   retinal	  
cells.	   Under	  more	   chronic	   neurodegenerative	   conditions,	   such	   as	   in	   ALS,	   VEGF	  
has	   been	   shown	   to	   function	   as	   a	   neuroprotective	   factor	   (Zheng	   et	   al.,	   2004;	  
Storkebaum	  et	  al.,	  2005).	  Based	  on	   the	   results	  of	  our	  protein	  secretion	  screen,	  
Cln3-­‐/-­‐	   astrocytes	   failed	   to	   secrete	   VEGF	   upon	   activation.	   This	   would	   severely	  
reduce	  the	  potential	  neuroprotective	  and	  axonal	  growth	  stimulating	  activities	  of	  
this	  protein	  over	  the	  course	  of	  disease	  progression.	  	  
	  
In	   vivo	   studies	   of	   the	   expression	   of	   VEGF,	   TNF-­‐α	   and	   Il-­‐6	   expression,	   or	   their	  
receptors,	  have	  not	  yet	  been	  carried	  out	  in	  either	  murine	  or	  human	  JNCL.	  If	  their	  
expression	   were	   found	   to	   be	   similarly	   altered	   in	   vivo,	   therapies	   based	   on	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enhancing	  the	  expression	  or	  functions	  of	  these	  neuroprotective	  factors	  could	  be	  
considered.	   Co-­‐cultures	   composed	   of	   different	   combination	   of	   WT	   and	   Cln3-­‐/-­‐	  
neurons	  and	  glia	  could	  be	  used	  as	  a	  starting	  point	  to	  test	   the	  potency	  of	   these	  
factors.	  However,	  all	  of	  these	  factors	  may	  also	  provoke	  undesired	  effects	  in	  vivo,	  
including	  altered	  blood	  brain	  barrier	  permeability,	   increased	  vessel	  density,	  and	  
inflammation	  associated	  with	  VEGF	  based	  therapies	  (Vezzani	  and	  Granata,	  2005;	  
Ivens	  et	  al.,	  2007;	  Rigau	  et	  al.,	  2007;	  Tomkins	  et	  al.,	  2007;	  Vezzani	  and	  Baram,	  
2007).	   Thus,	   any	   therapy	   based	   on	   such	   neuroprotective	   factors	   should	   be	  
designed	  in	  a	  way	  so	  that	  it	  only	  facilitates	  their	  regenerative	  activities.	  	  
	  
Similar	   protein	   secretion	   profiling	   to	   that	   described	   here	   for	   WT	   and	   Cln3-­‐/-­‐	  
astrocytes,	   has	   also	   been	   conducted	   on	  microglia	   cultures	   from	   these	  mice	   (S.	  
Dihanich,	   unpublished	   data).	   Protein	   screening	   profiling	   of	   Cln3-­‐/-­‐	   microglia	  
revealed	   reduced	   levels	   for	   a	   small	   but	   specific	   number	   of	   proteins;	   the	  
chemokines,	  MIP-­‐1γ,	  MIP-­‐2	  and	  RANTES,	  plus	  MMP9	  and	  Von	  Willebrand	  Factor	  
(VwF).	  Thus,	  changes	  in	  protein	  secretion	  appear	  to	  be	  a	  general	  property	  of	  glial	  
cells	  in	  JNCL,	  although	  astrocytes	  appear	  to	  be	  more	  severely	  affected.	  This	  could	  
lead	   to	   lack	  of	  communication	  between	  microglia	  and	  astrocytes	   in	   JNCL,	   since	  
this	   is	  dependent	  on	  the	  controlled	  secretion	  of	  such	  soluble	   factors	   (Liu	  et	  al.,	  
2011).	  Additionally,	  based	  on	  a	  small	  pilot	  study	  the	  protein	  secretion	  profile	  of	  
Ppt1-­‐/-­‐	  astrocytes	  was	  also	  seen	  to	  be	  altered,	  however	  these	  changes	  were	  very	  
different	   to	   those	   observed	   in	   Cln3-­‐/-­‐	   astrocytes.	   We	   observed	   an	   increased	  
secretion	  of	  IL-­‐4,	  MIP-­‐1α,	  VEGF,	  IL-­‐11,	  TIMP-­‐1,	  and	  a	  decreased	  secretion	  of	  IL-­‐6,	  
TNF-­‐α,	   MCP5,	   Lymphotactin,	   MIP-­‐1β	   and	   FGF-­‐9	   (unpublished	   data).	   In	   this	  
infantile	   form	   of	   NCL,	   glial	   activation	   is	   much	   more	   pronounced	   and	   disease	  
progression	   is	  much	  more	  rapid	   than	   in	   JNCL	   (Bible	  et	  al.,	  2004;	  Pontikis	  et	  al.,	  
2004;	  2005;	  Cooper,	  2010;	  Mole	  et	  al.,	  2011).	  Perhaps	  such	  dramatic	  differences	  
in	   the	   secretion	   of	   soluble	   factors	   by	   astrocytes	   may	   play	   key	   roles	   in	   the	  
different	  pathologies	  observed	  between	  different	  forms	  of	  NCLs.	  	  	  	  	  
	  
As	   a	   next	   step,	   it	   will	   be	   important	   to	   determine	  whether	   the	   changes	   in	   the	  
levels	   of	   proteins	   secreted	   by	   activated	   glial	   cells	   described	   above,	   are	   also	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apparent	   in	   vivo.	   Interestingly,	   treatment	   of	   Cln3-­‐/-­‐	   mice	   with	   the	  
immunosuppressant	  mycophenolate	  reduced	  the	  expression	  of	  GFAP	  and	  CD68,	  
markers	   of	   activated	   astrocytes	   and	   microglia	   respectively,	   and	   markedly	  
improved	  the	  motor	  performance	  of	  these	  mice	  (Seehafer	  et	  al.,	  2011).	  Based	  on	  
this	  study	  a	  reduction	  in	  the	  immune-­‐response	  mediated	  by	  glial	  cells	  appears	  to	  
be	  beneficial	  to	  Cln3-­‐/-­‐	  mice.	  To	  coincide	  with	  this	  observation,	  mixed	  Cln3-­‐/-­‐	  glial	  
cultures	   (containing	   both	   astrocytes	   and	   microglia)	   have	   a	   negative	   impact,	  
where	   as	  WT	   glial	   cultures	   have	   a	   positive	   impact,	   on	   both	   the	  morphological	  
complexity	  and	  survival	  of	  WT	  and	  Cln3-­‐/-­‐	  neurons	  (see	  data	  presented	  in	  Chapter	  
6).	  This	  negative	  impact	  of	  Cln3-­‐/-­‐	  glial	  cells	  could	  perhaps	  result	  from	  alterations	  
in	  protein	  secretion	  as	  described	  above.	  However,	  further	  studies	  will	  be	  needed	  
to	   confirm	   this	   hypothesis,	   possibly	   by	   attempting	   to	   reverse	   such	   negative	  
affects	   by	   adding	   cocktails	   of	   these	   missing	   proteins.	   To	   overcome	   these	  
secretion	   deficits,	   plausibly	   caused	   by	   a	   disrupted	   cytoskeleton	   in	   Cln3-­‐/-­‐	  
astrocytes,	  neuron	  derived	  growth	   factors,	   such	  as	  FGF	  and	  EGF,	   that	  have	   the	  
potential	   to	   facilitate	   re-­‐arrangements	   in	   the	   astrocyte	   cytoskeleton	   in	   a	   Rho	  
kinase	  signaling	  dependent	  manner,	  could	  also	  be	   tested	   (Kalman	  et	  al.,	  1999).	  
Additionally,	  cell	  inserts	  upon	  which	  glial	  cells	  are	  grown,	  could	  be	  placed	  in	  wells	  
containing	   cultured	   neurons	   to	   investigate	   directly	   the	   impact	   of	   glia-­‐secreted	  
proteins	   on	   neurons.	   Indeed,	   such	   studies	   may	   open	   up	   new	   avenues	   for	  
therapeutic	   approaches	   designed	   to	   overcome	   the	   negative	   aspects	   of	   these	  
secretion	  defects	  and	  to	  enhance	  any	  potential	  positive	  influences.	  	  
	  
Undisrupted	  lactate	  secretion	  in	  Cln3-­‐/-­‐	  astrocytes	  
Astrocytes	  play	  a	  fundamental	  role	  as	  energy	  providers	  in	  the	  CNS	  (Tsacopoulos	  
and	  Magistretti,	  1996;	  Pellerin	  et	  al.,	  1998;	  Pellerin	  and	  Magistretti,	  2012).	  The	  
Na+-­‐dependent	   uptake	   of	   glutamate	   into	   astrocytes	   leads	   to	   a	   cascade	   of	  
molecular	   events	   involving	   Na+-­‐K+-­‐ATPase,	   glycolytic	   processing	   of	   glucose	   and	  
subsequent	   release	   of	   lactate	   from	   astrocytes	   (Pellerin	   and	  Magistretti,	   1994;	  
Takahashi	   et	   al.,	   1995).	   Some	   evidence	   suggests	   that	   lactate	   may	   be	   the	  
preferred	  energy	  substrate	  for	  highly	  active	  neurons,	  directly	  coupling	  the	  energy	  
	   221	  
demand	   arising	   from	   synaptic	   activity	   with	   glucose	   utilization	   by	   astrocytes	  
(Magistretti	  and	  Pellerin,	  1999;	  Pellerin	  and	  Magistretti,	  2012).	  Our	  data	  revealed	  
that	  Cln3-­‐/-­‐	   astrocytes	   showed	  a	  normal	  ability	   to	   secrete	   lactate	  when	  glucose	  
was	  provided	  as	  a	  fuel	  for	   lactate	  production	  (Figure	  4.11).	  This	  result	   indicates	  
that	  when	  Cln3-­‐/-­‐	  astrocytes	  are	  provided	  with	  an	  energy	  substrate,	   their	  ability	  
to	  produce,	  and	  importantly	  secrete	  lactate,	  is	  not	  impaired.	  However,	  since	  the	  
process	  of	  lactate	  shuttling	  between	  astrocytes	  and	  neurons	  is	  strongly	  driven	  by	  
glutamate	  clearance,	  which	  we	  have	  shown	  to	  be	   impaired	   in	  Cln3-­‐/-­‐	  astrocytes	  
(see	  below),	  this	  overall	  process	  may	  be	  compromised	  in	  the	  Cln3-­‐/-­‐	  mouse	  brain.	  
Furthermore,	   CLN3	   has	   been	   suggested	   to	   interact	   indirectly	   with	   the	   Na+-­‐K+-­‐
ATPase,	  which	  is	  also	  a	  key	  player	  in	  the	  lactate	  shuttle	  process	  and	  the	  dynamic	  
trafficking	  of	  Na+-­‐K+-­‐ATPase	   at	   the	  plasma	  membrane	  was	   found	   to	  be	   altered	  
upon	  CLN3	  deficiency	  (Uusi-­‐Rauva	  et	  al.,	  2008).	  Therefore,	  despite	  the	  fact	  that	  
Cln3-­‐/-­‐	  astrocytes	  do	  not	  show	  altered	  lactate	  secretion,	  the	  decreased	  glutamate	  
clearance	  by	  these	  cells,	  taken	  together	  with	  potential	  alterations	  in	  the	  correct	  
trafficking	  of	  Na+-­‐K+-­‐ATPase,	  may	  perturb	  the	  lactate	  shuttle	  system	  in	  the	  JNCL	  
brain.	  	  	  
	  
In	  the	  brain,	  blood	  glucose	  in	  a	  major	  energy	  substrate	  that	  may	  be	  taken	  up	  by	  
both	  astrocytes	  and	  neurons	  via	  glucose	   transporters:	  GLUT1	   in	  astrocytes	  and	  
GLUT3	   in	   neurons	   (Pellerin,	   2003;	   Gladden,	   2004).	   It	   is	   believed	   that	   blood	  
glucose	  may	   be	   readily	   available	   to	   astrocytes	   since	   astrocyte	   end-­‐feed	   tightly	  
cover	   the	   surface	   of	   blood	   capillaries,	   providing	   a	   physical	   mechanism	   for	  
efficient	  glucose	  uptake	  from	  the	  blood	  (Pellerin	  et	  al.,	  1998;	  Simard	  et	  al.,	  2003;	  
Gladden,	  2004).	  Due	  to	  the	  morphological	  abnormalities	  we	  have	  documented	  in	  
Cln3-­‐/-­‐	   astrocytes,	   their	   capillary	   coverage	   via	   their	   end-­‐feet	   may	   be	  
compromised,	  which	  would	  alter	  their	  glucose	  uptake	  and	  energy	  metabolism	  in	  
the	  Cln3-­‐/-­‐	  mouse	  brain.	  Indeed,	  in	  terms	  of	  energy	  metabolism	  in	  Cln3-­‐/-­‐	  mice,	  a	  
shift	   towards	   gluconeogenesis	   and	   down-­‐regulation	   of	   genes	   associated	   with	  
energy	   production	   in	   mitochondria	   have	   been	   reported	   (Brooks	   et	   al.,	   2003;	  
Chattopadhyay	   et	   al.,	   2004;	   Luiro	   et	   al.,	   2006).	   This	   may	   be	   an	   indication	   of	  
enhanced	   energy	   demand	   arising	   from	   insufficient	   availability	   of	   energy	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providers	   such	   as	   glucose	   in	   the	   CNS	   of	   Cln3-­‐/-­‐	   mice,	   potentially	   caused	   by	  
alterations	   in	   astrocyte	   end-­‐feet	   connectivity	   with	   blood	   vessels.	  
Immunohistological	  investigation	  of	  interactions	  between	  astrocyte	  end-­‐feet	  and	  
blood	  vessels	  in	  the	  Cln3-­‐/-­‐	  mouse	  brain,	  and	  in	  brain	  sections	  from	  JNCL	  patients	  
would	  provide	  further	  insights	  into	  this	  matter.	  Under	  conditions,	  such	  as	  during	  
epileptic	  seizures,	  neuronal	  energy	  demand	   is	  extremely	  high	   (Cloix	  and	  Hévor,	  
2009),	   and	   demand	   for	   lactate	   produced	   via	   astrocyte	   glycogenolysis	   is	  
increased.	   It	  would	  be	   interesting	  to	   investigate	  whether	  this	  mechanism	  could	  
play	  a	  role	  in	  epileptogenesis	  in	  JNCL.	  
 
Excess	  glutamate	  is	  not	  cleared	  by	  Cln3-­‐/-­‐	  astrocytes	  	  
Glutamate	  is	  the	  major	  excitatory	  neurotransmitter	  in	  the	  mammalian	  CNS,	  and	  
it	   may	   act	   as	   a	   potent	   neurotoxin	   and	   glutamate	   excitotoxicity	   has	   been	  
implicated	  in	  a	  number	  of	  diseases,	  including	  epilepsy,	  stroke	  and	  ALS	  (Cendes	  et	  
al.,	  1995;	  Pitt	  et	  al.,	  2000;	  Hazell,	  2007).	  Glutamate	  transporters	  are	  expressed	  by	  
many	   different	   cell	   types	   in	   the	   CNS,	   including	   neurons,	   microglia,	  
oligodendrocytes,	  endothelial	  cells,	  and	  of	  course	  astrocytes.	  Indeed,	  astrocytes	  
are	  recognized	  as	  key	  players	  in	  maintaining	  the	  appropriate	  extracellular	  levels	  
of	  glutamate	  (Kanai	  and	  Hediger,	  1992;	  Rothstein	  et	  al.,	  1994;	  Kondo	  et	  al.,	  1995;	  
Domercq	   et	   al.,	   1999;	   O'Kane	   et	   al.,	   1999;	   Anderson	   and	   Swanson,	   2000).	  
Moreover,	   astrocyte-­‐based	   regulation	   of	   glutamate	   concentration	   in	   the	  
extracellular	   space	   is	   pivotal	   for	   the	   kinetics	   of	   glutamatergic	   synaptic	   activity	  
(Danbolt,	  2001;	  Minelli	  et	  al.,	  2001;	  Hertz	  and	  Zielke,	  2004).	  As	  such,	  our	  finding	  
of	  attenuated	  glutamate	  clearance	  by	  Cln3-­‐/-­‐	  astrocytes	  (Chapter	  4,	  Figure	  4.11)	  
could	  not	  only	  impact	  synaptic	  activity,	  but	  also	  ultimately	  expose	  neurons	  in	  the	  
JNCL	  brain	  to	  excitotoxicity.	  
	  
Why	  do	  Cln3-­‐/-­‐	  astrocytes	   show	  an	  attenuated	  ability	   to	  uptake	  glutamate?	  The	  
Na+	  -­‐dependent	   glutamate	   transporters:	  GLAST	   (EAAT1)	   and	  GLT-­‐1	   (EAAT2)	   are	  
the	  key	  players	  in	  astrocyte	  glutamate	  clearance	  (Pines	  et	  al.,	  1992;	  Storck	  et	  al.,	  
1992;	   Shashidharan	   and	   Plaitakis,	   1993;	   Shashidharan	   et	   al.,	   1994).	  
Immunohistological	   investigation	  of	  glutamate	  transporter	  expression	  in	  human	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JNCL	  post-­‐mortem	  tissue	  revealed	  reduced	  immunoreactivity	  particularly	  for	  the	  
EAAT2	   transporter	   (Hachiya	   et	   al.,	   2006).	   Such	   a	   reduced	   expression	   of	   a	  
glutamate	  transporter	  could	  dramatically	  alter	  the	  ability	  of	  Cln3-­‐/-­‐	  astrocytes	  to	  
take-­‐up	   glutamate.	   Disrupted	   expression	   of	   glutamate	   transporters	   has	   been	  
well	  established	   in	  epilepsy	  (Mathern	  et	  al.,	  1999;	  Proper	  et	  al.,	  2002),	  and	  the	  
astrocyte-­‐selective	   glutamate	   transporter	   EAAT2	   has	   also	   been	   shown	   to	   be	  
pivotal	   for	   maintaining	   extracellular	   glutamate	   below	   excitotoxic	   levels	  
(Rothstein	  et	  al.,	  1996).	  In	  the	  healthy	  brain	  astrocytes	  are	  strategically	  located	  in	  
close	   proximity	   to	   the	   synapse	   allowing	   the	   detection	   of,	   and	   reaction	   to,	  
increased	  levels	  of	  extracellular	  glutamate	  (Volterra	  and	  Meldolesi,	  2005).	  In	  the	  
JNCL	   brain,	   these	   actions	   of	   astrocytes	   may	   be	   compromised	   accelerating	   the	  
ongoing	   degenerative	   process	   and	   exposing	   the	   neurons	   to	   overstimulation	  
typical	  for	  epileptogenesis	  (Rossi	  and	  Volterra,	  2009).	  Studying	  the	  expression	  of	  
glutamate	   transporters	   by	   astrocytes,	   both	   in	   vitro	   and	   in	   vivo,	   would	   provide	  
important	  clues	  to	  mechanisms	  underlying	  glutamate	  metabolism	  in	  Cln3-­‐/-­‐	  mice.	  	  
	  
Cytoskeletal	  components	  have	  been	   implied	   to	  be	   involved	   in	  a	   range	  of	  signal	  
transduction	  pathways	   and	   in	   transporter	   trafficking	   (Apodaca,	   2001;	   Tuvim	  et	  
al.,	  2001;	  Najimi	  et	  al.,	  2002).	  For	  instance,	  inhibition	  of	  actin	  polymerization	  has	  
been	  shown	  to	  attenuate	  glutamate	  clearance	  by	  astrocytes	  (Duan	  et	  al.,	  1999),	  
whereas	   inhibition	   of	   microtubule	   formation	   had	   no	   effect	   on	   this	   process	  
(Jordan	  and	  Wilson,	  1998).	  Moreover,	  the	  actin	  cytoskeleton	  has	  been	  associated	  
with	  transporter	  function,	  intracellular	  protein	  trafficking	  and	  signal	  transduction	  
in	  many	  systems	  (Mills	  and	  Mandel,	  1994;	  Tsakiridis	  et	  al.,	  1994;	  Lamaze	  et	  al.,	  
1997;	   Wang	   et	   al.,	   1998).	   These	   findings	   suggest	   that	   the	   abnormal	   actin	  
cytoskeleton	   in	  Cln3-­‐/-­‐	  astrocytes	  may	  be	   the	  key	  element	   in	   reduced	  glutamate	  
clearance	  by	  these	  cells.	  Moreover,	  intermediate	  filament	  proteins,	  particularly,	  
GFAP,	  have	  been	  shown	  to	  be	  involved	  in	  the	  modulation	  of	  astrocyte	  glutamate	  
transporter	   trafficking	  and	   function	   (Hughes	  et	  al.,	  2004).	  Hence,	  abnormalities	  
in	   both	   intermediate	   filaments	   and	   actin	   cytoskeleton	   (Chapter	   3,	   Figure	   3.7)	  
could	   synergistically	   result	   in	   decreased	   glutamate	   clearance	   by	   Cln3-­‐/-­‐	  
astrocytes.	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Elevated	   levels	   of	   glutamate	   in	   the	   cerebellum	  and	   cortex	   of	  Cln3-­‐/-­‐	  mice	   have	  
been	  reported	  previously,	  suggesting	  that	  glutamate	  neurotransmission	  may	  be	  
altered	   in	   JNCL	   (Pears	  et	  al.,	  2005).	  The	   lack	  of	  astrocyte	  glutamate	  scavenging	  
reported	  here	   (Chapter	  4,	  Figure	  4.11)	  may	  offer	  a	   realistic	  explanation	   for	   the	  
increased	  levels	  of	  glutamate	  observed.	  Glutamate	  acts	  via	  its	  receptors	  (NMDA,	  
AMPA,	   kainate	   and	   metabotropic	   receptors)	   that	   may	   all	   modulate	   synaptic	  
transmission	  (Kew	  and	  Kemp,	  2005).	  Intriguingly,	  cerebellar	  granule	  cells	  derived	  
from	   Cln3-­‐/-­‐	   mice	   show	   a	   selectively	   increased	   sensitivity	   to	   AMPA-­‐type	  
glutamate	   receptor-­‐mediated	   toxicity	   (Kovács	  et	  al.,	  2006),	  and	   treatment	  with	  
specific	   AMPA	   antagonists	   resulted	   in	   a	   significant	   improvement	   in	   the	  motor	  
skills	  of	  one-­‐month-­‐old	  Cln3-­‐/-­‐	  mice	  (Kovács	  and	  Pearce,	  2008).	  Furthermore,	  the	  
neuronal	   cells	   derived	   from	   Cln3Δex7/8	   knock	   in	   mice	   are	   highly	   susceptible	   to	  
both	   AMPA-­‐and	   NMDA-­‐type	   glutamate	   receptor	   over-­‐activation	   (Finn	   et	   al.,	  
2011).	  Based	  on	  these	  key	  findings	  one	  can	  speculate	  that	  abnormally	  enhanced	  
glutamate	  receptor	  activity,	  which	  may	  well	  be	  down	  to	  the	  impaired	  regulation	  
of	   glutamate	   concentration	   by	   Cln3-­‐/-­‐	   astrocytes,	   contributes	   significantly	  
towards	   clinical	   manifestations	   and	   neuronal	   loss	   in	   JNCL.	   This	   suggests	   that	  
regulation	   of	   glutamate	   metabolism	   by	   astrocytes	   could	   be	   considered	   as	   a	  
potential	  therapeutic	  target	  in	  this	  disease.	  	  
	  
What	  could	  be	  the	  implications	  of	  the	  disrupted	  glutathione	  secretion	  in	  JNCL?	  
Direct	  GSH-­‐based	  connections	  between	  neurons	  and	  astrocytes	  have	  been	  well	  
established.	  Astrocytes	  release	  GSH	  (Yudkoff	  et	  al.,	  1990;	  Sagara	  et	  al.,	  1996)	  via	  
Mrp1	  (Hirrlinger	  et	  al.,	  2002;	  Minich	  et	  al.,	  2006),	  which	  is	  cleaved	  by	  astrocyte	  
and	   neuron-­‐associated	   ectoenzymes	   to	   provide	   the	   rate	   limiting	   substrate,	   L-­‐
cystine,	   for	   neuronal	   GSH	   synthesis	   (Dringen	   et	   al.,	   1997;	   1999b;	   2001).	   This	  
direct	   connection,	  enabling	  neuronal	  GSH	  production,	  may	  be	  altered	   in	  Cln3-­‐/-­‐	  
astrocytes,	  since	  these	  cells	   fail	   to	  secrete	  the	  GSH	  they	  synthesize	   (Figure	  4.9)	  
Given	  that	  GSH	  is	  the	  most	  abundant	  mammalian	  thiol-­‐containing	  antioxidant	  in	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the	   CNS,	   lack	   of	   GSH	   secretion	   by	   Cln3-­‐/-­‐	   astrocytes	   may	   have	   significant	  
consequences	  (Dringen,	  2000).	  
	  
The	  impaired	  glutathione	  secretion	  from	  Cln3-­‐/-­‐	  astrocytes	  could	  result	  from	  the	  
failure	  of	  several	  cellular	  mechanisms.	  It	   is	  plausible	  that	  GSH	  trafficking	  and	  its	  
secretion	   machinery	   could	   be	   impaired	   in	   Cln3-­‐/-­‐	   astrocytes,	   due	   to	   their	  
cytoskeletal	  abnormalities	  (Potokar	  et	  al.,	  2005;	  Stenovec	  et	  al.,	  2007;	  Potokar	  et	  
al.,	   2008).	   Indeed,	   disrupting	   the	   correct	   polymerization	   of	   actin	   cytoskeleton	  
with	   cytochalasin	   D	   in	   WT	   astrocytes	   demonstrated	   the	   importance	   of	   actin	  
cytoskeletal	   integrity	   for	  glutathione	  secretion	  by	   these	  cells	   (Chapter	  4,	  Figure	  
4.10).	   One	   cannot	   exclude	   the	   possibility	   that	   an	   abnormal	   IF	   network	  
organization	  may	  also	  play	  a	  role	  in	  this	  process.	  Alternatively,	  transport	  of	  GSH	  
via	  MRP1	  may	  be	  altered	  Cln3-­‐/-­‐	  astrocytes.	   Impaired	  MRP1-­‐mediated	  export	  of	  
products	   related	   to	   the	   GSH	   antioxidant	   system	   has	   been	   suggested	   to	   cause	  
accumulation	  of	  glutathione-­‐conjugated	  substrates	  in	  astrocytes,	  in	  a	  very	  similar	  
fashion	   to	   that	   described	   here	   for	   Cln3-­‐/	   astrocytes,	   subsequently	   leading	   to	  
increased	   oxidative	   stress	   and	   cellular	   degeneration	   in	   Alzheimer	   disease	  
(Sultana	   and	   Butterfield,	   2004).	   This	   possibility	   could	   be	   explored	   directly	   by	  
studying	  the	  expression,	  and	  by	  measuring	  the	  activity,	  of	  the	  MRP1	  transporter	  
in	  Cln3-­‐/-­‐	  astrocytes	  (Hipfner	  et	  al.,	  1999).	  	  
	  
CLN3	   has	   been	   proposed	   to	   play	   a	   protective	   role	   in	   managing	   the	   cellular	  
response	   to	   oxidative	   stress	   in	   a	   Drosophila	   model	   of	   JNCL	   (Tuxworth	   et	   al.,	  
2011).	   In	   this	  model,	   CLN3	   deficiency	   caused	   accumulation	   of	   reactive	   oxygen	  
species	   (ROS)	   leading	   to	   increased	   levels	   of	   oxidized	   cytosolic	   proteins,	   which	  
may	   ultimately	   result	   in	   lysosomal	   dysfunction	   and	   cell	   death.	   In	   addition,	  
increased	   oxidative	   stress	   has	   also	   been	   shown	   in	   a	   mouse	   model	   of	   JNCL	  
(Benedict	  et	  al.,	  2007).	  Furthermore,	  multiple	  regions	  of	  the	  Cln3-­‐/-­‐	  mouse	  brain	  
display	   a	   specific	   reduction	  of	   total	   glutathione,	  which	   could	  be	   caused	  by	   the	  
lack	  of	  GSH	  secretion	  from	  astrocytes,	  as	  reported	  in	  this	  study	  (Chapter	  4,	  Figure	  
4.9).	   Increased	   levels	   of	   manganese	   superoxide	   dismutase	   (MnSOD),	   which	   is	  
another	   antioxidant	   enzyme,	   in	   Cln3-­‐/-­‐	  mice	   could	   be	   one	   of	   the	   mechanisms	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employed	  to	  counteract	  such	  oxidative	  stress-­‐mediated	  damage	  (Benedict	  et	  al.,	  
2007).	   MnSOD	   is	   a	   mitochondrial	   antioxidant	   enzyme	   that	   is	   universally	  
produced	  by	  all	   cells,	  and	  astrocytes	  do	  not	  play	  any	  significant	   role	   in	  MnSOD	  
based	  antioxidant	  protection	  of	  neurons	  (Macmillan-­‐Crow	  and	  Cruthirds,	  2001).	  
Hence,	   the	   lack	   of	   glutathione	   secretion	   by	   astrocytes	   might	   initiate	   a	  
compensatory	  mechanism	   aimed	   to	   protect	   neurons	   against	   ongoing	   oxidative	  
stress	  in	  Cln3-­‐/-­‐	  mice.	  In	  addition	  to	  dysfunctional	  GSH	  secretion	  from	  astrocytes,	  
microarray	   studies	   on	   Cln3-­‐/-­‐	   mice	   have	   revealed	   an	   up-­‐regulation	   of	   many	  
proteins	   involved	   in	   oxidative	   stress	   responses	   (Brooks	   et	   al.,	   2003),	   further	  
highlighting	  the	  potential	  role	  of	  oxidative	  stress	  as	  part	  of	  the	  pathogenesis	  of	  
JNCL.	  	  
JNCL	   is	   certainly	   not	   the	   only	   neurological	   disease	   associated	   with	   oxidative	  
stress.	   In	   fact	   oxidative	   stress	   has	   emerged	   as	   one	   of	   the	   key	   players	   in	  
neurodegenerative	  mechanisms	  in	  numerous	  diseases,	  such	  as	  Alzheimer	  disease	  
(Nunomura	  et	  al.,	  2006),	  Parkinson	  disease	   (Hald	  and	  Lotharius,	  2005)	  and	  ALS	  
(Boillée	   et	   al.,	   2006).	   Common	   changes	   caused	   by	   oxidative	   stress	   in	   these	  
diseases	   include	   lipid,	   protein	   and	   DNA	   damage,	   and	   neurons	   appear	   to	   be	  
especially	   susceptible	   to	   oxidative	   damage,	   possibly	   due	   to	   a	   combination	   of	  
their	   longevity	   and	   high	  metabolic	   turnover	   (Halliwell,	   2006).	   Thus,	   the	   lack	   of	  
glutathione	   secretion	   from	   Cln3-­‐/-­‐	   astrocytes	   could	   make	   neurons	   highly	  
susceptible	   to	   oxidative	   damage.	   This	   would	   suggest	   that	   one	   of	   the	   primary	  
defects	   in	   JNCL	   pathogenesis	   could	   be	   the	   failure	   of	   astrocytes	   to	   respond	  
appropriately	   to	  oxidative	   stress.	   To	   explore	  whether	   the	   impaired	   glutathione	  
secretion	   by	   Cln3-­‐/-­‐	   astrocytes	   makes	   neurons	   more	   susceptible	   to	   cell	   death	  
under	   oxidative	   stress	   conditions,	   induced	   by	   for	   example	   by	   using	   H2O2	  
(Desagher	  et	  al.,	  1996;	  Dringen	  et	  al.,	  1999a),	  co-­‐cultures	  comprised	  of	  WT	  and	  
Cln3-­‐/-­‐	  astrocytes	   and	   neurons	   could	   be	   used,	   and	   L-­‐cysteine	   applied	   to	   rescue	  
any	  defects	  arising	  from	  impaired	  glutathione	  secretion	  by	  Cln3-­‐/-­‐	  astrocytes.	  	  
The	  lysosomal	  dysfunction	  that	  is	  apparent	  in	  JNCL	  could	  additionally	  contribute	  
to	   oxidative	   stress	   induced	   neurodegeneration,	   due	   to	   the	   unique	   ability	   of	  
lysosomes	   to	   effectively	   degrade	   oxidatively	   damaged	   molecules	   and	   proteins	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(Pivtoraiko	  et	  al.,	  2009).	  Indeed,	  lipofuscin	  accumulation,	  lysosomal	  dysfunction,	  
impaired	  ER	  and	  mitochrondrial	   function,	   all	   of	  which	  are	   common	   features	  of	  
pathogenesis	  of	  different	  forms	  of	  NCL,	  have	  all	  been	  shown	  to	  be	  consequences	  
of	  oxidative	  damage	  (Wei	  et	  al.,	  2008;	  Pivtoraiko	  et	  al.,	  2009;	  Kim	  et	  al.,	  2010b;	  
Mole	  et	  al.,	  2011).	  Indeed,	  oxidative	  damage	  has	  been	  reported	  in	  several	  other	  
forms	  of	  NCL	  including	  Ppt1-­‐/-­‐	  (Kim	  et	  al.,	  2010b),	  Cln6-­‐/-­‐	  (Heine	  et	  al.,	  2003)	  and	  
Cln8-­‐/-­‐	   (Guarneri	   et	   al.,	   2004).	   General	   mechanisms	   involved	   in	  
neurodegeneration	   in	   the	   NCLs	   could	   include	   synergistic	   effects	   of	   reduced	  
intracellular	   levels	   of	   GSH	   and	   reduced	   ATP	   production	   due	   to	   mitochondrial	  
dysfunction,	   which	   have	   been	   shown	   to	   increase	   the	   susceptibility	   of	  
dopaminergic	   neurons	   to	   both	   energy-­‐stress-­‐induced	   cell	   death	   and	  
excitotoxicity	   both	   in	   vitro	   and	   in	   vivo	   (Zeevalk	   et	   al.,	   1997;	   1998).	   Indeed,	  
dramatic	  changes	  in	  the	  catabolism	  of	  dopamine,	  leading	  to	  elevation	  in	  reactive	  
oxidative	   forms	   of	   dopamine	   have	   been	   proposed	   to	   be	   involved	   in	   the	  
progressive	  dopaminergic	  neuronal	   loss	   in	   the	  striatum	  of	  Cln3-­‐/-­‐	  mice	   (Weimer	  
et	  al.,	  2007).	  Attenuated	  activation	  of	  astrocytes	  (See	  Chapter	  3	  and	  Pontikis	  et	  
al.,	  2004;	  2005)	  and	  the	  lack	  of	  GSH	  secretion	  could	  also	  contribute	  to	  neuronal	  
cell	  death	  in	  JNCL	  (Mytilineou	  et	  al.,	  1999).	  Various	  different	  forms	  of	  antioxidant	  
based	  therapies	  have	  shown	  benefits	  regarding	  hindering	  the	  clinical	  progression	  
in	   JNCL	   patients,	   although	   these	   results	   have	   not	   been	   clinically	   verified	  
(Santavuori	   et	   al.,	   1988;	   1989;	   Westermarck	   et	   al.,	   1997).	   Thus,	   antioxidant	  
based	   therapies	   developed	   further,	   and	   in	   combination	   with	   other	   therapies,	  
may	   help	   inhibit	   the	   earliest	   pathological	   events	   that	   accumulatively	   lead	   to	  
progressive	  neuronal	  loss	  in	  JNCL.	  	  
	  
Why	  do	  Cln3-­‐/-­‐	  astrocytes	  migrate	  so	  slowly	  and	  what	  could	  this	  mean?	  
Migration	  was	  severely	  attenuated	  in	  Cln3-­‐/-­‐	  astrocytes	  (Chapter	  4,	  Figure	  4.12).	  
Such	  attenuated	  astrocyte	  migration	  may	  impact	  migration	  of	  reactive	  astrocytes	  
towards	  sites	  of	  damaged	  (Fawcett	  and	  Asher,	  1999;	  Saadoun	  et	  al.,	  2005),	  and	  
localized	   immune	   responses	   (Merrill	   and	   Benveniste,	   1996)	   in	   the	   JNCL	   brain,	  
since	   all	   of	   these	   functions	   require	   correctly	   orchestrated	   movement	   of	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astrocytes	   to	   particular	   locations	   within	   the	   CNS.	   The	   discovery	   of	   attenuated	  
Cln3-­‐/-­‐	   astrocyte	   migration	   is	   in	   keeping	   with	   previous	   finding,	   which	  
demonstrated	   a	   similar	   deficiency	   in	   the	  migration	  of	  Cln3-­‐/-­‐	  mouse	   embryonic	  
fibroblasts	   (Getty	   et	   al.,	   2011).	   The	   disruption	   of	   the	   putative	  Myosin-­‐IIβ-­‐CLN3	  
interaction	  was	  speculated	  to	  be	  the	  cause	  of	  this	  improper	  cell	  migration	  (Lo	  et	  
al.,	   2004;	   Vicente-­‐Manzanares	   et	   al.,	   2007;	   2009;	  Getty	   et	   al.,	   2011).	  Hence,	   it	  
seems	   that	   CLN3	   could	   indeed	   be	   involved	   in	   cell	   migration,	   via	   its	   proposed	  
interactions	  with	  cytoskeletal	  components.	  
Additionally,	   several	   other	   mechanisms,	   including	   defects	   in	   metabolic	   status,	  
proliferation,	   re-­‐arrangement	   of	   cytoskeletal	   components,	   correct	   polarization,	  
altered	   protein	   localization	   or	   deficient	   cell	   adhesion	   could	   each	   contribute	  
towards	   inhibited	   migration	   (Etienne-­‐Manneville	   and	   Hall,	   2001;	   Etienne-­‐
Manneville,	  2004).	  One	  can	  exclude	  the	  possible	  role	  of	  attenuated	  proliferation	  
of	  Cln3-­‐/-­‐	  astrocytes	  in	  inhibited	  migration,	  since	  the	  scratch	  assay	  was	  performed	  
on	   a	   confluent	   monolayer	   of	   astrocytes	   in	   the	   presence	   of	   Ara-­‐C	   containing	  
medium	  to	  block	  astrocyte	  proliferation.	  No	  detectable	  difference	  was	  observed	  
in	   viability	   between	   WT	   and	   Cln3-­‐/-­‐	   astrocytes	   under	   these	   experimental	  
conditions	  either.	  Thus,	  the	  attenuated	  migration	  of	  Cln3-­‐/-­‐	  astrocytes	  cannot	  be	  
caused	   by	   poor	   survival	   of	   these	   cells	   under	   these	   experimental	   conditions.	   In	  
this	   type	   of	   migration	   assay,	   primary	   astrocytes	   undergo	   a	   highly	   polarized	  
migration	  in	  a	  direction	  perpendicular	  to	  the	  scratched	  area	  (Etienne-­‐Manneville	  
and	   Hall,	   2001;	   Peng	   et	   al.,	   2008).	   Cell-­‐adhesion	   proteins,	   N-­‐cadherins	   and	  
integrins,	  have	  been	  shown	  to	  direct	  such	  polarization	  and	  oriented	  migration	  in	  
astrocytes	   (Camand	   et	   al.,	   2012).	   In	   embryonic	   CLN3	   deficient	   fibroblasts	   the	  
migration	  defect	  was	  not	  thought	  to	  be	  caused	  by	  cell	  adhesion	  defects,	  due	  to	  
an	   evidently	   normal	   distribution	   of	   adherens	   junctions,	   which	   are	   formed	   by	  
cadherin	  and	  catenin	  proteins,	  even	  in	  the	  absence	  of	  CLN3	  (Getty	  et	  al.,	  2011).	  
Thus,	   it	   is	   likely	   that	   the	   observed	   migration	   defects	   exhibited	   by	   Cln3-­‐/-­‐	  
astrocytes	  are	  not	  caused	  by	  problems	  in	  cell	  adhesion.	  This,	  however,	  should	  be	  
confirmed	   by	   examining	   the	   expression	   of	   N-­‐cadherins	   and	   integrins	   in	   these	  
astrocyte	   cultures.	   Intriguingly,	   inhibition	   of	   lysosome	   function	   by	   treating	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embryonic	   CLN3	   deficient	   fibroblasts	   with	   chloroquine	   exacerbated	   their	  
migration	   defects,	   whereas	   WT	   fibroblasts	   were	   able	   to	   overcome	   this	   insult	  
(Getty	  et	  al.,	  2011).	  Thus,	  alterations	  in	  lysosomes	  observed	  in	  Cln3-­‐/-­‐	  astrocytes	  
(Chapter	   3,	   Figures	   3.11	   and	   3.13),	   could	   together	   with	   abnormal	   myosin-­‐IIB-­‐
cytoskeleton	  dynamics	  decrease	  their	  ability	  to	  migrate.	  	  	  	  
	  
Generally,	   depolymerization	   of	   actin	   filaments	   or	   microtubules,	   and	   lack	   of	  
functional	   IFs	   impair	   the	   motility	   of	   astrocytes,	   and	   the	   correct	   interplay	  
between	   each	   of	   these	   cytoskeletal	   components	   is	   crucial	   for	   astrocytic	  
migration	  (Lepekhin	  et	  al.,	  2001;	  Etienne-­‐Manneville,	  2004).	  Thus,	  the	  abnormal	  
cytoskeleton	   and	   possibly	   disrupted	   myosin-­‐IIβ	   interaction	   may	   be	   the	   key	  
factors	   explaining	   the	   migration	   defects	   in	   Cln3-­‐/-­‐	   astrocytes.	   To	   examine	   this	  
further	   myosin-­‐IIB	   distribution	   could	   be	   explored,	   and	   inhibition	   of	   myosin-­‐IIB	  
with,	   for	   example,	   blebbistatin	   in	  WT	   astrocytes	   could	   be	   tested	   to	   see	   if	   this	  
resembles	  the	  migration	  defects	  seen	  in	  Cln3-­‐/-­‐	  astrocytes.	  	  
	  
Astrocyte	  migration	  has	  been	  observed	   in	  many	  CNS	  diseases,	   for	  example	   it	   is	  
necessary	  for	  Aβ	  clearance	  and	  the	  formation	  of	  a	  protective	  barrier	  between	  Aβ	  
deposits	  and	  neurons	  in	  the	  Alzheimer	  brain	  (Wyss-­‐Coray	  et	  al.,	  2003;	  Rossner	  et	  
al.,	   2005).	   Interestingly,	   cultured	   adult	   mouse	   astrocytes	   have	   been	   shown	   to	  
migrate	  in	  response	  to	  the	  MCP-­‐1	  chemokine	  that	  is	  present	  in	  Alzheimer	  disease	  
lesions	   (Wyss-­‐Coray	   et	   al.,	   2003).	   Our	   protein	   profiling	   analysis	   revealed	   that	  
secretion	   of	   this	   chemokine	   by	   Cln3-­‐/-­‐	   astrocyte	   was	   significantly	   reduced	  
(Chapter	  4,	  Tables	  4.1	  and	  4.2).	  MCP-­‐1	  mediated	  guidance	  of	  astrocyte	  migration	  
along	  with	   the	  attenuated	  ability	  of	  Cln3-­‐/-­‐	  astrocytes	   to	  migrate	   could	  perhaps	  
influence	  where	  reactive	  changes	  occur	  in	  the	  Cln3-­‐/-­‐	  mouse	  brain.	  Whether	  this	  
has	  a	  positive	  or	  negative	  impact	  upon	  disease	  progression	  would	  depend	  on	  the	  
exact	  role	  that	  these	  cells	  play	  in	  the	  pathogenesis	  of	  JNCL.	  	  
Indeed,	   astrocytes	   exert	   a	   wide	   range	   of	   crucial	   functions	   during	   CNS	  
development	  and	  during	  post-­‐natal	  stages,	  and	  many	  of	  them	  are	  dependent	  on	  
astrocyte	  migration	  and	  motility.	  For	  example,	  astrocytes	  guide	  the	  migration	  of	  
	   230	  
developing	  axons	  and	  certain	  neuroblasts	  (Powell	  and	  Geller,	  1999).	  Moreover,	  it	  
was	  recently	  reported	  that	  migrating	  astrocytes	  are	  allocated	  to	  spatial	  domains	  
in	   both	   the	   spinal	   cord	   and	   the	   brain,	   and	   that	   this	   is	   determined	   by	   their	  
embryonic	   sites	  of	  origin	   in	   the	   ventricular	   zone	   (Tsai	   et	   al.,	   2012).	   These	  data	  
reveal	   that	   region-­‐restricted	   astrocyte	   migration	   is	   a	   general	   part	   of	   CNS	  
development	  (Tsai	  et	  al.,	  2012).	  Based	  on	  this,	  the	  impaired	  migration	  ability	  of	  
astrocytes	   due	   to	   CLN3	   deficiency,	   could	   also	   alter	   the	   correct	   formation	   of	  
region-­‐specific	  astrocyte	  domains	  within	  the	  brain.	  Subsequently	  this	  could	  result	  
in	   abnormal	   synaptogenesis	   and	   neuronal	   dysfunction	   within	   these	   domains	  
(Molofsky	  et	  al.,	  2012;	  Tsai	  et	  al.,	  2012).	  More	  specific	  investigations	  are	  required	  
to	  determine	  whether	  astrocyte	  migration	  is	  actually	  altered	  in	  vivo	  in	  the	  Cln3-­‐/-­‐	  
mouse	   brain,	   and	   to	   determine	   the	   precise	   role	   of	   such	   impaired	   astrocyte	  
migration	  in	  the	  development	  and	  local	  regulation	  of	  synaptogenesis.	  
	  
Taken	  together	  these	  results	  imply	  that	  Cln3	  deficiency	  has	  a	  direct	  impact	  upon	  
astrocyte	   function.	   Our	   findings	   show	   a	   whole	   range	   of	   altered	   properties	   of	  
Cln3-­‐/-­‐	  astrocytes,	  with	  the	  disrupted	  cytoskeletal	  organization	  observed	  in	  these	  
cells	   potentially	   resulting	   in	   abnormal	   Ca2+	   signaling	   and	   a	   severely	   impaired	  
ability	   to	   secrete	   proteins,	   take-­‐up	   transmitters	   and	   to	   migrate.	   Although	   the	  
lack	  of	  a	  morphological	  response	  to	  stimulation	  that	  was	  observed	   in	  vitro	  does	  
correlate	   well	   with	   the	   incomplete	   morphological	   transformation	   observed	   in	  
vivo,	  we	  do	  not	  know	  whether	  any	  of	   the	   functional	  differences	   reported	  here	  
also	   occur	   within	   the	   diseased	   CNS.	   Thus,	   future	   studies	   will	   be	   needed	   to	  
determine	  how	  astrocyte	  functions	  are	  altered	   in	  vivo	   in	  Cln3-­‐/-­‐	  mice.	  Moreover,	  
it	  will	  be	  important	  to	  determine	  the	  direct	  impact	  of	  these	  deficits	  on	  neuronal	  
biology.	  This	  important	  question	  is	  the	  focus	  of	  experiments	  described	  in	  Chapter	  
6	  of	  this	  thesis.	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Chapter	  5	  
The	  basic	  biology	  of	  Cln3-­‐/-­‐	  
cortical	  neurons	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5.1	  Introduction	  	  
Although	   the	   precise	   function	   of	   CLN3	   remains	   unknown,	   many	   studies	   have	  
proposed	   that	   this	   protein	   may	   influence	   intracellular	   trafficking	   and	   the	  
expression	   of	   various	   molecules	   involved	   in	   neurotransmission	   (Chapter	   1,	  
Section	  1.2)	  (Järvelä	  et	  al.,	  1999;	  Haskell	  et	  al.,	  2000;	  Luiro	  et	  al.,	  2001;	  Fossale	  et	  
al.,	  2004;	  Kyttälä	  et	  al.,	  2004;	  Storch	  et	  al.,	  2007;	  Uusi-­‐Rauva	  et	  al.,	  2008;	  2012).	  
Given	   that	   the	   absence	   of	   CLN3	   was	   observed	   to	   have	   a	   profound	   effect	   on	  
astrocyte	  biology,	  at	  least	  in	  vitro	  (Chapters	  3	  and	  4),	  an	  obvious	  next	  step	  was	  to	  
use	  a	  similar	  approach	  to	  explore	  what	  influence	  the	  absence	  of	  this	  protein	  has	  
on	  the	  biology	  of	  neurons.	  To	  this	  end,	  cortical	  neuronal	  cultures	  derived	  from	  P0	  
WT	   and	   Cln3-­‐/-­‐	   mice	   were	   generated	   and	   evaluated	   for	   a	   range	   of	   potential	  
deficits	  based	  on	  the	  predicted	  function	  of	  CLN3	  in	  neurons.	  	  
	  
Many	  lines	  of	  evidence	  suggest	  that	  CLN3,	  via	   its	  proposed	  interaction	  partners	  
fodrin,	  Rab7	  and	  myosin	  IIB,	  may	  be	  involved	  in	  neurite	  growth	  and	  morphology	  
(Tullio	  et	  al.,	  2001;	  Saxena	  et	  al.,	  2005a;	  Ryu	  et	  al.,	  2006;	  Weimer	  et	  al.,	  2009),	  
which	  may	  alter	  synapse	  formation	  and	  neuronal	  connectivity	  in	  the	  JNCL	  brain.	  
Therefore,	  the	  impact	  of	  CLN3	  deficiency	  on	  neuronal	  size	  and	  neurite	  outgrowth	  
and	  complexity	  was	  explored.	  In	  addition,	  spontaneous	  epileptic	  seizures	  are	  one	  
of	   the	   most	   prominent	   clinical	   features	   of	   JNCL	   suggesting	   that	   the	  
electrophysiological	   properties	   of	   Cln3	   deficient	   neurons	   have	   been	   altered	  
making	   them	  more	   susceptible	   to	   over-­‐activation.	   It	   has	   recently	   been	   shown	  
that	  neurons	  can	  fine-­‐tune	  their	  excitability	  by	  activity-­‐dependent	  relocation	  of	  
the	  AIS	   along	   the	  axon	   (Grubb	  and	  Burrone,	   2010b).	  Hence,	   the	   localization	  of	  
AIS	   in	   neurons	   grown	   under	   basal	   conditions,	   and	   after	   chronic	   depolarization	  
was	   investigated.	   Neurotransmission	   has	   been	   shown	   to	   be	   impaired	   in	   other	  
forms	  of	  NCL	  (Kim	  et	  al.,	  2008;	  Koch	  et	  al.,	  2011),	  in	  particular	  the	  expression	  and	  
localization	   of	   SNARE-­‐complex	   proteins	   that	   are	   involved	   in	   synaptic	   vesicle	  
fusion	   and	   neurotransmitter	   release	   at	   the	   synapse	   (Kavalali,	   2002;	  Ungar	   and	  
Hughson,	  2003;	  Ramakrishnan	  et	  al.,	  2012)	  have	  been	  shown	  altered	  in	  different	  
NCLs	   (Virmani	  et	  al.,	  2005;	  Kim	  et	  al.,	  2008;	  Partanen	  et	  al.,	  2008;	  Kielar	  et	  al.,	  
2009).	   Given	   its	   synaptic	   localization	   (Järvelä	   et	   al.,	   1999;	   Haskell	   et	   al.,	   2000;	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Luiro	  et	  al.,	  2001;	  Kyttälä	  et	  al.,	  2004;	  Phillips	  et	  al.,	  2005;	  Storch	  et	  al.,	  2007),	  the	  
effect	  of	  CLN3	  deficiency	  on	  the	  expression	  level	  of	  SNARE-­‐complex	  proteins	  and	  
their	   distribution	   along	   neuronal	   processes	   was	   analysed	   in	   primary	   cortical	  
neuron	  cultures.	  
	  
To	   date,	   no	   one	   has	   studied	   post-­‐natal	   Cln3-­‐/-­‐	   cortical	   neurons	   in	   culture,	   a	  
region,	   along	   with	   the	   thalamus	   and	   cerebellum,	   where	   neurons	   in	   the	   JNCL	  
brain	   are	   profoundly	   affected.	   This	   approach	   will	   therefore	   not	   only	   provide	  
novel	  insights	  into	  the	  consequences	  of	  CLN3	  deficiency	  in	  cortical	  neurons,	  but	  
will	  specifically	   focus	  on	  the	   intrinsic	  biological	  changes	  that	  occur	  within	  these	  
cells	  rather	  than	  those	  resulting	  from	  interactions	  with	  other	  cell-­‐types,	  like	  glial	  
cells.	  
	  
5.	  2	  Results	  	  
Generation	  of	  cortical	  neuron	  cell	  cultures	  	  
In	  order	  to	  compare	  the	  biology	  of	  Cln3-­‐/-­‐	  and	  wild	  type	  cortical	  neurons,	  cultures	  
were	   generated	   from	   P0	   wild	   type	   or	   Cln3-­‐/-­‐	   mice	   ((Tararuk	   et	   al.,	   2006;	  
Semenova	   et	   al.,	   2007),	   also	   see	   Chapter	   2,	   Section	   2.3)	   and	   maintained	   in	  
serum-­‐free	   neurobasal	  medium	   supplemented	  with	   B27,	   to	   promote	   neuronal	  
maturation,	  and	  Ara-­‐C	  to	  inhibit	  glial	  proliferation.	  The	  purity	  of	  these	  neuronal	  
cultures	   was	   assessed	   after	   7	   DIV	   by	   immunocytochemistry,	   using	   MAP2	   and	  
NeuN	   to	   identify	   neurons,	   O4	   to	   identify	   oligodendrocytes,	   GFAP	   to	   identify	  
astrocytes	   and	   CD68	   to	   identify	  microglia	   (Figure	   5.1	   A,	   B	   and	   C).	  Most	   of	   the	  
cells	   in	   these	   WT	   and	   Cln3-­‐/-­‐	   neuronal	   cultures	   were	   MAP2/NeuN	   expressing	  
neurons	   (90.5±0.4%	   and	   91.7±0.9%	   respectively,	   Figure	   5.1	   A	   and	   D);	   with	  
3.9±0.2%	  (WT)	  and	  4.6±0.9%	  (Cln3-­‐/-­‐)	  being	  GFAP+	  astrocytes;	  0.1±0%	  (WT)	  and	  
0.1±0.1%	   (Cln3-­‐/-­‐)	   being	   CD68+	   microglia;	   and	   1.7±0.1%	   (WT)	   and	   0.9±0.0%	  	  	  
(Cln3-­‐/-­‐)	   being	   O4+	   oligodendrocytes	   (Figure	   5.1	   D).	   All	   the	   WT	   and	   Cln3-­‐/-­‐	  
neuronal	  cultures	  used	  in	  this	  study	  were	  generated	  as	  described	  above,	  and	  had	  
a	  similar	  composition.	  
	   	  


































	  	  	  
	  
	  
Figure	   5.1.	   Composition	   of	   P0	   cortical	   neuron	   cultures.	   Primary	   cortical	   neuron	  
cultures	   generated	   from	   P0	  Cln3-­‐/-­‐	   or	  WT	  mice	  were	   stained	  with	  MAP2	   and	  NeuN	   to	   identify	  
neuronal	   cells,	   GFAP	   to	   identify	   astrocytes,	   CD68	   to	   identify	   microglia	   and	   O4	   to	   identify	  
oligodendrocytes.	   DAPI	   was	   used	   to	   visualize	   all	   nuclei.	   Most	   of	   the	   cells	   were	   (A)	   MAP2	  
expressing,	   or	   (B)	   NeuN	   expressing	   neurons.	   (C)	   Glial	   contamination	   was	  mostly	   due	   to	   GFAP	  
expressing	  astrocytes	  with	  CD68	  expressing	  microglia	  and	  O4	  expressing	  oligodendrocytes	  rarely	  
being	  observed.	  The	  percentage	  of	  each	  cell	   type	  was	  determined	  by	  counting	  5	   random	  fields	  
per	  coverslip	  and	  a	  minimum	  of	  two	  coverslips	  per	  experiment.	  The	  means	  ±	  SEM	  shown	  in	  (D)	  
are	  from	  three	  separate	  experiments.	  Scale	  bar	  in	  (A)	  and	  (B)	  is	  20μm,	  and	  in	  (C)	  50μm.	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No	  accumulation	  of	  autofluorescent	  storage	  material	  occurs	  within	  Cln3-­‐/-­‐	  
cortical	  neuronal	  cultures	  	  
In	   JNCL,	  autofluorescent	   ceroid	   lipofuscin	  deposits	  enriched	   in	   subunit	   c	  of	   the	  
mitochondrial	  ATP	  synthase	  complex	  accumulate	  within	  most	  nerve	  cells	  and,	  to	  
a	  lesser	  extent,	   in	  numerous	  other	  cell	  types	  (Palmer	  et	  al.,	  1992;	  Seehafer	  and	  
Pearce,	  2006;	  Mole	  et	  al.,	  2011).	  We	  therefore	  explored	  whether	  there	  was	  any	  
accumulation	   of	   such	   autofluorescent	   storage	   material	   within	   Cln3-­‐/-­‐	   neuronal	  
cultures	   by	   viewing	   them	   at	   three	   different	   wavelengths,	   488nm,	   546nm	   and	  
633nm.	   Neither	   Cln3-­‐/-­‐	   nor	   WT	   neuronal	   cultures	   displayed	   any	   evidence	   for	  
punctate	  autofluorescence	  (Figure	  5.2),	  as	  was	   found	   in	  primary	  WT	  and	  Cln3-­‐/-­‐	  
astrocyte	   cell	   cultures	   (Chapter	   3,	   Figure	   3.10).	   However,	   despite	   this	   lack	   of	  
storage	   material	   accumulation,	   Cln3-­‐/-­‐	   neurons	   did	   have	   genotype-­‐specific	  












Figure	  5.2.	  No	  accumulation	  of	  autofluorescent	  storage	  material	  within	  Cln3-­‐/-­‐	  
neuron	  cultures.	  Cells	  were	  plated	  onto	  coverslips	  and	  fixed	  after	  7	  days	  in	  culture.	  DAPI	  was	  
used	   to	   visualize	   all	   cell	   nuclei.	   Cells	  were	   exposed	   to	   three	  wavelengths:	   488nm,	   546nm	   and	  
633nm,	   to	   visualize	   any	   autofluorescent	   material	   within	   cells.	   Neither	  WT	   nor	   Cln3-­‐/-­‐	   neurons	  
showed	  any	  apparent	  accumulation	  of	  autofluorescent	  storage	  material	  within	  their	  cell	  bodies.	  
Scale	  bar	  is	  50μm.	  	  
	  
Cln3-­‐/-­‐	  cortical	  neurons	  are	  small	  and	  less	  complex	  	  	  
The	   ability	   of	   a	   neuron	   to	   correctly	   grow	   an	   axon	   and	   a	   complicated	   dendritic	  
arbor,	   is	   vital	   for	   their	   connectivity	   and	   information	   processing	   (da	   Silva	   and	  
Dotti,	   2002;	   Goldberg,	   2003).	   This	   process	   of	   neurite	   outgrowth	   has	   not	   been	  
previously	  studied	   in	  vitro	   for	  any	  neurons	   lacking	   the	  CLN3	  protein,	  but	  based	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on	   in	  vivo	  evidence,	  dendritic	  arborization	  is	  altered	  in	  the	  cerebellum	  of	  Cln3-­‐/-­‐	  
mice	  (Weimer	  et	  al.,	  2009).	  	  
	  	  	  
Neuronal	   cultures	   established	   as	   described	   above	   were	   used	   to	   compare	   the	  
neurite	   complexity	   of	   WT	   and	   Cln3-­‐/-­‐	  cultures.	   After	   7DIV,	   cultures	   were	   fixed	  
with	  4%	  PFA	  and	   stained	  with	  MAP2,	  a	  neuron-­‐specific	  microtubule	  associated	  
protein,	   to	   visualize	   neurite	   morphology.	   When	   analyzing	   neurite	   complexity	  
(See	   Figure	   5.3	   C),	   we	   determined:	   the	   number	   of	   primary	   neurites	   (1),	  
secondary	   neurites	   (2),	   tertiary	   neurites	   (3),	   the	   total	   length	   of	   the	   primary	  
neurites,	   and	   the	   length	  of	   the	   longest	  primary	  neurite.	  Additionally,	   the	   soma	  
size	  of	  these	  neuronal	  cells	  was	  also	  measured	  (Chapter	  2,	  Section	  2.6).	  
	  
A	  typical	  MAP2	  expressing	  WT	  and	  Cln3-­‐/-­‐	  cortical	  neuron	  is	  shown	  in	  Figure	  5.3,	  
where	   it	   can	   be	   seen	   that	   the	   distribution	   of	  MAP2	   immunoreactivity	   appears	  
different	   in	   these	   two	   genotypes	   (Figure	   5.3	  A).	   In	  WT	  neurons	  MAP2	   staining	  
was	   relatively	   evenly	   distributed	   within	   both	   the	   cell	   soma	   and	   processes,	  
whereas	  in	  Cln3-­‐/-­‐	  neurons	  MAP2	  immunoreactivity	  appeared	  to	  be	  more	  intense	  
within	   the	   cell	   soma.	   In	   addition,	   the	   soma	   size	   of	   Cln3-­‐/-­‐	   neurons	   was	  
significantly	  smaller	  that	  that	  of	  WT	  cells	  (146.2±3.7	  μm2	  compared	  to	  187.2±9.9	  
μm2,	   respectively,	   see	   Figure	   5.3	   B),	   and	   their	   neurite	   complexity	   was	   altered	  
(Figure	  5.3	  C,	  b-­‐f).	  As	  shown	   in	  Figures	  5.3	  C,	  b,	  c	  and	  d,	   the	  neurites	  of	  Cln3-­‐/-­‐	  
neurons	   had	   slightly	   more	   branching	   points,	   seen	   as	   increased	   number	   of	  
neurites	  (1	  =	  4.7±0.1,	  2	  =	  1.4±0.2,	  3	  =	  0.4±0.0),	  when	  compared	  to	  WT	  neurons	  (1	  
=	   4.2±0.2,	   2	   =	   1.2±0.1,	   3	   =	   0.3±0.1),	   although	   these	   differences	   were	   not	  
statistically	  significant.	  The	  length	  of	  the	  longest	  primary	  neurite,	  however,	  was	  
significantly	   shorter	   in	   Cln3-­‐/-­‐	   neurons	   (104±6.1μm)	   than	   in	   WT	   neurons	  
(149.3±12.7μm)	  (Figure	  5.3	  C,	  e),	  and	  WT	  neurons	  displayed	  a	  significantly	  longer	  
network	   of	   primary	   neurites	   than	   did	   Cln3-­‐/-­‐	   neurons	   (279.8±27.9μm	   vs.	  
387.7±36.0μm,	   respectively,	   Figure	   5.3	   C,	   f).	   In	   conclusion,	   the	   Cln3-­‐/-­‐	   cortical	  
neurons	  showed	  specific	  alterations	  in	  their	  morphological	  appearance;	  their	  cell	  
soma	  size	  was	  smaller	  and	  the	  length	  of	  their	  primary	  neurites	  was	  significantly	  
	   237	  
decreased	  compered	  to	  WT	  cells,	  although	  the	  branching	  of	  these	  processes	  was	  



















	  	  	  	  	  	  	  	  	  	  
(Figure	  legend	  is	  on	  the	  following	  page)	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Figure	  5.3.	  Cln3-­‐/-­‐	  cortical	  neurons	  are	  small	  and	  have	  shortened	  processes.	  The	  
morphology	  of	  primary	  cortical	  WT	  and	  Cln3-­‐/-­‐	  neurons	  was	  compared	  quantitatively	  using	  ImageJ	  
after	   cultures	  were	   fixed	   and	   stained	  with	  MAP2.	   (A)	  MAP2	   expressing	  WT	   and	  Cln3-­‐/-­‐	   cortical	  
neurons	   showing	   that,	   unlike	   in	   WT	   cells,	   MAP2	   immunoreactivity	   is	   not	   evenly	   distributed	  
between	   the	   cell	   soma	   and	   processes	   in	   Cln3-­‐/-­‐	   neurons.	   (B)	   Quantification	   of	   cell	   soma	   size	  
revealed	   that	   WT	   neurons	   have	   a	   significantly	   bigger	   cell	   soma	   than	   Cln3-­‐/-­‐	   neurons.	   (C)	  
Quantitative	   assessment	   of	   neurite	   complexity,	   (a)	   schematic	   illustration	   of	   neurite	   branching,	  
showing	   primary	   neurites	   (1)	   originating	   directly	   from	   the	   cell	   body,	   secondary	   neurites	   (2)	  
originating	  from	  primary	  neurites,	  and	  tertiary	  neurites	  (3)	  originating	  from	  secondary	  neurites.	  
The	  length	  of	  each	  of	  the	  primary	  neurites	  was	  analyzed,	  and	  the	  sum	  of	  the	  length	  of	  all	  of	  these	  
neurites	  calculated.	  (b),	  (c)	  and	  (d)	  the	  number	  of	  each	  type	  of	  neurite	  did	  not	  differ	  between	  WT	  
and	   Cln3-­‐/-­‐	   neurons.	   (e)	   WT	   neurons	   had	   a	   longer	   primary	   neurite,	   and	   (f)	   an	   increased	   total	  
length	   of	   the	   primary	   neurites	   compared	   to	   Cln3-­‐/-­‐	   neurons.	   Data	   in	   (B)	   and	   (C)	   represent	  
mean±SEM	  from	  approximately	  40	  individual	  cells	  analyzed	  in	  each	  experiment.	  This	  experiment	  
was	  repeated	  three	  times.	  The	  scale	  bar	  in	  (A)	  is	  20μm.	  	  
	  
The	  AIS	  is	  located	  further	  from	  the	  cell	  soma	  in	  Cln3-­‐/-­‐	  neurons	  
Neurons	  contain	  multiple	  distinct	  membrane	  domains,	  one	  of	  which	  is	  the	  axon	  
initial	  segment	  (AIS).	  This	  region,	  normally	  located	  at	  the	  start	  of	  axon,	  is	  highly	  
enriched	   in	   ion	   channels,	   particularly	   Nav,	   whose	   function	   is	   to	   integrate	   the	  
input	   from	   synapses	   to	   produce	   an	   action	   potential	   (Palmer	   and	   Stuart,	   2006;	  
Atherton	  et	  al.,	  2008;	  Kole	  et	  al.,	  2008;	  Grubb	  and	  Burrone,	  2010b;	  Popovic	  et	  al.,	  
2011).	  Once	   the	  action	  potential	   is	   initiated	   in	   the	  AIS,	   it	  may	  propagate	  along	  
the	  axon	  toward	  the	  axonal	  terminal	  where	  the	  neuronal	  output	  is	  mediated	  by	  
the	   release	  of	  neurotransmitters.	   Importantly,	   changes	   in	  electrical	  activity	   can	  
result	   in	  the	  movement	  of	  the	  AIS	  along	  the	  axon	  (Grubb	  and	  Burrone,	  2010b).	  
For	   example,	   chronic	   depolarization	   of	   hippocampal	   neurons	   in	   vitro	   caused	   a	  
shift	  in	  the	  position	  of	  multiple	  components	  of	  the	  AIS,	  including	  the	  scaffolding	  
protein	  ankyrin	  G	  (AnkG),	  BIV-­‐spectrin,	  Nav,	  Neurofascin	  and	  FGF14	  (Figure	  5.4	  a)	  
(Zhou	  et	  al.,	   1998;	  Ogawa	  and	  Rasband,	  2008;	  Hu	  et	  al.,	   2009),	   away	   from	   the	  
soma	  of	  excitatory	  neurons	  leading	  to	  alterations	  in	  current	  thresholds	  for	  action	  
potential	   spiking	   (see	   Figure	   5.4	   b	   and	   (Grubb	   and	   Burrone,	   2010b)).	   This	  
endogenous	  mechanism	  enabling	  neurons	  to	  fine-­‐tune	  their	  activation/firing	  can	  
become	  vital	  during	  development	  and	  under	  pathological	  conditions	  (Grubb	  and	  
Burrone,	  2010b;	  Buffington	  and	  Rasband,	  2011).	  
	   	  









Figure	   5.4.	  AIS	   components	   and	  movement.	   (a)	  The	  basic	  components	  of	  the	  AIS	  are	  
Ankyrin	   G,	   which	   is	   the	   major	   scaffolding	   protein	   in	   the	   AIS,	   Nav-­‐channels,	   Neurofascin,	   B-­‐IV	  
Spectrin	  and	  fibroblast	  growth	  factor-­‐14	  (FGF14).	  (b)	  Under	  resting	  conditions	  the	  AIS	  is	  located	  
close	  to	  cell	   soma.	  High	  electrical	  activity	   induces	  chronic	  depolarization	  of	   the	  cell,	  which	  may	  
cause	  a	  shift	  in	  the	  position	  of	  the	  AIS	  distally	  along	  the	  axon	  and	  away	  from	  the	  cell	  soma.	  This	  
movement	   alters	   the	   current	   threshold	   for	   action	   potential	   spiking,	   making	   it	   harder	   for	   the	  
initiation	  of	  an	  action	  potential	  to	  occur.	  	  	  	  
	  
One	  of	   the	  most	  prominent	  clinical	  manifestations	  of	   JNCL	   is	  epileptic	  seizures,	  
which	  may	  be	  caused	  by	  overstimulation	  of	  neurons	  (see	  Chapter	  1,	  Section	  1.2).	  
Given	   that	   the	   AIS	   is	   essential	   for	   the	   integration	   of	   dendritic	   inputs	   to	   the	  
neuron	   into	   an	   action	   potential	   output,	   as	   well	   as	   for	   fine-­‐tuning	   neuronal	  
excitability,	   the	   location	   of	   the	   AIS	   was	   compared	   in	   Cln3-­‐/-­‐	   and	   WT	   cortical	  
neuronal	   cultures	  under	  basal	   conditions	  and	  upon	  chronic	  depolarization	  with	  
K+	  (15mM)	  for	  a	  period	  of	  two	  days.	  	  
	  
Cortical	  neuron	  cultures	  were	  grown	  on	  PDL	  coated	  coverslips	   for	  either	  5	  or	  7	  
days,	   then	   fixed	   and	   stained	   with	   Ankyrin	   G	   to	   visualize	   the	   AIS	   (Chapter	   2,	  
Section	  2.6).	  Images	  of	  neurons	  with	  an	  obvious	  AIS	  originating	  from	  their	  soma	  
were	   acquired	   using	   a	   Zeiss	   LSM	   710	   confocal	   microscope.	   A	   Matlab	   based	  
programme	   with	   custom-­‐written	   functions	   was	   then	   used	   to	   quantify	   the	  
location	   of	   the	   AIS	   in	   these	   cells	   (Chapter	   2,	   Section	   2.6,	   and	   see	   Grubb	   and	  
Burrone,	  2010b).	  The	  parameters	  used	  to	  define	  the	  AIS	  position	  along	  the	  axon	  
in	   this	   study	  were	   the	  START	  position	   (relative	   to	   the	  cell	   soma),	  MAX	  position	  
(maximum	   intensity	   of	   AnkG	   expression	   along	   the	   AIS),	   and	   END	   position	  
(relative	  to	  the	  cell	  soma).	  Some	  WT	  and	  Cln3-­‐/-­‐	  cultures	  were	  exposed	  to	  chronic	  
depolarization	  by	  treating	  them	  with	  15mM	  extracellular	  potassium	  from	  either	  
5	  to	  7DIV	  to	  study	  the	  AIS	  localization	  in	  younger	  neurons,	  or	  7	  to	  9DIV	  to	  study	  
the	  AIS	   localization	   in	  older	  neurons.	  Corresponding	  control	  cells	  were	  exposed	  
	   240	  
to	   15mM	   extracellular	   sodium	   to	   ensure	   isotonic	   experimental	   conditions	  
between	  depolarized	  and	  control	  conditions.	  
	  
In	  young	  WT	  neurons	  (5	  to	  7DIV)	  the	  AIS	  was	  located	  very	  close	  to	  the	  cell	  soma	  
under	  control	  conditions	  (Figure	  5.5	  A,	  a).	  However,	  under	  chronic	  depolarization	  
conditions,	  the	  AIS	  relocated	  distally	  away	  from	  the	  cell	  soma,	  with	  START,	  MAX	  
and	  END	  measurements	  all	  being	  significantly	  changed	  (START:	  9.0±0.8μm,	  MAX:	  
18.2±0.9μm,	   END:	   30.3±1.0μm,	   Figure	   5.5	   A,	   b	   and	   B)	   compared	   to	   control	  
unstimulated	   conditions	   (START:	   5.5±0.7μm,	   MAX:	   12.8±0.8μm,	   END:	  
22.1±0.9μm,	  Figure	  5.5	  A,	  a	  and	  B).	  In	  young	  Cln3-­‐/-­‐	  neurons	  the	  AIS	  was	  already	  
located	   slightly	   further	   away	   from	   cell	   soma	   under	   unstimulated	   conditions	  
(Figure	   5.5	   A,	   c).	   Global	   deloparization	   with	   high	   potassium	   again	   caused	   a	  
significant	   shift	   in	   the	   location	   of	   START	   and	  MAX	   positions,	  whereas	   the	  END	  
position	  remained	  unchanged	  (Compare	  c	  to	  d	  in	  figure	  5.5	  A)	  (AIS	  under	  High	  K+;	  
START:	  9.5±1.1μm,	  MAX:	  18.5±1.3μm,	  END:	  29.5±1.4μm,	  and	  AIS	  in	  unstimulated	  
conditions;	  START:	  6.7±0.5μm,	  MAX:	  15.6±0.7μm,	  END:	  28.2±0.8μm)	  (Figure	  5.5	  
B).	  By	  comparing	  the	  START,	  MAX	  and	  END	  positions	  of	  the	  AIS	  in	  young	  WT	  and	  
Cln3-­‐/-­‐	   neurons	   under	   both	   unstimulated	   and	   high	   potassium	   conditions,	   a	  
significant	  distal	  shift	  in	  the	  MAX	  and	  END	  positions	  of	  the	  AIS	  in	  Cln3-­‐/-­‐	  compared	  
to	   WT	   neurons	   was	   detected	   under	   unstimulated	   conditions,	   whereas	   such	  
significant	   differences	   could	   not	   be	   detected	   upon	   chronic	   depolarization	  with	  
high	  potassium	  (Figure	  5.5	  D).	  
	   	  






































Figure	   5.5.	   Cln3-­‐/-­‐	   neurons	   (5	   to	   7DIV)	   have	   a	   distally	   located	   AIS.	   Ankyrin	   G	  
staining	  was	  used	  to	  compare	  the	  position	  of	  the	  AIS	  in	  WT	  and	  Cln3-­‐/-­‐	  cortical	  neuronal	  cultures	  
under	  control	  conditions	  and	  when	  chronically	  depolarized	  with	  high	  potassium	  (15mM	  K+)	  over	  
period	  of	  two	  days	  (from	  5	  to	  7DIV).	  The	  cell	  soma	  is	  denoted	  with	  dashed	  line.	  (A)	  The	  START,	  
MAX	   and	   END	   positions	   of	   the	   AIS	   in	   WT	   and	   Cln3-­‐/-­‐	   cultures	   grown	   under	   control	   and	  
depolarization	   conditions.	   (B)	   The	   AIS	  moved	   away	   from	   the	   cell	   soma	   in	  WT	   cultures	   treated	  
with	   high	   K+.	   The	   already	   displaced	   AIS	   moved	   even	   further	   away	   from	   cell	   soma	   in	   Cln3-­‐/-­‐	  
cultures	  treated	  with	  high	  K+.	  (C)	  The	  AIS	  is	  located	  further	  away	  from	  cell	  soma	  in	  Cln3-­‐/-­‐	  neurons	  
than	   in	  WT	  neurons	  grown	  under	   control	   conditions.	  Data	   in	  B	  and	  C	  presented	  as	  mean±SEM	  
derived	  from	  40	  cells,	  three	  different	  coverslips	  in	  one	  experiment.	  A	  T-­‐test	  with	  Mann-­‐Whitney	  
U-­‐test	  was	  used	  in	  (B),	  and	  A	  T-­‐test	  was	  used	  in	  (C)	  for	  statistical	  analysis.	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In	  more	  mature	  WT	   cortical	   neurons	   (7	   to	   9DIV)	   the	   AIS	  was	   again	   located	   in	  
close	  proximity	  to	  the	  cell	  soma	  in	  unstimulated	  conditions	  (Figure	  5.6	  A,	  a	  and	  B,	  
START:	   6.4±0.6μm,	   MAX:	   15.2±0.8μm,	   END:	   27.1±1.2μm)	   and	   chronic	  
depolarization	  caused	  a	   significant	  distal	   shift	   in	   the	  position	  of	   the	  AIS	   (Figure	  
5.6	   A,	   b	   and	   B,	   START:	   12.3±0.7μm,	  MAX:	   20.4±0.8μm,	   END:	   32.6±1.0μm).	   As	  
observed	  in	  younger	  cultures,	  the	  AIS	  position	  had	  shifted	  distally	  away	  from	  the	  
cell	  soma	  in	  older	  Cln3-­‐/-­‐	  neurons	  under	  unstimulated	  conditions	  (Figures	  5.6	  A,	  c	  
and	  B,	  START:	  10.3±0.9μm,	  MAX:	  20.2±1.2μm,	  END:	  34.4±1.6μm),	  but	  only	  one	  
of	   the	  AIS	  position	  parameters,	   the	  START	   position,	  was	   significantly	   altered	   in	  
chronically	   depolarized	   older	   Cln3-­‐/-­‐	   neurons	   (Figures	   5.6	   A,	   d	   and	   B,	   START:	  
14.3±1.0μm,	  MAX:	   23.1±1.1μm,	   END:	   36.7±1.3μm)	   compared	   to	   unstimulated	  
controls	  (compare	  c	  to	  d	  in	  Figure	  5.6	  A).	  The	  observed	  distal	  shift	  displayed	  by	  
these	  Cln3-­‐/-­‐	  neurons	  in	  START,	  MAX	  and	  END	  AIS	  positions	  in	  control	  conditions,	  
as	   well	   as	   in	   END	   position	   upon	   chronic	   depolarization	   (Figure	   5.6	   C)	   was	  
significantly	  different	  to	  WT	  neurons	  of	  the	  same	  age.	  	  
	  
These	   analyses	   reveal	   that	   in	   Cln3-­‐/-­‐	   neurons	   the	   AIS	   is	   more	   distally	   located	  
along	   the	   axon	   than	   in	  WT	   neurons	   and	   that	   this	   distal	   shift	   becomes	   greater	  
with	   time	   in	   culture;	   reaching	   a	   distance	   from	   the	   cell	   body	   only	   seen	   in	  WT	  
neurons	   when	   they	   are	   chronically	   depolarized.	   This	   may	   suggest	   that	   Cln3-­‐/-­‐	  
neuronal	   cells	   are	   over-­‐stimulated,	   for	   which	   they	   attempt	   to	   compensate	   by	  
distally	  re-­‐locating	  their	  AIS	  away	  from	  cell	  body,	  thus	  potentially	  increasing	  their	  
threshold	  for	  initiation	  of	  action	  potential	  spiking.	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Figure	   5.6.	   Cln3-­‐/-­‐	   neurons	   (7	   to	   9DIV)	   have	   a	   distally	   located	   AIS.	   Ankyrin	   G	  
staining	  was	  used	  to	  compare	  the	  position	  of	  the	  AIS	  in	  WT	  and	  Cln3-­‐/-­‐	  cortical	  neuronal	  cultures	  
under	   control	   unstimulated	   conditions	   and	   when	   chronically	   depolarized	   with	   high	   potassium	  
(15mM	  K+)	  over	  a	  period	  of	  two	  days	  (from	  7	  to	  9DIV).	  The	  cell	  soma	  is	  denoted	  with	  a	  dashed	  
line.	   (A)	   The	   START,	  MAX	   and	   END	   positions	   of	   AIS	   in	   WT	   and	   Cln3-­‐/-­‐	   cultures	   grown	   under	  
unstimulated	  and	  depolarization	  conditions.	   (B)	  The	  AIS	  moved	  away	  from	  the	  cell	   soma	   in	  WT	  
cultures	  treated	  with	  high	  K+.	  Only	  the	  START	  position	  of	  the	  AIS	  moved	  further	  from	  cell	  soma	  in	  
Cln3-­‐/-­‐	  cultures	  treated	  with	  high	  K+.	  (C)	  The	  AIS	  is	  located	  further	  away	  from	  cell	  soma	  in	  Cln3-­‐/-­‐	  
neurons	   than	   in	  WT	  neurons	  grown	  under	  unstimulated	  conditions.	  The	  END	  position	  of	  AIS	   in	  
depolarized	  Cln3-­‐/-­‐	  was	  also	  further	  from	  the	  cell	  soma	  than	  in	  WT	  neurons.	  Data	  in	  B	  and	  C	  are	  
presented	  as	  the	  mean±SEM	  derived	  from	  40	  cells,	  three	  different	  coverslips	  in	  one	  experiment.	  
A	  T-­‐test	  with	  Mann-­‐Whitney	  U-­‐test	  was	  used	   in	   (B),	   and	  A	  T-­‐test	  was	  used	   in	   (C)	   for	   statistical	  
analysis.	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Distal	  movement	  of	  PanNav	  expression	  is	  also	  evident	  in	  Cln3-­‐/-­‐	  neurons	  
We	   next	   investigated	   whether	   the	   distal	   shift	   in	   AIS	   position	   seen	   in	   Cln3-­‐/-­‐	  
neuronal	  cells	  using	  AnKG	  as	  a	  marker,	  could	  also	  be	  seen	  by	  staining	  for	  other	  
components	  of	  AIS.	  To	  do	  this	  WT	  and	  Cln3-­‐/-­‐	  cortical	  neurons	  were	  grown	  under	  
unstimulated	  or	  depolarizing	  conditions	  (from	  7	  to	  9DIV)	  and	  were	  fixed	  and	  co-­‐
labeled	   with	   AnkG	   and	   PanNav,	   which	   labels	   all	   isoforms	   of	   the	   voltage-­‐gated	  
sodium	  channels	  concentrated	  in	  the	  AIS	  (Figure	  5.4,	  see	  Chapter	  2,	  Section	  2.6).	  
This	   analysis	   revealed	   that	   PanNav	   immunoreactivity	   was	   observed	   in	  
approximately	   the	  same	  axonal	   region	  as	   the	  AnkG	   labeling	   in	  cultures	  of	  both	  
genotypes	  under	  all	  experimental	  conditions	  tested	  (Figure	  5.7,	  co-­‐localization	  of	  
PanNav	  with	  AnkG	  marked	  with	  arrow	  heads	   in	  merged	   images).	   This	   indicated	  
that	  other	  components	  of	   the	  AIS	  had	  undergone	  a	  similar	  distal	   shift	   in	  Cln3-­‐/-­‐	  
neurons	   grown	   under	   basal	   conditions.	   Since	   the	   PanNav/AnkG	   co-­‐localization	  
was	  so	  evident,	  similar	  analyses	  to	  those	  described	   in	  Figures	  5.5	  and	  5.6	  were	  

















Figure	   5.7.	   Nav	   relocation	   with	   AnkG	   in	   Cln3-­‐/-­‐	   neurons.	   WT	   and	   Cln3-­‐/-­‐	   neuron	  
cultures	  grown	  under	  control	  or	  depolarization	  (15mM	  K+)	  conditions	  (7	  to	  9DIV)	  were	  co-­‐labeled	  
with	  AnkG	  and	  PanNav.	  In	  both	  genotypes	  the	  PanNav	  expressing	  voltage-­‐gated	  sodium	  channels	  
were	   localized	  to	  the	  same	  regions	  as	  AnkG	  under	  all	  experimental	  conditions	  tested.	  A	  distally	  
re-­‐located	  AIS	  was	  apparent	  with	  both	  AnkG	  and	  PanNav	  labeling	  in	  Cln3
-­‐/-­‐	  neurons	  under	  control	  
conditions,	   and	   high	   K+	   induced	   a	   distal	   shift	   in	  WT	  neurons.	   This	   immunostaining	  was	   carried	  
with	  cells	  from	  one	  neuronal	  culture.	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AIS	  re-­‐location	  occurs	  only	  in	  excitatory	  WT	  and	  Cln3-­‐/-­‐	  neurons	  
Previously	  it	  has	  been	  shown	  that,	  in	  primary	  hippocampal	  neuronal	  cell	  cultures,	  
AIS	  plasticity	  occurs	  mostly	  in	  excitatory	  neurons	  (Grubb	  and	  Burrone,	  2010b).	  In	  
order	   to	   investigate	   whether	   AIS	   plasticity	   differs	   between	   excitatory	   and	  
inhibitory	   neurons	  of	   the	   cortex,	  AIS	   positioning	  was	   studied	   in	  WT	  and	  Cln3-­‐/-­‐	  
GABAergic	   inhibitory	   neurons.	   To	   identify	   GABAergic	   inhibitory	   neurons	   a	  
cocktail	   of	   antibodies	   against	   parvalbumin,	   calbindin	   and	   calretinin	   was	   used	  
instead	  of	  primary	  antibodies	  against	  GABA	  due	  to	  the	  poor	  quality	  of	  the	  latter	  
(Figure	  5.8).	  Only	  very	  few	  GABAergic	  inhibitory	  neuronal	  cells	  could	  be	  found	  in	  
these	  cultures	  and	  the	  AIS	  position	  was	  not	  altered	  in	  these	  cells,	  but	  remained	  
in	   close	   proximity	   to	   the	   cell	   soma.	   This	   was	   true	   for	   both	   WT	   and	   Cln3-­‐/-­‐	  
GABAergic	   neurons	   grown	   under	   control	   conditions	   or	   after	   chronic	  
depolarization	  with	  high	  K+.	  This	  finding	  confirms	  that	  in	  primary	  cortical	  cultures	  
















Figure	  5.8.	  No	  AIS	  re-­‐location	   in	  cortical	  GABAergic	  neurons.	  GABAergic	  inhibitory	  
neurons	   within	   WT	   and	   Cln3-­‐/-­‐	   cortical	   cultures	   were	   identified	   using	   a	   cocktail	   of	   antibodies	  
(parvalbumin,	  calretinin	  and	  calbindin).	  Ankyrin	  G	  was	  used	  to	  localize	  the	  AIS	  in	  these	  cells	  under	  
control	  conditions	  and	  after	  chronic	  depolarization	  with	  15mM	  K+.	  The	  AIS	  was	  located	  close	  to	  
the	  cell	  soma	  in	  WT	  and	  Cln3-­‐/-­‐	  GABAergic	  neurons	  under	  all	  conditions	  tested.	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AIS	  movement	  is	  inhibited	  by	  blocking	  L-­‐type	  calcium	  channels	  
The	   precise	   positioning	   of	   the	   AIS	   can	   be	   regulated	   by	   many	   intrinsic	   and	  
extrinsic	   factors	   that	   are	   not	   yet	   fully	   understood	   (Goebel,	   1995;	   Grubb	   and	  
Burrone,	   2010a;	   2010b;	   Buffington	   and	   Rasband,	   2011;	   Grubb	   et	   al.,	   2011).	  
Generally,	   a	   high	   K+	   induced	   depolarization	   produces	   a	   chronic	   increase	   in	  
neuronal	   [Ca2+]I.	  Specific	  blockers	  such	  as	  Nifedipine,	  which	   is	  an	   inhibitor	  of	  L-­‐
type	   calcium	   channels,	   may	   completely	   abolish	   AIS	   relocation	   upon	   chronic	  
depolarization	  (Grubb	  and	  Burrone,	  2010b).	  We	  hypothesized	  that	  the	  observed	  
relocation	   of	   the	   AIS	   in	   cultured	   Cln3-­‐/-­‐	   neurons	   could	   be	   the	   result	   of	  
overstimulation	  caused	  by	  extrinsic	   factors,	  which	  may	  be	   inhibited	  by	  blocking	  
L-­‐type	  calcium	  channels.	  To	  determine	  whether	  this	  was	  the	  case,	  AIS	  re-­‐location	  
was	  investigated	  in	  WT	  and	  Cln3-­‐/-­‐	  cultures	  grown	  under	  control	  unstimulated	  or	  
in	  high	  potassium	  conditions	  in	  the	  presence	  or	  absence	  of	  Nifedipine	  (1μM)	  (Lee	  
et	  al.,	  2006;	  Grubb	  and	  Burrone,	  2010b).	  As	  with	  the	  investigation	  on	  AIS	  location	  
described	  in	  Figures	  5.5	  and	  5.6	  above,	  treatments	  were	  carried	  out	  at	  two	  time	  
points,	  from	  5-­‐7DIV	  and	  7-­‐9DIV.	  	  
	  
In	   young	  WT	   neurons	   (5	   to	   7DIV)	   the	   nifedipine	   treatment	   inhibited	   the	   high	  
potassium	  induced	  re-­‐location	  of	  the	  AIS	  (Figure	  5.9	  A,	  b	  and	  B),	  as	  determined	  
by	  a	  significant	  reduction	  in	  the	  START,	  MAX,	  but	  not	  in	  END,	  AIS	  position	  (START:	  
4.6±0.7μm,	  MAX:	   15.4±0.5μm,	   END:	   30.2±1.6μm)	   compared	   with	   non-­‐treated	  
cultures	  (START:	  9.0±0.8μm,	  MAX:	  18.2±0.9μm,	  END:	  30.3±1.0μm,	  Figure	  5.9	  B).	  
Nifedipine	   did	   not	   cause	   any	   significant	   alterations	   in	   the	   AIS	   position	   of	   WT	  
neurons	  grown	  under	  control	  unstimulated	  conditions	  (Figure	  5.9	  A,	  a	  and	  B).	  In	  
young	  Cln3-­‐/-­‐	  neurons	   nifedipine	   treatment	   inhibited	   the	   re-­‐location	   of	   the	   AIS	  
under	  control	  conditions,	  and	  after	  exposure	  to	  high	  potassium	  (Figure	  5.9	  A,	  c,	  d	  
and	  B).	  This	  was	  indicated	  by	  a	  significant	  reduction	  in	  the	  START,	  MAX	  and	  END	  
AIS	  positions	   in	  nifedipine	   treated	   control	   conditions	   (START:	   4.3±0.4μm,	  MAX:	  
13.0±0.6μm,	   END:	   25.3±0.7μm)	   compared	   to	   untreated,	   control	   conditions	  
(START:	   9.0±0.8μm,	   MAX:	   18.2±0.9μm,	   END:	   30.3±1.0μm),	   and	   in	   nifedipine	  
treated,	   chronically	   depolarized	   conditions	   (START:	   5.3±0.6μm,	   MAX:	  
12.6±0.8μm,	   END:	   26.6±1.0μm)	   compared	   to	   non-­‐treated,	   chronically	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depolarized	  conditions	  (START:	  9.5±1.1μm,	  MAX:	  18.5±1.3μm,	  END:	  29.5±1.4μm)	  
(Figure	   5.9	   B).	   Indeed,	   no	   significant	   differences	   were	   observed	   in	   the	   AIS	  
positions	   between	   corresponding	  WT	   and	   Cln3-­‐/-­‐	   neuronal	   cultures	   other	   than	  
the	  END	  position	  of	  the	  AIS	  in	  Nifedipine	  treated,	  chronically	  depolarized	  Cln3-­‐/-­‐	  
neuronal	   cells	   being	   significantly	   closer	   to	   the	   cell	   soma	   than	   in	   corresponding	  
WT	  neurons	   (Figure	  5.9	  C).	   Similar	  effects	  with	  Nifedipine	   treatment	  were	  also	  
seen	   in	   older	  WT	   and	   Cln3-­‐/-­‐	   cultures	   (See	   Figure	   5.10).	   Thus,	   by	   blocking	   the	  
activity	  of	  L-­‐type	  calcium	  channels,	  AIS	  movement	  away	  from	  the	  cell	  soma	  was	  
inhibited	   in	   both	   chronically	   depolarized	   WT	   neurons	   and	   in	   chronically	  
depolarized	  and	  non-­‐depolarized	  Cln3-­‐/-­‐	  neurons.	  This	  would	  suggest	  that	  Cln3-­‐/-­‐	  
neurons	  are	  over-­‐stimulated	  even	  when	  grown	  under	  basal	  conditions.	  
	   	  






































Figure	  5.9.	  Nifedipine	  blocks	  AIS	  movement	   in	  young	  WT	  and	  Cln3-­‐/-­‐	  neurons.	  
The	   location	  of	   the	  AIS	  was	   studied	   in	  nifedipine	   (1μM)	   treated	  WT	  and	  Cln3-­‐/-­‐	   cultures	   grown	  
under	  control	  conditions	  and	  with	  chronic	  depolarization	  (5	  to	  7DIV),	  using	  AnKG	  to	  identify	  the	  
AIS.	   (A)	   Representative	   cell	   images	   from	   all	   experimental	   conditions.	   (B)	   Nifedipine	   treatment	  
inhibited	   AIS	   movement	   in	   chronically	   depolarized	   WT	   neurons,	   and	   in	   Cln3-­‐/-­‐	   neurons	   under	  
control	  conditions	  and	  when	  chronically	  depolarized.	  (C)	  The	  END	  position	  of	  the	  AIS	  was	  closer	  
to	  the	  cell	  soma	  in	  nifidepine	  treated,	  chronically	  depolarized	  Cln3-­‐/-­‐	  neurons	  than	  in	  WT	  neurons.	  
Data	   in	   B	   and	   C	   represent	   the	   mean±SEM	   from	   40	   cells	   (three	   different	   coverslips	   from	   one	  
experiment).	  Statistical	  analysis	  on	  the	  effect	  of	  nifedipine	  treatment	  was	  carried	  out	  using	  a	  2-­‐
way	  ANOVA	  on	  ranked	  data	  (nifedipine	  x	  control/15mM	  K+)	  with	  Bonferroni	  correction	  in	  B,	  and	  a	  
T-­‐test	  was	  used	  in	  C.	  	  

























Figure	   5.10.	  Nifedipine	   blocks	  AIS	  movements	   in	   old	  WT	   and	  Cln3-­‐/-­‐	   neurons.	  
The	   location	  of	   the	  AIS	  was	   studied	   in	  nifedipine	   (1μM)	   treated	  WT	  and	  Cln3-­‐/-­‐	   cortical	   neuron	  
cultures	  grown	  under	  control	  conditions	  and	  with	  chronic	  depolarization	  (7	  to	  9DIV),	  using	  AnkG	  
to	  identify	  the	  AIS.	  (A)	  Representative	  cell	  images	  from	  all	  experimental	  conditions.	  (B)	  Nifedipine	  
treatment	  inhibited	  AIS	  movement	  in	  chronically	  depolarized	  WT	  neurons,	  and	  in	  Cln3-­‐/-­‐	  neurons	  
under	  control	  conditions	  and	  when	  chronically	  depolarized.	  (C)	  The	  END	  position	  of	  the	  AIS	  was	  
further	  away	  to	  the	  cell	  soma	  in	  nifidepine	  treated	  Cln3-­‐/-­‐	  neurons	  compared	  to	  WT	  under	  control	  
conditions.	   Data	   in	   B	   and	   C	   represent	   the	  mean±SEM	   from	   40	   cells	   (three	   different	   coverslips	  
from	  one	  experiment).	  Statistical	  analysis	  on	  the	  effect	  of	  nifedipine	  treatment	  was	  carried	  out	  
using	  2-­‐way	  ANOVA	  on	  ranked	  data	  (nifedipine	  x	  control/15mM	  K+)	  with	  Bonferroni	  correction	  in	  
B.	  T-­‐test	  was	  used	  in	  C.	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Cln3-­‐/-­‐	  cortical	  neurons	  distribute	  SNARE-­‐complex	  proteins	  and	  EEA1	  normally	  
but	  show	  an	  increased	  expression	  of	  SNAP25	  	  
Neurotransmission	   is	   based	   on	   the	   fusion	   of	   synaptic	   vesicles	  with	   the	   plasma	  
membrane	   to	   release	   the	   neurotransmitters	   they	   carry	   (Ramakrishnan	   et	   al.,	  
2012).	  An	  essential	  step	  in	  this	  process	  is	  the	  interaction	  of	  the	  synaptic	  vesicle	  
protein	  VAMP2,	   or	   its	   analogs,	  with	   syntaxin1	   and	   SNAP25-­‐like	   proteins	   in	   the	  
plasma	  membrane,	  to	  form	  a	  fusion	  complex	  referred	  to	  as	  the	  SNARE-­‐complex	  
(Rothman,	  1994;	  Jahn	  and	  Südhof,	  1999;	  Bruns	  and	  Jahn,	  2002;	  Kavalali,	  2002).	  
Prior	   to	   formation	   of	   the	   fusion	   complex,	   VAMP2	   binds	   to	   the	   vesicle	   protein	  
synaptophysin,	   which	   is	   thought	   to	   facilitate	   the	   subsequent	   SNARE-­‐complex	  
formation	  (Jahn	  and	  Südhof,	  1999).	  Early	  synaptic	  pathology	  has	  been	  observed	  
in	  mouse	  models	  of	  congenital	  NCL,	  INCL	  and	  vLINCL	  (Kim	  et	  al.,	  2008;	  Partanen	  
et	   al.,	   2008;	   Kielar	   et	   al.,	   2009;	   Schantz	   et	   al.,	   2009),	   suggesting	   that	  
neurotransmission	   may	   be	   perturbed	   in	   these	   diseases.	   Based	   on	   preliminary	  
data	   synaptic	  pathology	   is	   also	  evident	   in	  Cln3-­‐/-­‐	  mice	   (M.	  O’Hare,	  unpublished	  
data).	   Furthermore,	   endocytosis	   of	   neurotransmitter	   receptors,	   particularly	  
excitatory	   glutamate	   receptors,	   plays	   an	   important	   role	   in	   modulating	  
neurotransmission	  (Ehlers,	  2000;	  Kittler	  et	  al.,	  2000;	  Lin	  et	  al.,	  2000;	  Man	  et	  al.,	  
2000;	   Sheng	   and	   Kim,	   2002),	   and	   EEA1,	   an	   early	   endosomal	   protein,	   has	   been	  
shown	  to	  control	  vesicle	  fusion	  during	  endocytosis	  (Patki	  et	  al.,	  1997;	  Mills	  et	  al.,	  
1998;	   Simonsen	   et	   al.,	   1998;	   Rubino	   et	   al.,	   2000).	   CLN3	   has	   been	   linked	   with	  
EEA1	  expression	  and	  distribution	  of	  EEA1	  expressing	  early	  endosomes	  (Fossale	  et	  
al.,	   2004;	  Kyttälä	  et	  al.,	   2005;	  Uusi-­‐Rauva	  et	  al.,	   2012),	   although	  no	  changes	   in	  
these	   were	   observed	   in	   Cln3-­‐/-­‐	  astrocytes	   (Chapter	   3,	   Figure	   3.12).	   It	   has	   also	  
been	  shown	  that	  the	  AIS	  controls	  protein	  transport	  into	  the	  axon	  (Winckler	  et	  al.,	  
1999;	  Song	  et	  al.,	  2009;	  Al-­‐Bassam	  et	  al.,	  2012),	  thus,	  altered	  AIS	  positioning	   in	  
Cln3-­‐/-­‐	  neurons	  may	  also	  impact	  upon	  this	  process.	  Together,	  these	  observations	  
led	  us	  to	  investigate	  the	  expression	  and	  distribution	  of	  EEA1,	  the	  SNARE-­‐complex	  
proteins	  SNAP25,	  VAMP2,	  and	  synaptophysin	  in	  WT	  and	  Cln3-­‐/-­‐	  cortical	  neurons.	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Cln3-­‐/-­‐	  neurons	  show	  increased	  expression	  of	  SNAP25	  
The	  total	  expression	  of	  SNAP25,	  VAMP2,	  synaptophysin	  and	  EEA1	  was	  quantified	  
in	   9	   day	   old	  WT	   and	   Cln3-­‐/-­‐	   cortical	   neuron	   cultures	   by	  Western	   blot	   analysis	  
(Chapter	  2,	  Section	  2.7),	  and	  the	  levels	  of	  these	  proteins	  were	  normalized	  against	  
constitutively	   expressed	   β-­‐actin.	   The	   expression	   of	   SNAP25	   was	   significantly	  
increased	   in	  Cln3-­‐/-­‐	  cultures	   (65.6±2.5%	  of	   B-­‐actin	   expression)	   compared	   to	  WT	  
cultures	   (46.7±1.2%	   of	   B-­‐actin	   expression)	   (Figure	   5.11	   A),	   but	   no	   significant	  
expression	   differences	   between	   genotypes	   were	   observed	   for	   VAMP2,	  
Synaptophysin	  or	  EEA1	  (Figure	  5.11	  B,	  C,	  D	  respectively).	  Hence,	  only	  very	  subtle	  
differences	  exist	   in	  the	  expression	  of	  SNARE-­‐complex	  proteins	  between	  healthy	  






















Figure	   5.11.	   Cln3-­‐/-­‐	   neurons	   express	   more	   SNAP25	   protein.	   Cell	   lysates	   obtained	  
from	  cortical	  WT	  and	  Cln3-­‐/-­‐	  neuronal	  cultures	  were	  used	  to	  quantify	  the	  intracellular	  expression	  
levels	  of	  SNAP25,	  VAMP2,	  Synaptophysin	  and	  EEA1	  by	  Western	  blotting.	  β-­‐Actin	  expression	  was	  
used	   as	   an	   internal	   control	   of	   overall	   protein	   expression	   in	   each	   sample.	   (A)	   Cln3-­‐/-­‐	   neurons	  
express	   significantly	   more	   SNAP25	   protein	   than	   WT	   neurons.	   (B)	   Expression	   of	   VAMP2,	   (C)	  
synaptophysin,	   and	   (D)	   EEA1	   was	   not	   altered	   in	   Cln3-­‐/-­‐	   neurons.	   Date	   shown	   represents	   the	  
percentage±SEM	  from	  three	  experiments.	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Similar	  distribution	  of	  SNAP25,	  VAMP2,	  synaptophysin,	  and	  EEA1	  along	  
processes	  of	  WT	  and	  Cln3-­‐/-­‐	  neurons	  
To	   function	   properly,	   SNARE-­‐complex	   proteins,	   and	   EEA1	  must	   be	   transported	  
along	  neuronal	  processes	  to	  where	  they	  are	  needed	  at	  synaptic	  sites.	  In	  order	  to	  
investigate	  whether	   this	   trafficking	   is	  altered	   in	  Cln3-­‐/-­‐	  neurons,	   the	  distribution	  
of	  these	  proteins	  along	  the	  processes	  of	  WT	  and	  Cln3-­‐/-­‐	  neurons	  was	  compared.	  
For	   these	   experiments	   neurons	   were	   plated	   on	   PDL-­‐coated	   coverslips	   at	   a	  
density	  of	  250,000	  cells/coverslip	  and	  after	  7	  days	  in	  culture	  cells	  were	  fixed	  and	  
labeled	  with	  markers	  for	  SNAP25,	  VAMP2,	  synaptophysin	  and	  EEA1	  (Figure	  5.12	  
a,	   b;	   Figure	   5.13	   A-­‐C).	   Expression	   of	   these	   proteins	   was	   quantified	   along	   the	  
processes	   in	   two	  regions,	  0-­‐25μm	  and	  25-­‐50μm	  away	   from	  the	  cell	   soma	  using	  
ImageJ	   (Figure	   5.12	   c	   and	   d,	   for	   a	   high	  magnification	   image	   from	   the	   0-­‐25μm	  
region	  of	  WT	  and	  Cln3-­‐/-­‐	  neuronal	  processes).	   In	  each	  experiment,	  the	  numbers	  
of	   SNAP25,	   VAMP2,	   synaptophysin	   and	   EEA1	   immunoreactive	   puncta	   in	  Cln3-­‐/-­‐	  
neurons	   were	   compared	   to	   the	   corresponding	   numbers	   in	   WT	   neurons.	   All	  
images	   within	   each	   experiment	   were	   analyzed	   using	   identical	   acquisition	  
parameters,	   and	   immunopositive	   puncta	   were	   identified	   as	   regions	   of	  
fluorescence	   in	   the	   neuronal	   processes	   above	   the	   background-­‐subtracted	  
threshold	  (See	  examples	  in	  Figure	  5.12	  c	  and	  d,	  marked	  with	  yellow	  circles).	  The	  
quantification	  of	  these	  puncta	  was	  carried	  out	  manually.	  
	  
Even	   though	   the	   total	   SNAP25	   expression	   appeared	   higher	   in	   Cln3-­‐/-­‐	   neurons	  
than	   in	   WT	   neurons	   (Figure	   5.12,	   compare	   b	   to	   a),	   the	   number	   of	   SNAP25	  
immunopositive	  puncta	  along	  the	  two	  quantified	  regions,	  0-­‐25μm	  and	  25-­‐50μm	  
along	  neuronal	  processes,	  did	  not	  differ	  between	  the	  two	  genotypes,	  suggesting	  
that	   transportation	   of	   SNAP25	   along	   the	   processes	   of	   Cln3-­‐/-­‐	   neurons	   is	  
undisrupted	   (Figure	   5.12,	   e).	   However,	   the	   increased	   total	   SNAP25	   expression	  
level	   observed	   above	   (Figure	   5.11,	   A)	   may	   be	   explained	   by	   the	   marked	  
accumulation	  of	  SNAP25	  immunoreactivity	  in	  the	  soma	  of	  Cln3-­‐/-­‐	  neurons.	  	  	  
	   	  




































Figure	   5.12.	   Altered	   distribution	   of	   SNAP25	   in	   the	   soma,	   but	   not	   neurites	   of	  
Cln3-­‐/-­‐	  neurons.	   The	  distribution	  of	   SNAP25	   in	   the	   processes	   of	  WT	   and	  Cln3-­‐/-­‐	  neurons	  was	  
examined	   (0-­‐25μm	   and	   25-­‐50μm	   away	   from	   cell	   soma)	   by	   means	   of	   immunofluorescence	  
staining.	  Manual	  quantification	  was	  performed	  with	   ImageJ	   from	   images	  acquired	  using	  a	  Zeiss	  
AxioImager	  Z1	  fluorescence	  microscope.	  The	  number	  SNAP25	  immunopositive	  puncta	  (intensity	  
above	   background)	   in	  Cln3-­‐/-­‐	  neurons	  were	   normalized	   to	   the	   corresponding	  WT	   values.	  Cln3-­‐/-­‐	  
neurons	  (b)	  express	  more	  SNAP25	  in	  their	  soma	  than	  do	  WT	  neurons	  (a).	  Higher	  magnifications	  
shown	  in	  (c)	  and	  (d)	  represent	  the	  0-­‐25μm	  region	  along	  the	  processes	  away	  from	  the	  cell	  soma	  of	  
these	  cells,	  with	  examples	  of	  SNAP25	  immunopositive	  puncta	  marked	  with	  a	  yellow	  circle.	  (e)	  The	  
distribution	  of	  SNAP25	  along	  processes	  is	  not	  altered	  in	  Cln3-­‐/-­‐	  neurons.	  Scale	  bar	  in	  (a)	  is	  10μm.	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The	  somal	  expression	  of	  VAMP2	  appeared	  to	  be	  very	  similar	  between	  WT	  (5.13	  
A,	  a)	  and	  Cln3-­‐/-­‐	   (5.13	  A,	  b)	  neurons,	  and	   there	  was	  no	  significant	  difference	   in	  
the	  number	  of	  VAMP2	  immunopositive	  puncta	  along	  processes	  of	  WT	  and	  Cln3-­‐/-­‐	  
neurons	   (Figure	   5.13	   A,	   c).	   The	   expression	   of	   both	   synaptophysin	   and	   EEA1	  
seemed	   higher	   in	   the	   soma	   of	   Cln3-­‐/-­‐	   neurons	   (Figure	   5.13	   B,	   b	   and	   C,	   b	  
respectively)	  than	   in	  WT	  neurons	  (Figure	  5.13	  B,	  a,	  C,	  a	  respectively),	  but	  again	  
no	   difference	   was	   found	   in	   the	   distribution	   of	   these	   proteins	   along	   processes	  
(Figure	   5.13	   B,	   c	   and	   C,	   c).	   Thus,	   CLN3	   does	   not	   appear	   to	   be	   involved	   in	  
transport	   of	   SNARE-­‐complex	   proteins	   or	   early	   endosomes	   along	   processes	   in	  
primary	   cortical	   neuronal	   cells.	   Although	   there	   appeared	   to	   be	   pronounced	  
changes	  in	  the	  distribution	  of	  these	  proteins	  within	  the	  soma	  of	  Cln3-­‐/-­‐	  neurons,	  
these	  changes	  were	  not	  evident	  by	  Western	  blot	  analysis	  (Figure	  5.11).	  	  
	   	  





























Figure	  5.13.	  Distribution	  of	  VAMP2,	  Synaptophysin	  and	  EEA1	   is	  not	  altered	   in	  	  	  
Cln3-­‐/-­‐	   neurons.	   The	  distribution	  of	  VAMP2,	  synaptophysin	  and	  EEA1	  in	  the	  processes	  of	  WT	  
and	  Cln3-­‐/-­‐	  neurons	  was	   examined	   (0-­‐25μm	   and	   25-­‐50μm	   away	   from	   cell	   soma).	   There	  was	   no	  
difference	   in	   distribution	   of	   VAMP2	   (A)	   synaptophysin	   (B)	   or	   EEA1	   (C)	   immunopositive	   puncta	  
along	   processes	   of	   WT	   (a)	   and	   Cln3-­‐/-­‐	   	   (b)	   processes,	   but	   there	   appeared	   to	   be	   more	  
synaptophysin	  and	  EEA1	  in	  the	  cell	  soma	  of	  Cln3-­‐/-­‐	  neurons	  (compare	  a,	  b	  in	  B	  and	  a,	  b	  in	  C).	  Scale	  
bar	  in	  (A),	  (B)	  and	  (C)	  is	  10μm.	  	  	  
	  
5.3	  Discussion	  	  
These	  studies	  revealed	  that	  Cln3-­‐/-­‐	  neurons	  were	  morphologically	  compromised,	  
having	  smaller	  cell	  bodies	  and	  shorter	  primary	  neurites	  than	  WT	  neuronal	  cells.	  
The	  AIS	  was	  found	  to	  have	  moved	  away	  from	  the	  cell	  body	   in	  excitatory	  Cln3-­‐/-­‐	  
cortical	   neurons.	   This	   was	   possibly	   due	   to	   overstimulation	   caused	   by	   chronic	  
depolarization,	   since	   blocking	   of	   L-­‐type	   Ca2+	   channel	   activity	   resulted	   in	   AIS	  
localization	  being	  undistinguishable	  from	  that	  of	  WT	  neurons.	  Despite	  relocation	  
of	   the	   AIS,	   Cln3-­‐/-­‐	   neurons	   displayed	   a	   normal	   distribution	   of	   SNARE-­‐complex	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proteins,	  and	  EEA1	  along	  their	  processes,	  although	  total	  SNAP25	  expression	  was	  
up-­‐regulated,	   predominantly	   in	   the	   cell	   soma.	   These	   results	   suggest	   that,	   in	  
neurons,	  CLN3	  plays	  a	  role	   in	   the	  regulation	  of	  neuronal	  morphology,	  neuronal	  
excitability	   and	   the	   expression	   of	   specific	   synaptic	   proteins,	   but	   not	   in	   protein	  
transport	  along	  neurites.	  
	  
Why	  is	  the	  morphology	  of	  Cln3-­‐/-­‐	  neurons	  altered?	  	  
The	   maintenance	   of	   efficient	   neuronal	   circuits	   requires	   plasticity	   in	   the	  
connectivity	  of	  neurons	  (Bienenstock	  et	  al.,	  1982;	  Yuste	  and	  Denk,	  1995).	  Neurite	  
morphology,	   which	   we	   have	   shown	   to	   be	   altered	   in	   Cln3-­‐/-­‐	   neuronal	   cells	  
(Chapter	  5,	  Figure	  5.3),	  plays	  a	  pivotal	  role	  in	  this	  process	  (Tang,	  2001;	  Kiryushko	  
et	  al.,	  2004;	  Calabrese,	  2008;	  Meldolesi,	  2011).	  Neurite	  growth	  and	  complexity	  
has	   never	   been	   studied	   in	   any	   model	   of	   JNCL.	   However,	   disrupted	   neurite	  
outgrowth	   has	   been	   extensively	   reported	   in	   primary	   neuronal	   cultures	   from	  
many	  other	  models	  of	  LSDs,	  including	  the	  Ppt1-­‐/-­‐	  mouse	  model	  of	  INCL,	  the	  Cln8-­‐/-­‐	  
dog	   model	   of	   variant	   LINCL	   (Dunn	   et	   al.,	   1994;	   Virmani	   et	   al.,	   2005),	  
Mucopolysaccharidosis	   type	   IIIA	   (MPS-­‐IIIA,	   Sanfilippo	   syndrome)	   (Sutherland	  et	  
al.,	  2008)	  and	  Sandhoff’s	  disease	  (Sango	  et	  al.,	  2002;	  Pelled	  et	  al.,	  2003b;	  Sango	  
et	  al.,	  2005).	  All	  of	  these	  studies	  reported	  similar	  impairments	  in	  neurite	  growth	  
to	  those	  described	  here	  in	  Cln3-­‐/-­‐	  cortical	  neurons.	  In	  contrast,	  neurons	  isolated	  
from	   the	   GBa	   mouse	   model	   of	   Gaucher’s	   disease	   showed	   increased	   neurite	  
length	  (Bodennec	  et	  al.,	  2002),	  and	  overgrowth	  of	  neurites	  was	  also	  reported	  in	  
cortical	  neurons	  derived	   from	  the	  mouse	  model	  of	  mucopolysaccharidosis	   type	  
IIIB	  (MPSIIIB,	  Sanfilippo	  syndrome	  type	  B)	  (Hocquemiller	  et	  al.,	  2010).	  In	  the	  case	  
of	  MPSIIIB	   neurons,	   this	   neurite	   overgrowth	  was	   associated	  with	   an	   increased	  
expression	   of	   growth	   associated	   protein	   43	   (GAP43),	   and	   by	   correcting	   the	  
genetic	  defect	  in	  these	  cells	  both	  GAP43	  expression	  and	  neurite	  outgrowth	  were	  
normalized	   (Hocquemiller	   et	   al.,	   2010).	   GAP43	   is	   an	   intrinsic	   potentiator	   of	  
neurite	  outgrowth	   that	   interacts	  with	  PIP2	   in	   a	   calmodulin	   and	  PKC	  dependent	  
manner	   by	   determining	   F-­‐actin	   assembly	   and	   organization	   of	   microtubules	  
(Benowitz	  and	  Routtenberg,	  1997;	  Caroni,	  2001).	  Interestingly,	  the	  CLN3	  protein	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has	   been	   suggested	   to	   co-­‐localize	   with	   GAP43	   in	   neurons	   (Luiro	   et	   al.,	   2001;	  
Persaud-­‐Sawin	  et	  al.,	  2004),	  thus,	  impaired	  neurite	  outgrowth	  in	  Cln3-­‐/-­‐	  neurons	  
may	   be	   caused	   by	   altered	   GAP43	   expression.	   One	   would	   need	   to	   explore	   the	  
expression	  levels	  of	  GAP43	  in	  Cln3-­‐/-­‐	  cortical	  neurons	  to	  confirm	  this.	  	  
	  
Dynamic	  re-­‐arrangement	  of	  cytoskeletal	  components	  is	  essential	  for	  the	  process	  
of	  neurite	  outgrowth.	  The	  neural	  growth	  cone	  situated	  at	  the	  tip	  of	  the	  neurite	  is	  
enriched	   in	   actin	   filaments	   together	   with	   adapter	   proteins	   and	   filament	  
remodeling	   aiding	   proteins	   (Gordon-­‐Weeks,	   2004;	   Drees	   and	   Gertler,	   2008;	  
Mattila	   and	   Lappalainen,	   2008).	   The	   dynamic	   re-­‐modeling	   of	   the	   actin	  
cytoskeleton	   at	   growth	   cones	   may	   be	   regulated	   via	   factors	   such	   as	   mitogen-­‐
activated	   protein	   kinase	   (MAPKs),	   in	   particular,	   extracellular	   signal-­‐regulated	  
kinase	  (ERK),	  c-­‐Jun	  N-­‐terminal	  kinase	  (JNK),	  Phosphatidylinositol	  3-­‐kinase/Protein	  
Kinase	  B	  (PI3K/Akt),	  and	  small	  GTPases	  (Leppä	  et	  al.,	  1998;	  Higuchi	  et	  al.,	  2003;	  
Ayala	  et	  al.,	  2007;	  Heasman	  and	  Ridley,	  2008).	  Some	  evidence	  exists	  suggesting	  a	  
role	  for	  MAPKs	  in	  neurite	  growth	  in	  Cln3-­‐/-­‐	  neurons,	  since	  CLN3	  has	  been	  linked	  
with	  a	  protein	  called	  Mekk1	  (MAPKKK)	  (Tuxworth	  et	  al.,	  2011),	  which	  has	  been	  
associated	   with	   NGF-­‐induced	   neurite	   regrowth	   by	   balancing	   ERK1/2	   and	   JNK2	  
signaling	   (Waetzig	   and	  Herdegen,	   2005).	   Thus,	   it	  may	   be	   that	   abnormal	  MAPK	  
signaling	   contributes	   to	   attenuated	   growth	  of	  Cln3-­‐/-­‐	   neurons.	  Additionally,	   up-­‐
regulation	  of	  the	  dual	  specificity	  protein	  phosphatase	  2	  (DUSP2)	  gene	  has	  been	  
associated	  with	  mutation	  of	  the	  CLN3	  gene	  in	  JNCL	  patient	  samples,	  in	  cerebellar	  
Cln3Δex7/8	  precursor	  cells,	  and	   in	  acutely	  depleted	  CLN3	   in	  HELA-­‐cells	   (Lebrun	  et	  
al.,	   2011).	   DUSP2	   dephosphorylates	   both	   phosphotyrosine	   and	  
phosphoserine/threonine	   residues	   simultaneously	   within	   ERK,	   p38	   mitogen	  
activated	  protein	  kinases	  and	  JNK,	  thus,	  inhibiting	  these	  MAPK	  signaling	  cascades	  
associated	   with	   neurite	   outgrowth	   (Patterson	   et	   al.,	   2009).	   This	   becomes	  
relevant	   since	   up-­‐regulation	   of	   DUSP2	   in	   Cln3-­‐/-­‐	   neurons	   may	   inhibit	   MAPK	  
signaling	  and	  thereby	  decrease	  neurite	  outgrowth	  (Perron	  and	  Bixby,	  1999;	  Shin	  
et	  al.,	  2002;	  Liao	  et	  al.,	  2012;	  More	  et	  al.,	  2012).	  One	  could	  explore	  the	  activity	  of	  
MAPK	  signaling	  pathways	  in	  Cln3-­‐/-­‐neurons	  by	  using	  phospho-­‐specific	  antibodies	  
against	   the	   different	   components	   of	   MAPK	   signaling	   cascades.	   Then,	   for	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example,	  if	  ERK	  activation	  is	  found	  altered,	  the	  impact	  on	  Cln3-­‐/-­‐	  neurons	  of	  ERK	  
signaling	   promoters	   such	   as	   alpha-­‐lipoic	   acid,	   lithium	   and	   curcuminoids,	   that	  
have	  been	  shown	  to	  enhance	  neurite	  outgrowth	  (Wang	  et	  al.,	  2011a;	  2011b;	  Liao	  
et	  al.,	  2012),	  could	  be	  tested.	  	  	  
	  
Moreover,	   CLN3	   has	   been	   suggested	   to	   interact	   indirectly	   via	   Hook1	   with	   the	  
endosomal	   proteins	   Rab7,	   Rab9	   and	   Rab11,	   and	   also	   directly	  with	   active	   GTP-­‐
bound	  Rab7	  (Luiro	  et	  al.,	  2004;	  Uusi-­‐Rauva	  et	  al.,	  2012).	  Rab	  proteins	  have	  also	  
been	   shown	   to	   be	   involved	   in	   organelle	   trafficking,	   including	   the	   trafficking	   of	  
signaling	  receptors	   to	  neuronal	  processes	   (Tang,	  2001;	  Miaczynska	  et	  al.,	  2004;	  
Gerges	  et	  al.,	  2005;	  Hutagalung	  and	  Novick,	  2011).	  For	  example,	  Rab7	  has	  been	  
found	  to	  interact	  with	  TrkA,	  which	  is	  a	  receptor-­‐tyrosine	  kinase	  for	  NGF	  shown	  to	  
promote	   neuronal	   survival	   and	   neurite	   outgrowth	   (Snider,	   1994;	   Zhang	   et	   al.,	  
2000;	  Saxena	  et	  al.,	  2005a).	  Thus,	  perhaps	  the	  reduced	  neurite	  growth	  observed	  
in	   Cln3-­‐/-­‐	   cortical	   neurons	   could	   be	   explained	   by	   mechanisms	   involving	   Rab7	  
mediated	  trafficking	  of	  receptors	  for	  neurotrophic	  factors	  to	  the	  tips	  of	  growing	  
neurites.	   Indeed,	   evidence	   also	   exists	   that	   CLN3	   can	   interact	   with	   motor	  
components	   that	   drive	   microtubular	   trafficking,	   such	   as	   dynactin	   and	   dynein	  
(Uusi-­‐Rauva	   et	   al.,	   2012),	   and	   a	   lack	   of	   correct	   dynein-­‐CLN3	   interactions	   may	  
interrupt	   the	   dynein-­‐mediated	   vesicular	   transport	   of	   signaling	   receptors,	   like	  
TrkA,	  along	  microtubules	  (Yano	  et	  al.,	  2001;	  Bananis	  et	  al.,	  2004;	  Heerssen	  et	  al.,	  
2004).	   Further	   studies	   are	   required	   to	   confirm	   these	   hypotheses,	   for	   instance,	  
one	  could	  study	  both	  anterograde	  and	  retrograde	  trafficking	  of	  TrkA	  internalized	  
vesicles	   along	   the	   neurites	   of	   Cln3-­‐/-­‐	   cortical	   neurons	   by	   means	   of	   live-­‐cell	  
imaging	   (Ascaño	   et	   al.,	   2009).	   Additionally,	   investigation	   of	   the	   expression	   of	  
receptors,	  such	  as	  TrkA,	  at	  the	  tips	  of	  Cln3-­‐/-­‐	  neurites,	  would	  reveal	  whether	  such	  
receptors	  are	  present	  in	  similar	  numbers,	  or	  indeed	  at	  all	  in	  these	  cells.	  	  
	  	  
Microtubules	   are	   also	   involved	   in	   the	   primary	   transport	   of	   plasmalemmal	  
precursor	  vesicles	  (PPVs),	  required	  for	  the	  expansion	  of	  membrane	  at	  the	  tip	  of	  a	  
growing	   neurites	   (Letourneau	   et	   al.,	   1987;	   Ferreira	   et	   al.,	   1992;	   Peretti	   et	   al.,	  
2000;	   Pfenninger	   et	   al.,	   2003;	   Pfenninger,	   2009).	   MAPs	   are	   thought	   to	   be	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involved	   in	   microtubule-­‐based	   transportation	   of	   cargo	   along	   neurites	   (Matus,	  
1988;	  Zakharenko	  and	  Popov,	  1998;	  Liu	  et	  al.,	  1999;	  Buchstaller	  and	   Jay,	  2000;	  
Harada	  et	  al.,	  2002).	  Indeed,	  dendritic	  growth	  has	  been	  shown	  to	  be	  inhibited	  by	  
knocking	   down	  MAP2	   in	   vivo,	   and	   decreased	   expression	   of	   the	  MAP,	   tau,	   has	  
been	   associated	   with	   reduced	   axon	   outgrowth,	   as	   well	   as	   with	   the	   size	   and	  
motility	  of	  growth	  cones	  (Liu	  et	  al.,	  1999;	  Harada	  et	  al.,	  2002).	  When	  MAP2	  was	  
used	   to	   visualize	   the	  morphology	   of	  WT	   and	  Cln3-­‐/-­‐	   neurons,	   a	   difference	  was	  
revealed	   in	   the	   distribution	   MAP2	   in	   these	   cells	   (Chapter	   5,	   Figure	   5.3),	   with	  
MAP2	   appearing	   to	   accumulate	   in	   the	   cell	   body	   of	   Cln3-­‐/-­‐	   neurons	   and	   not	  
spreading	   evenly	   along	   the	   processes	   as	   in	   WT	   cells.	   Such	   differences	   in	  
localization	  of	  MAP2	  may	  cause	  problems	  with	  protein	  kinase	  A	  (PKA)	  targeting	  
to	   cellular	   compartments,	   since	   this	   protein	   uses	   MAP2	   for	   attachment	   to	  
microtubules.	  This	  in	  turn	  could	  lead	  to	  problems	  with	  PKA	  activation	  of	  CREB,	  a	  
transcription	   factor	   that	   is	   involved	   in	   regulating	  neurite	  growth	   (Schmid	  et	  al.,	  
1999;	   Cheng	   et	   al.,	   2002;	   Harada	   et	   al.,	   2002;	   Kao	   et	   al.,	   2002).	   Indeed,	   gene	  
expression	   analysis	   in	   primary	   cortical	   Cln3-­‐/-­‐	   neurons	   (E16.5)	   revealed	  
cytoskeleton	   related	   proteins	   as	   one	   of	   the	  most	   affected	   groups	   (Luiro	   et	   al.,	  
2006).	   The	  most	   down-­‐regulated	   gene	  was	   reported	   to	   be	   the	   dynactin	  motor	  
protein	   of	  microtubules.	   Additionally,	   Clasp2,	  which	   is	   a	  microtubular	   plus-­‐end	  
tracking	   protein	   (TIP),	   was	   found	   to	   be	   up-­‐regulated	   in	   Cln3-­‐/-­‐	   neurons.	   The	  
Clasp2	   protein	   is	   involved	   in	   stabilization	   of	   microtubules	   at	   neuronal	   growth	  
cones	  and	  has	  been	  shown	  to	  function	  as	  one	  of	  the	  key	  regulators	  of	  axon	  and	  
dendrite	   outgrowth,	   as	   well	   as	   synapse	   formation	   and	   activity	   (Galjart,	   2005;	  
Beffert	   et	   al.,	   2012).	   Thus,	   differential	   gene	   expression	   involving	   cytoskeletal	  
players	   like	   dynactin	   and	   Clasp2,	   together	   with	   Rab7	   and	  MAPK	   that	   mediate	  
intracellular	   signaling	   cascades,	   may	   all	   contribute	   towards	   the	   attenuated	  
neurite	  growth	  in	  Cln3-­‐/-­‐	  cortical	  neurons.	  	  
	  
A	   great	   number	   of	   extracellular	   signaling	   factors,	   like	   the	   neurotrophins	   (NGF,	  
BDNF,	   NT-­‐3	   and	   NT-­‐4/5,	   (Bibel	   and	   Barde,	   2000)),	   have	   been	   associated	   with	  
promoting	   neurite	   outgrowth.	   The	   impact	   of	   these	   factors	   may	   vary	   greatly	  
between	   different	   neuronal	   types	   and	   different	   neurotrophins	  may	   also	   act	   in	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concert	   (Deister	   and	   Schmidt,	   2006).	   For	   instance	   BDNF	   in	   combination	   with	  
either	  NGF	  or	  CNTF	  has	  a	  greater	  positive	  impact	  on	  axonal	  growth	  than	  it	  would	  
have	   alone	   (Lindsay	   et	   al.,	   1985;	   Goldberg	   et	   al.,	   2002).	   Trophic	   factors	   are	  
produced	  by	  both	  neuronal	  and	  glial	  cells	  (Schwartz	  and	  Nishiyama,	  1994;	  Rudge	  
et	  al.,	  1995;	  Ridet	  et	  al.,	  1997;	  Huang	  and	  Reichardt,	  2001;	  Albrecht	  et	  al.,	  2002;	  
Chang	  et	  al.,	  2003;	  Liberto	  et	  al.,	  2004).	  Thus,	  neurons	  may	  respond	  to	   trophic	  
factors	  produced	  and	  secreted	  by	  themselves,	  in	  a	  paracrine	  fashion,	  or	  to	  those	  
secreted	   by	   other	   neurons	   or	   glial	   cells	   (Markus	   et	   al.,	   2002;	   Kiryushko	   et	   al.,	  
2004;	   Deister	   and	   Schmidt,	   2006).	   The	   proteins	   secreted	   by	   WT	   and	   Cln3-­‐/-­‐	  
neurons	  were	  not	  compared	  in	  this	  study,	  so	  the	  possibility	  that	  Cln3-­‐/-­‐	  neurons	  
fail	  to	  secrete	  neurotrophic	  factors	  involved	  in	  neurite	  outgrowth	  remains	  to	  be	  
explored.	   Given	   that	   the	   protein	   secretion	   by	   Cln3-­‐/-­‐	   astrocytes	   was	   severely	  
altered	  (Chapter	  4,	  Tables	  4.1	  and	  4.2),	  and	  Cln3-­‐/-­‐	  microglia	  also	  showed	  specific	  
alterations	   in	   their	   protein	   secretion	   profile	   (S.	   Dihanich,	   unpublished	   data),	   it	  
would	  not	  be	  surprising	  to	  discover	  similar	  defects	   in	  Cln3-­‐/-­‐	  neurons.	  However,	  
one	  also	  needs	  to	  consider	  the	  fact	  that	  these	  neuronal	  cultures	  were	  not	  100%	  
pure,	   with	   4-­‐5%	   of	   cells	   being	   astrocytes.	   This	   small	   astrocyte	   contamination	  
could	   play	   a	   significant	   role	   in	   promoting	   neurite	   outgrowth,	   at	   least	   in	   WT	  
cultures	  (Wang	  et	  al.,	  1994;	  Powell	  et	  al.,	  1997b;	  Powell	  and	  Geller,	  1999;	  Costa	  
et	  al.,	  2002;	  Kanemaru	  et	  al.,	  2007).	   In	  contrast,	  the	  significant	  reduction	  in	  the	  
level	  of	  neurotrophic	  factors	  such	  as	  BDNF	  and	  NGF	  secreted	  by	  Cln3-­‐/-­‐	  astrocytes	  
could	   help	   explain	   the	   impaired	   neurite	   growth	   in	   these	   neuronal	   cultures.	  
Indeed,	   the	   presence	   of	   Cln3-­‐/-­‐	   glial	   cells	   was	   found	   to	   negatively	   impact	   the	  
neurite	  outgrowth	  of	  both	  WT	  and	  Cln3-­‐/-­‐	  neurons	  in	  co-­‐culture	  experiments	  (see	  
Chapter	  6,	  Figures	  6.4	  and	  6.5).	  	  
	  
Numerous	   other	   important	   molecules	   are	   also	   essential	   for	   correct	   neurite	  
growth.	   Surface-­‐expressed	   cell	   adhesion	  molecules	   (CAMs),	   such	   as	   neural	   cell	  
adhesion	   molecule	   (NCAM)	   and	   N-­‐cadherin,	   interact	   with	   the	   surrounding	  
environment	  via	  their	  extracellular	  domains,	  and	  use	  their	  intracellular	  domains	  
to	   bind	   with	   the	   cytoskeleton	   (Maness	   and	   Schachner,	   2007;	   Hansen	   et	   al.,	  
2008).	   Thus,	   CAMs	   are	   important	   intermediaries	   between	   extracellular	   and	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intracellular	   cues	   for	   promoting	   neurite	   growth	   (Maness	   and	   Schachner,	   2007;	  
Hansen	   et	   al.,	   2008).	   Various	   cell	   adhesion	   molecules,	   such	   as	   VLA-­‐6	  
(alpha6beta1)	   integrin,	  which	   is	   the	  major	  receptor	  for	   interaction	  with	   laminin	  
substrates	  (Hangan	  et	  al.,	  1997;	  Carloni	  et	  al.,	  2001),	  have	  been	  demonstrated	  to	  
be	   differentially	   expressed	   at	   the	   gene	   level	   in	   different	   models	   of	   JNCL	  
(Chattopadhyay	  et	  al.,	  2004;	  Lebrun	  et	  al.,	  2011),	  but	  no	  studies	  have	  ever	  been	  
conducted	   to	   determine	   whether	   this	   translates	   into	   defects	   in	   neuronal	   cell	  
biology.	  Thus,	  one	  cannot	  exclude	  the	  possibility	  that	  defects	  in	  the	  expression	  of	  
cell	   adhesion	  molecules	   could	   help	   explain	   the	   observed	   neurite	   phenotype	   in	  
Cln3-­‐/-­‐	  neurons.	  	  	  
	  
To	  overcome	  this	   lack	  of	  neurite	  growth,	  various	  neurite	  outgrowth	  stimulating	  
factors	   could	   be	   tested	   (Müller	   et	   al.,	   1995;	  More	   et	   al.,	   2012;	   Skaper,	   2012).	  
Indeed,	   by	   supporting	   the	   growth	   of	   various	   neuronal	   subtypes,	   BDNF-­‐TrkB	  
signaling	  has	  emerged	  as	  an	  important	  mediator	  of	  synaptic	  efficacy	  (via	  PLC	  and	  
IP3	   dependent	   intracellular	   Ca2+-­‐release),	   neuronal	   connectivity	   (via	   ERK	  
signaling)	   and	   survival	   (via	   PI-­‐3	   kinase/Akt)	   in	   other	   CNS	   affecting	   disorders	  
(Barde,	   1994;	   Lindvall	   et	   al.,	   1994;	   Patel	   and	  McNamara,	   1995;	   Larsson	   et	   al.,	  
1999;	   Lu	   and	   Chow,	   1999;	   McAllister	   et	   al.,	   1999;	   Schinder	   and	   Poo,	   2000;	  
Sergeeva	   et	   al.,	   2000;	   Liu	   et	   al.,	   2002;	   Mattson	   et	   al.,	   2004;	   Nagahara	   and	  
Tuszynski,	  2011;	  Weishaupt	  et	  al.,	  2012).	  For	  example,	  fibroblasts	  engineered	  ex	  
vivo	   to	   secrete	   BDNF	   have	   been	   shown	   to	   reduce	   cell	   loss	   and	   atrophy	   of	  
neurons	  in	  a	  spinal	  cord	  injury	  model	  (Liu	  et	  al.,	  2002),	  and	  BDNF-­‐TrkB-­‐signaling	  
has	   also	   been	   shown	   to	   protect	   certain	   neuronal	   populations	   against	   ischemic	  
damage	   in	  vivo	   (Larsson	  et	  al.,	  1999).	  Primary	  cortical	  neuronal	  cell	  cultures,	  or	  
perhaps	  neuron-­‐glial	  co-­‐culture	  systems,	  as	  described	  in	  Results	  Chapter	  6,	  could	  
be	   used	   to	   test	   the	   efficacy	   of	   such	   neurite	   outgrowth	   promoting	   factors	   on	  	  	  
Cln3-­‐/-­‐	  neurons.	  	  
	  
All	   in	   all,	   neurite	   outgrowth,	   encompassing	   both	   dendritic	   tree	   formation	   and	  
axonal	  growth,	   is	  one	  of	  the	  most	  fundamental	  properties	  of	  any	  neuron,	  since	  
these	   structures	   are	   required	   for	   synaptic	   transmission	   and	   neuronal	   circuit	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formation	  (Hobert,	  2009),	  and	  failure	  of	  neurons	  to	  connect	  and	  signal	  properly	  
can	   lead	   to	   degeneration	   and	   cell	   death	   (Horner	   and	   Gage,	   2000;	   Ciani	   and	  
Salinas,	  2005;	  Marmigère	  and	  Ernfors,	  2007).	  Thus,	   impaired	  neurite	  outgrowth	  
could	  result	  in	  problems	  with	  neuronal	  communication	  and	  this	  is	  turn	  could	  play	  
a	   pivotal	   role	   in	   some	   of	   the	   clinical	   manifestations	   involving	   higher	   brain	  
function	   observed	   in	   JNCL,	   such	   as	   mental	   retardation	   and	   other	   cognitive	  
deficits,	   as	   demonstrated	   in	   other	   neurological	   disorders	   (Ramakers,	   2002;	  
Billuart	  and	  Chelly,	  2003;	  Minshew	  and	  Williams,	  2007).	  	  	  
 
Why	  do	  Cln3-­‐/-­‐	  neurons	  have	  a	  displaced	  AIS?	  
Neuronal	  cells	  are	  capable	  of	  activity-­‐dependent	  plasticity,	  for	  instance,	  they	  are	  
able	   to	   control	   their	   own	   excitability	   by	   altering	   the	   position	   of	   an	   entire	  
subcellular	  compartment	  called	   the	  AIS,	  which	   is	  a	   specialized	  part	  of	   the	  axon	  
enriched	  with	  ion	  channels	  required	  for	  initiation	  of	  an	  action	  potential	  (Ogawa	  
and	  Rasband,	  2008;	  Grubb	  and	  Burrone,	  2010b).	  Under	  basal	  conditions	  the	  AIS	  
is	   located	   close	   to	   the	   cell	   soma	   of	   a	   neuron,	   and	   overstimulation,	   involving	  
chronic	   depolarization,	   causes	   a	   distal	   shift	   in	   the	   position	   of	   the	   AIS,	  
subsequently	   altering	   the	   excitability	   of	   that	   neuron	   (Grubb	   and	   Burrone,	  
2010b).	   In	  Cln3-­‐/-­‐	   neurons	   the	   AIS	  was	   surprisingly	   found	   to	   be	   distally	   shifted	  
under	  basal,	  unstimulated	  conditions,	  being	  at	  a	  similar	  position	  as	  the	  displaced	  
AIS	   in	   WT	   neuronal	   cells	   that	   have	   been	   chronically	   depolarized	   (Chapter	   5,	  
Figures	  5.5	  and	  5.6).	  In	  agreement	  with	  previous	  studies,	  such	  movement	  could	  
not	   be	   detected	   in	   either	   WT	   or	   Cln3-­‐/-­‐	   GABAergic	   interneurons	   (Chapter	   5,	  
Figure	   5.8),	   suggesting	   that	   AIS	   re-­‐localization	   in	   an	   exclusive	   property	   of	  
excitatory,	   cortical	   neurons	   (Grubb	   and	   Burrone,	   2010b).	   Thus,	   it	   appears	   that	  
neurons	   isolated	   from	  the	  Cln3-­‐/-­‐	  mouse	  cortex	  may	  have	  been	  overstimulated,	  
and	   remain	   so	   even	   when	   grown	   in	   non-­‐stimulating	   environment.	   We	   might	  
assume	  that	  the	  observed	  movement	  of	  the	  AIS	  in	  Cln3-­‐/-­‐	  neurons	   is	  an	  attempt	  
by	   these	   cells	   to	   become	   less	   excitable.	   Indeed,	   nifedipine	   treatment,	   which	  
blocks	   L-­‐type	   calcium	   channels	   (Lee	   et	   al.,	   2006;	   Grubb	   and	   Burrone,	   2010b),	  
resulted	   in	  AIS	  re-­‐location	  back	  to	  the	  start	  of	  the	  axon	   in	  Cln3-­‐/-­‐neurons	  under	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both	   basal	   conditions	   and	   when	   chronically	   depolarized	   with	   high	   potassium	  
(Chapter	  5,	  Figures	  5.9	  and	  5.10).	  This	  would	  strongly	  suggest	  that	  Cln3-­‐/-­‐	  neurons	  
are	   overstimulated	   due	   to	   the	   enhanced	   activity	   of	   L-­‐type	   calcium	   channels	  
resulting	  in	  increased	  calcium	  influx.	  
	  
Several	   explanations	   for	   such	  overstimulation	  of	  Cln3-­‐/-­‐	   neuronal	   cells	   could	  be	  
made	  based	  on	  the	  proposed	  functional	  roles	  of	  CLN3	  (Getty	  and	  Pearce,	  2011).	  
CLN3	  has	  been	  reported	  to	   interact	  with	   the	  cytoskeletal	  protein	  β-­‐spectrin	   (β-­‐
fodrin)	  (Uusi-­‐Rauva	  et	  al.,	  2008),	  one	  of	  the	  core-­‐stabilizing	  proteins	  of	  the	  AIS,	  
whose	  role	  is	  to	  anchor	  this	  whole	  subcellular	  structure	  to	  the	  actin	  cytoskeleton	  
(Komada	  and	  Soriano,	  2002;	  Lacas-­‐Gervais	  et	  al.,	  2004;	  Yang	  et	  al.,	  2007;	  Grubb	  
and	   Burrone,	   2010b).	   Another	   potential	   interacting	   protein	   partner	   of	   CLN3	   is	  
Hook1,	  which	   is	  a	  microtubule	  binding	  protein	   involved	   in	  endocytosis	   (Krämer	  
and	  Phistry,	  1996;	  1999;	  Walenta	  et	  al.,	  2001;	  Luiro	  et	  al.,	  2004),	  and	  Hook1	  may	  
interact	  with	  Ankyrin	  G,	  which	  is	  the	  main	  scaffolding	  protein	  of	  the	  AIS	  (Zhou	  et	  
al.,	  1998;	  Atherton	  et	  al.,	  2008;	  Grubb	  and	  Burrone,	  2010b;	  Grubb	  et	  al.,	  2011).	  
Thus,	  the	  lack	  of	  interplay	  between	  CLN3	  and	  β-­‐spectrin	  and/or	  CLN3	  and	  Hook1	  
could	  disrupt	  the	  correct	  assembly	  of	  AIS-­‐related	  components	  and/or	  connection	  
between	   the	   AIS	   and	   the	   actin	   cytoskeleton	   and	   could	   lead	   to	   the	   observed	  
altered	  position	  of	   the	  AIS	   in	  Cln3-­‐/-­‐	  neuronal	  cells.	  However,	   this	   is	  an	  unlikely	  
explanation	  for	  the	  observed	  AIS	  location	  in	  Cln3-­‐/-­‐	  neurons,	  since	  blocking	  of	  L-­‐
type	   calcium	   channels	  with	   nifedipine	   resulted	   in	   AIS	  movement	   back	   towards	  
the	   cell	   soma.	   Thus,	   lack	   of	   CLN3	   itself	   does	   not	   appear	   to	   prevent	   AIS	  
movement.	  	  
	  
CLN3	  has	  also	  been	  reported	  to	  connect	  with	  the	  Na+-­‐K+-­‐ATPase	  complex	  via	  β-­‐
spectrin	   (Uusi-­‐Rauva	   et	   al.,	   2008).	   The	   correct	   functioning	   of	   Na+-­‐K+-­‐ATPase	   is	  
pivotal	   for	   neurons,	   since	   pumping	   Na+	   out	   and	   K+	   into	   the	   cell	   is	   crucial	   for	  
maintaining	   and	   returning	   neurons	   back	   to	   their	   resting	   potential	   after	  
depolarization	   (Kaplan,	   2002).	   The	   ion	   pumping	   activity	   of	   Na+-­‐K+-­‐ATPase	   in	  
embryonic	  Cln3-­‐/-­‐	  cortical	  neurons	  (E16.5)	  was	  found	  to	  function	  normally	  (Uusi-­‐
Rauva	   et	   al.,	   2008),	   but	   the	   dynamic	   trafficking	   of	   the	   Na+-­‐K+-­‐ATPase	   to	   the	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plasma	   membrane	   was	   discovered	   to	   be	   significantly	   impaired	   in	   these	   cells	  
(Uusi-­‐Rauva	  et	  al.,	  2008).	  More	  specifically,	   it	  was	  shown	  that	   internalization	  of	  
the	  Na+-­‐K+-­‐ATPase	  was	  decreased	  in	  Cln3-­‐/-­‐	  neurons,	  and	  that	  CLN3	  may	  interact	  
with	   the	   ER-­‐resident	   chaperone	   protein	   CRP78/BiP	   that	   is	   vital	   for	   the	  
intracellular	  maturation	  of	  Na+-­‐K+-­‐ATPase	  (Bertorello	  et	  al.,	  2003;	  Uusi-­‐Rauva	  et	  
al.,	   2008).	   Thus,	   defective	   transport	   and	   targeting	   of	   Na+-­‐K+-­‐ATPase	   to	   the	  
plasma	  membrane	  of	  Cln3-­‐/-­‐	  neurons	   could	  alter	   their	   capacity	   to	  maintain	  and	  
return	  to	  their	  resting	  potential.	  Investigation	  of	  the	  dynamic	  expression	  of	  Na+-­‐
K+-­‐ATPase	  at	  the	  plasma	  membrane	  of	  Cln3-­‐/-­‐	  cortical	  neurons	  by	  means	  of	  FRAP-­‐
TIRF	  (fluorescence	  recovery	  after	  photobleaching	  (FRAP)-­‐total	  internal	  reflection	  
fluorescence	  (TIRF))	  microscopy	  would	  enable	  this	  hypothesis	  to	  be	  tested.	  	  
	  
Gene	   expression	   analysis	   performed	   in	   embryonic	   cortical	   Cln3-­‐/-­‐	   and	   WT	  
neuronal	  cells	  revealed	  that	  the	  most	  up-­‐regulated	  gene	  in	  Cln3-­‐/-­‐	  neuronal	  cells	  
was	  Gnb1,	  which	  is	  a	  β1	  subunit	  of	  the	  G	  protein	  complex	  involved	  in	  regulating	  
the	  activity	  of	  different	  voltage-­‐gated	  Ca2+	  channels,	  and	  thus	  mediates	  synaptic	  
transmission	  in	  neurons	  (De	  Waard	  et	  al.,	  1997;	  García	  et	  al.,	  1998;	  Luiro	  et	  al.,	  
2006).	  It	  is	  known	  that	  T-­‐	  and	  R-­‐type	  voltage-­‐gated	  Ca2+	  channels	  are	  co-­‐localized	  
with	   Na+	   channels	   in	   the	   AIS,	   and	   that	   activation	   of	   these	   Ca2+	   channels	   is	  
important	   for	  the	  generation	  and	  timing	  of	  action	  potential	  bursts	   (Bender	  and	  
Trussell,	   2009).	   Also,	   the	   presence	   of	   N-­‐type	   calcium	   channels,	   which	   are	   the	  
determining	   factor	   in	   pyramidal	   cell	   excitability	   (Yu	   et	   al.,	   2010),	   has	   been	  
reported	  in	  the	  AIS	  of	  cortical	  pyramidal	  neurons	  (Grubb	  et	  al.,	  2011).	  Thus,	  up-­‐
regulation	   of	   GnB1	   expression	   in	   Cln3-­‐/-­‐	   neurons	   may	   alter	   the	   activity	   of	  
different	  types	  of	  voltage	  gated	  Ca2+	  channels,	  leading	  to	  an	  abnormal	  Ca2+	  influx	  
and	  thus	  explaining,	  at	  least	  partially,	  the	  state	  of	  overstimulation	  seen	  in	  Cln3-­‐/-­‐	  
neurons	  as	  reflected	  in	  a	  distally	  displaced	  AIS.	  Basic	  calcium	  signaling	  has	  been	  
studied	   in	  embryonic	  Cln3-­‐/-­‐	  cortical	  neurons	   (E16.5),	   in	  which	  the	  baseline	  Ca2+	  
concentration	   and	   response	   to	   depolarization	   did	   not	   differ	   from	  WT	   neurons	  
(Luiro	  et	  al.,	  2006).	  However,	  upon	  selective	  blockade	  of	  N-­‐type	  Ca2+	   channels,	  
the	   recovery	   from	   depolarization	  was	   found	   to	   be	   slower	   in	   embryonic	  Cln3-­‐/-­‐	  
cortical	  neurons.	  This	  finding	  may	  be	  an	  indication	  of	  abnormally	  regulated	  Ca2+	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channels,	  which	  may	   lead	   to	   Ca2+	  mediated	   overstimulation	   of	  Cln3-­‐/-­‐	   neurons.	  
Critically,	  Ca2+	  mediated,	  slow-­‐onset	  excitatory-­‐induced	  neurodegeneration	  may	  
play	  a	   role	   in	   the	  neuron	   loss	  observed	   in	   JNCL,	  as	   it	  has	  been	  shown	   to	  do	   in	  
many	  other	  neurodegenerative	  disorders,	  such	  as	  ALS,	  Alzheimer,	  Parkinson	  and	  
Huntington	  diseases	  (Beal,	  1992;	  1995;	  Mattson	  et	  al.,	  2000a;	  Mattson,	  2006).	  In	  
order	   to	   test	   the	   impact	   of	   these	   Ca2+	   channels	   on	   the	   excitability	   of	   Cln3-­‐/-­‐	  
neurons,	   two-­‐photon	  microscopy	   and	  whole-­‐cell	   patch-­‐clamp	   recordings	   could	  
be	  used	  to	  examine	  the	  properties	  and	  role	  of	  these	  channels	  located	  in	  the	  AIS.	  
If	   a	   dysregulation	   of	   Ca2+	   signaling	   were	   found	   to	   be	   involved	   in	   the	  
overstimulation	  of	  Cln3-­‐/-­‐	  neurons,	  this	   information	  could	  be	  used	  as	  a	  basis	  for	  
novel	   therapies	   for	   JNCL.	   For	   example,	   a	   drug	   called	   MEM-­‐1003	   (Memory	  
Pharmaceuticals,	  Montvale,	  New	  Jersey,	  USA),	  which	  is	  a	  L-­‐type	  calcium	  channel	  
inhibitor	   could	   be	   used	   to	   prevent	   the	   excessive	   calcium	   influx	   that	   can	   cause	  
neurodegeneration	  (Bezprozvanny,	  2009).	  	  	  
	  
As	  mentioned	  above,	   the	  neuron	   cultures	  used	   in	   these	  experiments	  were	  not	  
completely	   free	   from	   glial	   contamination.	   Thus,	   one	   cannot	   exclude	   the	  
possibility	   that	   small,	   remaining	   populations	   of	   astrocytes,	   in	   particular,	   could	  
play	  a	  significant	  part	  in	  the	  excitability	  and	  re-­‐localization	  of	  the	  AIS	  in	  neurons	  
via	   cell-­‐cell	   interactions	  or	   via	   secreted	  of	   soluble	   factors	   (Debanne	  and	  Rama,	  
2011).	   It	   has	   been	   shown	   that	   astrocytes	   situated	   close	   to	   the	   axons	   of	   CA3	  
pyramidal	   neurons	   can	   cause	   the	   broadening	   of	   their	   action	   potentials	   by	  
activation	  of	  AMPA-­‐type	  glutamate	  receptors,	  leading	  to	  an	  intra-­‐axonal	  increase	  
in	  Ca2+	  concentration	  and	  release	  of	  glutamate	  at	  presynaptic	  sites	  (Sasaki	  et	  al.,	  
2011).	   The	   glutamate	   transporters	   situated	   on	   the	   surface	   of	   astrocytes	   may	  
regulate	  this	  activity	  by	  controlling	  the	  diffusion	  and	  concentration	  of	  glutamate	  
in	  the	  extracellular	  space	  (Rothstein	  et	  al.,	  1996;	  Bergles	  and	  Jahr,	  1998).	  Keeping	  
in	   mind	   the	   observation	   that	   glutamate	   clearance	   is	   attenuated	   in	   Cln3-­‐/-­‐	  
astrocytes	   (Chapter	   4,	   Figure	   4.11),	   the	   resulting	   excess	   of	   glutamate	   in	   the	  
extracellular	   space	   could	   induce	   overstimulation	   of	   Cln3-­‐/-­‐	   neurons,	   and	   hence	  
explain	   the	   alteration	   in	   AIS	   position	   observed.	   Another	   essential	   function	   of	  
astrocytes	  is	  their	  ability	  to	  act	  as	  a	  K+	  buffer,	  enabling	  neurons	  to	  cope	  with	  the	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locally	  increased	  levels	  of	  external	  K+	  arising	  from	  high	  neuronal	  activity	  (Wallraff	  
et	   al.,	   2006;	   Seifert	   and	   Steinhäuser,	   2011;	   Parpura	   et	   al.,	   2012).	   Indeed,	   K+	  
channels	  distributed	  in	  the	  AIS	  are	  important	  for	  both	  shaping	  action	  potentials	  
and	  setting	  the	  resting	  membrane	  potential	   (Kole	  et	  al.,	  2007;	  Shu	  et	  al.,	  2007;	  
Goldberg	   et	   al.,	   2008).	   Impairment	   in	   the	   K+	   buffering	   capacity	   of	   Cln3-­‐/-­‐	  
astrocytes	   could	   cause	   overstimulation	   of	   Cln3-­‐/-­‐	   neurons	   within	   the	   same	  
culture.	   It	   would	   be	   extremely	   useful	   to	   examine	   the	   AIS	   location	   in	   WT	   and	  	  
Cln3-­‐/-­‐	   neurons	   co-­‐cultured	   with	   either	   WT	   or	   Cln3-­‐/-­‐	   astrocytes	   to	   determine	  
whether	   astrocytes	   do	   really	   influence	   the	   excitability	   of	   these	   neurons	   and	  
whether	  this	  leads	  to	  altered	  AIS	  positioning.	  
	  	  	  
Since	   the	   AIS	   acts	   as	   a	   central	   regulatory	   element	   for	   action	   potential	  
modulation,	   it	   is	   particularly	   interesting,	   given	   the	   changes	   in	   AIS	   location	  
observed	  in	  Cln3-­‐/-­‐	  neurons,	  that	  one	  of	  the	  most	  prominent	  clinical	  features	  of	  
JNCL	  is	  epileptic	  seizures.	  A	  number	  of	  epilepsy-­‐associated	  mutations	  have	  been	  
found	   in	   AIS-­‐related	   ion	   channels,	   including	   Na+,	   K+,	   and	   Ca+	   (Wimmer	   et	   al.,	  
2010;	  Buffington	  and	  Rasband,	   2011).	   For	   instance,	   loss	  of	   functional	  Nav1.1	   is	  
associated	  with	   an	   early-­‐onset	   form	  of	   epilepsy	   known	  as	  Dravet	   syndrome	  or	  
severe	   myoclonic	   epilepsy	   in	   infancy,	   and	   missense	   mutations	   affecting	   the	  
voltage	  sensing	  domain	  of	  Nav1.2	  also	  cause	  Dravet	  syndrome	  (Shi	  et	  al.,	  2009;	  
Oakley	   et	   al.,	   2011).	   It	   has	   been	   proposed	   that	   the	   combined	   activities	   of	  
multiple	  mutant	  ion	  channels,	  many	  of	  which	  can	  be	  associated	  with	  the	  AIS,	  are	  
involved	   in	   the	   variability	   of	   epilepsy	   manifestations	   (Klassen	   et	   al.,	   2011).	  
Moreover,	  many	  of	  the	  AIS-­‐protein-­‐encoding	  genes	  have	  been	  recognized	  as	  risk	  
factors	   for	   a	   number	  of	   neurological	   disorders,	   including	   schizophrenia,	   autism	  
spectrum	  disorders	  and	  autoimmune	  disorders	  (Buffington	  and	  Rasband,	  2011).	  
Thus,	   the	   altered	   AIS-­‐positioning	   in	   Cln3-­‐/-­‐	   neurons	   may	   play	   a	   role	   in	   action	  
potential	   firing	   in	   epileptogenesis,	   and	   possibly	   also	   in	   other	   abnormal	   higher	  
brain	  functions	  in	  JNCL.	  
	  
Finally,	  the	  function	  of	  the	  AIS	  is	  not	  only	  to	  determine	  action	  potential	  initiation,	  
but	  also	   to	   control	  protein	   transport	   along	   the	  axon,	   thus,	   any	  alteration	   in	   its	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organization	   may	   impact	   protein	   compartmentalization	   and	   neurite	   identity	  
(Winckler	   et	   al.,	   1999;	   Song	   et	   al.,	   2009;	   Grubb	   and	   Burrone,	   2010a).	   Indeed,	  
recent	   findings	   confirm	   the	   role	   of	   the	   AIS	   as	   a	   vesicle	   filter	   that	   controls	   the	  
differential	  trafficking	  of	  transport	  vesicles	  between	  dendrites	  and	  the	  axon	  (Al-­‐
Bassam	  et	  al.,	  2012).	  Hence,	  given	  that	  cultured	  Cln3-­‐/-­‐	  neurons	  display	  a	  distally	  
located	   AIS	   possibly	   due	   to	   the	   environment	   encountered	   in	   vitro	   and	   the	  
potential	   disruption	   of	   CLN3/AIS	   protein	   interactions,	   the	   trafficking	   of	   vesicle	  
proteins	  into	  the	  processes	  of	  Cln3-­‐/-­‐	  neurons	  was	  also	  explored	  (Figures	  5.12	  and	  
5.13).	  However,	  this	  was	  found	  to	  be	  unaltered,	  at	  least	  for	  the	  proteins	  studied	  
(discussed	  below).	  	  	  	  
	  
In	   future	   experiments,	   electrophysiological	   recordings	   from	   Cln3-­‐/-­‐	   neurons	  
should	  be	  carried	  out	   in	  order	  to	  determine	  whether	  the	  distally	   located	  AIS	   in	  
these	   cells	   alters	   their	   electrophysiological	   properties.	   Also	   the	   examination	   of	  
the	   location	   of	   the	   AIS	   in	   excitatory	  Cln3-­‐/-­‐	  neurons	   in	   vivo,	   as	  well	   as	   in	   brain	  
sections	   from	   JNCL	   patients,	   will	   be	   essential	   to	   confirm	   if	   alterations	   in	   AIS	  
localization	  also	  occur	  in	  intact	  tissue.	  	  
	  
Overexpression	  of	  SNAP25	  in	  Cln3-­‐/-­‐	  neurons	  	  
The	   importance	   of	   SNARE-­‐complex	   proteins	   for	   synaptic	   transmission	   is	  
unquestionable	  (Kavalali,	  2002;	  Ungar	  and	  Hughson,	  2003;	  Ramakrishnan	  et	  al.,	  
2012).	  The	  most	  minimal	  machinery	  required	  for	  vesicle	  exocytosis	  is	  composed	  
of	   SNAP25	  and	   syntaxin	   1A,	   both	  pre-­‐synaptic	   plasma	  membrane	  proteins	   and	  
VAMP2,	   a	   vesicle	   associated	   membrane	   protein	   (Wang	   and	   Tang,	   2006).	  
Synaptophysin	  plays	  a	  role	   in	  VAMP2	  stabilization	  and	  synapse	  maturation,	  and	  
EEA1	   mediates	   vesicle	   fusion	   during	   endocytosis	   (Washbourne	   et	   al.,	   1995;	  
Becher	  et	  al.,	  1999;	  Selak	  et	  al.,	  2004;	  2006).	  Synaptic	  abnormalities	  have	  been	  
shown	  in	  a	  number	  of	  other	  models	  of	  NCL,	  and	  this	  is	  thought	  to	  be	  one	  of	  the	  
key,	   early	   neuropathological	   events	   in	   these	   diseases	   (Partanen	   et	   al.,	   2008;	  
Benedict	  et	  al.,	  2009;	  Kielar	  et	  al.,	  2009).	  However,	  the	  only	  difference	  observed	  
in	   the	   total	   expression	   of	   the	   synaptic	   proteins	   studied	   was	   that	   significantly	  
	   268	  
more	  SNAP25	  was	  expressed	  by	  Cln3-­‐/-­‐	  neurons	  compared	  to	  WT	  neurons.	  Also,	  
as	  stated	  above,	  the	  transport	  of	  these	  proteins	  along	  the	  processes	  of	  WT	  and	  
Cln3-­‐/-­‐	   neuronal	   cells	  was	   not	   significantly	   altered	   (Chapter	   5,	   Figures	   5.12	   and	  
5.13).	  	  
	  
These	  results	  were	  surprising	  because	  CLN3	  has	  been	  reported	  to	  localize	  to	  the	  
synaptic	  compartments	  of	  neurons,	  as	  well	  as	  to	  early	  endosomes	  (Järvelä	  et	  al.,	  
1998;	  Luiro	  et	  al.,	  2001;	  Phillips	  et	  al.,	  2005).	  Therefore,	  one	  might	  have	  expected	  
to	  detect	  more	  pronounced	  alterations	  in	  both	  the	  expression	  and	  distribution	  of	  
these	   synaptic	   proteins	   in	   the	   absence	   of	   CLN3.	   Furthermore,	   early	   signs	   of	  
synaptic	   dysfunction	   and	   degeneration	   have	   been	   shown	   to	   occur	   in	   other	  
models	   of	   NCLs,	   (Virmani	   et	   al.,	   2005;	   Kim	   et	   al.,	   2008;	   Partanen	   et	   al.,	   2008;	  
Kielar	   et	   al.,	   2009;	   Koch	   et	   al.,	   2011).	   For	   example,	   the	   expression	   of	   VAMP2,	  
synaptophysin,	  and	  SNAP25	  were	  all	  shown	  to	  be	  progressively	  downregulated	  in	  
different	   brain	   regions	   of	   Ppt1-­‐/-­‐	   mice	   (model	   of	   INCL)	   over	   the	   course	   of	   the	  
disease	   (Kielar	   et	   al.,	   2009).	   The	   general	   lack	   of	   altered	   synaptic	   proteins	  
distribution	  we	   saw	   in	   our	  Cln3-­‐/-­‐	   cultures	   could	   be	   explained	   by	   the	   relatively	  
short	   period	   of	   time	   these	   neurons	   were	   kept	   in	   culture	   prior	   to	   assessing	  
protein	  expression	  and	  distribution.	  Perhaps	  with	  prolonged	  periods	   in	  culture,	  
more	   pronounced	   alterations	   in	   expression	   of	   synaptic	   proteins	   would	   be	  
observed.	  Moreover,	   the	   link	   between	   abnormal	   AIS	   location	   and	   transport	   of	  
proteins	  to	  axons	  also	  requires	  additional	  investigation.	  This	  is	  because	  with	  the	  
current	   analysis	   methods	   no	   discrimination	   between	   axonal	   and	   dendritic	  
protein	   secretion	  was	  preformed.	  One	   could	   carry	   out	   co-­‐labeling	   experiments	  
with	  Ankyrin	  G	  and	  different	   SNARE-­‐complex	  proteins	   to	  examine	  whether	   the	  
transport	  of	  SNAREs	  is	  normal	   in	  axons	  of	  Cln3-­‐/-­‐	  neurons	  with	  a	  distal	  AIS.	  Also	  
these	   results	   would	   need	   to	   be	   confirmed	   with	   immunohistological	   studies	   in	  
Cln3-­‐/-­‐	  mice	  over	  the	  course	  of	  the	  disease.	  	  	  
	  
Up-­‐	   and	   down-­‐regulation	   of	   SNAP25	   expression	   has	   been	   associated	   with	  
hippocampal	   long-­‐term	  potentiation	  and	  passive	  avoidance	   learning,	  which	   is	  a	  
model	  of	  memory-­‐associated	  synaptic	  plasticity	  (Roberts	  et	  al.,	  1998;	  Hou	  et	  al.,	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2004;	  2006;	  O'Sullivan	  et	  al.,	  2007).	  Furthermore,	  substantial	  evidence	  associates	  
altered	   SNAP25	   gene	   expression	   with	   several	   cognitive	   impairments	   such	   as	  
attention	   deficit	   hyperactivity	   (ADHD)	   and	   schizophrenia	   (Hess	   et	   al.,	   1996;	  
Gabriel	  et	  al.,	  1997;	  Thompson	  et	  al.,	  1998;	  Young	  et	  al.,	  1998;	  Barr	  et	  al.,	  2000;	  
Brophy	  et	  al.,	  2002;	  Mill	  et	  al.,	  2002;	  Lewis	  et	  al.,	  2003;	  Thompson	  et	  al.,	  2003;	  
Wong	   et	   al.,	   2003;	   Mill	   et	   al.,	   2004;	   Jeans	   et	   al.,	   2007).	   In	   the	   case	   of	  
schizophrenia,	   a	   reduction	   in	   SNAP25	   expression	   in	   different	   brain	   regions	   has	  
been	  associated	  with	  overall	  synaptic	   loss	  (Glantz	  and	  Lewis,	  2000;	  Mukaetova-­‐
Ladinska	   et	   al.,	   2002;	   Thompson	   et	   al.,	   2003;	   Kolluri	   et	   al.,	   2005).	   In	   contrast,	  
elevated	  levels	  of	  SNAP25	  has	  also	  been	  detected	  in	  some	  brain	  regions	  (Gabriel	  
et	  al.,	  1997;	  Thompson	  et	  al.,	  1998).	  Thus,	  decreased	  SNAP25	  expression	  may	  be	  
associated	   with	   depressed	   functionality	   or	   certain	   neural	   circuits,	   but	   also	  
hyperactivity	  of	  other	  pathways	  may	  arise	  as	  a	  result	  of	  SNAP25	  over-­‐expression	  
(Corradini	   et	   al.,	   2009).	   The	   functional	   consequences	   of	   altered	   SNAP25	  
expression	   has	   been	   previously	   studied	   by	   means	   of	   recombinant	  
adenoassociated	   virus	   (AAV)-­‐mediated	   gene	   delivery	   into	   the	   rat	   dorsal	  
hippocampus	   (McKee	   et	   al.,	   2010).	   This	   chronic	   overexpression	   of	   SNAP25	  
caused	   a	   significant	   increase	   in	   the	   extracellular	   levels	   of	   glutamate,	   and	   a	  
reduction	  in	  paired-­‐pulse	  facilitation	  (a	  form	  of	  short-­‐term	  synaptic	  plasticity)	  in	  
the	   hippocampus,	   and	   produced	   cognitive	   deficits	   and	   impaired	   memory	  
formation.	  Based	  on	   this	   study,	   the	   increased	  expression	  of	   SNAP25	  may	   carry	  
significant	  functional	  implications	  for	  Cln3-­‐/-­‐	  neurons,	  and	  may	  be	  involved	  in	  the	  
cognitive	   deficits	   associated	   with	   JNCL.	   Furthermore,	   the	   SNARE-­‐complex	  
proteins	  such	  as	  VAMP2	  and	  SNAP25A	  has	  been	  proposed	  to	  play	  roles	  in	  neurite	  
elongation	  and	  sprouting	  (Shirasu	  et	  al.,	  2000;	  Kimura	  et	  al.,	  2003).	  Thus,	  altered	  
SNAP25	  expression	  may	  have	  implications	  in	  membrane	  expansion	  at	  the	  growth	  
cones	  of	  Cln3-­‐/-­‐	  neurites,	  mediated	  by	  vesicles	  fusion,	  and	  may	  therefore	  help	  of	  
explain	   the	  attenuated	  neurite	  growth	  observed	   in	  Cln3-­‐/-­‐	   neurons	   (Letourneau	  
and	   Kater,	   1991;	   Futerman	   and	   Banker,	   1996).	   Studies	   are	   now	   underway	   to	  
analyse	   the	   expression	   of	   SNAP25,	   along	   with	   other	   synaptic	   proteins,	   in	  
different	  brain	  regions	  known	  to	  be	  relevant	  for	  JNCL	  pathogenesis	  in	  both	  Cln3-­‐/-­‐	  
mice	  and	  brain	  sections	  from	  JNCL	  patients.	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These	   findings	   provide	   novel	   insights	   into	   how	   loss	   of	   CLN3	   impacts	   neuronal	  
biology.	   In	   summary,	   neuronal	   morphology,	   in	   particular,	   neurite	   growth	   was	  
found	  attenuated	  in	  Cln3-­‐/-­‐	  neurons.	  These	  neurons	  also	  appear	  be	  in	  a	  state	  of	  
overstimulation,	  and	  over-­‐express	  the	  synaptic	  protein	  SNAP25.	  Taken	  together,	  
these	  results	  may	  imply	  that	  neuronal	  connectivity	  and	  signaling	  is	  compromised	  
in	  Cln3-­‐/-­‐	  mice.	  Over	  time,	  these	  changes	  could	   lead	  to	  a	  disruption	  of	  neuronal	  
circuits,	   epileptic	   seizures	   and	   cognitive	   defects,	   leading	   to	   wide	   spread	  
neurodegeneration.	   This	   altered	   biology	   of	   Cln3-­‐/-­‐	   neurons	   may	   also	   be	  
exacerbated	  by	  Cln3-­‐/-­‐	  glial	  cells,	  which	  our	  data	  reveal	  display	  many	   functional	  
defects	   (Results	   Chapters	   3.	   and	   4,	   S.	   Dihanich,	   unpublished	   data).	   The	   impact	  
that	   Cln3-­‐/-­‐	   glial	   cells	   have	   on	   neuronal	   health	   is	   investigated	   using	   co-­‐culture	  
experiments	  in	  Chapter	  6.	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Chapter	  6	  
How	  do	  Cln3-­‐/-­‐	  glia	  impact	  
neuronal	  heath?	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6.1	  Introduction	  
Studies	  using	  mouse	  models	  of	   JNCL	  have	   indicated	   that	  glial	  activation	  always	  
precedes	  the	   loss	  of	  specific	  neuronal	  populations,	  particularly	   in	  the	  thalamus,	  
cortex,	   hippocampus	   and	   cerebellum	   (Katz	   et	   al.,	   1999;	  Mitchison	   et	   al.,	   1999;	  
Cotman	   et	   al.,	   2002;	   Pontikis	   et	   al.,	   2004;	   2005;	   Eliason	   et	   al.,	   2007).	   These	  
findings	   highlighted	   a	   potential	   connection	   between	   glial	   activation	   and	  
neurodegeneration	   in	   JNCL.	  My	   research	   has	   pinpointed	   several	   defects	   in	   the	  
biology	   of	   Cln3-­‐/-­‐	   astrocytes	   (Chapters	   3	   and	   4)	   that	   could	   directly	   impact	  
neuronal	  function	  and	  survival.	  These	  include,	  the	  failure	  of	  Cln3-­‐/-­‐	  astrocytes	  to	  
secrete	  proteins	  that	  have	  a	  positive	  impact	  on	  neurons,	  such	  as	  FGF2	  (Walicke	  
et	  al.,	  1986;	  Alzheimer	  and	  Werner,	  2002)	  and	  VEGF	  (Sun	  et	  al.,	  2003;	  Sköld	  et	  
al.,	   2005;	   Ma	   et	   al.,	   2011),	   and	   their	   reduced	   ability	   to	   take	   up	   glutamate	  
(Schousboe	   and	   Waagepetersen,	   2005).	   Specific	   defects	   have	   also	   been	  
identified	   in	  Cln3-­‐/-­‐	  microglia	   (S.	   Dihanich,	   unpublished	   data),	  which	   could	   also	  
significantly	   impact	   neuronal	   heath,	   either	   directly	   or	   via	   influencing	   astrocyte	  
biology	  (see	  Chapter	  4,	  Discussion	  4.3).	  For	  instance,	  attenuated	  microglial	  MIP-­‐2	  
secretion	   could	   impact	   both	   astrocytes	   and	   neurons,	   since	   both	   of	   these	   cell	  
types	  express	  MIP-­‐2	  receptor	  (CXCR2)	  (Hesselgesser	  and	  Horuk,	  1999;	  De	  Paola	  
et	  al.,	  2007),	  with	   the	  potential	   to	  exert	  either	  negative	   (De	  Paola	  et	  al.,	  2007;	  
Rhodes	  et	  al.,	  2009)	  or	  positive	  (Kielian	  et	  al.,	  2004;	  Luo	  et	  al.,	  2005;	  Watson	  and	  
Fan,	   2005)	   effects	   upon	   neuronal	   survival.	   Indeed,	   the	   lack	   of	   chemokine-­‐
secretion,	  such	  as	  MIP-­‐1γ,	  MIP-­‐2	  and	  RANTES,	  observed	  in	  both	  Cln3-­‐/-­‐	  microglia	  
and	   astrocytes	   (Results	   Chapter	   4,	   Tables	   4.1	   and	   4.2),	   is	   likely	   to	   alter	   the	  
communication	  between	  these	  two	  glia	  cell-­‐types.	  This	  communication	  is	  pivotal	  
for	  detecting	  and	  responding	  to	  alterations	  in	  the	  surrounding	  environment,	  as	  a	  
part	   of	   their	   CNS’s	   ‘surveillance	   system’,	   and	   this	   in	   turn	   could	   also	   impact	   on	  
neuronal	   health	   (Hesselgesser	   and	  Horuk,	   1999;	   Aloisi,	   2001;	   Ransohoff,	   2009;	  
McKimmie	   and	   Graham,	   2010;	   Semple	   et	   al.,	   2010;	   Rostène	   et	   al.,	   2011;	  
Ransohoff	  and	  Brown,	  2012).	  	  
	  
This	   chapter	   will	   describe	   experiments	   designed	   to	   begin	   to	   understand	   the	  
impact	  that	  JNCL	  glia	  may	  have	  on	  neuronal	  health.	  In	  these	  experiments	  WT	  and	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Cln3-­‐/-­‐	  mixed	  glial	  and	  neurons	  were	  cultured	  together	  in	  different	  combinations	  
and	   the	  health	  of	   the	  neurons	   in	   these	  co-­‐cultures	  assessed.	  Such	  experiments	  
not	  only	  allowed	  us	   to	  determine	  whether	   JNCL	  glia	  had	  a	  positive	  or	  negative	  
role	   on	   JNCL	   neurons	   but,	   possibly	   more	   importantly,	   whether	   WT	   glia	   could	  
improve	  some	  of	  the	  deficits	  observed	  in	  Cln3-­‐/-­‐	  neuronal	  cell	  biology	  (Chapter	  5).	  	  
	  
6.2	  Results	  	  
Mixed	  glia	  cultures	  
Before	   setting	   up	   co-­‐cultures	   with	   neurons,	   the	   cellular	   composition	   of	   our	  
mixed	  glia	  cultures	  was	  determined.	  These	  cultures	  were	  derived	  from	  P2-­‐P4	  WT	  
or	  Cln3-­‐/-­‐	  mice	   (see	  Chapter	   2,	   Section	  2.3)	   and	   grown	   for	   a	  minimum	  of	   three	  
weeks	   to	   allow	   sufficient	  microglia	   to	   be	   generated	   along	  with	   the	   astrocytes.	  
The	   cellular	   composition	   of	   these	   cultures	   was	   assessed	   by	  
immunocytochemistry	   using	   CD68	   to	   identify	   microglia,	   GFAP	   to	   identify	  
astrocytes	   (Figure	   6.1	   A),	   and	   O4	   to	   identify	   oligodendrocytes	   (Figure	   6.1	   B).	  
MAP2	   together	   with	   NeuN	   was	   used	   to	   confirm	   the	   lack	   of	   neuronal	  
contamination	   in	   these	   cultures	   (Figure	   6.1	  C).	   The	  majority	   of	   cells	   present	   in	  
WT	   and	   Cln3-­‐/-­‐	   mixed	   glia	   cultures	   were	   astrocytes	   (WT:	   57.2±2.7%,	   Cln3-­‐/-­‐:	  
63.8±1.9%)	   (Figure	   6.1	   A	   and	   D).	   Microglia	   made	   up	   31.3±2.3%	   of	   WT	   and	  
24.5±6.3%	  of	  Cln3-­‐/-­‐	  mixed	  glia	   cultures	   (Figure	  6.1	  A	  and	  D),	   and	   less	   than	  1%	  
were	  oligodendrocytes	  (Figure	  6.1	  B	  and	  D).	  All	   the	  mixed	  glial	  cultures	  used	   in	  
the	   following	   experiments	   have	   been	   generated	   as	   described	   here	   and	   had	   a	  
similar	  cellular	  composition.	  	  
	   	  
































Figure	   6.1.	   Composition	   of	   mixed	   glia	   cultures.	   Primary	   cortical	  mixed	   glia	   cultures	  
generated	  from	  P2-­‐P4	  Cln3-­‐/-­‐	  or	  WT	  mouse	  cortex	  were	  stained	  with	  CD68	  to	  identify	  microglia,	  
GFAP	   to	   identify	   astrocytes,	   O4	   to	   identify	   oligodendrocytes,	   MAP2	   and	   NeuN	   to	   identify	  
neuronal	   cells.	   DAPI	   was	   used	   to	   visualize	   all	   nuclei.	   (A)	   WT	   and	   Cln3-­‐/-­‐	   mixed	   glia	   cultures	  
contained	  mostly	  astrocytes	  and	  microglia,	  (B)	  very	  few	  oligodendrocytes	  and	  (C)	  no	  neurons.	  (D)	  
The	  overall	  composition	  of	  these	  cultures.	  The	  percentage	  of	  each	  cell	  type	  was	  determined	  by	  
counting	  5	  random	  fields	  per	  coverslip	  and	  a	  minimum	  of	  three	  coverslips	  per	  experiment.	  The	  
means	  ±	  SEM	  shown	  were	  calculated	  from	  three	  separate	  experiments.	  Scale	  bar	  in	  (A),	  (B)	  and	  
(C)	  is	  20μm.	  	  	  
	  
Cln3-­‐/-­‐	  mixed	  glial	  cultures	  induce	  neuronal	  death	  
To	   determine	   whether	   or	   not	   Cln3-­‐/-­‐	   mixed	   glial	   influenced	   neuronal	   health,	  
primary	  cortical	  WT	  or	  Cln3-­‐/-­‐	  neuronal	  cell	  cultures	  were	  plated	  on	  PDL-­‐coated	  
coverslips	  at	  a	  concentration	  of	  250,000	  cells/coverslip	  and	  grown	  for	  7	  days.	  At	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this	   stage	  WT	   or	   Cln3-­‐/-­‐	   mixed	   glia	   cultures	   were	   seeded	   on	   top	   of	   them	   at	   a	  
concentration	   of	   50,000	   cells	   per	   coverslip	   (see	   Chapter	   2,	   Section	   2.6).	   We	  
considered	  that	  by	  using	  a	  co-­‐culture	  system	  where	  glia	  cells	  and	  neurons	  were	  
in	  direct	  connection,	  we	  would	  enhance	  the	  probability	  of	  seeing	  an	  effect	  since	  
both	   cell-­‐cell	   interactions	   and	   secreted	   factors	   would	   be	   brought	   into	   play	  
(mimicking	   the	   in	   vivo	   situation).	  After	  2	   (2DIV)	  or	   an	  additional	  5	  days	   (7DIV),	  
some	   co-­‐cultures	  were	   used	   to	   assess	   total	   cell	   death	   in	   the	   cultures	   using	   an	  
LDH	  assay,	  while	  other	  co-­‐cultures	  were	  fixed	  to	   identify	  the	  types	  of	  cells	  that	  
were	   dying	   by	   using	   a	   Live/dead	   fixable	   dead	   cell	   staining	   kit	   (Invitrogen)	   in	  
combination	   with	   cell-­‐type	   specific	   phenotypic	   markers	   for	   neurons	   (MAP2),	  
astrocytes	  (GFAP)	  and	  microglia	  (CD68)	  (see	  Chapter	  2,	  Section	  2.6).	  
	  
Cln3-­‐/-­‐	  glia	  display	  a	  modest	  negative	  impact	  on	  neurons	  in	  co-­‐cultures	  after	  2	  
DIV	  
After	   two	  days	   in	  co-­‐culture	  hardly	  any	  dying	  cells	   (red	  nuclei	   indicates	  a	  dying	  
cell,	  that	  when	  co-­‐localized	  with	  a	  cell	  type	  specific	  marker	  (CD68/GFAP/MAP2)	  
visualized	  with	  a	  green	   fluorophore	  can	  be	  seen	  as	  a	   ‘yellowish’	  nucleus)	  could	  
be	   detected	   in	   co-­‐cultures	   of	  WT	   neurons	   grown	   together	  with	  WT	  mixed	   glia	  
(WT	  Glia)	  (Figure	  6.2	  A,	  ai,	  aii,	  bi	  and	  bii).	  There	  appeared	  to	  be	  slightly	  more	  cell	  
death	  in	  co-­‐cultures	  of	  WT	  neurons	  and	  Cln3-­‐/-­‐	  glia,	  but	  these	  dying	  cells	  appear	  
to	  be	  mostly	  astrocytes	  (Figure	  6.2	  A,	  ci,	  cii,	  di	  and	  dii,	  see	  arrowheads	  in	  di	  for	  
examples	   of	   dying	   astrocytes).	   The	   greatest	   cell	   death,	   at	   this	   stage,	   was	  
observed	  when	  Cln3-­‐/-­‐	  mixed	  glia	  were	  cultured	  with	  Cln3-­‐/-­‐	  neurons,	  and	  most	  of	  
these	  dying	  cells	  expressed	  MAP2	  (Figure	  6.2	  A,	  compare	  gii	  to	  cii,	  and	  hii	  to	  dii,	  
arrows	   in	   gii	   show	   examples	   of	   dying	   neurons).	   In	   these	   studies	   two	   different	  
MAP2	  antibodies	  were	  used,	  a	  polyclonal	   for	  double	   labelling	  with	  CD68,	  and	  a	  
monoclonal	   for	   double	   labelling	   with	   GFAP.	   Curiously,	   we	   noted	   that	   the	  
monoclonal	   antibody,	   the	   one	   routinely	   used	   in	   this	   thesis,	   stained	   neuronal	  
processes	  far	  more	  effectively	  that	  did	  the	  polyclonal	  antibody,	  which	  seemed	  to	  
predominantly	  stain	  neuronal	  cell	  bodies	   (Figure	  6.2	  A,	  compare	  aii	  with	  bii,	   cii	  
with	  dii,	  eii	  with	  fii	  and	  gii	  with	  hii).	   In	  the	  presence	  of	  Cln3-­‐/-­‐	  glia,	  Cln3-­‐/-­‐	  neurons	  
displayed	   their	   typical	   morphology;	   a	   small	   cell	   body,	   less	   complex	   neurite	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morphology	   and	  disrupted	  MAP2	   staining	   (such	   as	   observed	   in	  Cln3-­‐/-­‐	  neuronal	  
cultures,	   see	  Chapter	  5,	  Figure	  5.3).	  However,	  when	  cultured	  with	  WT	  glia,	   the	  
morphology	   of	   the	   Cln3-­‐/-­‐	   neurons	   improved,	   looking	   more	   like	   that	   of	   a	   WT	  
neurons	  (Figure	  6.2	  A,	  compare	  fii	  with	  hii,	  also	  see	  Figures	  6.4	  and	  6.5	  below),	  
suggesting	  that	  WT	  glia	  have	  a	  positive	  impact	  on	  Cln3-­‐/-­‐	  neurons.	  	  
	  
The	  amount	  of	  released	  LDH	  was	  also	  analyzed	  as	  an	  additional	  measurement	  of	  
total	   cell	   death	   occurring	   in	   these	   co-­‐cultures.	   However,	   at	   this	   time	   point	   no	  
significant	  difference	  could	  be	  detected	  in	  the	  amount	  of	  released	  LDH	  under	  any	  
condition	  tested	  (Figure	  6.2	  B).	  These	  results	  suggest	  that	  Cln3-­‐/-­‐	  glia	  have	  only	  a	  
mild	  effect	  on	  neuronal	   survival	  after	  a	   short	   time	   in	   contact,	  but	   that	  WT	  glia	  
can	  positively	  impact	  the	  morphology	  of	  Cln3-­‐/-­‐	  neurons	  during	  this	  time	  period.	  	  
	   	  































Figure	  6.2.	  Cln3-­‐/-­‐	  glia	  have	  little	  influence	  upon	  neuronal	  survival	  after	  2	  DIV.	  P0	  
cortical	  WT	   or	  Cln3-­‐/-­‐	   neurons	  were	   combined	  with	   either	  WT	   or	  Cln3-­‐/-­‐	  mixed	   glial	   cultures	   to	  
study	  the	  impact	  of	  these	  cells	  on	  neuronal	  survival.	  The	  level	  of	  cell	  death	  was	  investigated	  after	  
co-­‐culture	  by	  using	  a	  LIVE/DEAD	  Dye,	  where	  dead	  cells	  fluoresce	  red,	  together	  with	  staining	  for	  
MAP2	   (neurons),	   in	   combination	  with	   either	   CD68	   (microglia)	   or	  GFAP	   (astrocytes).	   Analysis	   of	  
the	   amount	   of	   LDH	   released	   from	   these	   co-­‐culture	   combinations	   was	   used	   as	   an	   additional	  
measurement	   of	   cell	   death.	   (A)	  WT	  mixed	   glia	   have	   a	   positive	   impact	   on	   both	  Cln3-­‐/-­‐	   and	  WT	  
neurons	  seen	  as	  decreased	  amount	  of	  dead	  cells	  (red	  nuclei)	  compared	  to	  co-­‐cultures	  containing	  
Cln3-­‐/-­‐	  glia.	  A	  slight	  increase	  in	  neuron	  death	  is	  observed	  when	  Cln3-­‐/-­‐	  glia	  are	  co-­‐cultured	  with	  WT	  
or	  Cln3-­‐/-­‐	  neurons,	  with	  the	  latter	  being	  more	  sensitive	  to	  the	  presence	  of	  Cln3-­‐/-­‐	  mixed	  glia	  (more	  
red	   nuclei).	   (B)	   There	  was	   no	   significant	   difference	   in	   the	   amount	   of	   LDH	   released	   among	   the	  
different	  co-­‐cultures	  after	  2DIV.	  These	   immunofluoresecence	  studies	  were	  performed	  on	   three	  
separate	  experiments.	  The	  data	  in	  (B)	  is	  presented	  as	  the	  mean±SEM	  derived	  form	  6	  separate	  co-­‐
culture	   experiments,	   in	   each	   experiment	   3	   technical	   replicates	   were	   measured.	   Scale	   bar	   is	  
20μm.	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Cln3-­‐/-­‐	  glia	  induce	  neuronal	  cell	  death	  in	  co-­‐cultures	  after	  7	  DIV	  
As	  might	  be	  expected,	  after	  7	  DIV	  co-­‐cultures	  of	  WT	  mixed	  glia	  and	  WT	  neurons	  
were	   still	   very	   healthy,	  with	   very	   few	  dying	   cells	   present	   (Figure	   6.3	  A	   and	  B).	  
However,	  the	  MAP2	  expressing	  processes	  of	  WT	  neurons	  grown	  with	  Cln3-­‐/-­‐	  glia	  
appeared	   punctate,	   suggesting	   that	   neuronal	   health	   was	   compromised	   in	   this	  
situation	  (Figure	  6.3	  A,	  compare	  cii	   to	  aii	  and	  dii	   to	  bii,).	  This	  was	  confirmed	  by	  
the	   increased	  number	  of	  neurons	  with	  red	  nuclei	  observed	   in	  these	  co-­‐cultures	  
(examples	   marked	   with	   arrows	   in	   Figure	   6.3	   A,	   cii).	   Intriguingly,	   WT	   neurons	  
seemed	  to	  induce	  the	  death	  of	  Cln3-­‐/-­‐	  glia,	  and	  of	  microglia	  in	  particular	  (example	  
marked	   with	   dashed	   circle	   in	   Figure	   6.3	   A,	   ci).	   Such	   changes	   in	   neuronal	  
morphology,	  or	   increases	   in	  neuron	  or	  glial	  death	  over	  time	  were	  not	  observed	  
when	  these	  cell-­‐types	  were	  grown	  individually	  (for	  neuronal	  cultures	  see	  Chapter	  
5,	  Figure	  5.1,	  and	  for	  glia	  see	  Chapter	  6,	  Figure	  6.1).	  As	  observed	  after	  2	  DIV,	  WT	  
glia	   had	   a	   positive	   influence	   on	   Cln3-­‐/-­‐	   neurons,	   with	   MAP2	   expressing	   Cln3-­‐/-­‐	  
neurons	   showing	   a	  more	   complex	   neurite	   structure	   (see	   Figure	   6.3	   A,	   fii,	   and	  
Figures	   6.4	   and	   6.5).	   Interestingly,	   after	   7	   days,	   Cln3-­‐/-­‐	   neurons	   clearly	   had	   a	  
negative	   impact	   on	  WT	   astrocytes	   (Figure	   6.3	   A,	   compare	   fi	   to	   bi).	   Indeed,	   in	  
these	  cultures	  many	  WT	  astrocyte	  nuclei	  were	  stained	  red	  with	  the	  live/dead	  dye	  
(Figure	   6.3	   A,	   arrow	   heads	   in	   fi).	   Again,	   the	   co-­‐culture	   combination	   of	   Cln3-­‐/-­‐	  
neurons	   with	   Cln3-­‐/-­‐	   glia	   appeared	   the	   most	   detrimental	   for	   neuronal	   heath	  
(Figure	   6.3	   A,	   gii	   and	   hii).	   An	   increased	   number	   of	   dying	   MAP2	   expressing	  
neurons	   (Figure	   6.3	   A,	   arrows	   in	   gii)	   could	   be	   seen	   in	   these	   co-­‐cultures,	  
compared	   to	   when	   WT	   glia	   were	   cultured	   with	   Cln3-­‐/-­‐	   neurons	   (Figure	   6.3	   A,	  
compare	  gii	  to	  cii	  and	  hii	  to	  dii).	  Indeed,	  most	  of	  the	  Cln3-­‐/-­‐	  neurons	  in	  these	  co-­‐
cultures	  were	  either	  dead	  or	  appeared	  severely	  compromised,	  as	  judged	  by	  their	  
morphology.	   It	   is	   worth	   noting	   that	   the	   morphology	   of	   Cln3-­‐/-­‐	   astrocytes	   also	  
differed	   depending	   whether	   they	   had	   been	   co-­‐cultured	   with	   WT	   or	   Cln3-­‐/-­‐	  
neurons.	   In	   the	   presence	   of	   Cln3-­‐/-­‐	   neurons,	   Cln3-­‐/-­‐	   astrocytes	   had	   smaller	   cell	  
bodies	  and	  longer	  more	  numerous	  processes	  (reminiscent	  of	  activated	  astrocytes	  
in	  culture),	  when	  compared	  to	  Cln3-­‐/-­‐	  astrocytes	  grown	  with	  WT	  neurons	  (Figure	  
6.3	  A,	  compare	  hi	  to	  di).	  The	  morphology	  of	  WT	  astrocytes	  was	  also	   influenced	  
by	  Cln3-­‐/-­‐	  neurons	  (Figure	  6.3	  A,	  compare	  fi	  to	  bi),	  appearing	  smaller	  and	  having	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thinner	  processes	   in	  these	  cultures,	  rather	  than	  a	  more	  rounded	  cell	  body	  with	  
fewer	  processes,	  as	  was	  seen	  in	  co-­‐cultures	  with	  WT	  neurons.	  
	  
These	  findings	  using	  the	  Live/dead	  dye	  labeling	  of	  cells	  correlated	  well	  with	  the	  
measurements	  of	  released	  LDH	  from	  the	  different	  co-­‐cultures	  (Figure	  6.3	  B).	  The	  
lowest	   LDH	   levels	  were	   observed	  when	  WT	   glia	   and	  neurons	  were	   co-­‐cultured	  
(%LDH:	   13.0±2.2%).	   These	   LDH	   levels	   increased	   dramatically	   when	   Cln3-­‐/-­‐	   glia	  
were	  co-­‐cultured	  with	  WT	  or	  Cln3-­‐/-­‐	  neurons	  (%LDH	  in	  Cln3-­‐/-­‐	  glia/WT	  neuron	  co-­‐
cultures:	   24.9±3.8%,	   and	   in	   Cln3-­‐/-­‐	   glia/Cln3-­‐/-­‐	   neuron	   co-­‐cultures:	   30.4±4.6%).	  
When	  Cln3-­‐/-­‐neurons	  were	  co-­‐cultured	  with	  WT,	  rather	  than	  Cln3-­‐/-­‐,	  glia	  a	   lower	  
level	   of	   LDH	   release	   was	   observed	   (%LDH	   20.8±3.7%),	   possibly	   due	   to	   the	  
supportive	   influence	   of	   the	   WT	   cells.	   As	   might	   be	   expected,	   there	   was	  
significantly	  more	   LDH	   released	   in	  Cln3-­‐/-­‐	  glia/Cln3-­‐/-­‐	   neuron	   co-­‐cultures	   than	   in	  
WT	  glia/WT	  neuron	  co-­‐cultures	  (Figure	  6.3	  B).	  	  
	  
These	  results	  suggest	  that	  Cln3-­‐/-­‐	  glia	  appear	  to	  be	  detrimental	  to	  the	  health	  of	  
both	  WT	  and	  Cln3-­‐/-­‐	  neurons,	  with	  Cln3-­‐/-­‐	  neurons	  being	  the	  most	  vulnerable.	   In	  
contrast,	   WT	   glia	   seem	   to	   have	   a	   positive	   influence	   on	   Cln3-­‐/-­‐	   neurons.	   A	   bi-­‐
directional	   interaction	   between	   neurons	   and	   glia	   is	   also	   evident	   in	   these	   co-­‐
cultures,	   as	   is	   apparent	   from	   the	   impact	   of	  Cln3-­‐/-­‐	  neurons	   upon	  WT	   astrocyte	  
morphology,	  re-­‐enforcing	  the	  importance	  of	  the	  interplay	  between	  neurons	  and	  
glia	  within	  the	  CNS.	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Figure	  6.3.	  Cln3-­‐/-­‐	  cells	  negatively	   impact	  WT	  cells	  after	  7	  DIV.	  P0	  cortical	  WT	  and	  
Cln3-­‐/-­‐	  neurons	  were	  combined	  with	  either	  WT	  or	  Cln3-­‐/-­‐	  mixed	  glia	  cultures	  to	  study	  the	  impact	  of	  
these	  cells	  on	  each	  other’s	  survival.	  The	   levels	  of	  cell	  death	  were	   investigated	  after	  7DIV	   in	  co-­‐
culture.	  (A)	  WT	  glia	  had	  a	  positive	  impact	  on	  both	  Cln3-­‐/-­‐	  and	  WT	  neurons.	  Cln3-­‐/-­‐	  glia	  accelerated	  
cell	   death	  when	   cultured	  with	   either	  WT	   or	  Cln3-­‐/-­‐	   neurons,	  with	  mutant	   neurons	   being	  more	  
sensitive	  (more	  red	  nuclei).	  (B)	  There	  was	  significantly	  more	  LDH	  released	  in	  WT	  neuron/WT	  glia	  
co-­‐cultures	  compared	  to	  Cln3-­‐/-­‐	  neuron/Cln3-­‐/-­‐	  glia	  co-­‐cultures.	  These	   fluorescence	  studies	  were	  
performed	  on	  three	  separate	  co-­‐culture	  experiments.	  The	  data	  in	  (B)	  is	  presented	  as	  mean±SEM	  
derived	   form	  6	  separate	  co-­‐culture	  experiments	  each	  with	   three	  technical	   repeats.	  Scale	  bar	   in	  
(A)	  is	  20μm.	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Reduced	  neurite	  complexity	  induced	  by	  Cln3-­‐/-­‐	  glia	  
In	  Chapter	  5	  (Figure	  5.3)	  Cln3-­‐/-­‐	  neurons	  were	  shown	  have	  smaller	  cell	  bodies	  and	  
shorter	   primary	   processes	   that	   WT	   neurons,	   suggesting	   that	   CLN3	   deficiency	  
impacts	  neuronal	  soma	  size	  and	  neurite	  length.	  In	  the	  intact	  brain,	  neurons	  are	  
greatly	   influenced	  by	  glia,	   for	   instance,	  astrocytes	  may	  directly	  regulate	  neurite	  
growth	  both	  by	  cell-­‐contact	  and	  the	  proteins	  they	  secrete	  (Tomaselli	  et	  al.,	  1988;	  
Powell	  et	  al.,	  1997b;	  Crone	  and	  Lee,	  2002;	  Araújo	  and	  Tear,	  2003).	  In	  contrast,	  in	  
the	   damaged	   or	   diseased	   brain,	   reactive	   astrocytes	   may	   negatively	   impact	  
neurite	   growth	  by	  over-­‐expressing	  growth-­‐inhibitory	  extracellular	  matrix	   (ECM)	  
proteins,	   such	   as	   chondroitin	   and	   keratan	   sulphate	   proteoglycans,	   and	   by	  
inhibiting	   the	   extension	   of	   regenerating	   axons	   (Silver	   and	   Miller,	   2004).	  
Moreover,	  microglia	  can	  also	   inhibit	  neurite	  outgrowth	  by	  acting	  as	  a	  source	  of	  
inhibitory	  proteoglycans	  (Bovolenta	  et	  al.,	  1993).	  Indeed,	  as	  described	  above,	  WT	  
astrocytes	   appeared	   to	  have	  a	  beneficial	   effect	  on	  Cln3-­‐/-­‐	  neurons,	  while	  Cln3-­‐/-­‐	  
astrocytes	  had	  a	  detrimental	  effect	  on	  these	  cells.	  We	  therefore	  analysed	  these	  
changes	  by	  using	  ImageJ	  to	  quantify	  the	  soma	  size	  of	  neurons	  and	  their	  neurite	  
complexity	  (see	  Chapter	  5,	  Figure	  5.3)	  in	  the	  different	  co-­‐culture	  combinations.	  	  
	  
Figure	  6.4	  illustrates	  a	  typical	  MAP2	  expressing	  WT	  neuron	  co-­‐cultured	  with	  WT	  
glia	   (a)	  or	  with	  Cln3-­‐/-­‐	  glia	   (b);	   and	  a	   typical	  MAP2	  expressing	  Cln3-­‐/-­‐	  neuron	   co-­‐
cultured	   with	   WT	   glia	   (c)	   or	   with	   Cln3-­‐/-­‐	   glia	   (d).	   Neurons	   of	   both	   genotypes	  
appeared	  very	  similar	  when	  grown	  with	  WT	  glia	  (Figure	  6.4,	  see	  a	  and	  c).	  This	  is	  
in	   contrast	   with	   the	   marked	   difference	   in	   the	   appearance	   of	   WT	   and	   Cln3-­‐/-­‐	  
neurons	   grown	   without	   glia	   (see	   Chapter	   5,	   Figure	   5.3),	   with	   Cln3-­‐/-­‐	   neurons	  
exhibiting	  significantly	  smaller	  cell	  soma	  and	  shorter	  primary	  processes	  than	  WT	  
neurons.	  MAP2	  expression	  was	  also	  more	  punctuate	   in	  WT	  neurons	  when	  they	  
were	   co-­‐cultured	   with	   Cln3-­‐/-­‐	   glia	   (see	   b,	   Figure	   6.4),	   and	   this	   was	   even	   more	  































Figure	  6.4.	  Cln3-­‐/-­‐	  glia	  negatively	  impact	  neuronal	  morphology.	  The	  influence	  of	  WT	  
and	  Cln3-­‐/-­‐	  glia	  cells	  on	  the	  morphology	  of	  WT	  and	  Cln3-­‐/-­‐	  neurons	  was	  explored	  in	  7	  day	  old	  co-­‐
cultures,	  in	  which	  neuronal	  morphology	  was	  visualized	  with	  MAP2	  and	  cell	  soma	  size	  and	  neurite	  
complexity	   was	   analyzed.	   Representative	   images	   of	  WT	   and	   Cln3-­‐/-­‐	   neurons	   co-­‐cultured	   either	  
with	  WT	  or	  Cln3-­‐/-­‐	  glia	  are	  shown.	  Cln3-­‐/-­‐	   glia	  cause	  MAP2	  staining	   in	  WT	  neuronal	  processes	   to	  
appear	  punctate,	  and	  this	  is	  more	  evident	  in	  Cln3-­‐/-­‐	  neuronal	  processes.	  In	  contrast,	  WT	  glia	  have	  
a	  positive	  impact	  on	  the	  morphology	  of	  Cln3-­‐/-­‐	  neurons.	  Scale	  bar	  is	  20μm.	  
	  
Analysis	  of	  neuronal	  soma	  sizes	  revealed	  that	  WT	  neurons	  co-­‐cultured	  with	  WT	  
glia	  had	  significantly	  bigger	  cell	  soma	  (180.6±5.6	  (μm)2)	  than	  Cln3-­‐/-­‐	  neurons	  co-­‐
cultured	   with	   Cln3-­‐/-­‐	   glia	   (151.4±3.2	   (μm)2)	   (Figure	   6.5	   A).	   Cln3-­‐/-­‐	   glia	   did	   not	  
significantly	   alter	   the	   soma	   size	   of	   WT	   neurons	   (164.1±2.8	   (μm)2)	   when	  
compared	  to	  those	  co-­‐cultured	  with	  WT	  glia	  (180.6±5.6	  (μm)2).	  However,	  Cln3-­‐/-­‐	  
glia	   significantly	   reduced	   the	   soma	   size	   of	   Cln3-­‐/-­‐	   neurons	   (151.4±3.2	   (μm)2),	  
when	  compared	  to	  those	  co-­‐cultured	  with	  WT	  glia	  (178.3±4.1	  (μm)2).	  	  
	  
The	  number	  of	  primary	  neurites	  observed	  was	  not	  altered	  in	  these	  different	  co-­‐
culture	   systems	   (Figure	   6.5	   B,	   a).	   WT	   neurons	   had	   a	   significantly	   increased	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number	   of	   secondary	   neurites	   when	   co-­‐cultured	   with	   WT	   glia	   (2.8±0.3),	  
compared	  to	  Cln3-­‐/-­‐	  neurons	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	   (1.5±0.1)	   (Figure	  6.5	  B,	  
b).	   The	   number	   of	   tertiary	   neurites	   was	   also	   significantly	   reduced	   in	   Cln3-­‐/-­‐	  
neuron/	   Cln3-­‐/-­‐	  glia	   co-­‐cultures	   (0.4±0.1),	   compared	   to	  WT	  neuron/	  WT	  glia	   co-­‐
cultures)	  (1.2±0.1)	  (Figure	  6.5	  B,	  c).	  Cln3-­‐/-­‐	  glia	  also	  caused	  a	  significant	  reduction	  
in	   the	   number	   of	   tertiary	   neurites	   displayed	   by	   WT	   neurons	   (0.6±0.1),	   when	  
compared	   to	   those	   co-­‐cultured	   with	   WT	   glia	   (1.2±0.1)	   (Figure	   6.5	   B,	   c).	  
Additionally,	  the	  total	  length	  of	  primary	  neurites	  was	  significantly	  reduced	  when	  
Cln3-­‐/-­‐	  neurons	  were	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	  (350.8±26.7μm),	  rather	  than	  WT	  
glia	   (476.0±22.2μm)	   (Figure	   6.5	   C,	   a).	   While	   the	   total	   length	   of	   the	   primary	  
neurites	   was	   found	   to	   be	   the	   greatest	   in	   WT	   neuron/	   WT	   glia	   co-­‐cultures	  
(567.9±35.3.7μm)	   (Figure	   6.5	   C,	   a),	   this	   length	   was	   slightly	   decreased	  
(423.7±59.6μm)	   when	   WT	   glia	   were	   replaced	   with	   Cln3-­‐/-­‐	   glia,	   although	   this	  
change	  was	  not	  found	  to	  be	  significant.	  The	  longest	  primary	  neurite	  of	  either	  WT	  
or	   Cln3-­‐/-­‐	   neurons	   was	   significantly	   longer	   when	   cultured	   with	   WT	   glia	  
(218.1±12.9μm),	   than	   when	   grown	   with	   Cln3-­‐/-­‐	   glia	   (WT	   neurons:	  
165.7.8±13.9μm,	   Cln3-­‐/-­‐	   neurons:	   119.8±6.3μm,	   Figure	   6.5	   C,	   b).	   Again,	   the	  
longest	   primary	   neurite	   was	   significantly	   longer	   when	   WT	   neurons	   were	   co-­‐
cultured	  with	  WT	  glia	  than	  when	  Cln3-­‐/-­‐	  neurons	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia.	  	  
	  
Taken	  together,	  these	  analyses	  of	  cell	  body	  size	  and	  neurite	  complexity	  revealed	  
that	  Cln3-­‐/-­‐	  glia	  had	  a	  detrimental	  effect	  upon	  neuronal	  morphology,	  with	  Cln3-­‐/-­‐	  
neurons	  being	  more	  susceptible	  than	  those	  from	  WT	  mice.	  Most	  importantly,	  WT	  
glia	  appeared	  to	  exert	  a	  positive	  influence	  on	  Cln3-­‐/-­‐	  neurons.	  	  
	   	  

































Figure	   6.5.	  Cln3-­‐/-­‐	   glia	   induce	   a	   reduction	   in	   neuronal	   somal	   size	   and	   neurite	  
complexity.	  (A)	  The	  soma	  size	  of	  MAP2	  expressing	  WT	  and	  Cln3-­‐/-­‐	  neurons	  co-­‐cultured	  with	  WT	  
or	  Cln3-­‐/-­‐	  mixed	  glia	  was	  quantified	  using	  ImageJ.	  Cln3-­‐/-­‐	  neurons	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	  had	  a	  
significantly	  smaller	  cell	  soma	  that	  did	  WT	  neurons	  co-­‐cultured	  with	  WT	  glia.	  The	  presence	  of	  WT	  
glia	  significantly	   increased	  the	  soma	  size	  of	  Cln3-­‐/-­‐	  neurons	  compared	  to	  co-­‐cultures	  with	  Cln3-­‐/-­‐	  
glia.	  (B)	  (a)	  The	  number	  of	  primary	  neurites	  (1.	  neurites	  that	  are	  extended	  from	  cell	  bodies)	  did	  
not	   differ	   between	   these	   co-­‐cultures,	   (b)	   Cln3-­‐/-­‐	   glia	   significantly	   reduced	   the	   number	   of	  
secondary	   neurites	   (2.	   neurites	   that	   branch	   off	   from	   primary	   neurites)	   in	   Cln3-­‐/-­‐	   neurons,	   (c)	  	  	  
Cln3-­‐/-­‐	  glia	  significantly	  reduced	  the	  number	  of	  tertiary	  neurites	  (3.	  neurites	  that	  branch	  off	  from	  
secondary	  neurites)	   in	  WT	  and	  Cln3-­‐/-­‐	  neurons.	   (C)	   (a)	  The	   total	   length	  of	  primary	  neurites	  was	  
significantly	   reduced	  when	  Cln3-­‐/-­‐	  neurons	  were	  co-­‐cultured	  with	  Cln3-­‐/-­‐	   glia	   compared	   to	  when	  
WT	  neurons	  were	  co-­‐cultured	  with	  WT	  glia,	  (b)	  Cln3-­‐/-­‐	  glia	  significantly	  reduced	  the	  length	  of	  the	  
longest	  primary	  neurite	   in	  both	  WT	  and	  Cln3-­‐/-­‐	   neurons,	   and	   the	   length	  of	   the	   longest	  primary	  
neurite	  was	  greater	  when	  WT	  neurons	  were	  co-­‐cultured	  with	  WT	  glia	  than	  when	  Cln3-­‐/-­‐	  neurons	  
were	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia.	  Data	  presented	  in	  (B),	  (C)	  and	  (D)	  are	  the	  mean±SEM	  from	  40	  
cells	  in	  each	  experiment	  and	  the	  experiment	  was	  repeated	  three	  times.	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Glial	  induced	  alterations	  in	  the	  expression	  of	  SNAREs	  in	  co-­‐cultured	  WT	  and	  
Cln3-­‐/-­‐	  neurons	  
It	   is	   well	   established	   that	   astrocytes	   can	   modulate	   the	   synaptic	   function	   of	  
neurons	  by	  releasing	  a	  number	  of	  transmitters	  and	  factors	  such	  as	  glutamate,	  D-­‐
serine,	  ATP	  and	  BDNF	  (Volterra	  and	  Meldolesi,	  2005;	  Parpura	  et	  al.,	  2010).	  This	  
release	  may	  occur	  via	  Ca2+-­‐dependent	  exocytosis,	  which	  also	  forms	  the	  basis	  for	  
astrocyte	  communication	  (Parpura	  et	  al.,	  2011;	  Zorec	  et	  al.,	  2012;	  Verkhratsky	  et	  
al.,	  2012a).	  Both	  Ca2+	  signaling	  and,	  in	  particular,	  protein	  secretion	  was	  found	  to	  
be	   severely	   affected	   in	   Cln3-­‐/-­‐	   astrocytes	   (see	   Chapter	   4,	   Tables	   4.1	   and	   4.2).	  
Specific	   alterations	   in	   protein	   secretion	   have	   also	   been	   identified	   in	   Cln3-­‐/-­‐	  
microglia	   (S.	   Dihanich,	   unpublished	   data),	   which	   may	   impact	   upon	   neuronal	  
synapses.	  Indeed,	  synaptic	  pathology	  has	  been	  recognized	  as	  one	  of	  the	  key	  early	  
events	  in	  the	  NCLs	  (Virmani	  et	  al.,	  2005;	  Kim	  et	  al.,	  2008;	  Partanen	  et	  al.,	  2008;	  
Kielar	   et	   al.,	   2009).	   We	   have	   already	   demonstrated	   that	   the	   distribution	   of	  
SNARE-­‐complex	  proteins	  and	  the	  early	  endosomal	  marker	  EEA1	  are	  unaltered	  in	  
Cln3-­‐/-­‐	   neuronal	   cultures	   (see	   Chapter	   5,	   Figures	   5.12	   and	   5.13).	   Now,	   in	   co-­‐
cultures,	  we	  investigated	  whether	  Cln3-­‐/-­‐	  (and	  WT)	  glia	  could	  influence	  the	  levels	  
of	  expression	  and	  localization	  of	  these	  proteins	  and	  hence	  potentially	   influence	  
synaptic	  function.	  	  
Which	  SNAREs	  are	  expressed	  by	  glia	  cells?	  
Astrocytes	   are	   known	   to	   express	   a	   variety	   of	   presynaptic	   proteins,	   including	  
SNARE-­‐complex	  proteins	  such	  as	  SNAP23	  and	  VAMP2,	  both	   in	  vivo	  and	   in	  vitro.	  
The	  expression	  of	   some	  of	   these	  proteins	   including	  SNAP25	  and	  synaptophysin	  
may	   be	   upregulated	   upon	   extended	   periods	   in	   culture	   (Wilhelm	   et	   al.,	   2004;	  
Schubert	   et	   al.,	   2011).	   Therefore,	   the	   expression	   of	   SNAP25,	   VAMP2	   and	  
synaptophysin	   was	   first	   studied	   in	   both	  WT	   and	   Cln3-­‐/-­‐	   mixed	   glia	   cultures	   to	  
determine	  whether	   any	   change	   in	   the	   level	  of	   expression	  of	   these	  proteins,	   as	  
determined	   by	   Western	   blot	   analysis,	   could	   be	   considered	   neuron-­‐specific	  
(Figure	   6.6	   A-­‐C).	   Mixed	   glial	   cultures	   from	   both	   genotypes	   were	   shown	   to	  
express	   VAMP2	   (Figure	   6.6	   A),	   but	   no	   expression	   of	   SNAP25	   or	   synaptophysin	  
could	  be	  detected	  (Figure	  6.6	  B	  and	  C).	  Thus,	  the	  expression	  of	  these	  latter	  two	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markers	  was	  explored	  in	  co-­‐cultures	  of	  WT	  and	  Cln3-­‐/-­‐	  neurons	  with	  either	  WT	  or	  





























Figure	  6.6.	  Mixed	  WT	  and	  Cln3-­‐/-­‐	  Glia	  do	  not	  express	  SNAP25	  or	  synaptophysin.	  
The	  expression	  of	  SNARE-­‐complex	  proteins	  was	  studied	  in	  WT	  and	  Cln3-­‐/-­‐	  mixed	  glial	  cultures	  by	  
immunostaining	  cells	  for	  VAMP2,	  SNAP25	  or	  synaptophysin	  in	  association	  with	  GFAP	  and	  CD68.	  
DAPI	  was	  used	  to	  visualize	  all	  nuclei.	  (A)	  VAMP2	  was	  expressed	  by	  both	  WT	  and	  Cln3-­‐/-­‐	  astrocytes,	  
but	  neither	  (B)	  SNAP25	  nor	  (C)	  synaptophysin	  was	  expressed	  by	  WT	  or	  Cln3-­‐/-­‐	  glia.	  Scale	  bar	  in	  all	  
images	  is	  20μm.	  	  
	  
Cln3-­‐/-­‐	  glia	  alter	  the	  neuronal	  expression	  of	  synaptophysin,	  but	  not	  SNAP25	  
To	  study	   the	  distribution	  of	   synaptic	  proteins,	  7	  day	  old	   co-­‐cultures	  were	   fixed	  
and	  stained	  with	  SNAP25	  or	   synaptophysin	   in	   combination	  with	  MAP2	   (Figures	  
6.7	   A	   and	   6.7	   A).	   Additionally,	   Western	   blot	   analysis	   was	   carried	   out	   on	   cell	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lysates	   derived	   from	   7	   day	   old	   co-­‐cultures	   to	   quantify	   the	   total	   expression	   of	  
SNAP25	   and	   synatophysin	   (Figures	   6.7	   B	   and	   6.7	   B).	   Expression	   levels	   were	  
normalized	  to	  the	  levels	  of	  β-­‐actin	  in	  each	  sample.	  	  
	  
SNAP25	  staining	  was	  predominantly	   localized	   to	   the	  cell	  bodies	  of	  WT	  neurons	  
co-­‐cultured	  with	  WT	  glia,	  but	  some	  SNAP25	   immunoreactivity	  was	  visible	  along	  
their	  neurites	  (Figure	  6.7	  A,	  a).	  The	  expression	  in	  the	  cell	  soma	  was	  similar	  in	  co-­‐
cultures	  in	  which	  WT	  neurons	  were	  grown	  with	  Cln3-­‐/-­‐	  glia,	  but	  immunoreactivity	  
for	  these	  proteins	  was	  markedly	  reduced	  in	  neurites	  in	  these	  co-­‐cultures	  (Figure	  
6.7	  A,	  b).	  SNAP25	   immunoreactivity	   in	  Cln3-­‐/-­‐	  neurons	  co-­‐cultured	  with	  WT	  glia	  
appeared	  marginally	   fainter	   in	   the	   soma	  with	   fewer	  SNAP25	  expressing	  puncta	  
along	   the	   neurites,	   when	   compared	   to	   WT	   neurons	   co-­‐cultured	   with	   WT	   glia	  
(Figure	  6.7	  A	  c,	  and	  compare	  c	  to	  a).	  This	  reduction	  in	  staining	  intensity	  was	  more	  
evident	  when	  Cln3-­‐/-­‐	   neurons	  were	   co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	   (Figure	   6.7	  A	  d,	  
compared	  d	  to	  a,	  b	  and	  c).	  When	  the	  total	  expression	  of	  SNAP25	  in	  the	  cultures	  
was	  quantified	  by	  Western	  blotting,	  the	  highest	  protein	  levels	  were	  observed	  in	  
WT	  neurons	  under	  both	  co-­‐culture	  combinations	  (Figure	  6.7	  B,	  WT	  neurons/WT	  
glia:	  23.4±1.1%,	  WT	  neurons/Cln3-­‐/-­‐	  glia:	  26.1±2.8%	  when	  normalized	  to	  β-­‐actin),	  
with	  the	  presence	  of	  Cln3-­‐/-­‐	  glia	  not	  significantly	  altering	  SNAP25	  protein	  levels	  in	  
WT	  neurons.	  However,	   there	  was	   significantly	   less	   SNAP25	  expressed	   in	  Cln3-­‐/-­‐	  
neurons	   cultured	  with	   either	  WT	   or	  Cln3-­‐/-­‐	   glial	   cells	   (10.6±2.4%	   and	   5.0±0.2%	  
respectively	  when	  normalized	  to	  β-­‐actin)	  (Figure	  6.7	  B).	  Moreover,	  WT	  neurons	  
co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	  had	  significantly	  more	  SNAP25	  expression	  than	  Cln3-­‐/-­‐	  
neurons	  co-­‐cultured	  with	  either	  WT	  or	  Cln3-­‐/-­‐	  glia.	  However,	  the	  level	  of	  SNAP25	  
in	  Cln3-­‐/-­‐	  neurons	  was	  not	  significantly	  different	  when	  cultured	  with	  Cln3-­‐/-­‐	  or	  WT	  
glia,	   suggesting	   that	  Cln3-­‐/-­‐	  glia	   did	   not	   have	   any	   further	   impact	   upon	   SNAP	  25	  
levels	  in	  Cln3-­‐/-­‐	  neurons	  (Figure	  6.7	  B).	  Therefore,	  WT	  neurons	  appear	  to	  express	  
more	  SNAP25	   than	  Cln3-­‐/-­‐	  neurons,	   regardless	  of	   the	  presence	  of	  glial	   cells.	  On	  
the	  contrary,	  Cln3-­‐/-­‐	  neurons	  expressed	  more	  SNAP25	  when	  grown	  without	  glia	  
(see	  Chapter	  5,	  Figure	  5.11).	  	  	  
	   	  





































Figure	  6.7.	  Glia	  do	  not	  alter	  neuronal	  SNAP25	  expression.	  The	  distribution	  and	  total	  
expression	  of	  SNAP25	  was	  studied	  in	  WT	  and	  Cln3-­‐/-­‐	  neurons	  co-­‐cultured	  with	  WT	  or	  Cln3-­‐/-­‐	  glia.	  
Immunofluorescence	  staining	  for	  SNAP25	  in	  combination	  with	  MAP2	  was	  used	  to	  study	  protein	  
distribution,	  and	  Western	  blotting	  was	  used	  to	  quantify	  total	  protein	  expression.	  (A)	  (a)	  SNAP25	  
was	  expressed	  in	  both	  the	  cell	  body	  and	  processes	  of	  WT	  neurons	  co-­‐cultured	  with	  WT	  glia,	  (b)	  
this	   expression	  was	   reduced	   in	   the	   soma	   and	  processes	   of	  WT	  neuronal	   cells	   co-­‐cultured	  with	  
Cln3-­‐/-­‐	  glia,	   (c)	   the	  expression	  of	  SNAP25	   in	  Cln3-­‐/-­‐	  neurons	  cultured	  with	  WT	  glia	  was	  mainly	   in	  
the	  soma	  with	  some	  expression	  in	  processes,	  (d)	  the	  expression	  of	  SNAP25	  is	  reduced	  in	  the	  cell	  
body	   and	   processes	   of	   Cln3-­‐/-­‐	   neurons	   co-­‐cultured	   with	   Cln3-­‐/-­‐	   glia.	   (B)	   Total	   intracellular	  
expression	   of	   SNAP25	   (normalized	   to	   β-­‐actin)	   is	   significantly	   reduced	   in	   Cln3-­‐/-­‐	  neurons	   grown	  
with	  either	  WT	  or	  Cln3-­‐/-­‐	  glia	  when	  compared	  to	  WT	  neurons	  grown	  with	  WT	  or	  Cln3-­‐/-­‐	  glia.	  Data	  
in	  (B)	  is	  presented	  as	  mean	  percentage±SEM	  from	  three	  separate	  biological	  samples.	  Scale	  bar	  in	  
A	  is	  20	  μm.	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As	   was	   the	   case	   with	   SNAP25,	   when	   co-­‐cultured	   with	   WT	   glia,	   WT	   neurons	  
expressed	   synaptophysin	  mainly	   in	   their	   cell	   bodies	  with	   some	  expression	   also	  
evident	   in	   their	   neurites	   (Figure	   6.8	   A,	   a).	   This	   expression	   appeared	   to	   be	  
reduced	  when	  WT	  neurons	  were	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	  in	  both	  the	  cell	  body	  
and	  processes	  (Figure	  6.8	  A,	  compare	  b	  to	  a).	  The	  Cln3-­‐/-­‐	  neurons	   in	  co-­‐cultures	  
with	  WT	  glia	  displayed	  very	   few	  synaptophysin	   immunoreactive	  puncta	   in	   their	  
cell	   bodies	   and	   processes	   (Figure	   6.8	   A,	   c).	   However,	   the	   expression	   of	  
synaptophysin	   seemed	   to	   be	   increased	   in	   both	   neurites	   and	   soma	   of	   Cln3-­‐/-­‐	  
neurons	   when	   co-­‐cultured	   with	   Cln3-­‐/-­‐	   glia	   (Figure	   6.8	   A,	   d).	   Indeed,	   Cln3-­‐/-­‐	  
neurons	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	  cells	  seemed	  to	  express	  more	  synaptophysin	  
than	  WT	  neurons	  cells	  grown	  with	  WT	  glia	  cells	  (Figure	  6.8	  A,	  compare	  d	  to	  a).	  	  
	  
These	   observations	   were	   confirmed	   by	   Western	   blotting,	   with	   total	  
synaptophysin	  expression	  being	  reduced	  in	  WT	  neurons	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  
glia	  rather	  than	  WT	  glia	  (1.1±0.1%	  and	  3.3±1.3%	  respectively	  when	  normalized	  to	  
β-­‐actin),	   but	   this	   difference	   was	   not	   statistically	   significant	   (Figure	   6.8	   B).	   As	  
suggested	   by	   immunostaining,	   Cln3-­‐/-­‐	   neurons	   expressed	   significantly	   more	  
synaptophysin	  when	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	  than	  when	  co-­‐cultured	  with	  WT	  
glia	  (4.5±0.5%	  versus	  1.3±0.0%	  when	  normalized	  to	  β-­‐actin)	  (Figure	  6.8	  B).	  
	  
In	  summary,	  neither	  WT	  nor	  Cln3-­‐/-­‐	  glia	  appeared	  to	  have	  a	  significant	  impact	  on	  
the	   neuronal	   expression	   of	   SNAP25,	   which	   overall,	   was	   higher	   in	  WT	   neurons	  
than	   in	   Cln3-­‐/-­‐	   neurons.	   Interestingly	   the	   expression	   and	   distribution	   of	  
synaptophysin,	  however,	  was	  upregulated	  in	  Cln3-­‐/-­‐	  neurons	  only	  in	  the	  presence	  
of	   Cln3-­‐/-­‐	   glia.	   Thus,	   it	   appears	   that	   interactions	   between	   glia	   and	   neurons	   of	  
different	  genotypes	  result	   in	  specific	  alterations	  in	  protein	  expression,	  detected	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Figure	   6.8	   Synaptophysin	   expression	   is	   increased	   in	   Cln3-­‐/-­‐	  neurons	   by	   Cln3-­‐/-­‐	  
glia.	   The	   distribution	   and	   total	   expression	   of	   synaptophysin	   was	   studied	   in	   WT	   and	   Cln3-­‐/-­‐	  
neurons	   co-­‐cultured	  with	  WT	  or	  Cln3-­‐/-­‐	   glia.	   Immunofluorescence	   staining	   for	   synaptophysin	   in	  
combination	  with	  MAP2	  was	  used	  to	  study	  protein	  distribution	  and	  Western	  blotting	  was	  used	  to	  
quantify	  the	  total	  protein	  expression.	   (A)	   (a)	  Synaptophysin	  was	  expressed	   in	  the	  cell	  body	  and	  
less	  so	  in	  the	  processes	  of	  WT	  neurons	  co-­‐cultured	  with	  WT	  glia,	  (b)	  this	  expression	  was	  reduced	  
in	  the	  soma	  and	  processes	  of	  WT	  neurons	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia,	  (c)	  Cln3-­‐/-­‐	  neurons	  cultured	  
with	  WT	   glia	   express	   low	   levels	   of	   synaptophysin	   mainly	   in	   their	   soma,	   (d)	   the	   expression	   of	  
SNAP25	  was	  high	  in	  both	  the	  soma	  and	  processes	  in	  Cln3-­‐/-­‐	  neurons	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia.	  
(B)	  Total	  expression	  of	  synaptophysin	  (normalized	  to	  β-­‐actin)	  was	  significantly	  reduced	  in	  Cln3-­‐/-­‐	  
neurons	   grown	   with	   WT	   glia	   compared	   to	   when	   grown	   with	   Cln3-­‐/-­‐	   glia.	   No	   other	   significant	  
differences	  were	   found.	  Data	   in	   (B)	   is	   presented	   as	  mean±SEM	   from	   three	   separate	   biological	  
samples.	  Scale	  bar	  in	  A	  is	  20	  μm.	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6.3	  Discussion	  	  
In	  this	  chapter,	  mixed	  glial-­‐neuronal	  co-­‐cultures	  were	  used	  to	  explore	  the	  impact	  
of	  Cln3-­‐/-­‐	  glia	  (both	  astrocytes	  and	  microglia)	  upon	  neuronal	  survival,	  morphology	  
and	  synaptic	  organization.	  Cln3-­‐/-­‐	  glia	  were	  observed	  to	  have	  a	  negative	   impact	  
on	   the	   survival	   and	   morphology	   of	   both	   WT	   and	   Cln3-­‐/-­‐	   neurons,	   with	   Cln3-­‐/-­‐	  
neurons	  being	  particularly	  vulnerable.	  In	  contrast,	  WT	  glia	  had	  a	  positive	  impact	  
on	  Cln3-­‐/-­‐	  neuron	  survival	  and	  morphology;	  increasing	  cell	  soma	  size	  and	  overall	  
neurite	  complexity.	  In	  addition,	  specific	  alterations	  in	  the	  expression	  of	  synaptic	  
proteins	  were	  discovered.	  While	  SNAP25	  expression	  was	  not	   influenced	  by	   the	  
presence	   of	   glia	   of	   either	   genotype,	   Cln3-­‐/-­‐	   glia	   induced	   an	   increase	   in	  
synaptophysin	  expression,	  but	  only	  in	  Cln3-­‐/-­‐	  neurons.	  These	  studies	  provide	  the	  
first	  direct	  link	  between	  the	  compromised	  biology	  of	  Cln3-­‐/-­‐	  glia	  and	  neuron	  loss	  
in	   JNCL,	   indicating	   that	   these	  cells	  are	  key	  players	   in	   the	  pathogenesis	  of	   JNCL.	  
Such	   information	   may	   ultimately	   be	   used	   to	   design	   novel	   therapies	   for	   this	  
disease,	  based	  on	  inhibiting	  the	  negative	  effects	  of	  altered	  glial	  biology.	  	  
	  
Why	  are	  Cln3-­‐/-­‐	  glia	  harmful	  to	  other	  neural	  cell	  types?	  
Mixed	   cultures	   of	   Cln3-­‐/-­‐	   glia	   had	   a	   negative	   impact	   on	   neurons	   of	   both	  
genotypes,	  and	  these	  became	  more	  apparent	  with	   increased	  time	   in	  co-­‐culture	  
(after	   7	  DIV),	   suggesting	   that	   the	  harmful	   effects	   of	  Cln3-­‐/-­‐	   glia	   are	   cumulative.	  
This	   is	   consistent	   with	   in	   vivo	   findings	   in	   JNCL	   mouse	   models,	   where	   glial	  
activation	   takes	   place	   early	   in	   the	   disease	   process	   and	   is	   followed	   by	  
neurodegeneration	   in	   the	   same	   brain	   regions	   (Pontikis	   et	   al.,	   2004;	   2005).	   In	  
addition	   to	   the	   toxicity	   of	   Cln3-­‐/-­‐	   glia,	   Cln3	  deficient	   neurons	   also	   appeared	   to	  
induce	   the	   death	   of	   WT	   astrocytes,	   suggesting	   that	   abnormal	   glial-­‐neuron	  
communication	  may	   exist	   in	   the	  Cln3-­‐/-­‐	  mouse	   brain.	   This	   astrocyte	   death	  was	  
not	  apparent	  in	  co-­‐cultures	  of	  Cln3-­‐/-­‐	  neurons	  and	  glia,	  possibly	  because	  the	  toxic	  
effect	  of	  the	  Cln3-­‐/-­‐	  glia	  on	  Cln3-­‐/-­‐	  neurons	  was	  the	  more	  dominant,	  since	  in	  these	  
co-­‐cultures	  neuronal	  death	  was	  already	  apparent	  after	  2	  DIV	  but	   the	  effects	  of	  
Cln3-­‐/-­‐	  neurons	  on	  astrocytes	  was	  not	  evident	  at	  this	  stage	  (see	  Chapter	  6,	  Figure	  
6.2).	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Healthy	   glial	   cells	   are	   known	   to	   support	   neuronal	   survival	   in	   many	   ways.	   For	  
instance,	   they	   regulate	   extracellular	   potassium	   and	   thus	   regulate	   neuronal	  
excitability,	   they	   sequester	   neurotrasmitters	   from	   the	   synaptic	   cleft	   to	   inhibit	  
their	  toxic	  accumulation,	  they	  secrete	  bioactive	  factors	  like	  the	  energy	  substrate	  
lactate	   and	   neurotrophic	   factors	   like	   NGF,	   FGFs	   and	   VEGF,	   and	   respond	   to	  
neuron	   derived	   neuropeptides	   such	   as	   vasoactive	   intestinal	   peptide	   (VIP)	   by	  
secreting	   neuroprotective	   factors	   including	   activity-­‐dependent	   neuroprotective	  
protein	   (ADNP)	   (Vernadakis,	  1988;	  Vernadakis	  and	  Mangoura,	  1988;	  Ang	  et	  al.,	  
1992;	  Martin,	  1992;	  Sass	  et	  al.,	  1993;	  Schmalenbach	  and	  Müller,	  1993;	  Giulian	  et	  
al.,	  1994;	  Wang	  et	  al.,	  1994;	  Gallo	  et	  al.,	  2000;	  Aloisi,	  2001;	  Furman	  et	  al.,	  2004;	  
Garden	  and	  Möller,	  2006;	  Liu	  et	  al.,	  2011;	  Singh	  et	  al.,	  2011;	  Pascual	  et	  al.,	  2012).	  
Given	  that	  glia	  carry	  out	  such	  a	  diverse	  range	  of	  functions	  to	  support	  neurons,	  it	  
is	   not	   surprising	   that	   impaired	   glial	   biology	   has	   been	   found	   to	   contribute	   to	  
neuronal	  dysfunction	  and	  loss	  in	  several	  CNS	  disorders,	  including	  MSD,	  NPC,	  ALS,	  
Alzheimer,	  Parkinson,	  and	  Huntington	  diseases	  (Garden	  and	  Möller,	  2006;	  Chen	  
et	  al.,	  2007;	  Zhang	  et	  al.,	  2008;	  Rossi	  and	  Volterra,	  2009;	  Möller,	  2010;	  Zhang	  et	  
al.,	  2010;	  Garwood	  et	  al.,	  2011;	  Kettenmann	  and	  Verkhratsky,	  2011;	  Panaro	  and	  
Cianciulli,	   2012;	   Phani	   et	   al.,	   2012;	   Tufekci	   et	   al.,	   2012;	  Di	  Malta	   et	   al.,	   2012a;	  
2012b).	  From	  experiments	  described	  in	  this	  thesis,	  we	  have	  observed	  that	  under	  
resting	   conditions	   Cln3-­‐/-­‐	   astrocytes	   displayed	   an	   impaired	   inability	   to	   take	   up	  
glutamate	  (Chapter	  4,	  Figure	  4.11)	  and	  had	  abnormal	  Ca2+	  signaling	  (Chapter	  4,	  
Figures	   4.1-­‐4.6).	   These	   deficits	   could	   directly	   impact	   neurons	   since	   impaired	  
glutamate	  clearance	  could	  lead	  to	  the	  induction	  of	  excitotoxity	  and	  altered	  Ca2+	  
signaling	  could	  impair	  neuron-­‐astrocyte	  and	  astrocyte-­‐astrocyte	  communication	  
(See	   discussion	   in	   Chapter	   4,	   Section	   4.3).	   Under	   basal	   conditions,	   Cln3-­‐/-­‐	  
microglia	  did	  not	  display	  any	  overt	   functional	  deficits	   (S.	  Dihanich,	  unpublished	  
data).	  Thus,	  neuronal	  loss	  caused	  by	  Cln3-­‐/-­‐	  glia	  in	  these	  co-­‐cultures	  may	  initially	  
be	  astrocyte-­‐driven.	  
	  
It	  has	  been	  suggested	  that	  glial-­‐regulated	  neuronal	  survival	   in	  vitro	   is	  mediated	  
at	  least	  partly	  by	  secreted	  soluble	  factors	  (Fishell	  and	  Hatten,	  1991).	  Under	  basal	  
conditions,	  Cln3-­‐/-­‐	   astrocytes	   secreted	   lower	   levels	   of	   the	  mitogen,	  M-­‐CSF,	   the	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chemokines,	  MIP-­‐1γ,	  GCP-­‐2	   (glutamate	   carboxypeptidase	   -­‐2	  metalloproteinase)	  
and	  TIMP-­‐1,	  but	   increased	  levels	  of	  tissue	  factor	  (see	  Chapter	  4,	  Tables	  4.1	  and	  
4.2).	  The	   implications	  of	   these	   secretion	  defects	  may	  be	  many	   fold	   since	   these	  
factors	   may	   act	   on	   both	   glia	   and	   neurons,	   having	   both	   harmful	   and	  
neuroprotective	  properties	   (Eddleston	  et	  al.,	  1993;	  Liu	  et	  al.,	  1994;	  Fujimoto	  et	  
al.,	  2008;	  Semple	  et	  al.,	  2010;	  Rostène	  et	  al.,	  2011;	  Sidoryk-­‐Wegrzynowicz	  et	  al.,	  
2011).	  For	  instance,	  M-­‐CSF	  is	  a	  hematopoietic	  cytokine	  that	  is	  secreted	  by	  both	  
neurons	   and	   glia.	   This	   cytokine	   induces	   microglial	   activation,	   enhancing	   their	  
proliferation,	  protein	  secretion	  and	  autophagy	   (Imai	  and	  Kohsaka,	  2002;	  Hamill	  
et	  al.,	  2005).	  Since,	  microglial	  activation	  has	  been	  associated	  with	  neuronal	  loss	  
via	   production	   of	   potentially	   toxic	   cytokines,	   reactive	   oxygen	   and	   nitrogen	  
species,	   and	  prostaglandins	   (McGeer	  and	  McGeer,	  2002;	  Nau	  and	  Brück,	  2002;	  
Danton	   and	   Dietrich,	   2003),	   M-­‐CSF	   might	   be	   considered	   to	   be	   detrimental	   to	  
neurons.	   However,	   this	   factor	   has	   also	   been	   shown	   to	   have	   neuroprotective	  
properties	   both	   in	   vivo	   and	   in	   vitro	   (Berezovskaya	   et	   al.,	   1996;	   Fedoroff	   et	   al.,	  
1997;	   Bruccoleri	   and	   Harry,	   2000;	   Vincent	   et	   al.,	   2002a;	   2002b).	   Additionally,	  
increased	   microglial	   expression	   of	   the	   M-­‐CSF	   receptor	   was	   found	   to	   be	  
neuroprotective	   in	   a	   microglia-­‐hippocampal	   organotypic	   co-­‐culture	   system	  
(Mitrasinovic	   et	   al.,	   2005).	   Thus,	   reduced	   M-­‐SCF	   secretion	   in	   co-­‐cultures	   with	  
Cln3-­‐/-­‐	   astrocytes	   could	   lead	   to	   altered	   microglial-­‐mediated	   neuroprotection.	  
Furthermore,	   abnormal	   regulation	   of	   GCP-­‐2,	   which	   is	   produced	   mainly	   by	  
astrocytes	   in	   the	   adult	   CNS,	   has	   been	   associated	   with	   various	   neurological	  
disorders,	   including	   ischemia,	   epilepsy	  and	  ALS	   (Tsai	   et	   al.,	   1991;	  Meyerhoff	   et	  
al.,	   1992a;	   1992b;	   Passani	   et	   al.,	   1997;	   Ghadge	   et	   al.,	   2003).	   GCP-­‐2	   is	   a	   key	  
mediator	   of	   glutamate	   signaling	   since	   it	   may	   either	   cleave	   N-­‐
acetylaspartylglutamate	   (NAAG)	   to	   release	   glutamate	   and	   N-­‐acetylaspartate	  
(NAA),	  and/or	  be	   indirectly	   involved	   in	  NAAG-­‐metabotropic	  glutamate	  signaling	  
(Zhou	  et	  al.,	  2005).	  The	  importance	  of	  this	  proteinase	  in	  the	  CNS	  is	  highlighted	  by	  
the	  fact	  that	  mice	  with	  an	  exon	  9/10	  deletion	  in	  the	  Gcp-­‐2	  gene	  are	  embryonic	  
lethal	   (Bacich	   et	   al.,	   2002;	   Tsai	   et	   al.,	   2003).	   Perhaps,	   the	   attenuated	   GCP-­‐2	  
secretion	   by	   Cln3-­‐/-­‐	   astrocytes,	   together	   with	   their	   reduced	   ability	   to	   take	   up	  
glutamate,	   results	   in	   aberrant	   glutamate	   signaling	   within	   these	   co-­‐cultures	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leading	   to	  excitotoxicity.	  Recently,	  GCP-­‐2	  activity	  has	  also	  been	   linked	  with	   the	  
degradation	  of	  Aß	  monomers	  and	  prevention	  of	  Aß-­‐induced	  neurotoxicity	   (Kim	  
et	   al.,	   2010a).	   Interestingly,	   altered	   processing	   of	   amyloid	   β-­‐protein	   precursor,	  
particularly	   in	   neurons,	   has	   also	   been	   reported	   in	   JNCL	   patient	   samples	  
(Wisniewski	  et	  al.,	  1990;	  Golabek	  et	  al.,	  2000).	  Thus,	   lack	  of	  GCP-­‐2	  secretion	  by	  
astrocytes	   in	   vivo	   could	   lead	   to	   accumulation	   of	   unprocessed	   Aß	   leading	   to	  
neuronal	   loss	   in	   JNCL.	   This	   theory,	   however,	   needs	   to	   be	   subjected	   to	   further	  
experimental	   verification.	   Furthermore,	   reduced	   TIMP-­‐1	   secretion	   could	   be	  
involved	   in	   the	   attenuated	   neurite	   growth	   observed	   in	   co-­‐cultures	  with	  Cln3-­‐/-­‐	  
glia	  (discussed	  below).	  Thus,	  the	  observed	  changes	  in	  protein	  secretion	  by	  Cln3-­‐/-­‐	  
astrocytes	  grown	  under	  basal	   conditions	  have	   the	  potential	   to	  adversely	  affect	  
neurons.	   However,	   interpreting	   the	   impact	   of	   altered	   protein	   secretion	   upon	  
neuronal	  health	  is	  difficult	  given	  that	  many	  of	  the	  factors	  secreted	  by	  glia	  display	  
multiple,	   context-­‐dependent	   functions,	   as	   discussed	   earlier	   (see	   discussion	   in	  
Chapter	  4,	   Section	  4.3).	   Furthermore,	   the	  protein	   secretion	  profile	  of	  microglia	  
and	  astrocytes	  may	  differ	  when	  these	  cell	  types	  are	  cultured	  alone,	  rather	  than	  
as	  mixed	  glia	  cultures	  or	   in	  co-­‐cultures	  with	  neurons	  (as	   in	  the	  protein	  profiling	  
studies	  described	   in	   (Zietlow	  et	  al.,	  1999;	  Petegnief	  et	  al.,	  2001;	  Crocker	  et	  al.,	  
2004;	  Jack	  et	  al.,	  2005;	  Saura,	  2007;	  Welser-­‐Alves	  et	  al.,	  2011).	  As	  such,	  it	  will	  be	  
important	   in	   the	   future	   to	   study	   protein	   secretion	   in	   both	  mixed	   glia	   cultures,	  
and	   in	  co-­‐cultures.	  Ultimately,	   the	  secretion	  of	   these	  soluble	   factors	  within	   the	  
CNS	  should	  also	  be	  investigated	  in	  vivo,	  even	  if	  this	  is	  a	  very	  challenging	  task,	  due	  
to	  these	  factors	  being	  expressed	  at	  low	  levels	  and	  the	  difficulty	  in	  isolating	  tissue	  
samples	   that	  are	   free	   from	  cytosolic	   contamination	   (Tracey	  and	  Cerami,	  1993).	  
However,	  overall	  quantification	  of	  soluble	  factor	  levels	  in	  vivo	  could	  be	  achieved	  
by	  measuring	   specific	   proteins	  with	   immuno	   assays	   (such	   as	   ELISAs)	   from	  CNS	  
homogenates	  derived	   from	  WT	  or	  Cln3-­‐/-­‐	  mice.	  Alternatively,	   secreted	   levels	  of	  
proteins	   in	   the	   CNS	   could	   be	   measured	   via	   microdialysis	   probes	   that	   allow	  
repeated	   sampling	   from	   freely	   moving	   mice,	   and	   permit	   the	   measurement	   of	  
metabolites	  in	  the	  extracellular	  fluid	  (Woodroofe	  et	  al.,	  1991;	  Merali	  et	  al.,	  1997;	  
Linthorst	  et	  al.,	  2000).	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Upon	   activation,	   the	  differences	   in	   the	   secretion	  profiles	   of	  WT	   and	  Cln3-­‐/-­‐	  glia	  
become	   more	   striking,	   with	   both	   Cln3-­‐/-­‐	   astrocytes	   and	   microglia	   failing	   to	  
secrete	  a	  range	  of	  proteins,	  although	  astrocytes	  are	  the	  more	  severely	  affected	  
(Chapter	   4,	   S.	   Dihanich,	   unpublished	   data).	   As	   discussed	   in	   Chapter	   4,	   these	  
changes	  have	  the	  potential	  to	  be	  detrimental	  to	  neuronal	  health.	  This	  is	  relevant	  
when	  it	  comes	  to	  hypothesizing	  why	  Cln3-­‐/-­‐	  glia	  might	  have	  a	  more	  pronounced	  
effect	  on	  Cln3-­‐/-­‐	  neurons,	  since	   in	  this	  co-­‐culture	  combination	  astrocytes	  appear	  
morphologically	  activated,	  particularly	  after	  7	  day	  in	  culture	  (see	  Figure	  6.3).	  The	  
cell	   bodies	   of	   these	   Cln3-­‐/-­‐	   astrocytes	   are	   shrunken	   and	   they	   have	   extended	  
processes	   resembling	   cultured	   astrocytes	   that	   are	   activated	   (Hu	   et	   al.,	   1998a;	  
1998b;	   Paradisi	   et	   al.,	   2004;	   Garwood	   et	   al.,	   2011).	   Therefore,	   this	   raises	   the	  
possibility	   that	  Cln3-­‐/-­‐	  neurons	  secrete	  a	  cocktail	  of	  astrocyte-­‐activating	   factors.	  
Indeed,	   in	   vitro	   studies	   have	   shown	   that	   FGF-­‐1	   released	   by	   motor	   neurons	  
exposed	   to	   oxidative	   stress,	   as	   could	   be	   caused	   by	   attenuated	   glutathione	  
secretion	   (see	   Chapter	   4,	   Figure	   4.9),	   can	   activate	   astrocytes	   (Cassina	   et	   al.,	  
2005).	   These	   activated	   astrocytes	   then	   initiated	   motor	   neuron	   apoptosis	   via	  
activation	   of	   the	   p75	   neurotrophin	   receptor	   (p75(NTR))	   (Cassina	   et	   al.,	   2005),	  
which	  is	  a	  member	  of	  tumor	  necrosis	  factor	  receptor	  superfamily	  (Dechant	  and	  
Barde,	  2002;	  Nykjaer	  et	  al.,	  2005),	  and	  is	  also	  known	  to	  be	  expressed	  by	  cultured	  
mouse	  cortical	  neurons	  (Lemkuil	  et	  al.,	  2011;	   Ibáñez	  and	  Simi,	  2012;	  Sun	  et	  al.,	  
2012).	  Thus,	  Cln3-­‐/-­‐	  neurons	  may	  initiate	  activation	  of	  astrocytes	  and	  in	  doing	  so	  
may	  aid	  their	  own	  death.	  	  
	  
One	   feature	   common	   to	   both	   Cln3-­‐/-­‐	   microglia	   and	   astrocytes	   was	   that,	   upon	  
isolation,	   both	   of	   these	   glial	   cell	   types	   appeared	  more	   activated	   than	  WT	   glia	  
(Chapter	   3,	   Figure	   3.6	   and	   S.	   Dihanich,	   unpublished	   data).	   Cln3-­‐/-­‐	   astrocytes	  
displayed	   increased	  GFAP	   immunoreactivity,	  while	  more	  Cln3-­‐/-­‐	  microglia	   had	   a	  
swollen	   cell	   body	  and	  had	   retracted	   their	  processes.	   Therefore,	   some	   signaling	  
cascades	   involved	   in	   glia	   activation	   may	   have	   already	   been	   initiated	   in	   vivo,	  
possibly	   due	   to	   the	   diseased	   environment.	   Equally,	   mutant	   glia	   may	   be	   more	  
sensitive	   to	   the	   isolation	   procedure,	   or	   to	   being	   maintained	   in	   culture.	  
Regardless,	  these	  changes	  could	  have	  an	  impact	  on	  the	  biology	  of	  the	  Cln3-­‐/-­‐	  glia	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used	  in	  these	  co-­‐cultures,	  even	  in	  the	  absence	  of	  further	  exogenous	  stimulation.	  
Indeed,	   activated	   astrocytes	   have	   previously	   been	   shown	   to	   cause	   neuronal	  
death,	   as	   well	   as	   increased	   neuronal	   susceptibility	   to	   1-­‐methyl-­‐4-­‐
phenylpyridinium	  (MPP+)	  and	  6-­‐hydroxydopamine	  (6-­‐OHDA)	  induced	  toxicity,	  in	  
a	  co-­‐culture	  system	  (McNaught	  and	  Jenner,	  1999).	  This	  toxic	  effect	  was	  partially	  
rescued	   either	   by	   addition	   of	   the	   NMDA/glutamate	   antagonist	   MK-­‐801,	   by	  
glutathione	   application	   or	   by	   inhibition	   of	   excess	   NO	   production.	  Moreover,	   it	  
has	  been	  reported	  that	  increased	  NO	  and	  NOS	  production	  by	  activated	  microglia	  
induced	  the	  death	  of	  co-­‐cultured	  cerebellar	  granule	  neurons,	  and	  that	  this	  effect	  
could	   be	   partially	   blocked	   by	   using	   an	   inhibitor	   of	   NO	   synthase	   (NG-­‐
nitroarginine),	   deactivation	   of	   NO	   with	   oxyhemoglobin,	   NMDA-­‐blockage	   with	  
MK-­‐801	   and	   APV,	   or	   stabilization	   of	   NO	   with	   superoxide	   dismutase	   (Boje	   and	  
Arora,	  1992).	  Hence,	   if	  Cln3-­‐/-­‐	  glia	  cells	  are	   ‘more	  activated’	  upon	   isolation	  they	  
could	  cause	  neuron	  loss	  via	  mechanisms	  involving	  overstimulation	  of	  glutamate	  
receptors,	   NO	   and	   NOS	   toxicity	   and/or	   collapse	   of	   the	   anti-­‐oxidant	   defense	  
system.	   Further	   support	   for	   this	   hypothesis	   comes	   from	   data	   linking	   CLN3	  
deficiency	  with	  abnormal	  NO	  signaling,	  as	  well	  as	  with	  enhanced	  oxidative	  stress	  
(Ramirez-­‐Montealegre	  and	  Pearce,	  2005;	  Benedict	  et	  al.,	  2007;	  Chan	  et	  al.,	  2009;	  
Tuxworth	  et	  al.,	  2011).	  Consistent	  with	  this,	  the	  lack	  of	  glutathione	  secretion	  by	  
Cln3-­‐/-­‐	  astrocytes	  may	  lead	  to	  increased	  oxidative	  stress,	  and	  potentially	  change	  
the	   neurotrophic	   effect	   of	   NO	   into	   a	   neurotoxic	   effect	   by	   compromising	   the	  
neuronal	   mitochondrial	   electron	   transport	   chain	   (ETC)	   and	   thus	   energy	  
production,	   triggering	   programmed	   cell	   death	   (Heales	   et	   al.,	   1996;	   Dringen,	  
2000;	   Canals	   et	   al.,	   2001;	   Gegg	   et	   al.,	   2005).	   Lack	   of	   CLN3	   has	   already	   been	  
associated	  with	  mitochondrial	  dysfunction,	  since	  the	  mitochondrial	  ATP	  synthase	  
subunit	  c	  is	  the	  major	  component	  of	  the	  storage	  material	  in	  JNCL.	  In	  addition,	  the	  
size	  and	  morphology	  of	  mitochondria	  is	  altered	  in	  different	  neuronal	  cell	  models	  
derived	  from	  Cln3-­‐/-­‐	  or	  Cln3Δex7/8	  mice	  (Fossale	  et	  al.,	  2004;	  Luiro	  et	  al.,	  2006),	  and	  
mitochondrial	   enzymes,	   such	   as	   ATP	   synthase,	   have	   been	   suggested	   to	   be	  
dysfunctional	  in	  patient	  fibroblasts	  and	  in	  the	  brains	  of	  Cln3-­‐/-­‐	  mice	  (Majander	  et	  
al.,	   1995;	  Das	   and	  Kohlschütter,	   1996;	  Dawson	  et	   al.,	   1996;	   Luiro	  et	   al.,	   2006).	  
Altered	   levels	   of	   high-­‐energy	   phosphate	   compounds	   are	   evident	   in	   patient	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fibroblasts	   (50%	   reduction	   in	   ATP	   levels,	   30%	   reduction	   in	   adenosine	  
diphosphate	   (ADT)	   levels)	   and	   in	   cerebellar	   precursor	   cells	   derived	   from	  
Cln3Δex7/8	  mice	  (1.3	  fold	  reduction	  in	  ATP	  compared	  to	  WT	  cells)	  (Das	  et	  al.,	  2001;	  
Fossale	   et	   al.,	   2004).	   Thus,	   toxicity	   resulting	   from	   reactive	   oxygen/nitrogen	  
species,	   together	   with	   reduced	   mitochondrial	   energy	   production	   could	  
potentially	  also	  contribute	  to	  neuronal	  cell	   loss	  in	  these	  co-­‐cultures,	  and	  should	  
be	   investigated	   further.	   Accumulation	   of	   reactive	   oxygen	   and	   nitrogen	   species	  
could	  be	  measured	  directly	  using	  commercially	  available	  fluorescent	  probes	  such	  
as	   dichlorodihydrofluorescein	   diacetate	   (DCFH-­‐DA),	   for	   measuring	   intracellular	  
H2O2	   and	  other	   oxidants,	   and	  dihydrorhodamine	   (DHR)	   for	  measuring	   nitrogen	  
species	   (Uy	   et	   al.,	   2011;	   Kalyanaraman	   et	   al.,	   2012).	   Finally,	   inhibitors	   of	   NO	  
synthesis	  or	  deactivation	  of	  NO,	  anti-­‐oxidant	  treatments	  and	  glutamate	  receptor	  
blockage	   could	   all	   be	   tested	   in	   these	   co-­‐cultures	   to	   investigate	  whether	   these	  
mechanisms	   contribute	   to	   the	   observed	   neuronal	   loss	   (Bolaños	   et	   al.,	   1997;	  
Dringen	  et	  al.,	  1999b;	  Dringen,	  2000;	  Dringen	  et	  al.,	  2001;	  Kemp	  and	  McKernan,	  
2002;	  Heales	  et	  al.,	  2004;	  Wu	  et	  al.,	  2004;	  Duncan	  and	  Heales,	  2005;	  Gegg	  et	  al.,	  
2005).	  	  
	  
The	  impaired	  Ca2+-­‐based	  intercellular	  communication	  between	  Cln3-­‐/-­‐	  astrocytes	  
that	  we	  have	  documented	   (see	  Chapter	   4,	   Figures	   4.1-­‐4.6)	   could	   prevent	   their	  
ability	   to	   synchronize	   any	   activities	   aimed	   to	   support	   neuronal	   survival.	   For	  
example,	   increased	   spontaneous	   Ca2+	   oscillations	   in	   astrocytes	   induced	   by	   Aß,	  
whose	  accumulation	  is	  the	  hallmark	  of	  Alzheimer	  disease,	  was	  demonstrated	  to	  
increase	  the	  death	  of	  co-­‐cultured	  neurons	  (Abramov	  et	  al.,	  2003).	  This	  neuronal	  
death	   was	   associated	   with	   Ca2+-­‐dependent	   glutathione	   depletion	   in	   both	  
astrocytes	  and	  neurons.	  We	  have	  shown	  that	  spontaneous	  Ca2+-­‐oscillations	  were	  
altered	  in	  Cln3-­‐/-­‐astrocytes	  (see	  Chapter	  4,	  Figures	  4.1.	  and	  4.2),	  which	  could	  help	  
explain	  the	  observed	  accumulation	  of	  glutathione	  within	  these	  cells	  (Chapter	  4,	  
Figure	  4.9).	  Subsequently,	  this	  could	  result	  in	  depletion	  of	  neuronal	  glutathione,	  
whose	   production	   is	   dependent	   on	   substrates	   derived	   from	   the	   glutathione	  
secreted	   by	   astrocytes,	   accelerating	   their	   death	   in	   co-­‐cultures	   with	   Cln3-­‐/-­‐	  glia.	  
Additionally,	   this	   abnormal	   Ca2+	   signaling	   may	   be	   further	   impaired	   by	   the	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mitochondrial	   dysfunction	   that	   has	   been	   suggested	   to	   be	   associated	  with	  Cln3	  
deficiency,	  leading	  to	  reduced	  ATP	  (Majander	  et	  al.,	  1995;	  Das	  and	  Kohlschütter,	  
1996;	  Dawson	  et	  al.,	  1996;	  Das	  et	  al.,	  2001;	  Fossale	  et	  al.,	  2004;	  Luiro	  et	  al.,	  2006;	  
Padilla-­‐Lopez	   and	   Pearce,	   2006).	   ATP	   released	   upon	   spontaneous	   Ca2+	  
oscillations	   in	   astrocytes	   has	   been	   shown	   to	   activate	   microglia,	   triggering	   the	  
production	   and	   release	   of	   a	   number	   of	   pleotrophic	   cytokines	   such	   as	   IL-­‐1β,	   or	  
neuronal	   survival	  promoting	   trophic	   factors	   such	  as	  FGFs,	  NGF,	  NT-­‐3	  and	  CNTF	  
(Verderio	  and	  Matteoli,	  2001;	  Hansson	  and	  Rönnbäck,	  2003;	  Bianco	  et	  al.,	  2005).	  
Thus,	   impaired	  Ca2+	   signaling	  observed	   in	  Cln3-­‐/-­‐	  astrocytes	  may	  not	  only	   cause	  
problems	   for	   astrocyte	   function,	   but	   may	   also	   inhibit	   mechanisms	   involved	   in	  
microglial-­‐mediated	  neuronal	  survival.	  	  
	  
In	   co-­‐culture	   experiments,	   Cln3-­‐/-­‐	   neurons	   were	   observed	   to	   be	   far	   more	  
vulnerable	   than	  WT	   neurons,	   when	   grown	   with	   Cln3-­‐/-­‐	  glia.	  While	   this	   may,	   in	  
part,	  be	  due	  to	  Cln3-­‐/-­‐	  glia	  being	  activated	  when	  cultured	  with	  Cln3-­‐/-­‐	  neurons	  (as	  
discussed	   above),	   it	   is	   also	   possible	   that	   Cln3-­‐/-­‐	   neurons	   have	   already	   been	  
sensitized	  by	   loss	  of	   the	  CLN3	  protein	  prior	   to	   isolation,	  or	  during	   the	   isolation	  
and	   culturing	   procedure.	   Cln3	   mRNA	   levels	   have	   been	   shown	   to	   be	   highest	  
during	   brain	   development	   and	   at	   early	   post-­‐natal	   stages,	   suggesting	   that	   the	  
protein	  is	  particularly	  required	  at	  these	  times	  (Mitchison	  et	  al.,	  1999;	  Pane	  et	  al.,	  
1999).	  Furthermore,	  it	  has	  been	  suggested	  that	  CLN3	  can	  interact	  with	  calsenilin	  
(Chang	   et	   al.,	   2007),	   which	   is	   a	   Ca2+-­‐binding	   protein	  with	   apoptosis	   enhancing	  
ability	  (Jo	  et	  al.,	  2001;	  Lilliehook	  et	  al.,	  2002).	  Indeed,	  CLN3	  deficiency	  has	  been	  
shown	   to	   accelerate	   neuronal	   cell	   death	   induced	   by	   high	   Ca2+	   (Chang	   et	   al.,	  
2007).	  This	  could	  suggest	  that	  CLN3	  may	  have	  anti-­‐apoptotic	  properties	  (Lane	  et	  
al.,	   1996;	   Puranam	   et	   al.,	   1999;	   Narayan	   et	   al.,	   2006a),	   although	   there	   is	   no	  
convincing	   evidence	   that	   this	   is	   the	   case.	   Nevertheless,	   Cln3-­‐/-­‐	   neurons	   would	  
therefore	  be	  more	  susceptible	   to	  apoptosis	   than	  WT	  neurons.	  Additionally,	   the	  
distally	   located	   AIS	   in	   Cln3-­‐/-­‐	   neurons	   (see	   Chapter	   5,	   Figures	   5.5	   and	   5.6)	  
suggests	   that	   these	  cells	  are	   in	  a	   state	  of	  overstimulation	   (Grubb	  and	  Burrone,	  
2010b),	  which	  could	  also	  add	  to	  their	  vulnerability.	  One	  can	   image	  that	  the	  AIS	  
was	   moved	   distally	   in	   an	   attempt	   to	   protect	   Cln3-­‐/-­‐	   neurons	   from	   increased	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excitation	   due	   to	   a	   diseased	   environment,	   perhaps	   contributed	   to	   by	  
dysfunctional	  glial	  cells	  (Schafer	  et	  al.,	  2009;	  Grubb	  and	  Burrone,	  2010b).	  Indeed,	  
neurons	   in	   different	   mouse	   models	   of	   JNCL	   display	   increased	   vulnerability	  
towards	  AMPA	  and	  NMDA	  receptors-­‐mediated	  excitotoxicity	  (Kovács	  et	  al.,	  2006;	  
Finn	  et	  al.,	  2011),	  and	  attenuating	  AMPA-­‐receptor	  activity	  resulted	   in	   improved	  
motor	   performance	   and	   pathology	   in	   Cln3-­‐/-­‐	   mice	   (Kovács	   and	   Pearce,	   2008;	  
Kovács	  et	  al.,	  2012).	  Based	  on	  these	  observations,	  the	  neuroprotective	  power	  of	  
selective	  AMPA-­‐	  and	  NMDA-­‐receptor	  antagonists	  could	  be	  explored	  in	  these	  co-­‐
culture	   systems	   to	   attempt	   to	   protect	   against	   neuronal	   cell	   death	   inflicted	   by	  
Cln3-­‐/-­‐	  glia.	  	  
	  
It	  is	  also	  possible	  that	  Cln3-­‐/-­‐	  neurons	  may	  be	  more	  susceptible	  to	  Cln3-­‐/-­‐	  glia	  due	  
to	  differences	   in	   receptor	   expression,	   particularly	   receptors	   for	   survival	   factors	  
such	   as	   TrkA	   and	   TrkB	   expressed	   by	   neurons	   within	   the	   cerebral	   cortex	  
(McMillan	  et	  al.,	  1996;	  Lee	  et	  al.,	  1998;	  Miller	  and	  Pitts,	  2000;	  Luiro	  et	  al.,	  2004;	  
Makkerh	   et	   al.,	   2005;	   Bruns	   and	   Miller,	   2007a;	   2007b;	   Walkley,	   2009).	  
Diminished	   receptor	   expression	   and	   recycling	   via	   signaling	   endosomes	   in	  
affected	  neuronal	  populations	   could	  accelerate	  neuronal	  dysfunction	  and	  drive	  
neurodegeneration	   (Blesch,	   2006;	   Twiss	   et	   al.,	   2006;	   Bronfman	   et	   al.,	   2007;	  
Walkley,	  2009).	   For	   instance,	   the	  expression	   levels	  of	   the	  TrkA	   receptor,	  which	  
binds	  NGF,	  has	  been	  found	  to	  be	  significantly	  reduced	  in	  different	  brains	  regions	  
of	   Alzheimer	   disease	   patients	   (Boissière	   et	   al.,	   1996;	   Hock	   et	   al.,	   1998;	   2000;	  
Counts	  and	  Mufson,	  2005),	  and	  in	  Parkinson	  disease	  (Nagatsu	  et	  al.,	  2000;	  Tong	  
et	   al.,	   2009).	   Furthermore,	   in	   embryonic	   striatal	   neurons	   derived	   from	  Npc1-­‐/-­‐	  
mice	  (model	   for	  Niemann-­‐Pick	  disease),	  TrkB	  signaling	  has	  been	  reported	  to	  be	  
severely	   compromised	   causing	   unresponsiveness	   to	   neurotrophins,	   and	   was	  
proposed	   to	   be	   one	   the	   neurodegenerative	   mechanisms	   in	   this	   disease	  
(Henderson	   et	   al.,	   2000).	   It	   was	   also	   suggested	   that	   typical	   cholesterol	  
accumulation	   in	   late	   endosomes/multivesicular	   bodies	   (MVBs)	   in	   Npc1-­‐/-­‐	   cells	  
alters	   the	   ability	   of	   these	   organelles	   to	   traffic	   Trks	   via	   impacting	   Rab7	   activity	  
(Henderson	   et	   al.,	   2000;	   Saxena	   et	   al.,	   2005a;	   2005b;	   Bronfman	   et	   al.,	   2007).	  
Interestingly,	  the	  small	  GTPase	  Rab7,	  which	  is	  a	  potential	   interacting-­‐partner	  of	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CLN3	  (Luiro	  et	  al.,	  2004;	  Uusi-­‐Rauva	  et	  al.,	  2012),	  has	  been	  shown	  to	  control	  the	  
endosomal	   trafficking	   of	   TrkA	   (Saxena	   et	   al.,	   2005a).	   Thus,	   lack	   of	   CLN3-­‐Rab7	  
interaction	   together	   with	   attenuated	   receptor	   recycling	   observed	   upon	   CLN3	  
deficiency	   (Luiro	  et	   al.,	   2004)	  may	   lead	   to	   altered	  TrkA	   receptor	   expression	  on	  
the	  cell	  membrane	   in	  Cln3-­‐/-­‐	   neurons.	  To	  determine	  whether	   this	   is	   indeed	   the	  
case	   in	   Cln3-­‐/-­‐	   neurons,	   TIRF-­‐microscopy	   could	   be	   used	   to	   investigate	   the	  
expression	  of	  Trks	  on	  the	  cell	  membrane.	  	  
	  
What	  could	  cause	  the	  death	  of	  WT	  astrocytes	  in	  co-­‐cultures	  with	  Cln3-­‐/-­‐	  neurons?	  
It	   is	  well-­‐established	   that	  neuronal	  activity	   can	  depolarize	  glial	   cells	   (Orkand	  et	  
al.,	  1966;	  Ransom	  and	  Goldring,	  1973;	  Van	  Essen	  and	  Kelly,	  1973;	  Schummers	  et	  
al.,	   2008).	   Given	   that	   Cln3-­‐/-­‐	  neurons	   could	   be	   intrinsically	   in	   a	   state	   of	   over-­‐
stimulation	   (Chapter	   5,	   Figure	   5.5-­‐5.10)	   this	   may	   also	   cause	   excessive	   glial	  
depolarization,	  altering	  the	  membrane	  potential	  of	  astrocytes	  and	  inducing	  their	  
death	  (Franco	  et	  al.,	  2006;	  Verkhratsky	  et	  al.,	  2012b).	  Altogether,	  these	  findings	  
emphasize	   the	   importance	   of	   the	   interplay	   between	   glia	   and	   neurons	   in	   JNCL.	  
However,	  gaining	  a	  better	  understanding	  of	  what	  kind	  of	  proteins	  Cln3-­‐/-­‐	  neurons	  
secrete	  would	  help	  provide	  a	  more	  complete	  image	  of	  these	  interactions.	  	  
Cln3-­‐/-­‐	  glia	  influence	  neurite	  complexity	  	  
It	  is	  well-­‐established	  that	  astrocytes	  promote	  neurite	  growth	  by	  providing	  a	  wide	  
range	  of	  diffusible	  and	  contact-­‐mediated	  factors	  (Tomaselli	  et	  al.,	  1988;	  Powell	  et	  
al.,	   1997b;	   Crone	   and	   Lee,	   2002;	   Araújo	   and	   Tear,	   2003).	   Moreover,	   upon	  
activation,	   astrocytes	   may	   overexpress	   growth-­‐inhibitory	   extracellular	   matrix	  
(ECM)	   proteins,	   like	   chondroitin	   and	   keratan	   sulphate	   proteoglycans,	   that	  may	  
prevent	  the	  extension	  of	  regenerating	  axons	  (Silver	  and	  Miller,	  2004).	  Cln3-­‐/-­‐	  glial	  
cells	  severely	  affected	  the	  morphology	  of	  neurons	  (soma	  size,	  neurite	  length	  and	  
number),	  with	  Cln3-­‐/-­‐	  neurons	  again	  being	  the	  most	  sensitive	  (see	  Figures	  6.4	  and	  
6.5).	   WT	   glia,	   on	   the	   other	   hand,	   seemed	   to	   ameliorate	   the	   morphological	  
defects	   of	  Cln3-­‐/-­‐	   neurons.	   These	   observations	   are	   significant	   since	  maintaining	  
their	   morphology,	   facilitated	   by	   undisrupted	   neurite	   growth,	   is	   pivotal	   for	  
neuronal	  connectivity	  (see	  discussion	  in	  Chapter	  5,	  Section	  5.3).	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Another	   way	   glial	   cells	   can	   impact	   neuronal	   growth	   is	   via	   Ca2+	   signaling.	  
Astrocytes	   display	   Ca2+	   transients	   evoked	   by	   neurotransmitters,	   and	   they	   also	  
exhibit	   spontaneous	   Ca2+	   oscillations	   independent	   of	   neuronal	   influence	  
(Verkhratsky	  et	  al.,	  1998;	  Parri	  et	  al.,	  2001;	  Aguado	  et	  al.,	  2002;	  Nett	  et	  al.,	  2002;	  
Hirase	  et	  al.,	  2004).	  These	  spontaneous	  astrocytic	  Ca2+	  oscillations,	   found	   to	  be	  
attenuated	   in	   Cln3-­‐/-­‐	   astrocytes	   (Chapter	   4,	   Figures	   4.1	   and	   4.2),	   have	   been	  
shown	   to	   facilitate	   neurite	   growth	   by	   inducing	   the	   expression	   of	   the	   cell-­‐
adhesion	   molecule,	   N-­‐Cadherin	   (Kanemaru	   et	   al.,	   2007),	   that	   is	   involved	   in	  
driving	  growth	  cone	  migration	   (Neugebauer	  et	  al.,	  1988;	  Tomaselli	  et	  al.,	  1988;	  
Williams	  et	  al.,	  1994;	  Müller	  et	  al.,	  1995).	  Thus,	  the	  attenuated	  spontaneous	  Ca2+	  
oscillations	   we	   observed	   in	   Cln3-­‐/-­‐	   astrocytes	   could	   also	   play	   a	   part	   in	   the	  
impaired	   neurite	   outgrowth	   we	   saw	   in	   co-­‐cultures.	   To	   investigate	   this	  
suggestion,	  the	  expression	  patterns	  of	  N-­‐cadherin	  and	  other	  adhesion	  molecules	  
could	  be	  investigated	  in	  neuron/Cln3-­‐/-­‐	  glia	  co-­‐culture	  systems.	  Interestingly,	  the	  
period	   when	   spontaneous	   Ca2+	   oscillations	   occur	   most	   frequently	   has	   been	  
shown	  to	  be	  the	  same	  stage	  of	  development	  when	  axons	  and	  dendrites	  actively	  
develop	   to	   form	   thalamocortical	   circuits	   (Parri	   et	   al.,	   2001).	   Thus,	   if	  Cln3-­‐/-­‐	   glia	  
have	  the	  same	  negative	  impact	  on	  neuronal	  growth	  in	  vivo,	  this	  could	  potentially	  
alter	   thalamocortical	   circuit	   formation	   in	   the	   Cln3-­‐/-­‐	   brain.	   Indeed,	  
thalamocortical	   neuron	   loss	   and	   localized	   reactive	   gliosis	   in	   the	   Cln3	   deficient	  
mice	   has	   been	   well	   characterized	   (Pontikis	   et	   al.,	   2004;	   2005;	   Weimer	   et	   al.,	  
2006).	   Since	   the	   thalamus	   processes	   and	   relays	   sensory	   information	   to	   the	  
cortex,	   the	   functional	  deficits	  documented	   in	  Cln3Δex7/8	  mice	  may	  be	  caused	  by	  
early	  dysfunction	  in	  the	  thalamocortical	  system	  (Pontikis	  et	  al.,	  2005;	  Staropoli	  et	  
al.,	  2012).	  The	  evidence	  provided	  in	  this	  thesis	  (Chapter	  5,	  Figure	  5.5,	  Chapter	  6,	  
Figures	   6.4	   and	   6.5)	   raises	   the	   possibility	   that	   this	   early	   dysfunction	   may	   be	  
caused	   by	   reduced	   neurite	   growth,	   that	  would	   have	   a	   significant	   impact	   upon	  
synaptic	   plasticity	   and	   connectivity,	   and	   that	   this	  may	   be	   caused	   by	   abnormal	  
glial	   function.	   It	   would	   be	   interesting	   to	   test	   the	   functional	   integrity	   of	   the	  
thalamocortical	   circuits	   in	   different	   mouse	   models	   of	   JNCL	   to	   confirm	   this	  
hypothesis	   by	   using	   thalamocortical	   slice	   cultures	   to	  measure	   neuronal	   circuit	  
activity	  via	  extracellular	  recordings	  of	  evoked	  field	  potentials	  (Song	  et	  al.,	  2012).	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Additionally,	  JNCL	  mice	  where	  either	  astrocytes	  only	  or	  microglia	  only	  carry	  the	  
most	  common	  Cln3	  mutation	  (in	  the	  process	  of	  being	  generated)	  could	  be	  used	  
to	  investigate	  the	  specific	  roles	  that	  these	  glial	  cells	  play	  in	  the	  dysfunction	  of	  the	  
thalamocortical	  system	  observed	  in	  this	  disease.	  	  
	  
As	  discussed	  earlier,	  soluble	  factors	  secreted	  by	  glial	  cells	  could	  also	  significantly	  
influence	  neurite	  growth	   in	  these	  co-­‐culture	  systems	  (see	  discussion	   in	  Chapter	  
5,	   Section	   5.3).	   We	   know	   that	   under	   basal	   conditions	   the	   secretion	   defect	   of	  
Cln3-­‐/-­‐	  astrocytes	  is	  restricted	  to	  a	  small	  and	  specific	  set	  of	  proteins	  (TIMP1,	  MIP-­‐
1γ,	   GCP-­‐2	   and	   M-­‐CFS),	   but	   this	   secretion	   defect	   becomes	   much	   more	   severe	  
upon	   stimulation	   (Chapter	   4,	   Tables	   4.1	   and	   4.2	   and	   Figure	   4.7).	   Under	   basal	  
conditions,	  Cln3-­‐/-­‐	  microglia	  secrete	  proteins	  normally,	  but	  also	   fail	   to	  secrete	  a	  
subset	   of	   factors	   upon	   activation	   (MIP-­‐2,	   RANTES,	  MIP-­‐1γ,	   vW	   and	  MMP-­‐9,	   S.	  
Dihanich,	   unpublished	   data).	   At	   the	   moment	   we	   do	   not	   know	   precisely	   how	  
protein	   secretion	   is	   changed	   in	   mixed	   glia-­‐cultures,	   or	   how	   the	   presence	   of	  
neurons	   may	   change	   this	   further,	   since	   all	   of	   these	   cell	   types	   are	   known	   to	  
interact	  with	  one	  another	  via	  protein	  secretion	   (Aloisi,	  2001;	  Bezzi	  et	  al.,	  2001;	  
Sofroniew	  and	  Vinters,	  2010;	  Kettenmann	  and	  Verkhratsky,	  2011;	  Kettenmann	  et	  
al.,	   2011;	   Parpura	   et	   al.,	   2011;	   Agulhon	   et	   al.,	   2012;	   Schafer	   et	   al.,	   2013).	  
Nevertheless,	  the	  data	  presented	  in	  this	  thesis,	  and	  data	  from	  studies	  on	  Cln3-­‐/-­‐	  
microglia	  (S.	  Dihanich,	  unpublished	  data),	  suggest	  that	  these	  cells	  do	  clearly	  have	  
protein	  secretion	  defects.	  Previously,	  it	  has	  been	  shown	  that	  the	  reduced	  neurite	  
extension	  ability	  of	  neurons	  cultured	  from	  the	  brains	  of	  newborn	  English	  setters	  
with	   NCL	   (caused	   by	   a	   mutation	   in	   Cln8)	   could	   be	   overcome	   by	   addition	   of	  
insulin-­‐like	   growth	   factor	   I	   (IGF-­‐I),	   EGF	   and	   PDGF	   to	   the	   cultures	   (Dunn	   et	   al.,	  
1994).	   Additionally,	   BDNF	   has	   been	   shown	   to	   significantly	   improve	   the	  
attenuated	  neurite	  outgrowth	  observed	   in	  retinas	  cultured	   from	  Sandhoff	  mice	  
(Sango	  et	  al.,	  2005).	  Therefore,	  the	  observed	  reduction	  in	  neurite	  growth	  when	  
neurons	  are	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia	  could	  be	  due	  to	  their	  failure	  to	  secrete	  
the	  appropriate	   factors.	  For	   instance,	  attenuated	  secretion	  of	  VEGF	  (Chapter	  4,	  
Table	   4.2	   and	   Figure	   4.7),	   which	   has	   been	   shown	   to	   increase	   the	   neurite	  
outgrowth	  of	  cerebral	  cortical	  neurons	  by	  interacting	  with	  VEGFR2	  and	  activating	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Rho/ROK	  (Jin	  et	  al.,	  2006),	  could	  help	  explain	  the	  reduced	  neurite	  growth	  in	  co-­‐
cultures	  with	  Cln3-­‐/-­‐	  glia.	   Indeed,	  one	  could	  test	  whether	  providing	  a	  cocktail	  of	  
neurite	   growth	   promoting	   factors,	   such	   as	   VEGF,	   IGF,	   EGF	   and	   PDGF,	   could	  
reverse	   the	   negative	   impact	   of	   Cln3-­‐/-­‐	  glia	   upon	   neurite	   growth	   from	  WT	   and	  
surviving	  Cln3-­‐/-­‐neurons.	  However,	   it	   is	  worth	   remembering	   that	   in	   the	   cortical	  
neuronal	   cultures	   described	   in	   Chapter	   5,	   complex	   neurite	   extensions	   are	  
observed,	  suggesting	  that	  factors	  from	  exogenous	  glial	  cells	  may	  not	  be	  needed	  
for	  this	  process.	  This	  suggests	  that,	  the	  reduced	  neurite	  complexity	  observed	  in	  
these	  co-­‐cultures	  may	  be	  better	  explained	  by	   the	   inhibitory	   influence	  of	  Cln3-­‐/-­‐	  
glia	  (as	  discussed	  above).	  	  	  	  
	  
Altered	   cell-­‐matrix	   within	   these	   co-­‐culture	   combinations	   could	   also	   influence	  
neurite	  growth.	  This	  includes	  laminin,	  whose	  production	  (Liesi	  et	  al.,	  1983;	  Costa	  
et	  al.,	  2002;	  Tardy,	  2002)	   could	  be	  attenuated	   in	  Cln3-­‐/-­‐	   astrocytes	   leading	   to	  a	  
non-­‐supportive	   cell-­‐matrix	   for	   neurite	   growth	   in	   co-­‐cultures	   that	   include	   these	  
cells.	  Additionally,	  modulation	  of	  the	  ECM	  by	  proteinases	  such	  as	  MMPs,	  which	  
are	  produced	  by	  both	  glial	  cell	  types,	  could	  also	  influence	  the	  composition	  of	  the	  
ECM	  (Costa	  et	  al.,	  2002;	  Ould-­‐yahoui	  et	  al.,	  2009;	  Welser-­‐Alves	  et	  al.,	  2011).	  For	  
example,	   the	  correct	  balance	  of	  MMP-­‐2,	  and	   its	   inhibitor	  TIMP-­‐2	  together	  with	  
laminin,	  have	  been	  shown	  to	  stabilize	  cell-­‐matrix	   interactions	  and	  help	  regulate	  
neurite	  outgrowth	  and	  migration	  (Costa	  et	  al.,	  2002).	  Both	  Cln3-­‐/-­‐	  astrocytes	  and	  
microglia	   secrete	   less	   MMP-­‐9,	   and	   Cln3-­‐/-­‐	   astrocytes	   also	   secrete	   less	   TIMP-­‐1	  
both	  under	  basal	  conditions	  and	  after	  stimulation	  (S.	  Dihanich,	  unpublished	  data,	  
Chapter	   4,	   Tables	   4.1	   and	   4.2),	   which	   could	   result	   in	   an	   environment	   that	   is	  
unfavorable	   for	   neurite	   growth.	   One	   could	   test	   these	   possibilities	   by	   using	  
laminin	  as	  a	  substrate	  for	  co-­‐cultures	  (grown	  in	  this	  study	  on	  PDL,	  see	  Chapter	  2,	  
Section	   2.3)	   and	   observing	   whether	   this	   restores	   neurite	   growth.	   Additionally,	  
the	   impact	   of	   recombinant	   MMPs,	   MMP-­‐neutralizing	   antibodies,	   or	   MMP-­‐
inhibitors,	  such	  as	  Ro	  31-­‐9790,	  on	  neurite	  growth	  could	  be	  investigated.	  	  
	  
Emerging	   evidence	   also	   points	   towards	   the	   importance	   of	   microglia	   in	   the	  
regulation	   of	   neuronal	   morphology	   (Trapp	   et	   al.,	   2007;	   Sisková	   et	   al.,	   2009;	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Kettenmann	  and	  Verkhratsky,	  2011;	  Kitayama	  et	  al.,	  2011;	  Schafer	  et	  al.,	  2013).	  
The	  glial	  cultures	  used	  in	  these	  studies	  were	  mixed,	  being	  mainly	  composed	  of	  
astrocytes	   and	  microglia.	   Therefore,	   any	   observed	   impact	   on	   neuronal	   health	  
could	   be	   caused	   by	   just	   astrocytes,	   just	  microglia	   or	   both	   of	   these	   cell-­‐types.	  
Like	  astrocytes,	  microglia	  can	  also	  sense	  neuronal	  activity	  via	  their	  wide	  range	  
of	  neurotransmitter	  receptors	  (Rock	  et	  al.,	  2004;	  Pocock	  and	  Kettenmann,	  2007;	  
Kettenmann	  et	  al.,	  2011).	  Based	  on	  in	  vivo	  evidence,	  microglia	  are	  constantly	  re-­‐
establishing	   connections	   with	   synaptic	   structures,	   indicating	   that	   dynamic	  
interactions	  exist	  between	  microglia	  and	  neurons	   in	   the	   intact	  brain	   (Wake	  et	  
al.,	  2009;	  Schafer	  et	  al.,	  2013).	  These	  interactions	  could	  be	  dictated	  by	  the	  levels	  
of	   neurotransmitters	   present,	   which	   may	   be	   dramatically	   different	   in	   the	  
different	   co-­‐culture	   combinations,	   due	   to	   differences	   in	   the	   cellular	  
homeostasis	   created	   by	   neuron-­‐glia	   interactions	   and	   by	   the	   expression	   of	  
different	  adhesion	  molecules.	  One	  way	   in	  which	  Cln3-­‐/-­‐	  microglia	  could	  exert	  a	  
negative	   influence	   on	   neuronal	   morphology	   is	   via	   their	   ability	   to	   remove	  
abnormally	  functioning	  synapses	  (Lindå	  et	  al.,	  2000;	  Trapp	  et	  al.,	  2007;	  Yamada	  
et	  al.,	  2008).	  Moreover,	  microglia	  can	  also	  synthesize,	  release	  and	  respond	  to	  a	  
distinct	  set	  of	  neurotrophins,	  including	  NGF,	  NT-­‐3,	  GDNF	  and	  BDNF	  with	  neurite	  
growth	  promoting	  ability	  (Elkabes	  et	  al.,	  1996;	  Heese	  et	  al.,	  1997;	  Morgan	  et	  al.,	  
2004;	  Coull	  et	  al.,	  2005;	  Nakajima	  et	  al.,	  2007).	  Some	  evidence	  also	  exists	  that	  
secretory	  proteases,	  particularly	  plasminogen-­‐plasminogen	  activator	   (PGn-­‐PA),	  
released	   by	   microglia	   may	   regulate	   neuronal	   growth	   and	   function	   and	   thus	  
could	  be	   involved	   in	   the	   regulation	  of	   neuronal	   circuits	   (Kohsaka	   et	   al.,	   1996;	  
Nakanishi,	   2003).	   Impaired	   secretion	  of	   neurotrophic	   factors	   and/or	   secretory	  
proteases	  by	  Cln3-­‐/-­‐microglia	  could	  partly	  explain	  the	  observed	  negative	  impact	  
on	  neuronal	   growth	  observed	   in	   co-­‐cultures	   of	  Cln3-­‐/-­‐	  glia	  with	  WT	  and	  Cln3-­‐/-­‐	  
neurons.	   This	   would	   obviously	   need	   to	   be	   tested,	   but	   our	   observation	   that	  
protein	   secretion	   is	   perturbed	   in	   these	   cells	   makes	   this	   a	   possibility	   worth	  
considering.	   Furthermore,	   both	   Cln3-­‐/-­‐	   astrocytes	   (Chapter	   3,	   Figure	   3.6)	   and	  
microglia	   (S.	   Dihanich,	   unpublished	   data)	   appear	   to	   be	   more	   activated	   than	  
their	  WT	  counterparts	  when	  cultured	  under	  basal	  conditions	   (see	  above).	  This	  
may	  help	  to	  explain	  their	  negative	  impact	  on	  neurite	  growth,	  an	  influence	  that	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activated	  glia	  are	  known	  to	  have	  (Reier	  and	  Houle,	  1988;	  McKeon	  et	  al.,	  1991;	  
Laywell	  et	  al.,	  1992;	  Norton	  et	  al.,	  1992;	  Norenberg,	  1994;	  Williams	  et	  al.,	  1994;	  
Dayton	  and	  Major,	  1996;	  Ridet	  et	  al.,	  1997;	  Raivich	  et	  al.,	  1999;	  Münch	  et	  al.,	  
2003;	  Kitayama	  et	  al.,	  2011).	  More	  specifically,	  we	  demonstrated	  that	  activated	  
Cln3-­‐/-­‐	  microglia	   secrete	   less	  MMP-­‐9,	  which	   is	   an	   important	   regulator	   of	  NGF-­‐
induced	   neurite	   elongation	   (Costa	   et	   al.,	   2002;	   Shubayev	   and	   Myers,	   2004;	  
Ould-­‐yahoui	  et	  al.,	  2009).	  Furthermore,	  the	  chemokine	  RANTES,	  another	  protein	  
secreted	   at	   lower	   levels	   by	   these	   cells	   upon	   activation,	   has	   been	   shown	   to	  
induce	   the	   neuronal	   expression	   of	   genes	   involved	   in	   promoting	   neurite	  
outgrowth	   and	   synaptogenesis	   (Valerio	   et	   al.,	   2004).	   Additionally,	   activated	  
astrocytes	  may	   produce	   and	   secrete	   arachidonic	   acid	  metabolites,	   TNF-­‐α	   and	  
NO	  that	  may	  have	  detrimental	  effects	  on	  neuronal	  biology	  and	  their	  ability	   to	  
retain	   their	  morphological	   integrity	   (Williams	   et	   al.,	   1995;	   Dayton	   and	  Major,	  
1996;	   Neumann	   et	   al.,	   2002).	   However,	   microglia	   may	   produce	   significantly	  
more	   of	   such	   cell	   damaging	   factors	   than	   astrocytes	   (Malipiero	   et	   al.,	   1990;	  
Vincent	  et	  al.,	  1996;	  Münch	  et	  al.,	  2003;	  Kitayama	  et	  al.,	  2011).	  Thus,	  the	  most	  
dramatic	  detrimental	  impact	  upon	  neurons	  may	  be	  mediated	  by	  microglia	  in	  the	  
long	   run	   instead	   of	   astrocytes.	   Finally,	   activated	  microglia	  may	   inhibit	   neurite	  
growth	   via	   increased	   expression	   of	   RGMa	   (repulsive	   guidance	   molecule),	   an	  
effect	   that	   can	   be	   reversed	   by	  minocycline	   treatment	   that	   inhibits	   microglial	  
activation	   (Kitayama	   et	   al.,	   2011).	   To	   investigate	   whether	   any	   of	   these	  
hypotheses	  explain	  the	  diminished	  neurite	  growth	  seen	  when	  co-­‐cultured	  with	  
Cln3-­‐/-­‐	   glia,	   production	   of	   these	   factors	   and	   expression	   of	   membrane	   bound	  
molecules	   should	   be	   investigated	   in	   these	   co-­‐cultures,	   to	   determine	   how	  
interaction	  between	  neurons	  and	  glia	  of	  different	  genotypes	  may	  influence	  the	  
glial-­‐based	  mechanisms	  that	  support	  neurite	  growth.	  	  
	  
To	  conclude,	  both	  astrocytes	  and	  microglia	  have	   the	  potential	   to	   regulate	   the	  
development	  of	  neurites	   in	   these	   co-­‐culture	   systems.	  Both	  of	   these	   cell-­‐types	  
are	   capable	   of	   monitoring	   the	   status	   of	   neurite	   development	   and	   neuronal	  
connectivity	   at	   synaptic	   sites.	   Indeed,	   both	   cell-­‐types	   may	   remodel	   neuronal	  
connectivity	   via	   alterations	   in	   neurite	   formation	   and	   synaptic	   pruning,	   and	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therefore	   participate	   actively	   in	   the	   maintenance	   and	   plasticity	   of	   neural	  
networks	   (Verkhratsky	   and	   Butt,	   2007;	   Araque	   and	   Navarrete,	   2010;	  
Kettenmann	   et	   al.,	   2011;	   Liu	   et	   al.,	   2011).	   In	   the	   future,	   co-­‐cultures	   in	  which	  
only	   Cln3-­‐/-­‐	   astrocytes,	   or	   only	   Cln3-­‐/-­‐	   microglia,	   are	   co-­‐cultured	  with	   neurons	  
will	  shed	  light	  on	  the	  role	  that	  each	  of	  these	  cell-­‐types	  play	  in	  this	  process.	  	  
	  
Expression	  of	  SNAREs	  is	  altered	  by	  glial	  presence	  
In	  comparison	  to	  Cln3-­‐/-­‐	  neuronal	  cultures,	  in	  which	  only	  SNAP25	  was	  found	  to	  be	  
significantly	  upregulated	  (Chapter	  5,	  Figure	  5.11),	  more	  and	  different	  changes	  in	  
SNARE-­‐complex	  proteins	  were	  evident	  in	  our	  co-­‐cultures,	  and	  particularly	  when	  
Cln3-­‐/-­‐	  neurons	  were	  present	  (Chapter	  6,	  Figures	  6.6	  and	  6.7).	  The	  expression	  of	  
SNAP25	  was	   reduced	  when	  Cln3-­‐/-­‐	  neurons	  were	  co-­‐cultured	  with	  either	  WT	  or	  
Cln3-­‐/-­‐	  glia.	  In	  contrast,	  the	  expression	  of	  synaptophysin	  was	  enhanced,	  but	  only	  
when	   grown	   with	   Cln3-­‐/-­‐	   glia.	   Indeed,	   the	   appropriate	   expression	   of	   synaptic	  
proteins	   can	   be	   considered	   as	   a	   surrogate	  marker	   of	   normal	   synaptic	   function	  
(discussed	   in	   Chapter	   5,	   Section	   5.3).	   It	   is	   well	   established	   that	   astrocytes	  
increase	   the	  number	  of	  mature,	   functional	   synapses	   in	   the	  CNS	  via	   the	   factors	  
they	  secrete,	  and	  are	  required	  for	  synaptic	  maintenance	  both	  in	  vitro	  and	  in	  vivo	  
(Mauch	  et	  al.,	  2001;	  Ullian	  et	  al.,	  2001;	  2004a;	  2004b).	  Emerging	  evidence	  also	  
highlights	   the	   importance	   of	  microglia	   in	   synaptic	   regulation	   (Kettenmann	   and	  
Verkhratsky,	  2011;	  Kettenmann	  et	  al.,	  2011;	  Stephan	  et	  al.,	  2012;	  Schafer	  et	  al.,	  
2013).	  	  
	  
Generally	   synaptic	   damage,	   seen	   here	   as	   altered	   SNAP25	   and	   synaptophysin	  
expression,	   is	   considered	   to	   be	   an	   early	   event	   in	   many	   neurodegenerative	  
disorders,	   including	   different	   forms	   of	   NCLs	   (Kay	   et	   al.,	   2006;	   Weimer	   et	   al.,	  
2007;	   Partanen	   et	   al.,	   2008;	   Kielar	   et	   al.,	   2009).	   Indeed,	   synaptic	   loss	   closely	  
correlates	  with	  cognitive	  decline	  in	  JNCL	  (DeKosky	  and	  Scheff,	  1990;	  Coleman	  et	  
al.,	  2004;	  Scheff	  et	  al.,	  2006;	  Mandolesi	  et	  al.,	  2010;	  Milnerwood	  and	  Raymond,	  
2010;	   Stephan	  et	   al.,	   2012).	  While	   there	   are	   some	   situations	   in	  which	   synapse	  
loss	   associated	   with	   neurodegeneration	   is	   considered	   to	   be	   a	   neuron-­‐
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autonomous	   event	   (Sisková	   et	   al.,	   2009;	   Perry	   and	   O'Connor,	   2010),	   many	  
studies	   suggest	   that	   glia	   are	   pivotal	   regulators	   of	   this	   process	   (Paradisi	   et	   al.,	  
2004;	   Alexander	   et	   al.,	   2008;	   Rosen	   and	   Stevens,	   2010;	   Schafer	   and	   Stevens,	  
2010;	   Garwood	   et	   al.,	   2011).	   In	   this	   study	   glia	   had	   an	   unexpected	   impact	   on	  
synaptic	   protein	   expression.	   Even	   though	  WT	   glial	   cells	  were	   shown	   to	   have	   a	  
positive	  impact	  on	  Cln3-­‐/-­‐	  neuronal	  survival	  and	  neurite	  growth	  (Results	  Chapter	  
6,	  Figures	  6.2,	  6.3,	  6.5),	   this	  did	  not	  extend	  to	  rectifying	  their	  aberrant	  SNAP25	  
expression,	   nor	   did	   the	  negative	   impact	   of	  Cln3-­‐/-­‐	   glia	   on	  WT	  neuronal	   survival	  
extend	   to	   a	   reduction	   in	   SNAP25	   expression.	   Thus,	   some	   synaptic	   changes	   in	  
Cln3-­‐/-­‐	  neurons	  could	  be	  intrinsic	  and	  caused	  by	  lack	  of	  functional	  synaptic	  CLN3	  
(Järvelä	  et	  al.,	  1998;	  Luiro	  et	  al.,	  2001;	  Kyttälä	  et	  al.,	  2005).	  Indeed,	  the	  observed	  
over-­‐expression	  of	   SNAP25	   in	  Cln3-­‐/-­‐	   neuronal	   cultures	   suggests	   that	   this	   is	   the	  
case	   (Chapter	   5,	   Figure	   5.11).	   The	   fact	   that	   SNA25	   expression	  was	   reduced	   in	  
Cln3-­‐/-­‐neurons	   in	  all	   co-­‐culture	  combinations	  with	  WT	  and	  Cln3-­‐/-­‐	  glia	   compared	  
to	  WT	  neurons	  remains	  unexplained.	  	  
	  
On	  the	  other	  hand,	  synaptophysin	  expression	  was	  increased	  in	  Cln3-­‐/-­‐	  neurons	  in	  
the	   presence	   of	   Cln3-­‐/-­‐	   glia.	   Based	   on	   previous	   studies,	   altered	   synaptophysin	  
expression	   has	   been	   associated	   with	   several	   neurodegenerative	   disease	   and	  
psychiatric	   disorders,	   such	   as	   Alzheimer	   disease	   and	   schizophrenia	   (Masliah	   et	  
al.,	  1994;	  Eastwood	  et	  al.,	  1995;	  Heinonen	  et	  al.,	  1995;	  Glantz	  and	  Lewis,	  1997;	  
2000;	   Glantz	   et	   al.,	   2000).	   Glial	   activation	   has	   been	   linked	   with	   loss	   of	  
synaptophysin	  expression,	  which	  is	  in	  contrast	  to	  findings	  in	  this	  study	  (Ojo	  et	  al.,	  
2012).	  However,	   in	  some	  cases	  synaptophysin	  protein	  expression	   levels	  did	  not	  
correlate	   with	   changes	   in	   mRNA	   levels.	   It	   was	   speculated	   that	   this	   could	   be	  
caused	   by	   abnormal	   post-­‐translational	   regulation	   of	   synaptophysin	   in	   the	  
diseased	  brain	  (Glantz	  et	  al.,	  2000),	  which	  could	  also	  explain	  the	  over-­‐expression	  
of	  synaptophysin	  in	  Cln3-­‐/-­‐	  neurons	  co-­‐cultured	  with	  Cln3-­‐/-­‐	  glia.	  	  
	  
Both	   astrocytes	   and	   microglia	   are	   important	   regulators	   of	   a	   whole	   range	   of	  
events	   involved	   in	   the	   maturation	   and	  maintenance	   of	   the	   synapse,	   including	  
formation,	   modification	   and	   elimination	   of	   synaptic	   structures,	   as	   well	   as	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synaptic	  plasticity	  (Allen	  and	  Barres,	  2009;	  Ricci	  et	  al.,	  2009;	  Perry	  and	  O'Connor,	  
2010;	   Kettenmann	   and	   Verkhratsky,	   2011;	   Tremblay	   and	   Majewska,	   2011;	  
Pascual	  et	  al.,	  2012;	  Schafer	  et	  al.,	  2013).	  For	  instance,	  cell	  death	  can	  be	  induced	  
in	   hippocampal	   neuronal	   cultures	   exposed	   to	   Aß	   (Takashima	   et	   al.,	   1993;	  
Goodman	   and	   Mattson,	   1994;	   Paradisi	   et	   al.,	   2004).	   However,	   astrocyte	  
conditioned	   medium	   can	   protect	   against	   this	   Aß-­‐induced	   neurotoxicity,	  
preventing	  neuritic	  dystrophy	  and	  synaptic	  damage,	  proposing	  a	  protective	  role	  
for	   non-­‐activated	   astrocytes	   (Paradisi	   et	   al.,	   2004).	   This	   protection	   was	   lost,	  
however,	  when	  astrocytes	  were	  activated	  by	  treatment	  with	  Aß,	  suggesting	  that	  
activated	   astrocytes	   can	   have	   a	   deleterious	   impact	   on	   neurons.	   The	  
morphological	   appearance	  of	  Cln3-­‐/-­‐	   astrocytes	   co-­‐cultured	  with	  Cln3-­‐/-­‐	   neurons	  
suggested	  that	  these	  cells	  are	  at	  least	  partially	  activated	  (Chapter	  6,	  Figures	  6.4	  
and	   6.5),	  which	  may	   alter	   their	   biology	   in	   a	  way	   that	   could	   damage	   synapses.	  
Evaluating	   protein	   secretion	   within	   these	   co-­‐cultures	   would	   enable	   us	   to	  
investigate	   this	   hypothesis.	   Additionally,	   emerging	   evidence	   indicates	   that	  
microglia	   send	  processes	   that	   dynamically	   survey	   synapses	   and	  may	  modify	   or	  
eliminate	   them	   depending	   upon	   the	   levels	   of	   neuronal	   activity	   (Pocock	   and	  
Kettenmann,	   2007;	   Kettenmann	   and	   Verkhratsky,	   2011;	   Seifert	   et	   al.,	   2011;	  
Krabbe	   et	   al.,	   2012)	   (Wake	   et	   al.,	   2009;	   Tremblay	   et	   al.,	   2010;	   Schafer	   et	   al.,	  
2013).	   Even	  when	   grown	  under	   resting	   conditions	  without	   glia,	  Cln3-­‐/-­‐	   neurons	  
were	  apparently	  in	  a	  state	  of	  overstimulation,	  as	  judged	  by	  the	  displacement	  of	  
their	   AIS	   (Chapter	   5,	   Figures	   5.5-­‐5.10).	   Thus,	   different	   levels	   of	   basal	   neuronal	  
activity	  evoked	   in	   co-­‐cultured	  neurons	   (Hild	  and	  Tasaki,	  1962;	   Lin	  et	  al.,	   2002),	  
could	  perhaps	  explain	  some	  of	   these	  observations.	   Indeed,	  cultured	  P0	  cortical	  
neurons	   have	   the	   ability	   to	   exhibit	   spontaneous	   electrical	   activity	   (Choi	   et	   al.,	  
1987;	   Li	   et	   al.,	   1998;	  Moody	   and	   Bosma,	   2005).	   Thus,	   chronically	  more	   active	  
Cln3-­‐/-­‐	   neurons	   could	   trigger	   stronger	   responses	   in	   glial	   cells,	   potentially	  
explaining	  why	  we	  see	  more	  synaptic	  alterations	  in	  Cln3-­‐/-­‐	  neuron	  containing	  co-­‐
cultures.	   It	  would	  be	  interesting	  to	  investigate	  the	  localization	  of	  the	  AIS	  within	  
these	   co-­‐cultured	   neurons	   as	   a	   surrogate	   measurement	   of	   on-­‐going	   levels	   of	  
neuronal	   activity.	   However,	   it	   is	   not	   yet	   known	   whether	   this	   type	   of	   activity-­‐
dependent	  microglial	  function	  leads	  to	  elimination	  or	  strengthening	  of	  synapses	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(Kettenmann	   et	   al.,	   2013).	   Nevertheless,	   activated	   microglia	   can	   physically	  
contact	  injured	  neurons	  and	  remove	  synapses	  or	  dendrites	  (Rappert	  et	  al.,	  2004;	  
de	  Jong	  et	  al.,	  2005;	  Stevens	  et	  al.,	  2007).	  For	  instance,	  both	  in	  vivo	  and	  in	  vitro	  
evidence,	  suggest	  that	  glutamate	  excitotoxicity,	  may	  contribute	  to	  pathogenesis	  
in	  Cln3-­‐/-­‐	  and	  Cln3Δex7/8	  mice	  (Pears	  et	  al.,	  2005;	  Kovács	  et	  al.,	  2006;	  Kovács	  and	  
Pearce,	   2008;	   Finn	   et	   al.,	   2011).	   This	   may	   lead	   to	   induced	   expression	   and	  
secretion	  of	  the	  chemokine	  CCL21	  that	  has	  been	  linked	  to	  activation	  of	  microglia	  
and	  subsequent	  dendritic	  degeneration	  of	  neurons	  (Rappert	  et	  al.,	  2004;	  de	  Jong	  
et	   al.,	   2005).	   Thus,	   synaptic	   deficits	   may	   involve	   microglial	   activation	  
orchestrated	  by	  a	  chemokine	  signaling	  cascade.	  Furthermore,	  such	  cascades	  may	  
be	  used	  as	  a	  means	  of	  communication	  between	  microglia	  and	  astrocytes,	  which	  
function	  together	  to	  either	  rescue	  or	  remove	  a	  synapse	  (Tran	  and	  Miller,	  2003;	  
Ransohoff,	  2009;	  Stephan	  et	  al.,	  2012).	  Activated	  Cln3-­‐/-­‐	  microglia	  and	  astrocytes	  
both	  showed	   impaired	  chemokine	  secretion	  (Chapter	  4,	  Tables	  4.1	  and	  4.2	  and	  
Figure	   4.7,	   S.	   Dihanich,	   unpublished	   data,)	   suggesting	   that	   communication	   via	  
chemokines	   could	   be	   interrupted	   in	   Cln3-­‐/-­‐	  mice.	   One	   important	   mediator	   of	  
communication	   between	   neural	   cells	   is	   the	   chemokine	   stromal	   cell-­‐derived	  
factor-­‐1	  (SDF-­‐1),	  secreted	  by	  astrocytes,	  which	  is	  the	  natural	  ligand	  of	  the	  CXCR4	  
receptor	  expressed	  by	  microglia,	  astrocytes	  and	  neurons	  (Tachibana	  et	  al.,	  1998;	  
Bezzi	  et	  al.,	  2001;	  Lazarini	  et	  al.,	  2003;	  Calì	  and	  Bezzi,	  2010;	  Wu	  et	  al.,	  2012).	  The	  
importance	  of	  this	  chemokine	  is	  demonstrated	  by	  deletion	  of	  the	  SDF-­‐1	  or	  CXCR4	  
gene	   being	   embryonic	   lethal	   (Nagasawa	   et	   al.,	   1999).	   It	   is	   thought	   that	   SDF-­‐
1/CXCR4	   is	   an	   integral	   part	   of	   the	   communication	   between	   glia	   and	   neurons.	  
SDF-­‐1	   secreted	   by	   astrocytes	   may	   induce	   rapid	   Ca2+-­‐based	   signaling	   events	   in	  
both	   these	   cell-­‐types	   (Zheng	   et	   al.,	   1999a;	   1999b),	   and	   also	   induce	   changes	   in	  
electrophysiological	   and	   synaptic	   properties	   of	   neurons	   (Zheng	   et	   al.,	   1999a;	  
Limatola	  et	  al.,	  2000).	  Additionally,	  SDF-­‐1	  may	  cause	  release	  of	  TNF-­‐α,	  glutamate	  
and	   PGE2	   from	   astrocytes	   leading	   to	   activating	   of	  microglial	   TNF-­‐α	   production	  
and	   release	   (Bezzi	   et	   al.,	   2001).	   Thus	   chemokine	   based	   signaling	   cascades	   link	  
both	  microglia	  and	  astrocytes	  to	  neuronal	  function	  via	  synaptic	  changes	  (Bezzi	  et	  
al.,	  2004;	  Rossi	  and	  Volterra,	  2009).	  Hence,	  it	  would	  be	  interesting	  to	  investigate	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whether	   SDF-­‐1	   based	   signaling	   has	   remained	   intact	   between	   Cln3-­‐/-­‐	   glia	   and	  
neurons.	  	  
	  
At	  present,	  however,	  there	  is	  no	  evidence	  that	  synapses	  are	  actually	  impaired	  in	  
these	   co-­‐cultures.	   To	   investigate	   this,	   co-­‐localization	  of	   the	  presynaptic	  marker	  
Bassoon	   and	   the	   postsynaptic	   protein	   called	   proline-­‐rich	   synapse-­‐associated	  
protein	   1	   (ProSAP1)/Shank2	   could	   be	   used	   as	   a	   measure	   of	   the	   number	   of	  
synapses	  present	  (Pyka	  et	  al.,	  2011).	  Also,	  spontaneous	  synaptic	  activity	  could	  be	  
measured	  to	  detect	  possible	  alterations	  in	  synapse	  function.	  Nevertheless,	  these	  
results	  provide	  a	   link	  between	   synaptic	   alteration	  and	  glial	   cells	   in	   JNCL.	  Given	  
that	  deficits	  in	  synaptic	  circuits	  are	  emerging	  as	  important	  underlying	  correlates	  
of	   neurological	   disorders	   (Rubenstein	   and	   Merzenich,	   2003;	   Belmonte	   et	   al.,	  
2004;	  LeBlanc	  and	  Fagiolini,	  2011;	  Melom	  and	  Littleton,	  2011),	  and	  knowing	  that	  
glia	  can	  mediate	  synaptic	  pruning	  via	  phagocytic	   immune	  pathways	  (Stevens	  et	  
al.,	  2007;	  Schafer	  and	  Stevens,	  2010;	  Schafer	  et	  al.,	  2013),	   it	   is	  highly	  likely	  that	  
both	   astrocytes	   and	  microglia	   together	   contribute	   to	   JNCL	   symptoms,	   at	   least	  
partly	  via	  aberrant	  neuronal-­‐glial	  signaling	  at	  synapses.	  	  	  	  
	  
A	  note	  on	  using	  mixed	  glial	  cultures	  
Various	  different	   types	  of	   co-­‐culture	   systems	  have	  been	  used	   to	  examine	  glial-­‐
neuron	  interactions	  under	  physiological,	  as	  well	  as	  pathological,	  conditions	  (Sass	  
et	   al.,	   1993;	   Giulian	   et	   al.,	   1994;	  Wang	   and	   Cynader,	   1999;	   Gegg	   et	   al.,	   2005;	  
Noble	  et	  al.,	  2009;	  Garwood	  et	  al.,	  2011;	  Shimizu	  et	  al.,	  2011;	  Jones	  et	  al.,	  2012;	  
Skaper	  and	  Facci,	  2012).	  To	  maximize	  the	  possibility	  of	  observing	  an	  effect	  in	  our	  
co-­‐culture	   experiments	  we	   chose	   to	   culture	  neurons	  with	   a	  mixed	   glial	   culture	  
(composed	   of	   astrocyte,	   microglial	   cells	   and	   the	   rare	   oligodendrocyte),	   rather	  
than	  with	  only	   astrocyte	  or	   only	  microglia	   cells.	   This	   approach	  had	   its	   benefits	  
and	   limitations.	  Of	   benefit,	   is	   the	   fact	   that	  mixed	   glial	   cultures	   resemble	  more	  
closely	   the	   environment	   in	   the	   brain,	   in	   which	   microglia	   and	   astrocytes	   are	  
intimately	  connected.	  However,	  the	  limitations	  of	  this	  approach	  are	  that	  (1)	  the	  
specific	   source	  of	  any	  negative	  or	  positive	   influence	  on	  neuronal	  health	  cannot	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be	  determined,	  (2)	  the	  biology	  of	  Cln3-­‐/-­‐	  microglia	  and	  astrocytes	  have	  only	  been	  
studied	   in	  >98%	  pure	  cultures	   (Chapter	  3	  and	  4,	  S.	  Dihanich	  unpublished	  data),	  
thus	   whether	   these	   biological	   changes	   will	   be	   exacerbated,	   ameliorated,	   or	  
whether	   new	   problems	  will	   arise	  when	   astrocytes	   and	  microglia	   are	   grown	   as	  
mixed	   cultures	   is	   unknown.	   For	   instance,	   it	  would	  be	  extremely	   informative	   to	  
study	   protein	   secretion	   in	   WT	   and	   Cln3-­‐/-­‐	   mixed	   glial	   cultures	   under	   basal	  
conditions	   and	   upon	   activation	   to	   explore	   whether	   the	   severely	   attenuated	  
protein	   secretion	   observed	   in	   Cln3-­‐/-­‐	   astrocytes	   is	   affected	   by	   the	   presence	   of	  
microglia.	   To	   take	   these	   co-­‐culture	   studies	   further,	   one	   could	   use	  
astrocyte/neurons	   or	  microglia/neuron	   co-­‐cultures	   to	   investigate	   the	   role	   each	  
of	  these	  glial	  cell	  types	  play	  in	  neuronal	  health.	  This	  would	  answer	  the	  question	  
of	  whether	   the	   negative	   impact	   of	  Cln3-­‐/-­‐	  mixed	   glial	   on	   neurons	   is	   due	   to	   the	  
presence	  of	  astrocytes	  or	  microglia,	  or	  whether	  both	  of	  these	  cell	  types	  work	  in	  
concert	   to	   exert	   the	   observed	   effects.	   To	   further	   define	   the	   types	   of	   cell-­‐cell	  
interactions	   involved,	  one	  could	  use	  co-­‐culture	  systems	   in	  which	  glia	  are	  not	   in	  
physical	  connection	  with	  neurons,	  but	  are	  separated	  by	  a	  membrane	  that	  allows	  
the	   free	   diffusion	   of	   soluble	   factors	   between	   the	   different	   cell	   types.	   This	  
approach	  would	  help	  determine	  whether	  soluble	   factors	  alone	  are	  sufficient	   to	  
recapitulate	   the	   observations,	   and	   such	   experiments	   are	   now	   ongoing	   in	   the	  
laboratory.	   Nevertheless,	   using	   mixed	   glial	   cultures	   proved	   to	   be	   a	   very	  
informative	   initial	   step	   in	   gaining	   a	   better	   understanding	   of	   the	   relationship	  
between	  neurons	  and	  glia	  in	  JNCL.	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Chapter	  7	  
General	  discussion	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The	   main	   objective	   of	   this	   thesis	   was	   to	   investigate	   how	   Cln3	   deficiency	  
influenced	   the	   biology	   of	   astrocytes,	   and	   whether	   Cln3	   deficient	   glia	   had	   a	  
detrimental	  influence	  on	  neuronal	  health.	  	  
	  
Early	  glial	  activation	  that	  precedes	  neuronal	   loss	   is	  a	  well-­‐characterized	   feature	  
of	   many	   different	   forms	   of	   NCLs,	   including	   JNCL	   (Braak	   and	   Goebel,	   1978;	  
Chronister	  et	  al.,	  1995;	  Tyynelä	  et	  al.,	  1997;	  Herva	  et	  al.,	  2000;	  Nakanishi	  et	  al.,	  
2001;	   Koike	   et	   al.,	   2003;	   Oswald	   et	   al.,	   2005;	   Pontikis	   et	   al.,	   2005;	   Kay	   et	   al.,	  
2006;	  Luiro	  et	  al.,	  2006;	  Eliason	  et	  al.,	  2007;	  Partanen	  et	  al.,	  2008;	  Kuronen	  et	  al.,	  
2012;	   Schmiedt	   et	   al.,	   2012).	   However,	   prior	   to	   the	   research	   described	   in	   this	  
thesis	  very	  little	  was	  known	  about	  the	  biology	  of	  NCL	  glia,	  or	  whether	  these	  cells	  
actually	   contribute	   to	   NCL	   pathogenesis.	   Using	   an	   in	   vitro	   approach	   we	   have	  
identified	   a	   number	   of	   functional	   deficits	   in	   astrocytes	   isolated	   from	   the	   Cln3	  
deficient	  mouse	  model	  of	  JNCL,	  most	  of	  which	  could	  be	  caused	  by	  the	  abnormal	  
cytoskeletal	  organization	  displayed	  by	  these	  cells.	  For	  instance,	  Cln3-­‐/-­‐	  astrocytes	  
exhibited	   an	   impaired	   ability	   to	   change	   morphologically	   in	   response	   to	  
stimulation,	  to	  divide,	  to	  migrate,	  to	  secrete	  proteins	  and	  to	  take	  up	  glutamate.	  
In	  addition,	  their	  Ca2+	  signalling	  was	  abnormal	  and	  their	  endo/lysosomal	  pathway	  
appeared	  disrupted	  (summarized	   in	  Figure	  7.1	  A).	  Using	  a	  similar	  approach,	  we	  
also	   revealed	   that	   CLN3	   deficiency	   also	   resulted	   in	   specific	   alterations	   to	   the	  
biology	  of	   neurons,	   including	   compromised	  morphology,	   overexpression	  of	   the	  



















































Figure	  7.1.	  CLN3	  deficiency	  causes	  impairments	  in	  the	  biology	  of	  astrocytes	  and	  
neurons.	  (A)	  Studies	  on	  astrocyte	  cultures	  derived	  from	  the	  cortex	  of	  either	  Cln3-­‐/-­‐	  or	  WT	  mice	  
(P1-­‐P2)	   revealed	   a	   range	   of	   biological	   alterations.	  Many	   of	   these	   deficits	   can	   be	   linked	   to	   the	  
cytoskeletal	  abnormalities	  observed	  in	  Cln3-­‐/-­‐	  astrocytes.	  (B)	  Studies	  on	  neuronal	  cultures	  derived	  
from	  the	  cortex	  of	  either	  Cln3-­‐/-­‐	  or	  WT	  mice	  (P0)	  also	  revealed	  a	  range	  of	  specific	  alterations	   in	  
neurons.	  	  
	  	  
Most	   importantly,	   co-­‐culture	   experiments	   carried	   out	   in	   this	   thesis	   have	  
provided	   the	   first	  evidence	   that	  Cln3-­‐/-­‐	   glia	  can	   impact	  neuronal	  health.	   In	   fact,	  
Cln3-­‐/-­‐	  glia	  had	  a	  negative	   impact	  on	  the	  survival	  and	  morphological	   integrity	  of	  
both	  WT	  and	  Cln3-­‐/-­‐	  neurons.	  Synaptic	  protein	  expression	  was	  also	  altered,	  but	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only	   in	   Cln3-­‐/-­‐	   neurons.	   In	   contrast,	  WT	   glia	   were	   able	   to	   ameliorate	   some	   of	  
these	  defects	  by	  promoting	  both	  survival	  and	  neurite	  growth	   in	  Cln3-­‐/-­‐	  neurons	  
(summarized	  in	  Figure	  7.2).	  	  
	  
The	  impact	  of	  Cln3-­‐/-­‐	  glia	  upon	  Cln3-­‐/-­‐	  neurons	  (summarized	  in	  Figure	  7.2),	  could	  
be	  explained,	  at	  least	  in	  part,	  by	  the	  attenuated	  protein	  secretion	  profile	  of	  these	  
cells	   upon	   activation,	   that	   appears	   to	   be	   caused	   by	   the	   presence	   of	   Cln3-­‐/-­‐	  
neurons	   (Chapter	   6,	   Figures	   6.2	   and	   6.3,	   discussion	   in	   Section	   6.3).	   This	   could	  
result	  in	  a	  lack	  of	  neuroprotective	  factors	  and	  the	  antioxidant	  glutathione	  in	  the	  
medium,	   and	   this	   situation	   may	   be	   further	   exacerbated	   by	   the	   impaired	  
glutamate	   clearance	   of	   the	   Cln3-­‐/-­‐	   astrocytes	   leading	   to	   excitotoxicity.	  
Additionally,	   the	   evident	   impaired	   secretion	   of	   proteins	   from	   both	   Cln3-­‐/-­‐	  
microglia	   and	   astrocytes	   may	   alter	   pivotal	   communication	   pathways,	   not	   only	  
between	   these	   glial	   cell	   types,	   but	   also	   between	   glia	   and	   neurons.	   This	   may	  
ultimately	  result	  in	  abnormal	  modulation	  of	  fundamental	  physiological	  processes	  
such	  as	  neuronal	  development,	   synaptic	   transmission	  and	  plasticity,	  potentially	  
leading	  to	  cell	  death	  (see	  discussion	  in	  Chapter	  6,	  Section	  6.3)	  (Hesselgesser	  and	  
Horuk,	  1999;	  Bezzi	  et	  al.,	  2001;	  John	  et	  al.,	  2003;	  Liberto	  et	  al.,	  2004;	  Ramírez	  et	  
al.,	  2005;	  Röhl	  and	  Sievers,	  2005;	  Röhl	  et	  al.,	  2008;	  Ransohoff,	  2009;	  Sofroniew	  
and	  Vinters,	  2010;	  Lee	  and	  Haydon,	  2011;	  Liu	  et	  al.,	  2011;	  Singh	  et	  al.,	  2011;	  Luo	  
and	  Chen,	  2012;	  Tian	  et	  al.,	  2012).	  Cellular	   communication	  between	  astrocytes	  
and	  other	  glia	  cell-­‐types	  as	  well	  as	  between	  astrocytes	  and	  neurons	  may	  also	  be	  
affected	  by	  the	  failure	  of	  Cln3-­‐/-­‐	  astrocytes	  to	  form	  a	  propagating	  calcium	  wave,	  
leading	   to	   insufficient	   activation	   of	   neighboring	   astrocytes	   as	  well	   as	  microglia	  
(Verderio	  and	  Matteoli,	  2001;	  Schipke	  et	  al.,	  2002;	  Davalos	  et	  al.,	  2005;	  Scemes	  
and	  Giaume,	  2006;	  Liu	  et	  al.,	  2011),	  further	  worsening	  their	  already	  attenuated	  
secretion	   of	   cytokines	   (Hide	   et	   al.,	   2000;	   Bianco	   et	   al.,	   2005;	   Nedergaard	   and	  
Dirnagl,	  2005)	  and	  any	  associated	  protective	  functions	  (see	  discussion	  in	  Chapter	  
4,	  Section	  4.3).	  Abnormal	  Ca2+	  signaling	  may	  also	  alter	  the	  synchronization	  of	  any	  
efforts	   within	   the	   astrocyte	   syncytium	   to	   maintain	   a	   favorable	   neuronal	  
homeostasis,	  via	  K+	  buffering	  and	  scavenging	  of	  excitatory	  glutamate	  (Fiacco	  and	  
McCarthy,	  2006;	  Scemes	  and	  Giaume,	  2006;	  Agulhon	  et	  al.,	  2012;	  Parpura	  et	  al.,	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2012)	   (see	   Discussion	   4.3).	   In	   summary,	   interrupted	   glia-­‐neuronal	   interactions	  
have	  the	  capability	  not	  only	  to	  underlie	  some	  of	  the	  disease	  symptoms,	  but	  also	  



















Figure	  7.2.	  Cln3-­‐/-­‐	  glia	  negatively	  impact	  neurons.	  Co-­‐culture	  experiments	  were	  carried	  
out	  to	  determine	  the	  direct	  impact	  of	  Cln3-­‐/-­‐glia	  upon	  neurons.	  In	  comparison	  to	  WT	  glia,	  which	  
had	  a	  positive	  impact	  on	  Cln3-­‐/-­‐	  neurons,	  Cln3-­‐/-­‐	  glia	  had	  a	  pronounced	  negative	  impact.	  Impaired	  
protein	   secretion,	  as	  well	   as	  attenuated	  glutamate	  clearance	  by	  Cln3-­‐/-­‐	   glial	  may	  alter	  neuronal	  
homeostasis	  and	  cause	  the	  observed	  effects.	  	  	  
	  
Taken	   together	   our	   data	   provide	   the	   first	   evidence	   that	   astrocyte	   biology	   is	  
compromised	   in	   JNCL,	   and	   reveals	   a	   direct	   link	   between	   glia	   and	  
neurodegeneration	   in	   this	   disease.	   In	   addition,	   isolated	   Cln3-­‐/-­‐	   neurons	   also	  
displayed	  biological	  defects	  (see	  Figure	  7.1	  B)	  that	  may	  alter	  their	  excitability	  and	  
connectivity,	  making	   them	  more	   vulnerable	   to	   further	   stress,	   and	  may	   explain	  
why	  these	  cells	  are	  more	  susceptible	  to	  Cln3-­‐/-­‐	  glia.	  	  
	  
This	   research	   suggests	   that	   targeting	   glia	   could	   be	   a	   beneficial	   therapeutic	  
approach	  for	  JNCL.	  Moreover,	  these	  results	  may	  offer	  clues	  to	  the	  role	  that	  glia	  
may	  play	  in	  the	  pathogenesis	  of	  other	  forms	  of	  NCL.	  However,	  it	  is	  worth	  bearing	  
in	  mind	   that	   this	   study	  provides	   information	  on	   cultured	  Cln3-­‐/-­‐	  astrocytes,	   and	  
these	  may	  differ	   fundamentally	   from	  astrocytes	   in	  vivo	   (Barres,	  2008;	  Cahoy	  et	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al.,	   2008;	   Allen	   and	   Barres,	   2009;	   Zhang	   and	   Barres,	   2010).	   The	   functional	  
properties	   of	   astrocytes	   in	   vivo	   are	   still	   not	   well	   understood,	   mainly	   because	  
studying	   them	   is	   difficult	   since	   they	   are	   non-­‐excitable	   cells	   that	   interact	   with	  
multiple	  cell	  types	  in	  the	  CNS,	  including	  neurons,	  vascular	  cells,	  oligodendrocytes	  
and	   microglia	   and	   they	   express	   a	   very	   similar	   range	   of	   receptors	   to	   neurons	  
(Volterra	   and	   Meldolesi,	   2005;	   Verkhratsky	   and	   Butt,	   2007;	   Allen	   and	   Barres,	  
2009;	   Verkhratsky	   and	   Parpura,	   2010).	   Additionally,	   human	   astrocytes	   are	  
considered	   to	  be	   significantly	  more	  complex	   than	   rodent	  astrocytes	   (Oberheim	  
et	  al.,	  2006;	  2009;	  2012).	  Studying	  human	  astrocytes	  derived	  from	  differentiated	  
iPSCs	  from	  JNCL	  patients,	  together	  with	  in	  situ	  investigations	  of	  rodent	  astrocytes	  
using	  organotypic	  slice	  cultures,	  would	  enable	  our	  results	  to	  be	  verified	  both	  in	  
human	  cells	  and	  in	  situ.	  
	  
Are	  glia	  really	  the	  bad	  guys	  in	  JNCL?	  
Because	  JNCL	  is	  a	  predominantly	  neurological	  disorder	  most	  attention	  has	  been	  
focused	  upon	  the	  profound	  loss	  of	  neurons	  that	  occurs	  in	  this	  disease.	  However,	  
an	   increasing	   number	   of	   studies	   have	   shown	   that	   glial	   activation	   can	   play	   a	  
fundamental	   role	   in	   CNS	  disease	   progression	   and	   influence	  neurodegeneration	  
(Liberto	   et	   al.,	   2004;	   Raivich,	   2005;	   Garden	   and	   Möller,	   2006;	   Sofroniew	   and	  
Vinters,	  2010;	  Tremblay	  et	  al.,	  2010;	  Verkhratsky	  and	  Parpura,	  2010;	  Garwood	  et	  
al.,	  2011;	  Macauley	  et	  al.,	  2011;	  Schafer	  et	  al.,	  2013).	  Indeed,	  there	  is	  evidence	  in	  
several	   LSDs,	   including	   the	   NCLs,	   indicating	   that	   glia	   contribute	   to	   the	  
pathogenesis	  of	  these	  diseases	  (German	  et	  al.,	  2002;	  Chen	  et	  al.,	  2007;	  Macauley	  
et	  al.,	  2011;	  Di	  Malta	  et	  al.,	  2012a;	  2012b).	  For	   instance,	  Niemann-­‐Pick	  type	  C1	  
(Npc-­‐1)	   deficient	   astrocytes	   have	  been	   shown	   to	   reduce	  neurite	   growth	   in	  WT	  
neurons	   in	   vitro	   due	   to	   reduced	   estradiol	   secretion	   (Chen	   et	   al.,	   2007),	   and	  
correction	  of	  the	  gene	  defect	  specifically	  in	  astrocytes	  of	  Npc1-­‐/-­‐	  mice	  enhanced	  
their	   survival	   (Zhang	   et	   al.,	   2008).	   In	   parallel	   with	   this,	   decreased	   neuronal	  
storage	   of	   cholesterol,	   neurodegeneration	   and	   astrocytosis,	   was	   observed,	   as	  
well	   as	   improved	   myelination	   (Zhang	   et	   al.,	   2008).	   Furthermore,	   astrocyte-­‐
specific	   deletion	   of	   the	   Sumf1	   gene	   (deficient	   in	   multiple	   sulfatase	   deficiency	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(MSD),	  a	  severe	  lysosomal	  storage	  disorder)	  was	  sufficient	  to	  induce	  cell	  death	  in	  
cortical	   neurons	   both	   in	   vivo	   and	   in	   vitro	   (Di	   Malta	   et	   al.,	   2012a).	   This	   toxic	  
impact	   of	   astrocytes	   in	   MSD	   was	   attributed	   to	   dysfunctional	  
lysosomes/autophagy	  (Di	  Malta	  et	  al.,	  2012b).	  These	  data	   indicate	  that	  a	  single	  
gene	  mutation	  solely	   in	  glia	   is	  sufficient	  to	  cause	  serious	  problems	  for	  neurons.	  
Thus,	  it	  is	  likely	  that,	  at	  least	  in	  some	  LSDs,	  non-­‐cell	  autonomous	  mechanisms	  for	  
neurodegeneration	  occur	  and	  these	  effects	  may	  be	  mediated	  by	  astrocytes	  alone	  
or	   in	   combination	   with	   other	   glia.	   Conversely,	   impairing	   astrocytosis	   in	   Ppt1-­‐/-­‐	  
mice	  resulted	   in	  an	  acceleration	  of	  disease	  progression	  (Macauley	  et	  al.,	  2011).	  
Thus,	   in	   INCL	   astrocytes	   appear	   to	   protect	   neurons	   against	   pathogenic	  
challenges.	  It	  is	  therefore	  evident	  that	  the	  role	  of	  astrocytes	  varies	  depending	  on	  
the	  pathological	  situation	  and	  gene	  defect	  in	  question.	  Nevertheless,	  astrocytes	  
appear	  to	  be	   integral	  components,	  not	  only	   in	   JNCL	  pathogenesis,	  but	  also	   in	  a	  
range	  of	  other	  LSDs	  and	  this	  suggests	  that	  modulation	  of	  astrocyte	  activities	  may	  
offer	  a	  valuable	  way	  to	  impact	  disease	  progression.	  
	  
Experiments	   are	   at	   present	   underway	   to	   study	   the	   direct	   impact	   of	   glia	   upon	  
disease	   progression	   in	   JNCL,	   by	   creating	   mice	   in	   which	   only	   astrocytes,	   only	  
microglia,	   or	   both	   cell	   types	   carry	   the	  most	   common	  human	  mutation	   for	   this	  
disease.	  Such	  studies	  will	  also	  provide	  evidence	  on	  the	  importance	  of	  each	  glial	  
cell	   type	   to	   disease	   progression	   and	   this	   in	   turn	   may	   help	   inform	   future	  
therapeutic	  strategies	  for	  JNCL.	  	  
	  
Could	  glia	  based	  therapies	  be	  useful	  in	  JNCL?	  
Currently,	  there	  are	  no	  treatments	  available	  for	  JNCL,	  mainly	  due	  to	  the	  fact	  that	  
CLN3	   is	   a	   transmembrane	  protein	  whose	  normal	   function	   is	   unknown.	   Being	   a	  
transmembrane	  protein,	  many	  therapies	  that	  have	  the	  potential	  to	  be	  successful	  
in	  other	  forms	  of	  NCLs,	  such	  as	  enzyme	  replacement,	  gene	  transfer	  or	  even	  stem	  
cell	  therapy	  (Griffey	  et	  al.,	  2006;	  Wong	  et	  al.,	  2010;	  Mole	  et	  al.,	  2011;	  Roberts	  et	  
al.,	  2012),	  are	  not	   feasible	  options	   in	   JNCL	   (Cooper,	  2008).	  These	   therapies	  are	  
based	  on	  the	  principle	  of	  cross	  correction,	  where	  a	  soluble,	  diffusible	  protein	  can	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be	   taken	  up	  by	  neighbouring	  cells	   to	  correct	  of	   their	  enzyme	  deficiency	   (Sands	  
and	   Davidson,	   2006;	   Wong	   et	   al.,	   2010).	   This	   approach	   is	   not	   feasible	   in	   the	  
forms	   of	   NCL,	   like	   JNCL,	   that	   are	   caused	   by	   mutations	   in	   transmembrane	  
proteins.	   However,	   with	   advances	   in	   gene	   transfer	   methodologies,	   it	   may	   be	  
possible	  in	  the	  future	  to	  introduce	  a	  functional	  copy	  of	  the	  defective	  gene	  into	  a	  
sufficient	  number	  of	  cells	  to	  have	  a	  therapeutic	  impact.	  	  
	  
In	   infantile	   NCL	   storage	   material	   clearance	   with	   drugs	   such	   as	   cystagon	   may	  
theoretically	   have	   beneficial	   impact	   (Mole	   et	   al.,	   2011),	   but	   this	   is	   yet	   to	   be	  
realized	   in	   either	   Ppt1-­‐/-­‐	   mice	   or	   human	   patients.	   As	   yet	   there	   is	   no	   direct	  
evidence	   that	   storage	   material	   is	   the	   primary	   pathogenic	   player	   that	   leads	   to	  
neuron	  loss	  in	  the	  NCLs,	  and	  this	  includes	  JNCL.	  In	  cultured	  cells	  no	  accumulation	  
of	   storage	   material	   was	   observed,	   suggesting	   that	   neither	   the	   phenotypes	   of	  
Cln3-­‐/-­‐	  astrocytes	  or	  neurons	  described	   in	   this	   thesis,	  nor	   the	  negative	  effect	  of	  
Cln3-­‐/-­‐	  glia	  upon	  neurons	  were	  caused	  by	  this.	  This	  study	  does	  however	  provide	  
several	   possibilities	   for	   novel	   therapies	   for	   JNCL	   based	   on	   correcting	   the	  
functional	  deficits	  observed	  in	  Cln3-­‐/-­‐	  astrocytes	  (see	  Figure	  7.3).	  	  
	  
Protein	  secretion:	  One	  of	  the	  most	  prominent	  features	  of	  Cln3-­‐/-­‐	  astrocytes	  was	  
impaired	  protein	  secretion	   (chemokines,	  anti-­‐	  and	  pro-­‐inflammatoric	  cytokines,	  
trophic	   factors,	   see	   Chapter	   4,	   Discussion	   4.3).	   As	   stated	   above,	   this	   could	  
severely	   alter	   both	   glial/glial	   and	   glial/neuronal	   interactions	   within	   the	   JNCL	  
brain	  (Saad	  et	  al.,	  1991;	  Eddleston	  and	  Mucke,	  1993;	  Hewett	  et	  al.,	  1993;	  Ridet	  et	  
al.,	  1997;	  Krieglstein	  et	  al.,	  1998;	  Hewett,	  1999;	  John	  et	  al.,	  2003;	  Liberto	  et	  al.,	  
2004;	  Miklic	  et	  al.,	  2004;	  Villoslada	  and	  Genain,	  2004;	  Hamby	  et	  al.,	  2008;	  Mena	  
and	  García	  de	  Yébenes,	  2008;	  Hamby	  and	  Sofroniew,	  2010;	  Singh	  et	  al.,	  2011),	  
and	   may	   be	   a	   key	   element	   in	   the	   observed	   glial	   response	   and	   initiation	   of	  
neurodegeneration	  in	  these	  mice.	  For	  example,	  activated	  Cln3-­‐/-­‐	  astrocytes	  failed	  
to	   secrete	   anti-­‐inflammatory	   cytokines,	   such	   as	   IL-­‐4,	   IL-­‐10	   and	   IL-­‐2,	   as	   well	   as	  
neuroprotective	   factors,	   such	   as	   VEGF	   and	   FGF.	   Indeed,	   both	   genetic	   and	  
pharmaceutical	   approaches	   to	   attenuate	   the	   adaptive	   immune	   response	   have	  
been	  shown	  to	  resulted	  in	  a	  significant	   improvement	   in	  the	  pathology	  of	  Cln3-­‐/-­‐	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mice	  (Seehafer	  et	  al.,	  2011),	  and	  experiments	  are	  now	  underway	  to	  determine	  if	  
targeting	  the	   innate	   immune	  response	  will	  offer	   further	  therapeutic	  benefit	   (JD	  
Cooper	  &	  BP	  Williams,	   personal	   communication).	   There	   is	   a	   precedent	   for	   this	  
approach,	   since	   non-­‐steroidal	   anti-­‐inflammatory	   drugs	   (NSAIDs)	   together	   with	  
substrate	  reduction	  therapy	  (SRT)	  prolonged	  the	  lifespan	  and	  delayed	  the	  onset	  
of	  clinical	  signs	  in	  NPC1	  mice	  (Smith	  et	  al.,	  2009).	  Based	  on	  these	  findings	  we	  are	  
now	   treating	   JNCL	   mice	   with	   a	   combination	   of	   anti-­‐inflammatory	   drugs,	  
neuroprotective	   drugs	   and	   immunosuppressants	   to	   determine	   if	   this	   will	  
enhance	   the	  benefit	   seen	  when	   treating	   these	  mice	  with	   immunosuppressants	  
alone	   (Seehafer	   et	   al.,	   2011).	   Another	   possibility	   might	   be	   to	   transplant	  
genetically	  modified	   stem	   cells	   that	  would	   produce	   and	   secrete	   specific	   set	   of	  
molecules,	   such	   as	   neuroprotective	   factors.	   This	   approach	   has	   been	   trialed	   in	  
other	  neurodegenerative	  diseases,	  like	  ALS,	  where	  successful	  protection	  of	  dying	  
motor	  neurons	  was	  achieved	  (Suzuki	  et	  al.,	  2007;	  Behrstock	  et	  al.,	  2008).	  
	  
Glutamate	  clearance:	  Glutamate	  clearance	  by	  astrocytes	  has	  been	  shown	  to	  be	  
impaired	  in	  various	  neurodegenerative	  conditions,	  such	  as	  spinocerebellar	  ataxia	  
type	  7	  (SCA7),	  Huntington	  disease	  and	  ALS,	  and	  here	  we	  show	  that	  this	  is	  also	  the	  
case	  with	  Cln3-­‐/-­‐	  astrocytes	  (Rothstein	  et	  al.,	  1992;	  1996;	  Wang	  et	  al.,	  2003;	  Shin	  
et	   al.,	   2005;	   Custer	   et	   al.,	   2006).	   Additionally,	   EAAT2	   (glutamate	   receptor)	  
expression	   has	   been	   shown	   to	   be	   reduced	   in	   JNCL	   patient	   tissue	   samples	  
(Hachiya	   et	   al.,	   2006),	   and	   elevated	   glutamate	   levels	   have	   been	   detected	   at	  
presynaptic	  sites	  in	  Cln3-­‐/-­‐	  mice	  (Chattopadhyay	  et	  al.,	  2004).	  Thus,	  manipulating	  
glutamate	   clearance	  by	   astrocytes	   could	   be	  one	  way	   to	   help	   prevent	   neuronal	  
overstimulation,	  as	  our	  data	  suggest	  to	  be	  the	  case	  by	  the	  presence	  of	  a	  distally	  
located	   AIS	   in	   isolated	   cortical	   excitatory	   neurons.	   For	   instance,	   glutamate	  
clearance	   by	   Cln3-­‐/-­‐	   astrocytes	   could	   theoretically	   be	   augmented	   using	   a	   drug	  
called	   parawexin	   1	   that	   has	   been	   previously	   shown	   to	   use	   this	  mechanism	   to	  
protect	  neurons	  against	  glutamate	  mediated	  excitotoxicity	  (Fontana	  et	  al.,	  2003;	  
2007).	  Additionally,	  certain	  ß-­‐lactam	  antibiotics	  have	  been	  shown	  to	  potentiate	  
astrocyte-­‐mediated	  glutamate	   clearance	   through	   increased	   transcription	  of	   the	  
Glt1	   (glial	   glutamate	   transporter	   1)	   gene	   (Rothstein	   et	   al.,	   2005).	   The	  ß-­‐lactam	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antibiotic,	   ceftriaxone,	   was	   shown	   to	   be	   neuroprotective	   in	   mouse	   models	   of	  
ischaemic	  injury	  (Lipski,	  2007),	  motor	  neuron	  disease	  (Rothstein	  et	  al.,	  2005)	  and	  
Parkinson’s	  disease	  (Rothstein	  et	  al.,	  2005;	  Leung	  et	  al.,	  2012).	  It	  would	  therefore	  
be	   interesting	   and	   feasible	   to	   test	   the	   neuroprotective	   potential	   of	   this	  
commercially	  available	  antibiotic	  in	  JNCL	  mouse	  models.	  
	  
Another	   approach	   to	   combat	   the	   excess	   glutamate-­‐induced	   excitotoxicity	   and	  
particular	   vulnerability	  of	  neurons	   to	  AMPA	  and	  NMDA-­‐receptor	   stimulation	   in	  
Cln3-­‐/-­‐	   mice	   (Kovács	   et	   al.,	   2006;	   Kovács	   and	   Pearce,	   2008;	   Finn	   et	   al.,	   2011;	  
Kovács	   et	   al.,	   2011)	   could	   be	   to	   use	   glutamate	   receptor	   blockers.	   Indeed,	  
previous	   studies	   have	   shown	   that	   acute	   attenuation	  of	  AMPA-­‐receptor	   activity	  
by	   the	   non-­‐competitive	   AMPA	   antagonist,	   EGIS-­‐8332,	   improved	   motor	  
coordination	  and	  lifespan	  of	  these	  mice	  (Kovács	  and	  Pearce,	  2008;	  Kovács	  et	  al.,	  
2011).	   Moreover,	   memantine	   application,	   which	   results	   in	   the	   inhibition	   of	  
NMDA-­‐glutamate	  receptors,	   induced	  an	  improvement	  of	  motor	  skills	  (Kovács	  et	  
al.,	  2012),	  although,	  this	  treatment	  did	  not	  impact	  overall	  microglial	  or	  astrocytes	  
activation,	  or	  the	  survival	  of	  sensitive	  neuron	  populations.	  Treatment	  with	  EGIS-­‐
8332,	  however,	  did	  decrease	  astrocytosis	   in	  the	  somatosensory	  cortex	  of	  Cln3-­‐/-­‐	  
mice	   (Kovács	   et	   al.,	   2012),	   which	   is	   consistent	   with	   another	   recent	   study	  
revealing	   that	   chronic	   inhibition	   of	   AMPA	   receptors	   with	   a	   non-­‐competitive	  
blocker	   called	   talampanel	   prevents	   astrocyte	   activation	   (Greene	   et	   al.,	   2008).	  
Thus,	   inhibition	   of	   glutamate-­‐receptor	   over-­‐activation	   may	   also	   lead	   to	   the	  
attenuation	   of	   reactive	   astrocytosis,	   emphasizing	   the	   importance	   of	   balanced	  
communication	  between	  neurons	  and	  glia,	  and	  therefore	  treating	  both	  of	  these	  
events	  in	  Cln3-­‐/-­‐	  mice	  might	  be	  particularly	  beneficial.	  
	  
Oxidative	   stress:	   Astrocytes	   are	   the	  major	   source	   of	   GSH	   in	   the	   CNS,	   an	   anti-­‐
oxidant	   that	   plays	   a	   crucial	   role	   in	   protecting	   neurons	   against	   oxidative	   stress	  
(Dringen,	   2000;	   Chen	   et	   al.,	   2001;	   Swanson	   et	   al.,	   2004;	   Duncan	   and	   Heales,	  
2005;	  Gegg	  et	  al.,	  2005;	  Benedict	  et	  al.,	  2007).	  Cln3-­‐/-­‐	  astrocytes	  can	  still	  make,	  
but	   fail	   to	   secrete,	   glutathione,	   and	   therefore	   this	   protection	   may	   be	   lost.	  
Modulating	  GSH	  secretion,	  or	  providing	  the	  essential	  rate	  limiting	  GSH	  substrates	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for	  neuronal	  GSH	  production	  (such	  as	  cysteine),	  may	  help	  guard	  against	  oxidative	  
stress	  (Shih	  et	  al.,	  2003;	  Darlington,	  2005;	  Vargas	  et	  al.,	  2008;	  Chen	  et	  al.,	  2009;	  
Fuller	   et	   al.,	   2009).	   Indeed,	   enhancing	   glutathione-­‐based	   detoxification	   of	  
oxidative	  factors	  has	  been	  shown	  to	  be	  neuroprotective	  in	  various	  models,	  such	  
as	  Parkinson	  disease	  and	  ALS	  (Shih	  et	  al.,	  2003;	  Vargas	  et	  al.,	  2008;	  Chen	  et	  al.,	  
2009),	   and	   this	   approach	   could	   feasibly	   also	   be	   trialed	   in	   JNCL	   (Schmidt	   and	  
Dringen,	  2010).	  For	  instance,	  fumaric	  acid	  esters	  (FAE)	  have	  been	  recognized	  as	  a	  
promising	   therapy	   form	   for	   autoimmune-­‐based	   neurological	   disorders,	   such	   as	  
multiple	   sclerosis	   (Moharregh-­‐Khiabani	   et	   al.,	   2009;	   Gold	   et	   al.,	   2012;	   Schmidt	  
and	   Dringen	   2010),	   based	   on	   their	   ability	   to	   deplete	   astrocyte	   GSH	   content	  
(Mrowietz	  and	  Asadullah,	  2005).	  	  
 
Calcium	   signaling:	   Spontaneous	   Ca2+	   oscillations	   were	   attenuated	   in	   Cln3-­‐/-­‐	  
astrocytes,	   and	   these	   cells	   failed	   to	   generate	   a	   synchronized	   calcium	   wave.	  
Abnormal	   ER	   Ca2+	   release	   followed	  by	   attenuated	   cytosolic	   Ca2+	   clearance	  was	  
also	  evident.	  Abnormal	  Ca2+	  signaling	  has	  previously	  been	  reported	  in	  other	  LSD	  
models	   (Pelled	  et	  al.,	  2003a;	  Ginzburg	  and	  Futerman,	  2005;	  Pelled	  et	  al.,	  2005;	  
Lloyd-­‐Evans	   et	   al.,	   2008;	   Lloyd-­‐Evans	   and	   Platt,	   2011).	   For	   instance,	   abnormal	  
Ca2+	   storage	   in	   these	   acidic	   compartments	   is	   an	   important	   initiating	   factor	   in	  
NPC1	   disease	   pathogenesis	   (Lloyd-­‐Evans	   et	   al.,	   2008).	   Cytosolic	   Ca2+	  
normalization	   with	   curcumin,	   which	   is	   an	   inhibitor	   of	   the	   histone	  
acetyltransferase	  (HAT)	  p300	  as	  well	  as	  a	  SERCA	  pump	  antagonist	  (Bilmen	  et	  al.,	  
2001;	  Marcu	  et	  al.,	  2006),	  abolished	  typical	  NPC1	  disease	  phenotypes	   in	  NCP1-­‐
mutant	   glia	   cells	   and	   slowed	  disease	  progression	   in	  NPC1	  mice	   (Lloyd-­‐Evans	  et	  
al.,	  2008).	  Furthermore,	  curcumin	  is	  a	  promising	  therapeutic	  option	  in	  a	  number	  
of	   neurological	   diseases	   based	   on	   its	   anti-­‐inflammatory	   and	   antioxidant	  
properties	  (Natarajan	  and	  Bright,	  2002;	  Marcu	  et	  al.,	  2006;	  Laird	  et	  al.,	  2010;	  Lin	  
et	   al.,	   2011).	   Curcumin	   has	   also	   been	   shown	   to	   increase	   epileptic	   seizure	  
thresholds,	   via	   modulation	   of	   free	   radicals	   and	   NOS	   (DU	   et	   al.,	   2012),	   an	  
approach	  which	  might	  also	  be	  beneficial	  in	  JNCL	  since	  these	  patients	  suffer	  from	  
spontaneous	  epileptic	  seizures	  (Mole	  et	  al.,	  2011).	  Thus,	  it	  would	  be	  interesting	  
to	   examine	   the	   impact	   of	   curcumin	   on	   Ca2+-­‐signaling	   in	  Cln3-­‐/-­‐	   astrocytes,	   and	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whether	  activities	  dependent	  on	  correct	  Ca2+-­‐signaling,	  such	  as	  gliotransmission,	  
are	  influenced	  by	  this	  treatment.	  In	  addition,	  the	  efficacy	  of	  curcumin	  to	  improve	  
the	  anti-­‐inflammatory	  response	  and	  to	  reduce	  seizure	  probability	  could	  also	  be	  
tested	  in	  JNCL	  mouse	  models.	  	  	  	  
	  
Cytoskeletal	   disruption:	   Both	   the	   actin	   and	   the	   intermediate	   filament	  
cytoskeleton	  were	  found	  to	  be	  disrupted	  in	  Cln3-­‐/-­‐	  astrocytes.	  Ultimately	  many	  of	  
the	   deficits	   we	   have	   discovered,	   including	   attenuated	   migration,	   division,	  
secretion,	   glutamate	   clearance	   and	   Ca2+	  wave	   propagation	   in	   these	   cells	   could	  
plausibly	   be	   caused	   by	   this	   lack	   of	   proper	   cytoskeletal	   organization.	   The	   Rho	  
subfamily	   of	   small	   GTPases	   (Rho	   and	   Rac)	   have	   been	   recognized	   as	   pivotal	  
regulators	   of	   cytoskeletal	   organization	   (Van	   Aelst	   and	   D'Souza-­‐Schorey,	   1997;	  
Hall,	  1998;	  Kaibuchi	  et	  al.,	  1999;	  Ridley,	  2001a;	  2001b;	  Etienne-­‐Manneville	  and	  
Hall,	  2002;	  Schmidt	  and	  Hall,	  2002;	  Heasman	  and	  Ridley,	  2008).	  Several	  studies	  
have	   shown	   that	  growth	   factors,	   such	  as	  FGF	  and	  EGF,	  may	   stimulate	  Rho	  and	  
Rac	  GTPase	   activities	   and	   induce	   cytoskeletal	   reorganization	   (Hou	   et	   al.,	   1995;	  
Kalman	  et	   al.,	   1999;	  Maddala	   et	   al.,	   2003).	  Alternatively,	   the	   activation	  of	   Rho	  
GTPases	  could	  be	  enhanced	  by	  guanine	  nucleotide	  exchange	  factors	  (GEFs),	  such	  
as	   Tiam1,	   Net1	   and	   Vav	   (Schmidt	   and	   Hall,	   2002;	   Erickson	   and	   Cerione,	   2004;	  
Rossman	   et	   al.,	   2005;	   Buchsbaum,	   2007).	   Thus,	   both	   growth	   factors	   and	   GEFs	  
may	  offer	  a	  solution	  to	  help	  correct	   the	  disrupted	  cytoskeleton	  and	  dependent	  
activities	   in	  Cln3-­‐/-­‐	  astrocytes,	  although	  the	  likely	  potential	  of	  many	  non-­‐specific	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In	   summary,	   our	   analysis	   of	   astrocytes	   and	   neurons	   revealed	   that	   CLN3	  
deficiency	  caused	  newly	  identified	  alterations	  in	  the	  biology	  of	  both	  of	  these	  cell	  
types.	  Importantly,	  glia	  were	  shown	  to	  directly	  impact	  the	  health	  of	  both	  WT	  and	  
Cln3-­‐/-­‐	  neurons,	   with	   the	   latter	   being	   more	   sensitive	   possibly	   because	   of	   their	  
intrinsic	  biological	  defects.	  Thus,	   it	  appears	  that	  glia	  could	  be	  key	  players	  in	  the	  
pathogenesis	   of	   JNCL.	   In	   light	   of	   the	   recent	   findings	   demonstrating	   that	   other	  
LSDs	  can	  be	  treated	  with	  therapeutic	  interventions	  that	  specifically	  target	  glia,	  it	  
will	  be	  important	  to	  explore	  whether	  such	  approaches	  could	  also	  be	  beneficial	  in	  
JNCL.	  Maybe	   it	  will	  prove	  most	  beneficial	   to	  use	  a	  combination	  of	   therapies	   to	  
target	  glia,	  such	  as	  antioxidants,	  inhibitors	  of	  excitotoxicity,	  immunosuppressive	  
drugs	  and	  supplementation	  of	  trophic	  factors,	  with	  treatment	  being	  initiated	  as	  
early	   as	   possible	   to	   halt	   the	   progression	   of	   early	   pathological	   changes.	  
Furthermore,	  since	  CLN3	  is	  expressed	  across	  the	  whole	  body,	  not	  only	  in	  the	  CNS	  
(The	   International	   Batten	   Disease	   Consortium	   1995;	   Pane	   et	   al.,	   1999;	  
Chattopadhyay	  and	  Pearce,	  2000;	  Mole	  et	  al.,	  2011),	  and	  has	  been	  proposed	  to	  
serve	   ‘housekeeping’	   functions	   in	   the	   cell	   (Mole	   et	   al.,	   2011),	   combination	  
therapy	   approaches	   designed	   to	   treat	   the	   whole	   body	   together	   with	   the	   CNS	  
may	  be	  necessary.	  The	  benefit	  of	  such	  an	  approach	  was	  demonstrated	  recently	  
for	   INCL,	   in	  which	  CNS-­‐directed	  AAV2/5-­‐mediated	   gene	   therapy	  was	   combined	  
with	   bone	  marrow	   transplant	   (BMT)	   in	   newborn	  Ppt1-­‐/-­‐	  mice	   (Macauley	   et	   al.,	  
2012).	   This	   resulted	   in	   a	   two-­‐fold	   increase	   in	   the	   lifespan	   of	   the	   mice,	   and	  
prolonged	  improvements	  in	  motor	  function	  (Macauley	  et	  al.,	  2012).	  	  	  	  	  	  
	  
From	  the	  work	  described	  here	  on	  JNCL,	  and	  published	  work	  on	  other	  LSDs,	   it	   is	  
evident	  that	  glia	  play	  a	  pivotal	  role	  in	  these	  diseases.	  Based	  on	  these	  data	  we	  are	  
beginning	  to	  use	  similar	  approaches	  to	  study	  glial	  biology	  in	  other	  forms	  of	  NCL	  
and	   to	   determine	   whether	   such	   changes	   are	   beneficial	   or	   detrimental	   to	  
neuronal	  health.	  Certainly,	  preliminary	  data	  from	  Ppt1-­‐/-­‐	  astrocytes	  suggests	  that	  
these	   cells	   also	   have	   an	   altered	   protein	   secretion	   profile	   upon	   stimulation	   in	  
vitro,	   in	   this	   case	   with	   enhanced	   secretion	   of	   many	   proteins,	   including	  
neuroprotective	   factors.	  This	  correlates	  well	  with	   the	   in	  vivo	   findings	   indicating	  
	   326	  
that	   reactive	   astrocytosis	   protects	   neurons	   against	   cell	   death	   in	   Ppt1-­‐/-­‐	   mice	  
(Macauley	  et	  al.,	  2011).	  	  
	  
In	   conclusion,	   the	   research	   presented	   in	   this	   thesis	   not	   only	   expands	   our	  
understanding	  of	   JNCL	  pathogenesis,	  highlighting	   the	   importance	  of	  astrocytes,	  
but	   crucially	   these	   data	   also	   emphasize	   a	  whole	   range	   of	   potential	   targets	   for	  
therapeutic	  intervention.	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